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Gamma-aminobutyric acid type A receptors (GABAAR) are transmembrane pentameric 
ligand-gated chloride ion channels that respond to GABA, the major inhibitory neurotransmitter 
in the central nervous systems (CNS). The benzodiazepines (BZDs) bind at the extracellular 
interface of the α+γ2-subunits of GABAAR. The binding of ligands at different subunits of 
GABAA receptors specifically at α1-6β2/3 γ2 ion channels, can affect a wide variety of brain 
functions. The α1-subtype selective ion channels of GABAARs are involved in the sedative, ataxic, 
amnesic, anticonvulsant and addictive effects, which should be avoided, with the exception of the 
anticonvulsant effects, when designing ligands for this BZ allosteric modulatory site. The α2/3-
containing GABAARs have been implicated by many, in the anxiolytic, anticonvulsant, 
and antinociceptive activities. At higher doses, muscle relaxation may be mediated by interaction 
at α3 subtypes. It is known that α5-containing GABAARs are involved in cognition, as well 
as learning and memory processes. The disruption of GABA activity at α5 subtypes 
on GABAAR plays a role in the pathophysiology of CNS disorders such as schizophrenia, major 
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depressive disorder (MDD), bipolar disorder and certain anxiety disorders such as OCD. The α5 
subtypes in the lung play a major role in potential new treatments for asthma.  
Based on the "privileged imidazodiazepine (IMZD) structures" derived from the 
unified pharmacophore model of Milwaukee, the design, synthesis and biological activities of 
more than 120 novel chiral GABAAR α2/α3/α5 or α5 subtype selective imidazodiazepines (IMDZs) 
related to  SH-053-2'F-R-CH3, and its  enantiomer SH-053-2'F-S-CH3, as well as the key achiral 
ligand  Hz-166 are described. The goal of this research is to develop new analogs with 
improved metabolic stability that also retain the desired biological properties with little or no side 
effects for the treatment of CNS disorders, as well as asthma. 
Several compounds from the α5 subtype selective group are anxiolytic, antidepressant, as 
well as pro-cognitive, and are targeted toward the treatment of major depressive disorders. About 
20 grams of one lead compound (GL-II-73), and more than 80 analogs were designed, synthesized 
and evaluated. The α5 selective chiral lead amide, GL-II-73, looks very good in rodent models for 
the treatment of depression. It exhibited an excellent pharmacokinetic profile, as well as anti-
depressant and anxiolytic activities in mice. This antidepressant effect has been realized with no 
side effects such as sedation nor motor impairment that benzodiazepine drugs would normally 
effect. In addition, the much sought after improved cognitive effects were clear in mice; this is a 
key in treating depression or schizophrenia. Examination of the data in the most recent study 
indicated that the administration of a single dose of GL-II-73 within 30 minutes could reverse the 
stress-induced or normal aging-related working memory deficits in old mice back up to  80-90 %, 
which is almost at the level of a young mouse. Whereas the old mice or stressed young mice will 
normally perform at about a level of 50-60 %. Furthermore, the brain cells, which had shrunk in 
older mice associated with aging, grew back (dendrites and spines) to a level that is similar to the 
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young mice. This is extremely exciting and occurred after two months of the administration of GL-
II-73 to the old mice in their drinking water. These results were presented by our collaborator, Dr. 
Etienne Sibille in an interview with the BBC, but also resulted in three papers and two patents. It 
is hoped the CAMH group of Sibille can push this project forward to human trials within two years 
as proposed. Additional research on these key compounds by several groups is ongoing. One can 
imagine the use of GL-II-73 or analogs in other neurodegenerative diseases of the CNS.  
After evaluation of a series of novel IMDZs that were α5 subtype selective for the treatment 
of asthma, one compound MIDD0301 (originally named GL-II-93) was found to be orally 
active and also as an inhalant in rodent asthma models. Ligand MIDD0301 was active in 
the airway smooth muscle (ASM) relaxation assay, in the airway hyper-responsiveness model, in 
the human and guinea pig tracheal bath assays. Moreover, it does not induce any immunotoxicity 
in animal models. Taken together this data suggests that this novel ligand can be a potential 
candidate for the treatment of asthma. About 50 grams of the ligand has been synthesized in good 
yield to support all the different biological assays from our collaborators. Furthermore, the large 
scale total synthesis of MIDD0301 was presented to the Alcami Corporation for a 
proposed kilogram scale synthesis of GMP material for further research on toxicity and safety. 
This research has resulted in three new publications over the last year. This compound provided 
some of the impetus to found a new company, Panthergenics, to try to get it through the FDA. Dr. 
Arnold and Dr. Stafford founded the company via UW-Milwaukee. 
In regard to the design of new α2/3 subtype selective agents to treat anxiety disorders, 
neuropathic pain and epilepsy, an improved large scale synthesis of Hz-166, MP-III-080, and 
KRM-II-81 was executed. These ligands are anxiolytic, anticonvulsant and antinociceptive agents. 
They were prepared under milder conditions and with much improved yields. Moreover, an 
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alternative reduction process, which was developed for the synthesis of the key aldehyde 
intermediate from the ethyl ester, was optimized. This new process overcame the long-standing 
problem of imine reduction in good yield. These methods can be employed for larger scale 
reactions. In addition, there is no need for column chromatography for most of the compounds, 
which provided a much more practical route. With the improved synthesis, large quantities of these 
three α2/3-subtype selective GABAARs PAMs, which exhibited anxiolytic, anticonvulsant and 
antinociceptive effects in many animal tests, can be supplied with high-efficiency and quality to 
our collaborators. The large-scale synthesis and the analog research will permit investigation of 
ADME toxicity and for other behavior assays including those in primates. Studies in animal 
models for anxiety and epilepsy, as well as for neuropathic pain require gram quantities of 
compounds, which can now be provided. This will also permit the execution of long-term safety 
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Chapter 1. Introduction 
1.1. The GABAA receptors 
In the central nervous system (CNS) in the mammalian brain, gamma (γ)-amino butyric 
acid (GABA), the chief inhibitory neurotransmitter, is principally responsible for the inhibition of 
excess decrease in the neuronal activity.1 The inhibitory effect of GABA can be triggered via 
binding to GABA receptors, which are composed of two major classes: GABAA receptors 
(GABAAR) and GABAB receptors (GABABR). The GABAA-rho receptors, previously named 
GABAC receptors, are now classified into GABAA receptors as a subclass due to the composition 
of ρ (rho) subunits related to GABAAR. This subclass is not discussed here.
2 The GABAARs are 
contained in fast-acting transmembrane ligand-gated chloride ion channels. Upon activation, 
GABAAR causes a conformational change in the ion channel permitting chloride ions to pass 
through the pentameric channel, which results in the hyperpolarization of the gradient, which 
reduces neuronal transmission.3 Whereas the slow-acting GABABR are members of the G-protein 
coupled receptor family and are linked to the mediation of the activity of potassium and calcium 
channels.4 The accumulating evidence has long indicated that disruption of the proper function of 
GABAAR is associated with a wide variety of CNS disorders, such as schizophrenia,
5 major 
depressive disorder (MDD),6 anxiety,7 epilepsy8 as well as neuropathic pain.9  
To study the relationship between the function of GABAAR and different CNS disorders, 
a large body of research has been conducted to explore the structures and activities of GABAARs. 
The leading cause of different pharmacological effects is the multiplicity of the specific 
combination of GABAAR subunits.
10 In humans, there is a total of 19 subunit isoforms (α1-6, β1-
3, γ1-3, δ, ε, π, θ, ρ1-3).11 The minimal requirement of the most common and well investigated 
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GABAAR is the combination of α, β and γ subunits (α1-6β1-3γ2) in a stoichiometric ratio of 2:2:1.
2 
This is required for a fully functional allosteric effect of benzodiazepines at the α and γ interface. 
Immunocytochemistry studies have been employed by Wisden et al.12 to determine the 
occurrence of GABAAR in the CNS of rodents, as well as the distribution of different assemblies 
of GABAAR. It has been well documented that α1 β1-3 and γ2 are highly expressed throughout 
the brain both synaptically and extrasynaptically.13 The most abundant combination of GABAAR 
in the rat brain is α1β2γ2, which accounts for at least 60 % of total GABAAR.
13-15 The α2 and α3 
containing GABAARs have similarly high prevalence and account for approximately 20-30 % of 
GABAAR in rat brain.
13-15 The α5 containing GABAAR are localized predominately in the cortex, 
and the hippocampus, and represent about 5 % of the total GABAAR. This prevalence is much 
lower, as compared to other subtype assembles in rat brain.13-16 Moreover, GABAARs are not 
restricted to the CNS; a large amount of evidence indicates that GABAAR can also be found in 
other tissues outside of brain including the lungs, stomach, heart sinus node, intestines, etc. 1  
 
Figure 1. A proposed GABAAR subunit topology. The extracellular domain starts with the N-terminal end, and 
the M1-M4 are regions within the membrane. (Modified from the Figure in Burt, et al. 17 and Clayton, et al.)18 
 
The approximate molecular mass of GABAAR subunits is ~50 kD, and the structure of the 
receptors exhibit high homology. Each subunit contains four transmembrane domains M1-M4, 
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embedded in the lipid bilayer of its neuron. Both the C- and N- terminal of the subunit are located 
in the extracellular region, which includes potential glycosylation sites and a “cys-loop” formed 
by a disulfide bond at the N-terminal end. The large intracellular region is located between domain 
3 and 4, which is responsible for the regulation of GABAAR at possible phosphorylation sites 
(Figure 1). Five monomeric subunits can arrange in a ring to form the hetero- or homo- pentameric 
chloride channel (Figure 2).17-19 
 
 
Figure 2. The schematic representations of GABAAR, the ligand-gated chlorine ion channel in longitudinal 
vision (A) and cross-sectional vision (B). The number 1-4 represents the M1-M4 transmembrane domains. The 
domain M2 contributes to most of the pore lining within the lipid bilayer membrane. (Modified from the Figure 
in Keramidas et al.19, and Clayton et al.)18 
 
It has been well studied that besides the two binding sites for GABA,  GABAARs contain 
a series of other binding sites for psychoactive compounds including benzodiazepines, barbiturates, 
anesthetics, neurosteroids, ethanol, etc., at the synapse and inside the channel as well.1-2, 10, 14, 18 
The view from the extracellular region of the clockwise-arranged αβαβγ subunits illustrates the 
binding sites of GABAAR (Figure 3). GABA binds at the two interfaces of the α
-β+ subunits, 
whereas the benzodiazepines bind at the interface of the γ-α+ subunits.1-2, 7, 18 The interface of β-α+ 
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is also the binding site of newly discovered subtype-selective target CGS 9895 by Seighert, Ernst, 
Cook et al.18, 20-21 More recently Knutson et al, have shown this receptor can be alpha 6 subtype 
selective.22-24 In addition, drugs such as barbiturates1-2, 15 and ethanol,25-26  can also bind in the 
interior portion of the ion channel, which not only enhance the response of GABA but also opens 
the chloride ion pore directly to a degree, which results in the addiction potential or even death.1-
2, 10, 14-17 
 
Figure 3. The arrangement of the 132 GABAAR subtypes as viewed from the synaptic cleft. The binding 
sites of GABA are located at the interfaces between + and - subunits and the BZD binding site is located at 
the interface of the +- subunits. The + represents the loop C of each subunit. (Modified from the Figure in 
Clayton, et al.18 and Ernst, et al.)27  
 
1.2. Benzodiazepines (BZD) 
Benzodiazepines (BZDs), as a class of psychoactive drugs, were first discovered in 1955 
by Leo Sternbach. The first and most successful BZD drug, diazepam, was marketed as Valium in 
1963.28 Due to their potent activity, low toxicity29, minimal drug-drug interactions in the liver,30 
rapid penetration across the blood-brain barrier (BBB), rapid absorption from the gastrointestinal 
tract, and ready distribution in the brain,31-33 BZDs have been prescribed for the treatment of a 
series of CNS disorders such as anxiety, seizures, and insomnisia28, 34 for over 50 years. Traditional 
5 
 
BZDs share a core structure of a benzene ring fused with a seven-membered diazepine ring, 
together with a pendant phenyl C ring (Figure 4).35  
Classical 1,4-benzodiazepines such as diazepam (Figure 4) and alprazolam exhibit a high 
affinity for Bz/GABAAR non-selectively at the benzodiazepine binding site (BzR), at the interface 
of the γ-α+ subunits.1-2, 7, 18 Therefore, the α and γ subunits are much more critical than β subunits 
in terms of the influence on the pharmacological effects of BZDs.36 It has been illustrated that 
BZDs interact with α1-3,5β2/3γ2 GABAAR subtypes, but exhibit fewer effects at γ1,3 subtypes.
37 
Besides the major diazepam-sensitive (DS) GABAAR subtypes, two other subtypes, α4- and α6-
containing GABAAR, account for a much less percentage in the brain,
38 as compared to the DS 
GABAAR subtypes. It has been demonstrated that the binding pocket of diazepam-insensitive (DI) 
subtypes is not able to tolerate the pendent phenyl C ring of BZD ligands, such as the 1,4-
benzodiazepine diazepam and the imidazodiazepine (IMDZ) midazolam (Figure 4).39-40 However, 
drugs such as flumazenil (Figure 4), which lack the pendent phenyl C ring, can bind to all 6 major 




Figure 4. The structures of common BZDs: diazepam, chlordiazepoxide, imidazodiazepine (IMDZ) midazolam 
and flumazenil. The atoms are labeled for both BZDs and IMDZs. Diazepam, chlordiazepoxide, and midazolam 
can bind only to the DS sites, whereas flumazenil can bind to both the DS and DI sites. 
 
In the absence of GABA, a BZD itself is not able to modulate GABAAR directly.
41 Once a 
BZD is bound to GABAAR ion channel, the affinity of GABA to GABAAR is enhanced, which 
results in a much higher frequency of the chloride ion channel opening and hyperpolarization of 
the membrane potential.42 This results in inhibition of neuronal firing which is responsible for a 
series of pharmacological properties; for instance, anxiolytic, ataxic, amnesic, and sedative effects, 
as well as anticonvulsant effects, etc., which permits the use of BZDs for a variety of CNS 
disorders including GAD, SAD, PTSD, status epilepticus, and panic disorders. However, despite 
all the advantages, BZDs do, unfortunately, produce a series of adverse effects that are due to the 
simultaneous non-selective binding and efficacy at many GABAARs.
2, 28 The common side effects 
of BZDs include sedation, ataxia, amnesia, addiction, fatigue, dependence, withdraw issues, 
muscle-relaxation, and tolerance to the antinociceptive and anticonvulsant effects.43-45 Therefore, 
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there is a large unmet medical need for improved BZDs that could retain the desired 
pharmacological properties, but be devoid of the unnecessary side effects for better treatment of a 
series of CNS disorders. 
 
1.3. Modulation of BZDs on the Pharmacological Effects of GABAAR  
The converging lines of evidence have demonstrated that the pharmacological effects of 
the GABAARs depend on modulation of receptor subtypes, principally due to the type of αx 
subunits. Due to the pioneering work of Mohler, Sieghart, McKernan, Sigel, Seeburg, Squires, and 
Haefely, the identification of the associated effect for each subunit was achieved by using receptor 
binding, pharmacology and a molecular genetic approach, which introduced a point mutation into 
a specific α subunit. This involved replacement of the histidine amino acid (AA) by an arginine 
AA in the α1 subunit (α1His101Arg),46 α2His101Arg, α3His126Arg,47 and α5His105Arg.48 The 
rodents which contained the specific mutations above were treated with diazepam, and the change 
of the behavioral response (or lack thereof) was considered to be mediated by the mutated subunits 
as compared to the wild-type animals.46-48 The pharmacological effects of different subtypes are 
presented in Table 1, which is summary of many years of work by Mohler, Rudolph, McKernan, 
Sieghart, Siegel et al.   
Table 1. The CNS effects at GABAA α1-6β1-3γ2 receptor subtypes.18, 46-58 Presented at the Mona Symposium (2014), 
University of the West Indies.59 Earlier reported, in part, by Mckernan et al. (ACNP). 
Subtype Associated Effect 
 Sedation, anterograde amnesia, ataxia, some anticonvulsant action, addiction, 
dependence, as well as involved in the development of tolerance, and muscle 
relaxation  
 Anxiolytic, anticonvulsant action, antihyperalgesic effects 
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 Some anxiolytic action, some antinociceptive effects, anticonvulsant action at 
higher doses, some muscle relaxation at higher doses 
 Diazepam-insensitive (DI) site, important in lung disorders in the periphery  
 Cognition, learning, temporal and spatial memory (maybe memory component of 
anxiety); schizophrenia, depression and in the peripheral-asthma 
 Diazepam-insensitive (DI) site, important in Tic disorders, Tourette's syndrome, 
migraine, trigerminal or a facial pain and perhaps schizophrenia 
Pharmacology indicated in red was discovered by pharmacologists in collaboration with the Milwaukee group. 
Presented at the ASPECT meeting, Cook et al. April 9th, Orlando FL. 
 
The α1-containing GABAARs have been found to mediate sedative effects, anterograde 
amnesia, ataxia, development of tolerance, addiction, dependence, and some anticonvulsant action, 
as well as muscle relaxation.46, 50 The α2-containing GABAARs play a prominent role in anxiolytic, 
antinociceptive and some anticonvulsant effects;47, 51 perhaps some hypnotic effects and some 
muscle relaxation at higher doses. Much of the antihyperalgesic effects from the GABAAR, 
however, occur in the spinal cord, as confirmed by a triple-point mutation study, as well as other 
work by Zeilhofer, Cook et al. using ligand Hz-166.49, 55 The α3-containing GABAARs are possibly 
involved in the anxiolytic-like effects, anticonvulsant action, antinociceptive effects and muscle 
relaxation at higher doses.47, 51-53 The α5-containing GABAARs contribute to cognition, memory, 
and spatial learning, as well as a possible memory component of anxiety.48, 54 The α4- and α6-
containing GABAAR are DI subtypes that lack the large binding pocket for the pendant C ring of 
some BZDs, especially 1,4-benzodiazepines and IMDZs, therefore, no corresponding ataxic or 
sedative CNS effect is associated with these two subtypes.39-40 Recent studies have shown that not 
only α5- but also α4-containing GABAARs are expressed in the peripheral nervous system (PNS), 
notably in lungs,56-58 which provided another possible treatment for asthma using BZDs. Recently, 
Knutson et al. have shown that the α6 Bz/GABAergic subtypes, at the PQ site, are involved in 
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migraine, trigeminal pain, Tic diseases such as Tourette's syndrome, OCD and perhaps 
schizophrenia.22-24 
In addition to the multiplicity of receptor subtypes, the chloride ion influx plays an essential 
role in the pharmacological effects of GABAARs in the CNS from the allosteric modulation of 
GABA. BZDs such as diazepam bind to the GABAAR BZD allosteric site on the ion channel and 
lock it into an agonist conformation. This action increases the orthosteric binding of GABA to the 
ion channel. Once bound to GABA, the receptor changes conformation within the membrane, 
which increases the frequency of opening of the chloride ion channel. This effect results eventually 
in a decrease in the membrane potential (Figure 5). This hyperpolarization of the neurons further 
inhibits neuronal transmission, which results in sedative, anxiolytic, hypnotic, amnesic, and 
anticonvulsant in the CNS, as well as muscle relaxant effects. BzR ligands are not able to influence 
the intrinsic chloride ion channel in the absence of GABA; however, they can mediate the ion 
influx and change the opening frequency of the complex as allosteric modulators.60-62 The BZDs 
that are able to interact with GABAA/BzR fall into three categories: agonist, inverse agonist, and 
antagonist. BZD agonists, termed positive allosteric modulators (PAM), are the compounds that 
can increase the chloride ion influx and further enhance the actions of GABA. It should be noted 
that BZD PAMs do not bind at the GABA binding site as other agonists by definition. On the other 
hand, the inverse agonists, termed negative allosteric modulators (NAM) bind to the BZD site and 
elicit the opposite effect and reduce the GABA-induced chloride ion influx. This results in the 
depolarization of the membrane and increases the chance of neuronal firing activity. In addition to 
the full agonists and inverse agonists, the compounds that elicit variable efficacy in between the 
maximum enhancement or reduction as a partial effect are considered as partial agonists and partial 
inverse agonists,10 respectively. The third type of BZDs (antagonists)2 do not enhance nor impair 
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the action of GABA, which results in no pharmacological effect. However, these antagonists block 
the interaction of  PAMs and NAMs at the BzR site because of their more potent binding affinity 
for BzR sites over other BZD ligands.18 Consequently, because of the ability to occupy the BzR 
site and restrict the binding of other BZDs, antagonists such as flumazenil, βCCt and 3PBC are 
commonly used to reverse the effects of a BZD-mediated response. Flumazenil, for more than 40 
years, has been employed as an antidote to reverse BZD overdose.63  
 
Figure 5. The membrane potential overtime when a depolarizing stimulus initiates a nerve signal. A 
hyperpolarized state indicates a potential further away from the threshold potential. (Modified from the Figure 
in the Ph.D. thesis of Terry Clayton)64 
 
The concept of the multiplicity of GABAAR subtypes and BZD allosteric modulation are 
essential for the understanding of the complex pharmacological effects from GABAAR, as well as 
a guide for further ligand design for the treatment of different CNS disorders. For instance, ligands 
that are α1 subtype selective agonists can be used as hypnotic and sedative agents. On the other 
hand, α1 subtype selective antagonists are suitable for reversing the hypnotic, ataxic, amnesic or 
sedative effects as well as the respiratory depression of clinical BZDs. Most importantly, ligands 
which exhibit α2/3/5 or α2/3 subtype selective agonist or partial agonist activity with α1 subtype 
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antagonist effects, or inverse agonists, or no α1 subtype efficacy at all, can elicit desirable effects 
to treat anxiety disorders, convulsions, diabetic neuropathy, neuropathic pain, inflammatory pain, 
complex regional pain disorders, fibromyalgia, and panic disorders etc. with little or no sedative 
effects from α1 subtype efficacy. Furthermore, α5 subtype selective inverse agonists have been 
shown to be effective in improving learning and memory deficits without causing unwanted side 
effects from inverse agonist effects (anxiety, convulsions) at the α1 subtype. Thus, the variable 
efficacy at different subtypes can be employed, accordingly, to develop a specific spectrum of 
pharmacological effects. 
 
1.4. Molecular Modeling – Pharmacophore Model 
Although BZDs posses a series of important CNS pharmacological effects clinically, the 
further improvement and design of novel BZDs in recent years has been hampered due to the 
failure of numerous attempts to crystallize the transmembrane protein GABAAR, especially the 
most critical recombinants of α1-6β1-3γ2. Consequently, previous to the solution of the structure of 
the α1β3γ2 ion channel this year by electron microscopy, fragment-based molecular modeling, and 
structure-activity relationship (SAR) studies were considered the best two methods to investigate 
the overall effects of BZDs, as well as to develop new drugs which have more selectivity to treat 
specific diseases.   
Over the past few decades, based on in vitro binding affinities at BzR subtypes of more 
than 150 BZD ligands including all three types: agonists, inverse agonists, and antagonists,18, 65-67   
the Unified Pharmacophore/Receptor Model has been developed18, 65-66 in Milwaukee.67 Subtype 
selective ligands for each α1-6β2/3γ2 GABAAR from 15 classes of structural families such as  
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BZDs,68-69 β-carbolines,70-72 triazolopyrimidines,73 pyridodiindoles,74-75 imidazopyridines76, and 
pyrazoloquinolines.77 were overlaid on a planar template ligand within the BZD binding site to 
generate the approximate binding pockets. Illustrated in Figure 6 are the locations and descriptors 
of the two-dimensional representation of the comprehensive pharmacophore model. The model 
consisted of four critical descriptors used as anchor points and assigned as H1 (Y210), H2 (H102), 
A2 (T142) and L1, where H1 and H2 represent two hydrogen bond donor sites on the protein, A2 
represents one hydrogen bond acceptor site important for inverse agonist action in vivo, and L1 
represents a lipophilic pocket. In addition, there are three additional lipophilic regions (L2, L3, and 
LDi), where the interactions between the ligand and the protein are mediated by van der Waals 
interactions, as well as p – π and π – π stacking. Moreover, three negative steric repulsive regions 
(S1, S2, and S3) have been proposed as well, which represents the proteins themselves. The 
extracellular domain lines in the region of carbon atoms 6 and 7 in the LDi region.




Figure 6. The locations of the descriptors and areas of the Milwaukee-Unified Pharmacophore/Receptor Model 
for BZD at GABAAR BzR. Depicted here is pyrazolo[3,4-c]quinolin-3-one CGS-9896 as a dotted line, a 
diazadiindole as a thin line, and diazepam as a thick line aligned within the unified pharmacophore/receptor 
model for the BzR. H1 and H2 stand for the hydrogen bond donor sites within the BzR, while A2 stands for a 
hydrogen bond acceptor site that may be necessary for potent inverse agonist activity in vivo.  L1, L2, L3, and 
LDi represent the four lipophilic regions and S1, S2, and S3 represent the regions of negative steric repulsion. LP 
stands for the lone pair of electrons on the nitrogen (N) or oxygen (O) atoms of the ligands. (Modified from the 
Figure in Clayton et al.)18 
 
From the ligand docking study at the BzR via use of the pharmacophore model, several 
important trends were proposed to explain the relationship between subtype selectivity and the 
ligand structure (Figure 7), which were extremely valuable for the future ligand design and 
modification.18 1. There is a slight difference between the induced volumes of α1 and α2 subtypes 
in the region L2. 2. The included volume demonstrated that the size, lipophilicity, and shape of the 
binding pocket of the α2 and α3-containing GABAAR subtypes are very similar to each other. 3. 
The examination of the induced volume of the α4, and α6 subtypes indicated that the volume of 
the α4 subtype is smaller than that of α6 subtype, especially in the L2 and LDi regions. 4. By viewing 
the overlap of the included volume of the α1 subtypes vs the α4 and α6 subtypes, it is clear that 
the L3 lipophilic pocket is almost non-existent in α4 and α6 subtypes. This explains why these two 
subtypes are DI sites, as compared to other subtypes since they lack the binding pocket for the 
pendant phenyl ring present in most of the BZDs and IMDZs. 5. The volume of the L2 region in 
α5 subtypes is somewhat larger than in the α1 subtypes as well as the α2 and α3 subtypes. This is 
an important feature for α5 subtype-selectivity with decreased binding at α1 subtypes. For instance, 
a switch from a chlorine atom (diazepam) to an ethinyl group (QH-II-66) at the C(7) position 
(Figure 8),65, 78 altered the ratio of α5 over α1 subtypes from 1.27 to 11.22, which significantly 
increased the selectivity at the α5 subtype in comparison to the binding affinity of the α1 subtype 
at the same time and led to a potential anticancer drug, QH-II-66. Furthermore, a recent study by 
Mohler et al. has demonstrated that the development of tolerance to the antinociceptive effects of 
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BZD’s resulted from the coupling of α1 to α5 subtypes.79 Therefore, the strategy of limiting the 
binding affinities and efficacy at both these subtypes has provided a series of compounds that 
exhibited antinociceptive activity with no observation of the development of tolerance in 
agreement with the effect proposed by Mohler 80-82 in the area of anticonvulsant drugs. Recall that 
clinical BZDs are active against status epilepticus in humans for about 3 days, whereas α2/α3 
subtype selective ligands appear to be devoid of the development of tolerance in convulsions 
and pain in animal models (ASPECT talk, April 9th 2019, Orlando, FL) 
 
Figure 7. Overlap images between the induced volumes derived from receptor subtype selective ligands: a) α1 
and α2 subtypes; b) α2 and α3 subtypes; c) α4 and α6 subtypes; d) α1 and α6 subtypes; e) α1 and α5 subtypes; 
f) diazepam and the descriptors of the unified pharmacophore model in the included volume of the α1 subtype. 





Figure 8. Bz/GABAAR in vitro binding data of diazepam and QH-II-066. (Modified from the Figure in the Ph. 
D. thesis of M. Poe and T. Clayton) 65, 78 
 
Over the past few years, the updated pharmacophore model and homology model for α5 
GABAAR subtypes has been published by Clayton, et al. in 2015.
67 In addition to the binding 
affinities and updated compound library, a new lipophilic region L4 was identified with the chiral 
methyl enantiomers at the C(4) position from the IMDZ class: the α5 subtype-selective ligand SH-
053-2'F-R-CH3 (1), and its enantiomer the α2/3/5 subtype-selective ligand SH-053-2'F-S-CH3 
(2),83 see Figure 9. This recent work indicated that the new binding pocket (L4) was only located 
in the α5 subtype, and was not present in the α2 or α3 subtypes. Both enantiomers (R and S) can 
fit in the binding pocket of the α5 subtype (see included volume). However, the pendant phenyl 
ring of the R-isomer (1) did not fit in the binding pockets of the α2 nor α3 subtypes. This phenyl 
group protruded outside of the included volume, which resulted in no efficacy for the R-CH3 
isomer at α2 nor α3 subtypes (Figure 10). On the other hand, the S-isomer (2) was very well 
accommodated in all three α2, α3, and α5 subunits, since α2 and α3 subunits share a similar shape 
and size. Taken together, the results from the pharmacophore model are consistent with the 








Figure 10: Ligand occupation of SH-053-2'F-R-CH3 (1) and SH-053-2'F-S-CH3 (2) in the 𝛼5 and 𝛼2 




1.5. Research Objectives 
With the aid of the unified pharmacophore model, the first goal of this research was to 
design and synthesize a series of novel optically active BZD compounds that have good or better 
binding affinity and efficacy at BzR, but are devoid of the BZD side effects by reducing the 
efficacy or affinity at the α1 subtypes. It was also desirable to reduce the efficacy at both α1 and 
α5 subtypes to limit the development of tolerance.80-82 The new ligands were not only employed 
in the study of the SAR but also in the pharmacological effects of the potential drugs on individual 
or a combination of GABAAR subtypes. The ligands necessarily had to be evaluated in different 
in vitro assays and in vivo animal models to further determine their effectiveness in the treatment 
of diseases such as asthma, schizophrenia, MDD, anxiety, epilepsy as well as pain disorders. In 
addition to the development of potential new drugs, the second goal of the research was to improve 
the synthesis of several key compounds on a larger scale for better yields, as compared to the 
previous routes. This was necessary in order to provide an efficient and consistent supply of the 








Chapter 2. Design and Synthesis of Chiral α2/α3/α5 or α5 Subtype 
Selective Ligands and Their Use for the Treatment of Schizophrenia, 
Major Depressive Disorder as well as Asthma 
2.1. Introduction of Chirality in Drug Design 
Chirality, a geometric property, is a universal phenomenon that exists in microscopic 
objects at the molecular level, and in macroscopic objects as well, such as proteins, and key 
components of living creatures in nature.  A chiral object has two forms, termed enantiomers. 
These asymmetric enantiomers are non-superimposable  mirror-images to each other.84-86  It is 
well known that chirality plays an essential role not only in the field of chemistry but also in 
people’s daily life. The concept of chirality has widely been applied to flavors, agricultural agents 
and especially medications.  Long before the development of the pharmaceutical industry or even 
the knowledge of chirality, medicines were usually given as a single enantiomer, since they were 
derived from crude extracts or semi-synthetically from plants or animals without enantiomeric 
purification.84 However, since the rapid development of total synthesis in the pharmaceutical 
industry in the 1950s, most of the drugs at that time were racemic. This was due to optically 
inactive starting materials and racemic preparations. There were also less restrictions by the federal 
governmental, the Food and Drug Administration (FDA). The thalidomide tragedy87 raised the 
concern of chirality in drug development and at the FDA. The (S)-enantiomer of thalidomide 
caused a series of severe birth-deficits, and unfortunately, use of the pure (R)-isomer itself would 
not prevent the problem, due to the spontaneous racemization in the body (Figure 11).85-86 Since 
the 1990s, the FDA announced a series of regulations for the requirement of stereochemically pure 
drug submissions, which significantly reduced the use of racemates for the treatment of diseases 
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to avoid possible issues. However, these restrictions also raised the cost of drug development 
significantly.  
 
Figure 11. The structures of both enantiomers of thalidomide. 
 
In addition to the brief history of chiral drugs, clinical studies have also clearly illustrated 
that the enantiomers of a racemic drug usually exhibited differences in activity, metabolism, 
pharmacokinetics (PK), toxicity, absorption, excretion, etc., and most importantly in potency. One 
enantiomer maybe pharmacologically active, whereas the other enantiomer may be inactive, have 
the same effect, a different phenotype or a completely opposite effect,86 as well as an important 
antagonist at this receptor. Furthermore, the “chiral switch” might be used as a strategy to extend 
patent life and establish an improved profile for previously developed racemic drugs,84 which was 
illustrated clearly by the development and use of a pure enantiomer of Prozac in the clinic by 
Sepracor to overcome the Lilly patent.  
Since more and more evidence has demonstrated the importance of chirality in different 
fields, the synthesis of stereoselective compounds has become a popular topic worldwide. In recent 
years many methods have been developed and employed for production and separation of the 
enantiopure compounds, including enantioselective catalysis, internal asymmetric induction, 
external asymmetric acid-base reactions for the resolution of diastereomeric salts, and chiral high-
performance liquid chromatography (HPLC).88-89  
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Taken together these facts suggest that it is very important to keep chirality in mind while 
designing new ligands. Over the past decades, based on the Milwaukee-unified pharmacophore 
model,18, 65-67 a series of enantiopure ligands have been designed, synthesized and studied in 
different in vitro assays and in vivo animal models. According to the data up to date, it has been 
well demonstrated that the R and S 4-substituted chiral IMZDs exhibit different subtype selectivity 
at Bz/GABA(A)ergic receptors. It has been shown that the ligands which contain a chiral (S)-
methyl group at the C(4) position of the IMDZ tend to be α2/3/5 subtype selective ligands, whereas 
the (R)-isomers are α5 subtype selective ligands.83 This is an important finding by the group in 
Milwaukee. Based on the different subtype selectivity profiles, the two enantiomers behaved 
differently in animal models, as expected, and exhibited completely opposite metabolic rates on 
human liver microsomes (HLM).90 This will be further discussed in later chapters. In this vein, 
one specific goal for this research was to design and synthesize a series of novel stereospecific 
enantiomers for the application to different disorders, such as schizophrenia, MDD, anxiety, 
epilepsy, pain as well as asthma depending on their subtype selectivities. This early strategy 
focused entirely on ligands that interacted with α2, α3 or α5 subtypes, with little or no efficacy or 









2.2. Schizophrenia and Major Depressive Disorder (MDD) 
Section 2.2.2. to Section 2.2.3.2. of this dissertation have been adopted from the following article: 
• Li, G.; Stephen, M. R.; Kodali, R.; Zahn, N. M.; Poe, M. M.; Tiruveedhula, V. V. N. P. B.; 
Huber, A. T.; Schussman, M. K.; Qualmann, K.; Panhans, C. M.; Raddatz, N. J.; Baker, D. 
A.; Prevot, T. D.; Banasr, M.; Sibille, E.; Arnold, L. A.; Cook, J. M., Synthesis of chiral 
GABAA receptor subtype selective ligands as potential agents to treat schizophrenia as 
well as depression. ARKIVOC 2018, iv, 158-183. 
 
2.2.1. Introduction  
Schizophrenia is one of the most complex central nervous system (CNS) disorders known. 
Approximately 1% of the population worldwide91 is affected by this disease. The symptoms fall 
into three broad categories: positive symptoms including hallucinations and delusions; negative 
symptoms such as the blunted affect, social dysfunction and lack of motivation or pleasure in daily 
life, and cognitive abnormalities. For instance, in the disruption of cognition, symptoms such as 
impairments in working memory, verbal memory, attention and executive deficits, which can lead 
to severe emotional distress, are prominent.91 The treatments commonly used to manage positive 
symptoms are typical and atypical antipsychotic drugs, which target and block the over-activation 
of dopamine receptors92 in patients with schizophrenia. In fact, the drugs prescribed, to date, only 
reduce the positive symptoms in the majority of schizophrenia patients. They are often not 
effective especially in patients with negative symptoms and cognitive abnormalities.93 Moreover, 
the antipsychotics in many patients induce adverse effects such as tolerance, addiction, sedation, 
drug-resistance, weight gain and liver toxicity.94 The lack of proper medications and limited 
23 
 
efficient psychosocial therapy together increase the psychological and financial burden rapidly not 
only for the patients and their family but also for society as a whole. Consequently, there is an 
urgent clinical need for novel drug candidates that can address all aspects of schizophrenia 
including the alleviation of the negative and cognitive symptoms with decreased side effects. 
 
2.2.2. Background 
It is well known that asymmetry plays an essential role in physiological processes; 
therefore, a large number of drugs are chiral molecules, in which one enantiomer of a drug may 
have the desired beneficial effect, while the other enantiomer may cause serious adverse effects.88-
89 This was observed with thalidomide.87 Based on our earlier established BZD/GABAA 
pharmacophore model18 that was developed by ligand binding data, a series of chiral molecules 
have been designed, synthesized and studied. Ligand SH-053-2'F-R-CH3 (1) was the lead 
stereospecific GABAAR α5-subtype selective positive allosteric modulator (PAM) because of the 
chiral (R)-methyl group at the C-4 position of the imidazodiazepine (IMDZ) nucleus, as shown in 
Figure 9. This resulted in increased potency at α5 GABAA receptor subtypes, accompanied by a 
concomitant decrease at the α1, α2, and α3 subtypes. This α5-selective ligand has been reported to 
successfully alleviate the hyperactivity of the dopamine system induced by amphetamine in the 
methylazoxymethanol acetate model (MAM) of schizophrenia.95-96 Moreover, this ligand 1 in an 
animal behavioral model of depression exhibited anxiolytic and antidepressant effects in female 
mice that were exposed to unpredictable chronic mild stress (UCMS) in a sex-dependent manner. 
The effects on male mice in the same paradigm were very weak or none at all.97 Furthermore, 
analogs of 4(R)-CH3 enantiomer 1, such as the methyl amide MP-III-022 (35),




99, etc., which are more potent at the α5-subtypes than 1, have also 
been investigated and undergone a number of behavioral studies.56, 58  
In order to study how the chirality at the C-4 position of IMDZ could affect the 
pharmacological response, the enantiomer of 1, SH-053-2'F-S-CH3 (2) was synthesized.
82 As 
expected, these two enantiomers exhibited vastly different GABAergic efficacy and binding 
affinity at Bz/GABA(A) receptor sites. Ligand 2 was found to be an α2-, α3-, α5-β3γ2 subtype 
selective IMDZ, while 1 was an α5 subtype selective ligand. Since 1 and 2 both target the α5-
subunit, they have been assayed in several behavioral models. Examination of the results revealed 
2 exerted anxiolytic effects in both rhesus monkeys100 and rats101, while 1 had only a minimal 
anxiolytic effect when much higher doses were applied. Interestingly 2 also successfully mitigated 
the amphetamine-induced hyperactivity in a poly (I:C) animal model of schizophrenia.102  
The results of these studies indicated that both enantiomers might be useful in the treatment 
of the symptoms of schizophrenia, while the α2/3/5 agonist 2 exhibited the potential for the 
treatment of conditions comorbid with schizophrenia, such as anxiety, which commonly coexists 
in patients with schizophrenia. Unfortunately, during other studies, ligand 2 was shown to be 
metabolized at a very high rate in vitro in the presence of human liver microsomes (HLM);103 3% 
of 2 remaining after incubation at 37 oC for 30 minutes, while ligand 1 was stable in HLM with 
100% remaining under the same conditions, as presented in Table 2. The principal aim of this 
research was to improve the metabolic stability of the ester functional group while retaining the 
properties potentially useful for the treatment of schizophrenia and depression. Schizophrenia and 
some forms of depression (bipolar I disorder and perhaps major depressive disorder) are linked 
both genetically and etiologically. Herein we present the synthesis and characterization of novel 
analogs of SH-053-2'F-S-CH3 (2) including esters, thioesters, amides, carboxylic acids and the 
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ester bioisostere oxadiazoles at the C(3) position together with modifications at the C(8) position. 
The newly designed ligands were prepared and investigated in in vitro metabolism studies, 
cytotoxicity assays and in vivo in mice with a rotarod study to identify ligands with a lower 
systematic clearance rate, low toxicity, little or no sedative/ataxia activity, which might be useful 
in the management of the symptoms schizophrenia18 and depression.96 This go/no-go point is 
important for the development of a safe treatment for schizophrenia and depression that can occur 
at any age. 
Table 2. In vitro liver microsomal stability of 1 and 2. 
Ligand 
Liver microsomal stability (%-remaining) 







SH-053-2'F-R-CH3 (1) 100.0 90.3 59.1 5.4 
SH-053-2'F-S-CH3 (2) 2.3 90.7 66.5 6.0 
a
 Human liver microsomes (HLM), 
b
 dog liver microsomes (DLM), 
c
 mouse liver microsomes (MLM), and 
d
 
rat liver microsomes (RLM). 
 
2.2.3. Chemistry and Results 
2.2.3.1. Comparison of Enantiomers  
2.2.3.1.1. Synthesis of SH-053-2'F-R-CH3 (1) and SH-053-2'F-S-CH3 (2) 
Both enantiomers were resynthesized on a large scale for the SAR of the analogs. The 
preparation of both 1 and 2 followed the same synthetic route with similar yields. The chirality 
difference was achieved by using N-Boc-D-alanine for the chiral building block of the R-isomer 
(1), whereas N-Boc-L-alanine was employed for the S-enantiomer (2), as demonstrated in Scheme 
1 and Scheme 2, respectively.  
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For the amidation reaction, N-Boc-D-alanine was coupled with the commercially available 
(2-amino-5-bromophenyl)(2-fluorophenyl)methanone 3 by using a dehydrating agent N,N'-
dicyclohexylcarbodiimde (DCC) to afford amide 4 in 97 % yield on a 150-gram scale. Note, DCC 
should be first dissolved in DCM to form a homogenous solution, which was then added 
dropwise to the mixture of alanine and benzophenone 3 in DCM at 0 ˚C. If DCC was added 
in one portion or at rt, a dimerization to a dimer of DCC urea would occur due to the concentration 
of DCC. Moreover, the quality of DCC also affected the yield of this reaction significantly. The 
DCC should be stored properly to avoid moisture and the solvent should be anhydrous. The 
reaction progress was monitored by HPLC/PDA (Shimadzu LCMS 2020 instrument) and the 
molecular mass of the unwanted dimer (m/z 450) was observed in the mass spectra when an 
improper addition operation was carried out; see Appendix A for the HPLC/PDA Analysis Report 
for details. The  Boc-deprotection step was carried out by stirring the amide 4 in a saturated 
solution of HCl gas in DCM at 0 ˚C for 1 hour, and this was followed by the cyclization to the 7-
membered ring in the 3:2 ratio of methanol and water mixture after adjusting the pH to 8.5 with 2 
N aq NaOH solution. The desired 1, 4-benzodiazepine 5 precipitated out of the solution in 73 % 
yield. A mild exotherm was observed, as expected, during the slow addition of a saturated aq 
NaHCO3 solution workup. The recrystallization of the benzodiazepine 5 was conducted in a 
mixture of EtOAc and hexanes in a ratio of 1:9 after adding seed crystals. The imidazole ring was 
prepared by the treatment of the benzodiazepine 5 with potassium t-butoxide and diethyl 
chlorophosphate at -50 ̊ C, and this was followed by addition of ethyl isocyanoacetate and a second 
portion of potassium t-butoxide at -78 ˚C. This gave the desired IMZD 6 in 75 % yield. The 
majority of this bromide 6 can be recrystallized from methyl t-butyl ether or EtOAc after cooling 
from 60 ˚C. An additional portion was obtained by purification of the mother liquor by flash 
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column chromatography (silica gel, EtOAc:hexane, 3:2). This chiral bromide 6 was then reacted 
with trimethylsilylacetylene in the presence of a palladium catalyst via a Heck-type coupling 
reaction to obtain the TMS-analog 7 in 78 % yield, or via an alternative coupling reaction by 
mixing the TIPS-acetylene, palladium acetate, tri(O-tolyl)phosphine and the bromide 6 in one pot 
under refluxing conditions for 4 hours. This second procedure gave the TIPS acetylene analog 8 
in an improved yield (86 %). This latter Greg Fu-type process was easier to handle for no 
degassing was needed, and the catalyst was generated in situ. Moreover, the TIPS-product 8 
has a higher Rf value than the TMS-analog, which resulted in a much easier purification by 
flash column chromatography, as compared to the purification of the TMS-analog 7.  The 
fluoride-mediated desilylation was executed by stirring 7 or 8 with tetra-n-butylammonium 
fluoride in THF to provide 1 (SH-053-2'F-R-CH3) in 96 % or 90 % yield, respectively, as shown 
in Scheme 1. The S-isomer SH-053-2'F-S-CH3 2 was prepared by utilizing the same route but with 
N-Boc-L-alanine in place of N-Boc-D-alanine in the first step. The yield of each step was similar 









Scheme 2. Synthesis of SH-053-2'F-S-CH3 (2). 
 
2.2.3.1.2. Biology on the R and S Enantiomers 
The characterization of the biology of lead compound 2 was carried out simultaneously 
with the synthesis and assessment of novel analogs. Due to the ability of 2 to potentiate the α5 
containing GABAAR as well as the α2 and α3 subtypes, while inactive at the α1 containing 
GABAAR, which mediates sedation and other adverse effects, ligand 2 was evaluated in behavioral 
models in direct comparison with its enantiomer 1. For cataleptic behavior in the studies of 
schizophrenia,104 the control antipsychotic, haloperidol, elicited a significant cataleptic response. 
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In contrast, both the C(4)-methyl substituted ligands 1 and 2 did not show any signs of the catalepsy 
(side effect) in comparison to the vehicle, as illustrated in Figure 12. Moreover, in the prepulse 
inhibition (PPI) assay, which was used as a classical animal model of schizophrenia, the S-isomer 
2 significantly reversed the PPI deficit induced by phencyclidine hydrochloride (PCP), an N-
methyl-D-aspartate (NMDA) antagonist.105 Ligand 1 did antagonize the deficit compared to the 
vehicle but failed to reach a significant effect at the same dosage, as depicted in Figure 13. 
However, the results on PPI with the R-isomer 1 were trending toward significance but would have 
required a larger number of animals to reach significance which was cost limiting. Additionally, 
in the 6 Hz electroshock (3 seconds duration) assay, both ligands were evaluated for their ability 
to protect against epileptic seizures. As shown in Figure 14, ligand 2 was able to protect mice from 
the electroshock-induced seizures at all time points (1/4, 1/2, 1, 2, and 4 hours), which was 
predicted due to the activation of α2 and α3 subtypes (Figure 14A) as well as α5 subtypes. However, 
the R-enantiomer (α5) 1 was not effective at any time at a relatively higher dose in the 6 Hz 
paradigm. For the rotarod (n=8) assay, neither 1 nor 2 produced any ataxia or sedation at 100 
mg/kg i.p. in mice (Figure 14B). This was in complete agreement with the poor efficacy at α1β3γ2 






































Figure 12. Impact of 1 or 2 treatment (30 mg/kg, i.p.) on cataleptic behavioral. Haloperidol, but not 1 nor 2 
produced a significant cataleptic response at 30, 60, and 120 minutes post-injection. The data are expressed as 
the mean (+SEM) time (sec) subjects spent with both front paws on an elevated bar; *p<0.001, the difference 




































Figure 13. Impact of 1 or 2 treatment (30 mg/kg, IP) on prepulse inhibition. Ligand 2, but not 1 reversed the 
PPI deficits induced by PCP when given one hour before testing. The data are expressed as the mean (+SEM) 
percent prepulse inhibition of the startle response to an auditory stimulus when preceded by a nonstartle-
eliciting auditory cue at 5, 10, and 15 decibels. Disruption of prepulse inhibition was obtained in rats by an 
acute injection of phencyclidine (PCP·HCl, 1.5 mg/kg, SC) ten minutes prior to testing; *p<0.05, difference 


































































Figure 14. Impact of 1 or 2 treatment on anticonvulsant effects. A) Mice were dosed i.p. with either 1 (150 
mg/kg) or 2 (100 mg/kg) and a 6 Hz shock by a corneal electrode was administered at various time points, and 
the animal observed for convulsions. Ligand 2 was able to protect some subjects while 1 was not able to protect 
mice from electroshock-induced seizures. B) In the rotarod assay, mice were dosed i.p. with 1 or 2 (100 mg/kg) 
30 minutes prior to testing on a rotating rod (6 rpm). Mice that fell 3 times during a 1-minute trial were deemed 
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toxic (ataxic or sedated). Also there was no indication of toxicity nor sedation  in rhesus monkeys at 10 mg/kg 
(Fischer, et al, 2010).83 
 
2.2.3.2. Analogs of the S-isomer 
2.2.3.2.1. Synthesis of Analogs of SH-053-2'F-S-CH3 (2) 
Previously, evidence from the ligand-based GABAAR pharmacophore/receptor model and 
SAR18, 67 have indicated that subtle changes in the IMDZ substituents will affect the 
BzR/GABA(A)R subtype selectivity dramatically. For instance, the loss of the chiral methyl group 
at the C(4) position will decrease the α5-subtype selective efficacy, while the efficacy at α2/α3-
β3γ2 GABA(A)ergic subtypes will increase dramatically. Efficacy at the α1 subtype will increase 
with a 2'-F substituent on the C(6) pendent phenyl ring, but the 2'-N and 2'-H analogs remain α2/α3 
subtype selective. It has also been shown that the α5 selectivity can be modified by the presence 
of different lipophilic groups at the C(8) position. Analogs, which have been optimized at the C(3) 
position demonstrated higher affinity and potency at α5-106 or α2/3-107-109 subtypes, which led to 
better and longer physiological effects. For these reasons, the C(3) and C(8) positions are 
considered to be the optimal regions for ligand improvement. To evaluate the modification of the 
lead compound 2 at these two positions, a series of novel analogs were designed, synthesized and 





Figure 15. Chiral analogs and bioisosteres of the lead compound S-isomer 2. 
 
As mentioned earlier, the C(8)-acetylene and C(4) methyl function were found to enhance 
the α5-subtype selectivity, therefore a cyclopropyl group, which is commonly incorporated into 
biologically active materials, was introduced into the parent compound 2 as a substituent to extend 
the SAR. As a result of its flexible rotation at the C(8) position, it should fill a similar volume of 
electron density as the ethynyl moiety. Consequently, it might be expected to exhibit parallel 
physiological effects and enhanced subtype selectivity due to similar interactions in the lipophilic 
binding pocket (L2, see Figure 6).87 Moreover, the metabolism by liver microsomes would be 
expected to be different for a cyclopropyl substituent as compared to an ethynyl functional group. 
Hence, the C(8)-substituted cyclopropyl analog GL-I-78 (13) was prepared based on this 
hypothesis. The cyclopropyl ligand 13 was synthesized from cyclopropyl boronic acid via a 
Suzuki-coupling reaction110 with the aryl bromide SH-I-48B (15), whose synthesis had been 
previously described. 48 The coupling reaction was carried out in the presence of potassium 
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phosphate and a 10 mol% Pd-catalyst, bis(triphenylphosphine)palladium(II) diacetate, in toluene 
at 100 oC for 12 hours. This process was executed in good yield (82%), as shown in Scheme 3. 
 
Scheme 3. Synthesis of 8-cyclopropyl-4-(S-CH3) imidazodiazepine 13 from bromide 14.48 
 
Based on the results described previously, the ethyl ester 2 was rapidly degraded in the 
HLM, which suggested modification of the ester might play an essential role in metabolism, as 
well as efficacy, as compared to the lead compound 2. Therefore, a series of esters, which 
contained different alkyl groups other than ethyl were synthesized. The synthesis of the C(8)-
bromo methyl ester MP-III-059 (14) and the C(8)-ethynyl methyl ester MP-III-021 (16) were 
achieved in the presence of sodium methoxide in methanol in good yields, as depicted in Scheme 
4. The majority of the reactions were carried out via a transesterification process111 with pieces of 
freshly cut lithium rod in the presence of alcohols in THF at 40 oC for 0.5 hours to generate the 
corresponding alkoxides. To this solution, ester 2 was added, which had been dissolved in dry THF, 
and full conversion was observed after 15 to 30 minutes. New ester analogs generated via this 
general route were: propyl ester GL-I-32 (17), isopropyl ester GL-I-31 (18), t-butyl ester GL-I-30 
(19) and 2-methyl butyl ester GL-I-33(20), respectively. The yields were good to excellent (77-
97%), as illustrated in Scheme 5. However, the trifluoroethyl ester GL-I-36 (21), and the 
cyclopropyl ester GL-I-38 (22) were not obtained under these conditions due to electronic and 
steric effects. As a result, both analogs were prepared by an alternate procedure. The ester 2 was 
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saponified to form the carboxylic acid, SH-053-2'F-S-CH3-acid (23), with sodium hydroxide in 
ethanol at reflux for 1 hour in nearly quantitative yield (99%) after acidic workup, as illustrated in 
Scheme 6. The subsequent reactions for the synthesis of ester 21 and 22 were conducted with 
thionyl chloride in dichloromethane at reflux to give the acyl chloride, which was converted into 
ester 21 and 22 on addiction of 2,2,2-trifluoroethanol and cyclopropanol, respectively. 
Additionally, it must be pointed out that the acid 23 was synthesized not only because it was an 
important intermediate for the majority of the analogs, but also because the enantiomer (R)-CH3 
carboxylic acid in the C(4)R-isomer series significantly increased the α5-subtype selectivity and 
potency.98 It was hoped that the acid 23 in the C(4)S-isomer series might effect a similar increase 
in the selectivity and potency at the α2/α3/α5-subtypes.  
 
Scheme 4. Synthesis of methyl esters 14 and 16 from ethyl ester 15 or 2, respectively.48    
                                                                                                                                                                                                                                                         
 




In a previous study, it was shown that a heteroatom attached directly to the carbonyl at C(3) 
would affect the GABAAR subtype selectivity. For example, a thioester function at C(3) in the 2'N 
series exerted no efficacy at the α1-subtype even at higher concentrations in comparison with the 
corresponding oxygen substituted ester, but with a slightly higher preference for the α3-subtype.112 
Therefore, it was decided to replace the oxygen atom in lead compound 2 at the C(3) position with 
a sulfur atom. The thioethyl ester GL-I-77 (24) was synthesized from the carboxylic acid 23 
following the general procedure as mentioned below in Scheme 6 with ethanethiol as the 
nucleophile. 
Besides the slight changes in steric effects, as compared to lead ester 2, the amide analogs 
are well-known stable replacements for metabolically labile ester moieties. The amides were 
considered to be important replacements for ester functions to improve the in vivo stability, as well 
as the bioavailability when compared to the stability of esters. To evaluate the potential activity of 
the amides in regard to future SAR, a series of amide analogs 25-30 were synthesized to enable a 
comparison between esters and amides in regard to in vitro metabolic stability, cytotoxicity and in 
vivo locomotor activity. The methyl amide MP-III-023 (25) was prepared by the direct amidation 
of ethyl ester 2 in the presence of methylamine in dichloromethane in a sealed tube. As indicated 
in Scheme 6, the rest of the amide analogs were synthesized from carboxylic acid 23 via an acyl 
chloride intermediate, using the corresponding primary or secondary amine as the nucleophile. 
This process gave the ethyl amide GL-I-43 (26), cyclopropyl amide GL-I-55 (27), isopropyl amide 
GL-I-57 (28), t-butyl amide GL-I-41 (29) and dimethyl amide GL-I-54 (30), respectively, in good 




Scheme 6. Synthesis of analogs 21-30. 
 
Ester bioisosteres have been utilized commonly in drug design in order to render them 
metabolically more stable than the corresponding esters with less adverse effects and to provide 
better clinical candidates.113 The previous results 98,114 indicated that replacement of ester functions 
by substituted 1,2,4-oxadiazoles significantly increased the in vitro and in vivo stability, as well as 
slightly improved the hydrophilicity of the ligands. Moreover, the efficacy at BZD receptors was 
enhanced, as compared to the corresponding ester ligands as well. Encouraged by this previous 
evidence, the substituted 1,2,4-oxadiazoles 31-33 were designed and synthesized from lead 2. The 
condensation of the ethyl ester 2 and corresponding amidoximes in the presence of sodium hydride 
in THF was employed to prepare the C(3)-substituted oxadiazole ligands, respectively. This route 
was successfully applied previously with achiral ligands at the C(4) position.113 However, the 
desired oxadiazoles with the C(4) chiral methyl group were obtained only in moderate yield (30-
40%). The reason for this low yield was the formation of a byproduct (50-60% yield), in which 
the C(5)-C(6) imine bond isomerized to the C(4)-C(5) position. As a result, the chirality at the C(4) 
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position was lost. To overcome this problem, the amount of strong base, sodium hydride, which 
could readily lead to isomerization of the imine bond, was reduced from 4 equivalents to 1.1 
equivalents. In addition, the amidoxime was stirred longer with NaH before the ester was added to 
the mixture. This process gave methyl oxadiazole GL-I-65 (31), ethyl oxadiazole GL-I-66 (32) 
and isopropyl oxadiazole GL-I-81 (33) in improved yields of 79-85%, respectively, as depicted in 
Scheme 7. Moreover, the chirality remained intact. 
 
Scheme 7. Synthesis of oxadiazoles 31-33. 
 
To explore the extent of flexibility of the hydrogen-bond acceptor in the binding pocket 
designed H1 in the pharmacophore/receptor model (see Figure 6),98 it was decided to synthesize 
the linear nitrile at the C(3) position. This substituted group sometimes is employed to increase 
water solubility of a ligand and has been used to reduce the possible oxidative metabolism by the 
liver in clinical studies.115 The nitrile MP-III-018.A (34) was produced from the ester 2 via 
reaction with dimethyl aluminum amine116 in xylene at 80 oC in 75% yield, as shown in 
Scheme 8. The dimethylaluminum amine was prepared freshly by adding trimethylaluminum into 




Scheme 8. Synthesis of the C(3)-substituted nitrile 34. 
 
2.2.3.2.2. Biological Activity: Metabolism, Cytotoxicity and Rotarod Studies 
The parent compound 2, which was prepared in the last section, and its analogs were then 
assayed for metabolic stability in vitro on HLM and mouse liver microsomes (MLM) to identify 
the most stable analogs and the possible trend of steric effects with respect to metabolic stability. 
Moreover, it was important to evaluate stability in both species with respect to applied animal 
models and future treatment with of humans with such a diverse array of functional groups at C(3). 
The results of this study are shown in Table 3. 
 
Table 3. In vitro microsomal stability of analogs of SH-053-2'F-S-CH3 (2). 
Entry  Structure at C(3) 
with C(8)-ethynyl 
Microsomal stability 
(HLM) after 2 hr 
Microsomal stability 










2 ester CO2CH2CH3          < 5
b
      < 5.0
b
   155 ± 9
d
    78.0 ± 0.2
d
    
13  CO2CH2CH3
e          < 5
b
      < 5.0
b
     46 ± 3  16.0 ± 0.4  
14  CO2CH3
f     10 ± 1
d
   2.0 ± 0.3
d
   116 ± 13  41.0 ± 0.6  
15  CO2CH2CH3 
f
          < 5
b
      < 5.0
b
          < 5
b
      < 5.0
b
  
16  CO2CH3   119 ± 21
d
    43.0 ± 0.4
d
      216 ± 28  62.0 ± 0.5  
17  CO2CH2CH2CH3          < 5
c
      < 5.0
c
     24 ± 0
d
    12.0 ± 0.2
d
    
18  CO2CH(CH3)2     57 ± 2
d    47.0 ± 0.2d      227 ± 16d    83.0 ± 0.1d    
19  CO2C(CH3)3   514 ± 115
d
    89.0 ± 0.2
d
      196 ± 20
d
    78.0 ± 0.2
d
    
21  CO2CH2CF3          < 5
a
      < 5.0
a
          < 5
b





22  CO2-cyclopropyl          < 5
a
      < 5.0
a
     19 ± 2
d
    11.0 ± 0.2
d
    
23 acid COOH   358 ± 56  74.0 ± 0.4    139 ± 11
d
    54.0 ± 0.3
d
    
24 thioester COSCH2CH3   101 ± 19  28.0 ± 0.3      46 ± 6    9.0 ± 0.5  
25 amide CONHCH3 1780 ± 39  92.0 ± 0.3    845 ± 5  86.0 ± 0.2  
26  CONHCH2CH3 1978 ± 50  93.0 ± 0.3  1961 ± 46  92.0 ± 0.3  
27  CONH-cyclopropyl 1625 ± 803
d
    89.0 ± 0.4
d
      320 ± 34
d
    72.0 ± 0.3
d
    
28  CONHCH(CH3)2   107 ± 10  38.0 ± 0.5      28 ± 0  75.0 ± 0.3  
29  CONHC(CH3)3   205 ± 14  63.0 ± 0.3    142 ± 9  52.0 ± 0.3  
30  CON(CH3)2     59 ± 5
d
    41.0 ± 0.9
d
        24 ± 2
d
    19.0 ± 0.9
d




3-CH3   866 ± 213  86.0 ± 0.3    443 ± 66  81.0 ± 0.4  
32 3-CH2CH3   563 ± 123  80.0 ± 0.4    213 ± 17  63.0 ± 0.3  
33 3-CH(CH3)2 2584 ± 1920  91.0 ± 0.3    500 ± 109  79.0 ± 0.5  
34 nitrile CN      41 ± 5    9.0 ± 0.3      58 ± 6  17.0 ± 0.6  
a
 Compound was not detected after 10 minutes. 
b
 Compound was not detected after 20 minutes. 
c
 Compound 
was not detected after 30 minutes. 
d
 Compound was assessed at 1-hour pre-incubation time. 
e 
C(8)-cyclopropyl. 
f C (8)-bromo.  
 
The lead compound 2, as mentioned before, was found to be rapidly metabolized on HLM 
with less than 5% remaining after 20 minutes, while 2 exhibited good stability for MLM with 78% 
remaining after 1 hour. Among the ester analogs, 13-19, 21and 22, an increasing trend in metabolic 
stability in HLM was observed as the size of the alkyl chain of the ester function increased. 
However, esters bearing a linear 2-3 carbon chain (13, 15, 17, 21, and 22), regardless of the 
functional group at the C(8) position (-bromo, -cyclopropyl or -ethynyl), were metabolized very 
rapidly with less than 5% remaining after 10, 20, and 30 minutes in HLM. A similar trend was 
observed for MLM; however, the C(8)-bromo and -cyclopropyl replacement of the ethynyl group 
decreased the metabolic stability (see 2 vs 13, 15; 14 vs 16). It is important to point out that the 
introduction of an ester function with a longer carbon atom side chain or a terminal CF3 group 
reduced the metabolic stability significantly, as shown in Table 3; both ligands 15 and 21 were not 
detected anymore after 20 minutes in HLM or MLM, respectively. Most of the esters are only 
slightly more stable in MLM, as compared to HLM, which suggests that longer lipophilic linear 
41 
 
alkyl chains in the ester functional group should be avoided in the ligand design. The carboxylic 
acid 23 was slightly more stable, as compared to the esters. The stability of thioethyl ester 24 for 
HLM was improved slightly compared to ethyl ester 2, which suggests a sulfur atom in place of 
an oxygen atom would provide greater metabolic stability. Electronegativity might play a role here. 
The nitrile 34 was metabolized at a rapid rate with only 9% and 16% of 34 remaining after two 
hours in HLM and MLM, respectively. As expected, the amide analogs enhanced the metabolic 
stability remarkably in both HLM and MLM. Unlike the esters, the trend regarding steric effects 
on the rate of metabolism of the amides was opposite to the esters; ligand, which contained bulkier 
substituents, were less metabolically stable. Presumably, bulkier esters are more lipophilic and 
react faster with CYP450 enzymes of the liver microsomal extract. The ethyl amide 26 exhibited 
the best stability with more than 92% of 26 remaining after 2 hours, as well as the longest half-life 
for both types of liver microsomes among all the amides. The isopropyl amide 28 was the only 
ligand, whose metabolism was a little inconsistent, as a result, the isopropyl ester 18 and amide 28 
shared a similar metabolic pattern. As expected, the replacement of the ester moiety with the 
oxadiazole bioisosteres 31-33 significantly improved the metabolic stability over a two-hour 
period of incubation in both HLM and MLM. It was notable that the isopropyl oxadiazole 33 
exhibited the longest half-life (2584 minutes), as compared to all the analogs investigated in the 
SH-053-2'F-S-CH3 (2) series. In brief, it is clear that the amides and substituted oxadiazole 
functionality at the C(3) position provide the desired ligands with longer half-life values, as 
compared to other functional groups. Further evaluation of these analogs involved a study 
of potential cytotoxicity in both HEPG2 (liver) and HEK293 (kidney) cell lines, as 




Table 4. In vitro cytotoxicity of SH-053-2'F-S-CH3 (2) analogs. 
Entry 
Structure at C(3) 
with C(8)-ethynyl HEK293 LD50 (μM)
a  HEPG2 LD50 (μM)
a 
2 ester CO2CH2CH3   28.0 ± 4.1      73.5 ± 14.4 
13  CO2CH2CH3
b
   58.0 ± 6.0    87.0 ± 6.6 
14  CO2CH3
c
   98.5 ± 7.9           136.8 ± 6.3 
15  CO2CH2CH3
c
   187.0 ± 49.7 >400 
16  CO2CH3   68.2 ± 4.3           136.6 ± 6.3 
17  CO2CH2CH2CH3   53.2 ± 4.4    56.3 ± 4.0 
18  CO2CH(CH3)2   48.9 ± 4.4    39.9 ± 2.8 
19  CO2C(CH3)3   12.3 ± 1.6    21.4 ± 1.9 
20  CO2C(CH3)2CH2CH3   17.2 ± 1.6    17.1 ± 1.4 
21  CO2CH2CF3    138.1 ± 31.8 >400 
22  CO2-cyclopropyl   35.8 ± 3.3    85.1 ± 3.8 
23 acid COOH >400 >400 
24 thioester COSCH2CH3    20.5± 4.7    30.2 ± 9.7 
25 amide CONHCH3 >200 >200 
26  CONHCH2CH3    95.5 ± 12.6    65.4 ± 7.3 
27  CONH-cyclopropyl  63.8 ± 3.0    93.5 ± 5.7 
28  CONHCH(CH3)2    80.2 ± 11.1    56.9 ± 4.8 
29  CONHC(CH3)3  33.6 ± 3.0    43.4 ± 4.0 




3-CH3       69.3 ± 2.3    >180 
32 3-CH2CH3    46.9 ± 6.6    35.1 ± 3.7 
33 3-CH(CH3)2    32.5 ± 7.6    21.7 ± 1.8 
34 nitrile CN    81.6 ± 6.7    57.1 ± 5.6 
a
 Compounds were incubated at different concentrations with the specific cells for 48 h, followed by detection 
of cell viability using a Cell-Titer Glo (Promega). The results were normalized using DMSO (negative control) 
and 3-dibutylamino-1-(4-hexyl-phenyl)-propan-1-one (150 mM in DMSO final concentration, positive control). 
Data were acquired by three independent experiments carried out in quadruplet. 





Examination of the cell viability assay indicated that ligands with a C-3 carboxylic acid 
substituent of the S-isomer analog 23 or dimethyl amide 30 moiety were non-toxic even at 400 µM 
(LD50 > 400 μM) in the presence of HEK293 and HEPG2 cells. Esters represented by C(8)-bromo 
ethyl ester 15 and trifluoroethyl ester 21 were non-toxic at doses higher than 400 µM (LD50  > 400 
μM) for the HEPG2 cells, and they exhibited an LD50 of 187 µM and 138 µM in HEK293 cells, 
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respectively. They were non-toxic at any clinically important level. The methyl amide 25 was non-
toxic at concentrations of 200 µM for both cell lines. The esters 13, 14, 16, 17, amides 26-28, 
methyl oxadiazole 31 and nitrile 34, were safe at lower concentrations with LD50 values of >50 
μM for both cell lines. Usually, these ligands in vivo potentiate the GABAARs at nanomolar 
concentrations, consequently the cytotoxicity concentration with LD50 values at 50 μM would be 
far above the clinical concentrations of the ligands used in patients. Ligands with moderate 
cytotoxicity (30 μM <LD50 <50 μM) were ligands with the isopropyl ester 18, cyclopropyl ester 
22, t-butyl amide 29 and ethyl oxadiazole 32. Ligands that exhibited cytotoxicity (LD50 <30 μM) 
for HEK293 kidney cells were ethyl ester 2, t-butyl ester 19, 2-methyl butyl ester 20, thioethyl 
ester 24, and isopropyl oxadiazole 33. These data revealed that increasing the size of the substituent 
of the oxadiazole moiety may increase cytotoxicity; most of the esters are considered to be 
cytotoxic if given at very high doses (much higher than any therapeutic dose), unless a different 
group at C(8) was introduced (see 13-15). The trifluoroethyl ester was fairly cytotoxic perhaps 
because the trifluoroethanol group is a much better leaving group and maybe toxic itself. In vitro 
toxicity can be used as a measure to estimate in vivo toxicity, however, variations can occur. For 
instance, lead compound 2 exhibited a fairly low LD50 value, however it was not toxic in vivo in a 
number of pharmacological assays in mice, rats and primates. The cytotoxicity assays indicated 
which analogs were the least cytotoxic but were not potent enough (nM) in regard to cytotoxicity 
to rule out further pharmacological studies in models of schizophrenia or depression. 
To assess the possibility of undesired CNS side effects (α1-mediated), a locomotor 
coordination study of each analog was conducted by placing mice on a rotating rod for a maximum 
of 3 minutes after oral administration by gavage at a dose of 40 mg/kg (Figure 16). The mice were 
also observed for loss of righting reflex, an indication of undesired CNS effects. Most of the mice 
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treated with the compounds exhibited no sedation or ataxia, nor loss of righting reflection vs the 
control diazepam. Most of the compounds exhibited sensorimotor steadiness at all three time-
points, which indicated no sedative/ataxic effects. However, some amides did exhibit some 
sensorimotor deficits. The methyl amide 25 and ethyl amide 26 effected severe motor impairment, 
while the cyclopropyl amide 27 and dimethyl amide 30 exhibited only minor motor impairment. 
The bulkier isopropyl amide 28 and t-butyl amide 29 did not show any motor impairment. These 
results suggested that these particular amides, which produced sedation/ataxia, are sedating 
presumably, because of some efficacy at the α1-GABAAR subtype. In regard to the 
pharmacological effects of the amide side chain, it is obvious that a smaller alkyl chain promoted 
a more sedating effect. This effect presumably did not result from metabolism nor cytotoxicity 
































Figure 16. Effect of analogs of 2 on sensorimotor coordination. Mice were placed on the rotarod at three 
separate time points of 10, 30, and 60 minutes after each oral gavage drug administration at 40 mg/kg. Their 
performance on the rotarod for 3 minutes was recorded and analyzed. After a second fall, it would be 
considered a fail, and that time point would be recorded. 
 
After examination of all the results for the series of C(4)-S-CH3 substituted enantiomers 
described above, the best two compounds, which exhibited excellent stability, minimal or no 
toxicity and did not exhibit motor impairments, were cyclopropyl amide GL-I-55 (27) and methyl 
oxadiazole GL-I-65 (31). Moreover, it was suggested that the bioisosteres GL-I-66 (32) and GL-
I-81 (33), which were very metabolically stable and exhibited no sensorimotor impairment, will 
need to be administrated at low concentrations in behavioral studies to avoid adverse chronic side 
effects. Amides 25 and 26 exerted excellent stability and no cytotoxicity, however, these two 
ligands were sedating at 40 mg/kg p.o. Esters (13-19) including the lead compound 2 exhibited 
either cytotoxicity or were metabolically less stable in the presence of HLM and MLM. Thioester 
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24, isopropyl amide 27 and nitrile 34 were not metabolically stable enough to encourage further 
studies. The carboxylic acid 23 exhibited excellent properties in all three assays, however, the acid 
functionality will prevent the penetration through the blood-brain barrier, which was demonstrated 
for the R enantiomer.98 This property is not suitable for the treatment of schizophrenia and 
depression. The cognitive deficits developed in these two disease states are still poorly managed 
with current drugs. Although the data is only preliminary, the S-CH3 ligand 31 demonstrated pro-
cognitive effects (C+) in the Y-maze paradigm at CAMH. The S-CH3 ligand GL-I-54 (30) was 
active in the antidepressant assay (forced swim test) and pro-cognitive (A++ and C++) assay.117 
However, 30 was metabolized fairly rapidly in HLM, as shown in Table 3. To date, these two 
ligands, dimethyl amide GL-I-54 (30) and methyl oxadiazole GL-I-65 (31), along with 
cyclopropyl amide GL-I-55 (27) in this S-enantiomeric series seemed to be the best 
candidates for additional preclinical behavioral testing (data described in the later biological 
screening sections 2.2.3.4.), while in the R-CH3 series (α5 subtype selective series) a number of 
ligands have demonstrated promising pharmacological effects for the treatment of schizophrenia 
and depression.18, 67, 83, 95-96, 117 
 
2.2.3.3. Analogs of the R-isomer 
As mentioned above, in addition to the studies of SH-053-2'F-S-CH3 (2) and its (S)-analogs,  
the research on the SH-053-2'F-R-CH3 (1) series was ongoing at the same time, due to its α5-
GABAAR subtype selectivity as compared to the other series of IMDZs. It was felt that the (R)-
isomers might provide a better lead to further study the effect on cognitive effects, learning process, 
and working memory from the interactions with α5-GABAARs and Tony Grace and others have 
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shown in MAM rats, SH-053-2'F-R-CH3 (1) was a better ligand in models of  schizophrenia
95-96, 
98 and depression.97, 118-119 
 
2.2.3.3.1. Medicinal Chemistry Strategy of Analog Search in the (R)-CH3 Series 
In order to perform a comprehensive SAR study, the design of analog of the α5 subtype 
selective parent compound 1 was based on the pharmacological data collected from previous 
studies carried out at Milwaukee.18, 66-67, 82-83, 95-97, 120 There are four positions in the molecule that 
can be modified, as depicted in Figure 17, depending on the requirement of specific subtype 
selectivity and pharmacokinetic profile in addition to the use of the unified BzR/GABA(A) 
pharmacophore model.  
 
Figure 17. Medicinal chemistry strategy of analog research from the parent compound 1, based on previous 
work on the C(4)-S-CH3 isomer and the C(4) achiral analogs. 
 
Without the chiral substituent at the C(4) position, the IMDZ acts preferentially as PAMs 
at α2 and α3-subtypes. The α5 subtype selectivity can be improved by introducing a chiral methyl 
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function at the C(4) position of the basic “privileged framework.” The R-isomer was known to be 
more α5 subtype selective, whereas the enantiomeric S-methyl group usually leads to an α2/3/5 
subtype selective ligand, as mentioned, with better binding affinity and potency than the R-isomers. 
18, 67, 83  
The BZD binding pocket of α1 subtypes appears from molecular modeling to be smaller 
than the α5 binding site,18, 67 therefore, a larger group at the C(8) position would exhibit less or no 
binding at α1β3γ2 subtypes, such as an ethinyl and a cyclopropyl group.67 On the other hand, the 
smaller group at the C(8) position, would increase the binding affinity and efficacy at all subtypes, 
which results in sedation and ataxia. Therefore, the best scenario is to achieve the balance so that 
the size of the substituent at the C(8) position is large enough to retard high affinity at α1 subtypes, 
but not too large so as to lose high potency at the desired subtypes.  
By changing the atoms at the 2' prime position at the C(6) pendant phenyl ring of the IMDZ, 
the subtype selective varies accordingly. The IMDZs bearing a 2' halogen atom such as Cl and F 
usually exhibited more potent binding affinity at all subtypes, as compared to the 2'H compounds. 
The ligands in the 2'N series exhibited the least binding affinity, as compared to other 2' phenyl 
substituents, hence the binding affinity order influenced by the atom at 2 prime position would be 
Cl, F > H > N. However, the efficacy profile of each ligand is not always proportional to the 
binding affinity. Therefore, both factors should be taken into consideration other than just focusing 
on improving one parameter while designing new compounds.  
Aside from the modifications at the C(4), C(8), and 2' phenyl position, different 
functionality at the C(3) position can provide a distinct influence on the PK profile and induce a 
variety of behavioral effects in animal models. As previously described in the research on the 
analog of the S-isomer 2,90 the presence of a linear ester functional group at the C(3) position 
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increased the metabolic rate of hydrolysis by the microsomes in the liver. In contrast, the branched 
ester group can improve the stability of the molecule but also increase the cytotoxicity. The amide 
groups at the C(3) position are usually much more metabolically stable and less cytotoxic than the 
corresponding esters. However, the stability trend is opposite to the esters in that the branched 
chain amides exhibited reduced stability as compared to the linear functionalized amides. 
Moreover, the smaller size amides might exert mild sedative effects in the rotarod study based on 
the effects in the C(4)-S-CH3 enantiomeric isomers. The thioamides as isosteres of amides, the 
oxadiazole and oxazole bioisosteres of esters are commonly used to improve the metabolic stability, 
PK (solubility-hydrophilicity), as well as pharmacological activity in drug discovery. The 
carboxylic acid of the parent compound 1 (SH-053-2'F-R-CH3) was not able to pass through the 
BBB, therefore, this type of analogs was not studied for the treatment of CNS disorders since the 
ligands are required to penetrate the BBB to affect brain function. However, those compounds 
were used in the treatment of asthma since they had no CNS effects because there was no 
penetration through the BBB.  
Based on the strategy involved in medicinal chemistry, a series of IMDZ analogs of the 
(R)-enantiomer 1 were designed, synthesized and evaluated in varies animal models. Since most 
of the esters were metabolized rapidly in rodents, therefore, the synthetic strategy concentrated on 
the more stable analogs, such as the amide, oxadiazole and oxazole analogs, as summarized in 
Tables 5, 6, and 7. 




• The first row of amides are direct amide analogs of SH-053-2'F-R-CH3 (1), with different alkyl groups on 
the amide nitrogen atom depicted in the order of increasing the size of the alkyl group from methyl to a 
larger group.  
• The second row of amides are the S-enantiomers of the amides in the first row (R-series), except the S-t-
butyl amide, whereas the pyrrolidine amide had the largest alkyl size in the R series.  
• The third row of amides are the thioamide analogs of the corresponding amide in the first row. 
• The fourth row are the amides with a C(8)-bromo functional group instead of ethinyl. Note, RV-II-04 is an 
achiral amide without a chiral methyl group at the C(4) position, as compared to other amides. 
• The fifth row are the amides bearing a C(8)-cyclopropyl group. 













Alkyl group on the nitrogen atom
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• All amides listed above are the amides in the 2'F series, except the amide in the last row, which is in 2'N-R 
amide. 
 
Table 6. Oxadiazole derivatives related to the α5 subtype selective PAM, SH-053-2'F-R-CH3 (1). 
 
• The first two columns of oxadiazole analogs are all methyl substituted on the oxadiazole ring, the first 
column is the oxadiazoles from the 2'N-R series, whereas the 2'F-R series is in the second column.  
• The third and fourth columns are for the oxadiazoles with ethyl and isopropyl groups, respectively. 
• The first row contains the oxadiazoles in the R-isomer series. 
• The second rows are the S-enantiomers of the corresponding oxadiazoles in the first row, except 52, which 
is an achiral methyl oxadiazole. 
• The third row are the oxadiazoles with a C(8)-bromo substituent instead of ethinyl group, as compared to 
the first row of ligands. 
• The fourth row are the oxadiazoles bearing a C(8)-cyclopropyl group. 
 
Ethyl Isopropyl











Table 7. The 1,3-oxazole analogs related to the α5 subtype selective PAM, SH-053-2'F-R-CH3 (1). 
 
• The first row are the oxazoles bearing a C(8)-bromo atom in both R and S enantiomers. 
• The second row are the oxazoles with a C(8)-ethinyl group in both the R and S enantiomers. 
 
2.2.3.3.2. A Study of the Biology of MP-III-022, a Potent Analog of SH-053-2'F-R-CH3 (1) 
The methyl amide analog of 1, MP-III-022 (35), which was first synthesized by Michael 
Poe, was found to be a much more potent α5-GABAAR PAM in regard to receptor efficacy than 
the parent compound 1 at all concentrations,121 as illustrated in Figure 18. The binding affinity of 
the amide 35 at α5 subtypes was 55 nM,83, 121  which was nearly one half of the Ki value of 1, as 
shown in Table 8, and was much more selective as compared to other subtypes in agreement with 
the electrophysiological response. To achieve substantial α5 selectivity without potentiating other 
subtypes, the administrative dose range was determined by Savic et al.121 to be 1-10 mg/kg by 
measurement of the compound concentration in the rat brain, whereas the range of parent 
compound 1 was 10-200 mg/kg. As a result of better α5 subtype selectivity, the amide 35 was 







dichloromethane. The same procedure had been used for the methyl amide of the S-isomer 90 and 
the R-CH3 amide (35) was subjected to further biological evaluation.  
 
Figure 18. The electrophysiological response of 35 (A) and 1 (B) . The GABA EC3 (3% of the maximal GABA 
current) measurement was illustrated on the concentration-response curves at α1-3,5β3γ2 GABAARs of rat 
recombinant receptors. The dose range of 35 (MP-III-022) to provide a selective potentiation at α5 was 1-10 
mg/kg, whereas it was 10-200 mg/kg for compound 1. (Modified from the Figure in Stamenić et al.)121 
 
Table 8. The binding affinity of 1 and 35; the Ki values are reported in nM.83, 121  
Compound α1  α2  α3  α5  
SH-053-2'F-R-CH3 (1)
83 759.1 948.2 768.8 95.2 
MP-III-022 (35)121 850 360 660 55 
 
The methyl amide 35  (MP-III-022) did not induce spontaneous hyperlocomotor activity at 
the highest α5 selective dose at 10 mg/kg, only slight hyperlocomotor was observed at the lowest 
non-selective dose (15 mg/kg),121 which might result from the slight potentiation of α2/3, but not 
from α1 subtypes. However, 35 did not present any effect on wild-type rats during the 
amphetamine-induced locomotor stimulation assay,121 whereas the parent compound 1 exhibited 
a significant suppression of the locomotor response induced by amphetamine in MAM rats, which 
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demonstrated an anti-psychotic property.96 Moreover, the lack of activity in the elevated plus maze 
assay indicated that amide 35 did not possess any anxiolytic property in this assay.  
Recently, the ligand 35 (MP-III-022) was evaluated in the lipopolysaccharide (LPS) -
induced maternal immune activation model; it is a common model for research on the onset 
schizophrenia. It was illustrated that amide 35 at a dose of 2 mg/kg daily, i.p. prevented the deficit 
locomotor activity due to prenatal maternal immune activation by LPS (100 μg/kg, i.p.), as well as 
the diminished reactivity to amphetamine (0.5 mg/kg, i.p.) in adult female mice to a certain extent, 
but not in male mice.122 During the examination of the LPS-induced immune response by cytokine 
(IL-6) expression after 6 hours of the LPS treatment, the GABA concentration was significantly 
increased in the whole fetal brain, whereas a significant decrease of glutamate concentration was 
also observed at the same time. The imbalance of GABA/glutamate can profoundly influence the 
development of the GABAergic system, especially in the fetal brain even for just a few hours. The 
observation that the locomotor reactivity in the LPS-induced immune activation in female 
adult mice has been improved with the treatment with α5 PAM 35, might provide a novel 
strategy for the early prevention of schizophrenia with the intervention via use of α5 
GABAAR subtypes. Therefore, taken together with the previous pharmacological activity,97, 118, 
122 potentiation at α5 subtypes, and the most recent published results from the research based on 
the models of schizophrenia, a series of IMDZ analogs were designed and synthesized for further 
study on the influence of α5-containing GABAARs for schizophrenia, as well as depression. This 
was based on the structure of the α5 subtype selective ethyl ester 1 and its more potent methyl 





2.2.3.3.3. Synthesis of the Analogs of SH-053-2'F-R-CH3 (1) 
In order to explore the SAR of amides with different alkyl substituents in addition to the 
methyl amide 35, the first set of C(8)-ethinyl-C(3)-amide analogs of the parent compound 1 were 
designed and synthesized following the general procedure of amide synthesis in the (S)-CH3 series 
(Li, Arkivoc 2018).90 First, the ethyl ester 1 was hydrolyzed to the carboxylic acid SH-053-2'F-R-
CH3-acid (68) by treatment with sodium hydroxide in ethanol and this was followed by adjusting 
the pH to 5 with a cold aq 1 M solution of HCl, which gave the desired acid 68 as a white precipitate. 
The acid 68 was then treated with thionyl chloride to form the intermediate acyl chloride, and this 
was followed by the addition of the corresponding amines (individually) to yield the dimethyl 
amide GL-II-73 (36), ethyl amide GL-II-74 (37), cyclopropyl amide GL-II-75 (38), isopropyl 
amide GL-III-66 (39), and pyrrolidine amide GL-II-76 (40) in good yield (70-82 %), respectively, 
as illustrated Scheme 9. The synthesis of the corresponding amides in the S-isomer series: the 
methyl amide MP-III-023 (25), dimethyl amide GL-I-54 (30), ethyl amide GL-I-43 (26), 
cyclopropyl amide GL-I-57 (27), and isopropyl amide GL-I-41 (28), were described in the 




Scheme 9. Synthesis of the C(8)-ethinyl amide analogs 35-40 of the parent ethyl ester 1 (SH-053-2'F-R-CH3). 
 
The thioamides are known as one of the isosteres of amides. Due to the reduced 
electronegativity and larger atomic size of a sulfur atom, the C=S carbon is less electron deficient 
and less prone to undergo attack by an electron-rich nucleophile as compared to an amide C=O. 
The larger and uncharged sulfur atom is able to accept more charge density to transfer from the 
nitrogen atom in a thioamide, as compared to an amide moiety.123 Moreover, from the ground state 
to the transition state, the rotational barrier of the C-N bond is larger in a thioamide than amide,124 
which results from the relatively larger dipole moment in a thioamide. With a higher polarity, 
thioamides are much better H-bond donors than the corresponding amides due to less 
electronegativity on the sulfur atom and higher electron density as compared to the C-N bond. On 
the other hand, amides are better H-bond acceptors than thioamides. In order to study the electronic 
effect at the C(3) position on stability, the thioamide family was prepared. This would lead to the 
direct SAR comparison between amides and thioamides. Therefore, several thioamides were 
prepared by using Lawesson’s reagent (LR)125-126 in refluxing THF; the four amides 35-38 were 
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converted into their corresponding thio-derivatives, respectively: the methyl thioamide GL-III-84 
(41), dimethyl thioamide GL-III-85 (42), ethyl thioamide GL-III-86 (43), and methyl thioamide 
GL-III-87 (44), as presented in Scheme 10. Caution, LR has a very unpleasant sulfur smell, it 
should be handled carefully in a fume hood. After removing the solvent from the mixture, the 
residue was dissolved in DCM and loaded onto a silica gel flash column. The LR byproduct was 
flashed off with 2:3 EtOAc and hexanes in the first fraction as a cloudy white solution. The 
thioamide was purified in later fractions from the same flash column. 
 
Scheme 10. Synthesis of the C(8)-ethinyl thioamide analogs 41-44 from corresponding amides 35-38. 
 
Due to the more potent binding affinity from the C(8)-bromo substituent at lower 
concentrations in same cases, as compared to the ethinyl group, the synthesis of the C(8)-bromo 
amides were also prepared from the C(8)-bromo ethyl ester SH-I-047 (6). This required the same 
general synthetic procedure for the amides, with the corresponding amine, to form the C(8)-bromo 
dimethyl amide GL-III-69 (45) and the C(8)-bromo ethyl amide GL-III-67 (46), respectively, as 
indicated in Scheme 11. As previously mentioned, the C(8)-cyclopropyl group can flexibly rotate 
and should have a similar volume of electron density as the ethinyl group. This similar electron 
density profile might result in parallel pharmacological effects. Furthermore, the metabolism of 
the cyclopropyl group would be expected to be different from the C(8)-ethinyl or Br groups. 
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Therefore, based on these hypotheses, the C(8)-cyclopropyl analogs were prepared via a Pd 
catalyzed Suzuki cross-coupling reaction process with the cyclopropyl boronic acid and the 
corresponding C(8)-bromo amido analogs to yield the C(8)-cyclopropyl dimethyl amide GL-III-
70 (47) and the C(8)-cyclopropyl ethyl amide GL-III-68 (48), respectively, as shown in Scheme 
11. 
 
Scheme 11. Synthesis of C(8)-bromo amides 45-46 and C(8)-cyclopropyl amides 47-48 from SH-I-47 (6).82, 120 
 
In addition to the 2'F series, the analogs in the chiral 2'N series were synthesized as well to 
compare the SAR between the two series. The 2'N-R ethyl ester was prepared via the same route 
employed for esters 1 and 2, except the 2'-pyridyl ketone 70 was substituted for the 2'F 
benzophenone in the first step. The synthesis is illustrated in Scheme 12. The intermediate amide 
71 was obtained from the amidation reaction, which employed the coupling reagent (DCC) in 99.2 % 
yield on a 100-gram scale. The Boc-deprotection of the amide 71 was carried out in a saturated 
solution of HCl (gas) solution in DCM at 0 ˚C. The mixture was stirred for one hour and this was 
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then followed by the cyclization to the 7-membered ring. The crystallization was carried out in the 
1:1 mixture of methanol and water after adjusting the pH to 9 by addition of 2 N aq NaOH solution. 
The desired 1, 4-benzodiazepine 72 precipitated out of the solution in 94 % yield. The 
recrystallization of the benzodiazepine 72 was conducted in a mixture of EtOAc and hexanes in a 
ratio of 1:1, after adding seed crystals. The imidazole ring was added on to 72 by treating 
benzodiazepine 72 with potassium t-butoxide and diethyl chlorophosphate at -50 ˚C, and this was 
followed by addition of ethyl isocyanoacetate and a second portion of potassium t-butoxide at -78 
˚C. This addition reaction was carried out in 68 % yield on a 150-gram scale. The majority of the 
bromide 73 can be recrystallized after cooling from 60 ˚C to room temperature. The material left 
in the mother liquor was purified by flash column chromatography (silica gel, EtOAc: hexane, 3:2). 
This bromide 73 was then reacted with trimethylsilylacetylene in the presence of a palladium 
catalyst via a Heck-type coupling reaction to obtain the TMS-analog 74 in 90 % yield. The 
fluoride-mediated desilylation was carried out by treatment of 74 with tetra-n-butylammonium 
fluoride to provide 75 (GL-II-19-2'N-R-CH3) in 95 % yield, as shown in Scheme 12. The methyl 
amide of 75 was prepared via direct amidation in a similar fashion to amide 25 prepared earlier 90 




Scheme 12. Synthesis of analogs in the 2'N-R-CH3 series. 
  
As a common ester bioisostere, 1,2,4-oxadiazoles in the 2'F-R-CH3 and 2'N-R-CH3 series 
were synthesized either from the C(8)-ethinyl or bromo ethyl ester, respectively. The general 
procedure employed here for the synthesis of 1,2,4-oxadiazoles was executed with different 
substituted oximes to form the corresponding analogs:  2'N-R-CH3 series: C(8)-ethinyl methyl 
oxadiazole GL-II-33 (51), 2'N-R-CH3-C(8)-bromo methyl oxadiazole GL-II-54 (53); 2'F-R-CH3-
C(8)-ethinyl series: methyl oxadiazole MP-IV-004 (55), ethyl oxadiazole MP-IV-005 (56), 
isopropyl oxadiazole MP-IV-010 (57); 2'F-R-CH3 C(8)-bromo series: methyl oxadiazole GL-III-
60 (58), ethyl oxadiazole GL-III-98 (59), isopropyl oxadiazole GL-IV-01 (60), as illustrated in 
Scheme 13. The cyclopropyl oxadiazole was prepared via a Suzuki Pd-mediated cross-coupling 
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reaction with cyclopropyl boronic acid and the corresponding C(8)-bromo oxadiazoles to yield the 
analogous C(8)-cyclopropyl oxadiazole analogs: 2'N methyl oxadiazole GL-III-64 (54); 2'F-R-
CH3-C(8)-cyclopropyl series: methyl oxadiazole GL-III-63 (61), ethyl oxadiazole GL-IV-03 (62), 
isopropyl oxadiazole GL-IV-04 (63). The achiral methyl 2'F-C(8)-ethinyl oxadiazole GL-III-23 
(52) was synthesized from JY-XHe-053 with the methyl oxime (Scheme not shown). The synthesis 
of oxadiazoles from the S-CH3 enantiomeric series 31-33 were described in the previous section.  
 
Scheme 13. Synthesis of 1,2,4-oxadiazole analogs 51-63 with the C(8)-ethinyl, bromo or cyclopropyl group in 
the 2'F or 2'N pendant phenyl series. 
 
In addition to the traditional 1,2,4-oxadiazole, bioisosteres, the 1,3-oxazoles are unique 
bioisosteres and possess a very similar electron density map to that of an ester. It has been reported 
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that the molecules containing the 1,3-oxazole moiety exhibited the desired pharmacological effects 
in animal models with better therapeutic and PK profiles.127-129 Furthermore, the 1,3-oxazoles 
should be easier to patent than the often used 1,2,4-oxadiazoles. 
The 1,3-oxazole analog of α2/3 PAM Hz-166 (76), termed KRM-II-81 (77) is an achiral 
and very selective α2 and α3 subtype selective IMDZ GABAAR ligand, which has proven to be 
active in models of anxiety, epilepsy, pain, and depression, which will be discussed in detail in the 
last chapter. The success of 1,3-oxazole 77 directed attention to this fairly unique moiety in regard 
to analogs in the chiral series in order to improve the duration of action, which should be a better 
candidate for both schizophrenia and depression. In addition, it might provide some anxiolysis 
which would be important since anxiety is always comorbid with for these two CNS disorders.  
However, the synthesis of the 1,3-oxazole in the chiral series met with a number of 
difficulties. The standard route employed previously, not only encountered [N(5)-C(6)] imine bond 
reduction of the C(3) ester function on attempts to prepare the C(3) aldehyde with DIBAL, which 
was a similar problem observed in the synthesis of 77, but also underwent [N(5)-C(6)] imine to 
[N(5)-C(4)] imine migration to the C(4)-N(5) position. This resulted in the loss of the correct 
chirality at the C(4) position. The problem of imine reduction and isomerization was resolved and 
was published (Li, SYNTHESIS, 2018)130 by using a more hindered reducing reagent than DIBAL. 
The potassium diisobutyl-t-butoxy aluminum hydride (PDBBA) solution was prepared and found 
to reduce the C(3) ester to the desired aldehyde, but did not reduce the [N(5)-C(6)] imine moiety 
due to the bulky steric size of the PDBBA reagent. The details of this reaction will be presented in 
the last chapter. It was felt once the aldehyde GL-III-35 (78) had been formed readily, the 
remaining synthesis would go smoothly. On the contrary, the van Leusen reaction in the chiral 
series was not as simple as in the achiral series. During the reaction, in the chiral series, the 
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majority of the product was the desired 1,3-oxazole GL-III-36 (64), on analysis by TLC (silica 
gel). However, after the reaction mixture was worked up, a large portion of the desired oxazole 
were converted into another compound (45 %), which proved to be the [N(5)-C(6)] imine 
migration byproduct GL-III-36A (79) without the correct chirality at the C(4) position (NMR and 
LCMS).  
To find the cause of the unexpected formation of the byproduct, the reaction was conducted 
exactly the same way as the first time; however, the reaction mixture was monitored very carefully 
after each workup step (analysis by TLC). With the help of TLC, analysis of this data indicated 
that the conversion was complete but the isomerization occurred during the removal of methanol 
at 50 degrees under reduced pressure. Presumably, as the solvent became more concentrated, the 
tosic acid concentration increased while reducing the solvent volume at higher temperature. The 
imine bond was hydrolyzed by the concentrated tosic acid to the keto form. When the imine was 
regenerated by cyclization, the deprotonation of the iminium ion in the transition state would most 
likely take place in two directions, as illustrated in Figure 19. It would occur either from the proton 
on the imine nitrogen atom or the proton from the chiral carbon atom. Apparently, the 
deprotonation of the latter case requires more energy than the direct deprotonation from the 
nitrogen atom. However, the byproduct 79 presumably would be more stable than the desired 
product 64 due to better electron delocalization into the adjacent imidazole ring system. This 
energy barrier can be reached by applying heat, which occurred while reducing the solvent volume 
on heating the solution to 50 degrees centigrade. Once the energy overcame the transition state 
barrier, the more stable byproduct 79 would likely form than the less stable desired product 64. 




Figure 19. The proposed mechanism for the formation of the byproduct 79 from workup of the van Leusen 
reaction; an effect of tosic acid on the [N(5)-C(6)] imine to [N(5)-C(4)] imine rearrangement (tautomerism). 
 
It is also possible the concentrated tosic acid protonated the imine nitrogen atom and with 
heat the chiral proton was lost to provide the more stable C(4)-N(5) double bond. 
To avoid the byproduct formation, 4 more equivalents of base and a large amount of water 
were added after the reaction during workup, which was completed at room temperature. The 
mixture was stirred for an extra one hour to neutralize the tosic acid. The temperature was also 
reduced, while removing the solvent, to 40 degrees to lower the possible energy for byproduct 
formation. The product yield was improved to 82 %, as compared to 50 % for the initial reaction, 
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with an only a trace of byproduct observed. The C(8)-bromo 1,3-oxazole was converted into the 
TMS analog GL-III-72 (80) with ease and this was followed by removal of the trimethylsilyl 
function to furnish the C(8)-ethinyl-C(3)-1,3-oxazole, which overcame a long-standing problem, 
as presented in Scheme 14. In the S-CH3 series, the C(8)-bromo ethyl ester was reduced to the 
desired aldehyde GL-III-75 (81). The 1,3-oxazole C(8)-bromo GL-III-76 (65) were prepared via 
the same simplified route from aldehyde 81. The olefinic byproduct GL-III-76A in the S-CH3 
series was identical to the 79 from the R-CH3 series. The C(8)-TMS-acetylene was introduced to 
form the TMS-analog (82), after deprotection of which, the C(8)-ethinyl GL-III-78 (67) was 
achieved. Simply be aware of the tosic acid during workup.  
 





2.2.3.4. Biological Screening for the Selection of Lead Compounds  
In order to select the lead compounds, a series of biological screenings, such as metabolism 
studies in HLM and MLM, cytotoxicity assays, rotarod tests, receptor binding studies, 
electrophysiology recording assays as well as PK studies, were performed with all newly designed 
IMDZs before behavioral studies in critical animal models. Only the compounds that were 
metabolically stable, non-toxic, and subtype-selective with good PK profiles but devoid of other 
possible receptor interactions, such as hERG or PBR, would be further investigated. This would 
be executed in specific disease-related animal models to reduce the possible failure of candidates 
in the later drug development stages. 
 
2.2.3.4.1. Study of Metabolism 
2.2.3.4.1.1. In Vitro Metabolic Stability in HLM and MLM 
The first sets of the R-CH3 amide and oxadiazole analogs were assayed for metabolic 
stability in vitro on HLM and MLM at 10 µM concentration (see Table 9). After 2-hours of 
incubation at 37 degrees, the most stable analogs were determined, and a possible trend of steric 
effects with respect to metabolic stability was determined. The half-life and percent remaining of 
the compound at the end of two hours for the R-CH3 isomers are presented in Table 9, while those 
half-lives for the corresponding S-CH3 enantiomers can be found in Table 10.   
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Table 9. Metabolic stability of amides and oxadiazoles. Unpublished data. (R-CH3 isomers) 
 
• Data presented in half-life (minute) and % remaining after 2 hours of incubation, respectively for both 
HLM and MLM. 
• Data of compound without the star * were obtained from Dr. Arnold’s group by Revathi Kodali. All ligands 
were incubated with human liver microsomes (HLM) or mouse liver microsomes (MLM) for 2 h (except 
for MP-III-022 incubated for 1 h) at 37 oC at a final concentration of 10 µM. The percentage of compound 
remaining after incubation was measured by LC-MS/MS. 
• Data with a star * was obtained from Eli Lilly. The assay was performed with Hep microsomes at 4 µM for 
30 min at 37 oC.  
• Different alkyl groups on the amide nitrogen atoms or oxadiazole rings are listed in the first column. 
Examination of the data in the second column indicates the 2 prime substituents, the compounds are either 
from the 2'F or the 2'N series. 
• Amides are in red rectangles, oxadiazoles are depicted in yellow. 
• ND: not determined.  
 




• Data presented in half-life (minute) and % remaining after 2 hours of incubation, respectively for both 
HLM and MLM. 
• Data of compound without the star * were obtained from Dr. Arnold’s group by Revathi Kodali. All ligands 
were incubated with human liver microsomes (HLM) or mouse liver microsomes (MLM) for 2 h at 37 oC 
at a final concentration of 10 µM. The percentage of compound remaining after incubation was measured 
by LC-MS/MS. 
• Data with a star * was obtained from Eli Lilly. The assay was performed with Hep microsomes at 4 µM for 
30 min at 37 oC.  
• Different alkyl groups on the amide nitrogen or oxadiazole ring are listed in the first column. Examination 
of the data in the second column indicates the 2 prime substituents, the compounds are either from the 2'F 
or the 2'N series. 
• Amides are in red rectangles, oxadiazoles are depicted in yellow. 
 
In the amide family, on human liver microsomes (HLM), the methyl amides 50 and 25 are 
more stable with more than 90 % remaining after 2 hours of incubation. In comparison, the stability 
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of the methyl amide of the enantiomeric R-CH3 series 35, as compared to the S-isomer 25, the S-
methyl amide 25 was more stable than the R enantiomer 35, which is reversed in the case of the 
dimethyl amide 36 (R) and 30 (S) in regard to the structural configurations: the R-isomer 36 was 
more stable than the S enantiomer 30, with 73.4 % and 36.4 % remaining after 2 hours in HLM, 
respectively. All other compounds were more stable than 60% except the R-pyrrolidine amide 40, 
which was less stable after 2 hours of incubation. In MLM, the lower stability was observed for 
29, 30, 37, 38, and 40, while other compounds were more stable than 60% after 2 hours of 
incubation and methyl amide in the 2'N-R-CH3 50 was much more stable with 93 % remaining 
after 2 hours.  
In both HLM and MLM after two hours, the oxadiazole analogs were stable above 80%, 
and a higher stability of 95 % was observed in case of MLM for ligand 51. The oxadiazoles 52 
and 53 were more stable in MLM with more than 90 % remaining after 2 hours of incubation. In 
terms of stability trends, oxadiazoles, as expected, are much more stable than amides and the 
stability tends to decrease with increasing alkyl chains for amides and oxadiazoles in both 
enantiomeric series in HLM as well as MLM. The more lipophilic compounds are attacked much 
more readily by CYP enzymes, as expected. The ligands are more lipophilic but also contain more 
CH2 or benzylic CH2 groups to be attacked by CYP enzymes. Moreover, the higher metabolic 
stability (> 90 % remaining) and longer half-life were observed in more polar 2'N series than the 
analogs in the 2'F series. The compounds that exhibited moderate to high metabolic stability 






2.2.3.4.1.2. Proposed Possible Metabolites 
It is critical to understand the possible pathways of the metabolism of these IMDZs for a 
suitable duration of action depending on this necessary requirement. The study of the metabolism 
of BZD and BZD-related compounds is well known, and it is desirable to understand it at a deeper, 
perhaps, molecular level as possible. With accumulating evidence, along with the possible 
metabolism of the tricyclic BZD such metabolism of IMDZ includes cytochrome P450 oxidation 
and then further glucuronidation for excretion.131 Using the dimethyl amide GL-II-73 (36) as an 
example, the metabolism of amide analogs of IMDZ might undergo the following possible 
pathways, as illustrated in Figure 20.  
The ligand may undergo an aromatic hydroxylation by P450, and a hydroxyl group can be 
introduced in ring A or ring C at the two positions as indicated in I and II.132  The N-oxidation 
might occur at the imine nitrogen atom to form the metabolite III.133 The C-4 hydroxylation was 
reported to lead to an active metabolite by CYP3A4 and CYP2A19, and this was followed with 
OH-glucuronidation.134 However, because there is a chiral methyl group at the C(4) position, it is 
not clear whether the traditional hydroxylation would still occur at that position (IV) or it would 
be at the C(4)methyl group (V). The chirality would also affect the metabolic process at this 
position. The N-dealkylation processes of the C(3) amide would result in a carbinol-amide as an 
intermediate (VI) catalyzed by P450, followed by facile elimination of an aldehyde moiety to yield 
a secondary amide (VII), which would substantially undergo the same process to form another 
carbinol-amide intermediate (VIII), and then further provide a primary amide (IX).135 The ethinyl 
group can be metabolized by P450 enzymes with two mechanisms. One is to form an oxirene (X), 
which is very difficult but might be followed by heme- or apoprotein alkylation. An alternative 
mechanism would be to produce a reactive ketene intermediate (XI) by a 1,2-hydrogen shift of the 
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terminal hydrogen to the adjacent carbon of the triple bond by P450 oxidation. The ketene might 
then proceed to two fates: either undergo the heme alkylation by P450s and/or apoprotein (XII), 
or react with the surrounding water to yield a carboxylic acid metabolite (XIII), which can 
bind with proteins (XIV).136 If the compound is administrated orally, at gastric acid pHs (pH = 
1.5-3.5), imine hydrolysis may first occur to form the iminium ion (XVI) before it is distributed to 
the liver and it could also form salts with the nitrogen from the imidazole ring (XV). However, the 
unstable iminium ion would favor the reformation of the 7-membered ring at physiologic pH. Last 
but not least, since GL-II-73 is an amide, it can be hydrolyzed to its carboxylic acid metabolite by 






Figure 20. Proposed metabolites of key dimethyl amide 36 (GL-II-73). 
 
2.2.3.4.1.3. P450 Inhibition 
Cytochrome P450-drug interactions is one of the key factors that raises concerns during 
drug development. Therefore, it is important to study if there is any possible P450 inhibitions or 
toxicity induced from the drug candidate. The P450 inhibition study for one of the key compounds 
GL-II-73 (36) was carried out via a commercially available kit (Vivid® P450 Metabolism assays). 
The Vivid® substrates are blocked dyes that can be metabolized by P450 oxidation, which results 
in high fluorescence. If a test compound is a P450 inhibitor, the production of the fluorescent 
metabolite of the blocked dyes would be prevented. The test compound is added to a mixture of 
NADPH and P450, followed by the addition of the substrate. The red fluorescence signal indicates 
the degree of P450 inhibition. The results of the CYP3A4 inhibition of GL-II-73 is presented in 
Figure 21. At both 10 and 50 µM high concentrations, dimethyl amide 36 only exhibited very little 
inhibition, and its fluorescence signal was nearly the same as the vehicle, which confirmed that 
this ligand 36 did not inhibit in CYP3A4 enzymes to any appreciable degree. Since CYP3A4 is 
the most abundant and relevant CYP450 for interactions, this result is very important. However, 
other CYP450 enzymes such as CYP2C9 and CYP2D6 will also need to be assayed with GL-II-




Figure 21. The CYP3A4 inhibition of GL-II-73 (36). Not much effect even at 50 µM. This is an important 
result. Unpublished data. 
 
2.2.3.4.2. Cytotoxicity Study 
 The cytotoxicity assay was performed in both human embryonic kidney cells (HEK293T) 
and human liver cancer cell lines (HEPG2) to investigate the toxicity of all analogs at the cellular 
level for the selection of safe lead compounds. The results are shown in Table 11.  
Table 11. Cytotoxicity data of all synthesized analogs from both R and S enantiomeric series, as well as achiral 
















42 GL-III-84 F Methyl R Acetylene  >400 
43 GL-III-85 F Dimethyl R Acetylene  >400 
44 GL-III-86 F Ethyl R Acetylene  >400 
45 GL-III-87 F Cyclopropyl R Acetylene  >400 
Amide 
35 MP-III-022 F Methyl R Acetylene >200 >200 
25 MP-III-023 F Methyl S Acetylene >200 >200 
75 
 
36 GL-II-73 F Dimethyl R Acetylene >200 >400 
37 GL-II-74 F Ethyl R Acetylene >50 >200 
38 GL-II-75 F Cyclopropyl R Acetylene >50 >200 
39 GL-III-66 F Isopropyl R Acetylene  >240 
40 GL-II-76 F Pyrrolidine R Acetylene >100 >400 
30 GL-I-54 F Dimethyl S Acetylene >400 >400 
26 GL-I-43 F Ethyl S Acetylene >100 >60 
27 GL-I-55 F Cyclopropyl S Acetylene >60 >90 
28 GL-I-57 F Isopropyl S Acetylene >80 >50 
29 GL-I-41 F t-Butyl S Acetylene >30 >40 
49 RV-II-04 F Methyl A* Br >200 >200 
45 GL-III-69 F Dimethyl R Br  >400 
46 GL-III-67 F Ethyl R Br  >240 
47 GL-III-70 F Dimethyl R Cyclopropyl  >400 
48 GL-III-68 F Ethyl R Cyclopropyl  >400 
50 GL-II-31 N methyl R Acetylene >400 >400 
Ester 
73 GL-II-05 N Ethyl ester R Br  >400 




75 GL-II-19 N Ethyl ester R Acetylene  >400 
Oxadia-
zole 
51 GL-II-33 N Methyl  R Acetylene >400 >400 
53 GL-II-54 N Methyl R Br >400 >400 
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54 GL-III-64 N Methyl R Cyclopropyl  >400 
55 MP-IV-004 F Methyl R Acetylene   
56 MP-IV-005 F Ethyl R Acetylene  >400 
57 MP-IV-010 F Isopropyl R Acetylene  >30 
52 GL-III-23 F Methyl A* Acetylene >100 >100 
31 GL-I-65 F Methyl S Acetylene >50 >100 
32 GL-I-66 F Ethyl S Acetylene >40 >30 
33 GL-I-81 F Isopropyl S Acetylene >30 >20 
58 GL-III-60 F Methyl R Br  >400 
59 GL-III-98 F Ethyl R Br  >120 
60 GL-IV-01 F Isopropyl R Br  >400 
61 GL-III-63 F Methyl R Cyclopropyl  >100 
62 GL-IV-03 F Ethyl R Cyclopropyl  >30 
63 GL-IV-04 F Isopropyl R Cyclopropyl  >400 
Oxazole 
78 GL-III-35 F aldehyde R Br  >400 
64 GL-III-36 F 
No 
substituent 
R Br  >400 







66 GL-III-73 F 
No 
substituent 
R Acetylene  >400 
81 GL-III-75 F aldehyde S Br  >240 
65 GL-III-76 F 
No 
substituent 
S Br  >400 
79 GL-III-76A F 
No 
substituent 
S Br  >50 
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67 GL-III-78 F 
No 
substituent 
S Acetylene  >240 
• Ligands was incubated with HEK293T cells and HEPG2 cells, respectively, for 48 hours followed by 
detection of cell viability using a Cell-Titer Glo (Promega). The results were normalized using DMSO as a 
negative control and 3-dibutylamino-1-(4-hexyl-phenyl)-propan-1-one (150 mM in DMSO final 
concentration, as a positive control). Data was determined by three independent experiments carried out 
in quadruplet. 
• The LD50 values in HEK293 and HEPG2 cell lines of each compound was presented in the last two columns, 
respectively. 
• The first column indicates the genus of each compound. 
• The columns from left to right indicates the difference at the 2 prime, C(3), C(4), and C(8), respectively. 
• Most of the compounds are non-toxic, only the compounds with LD50 values less than 50 µM were depicted 
in red. 
• The ligands that are depicted in red and cytotoxic at less than 50 µM raise some concerns. 
 
The LD50 values in HEPG2 cell lines for most of the compounds were greater than 200 µM 
in all series indicating these compounds are safe and not cytotoxic. Some of the compounds that 
exhibited an LD50 value higher than 100 µM are safe to use, but the concentration in the clinic 
should not be above 100 µM to avoid any possible cytotoxicity. In-depth, toxicity assays must be 
run for ADME as well. The compounds that have an LD50 value between 30 to 50 µM might show 
moderate cytotoxicity, such as compounds 28, 29, 32, and 79. However, since the pharmacological 
range of potentiation at GABAAR is at nanomolar concentrations, this indicates even 30 µM is far 
greater than the concentration that could induce cytotoxicity. On the other hand, if the compound 
has an LD50 value below 30 µM, as ligand 33, it would not be carried on for further studies. The 
LD50 value of the same compound most of the time is lower in the kidney HEK293 cell lines than 
the liver HEPG2 cell lines, which is not difficult to understand since more metabolic enzymes are 
located in the liver rather than the kidney. However, the LD50 value in HEK293 cells should be 
considered more carefully than the value in HEPG2 in order to avoid possible cytotoxicity that 
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could cause kidney failure. Notably, most of the compounds with moderate cytotoxicity are from 
the S-series, which comprise the compounds mentioned above. The desired R-isomers are much 
safer to use than the natural S enantiomeric analogs. The more the branched the alkyl chain, the 
more cytotoxicity was observed again providing a more lipophilic ligand with more sites for 
radical oxidation as well, as compared to compounds with smaller alkyl chains.  
Therefore, the summary of the cytotoxicity of the analogs in all the different series can be 
described by the following bullet points: 1. The thioamides improved the safety profile of the 
corresponding amides up to a non-toxic level. 2. The safety trend among different types of analogs 
is as follow: thioamide > unsubstituted oxazole > oxadiazole > amide. Since esters are hydrolyzed 
rapidly in the liver, they were not included in the above comparison. 3. The analogs in the 2'N 
series provided a much better safety profile than the analogs in 2'F series. 4. The larger alkyl 
substituents should be given less consideration due to the observation of cytotoxicity from the 
larger size of the alkyl group. 5. The R-isomer analogs are much safer to use than the α2/α3/α5 S-
isomers. However, the latter S-series exhibits better binding efficacy but with less α5 subtype 
selectivity. When designing new ligands, the possible cytotoxicity from the S-isomers should 
always be kept in mind. 6. The imine-migration byproduct, [N(5)-C(4) olefin] with no chirality 
significantly decreased the LD50 value of the corresponding oxazole, which indicated a structure 
with the wrong backbone with no chirality could introduce cytotoxicity and should not be taken to 
the next level of study in the series described here. 7. The different substituents at the C(8) position 
did not change the cytotoxicity profile. 8. The HEK293 kidney cell line usually provides a lower 
LD50 value than the liver HEPG2 cell line, thus the kidney LD50 value should be considered of 




2.2.3.4.3. Evaluation of the CNS Effects  
This CNS screen delineates their influence on motor activity with an aim to preliminary 
evaluation of the appropriateness of these ligands for further research. 
2.2.3.4.3.1. Rotarod Test via Oral Gavage 
In order to compare the sensorimotor coordination of the amides in the R-series with the S-
series, all amide analogs with different substituents at C(3), C(4), (8) and 2' phenyl positions were 
assessed on the rotarod test. The results are shown in Figures 22-25. 
The comparison of the effects from the amides demonstrated that the S-amides at the C(4) 
exhibited more sedative effects than the corresponding R-CH3 substitute amides. Most of the 
amides in the S-series including diazepam as the positive control (5 mg/kg), elicited the greatest 
impairment of sensorimotor steadiness at 10 minutes, followed by 30 and 60 minutes on the rotarod. 
Several of the compounds were not soluble in the vehicle (10 % DMSO, 50 % PBS, 40 % 
propylene glycol,) and could not be tested. Consequently, all compounds were subsequently 
administered via oral gavage at 40 mg/kg in a vehicle of 2 % polyethylene glycol and 2.5 % 
hydroxypropylmethylcellulose solution. The compounds that caused the most severe motor 
impairment were S-isomers 25, 26 and 30. As previously described, the more the steric size of the 
groups on the amides, the less sensorimotor impairment in the S-series. None of the compounds in 
the R-series exhibited cytotoxicity nor sensorimotor impairment regardless of the alkyl branches 
on the amide, as illustrated in Figure 22. The thioamides did not induce any sedative effects on 
mice at all 5-time points, expect dimethyl thioamide 42, whereas in two fell off the rotarod in the 
first 10 minutes. The C(8)-bromo-dimethyl amide 45 and the C(8)-cyclopropyl ethyl amide 48, as 
well as the 2'N-R methyl amide 50 did not exhibit any sedation nor ataxia at all time points. The 
80 
 
C(8)-bromo-ethyl amide 46 and the C(8)-cyclopropyl dimethyl amide 47 exerted moderate 
sensorimotor deficits as compared to other compounds. Only one compound, the C(8)-bromo-
methyl amide 49 in the achiral 2'F series showed severe motor impairment, and it was worse even 
than the positive control diazepam, as shown in Figure 23. These results indicated that the (R) 
chirality at the C(4) position was important to reduce sedation and ataxia. Moreover, as shown 
before, the combination of the achiral ligand with a C(8)-bromine atom might want to be avoided 
while designing new ligands.  
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Figure 22. The effect of amides from the R-series (36-40) and the S-series (25-30) on the sensorimotor 
coordination on the rotarod in vivo. Swiss Webster mice received an oral gavage of the compound at 40 mg/kg 
or diazepam (5 mg/kg i.p.) and were placed on a rotarod at 15 rpm for 3 minutes, and the performance was 
recorded after 10, 30 and 60 minute time points after drug administration. A fail was assigned to a mouse if 
they have fallen twice within 3 minutes. The latency to fall is presented as mean ± SEM (n = 9). The vehicle was 
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*All Compounds Administered via Oral Gavage at 40mg/kg









Figure 23. The effect of thioamides from the R-series (41-44), the amides with either a Br or a cyclopropyl group 
at the C(8) position (45-48), an achiral C(Br) methyl amide (49), as well as a methyl amide (50) in the 2'N series 
on the sensorimotor coordination assay on the rotarod assay in vivo. Swiss Webster mice received an oral 
gavage of the compound at 40 mg/kg or diazepam (5 mg/kg i.p.) and were placed on a rotarod at 15 rpm for 3 
minutes, and the performance was recorded after 10, 30 and 60 minute time points (additional time points at 
120 and 240 minutes for the thioamides) after drug administration. A fail was assigned to a mouse if they had 
fallen twice within 3 minutes. The latency to fall is presented as mean ± SEM (n = 7-8). The vehicle was used as 
the negative control, and diazepam as the positive control. Unpublished data. 
 
The 1,2,4-oxadiazoles in all series did not exhibit any locomotor impairment regardless of 
any modification at different positions in the molecule at all time points, as shown in Figure 24. 
Whereas the other bioisostere, the 1,3-oxazoles exhibited slight sensorimotor steadiness than the 
oxadiazole analogs, except the R-C(8)-bromo oxazole 64 and S-C(8)-ethinyl oxazole 67, as 
presented in Figure 25. In the S-series, all Br analogs are more sedating than the ethinyl oxazoles, 
82 
 
which might occur due to the electronegative character of the Br atom as opposed to an electron 
rich than ethinyl group, which probably lead to a stronger agonist interaction at alpha 1 subtypes. 
However, contradictory results were observed in the R-enantiomer series: the C(8)-ethinyl ligand 
is slightly more sedating than Br analog. One may need to repeat the rotarod experiment for further 
confirmation. 















































































200 10 min 30 min 60 min
*All Compounds Administered via Oral Gavage at 40mg/kg









Figure 24. The effect of oxadiazoles on the sensorimotor coordination on the rotarod test in vivo. The Swiss 
Webster mice received an oral gavage of the compound at 40 mg/kg or diazepam (5 mg/kg i.p.) and were placed 
on a rotarod at 15 rpm for 3 minutes, and the performance was recorded after 10, 30 and 60 minute time points 
(additional time points at 120 and 240 minutes for later compounds) after drug administration. A fail was 
assigned to a mouse if they had fallen twice within 3 minutes. The latency to fall was presented as mean ± SEM 
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Figure 25. The effect of 1,3-oxazoles on the sensorimotor coordination on the rotarod test in vivo. The Swiss 
Webster mice received an oral gavage of the compound at 40 mg/kg or diazepam (5 mg/kg i.p.) and were placed 
on a rotarod at 15 rpm for 3 minutes, and the performance was recorded after 10, 30 and 60 minute time points 
after drug administration. A fail was assigned to a mouse if they had fallen twice within 3 minutes. The latency 
to fall is presented as mean ± SEM (n = 4-7). The vehicle was used as the negative control, and diazepam as the 
positive control. Unpublished data. 
 
2.2.3.4.3.2. Rotarod Test via I.P. Administration  
In addition to the oral administration, the rotarod test of these compounds was also tested 
via i.p. administration at 10 mg/kg in mice for 20 minutes. The results for the first batch of amide 
analogs GL-II-73, 74, and 75 (36, 37, and 38) of the parent compound 1 and the methyl amide 35 
are presented in Figure 26. It is clear that a different route of administration can exhibit totally 
different results. The dimethyl amide 36 did not exhibit any sedation nor ataxia on the rotarod 
performance; however, 37 and 38 exerted impairment of locomotor coordination, which was not 
seen in the rotarod test with oral gavage. Also examination of the results indicated that the larger 
alkyl substituents on the amide group, presumably, would increase the CNS effects by passing 
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through the BBB more rapidly than smaller chain amides due to the higher lipophilicity. Moreover, 
the i.p. injection allowed the ligands to bypass first-metabolism in the stomach and directly act on 
the brain much faster than the oral administration. However, 36 did not induce any sedative effect 
or ataxia or any locomotor impairment by both routes of administration, which is very important.  
 
Figure 26. The effect of GL-II-73 (36), GL-II-74 (37) and GL-II-75 (38), all dosed i.p. at 10 mg/kg, on the average 
time on the rotarod 20 minutes after administration of the drug in mice. All data are presented as the mean ± 
S.E.M. Number of animals per treatment group (Vehicle, GL-II-73, GL-II-74, and GL-II-75) was 5, 7, 12 and 
9, respectively. **p < 0.01 and ***p < 0.001 compared to Vehicle, ###p < 0.001 compared to GL-II-73 (36). 
Unpublished data. 
 
In order to assess the dose-dependent influence of amides 35-38 on motor coordination, as 
well as the capability of flumazenil to prevent rotarod incapacitation induced by the lowest fully 
effective dose of those ligands, the rotarod assay was performed in adult male C57/BL6 mice 
(n=55). Examination of the data in Figure 27 illustrates the latencies to fall from the rotating rod 
recorded in mice injected i.p. with the tested ligands, on their own and in combination with 
flumazenil, the non-selective antagonist of the benzodiazepine binding site of GABAARs. It can 
be observed that all compounds exhibited a similar dose-dependance effect on the time that the 
animals were able to stay: with the increase of the dose the locomotor impairment was more 
significant. Importantly, the reliably incapacitating dose of all ligands, 35, 37 and 38, was 10 mg/kg, 
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and their impairing effect was prone to prevention by the administration of flumazenil. On the 
other hand, 36 displayed a much wider margin of safety, and the incapacitating effect of 90 mg/kg 
dose (i.p.) was also prevented by the co-administration of flumazenil. This indicated that impairing 







Figure 27. The effects of increasing doses of MP-III-022 (a), GL-II-73 (b), GL-II-74 (c) and GL-II-75 (d) on the 
rotarod performance assessed 20 minutes and 1 hour after i.p. administration in male C57/BL6 mice (n = 1–4 
per treatment). The doses administered were 5, 10, 15 and 20 mg/kg for MP-III-022; 10, 15, 20, 30, 45, 60 and 
90 mg/kg for GL-II-73; 5, 10, 15 and 20 mg/kg for GL-II-74 and 3, 5, 10, 15 and 20 mg/kg for GL-II-75. 
Additionally, the reliably incapacitating dose of each of the ligands was co-administered with flumazenil at a 
dose of 15 mg/kg and that influence on the rotarod performance was also observed. 
 
The rotarod test with i.p. administration was performed for another batch of novel ligands 
GL-III-66 (39), GL-III-67 (46), GL-III-70 (47), GL-III-68 (48), GL -III-64 (54), GL-III-60 (58), 
and GL-III-63 (61), as presented in Figure 28 with the dose-response values. No consistent 
incapacitating doses of any of the ligands tested were observed, except of ligands 39 and 46. When 
given at a dosage of 40 mg/kg and 20 mg/kg, respectively, these two ligands decreased the average 
time on the rotarod and incapacitated an animal. No sedation nor motor impairment was observed 
with other test compounds. As expected, the amides (39, 46, 47 and 48) produced slightly more 




















Figure 28. The observed effect of GL-III-66 (39), GL-III-67 (46), GL-III-70 (47), GL-III-68 (48), GL -III-64 
(54), GL-III-60 (58), and GL-III-63 (61) dosed i.p. at 20, 30 and 40 mg/kg on average time on the rotarod 20 





Immediately after the test on the rotarod, rats underwent the grip strength test with 
compounds GL-III-66 (39), GL-III-67 (46), GL-III-70 (47), GL-III-68 (48), GL -III-64 (54), GL-
III-60 (58), and GL-III-63 (61). The muscle strength was assessed by the grip strength meter. When 
pulled by the tail, the rat grasps the trapeze connected to a force transducer, and the apparatus 
measures the peak force of experimenter's pull (in grams) necessary to overcome the strength of 
the animal's forelimb grip. Each animal was given three consecutive trials, and the median value 
of three readings was reported. Results of the grip strength test (normalized against the animals’ 
body weight) are given in Figure 29. There are no consistent differences in the peak force of the 
experimenter’s pull necessary to overcome the strength of the animals’ grip after treatment, except 
after administration of 46. Given in a dose of 20 mg/kg or higher, 46 might reduce the muscle 




















Figure 29. The observed effect of GL-III-66 (39), GL-III-67 (46), GL-III-70 (47), GL-III-68 (48), GL -III-64 
(54), GL-III-60 (58), and GL-III-63 (61) dosed intraperitoneally at 20, 30 and 40 mg/kg on muscle strength right 
after the rotarod testing. All data are presented as the mean ± S.E.M. Number of animals per treatment group 




2.2.3.4.3.3. Spontaneous Locomotor Activity 
The influence of 36-38 on spontaneous locomotor activity (SLA) was assessed in adult 
male C57/BL6 mice (n=27). The overall distances traveled during 60 minutes of recording are 
presented in Figure 30, while examination of Figure 31 shows distances traveled in 5-min bins. 
The locomotor effect of 36 was identical with the control, which indicates no locomotor 
impairment induced by this compound. However, an apparent hyperlocomotor effect of 37 versus 
SOL group was not significant despite a nominal P value of 0.021, because no significant 
difference was found between the two means that enclose that comparison; the only significant 
difference in post hoc analysis was that between the groups treated with 37 and 38. The 
hyperlocomotor response was observed with the treatment of 37 in time intervals 0-5 minute and 
50-55 minute. The compound 38 exhibited a similar stimulant-like effect in the first 5 minutes of 
the trials, while with a consistent hypolocomotion response was observed with 38 in the 15-40 




Figure 30. The effect of GL-II-73 (36), GL-II-74 (37) and GL-II-75 (38), all dosed i.p. at 10 mg/kg, on 
spontaneous locomotor activity during 60 minutes of recording in mice. All data are presented as the 
mean±S.E.M. Number of animals per treatment group was 7, with the exception of GL-II-73 (n=6). ++P<0.01 
between GL-II-74 and GL-II-75 groups. 
 
 
Figure 31. The effect of GL-II-73 (36), GL-II-74 (37) and GL-II-75 (38), all dosed i.p. at 10 mg/kg, on distance 
traveled in 5-min bins during recording on the locomotor activity test in mice. All data are presented as the 
mean±S.E.M. *P<0.05, **P<0.01 and ***P<0.001 versus SOL group. 
 
The influence of RV-II-04 (49), GL-II-31 (50), MP-III-023 (25), GL-I-54 (30), GL-III-23 
(52), GL-II-33 (51), GL-II-54 (53) and GL-I-65 (31), all dosed at 10 mg/kg (i.p.), on the SLA was 
assessed in adult male Wistar rats weighing 350-400 g (n=48). The overall distances traveled 
during 60 minutes of recording are presented in Figure 32, while examination of Figure 33 shows 
distances traveled in 5-min bins. According to the post hoc test, 25, and especially 49 induced 
profound sedation during nearly the whole period of recording. In the vast majority of bins, the 
animals treated with 49 or 25 traveled lower distance than SOL. Other compounds did not induce 




Figure 32. The effect of RV-II-04 (49), GL-II-31 (50), MP-III-023 (25), GL-I-54 (30), GL-III-23 (52), GL-II-33 
(51), GL-II-54 (53) and GL-I-65 (31), all dosed i.p. at 10 mg/kg, on spontaneous locomotor activity during 60 
min of recording in rats. All data are presented as the mean±S.E.M. Number of animals per treatment group 
was 5, with the exception of 51, 53 and 52, and SOL (n=6). **P<0.01 and ***P<0.001 versus SOL group. Other 
differences were not presented; in general, the animals treated with 49 were sedated when compared to all 
other groups, with the exception of 25. Unpublished data. 
 
 
Figure 33. The effect of RV-II-04 (49), GL-II-31 (50), MP-III-023 (25), GL-I-54 (30), GL-III-23 (52), GL-II-33 
(51), GL-II-54 (53) and GL-I-65 (31), all dosed i.p. at 10 mg/kg, on distance traveled in 5-min bins during 
98 
 
recording in the locomotor activity test in rats. All data are presented as the mean±S.E.M. Statistical 
significances were not presented. Unpublished data. 
 
Another series of novel ligands as putative selective modulators of GABAARs, which effect 
the α5 subunit are GL-III-66 (39), GL-III-67 (46), GL-III-70 (47), GL-III-68 (48), GL -III-64 (54), 
GL-III-60 (58), and GL-III-63 (61). These ligands were assessed in the SLA by Savic et al. The 
total distance traveled during 60 minutes of recording are presented in Figure 34A, while Figure 
34B shows the % of time in the central zone over the same time period. Although there was no 
statistical significances in these assays, certain differences between groups can be observed (most 
prominent difference occurred between the control and the ligand 39). It was observed a decrease 
in both total distance traveled and % of time in the central zone after administration of 15 mg/kg 
of 39. It implies that this ligand, given in doses higher than 15 mg/kg, might have the potential to 
produce sedative and/or anxiogenic effects. The observed difference between the control values of 
total distance traveled in animal groups receiving 10 and 15 mg/kg can be ascribed to the 






Figure 34. The effect of GL-III-66 (39), GL-III-67 (46), GL-III-70 (47), GL-III-68 (48), GL -III-64 (54), GL-III-
60 (58), and GL-III-63 (61), dosed intraperitoneally at 10 mg/kg (dark symbols) and 15 mg/kg (light symbols), 
on total distance travelled (A) and % of time in the central zone (B) during 60 min of recording in rats. All data 
are presented as the mean ± S.E.M. Number of animals per treatment group was 4 (10 mg/kg) and 6, 6, 7, 6, 8, 




The results of the effects of i.p. and orally administered novel ligands on motor 
performance in mice and rats shared a similar effect pattern and illustrated that some of them 
possess a clear potential to induce sedative and/or locomotor impairment, which is commonly seen 
as characteristics for BZD-like drugs, such as ligands 25 and 49. The isopropyl amide 39 might 
exhibit sedative and anxiogenic potential in rats at a dose higher than 15 mg/kg in the spontaneous 
locomotor activity assay and ataxic potential at a dose higher than 40 mg/kg in rotarod test. The 
bromo ethyl amide 46 might exert muscle relaxation in rats when given in a dose higher than 20 
mg/kg, as measured, in grip strength test. Other compounds in this behavioral study were 
pharmacologically inert over a wide dose range, like 36, 37 and 38, and as such can be considered 
as ligands possibly more silent at α1 GABAARs and also more selective for α5 GABAARs. The 
motor-impairing potential of certain ligands was slight, and the present set of data emphasizes the 
wide margin of safety from the prospect of unwanted motor-impairing effects of the dimethyl 
amide 36, oxadiazoles 54, 58 and 61. Taken together, it can be concluded from examination of 
these data that all other ligands except 25, 26, 35, 39, 46 and 49 might represent suitable candidates 
for examination of the effects mediated by α5 GABAARs. Most of all the anxiolytic, pro-cognitive 
and antidepressant effects were fully devoid of adverse motor effects at doses effective in distinct 
animal models of human psychopathology. 
 
2.2.3.4.4. Receptor Binding Studies  
In order to understand if any other receptor interactions would occur throughout the body, 
all of the novel ligands were sent to the National Institute of Mental Health (NIMH) Psychoactive 
Drug Screening Program (PDSP) to screen the ligands on a series of CNS receptors, ion channels, 
and transporters to determine if any possible receptor bindings interaction occurred (Dr. Bryan 
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Roth, UNC).137 A primary binding assay was conducted first to determine if there was any 
significant inhibition (over 50%), which one would consider as a hit and would be further tested 
in the secondary binding assay to obtain a Ki (nM) value.  
As shown in Appendix B, most of the compounds have exhibited inhibition at BzR rat 
brain synaptosomal membranes in the primary PDSP binding assay, which indicates binding 
affinity at GABAARs; however, these data were not able to indicate the binding affinity at different 
Bz alpha-subtypes. In addition, the test compounds did not bind to either calcium channels, which 
indicated no disruption of any physiological events on cardiac and smooth muscle cells,138 or 
NMDA receptors to affect any possible synaptic organization or plasticity.139 It was noticed that 
only the compounds with a C(8) TMS-acetylene group exerted a slightly undesired binding to 
hERG regardless of other modifications in the backbone structure, such as changes at the 2' phenyl 
position, or any different moieties at the C(3) position. The structures and the corresponding Ki 
values are shown in Table 12. 
Table 12. Binding affinities at hERG, only the TMS-acetylene compounds among the entire compound 
library have slight affinity to hERG (PDSP). Unpublished data. 
PDSP 
Code 
Cook Code Structure 
Binding affinity at hERG 
 % inhibition 
(primary) 
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The peripheral benzodiazepine receptor (PBR), later renamed as translocator protein 
(TSPO), was also selected for screening in regard to binding affinity. PBRs are responsible for 
numerous biological process, such as the regulation of neurological damage, cellular proliferation, 
apoptosis, transportation of anions for mitochondrial transmembrane potential, as well as 
regulation of steroidogenesis and heme biosynthesis.140 There are some compounds that exhibited 
binding affinity at PBR, as shown in Table 13 for the selected novel compounds, which have a 
wide variety of functional groups at different positions. Most of them have a Ki value in the range 
of 300-3800 nM, except 54 (GL-III-64). This oxadiazole 54 exhibited a high affinity at PBR in 
103 
 
the nanomolar range (29 nM), which is even more potent than the classical achiral BZD, 
Ro5-4846 (53 nM) that was reported to stimulate steroidogenesis.141 Since 54 is a metabolically 
stable bioisostere devoid of any CNS effects, it might be an interesting ligand for exploration of 
its pharmacological effects, in addition to the current lead compounds with the aid of further 
confirmation of its effect in a functional assay. 




Cook code Structure 
Binding affinity at PBR 
 % inhibition 
(primary) 
















































Besides the binding affinity at the receptors illustrated above, it is interesting to see that 
most of the IMDZs were not only potent enough to inhibit the BzD rat brains site, but also exhibit 
inhibition at kappa opioid receptors (KOR). Such compounds are not limited to a certain functional 
group, oxadiazole, oxazoles, esters, and amides have all exerted different affinities at KOR, as 
listed in Table 14. All S-isomer analogs have higher affinity at KOR than the corresponding R-
isomer analogs. Other trends are increasing affinity in the following order: ester > amide/ 
oxadiazole/oxazole; 2'F > 2'N; large alkyl group size > small. 




Binding affinity at KOR 
% Inhibition 
(primary) 
Ki in nM 
(secondary) 
30611 SH-053-2'F-R-CH3 90.9 240 
30612 SH-053-2'F-S-CH3 95.7 90 
30613 MP-III-004 80.3 599 
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30614 MP-III-021 97.5 122 
30615 MP-III-019 45.5 3367 
30616 MP-III-018.A 71.1 1182 
30617 MP-III-022 87 381 
30618 MP-III-023 96.1 119 
30619 SH-I-85 95.6 162 
37719 MP-III-018.B 50.9 3072 
37720 MP-III-019.B 62.1 2621 
37721 MP-IV-004 86 637 
37722 GL-I-65 88.4 222 
37723 MP-IV-005 89.3 380 
37724 GL-I-66 91.7 296 
37725 MP-IV-010 93.6 149 
37726 GL-I-81 92.9 127 
42633 Ro5-4846 57.5 1323 
42638 GL-II-06 78.8 401 
42644 GL-II-33 88.8 193 
42648 GL-II-54 80 504 
42656 GL-I-30 94.9 27 
42657 GL-I-31 94.2 65 
42658 GL-I-32 94.5 64 
42659 GL-I-33 93.7 34 
42660 GL-I-38 95.2 68 
42661 GL-I-36 84.9 411 
42662 GL-I-43 95.2 102 
42663 GL-I-41 97 39 
42664 GL-I-55 93.1 150 
42665 GL-I-54 77.9 788 
42666 GL-I-77 95 125 
42667 GL-I-78 95.7 48 
50094 SH-I-047 82.4 110 
50096 MP-III-058 83.6 249 
50098 SH-I-048B 95.2 63 
50104 GL-II-73 58.1 1402 
50105 GL-II-74 86 229 
50106 GL-II-75 80.9 354 
50107 GL-II-76 80.4 418 
50125 GL-III-35 77 912 
50126 GL-III-36 87.8 253 
50127 GL-III-36A 62 2398 
50130 GL-III-73 74.3 452 
50132 GL-III-42 86.1 213 
50133 GL-III-43 50.2 1927 
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50135 GL-III-53 91.7 227 
50137 GL-III-60 87.4 391 
50138 GL-III-63 77.5 796 
50139 GL-III-64 60.2 2640 
50140 GL-III-66 62.9 241 
50141 GL-III-67 87.3 181 
50142 GL-III-68 88.3 212 
50143 GL-III-69 75.1 627 
50144 GL-III-70 67.7 1080 
50145 GL-III-75 61.2 1569 
50146 GL-III-76 83.2 460 
50149 GL-III-78 74.1 571 
 
It seems as though as long as the ligand contains a chiral methyl group at the C(4) position, 
the ligand will bind to KOR at a certain extent, although it will not be potent affinity. Since KOR 
agonists are a big concern in drug addiction, it is important to know if these IMDZs function as 
agonists or antagonists at KOR. If they turned out to be potent KOR agonists, the compounds 
would have been dropped from the next screening panel for other behavioral studies. However, if 
they acted as antagonists or very weak agonists, the activity would be much less of concern. 
Therefore, the secondary assay was conducted to determine the function for these ligands. The 
results are shown in Table 15. The test compounds have weak kappa agonist activity since the 
potencies are at micromolar concentrations. For comparison, if a compound was a kappa agonist 
with potent activity, the nanomolar potency would be the range to focus on. In Table 15, two kappa 
compounds Salvinorin A and U-50488 were used as controls to ensure the assays were functioning 
correctly. Both Salvinorin A and U-50488 exhibited nanomolar potencies, which means that not 
very much of those compounds are needed to stimulate a response to the kappa opioid receptor. 
However, the selected test compounds were in a range of micromolar concentration for the 
stimulation response, which indicated that these compounds have some kappa activity, but their 
activity at the kappa receptor is considered fairly weak and inconsequential. 
108 
 
Table 15. Selective compounds for KOR stimulation response. 









Salvinorin A 0.0000341 8.64E-06 100.9 0.3687 3 
30 (GL-I-54) 3.689 0.3098 112 1.021 3 
31 (GL-I-65) 0.9739 0.4672 105.5 2.967 3 
51 (GL-II-33) 6.25 3.737 119.1 31.57 2 
53 (GL-II-54) 1.573 0.3111 107.4 1.754 3 
36 (GL-II-73) 1.511 0.3532 104.4 1.441 3 
37 (GL-II-74) 0.1236 0.04516 101.3 0.09095 3 
38 (GL-II-75) 0.3157 0.0704 102.7 0.8377 3 
U50488 0.0001509 8.01E-05 99.34 0.2595 3 
 
Several key compounds were tested in further binding assays at α1/2/3/5-GABAARs. As 
shown in Table 16, the results indicated that all three amides 36, 37 and 38 exhibited more potent 
selective-affinity to the α5-subtypes as PAMs than other α-subtypes, whose Ki values were 6-15 
fold more potent, as compared to the other subtypes. Notably, the dimethyl amide 36 exhibited the 
least potent affinities with Ki values in a low μM range, as compared to 37 and 38. The cyclopropyl 
amide 38 had an overall low potency but a similar binding pattern than the positive control DZP.  
In contrast to these new ligands, DZP demonstrated a potent but non-subtype selective-affinity at 
all α-subtypes.  
Table 16. Ki values for all three compounds at α1/2/3/5β3γ2 receptors. 
 132 232 332 532 
36 (GL-II-73) 55 ± 4µM 30 ± 5 µM 63 ± 7µM 5 ± 2 µM*** 
37 (GL-II-74) 1060 ± 100 nM 809 ± 130nM 1250 ± 51nM 83 ± 12nM*** 
38 (GL-II-75) 542 ± 88 nM 789 ± 130 nM 480 ± 62 nM 79 ± 2 nM** 
DZP 22.4 ±  5.4 nM 13.4 ±1.1 nM 20.4 ± 2.8 nM 12.1 ± 1.2 nM 
Significance towards 1 3 2 ; *:p<0.05,**:p<0.01,***:p<0.001. Values determined by Dr. Janet Fisher on 





2.2.3.4.5. Potentiation at GABAARs 
To investigate the effects of novel IMDZs on GABAARs, the potentiation of GABA 
signaling at α1-6β3γ2 containing recombinant GABAARs has been assessed at 100 nM and 1 µM 
concentration, as compared to the response to GABA alone.  
As shown in Figure 35 a-d, at 100 nM, electrophysiological traces at α5β3γ2 GABAARs 
showed that 37 and 38 exhibited a significant allosteric modulation with α5 Bz/GABA(A) subtypes, 
respectively 169.9% and 182.4% potentiation of the percentage of response to GABA alone. At 
this concentration, 36 and 39 exhibited a lower potentiation at α5β3γ2 GABAARs. The compound 
38 also exhibited high potentiation at α1, α2, and α3 receptor subtypes, characterized by the 
potentiation of the response of GABA alone above 180% for each subunit (203%, 194% and 183% 
for α1, α2, and α3 respectively). The percentage of response to GABA with co-application of 
diazepam (DZP) was also assessed, and the potentiation obtained at each GABAAR subtype (α1-
6β3γ2) was very similar but slightly more potent to the obtained for 38. It appeared that the 
compound GL-II-75 might share electrophysiological properties with DZP. At 1µM concentration, 
all compounds tested elicited a significant allosteric modulation at the α5β3γ2 GABAA receptor, 
with potentiation values obtained around and higher than 250%. The potentiation of 36 and 37 at 
α1, α2, and α3 were lower than α5, which indicated that these two ligands were more α5 preferred. 
Again, at 1µM, 38 also exhibited high potentiation of α1, α2 and α3 subunits (>300%) while the 
other compounds had a moderate efficacy (<200%) to these subunits. As expected, none of the 
compounds potentiated receptors containing α4 or α6 subunits. (Figure 35 a-d), suggesting a 
similar subtype dependent response as DZP at BZR. A similar potentiation at GABAARs with β1 
or β3 subtypes were observed for 36-39, indicating that there was no significant impact between 
different β subunits on the efficacy of the novel compounds, as presented in Figures 35 e-h.  
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Based on the estimated free brain concentration, it appeared that the doses of 1 mg /kg and 
10 mg/kg used for behavioral assessments elicited a different pattern of GABAAR potentiation. 
With 36, 37 or 38 administered at 1 mg/kg, neither α5 nor α1 were potentiated (less than 120 %). 
However, at 10mg/kg, the potentiation of α1 and α5 were significant for all compounds. At this 
dose, 36 exhibited a moderate to strong α5 potentiation (180%) as well as a slight potentiation at 
α1 (130%). This pattern of potentiation was even greater with 37 that exhibited 275% at α5 and 
155% at α1. However, 38 elicited a stronger potentiation at α1 (280%) than α5 (240%), which is 
very similar to the pattern of DZP. Altogether, these results confirmed that each compound had 
allosteric modulation effects at α5-containing GABAARs, as well as α1, α2, and α3. Nevertheless, 
at 10 mg/kg, the potentiation at α1 subtypes of 36, 37 and 38 was lower than that of DZP at 1.5 






Figure 35. Efficacy data of 36 (a), 37 (b), 38 (c) and 39 (d) at 100 nM or 1 μM for α1-6-containing GABAARs. 
Comparison of α1β1γ2 and α1β3γ2 for 36 (e), 37 (f), 38 (g) and 39 (h) at 100 nM or 1 μM.  The EC3–5 GABA 
value is presented in percentage of response to GABA alone. * p < 0.05, ** p < 0.01, and *** p < 0.001 compared 
to 100%; + p <0.05 compared to α5β3γ2; # p < 0.05 compared to α1β3γ2. The estimated free brain 
concentrations were illustrated on the dose-response curves for the approximated electrophysiological 
responses of 36 (i), 37 (j), 38 (k), and DZP (l). (Adopted from the figure in Prevot et al.)117 
 
Besides the amide analogs 36-39, a series of other amides, thioamides, and oxadiazoles 
were assessed for their potentiation at α1,2,3,5-containing GABAARs at 100 nM (Figure 36) and 
1 μM (Figure 37), as compared to 36 (GL-II-73). The % response value at α4 subtypes was nearly 
at the baseline, which indicated all those analogs did not potentiate α4-containing GABAARs (data 
was not shown). Among all the test compounds, the C(8)-bromo ethyl amide 46 (GL-III-67) 
exhibited the greatest potentiation at all subtypes, however, with slightly more potentiation at α1 
receptors at 100 nM and a slight preference for α5 receptors at 1 μM concentration. As previously 
demonstrated on the rotarod studies, this ligand exhibited a slight sedative effect, which was now 
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confirmed by the potentiation at α1-subtypes at lower concentrations. A cyclopropyl group at the 
C(8) position significantly reduced the potentiation at all subtypes as illustrated via a direct 
comparison of amide 36 to 47 (GL-III-70), and 46 to 48 (GL-III-68). The C(8)-cyclopropyl 
dimethyl amide 47 lost almost all the efficacy at all subtypes at 100 nM, and only a slightly 
potentiation was observed at 1 μM with more efficacy at α1 subtypes than the other subtypes. The 
potentiation elicited by the C(8)-cyclopropyl methyl amide 48 was less than the C(8)-bromo 
compound after the introduction of the C(8)-cyclopropyl group. However, it still exhibited a 
similar pattern of efficacy as ligand 46, but even much lower efficacy at 1 μM. In the thioamide 
series, with the exception of the dimethyl thioamide 42 (GL-III-85), which demonstrated almost 
no potentiation at all subtypes at both concentrations, the other three thioamides: methyl thioamide 
41 (GL-III-84), ethyl thioamide 43 (GL-III-86) and cyclopropyl thioamide 44 (GL-III-87) all 
exhibited better potentiation than 36 at all subtypes, especially at α2 and α3 subtypes. At 100 nM, 
they shared a similar efficacy pattern to that of 38 (GL-II-75) with a slight preference for α1 
subtypes, similar to the pattern for 37 at 1 μM. In regard to the oxadiazole series, the methyl 
oxadiazole 31 (GL-I-65) in the 2'F-S-series, elicited a stronger potentiation than 36 with a similar 
potentiation profile to that of 38 at 100 nM, and to the profile of 36 at 1 μM. The C(8)-ethinyl 
methyl oxadiazole 51 (GL-II-33) and its C(8)-bromo analog 53 (GL-II-54)  in the 2'N-R-series, 
exhibited only slight efficacy at 100 nM, and only at 1 μM did they significant produce the 
potentiation at GABAARs. At this concentration, the ligand 51 exhibited an efficacy profile similar 
to 38 with more efficacy at α1 subtypes, whereas, the bromo analog 53 resembled the more efficacy 












































Figure 36. Efficacy data of GL-II-73, GL-III-67, GL-III-68, GL-III-70, GL-III-84, GL-III-85, GL-III-86, GL-












































Figure 37. Efficacy data of GL-II-73, GL-III-67, GL-III-68, GL-III-70, GL-III-84, GL-III-85, GL-III-86, GL-
III-87, GL-II-33, GL-II-54 and GL-I-65  at 1 μM for α1,2,3,5-containing GABAARs. Unpublished data. 
 
In addition to the ester, amide, and oxadiazole moieties at the C(3) position of the targe, 
several chiral oxazole analogs 64 (GL-III-36), 65 (GL-III-76), 66 (GL-III-73), 67 (GL-III-78), and 
79 (GL-III-76A) were also assessed for their potentiation at α1-5 GABAARs at 100 nM and 1 μM 
concentrations, as illustrated in Figures 38 and 39, respectively. As expected, there was no efficacy 
at α4 subtypes for all IMDZ compounds. However, the distinct difference between R and S-isomers 
was observed. The S-analogs elicited a stronger non-subtype selective potentiation at α1/2/3/5 
subtypes at both concentrations at 100 nM and 1 μM. The C(8)-bromo analogs were more potent 
than the corresponding ethinyl analogs in the S-series. However, efficacy in the R-series was 
visible only at 100 nM. The R-analogs tended to elicit a slightly higher α5 preference than at the 
other subtypes at 100 nM, but lost selectivity at 1 μM. Moreover, 65 exhibited the highest 
potentiation at both concentrations for all subtypes, as compared to the other compounds. Notably, 



































Figure 38. Efficacy data of (R) 64 (GL-III-36), (S) 65 (GL-III-76), (R) 66 (GL-III-73), (S) 67 (GL-III-78), and 






































Figure 39. Efficacy data of (R) 64 (GL-III-36), (S) 65 (GL-III-76), (R) 66 (GL-III-73), (S) 67 (GL-III-78), and 
79 (GL-III-76A) at 1 μM for α1-5-containing GABAARs. Unpublished data. 
 
2.2.3.4.6. Studies of Pharmacokinetics 
The pharmacokinetic studies of the first batch of test compounds 36-38 and DZP were 
carried out after 10 mg/kg i.p. administration to mice, as presented in Figures 40 a–d. The brain 
and plasma free fractions for 36 were 12.14 and 20.39 %, 4.49 and 6.34 % for 37, 1.34 and 5.08 % 
for 38, and 6.38 and 16.25 % for DZP, respectively. The half-life for the test compounds indicated 
that the ethyl amide 37, as well as DZP, are the most stable compounds in mouse plasma, as 
compared to all the other ligands, while 36 exhibited the highest stability in the mouse brain. The 
ligand DZP and 37 reached the Cmax in the brain in 5 minutes, whereas it took 10 and 20 minutes 
for 36 and 38 to obtain a similar free fraction, respectively. The ligand 37 presented the highest 
maximum brain concentration over the other two compounds, suggesting an optimization might 
be applied for dosage in the brain. The brain-to-plasma partition coefficient values (Kp) for 37 
indicated that it exhibited excellent brain permeability, as compared to the other two ligands. The 
ratio of unbound brain to unbound plasma ligand concentration values (Kp,uu), which measures 
the net transport through the BBB, further demonstrated similar results those as obtained from the 
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Kp value. This brain penetration efficiency suggested that 36 may be subject to an efflux transport 
mechanism at the BBB. The ligands 37 and 38 exhibited a much higher AUC in the brain than 
DZP, whereas 36 was slightly lower but was similar to DZP. The PK studies illustrated that all 3 
ligands have good brain penetration in an efficient manner with the following order: DZP > 37 > 
38 > 36. Accordingly, all of these compounds were further evaluated for in vivo behavioral activity 






Figure 40. Plasma and brain concentration-time profiles of 36 (a), 37 (b), 38 (c), and DZP (d) after 10 mg/kg 
i.p. administration in male C57BL/6 mice (n = 3 per time point). (Adopted from the figure in Prevot et al.)117 
 
In addition to ligands 36-38, several amides 49 (RV-II-04), 50 (GL-II-31), 25 (MP-III-023), 
30 (GL-I-54), 39 (GL-III-66), 46 (GL-III-67), 47 (GL-III-70), and 48 (GL-III-68), and oxadiazole 
analogs 52 (GL-III-23), 51 (GL-II-33), 53 (GL-II-54), 54 (GL-III-64), 58 (GL-III-60), 61 (GL-III-
63), and 31 (GL-I-65) were also evaluated for their PK profiles in mice and rats after i.p. dosing 
at 3 mg/kg. The data is presented in Appendix C: Tables 1 and 2, Figures 1-18.  
By comparing the AUC and Cmax values in plasma from the respective concentration-time 
profiles of all test compounds (see Appendix C Figures 1-18), the examination of the data 
illustrated the potential for systemic exposure was generally quite high, regardless of the route of 
administration routes. The AUC values from time 0 to 12 h or infinite time post-dosing values in 
both plasma and brain indicated around a 2-fold greater exposure of animals to 54, 58, and 61, as 
compared to the other ligands. Moreover, the calculated Kp values (1.15 for 49, 0.33 for 50, 1.15 
for 25, 0.19 for 30, 2.37 for 52, 1.46 for 51, 1.17 for 53 and 1.29 for 31) indicated that all ligands 
exhibited good brain penetration after i.p. administration in mice, which is critical for research in 
any in vivo animal model. Generally, the values of Kp close to or greater than one unity indicate 
excellent brain penetration of the test compound. In order to compare concentrations obtained in 
vivo and in vitro, it is illustrative to express the kinetic results in molar beside the weight 
concentrations. After i.p. dosing at 3 mg/kg in mice, compounds 50, 51, 31, and 39 reached 
moderate to high submicromolar concentrations; compounds 30, 53, 47, and 48 reached high 
submicromolar to low micromolar values, while compounds 49, 25, 52, 39, 54, 58, and 61 reached 
micromolar concentrations in brain tissue, and similar results were obtained in rat brain.  
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All of the test compounds are orally active, which is usually considered as an optimal 
delivery route for active CNS drugs. The calculated F values (oral bioavailability) after i.p. 
administration in mice are as follows: 1.25 for 49, 1.43 for 50, 1.08 for 25, 0.74 for 30, 2.88 for 
52, 3.77 for 51, 1.24 for 53 and 3.17 for 31. Usually a relatively high bioavailability is expected 
for the BZD-like compounds; however, if the F values were above unity, it might suggest that the 
compound after i.v. injection may have undergone precipitation or crystallization, which would be 
connected with a probable rupture of the tail vein, while administering the volume of about 0.3 
mL. This would be due to the low solubility of the ligands under study. On the other hand, the 
calculated F value for 36 after iv. or p.o. administration at the 3 mg/kg dose in rats was 0.33, not 
near a value of unity. 
The elimination half-time (t1/2) after i.p. administration of the test compounds in mice 
plasma was in the range between 0.53 h (for 38) and 8.89 h (for 39). A relatively wide range of 
half-life values suggests that most of the compounds would be appropriate for a repeated-dose 
treatment with a t1/2 longer than 1 hour, while those with t1/2 < 1 hour (38 and 30) would be more 
applicable for short-acting agents. Nonetheless, the elimination from mouse brain tissue after i.p. 
administration tends to be consistently above 1 h (a t1/2 was calculated slightly less than 1 hour 
only for 49, 25 and 30), which further confirmed that most of the compounds meet the requirements 
for a potential CNS-active drug. Qualitatively, a similar pattern was observed from the PK data 
obtained by other administration routes (i.v. or p.o.) in mice. With regard to the data from rat 
plasma and brain, the elimination half-lives are usually slightly longer than in mice, as expected. 
The t1/2 of the test compounds in both plasma and brain are consistently higher than 2 h after i.p. 
administration in rats in the case of 50-53 and 31; the pharmacokinetic profiles of 36-38, and later 
analogs after i.p. administration in rats are have yet to be determined. 
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Taken together, it can be concluded that 31, 36, 51, 53, 54, 58, and 61 probably represent 
suitable candidates for further evaluation of the effects mediated by α5 or α2/3/5-containing 
GABAARs, in vivo in regard to anxiolytic, pro-cognitive and antidepressant effects. 
 
2.2.3.5. Schizophrenia 
2.2.3.5.1. Neuroinflammatory Effects and Schizophrenia 
In recent years, the accumulation of a large amount of evidence has suggested the 
importance of the link between multiple inflammation processes and neuropsychiatric/ 
neurodegenerative disorders such as schizophrenia, depression, Alzheimer’s disease, and Autism 
spectrum disorders (ASD).142-146 The immune responses to oxidative stress and neuroinflammation 
might be applied to represent the abnormal aging process, as well as mental impairments.142 The 
primary immune cells in the CNS are microglia, which represent a majority of cell types in the 
brain. Microglia are involved in numerous critical processes such as regulation of the immune 
response and neuroinflammation, and cytotoxicity through the release of oxidative secreta and 
cytokines, which induce nitric oxide (NO)-synthase, etc. Upon activation of microglia, nitric oxide 
(NO)-synthase produces an increase in the amount of NO in the brain, which leads to a toxic 
neuronal effect and a decrease in the function of natural killer (NK) cells. The observation of NK 
reduction was reported in postmortem studies on schizophrenia patients, whereas not in bipolar 
depression patients.146  
Up to date, only the α1, α3, and β1-containing GABAARs have been identified in glia.
147  
In order to evaluate effect of the IMDZs on the modulation of the inflammatory response from 
microglia, the first set of α2/3 and α2/3/5 subtype selective ligands with a higher preference at α3 
121 
 
subtypes were tested in the Griess assay in GABAAR-containing immortalized microglia to 
determine for their influence on NO production at 50 µM in combination with 1 µM GABA, along 
with 100 nM dexamethasone as positive control and 1 mM CBT as a cytotoxicity control (Figure 
41). GABA alone was not capable of reducing NO levels, however, 8 out of the first 19 compounds 
studies elicited significant reductions in NO production (at 50 μM). Other compounds, which did 
not show a significant reduction in NO production or demonstrated toxicity were eliminated from 
consideration. The active compounds were further investigated subsequently for dose-response 
effects in a range of 1 nM – 50 μM, as depicted in Figure 43. This NO reduction was not the result 
from toxicity, except with ligand 32 (GL-I-66), which showed slight cytotoxicity (Figure 42), as 
compared to other active compounds.  It is interesting that the α2/3 or α3 subtype selective ligands 
such as 84 (KRM-II-81), 85 (MP-III-080), etc. did not decrease NO production. On the other hand, 
the C(4) chiral methyl analogs, which were expected to have characteristics compatible with α5 
subtype selective ligands, were the only compounds that exhibited the desired effects. None of the 
effects on NO were observed in the achiral series. For instance, the achiral 2'F oxadiazole did not 
reduce NO production, whereas the R-chiral analog 55 (MP-IV-004) did. Moreover, the R-chiral 
analogs exhibited a better reduction of NO in the Griess assay than the corresponding S-chiral 
analogs, as seen in the comparison of 55 vs. 31. Comparison of the size of the alkyl group on the 
oxadiazole ring (R-series: 55 vs. 56 vs. 57; and S-series: 31 vs. 32 vs. 33), it was obvious a larger 
group on the bioisostere portion produced more NO reduction regardless of the R or S chirality. In 
addition, the C(8) substituents influenced the NO reduction greatly, and it followed the trend of 
decreasing activity: cyclopropyl > Br > acetylene, regardless of the 2' prime pendent phenyl 
substituent.  The trend can be seen in the 2'N series: 54 > 53 > 51 or in the 2'F series: 61 > 58 > 
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55. The isopropyl oxadiazole MP-IV-010 (57) exhibited the highest efficacy in the Griess assay, 
and therefore, was chosen as the lead compound for further evaluation. 


























































































































































Figure 41. NO production via the Griess assay. Test compounds were screened at 50 μM with 1 μM GABA in 
mouse microglia activated with 150 U/mL IFNγ and 50 ng/mL LPS, along with 100 nM dexamethasone as a 
positive control and 1 mM CBT as the cytotoxicity control. Unpublished data. 
 


















































































































































Figure 42. Cytotoxicity via the Cell-Titer Glo Assay. Control compounds dexamethasone and CBT were run at 
concentrations of 100 nM and 1 mM respectively. Unpublished data. 
 











































































































































































































































































































































































































































































































































Figure 43. Dose-response of the active compounds from the Griess assay. The test compounds were screened at 
50 μM with 1 μM GABA in mouse microglia activated with 150 U/mL IFNγ and 50 ng/mL LPS, along with 100 
nM dexamethasone as a positive control and 1 mM CBT as a cytotoxicity control. Unpublished data. 
 
In addition to the first series of compounds that were assayed, the chiral oxazoles 64 (GL-
III-36), 65 (GL-III-76), 66 (GL-III-73), 67 (GL-III-78), 69 (GL-III-76A), 80 (GL-III-72) and 82 
(GL-III-77), were also evaluated to provide a better SAR. As illustrated in Figure 44, the C(8)-
bromo or cyclopropyl analogs 64, 65, 66, and 67 did not reduce the NO production, indicating they 
were not active in the Griess assay. A significant reduction in NO was seen with both the R and S 
C(8)-TMS-ethinyl analogs 80 and 82, which were nearly as potent as the lead compound 57. 
However, as previously described, all analogs contain the TMS-acetylene function at the C(8) 
position bind, albeit weakly to hERG channels. Due to cytotoxicity, which was confirmed in the 
toxicity assay, as shown in Figure 45, these TMS-acetylene oxazoles were the only two compounds 
that produced toxicity. Therefore they were eliminated from further studies. Interestingly, 79 (GL-
III-76A), the imine migration byproduct of 66, exhibited a significant reduction of NO with no 
cytotoxicity observed. Notably, from the electrophysiological recording assay of these oxazole 
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compounds, 79 was the only one that did not potentiate any GABAAR subtypes at all concentration, 
which suggested that 79 could affect NO production but not through a GABAAR mechanism, or 
this ligand acts as a GABAAR antagonist.  
All of the test compounds exhibited binding affinity to the BzD rat brain sites, as 
demonstrated by an examination of the PDSP data. When picrotoxin and flumazenil, which are 
non-competitive antagonists of GABAAR were introduced into the Griess assay along with 57, the 
effect on NO levels was expected to be diminished or reversed. However, the results were not as 
predicted; the NO production was still significant, as illustrated in Figure 44. This result together 
with the evidence on ligand 79 suggests that 57 may not be acting through the GABAAR, or only 
partially through GABAAR in the microglia. According to the PDSP binding data, these ligands 
also bound to KOR weakly most notably as well as the Sigma2 receptors, and further investigation 








































































































































Figure 44. NO production via the Griess assay for the oxazole compounds as well as the GABAAR antagonist 
picrotoxin at 50, 100 μM and flumazenil at 500 nM. Test compounds 64 (GL-III-36), 65 (GL-III-76), 66 (GL-
III-73), 67 (GL-III-78), 69 (GL-III-76A), 80 (GL-III-72) and 82 (GL-III-77),  were screened at 50 μM with 1 
μM GABA in mouse microglia activated with 150 U/mL IFNγ and 50 ng/mL LPS, along with 100 nM 
dexamethasone as a positive control and 1 mM CBT as a cytotoxicity control. Unpublished data. 
 
































































































































Figure 45. Cytotoxicity via the Cell-Titer Glo Assay for oxazole compounds 64 (GL-III-36), 65 (GL-III-76), 66 
(GL-III-73), 67 (GL-III-78), 69 (GL-III-76A), 80 (GL-III-72) and 82 (GL-III-77), as well as GABAAR antagonist 
picrotoxin at 50, 100 μM and flumazenil at 500 nM. Control compounds dexamethasone and CBT were run at 




2.2.3.5.2. Behavioral Studies in an Animal Models of Schizophrenia 
To study the neurobiological basis of schizophrenia, a series of animal models have been 
developed and applied during the past decades for further design of novel drugs. All currently 
available animal models of schizophrenia can be classified into four categories: 
neurodevelopmental models during the perinatal period such as MAM and post-weaning social 
isolation; drug-induced pharmacological models such as amphetamine- or PCP-induced models; 
lesion models such as neonatal ventral hippocampal lesions; or genetic manipulation models using 
knock-out mice.148 Several IMDZs synthesized in the Milwaukee research lab were evaluated in 
the previously utilized animal models for their effects on the potential treatment of schizophrenia, 
such as the MAM model,95-96  the amphetamine-induced hyperactivity in poly (I:C) animal 
model102  as well as the PPI of the acoustic model.90  
Recently, another drug-induced pharmacological model, the NMDA antagonist MK-801-
induced hyper-locomotor model, was applied as an activity to combat model for the selection of 
novel ligands that possess the symptoms of schizophrenic. It has been reported that reduction of 
the parvalbumin-immunoreactive GABAergic interneurons is related to the onset of schizophrenia 
during the neurodevelopmental process.149 The proliferation of these interneurons is affected by 
glutamate through the mediation of NMDA receptors, the major excitatory neurotransmitter 
receptors. By blocking the NMDA receptors, the neurodevelopment of the GABAergic system 
would be influenced, which would further lead to a hyperlocomotive response to the 
noncompetitive NMDA receptor antagonists such as PCP or MK-801, as well as dopamine 
receptor agonists such as methamphetamine.150 
The aim of this preclinical study was to assess the putative anti-schizophrenic-like 
properties of four novel α5-containing GABA (A) receptor PAM, 64 (GL-III-36), 65 (GL-III-76), 
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66 (GL-III-73), and 67 (GL-III-78), by measuring their influence on MK-801-induced 
hyperlocomotion as an animal model of schizophrenia, as well as evaluation on basal motor 
activity in the spontaneous locomotor activity assay (SLA) in C57BL6 mice, as a measure of 
anxiolysis. 
In regards the behavioral parameter, total distance traveled in the SLA, as shown in Figure 
46, all the ligands are brain-penetrant and behaviorally active, but with pretty different types of 
their respective interactions with MK-801. It can be concluded that 66 did not influence the MK-
801-induced hyperlocomotion, ligands 64 and 67 partially decreased this effect; however, ligand 
65 managed to completely reduce the hyperlocomotor and bring it down to the level of the control 





Figure 46. Total distance traveled in the MK-801-induced hyper-locomotor model. The data analyzed has 
been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, SAL + GL-III-73 10 
mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 0.32 mg/kg + SOL, MK-801 0.32 
mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 
mg/kg or MK-801 0.32 mg/kg + GL-III-78 10 mg/kg and Trial = Habituation trial or MK-801 challenge trial. 
Unpublished data. 
 
The average speed in the MK-801-induced hyper-locomotor paradigm is another 
behavioral parameter that demonstrated similar results as did the total distance traveled. The R-
isomer analogs 64 and 66 exhibited a higher average speed than the corresponding S-isomer 
analogs 65 and 67. Furthermore, the C(8)-bromo ligands indicated a lower average speed than the 
ethinyl analogs in both series of assays. In summary, a similar pattern was observed in both 
parameters, that 65 brought the speed level down to nearly the same level as the control animals, 




Figure 47. Average speed in the MK-801-induced hyper-locomotor model. The data analyzed has been limited 
in the following way: Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + 
GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 
10 mg/kg, MK-801 0.32 mg/kg + GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 
0.32 mg/kg + GL-III-78 10 mg/kg and Trial = Habituation trial or MK-801 challenge trial. Unpublished data. 
 
The results on total time immobile in the MK-801-induced hyper-locomotor model, again, 
is consistent with other behavioral parameters. The MK-801 induced hyperlocomotor activity was 
reduced by all four ligands, which resulted in increasing the time immobile, as compared to the 
MK-801 challenged animals, as depicted in Figure 48. The S-C(8)-bromo oxazole 65 exhibited the 
longest time immobile, as compared to the other three ligands, which almost reached control levels. 
The total time animals were mobile was the opposite to the total time immobile, which aligned 
well to the total distance traveled. Ligand oxazole 65 experienced the least mobile time and shared 
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Figure 48. Total time immobile in the MK-801-induced hyper-locomotor model. The data analyzed has been 
limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, SAL + GL-III-73 10 mg/kg, 
SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-
III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-
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Figure 49. Total time mobile in the MK-801-induced hyper-locomotor model. The data analyzed has been 
limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, SAL + GL-III-73 10 mg/kg, 
SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-
III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-
801 0.32 mg/kg + GL-III-78 10 mg/kg and Trial = Habituation trial or MK-801 challenge trial. Unpublished 
data. 
 
The examination of these results suggests that oxazole 65 exhibited strong anti-
schizophrenic-like activity in the murine model of MK-801 induced hyperlocomotion, while 
devoid of sedative properties. It is planned to run a basic kinetic study on these four ligands. It 
appears that 65 may be especially interesting with respect to its potential development as an anti-
psychotic drug. However, behavioral parameters total mobile/immobile episodes and rotations of 
the animal’s body require further analysis. The statistical data and related figures are included in 
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2.2.3.6.1. Elevated Plus Maze to Determine Anxiolytic Effects 
The elevated plus maze (EPM) is a one of the most commonly used anxiety behavioral 
models that employed to screen most GABA-related putative anxiolytic compounds, such as 
IMDZs. Based on the rodents’ nature to avoid open spaces indicating anxiety, the anxiolytic effect 
is determined if the rodent spends more time in the open space, which is used to calculate the 
percentage of time in the open arms of EPM over the total time.151 Animals who are anxious do 
not go out and explore the open spaces in the arms of the EPM. 
The key chiral ligands 36, 37, 38, and the control DZP were evaluated in the EPM assay 
for observation of anxiolytic properties. The test results are presented in Figure 50. As shown, 
administration of amides 36 and 37 demonstrated a significant increase in time spent in the open 
arms of the maze after i.p. administration of 10 mg/kg (p < 0.03), whereas ligand 38 did 
demonstrate an increase but it did not reach significance (p = 0.07). The well-known anxiolytic 
DZP induced a significant increase of time spent in the open arm spaces (p = 0.02) at 1.5 mg/kg, 
as expected. 
 
Figure 50. Anxiolytic-like properties of novel ligands 36-38 as compared to DZP. Potential anxiolytic IMDZ 
ligands (a) GL-II-73 (36), (b) GL-II-74 (37), and (c) GL-II-75 (38) at 5 or 10 mg/kg and DZP (1.5 mg/kg; d) 
were assessed in mice (50% females) in the EPM test. Mice received either vehicle or the test compound  36 
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(n(0) = 13, n(5) = 13, and n(10) = 14), 37 (n(0) = 14, n(5) = 13, and n(10) = 14), 38 (n(0) = 13, n(5) = 14, and n(10) 
= 13), or DZP (n(0) = 11 and n(1.5) = 10) 30 min before testing. Possible anxiolytic effects were indicated by an 
increase in time spent in the open arms of the EPM. Sex was not significant factor (p ≥0.17) as a cofactor. 
(Modified from the figure in Prevot et al.)117  
 
The related analogs synthesized later included 31, 36-38: 39 (GL-III-66), 46(GL-III-67), 
47 (GL-III-70), 48 (GL-III-68), 54 (GL-III-64), 58 (GL-III-60), and 61 (GL-III-63). These analogs 
were also evaluated for their potential anxiolytic effects in the EPM. Together with the test 
compounds, an α5 selective NAM, MRK-016, was also included in the screening panel to 
determine whether this antidepressant compound possessed any anxiolytic effects. The test results 
are presented in Figure 51. After 10 mg/kg i.p. administration of the test compounds, only the 
C(8)-bromo ethyl amide 48 induced a significant anxiolytic-like effect in the EPM, as opposed to 
all the other test compounds including MRK-016. 
 
Figure 51. Anxiolytic-like properties of the ligands of GL-III series and the NAM (MRK-016) in the elevated 






2.2.3.6.2. The Forced Swim Test to Assess Antidepressant Properties of the Ligands 
The forced swim test (FST) is a widely used behavioral assay for the assessment of 
potential antidepressant-like properties of test compounds in rodents. The antidepressant effect in 
the FST is characterized by a decrease in the time spent immobile and as compared to the 
movement for the animal to stay afloat in an inescapable transparent tank. The tank is filled with 
water to a level that the animal is not capable of standing at the bottom or escaping. The escape 
related behavior of the animal is recorded and analyzed. The success of the FST results from its 
straightforward and easy handling procedure, also a minimum requirement for specialized 
equipment, and the reduced unwarranted stress to the animals. Therefore, the selective compounds 
from the first batch, which possessed good PK value, decreased CNS side effect, low cytotoxicity, 
stable metabolism, as well as a good GABAAR efficacy and binding profile, were evaluated in the 
FST for their potential antidepressant-like activity. This is a very select group of compounds. 
The first batch of ligands, amides 36-38 all exhibited an antidepressant effect in the FST 
by reducing the time spend immobile of the animals in the water tank, which represented an 
antidepressant property of the test compounds, as depicted in Figure 52. The dimethyl amide 36 
significantly reduced the immobility at 10 mg/kg, whereas the other two amides 37 and 38 started 
to show the antidepressant effect at a lower dosage of 5 mg/kg. In contrast, the classic non-selective 
DZP significantly increased the immobility, which is probably a result of its hyperlocomotor side 
effects of sedation and ataxia since it greatly potentiates α1-containing GABAARs greatly, 
therefore it is possible the antidepressant effect was precluded. It is now known this is true. Witkin, 
Babu et al. demonstrated if given diazepam admixed with the α1 preferring antagonist bCCt, the 




Figure 52. Antidepressant properties of 36-38. Potential antidepressant effect of IMDZ ligands 36 (a), 37 (b), 
and 38 (c) at 1, 5 or 10 mg/kg and DZP (1.5 mg/kg; d) was assessed in male mice in the FST after i.p 
administration. An inescapable transparent tank filled with water was used to place the mice (25 cm, 26 ± 1 °C) 
for 6 minutes. The minimum amount of movement for staying afloat indicated the immobility, between 2-6 min 
testing period.  and the sixth minute of testing. (36: n(0) = 8, n(1) = 8, n(5) = 6, and n(10) = 8; 37: n(0) = 8, n(1) 
= 8, n(5) = 8, and n(10) = 8; 38: n(0) = 8, n(1) = 8, n(5) = 8, and n(10) = 9) or DZP (n(0) = 12 and n(1.5) = 12). 
The potential antidepressant-like profile was indicated by any significant decrease of immobility induced by 
the test compound. * p < 0.05, ** p < 0.01, and *** p < 0.001 compared to vehicle. All values are represented as 
mean ± standard error of the mean. (Modified from the Figure in Prevot et al.)117 
 
The second batch of oxadiazoles and amides were evaluated for their antidepressant effects 
as well. However, only two ligands exerted the desired effect. Please see Table 17 for the results 
of the FST on all test compounds assayed to date. The C(8)-bromo methyl oxadiazole in the 2'N 
series 53 (GL-II-54) exhibited a decrease in immobility at 10 mg/kg,  as presented in Figure 53 A. 
The enantiomer of 36 (GL-II-73), the dimethyl amide in the S series 30 (GL-I-54), significantly 
reduced the time spent immobile at a lower dose, 5 mg/kg, as compared to the control vehicle, as 




Figure 53. Effect of 53 (GL-II-54) and 30 (GL-I-54) on time spent immobile in the FST. The ligand 53 (A) at 10 
mg/kg, and the ligand 30 (B) at 5 mg/kg i.p. administered (24, 20, 1 h before testing) induced a significant 
antidepressant-like action when compared to the vehicle group (n = 9). *p<0.05 and ***p<0.001 when compared 
to the vehicle group. Unpublished data. 
 
The results of all the compounds that were assessed in the FST, are summarized in Table 
17. The parent compound 1, which is the first reported antidepressant IMDZ, showed the desired 
effect at 30 mg/kg due, presumably, to its good α5 subtype selectivity. The S-isomer 2, the 
enantiomer of 1, did not show any effect due to the fast-metabolic rate of this ligand. The first 
amide analog prepared 35 had an improved α5 subtype preference and demonstrated a better 
antidepressant effect at a lower dosage 10 mg/kg, as compared to the lead compound 1. The 
enantiomer of 35, the S-methyl amide 25, did not produce an antidepressant effect due to the 
sedative effect by 25 on the animal. The amides 36-38 from the R series, as described above, 
significantly reduced the immobility, as well as did the S-isomer, dimethyl amide 30.  The other 
amides 49 and 50 did not display any effect due to the sedating side effects or they were just 
inactive. The only oxadiazole that exhibited an antidepressant property was 53 (GL-II-54), the 
C(8)-bromo methyl oxadiazole in the 2'N series (10 mg/kg).  
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Table 17. Antidepressant effect of all test compounds in the FST. Unpublished data. 
Genus Compound 




Observation Global Effect 
Ester 
1 (SH-053-2'F-R-CH3) 30 mg/kg ip Antidepressant Antidepressant + 
2 (SH-053-2'F-S-CH3) ND (fast metabolism) 
Amide 
35 (MP-III-022) 10 mg/kg ip Antidepressant Antidepressant + 





Antidepressant + 5 mg/kg No effect 
10 mg/kg Antidepressant 





Antidepressant ++ 5 mg/kg Antidepressant 





Antidepressant ++ 5 mg/kg Antidepressant 
10 mg/kg Antidepressant 
40 (GL-II-76) ND (low brain fraction) 
49 (RV-II-04) 10 mg/kg ip SEDATION SEDATION 
50 (GL-II-31) 10 mg/kg ip No effect No effect 
Oxadiazole 
31 (GL-I-65) 10 mg/kg ip No effect No effect 
51 (GL-II-33) 10 mg/kg ip No effect No effect 
52 (GL-III-23) 10 mg/kg ip No effect No effect 
53 (GL-II-54) 10 mg/kg ip Antidepressant Antidepressant + 
ND: not determined. Significance was indicated by + or ++. 
 
2.2.3.6.3. Evaluation of Spatial Working Memory by the Y-maze Test  
During the past few decades, altered GABAergic function has been continually reported in 
related to aging, as well as neurodegenerative and psychiatric disorders. Somatostatin (SST) co-
expressed GABA interneuron deficits are associated with MDD, other mood symptoms, and 
cognition.152 Since SST signaling occurs partially through the GABAARs system in the prefrontal 
cortex in the CNS. This implicates GABA in systems in the regulation of mood and cognition.153 
Therefore, it is hypothesized that an enhancement of the response of GABAARs might have the 
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potential to improve cognitive dysfunction, which is a key feature that is usually disrupted in 
patients with depression, schizophrenia, and neurodegenerative diseases. The spontaneous 
alternation Y-maze is broadly used for the evaluation of short-term spatial working memory by 
utilizing the exploratory nature of rodents. A series of IMDZs were assessed in the Y-maze test 
for their potential pro-cognitive effects.  
 
2.2.3.6.3.1. Reversal of Stress-Induced Working Memory Deficits  
Adult mice subjected to chronic restraint stress (CRS) are known to undergo working 
memory impairment, which can be identified in the spontaneous alternation Y-maze task. The 
injection of vehicle or test compounds 36-38 can be administrated at different doses, as 
demonstrated in Figure 54. The mice exposed to CRS exhibited a reduction of alternation rates, as 
compared to the vehicle control mice. The alternation rate of the 10 mg/kg 36-treated animal was 
significantly brought back up to a similar level of the non-CRS vehicle control mice. (p = 0.01). 
However, at the lower dose of 1-5 mg/kg of amide 36 administrated to mice, did not have an effect 
on the CRS mice. On the contrary, the administration of 37 reduced the alternation rate of mice at 
5 and 10 mg/kg, which indicated it was inactivity on working memory at these doses (p > 0.97). 
The alternation rate in mice treated with 38 was reversed to the level of the vehicle control group 
at 5 and 10 mg/kg (p < 0.045), which indicated it was active in this Y-maze assay. The cognitive 
deficits were not restored with the treatment of DZP at 1.5 mg/kg, as expected (p = 0.94). In a 
parallel experiment, the baseline effect in non-CRS mice was tested, as depicted in Figure 55. The 
ligands 36 and 38 did not induce any effect on the alternation rates at both 5 and 10 mg/kg. 
However, a decrease in the alternation rate was observed in the animals on the administration of 
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10 mg/kg of 37 or 1.5 mg/kg of DZP, which would indicate a detrimental influence on working 
memory or sedation, both of which could be elicited by a PAM interaction at α1β3γ2 subtypes. 
 
Figure 54. Pro-cognitive effect of ligands 36-38 on working memory impairment induced by stress. The 
spontaneous alternation Y-maze task was employed to determine the effects on working memory using a 90-
second intertrial interval. The cognitive deficit was introduced by exposing mice to daily CRS, 1 h twice a day 
for 1 week before the experiment. Young mice (50% females) received i.p. administrated vehicle or 1, 5, or 10 
mg/kg of 36 (a; n(0-NS) = 10, n(0-S) = 10, n(1) = 5, n(5) = 10, n(10) = 12), for 37 (b; n(0-NS) = 8, n(0-S) = 8, n(1) 
= 4, n(5) = 10, n(10) = 4), 38 (c; n(0-NS) = 8, n(0-S) = 8, n(1) = 6, n(5) = 4, n(10) = 9), and DZP (d; n(0-NS) = 6, 
n(0-S) = 6, n(1.5) = 6) 30 min prior testing. * p < 0.05, ** p < 0.01, *** p < 0.001 compared to “No stress vehicle.” 





Figure 55. Effect of 36-38 and DZP on alternation rate in a spontaneous alternation Y-maze task to evaluate 
the potential cognitive deficit under baseline conditions induced by test compounds at 5 or 10 mg/kg, or 
1.5mg/kg of DZP in non-CRS mice. Prior to 30 min for the test, the i.p. injection of PAM or DZP was 
administrated. A reduced alternation rate was only seen in mice treated with 10 mg/kg of 37, as compared to 
DZP. **p<0.001 compared to the “No Stress-Vehicle” group. (Adopted  from the figure in Prevot et al.)117 
 
In addition to the amide ligands 36-38, several of their analogs were also evaluated in the 
Y-maze test for possible pro-cognitive effects. The enantiomer of 36, 30 (GL-I-54) restored the 
alternation rates at 5 and 10 mg/kg, which is very similar to the data for 36, as presented in Figure 
56. Although CRS animals administered with 30 at 5 and 10 mg/kg were not statistically different 
from the CRS vehicle groups, they were also not statistically different from the vehicle control 
group either. However, administration of the S-dimethyl amide 30 at 10 mg/kg was significant 





Figure 56. Effect of 30 (GL-I-54) on the percent alternation rate in the Y-maze spatial alternation task assessing 
working memory in mice. Mice subjected to CRS were injected with 30 (0, 1, 5, 10 mg/kg) i.p. 30 min before 
testing). ANOVA revealed statistical significance on the overall effect of stress and treatment with 30 at 5 and 
10 mg/kg. Differences between groups were tested using the posthoc analysis of Scheffe (**p<0.01 compared to 
the “Control-Vehicle” group) n=5-9. Unpublished data. 
 
The results of administration of the racemic mixture of 36 + 30 on CRS-mice demonstrated 
significant differences between groups (ANOVA: F(2,10)=16.82; p=0.0006). The CRS animals 
exhibited a significant reduction in working memory and the CRS mouse group injected with the 
racemic mixture (36 + 30) were statistically different from the CRS-vehicle group, as indicated in 
Figure 57. Administration of the racemic mixture of 36+30 (GL-II-73 and GL-I-54) produced a 
reversal of the cognitive impairment induced by CRS. This effect (p=0.003) was more significant 
than that of the pure amide 36 alone (p = 0.01), at the same dose (10 mg/kg), as compared to the 
CRS-vehicle group, which can result from the fast-acting profile of 30. This data suggested an 
alternative approach, using the mixture of R and S dimethyl amide (36 and 30), to achieve a more 







Figure 57. Effect of the racemic mixture of 36/30 (GL-II-73/GL-I-54) on percent alternation rate in the Y-maze 
spatial alternation task assessing working memory in mice. Mice subjected to CRS were injected with the 
racemic mixture solution (10 mg/kg, ip., 5 mg/kg each enantiomer, 30 min before testing) or vehicle. ANOVA 
revealed statistical significance on the overall effect of manipulation. Differences between groups were tested 
using the posthoc analysis of Scheffe (***p<0.001 compared to the “Control-Vehicle” group / $$p<0.01 




Besides amide analogs related to GL-II-73 (36), oxadiazoles were also assessed in the Y-
maze test. Analysis of the data showed significant differences between groups for 31 (GL-I-65) 
and 51 (GL-II-33) at 10 mg/kg, respectively (ANOVA: 31 F(2,28)=5.38; p=0.0105, 51  
F(2,11)=4.2; p=0.0439), as presented in Figure 58. Scheffe post hoc analysis revealed decreased 
performance in the CRS-vehicle treated animals (31: p=0.012; 51 p=0.05) and an increase in 
alternation rate after 31 or 51 (10 mg/kg) not significantly from the control-vehicle group, which 
indicated a pro-cognitive effect. Although 31 and 51 mouse groups were not statistically different 
from the CRS-vehicle mouse group using the Scheffe post hoc analysis (p=0.12, p=0.16), a 





Figure 58. The effect of GL-I-65 (A) and GL-II-33 (B) on the percent alternation rate in the Y-maze spatial 
alternation task assessing working memory in mice. The mice subjected to the CRS were injected with GL-I-
65 or GL-II-33 (10 mg/kg, i.p., 30 min before testing). ANOVA revealed statistical significance on the overall 
effect of manipulation. The CRS animals showed a significant reduction of working memory performance and 
the CRS mouse group injected with GL-I-65 were not statically different from the control-vehicle group. 
Differences between groups were tested using the posthoc analysis of Scheffe (*p<0.05 compared to the 




The effects of 39, 46-48, 54, 58, and 61 (GL-III-60/63/64/66/67/68/70) were assessed in 
the Y-maze alternation task, as shown in Figure 59. Two of the test compounds, 48 (GL-III-68), 
and (58) GL-III-60 had potential pro-cognitive effects in the stressed-induced working memory 
deficit, which requires further testing to be validated. The C(8)-cyclopropyl dimethyl amide 47 
(GL-III-70), was confirmed with its pro-cognitive effect at different doses from 1, 5, and 10 mg/kg. 
Importantly, ligand 47 significantly reversed the alternation rates of the treated mice group, as 
compared to the CRS-vehicle treated mice and brought them back to the level of the non-CRS 






Figure 59. The effects of GL-III-70 (47) on the percent alternation rate in the Y-maze spatial alternation task 
assessing working memory in mice. The chronic restraint stress (CRS) paradigm was used to induce a working 
memory deficit in young (2-3 months) mice. The mice were injected with GL-III-70 (0, 1, 3, or 10 mg/kg) i.p. 30 
min before testing. ANOVA revealed statistical significance on the overall effect of the treatment 
(F(4,46)=15.008; p<0.0001). Differences between groups were detected using post-hoc Scheffe analysis 
(**p<0.01 and ***p<0.001 compared to the “Control-Vehicle” group / $p<0.05 and $$$p<0.001 compared to 
the “CRS-Vehicle” group). Unpublished data. 
 
This ligand 47 was further assessed in a parallel experiment with respect to the α5 NAM 
MRK-016. Both 47 and MRK-016 alone did not exhibit an effect as compared to the vehicle group, 
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mice to a similar level to the non-CRS vehicle group, as shown in Figure 60. This indicated ligand 
47 might share a similar effect in Y-maze task as MRK-016.  
 
Figure 60. The pro-cognitive efficacies of GL-III-70 (10mg/kg) and the NAM MRK-016 in the Y-maze 
alternation task. Statistical data not shown, unpublished data. 
 
As summarized in Table 18, the compounds described above were all active in the Y-maze 
test induced by CRS, however, the rest of the compounds in the screening panel did not restore the 
alternation rates after 5 or 10 mg/kg drug treatment. Two of the active compounds in the FST, such 
as 35 (MP-III-022) and 53 (GL-II-54), did not show any effect in the Y-maze test. Therefore, they 
were placed lower on the lead compound list, since cognitive dysfunction is one of the critical 
features in patients with depression or schizophrenia, it would be nice to successfully treat. On the 
other hand, the compounds only active in Y-maze test but not the FST, such as 31 (GL-I-65) and 
51 (GL-II-33) would also put lower on the list of lead compounds because they were inactive in 
the FST. Indeed, several newer compounds have not been tested in the FST and will be evaluated 
for their antidepressant effect first, then based on those results the go/no go decision of whether to 
be studied on the next stage will be made. The compound 30 (GL-I-54) was active in both the FST 
and Y-maze but was not chosen because of the rapid metabolism rate in mice, only 19 % remaining 
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after 2 hours of incubation in the MLM. Therefore, only two compounds, 36 (GL-II-73) and 38 
(GL-II-75) were carried on for future evaluation due to their desired pharmacological properties 
including antidepressant effects as well as an overall pro-cognitive effect.  






Observation Global Effect  
Ester 
1 (SH-053-2'F-R-CH3) 30 mg/kg ip No effect  No effect  
2 (SH-053-2'F-S-CH3) ND (fast metabolism) 
Amide 
35 (MP-III-022) 5 mg/kg ip No effect  No effect  




No effect  
Pro-cognitive + 
5 mg/kg No effect  
10 mg/kg Pro-cognitive  




No effect  
Pro-cognitive ++ 5 mg/kg Slight pro-cog 




No effect  
No effect  5 mg/kg No effect  




No effect  
Pro-cognitive ++ 5 mg/kg Pro-cognitive  
10 mg/kg Pro-cognitive  
39 (GL-III-66) 10 mg/kg ip No effect  No effect  
40 (GL-II-76) 10 mg/kg ip No effect  No effect  





Pro-cognitive ++ 3 mg/kg Slight pro-cog 
10 mg/kg Pro-cognitive 
48 (GL-III-68) 10 mg/kg ip Pro-cognitive Pro-cognitive + 
49 (RV-II-04) 5 mg/kg ip No effect  No effect  
50 (GL-II-31) 10 mg/kg ip No effect  No effect  
Oxadiazole 
31 (GL-I-65) 10 mg/kg ip Pro-cognitive Pro-cognitive + 
51 (GL-II-33) 10 mg/kg ip Pro-cognitive Pro-cognitive + 
52 (GL-III-23) 10 mg/kg ip No effect  No effect  
53 (GL-II-54) 10 mg/kg ip No effect  No effect  
54 (GL-III-64) 10 mg/kg ip Slight pro-cog Slight pro-cog 
58 (GL-III-60) 10 mg/kg ip Pro-cognitive Pro-cognitive + 
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61 (GL-III-63) 10 mg/kg ip No effect  No effect  
ND: not determined. Significance was indicated by + or ++. 
 
2.2.3.6.3.2. Reversal of Age-Induced Working Memory Deficits in the Y-maze Task 
According to the results of the antidepressant effects from the FST and the stress-induced 
working memory deficits in the Y-maze task, 36 (GL-II-73) and 38 (GL-II-75) were further 
evaluated in the Y-maze task but induced by age on old male mice. The significant difference was 
observed among three groups, young, old, and drug-treated old mice group by ANVOAs (F > 12.3; 
p < 0.0015), as illustrated in Figure 61. The alternation rates of 22-month old mice were 
significantly lower than the young mice control group to the chance level, indicating the 
deleterious effects of cognition. The spatial working memory deficits were significantly restored 
on the administration of 5 mg/kg of 36 or 38, to a level almost indistinguishable from the vehicle 
control group in young mice, as compared to the vehicle control group in old mice. (p < 0.03) 
 
Figure 61. The potential pro-cognitive effect of 36 (GL-II-73) and 38 (GL-II-75) in the age-induced Y-maze 
task. The same experimental protocol was used for old mice but with a shorter interval to 1 minute. Old male 
mice were treated with either vehicle or test compound 36 (E; n(0-Young) = 5, n(0-Old) = 5, n(5) = 6) or 38 (F; 
n(0-Young) = 5, n(0-Old) = 5, n(5) = 4). The significance was obtained by comparing the treated group with the 
young and old vehicle control groups. The significance was not achieved with a sex cofactor. (p ≥ 0.49). Results 
are shown as the mean of the percentage of alternation ± SEM. Effect of age: ++ p < 0.01 or +++ p < 0.001 
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compared to “Young vehicle.” Effect of the ligand: $ p < 0.05 compared to “Stress vehicle” or “Old vehicle.”  
(Adopted from the figure in Prevot et al.)117 
 
The two test compounds, 36 (GL-II-73) and 38 (GL-II-75) that restored the working 
memory deficits induced by CRS with a single acute i.p. injection, were further evaluated for their 
pro-cognitive properties in the CRS-induced Y-maze task via sub-chronic administration (p.o.) in 
drinking water over a period of 10 consecutive days in both young and old mice. The detrimental 
effects on working memory were observed that were induced by either CRS or age, as compared 
to the no-stress group and young vehicle group, respectively. The test compounds were diluted in 
water for a 30 mg/kg dose to match the brain concentration of the compound with an i.p. injection 
at 10 mg/kg. This solution was prepared fresh daily for administration for 10 consecutive days. 
From the test results, as presented in Figure 62 A and B, only compound 36 (GL-II-73) exhibited 
a significant reversal of alternation rates in the Y-maze in young adult mice, whereas treatment 
with 38 (GL-II-75) did display a slight reversal, but not at the level of significance. In the 
experiment with the old mice, as demonstrated in Figures 62 C and D, after sub-chronic 
administration of both compounds, again, 36 produced a profound pro-cognitive effect in old mice 
group, as compared to the old vehicle group, and even improved the cognition of the young vehicle 
group slightly. On the other hand, 38 exhibited a similar alternation rate as the old vehicle control 





Figure 62. The pro-cognitive effect assessment of 36 (GL-II-73) and 38 (GL-II-75) on stress-induced and age-
related working memory deficits. Effects of 36 (a, c) and 38 (b, d) were evaluated in young (a, b) and old (c, d) 
male mice via the sub-chronic administration (p.o.) in the drinking water for 10 consecutive days in the Y-maze 
task. Prior to the experiment, cognitive impairment in young mice was induced by CRS exposure for 7 days. 
The young mice were treated sub-chronically with 36 (n(0-NS) = 6, n(0-S) = 5, n(30) = 6) or 38 (n(0-NS) = 5, 
n(0-S) = 5, n(30) = 6) dosed at 30 mg/kg. The old mice mice were treated sub-chronically with 36 (n(0-Young) 
= 5, n(0-Old) = 6, n(30) = 4) or 38 (n(0-Young) = 6, n(0-Old) = 5, n(30) = 5) dosed at 30 mg/kg. The results are 
presented as the mean of the percentage of alternation ± SEM. Effect of the stress: * p < 0.05, ** p < 0.01, and 
*** p < 0.001 compared to “No stress vehicle.” Effect of the ligand: $$$ p < 0.001 compared to “Stress vehicle” 





2.2.3.6.3.3. The Effect of Blockade of the α1 and α5 Bz/GABA(A) Subtypes 
The antagonist experiments were carried out in order to investigate the mechanism of the 
beneficial effects of 36 (GL-II-73), by antagonizing one subunit or the other to determine if that 
abolished the pro-cognitive effects and antidepressant actions of 36. The ligands chosen to conduct 
the experiment were flumazenil, βCCt, and Xli-093 in combination with the pro-cognitive ligand 
36 due to their specific effects as selective antagonists, as well as the selective antagonist 
flumazenil. Because flumazenil is a non-selective antagonist of GABAARs, as a competitive 
antagonist to reverse the effects of BZD by blocking the BzR binding site. It was used to block 
all subtypes in the experiment. Previously, it has been reported the cognitive impairment, induced 
by the non-subtype selective DZP, was reversed to the control level by administration of the α1 
antagonist beta-CCt (βCCt) at the doses of 5 and 15 mg/kg, but was potentiated by the α5 
antagonist Xli-093 at 10 mg/kg, indicating both α1 and α5 subtypes might be involved in the 
cognitive process.118 Therefore, βCCt and Xli-093 were also selected to antagonize the effects on 
α1 and α5 subtypes, respectively.   
The experiment was conducted using the general Y-maze protocol but with an 
administration of a mixture. Animals were subjected to CRS to induce a cognitive deficit in 
working memory prior to the antagonist experiment. Mice were then treated with vehicle, 36 (10 
mg/kg) or a combination of 36 at 10 mg/kg and flumazenil, or βCCt, or Xli-093 (10 mg/kg), i.p., 
respectively. The antagonist results are shown in Figures 63, 64, and 65 for the effects of the three 
different combinations, respectively. By blocking the BzR binding site at the GABAARs with the 
non-selective flumazenil, this prevented 36 from exerting its beneficial action on cognitive 
performance, which demonstrated that the efficacy of 36 was mediated by acting at the BZD site 
of GABAARs. By blocking the α1 or α5-GABAARs, by administrating the mixture of 36 with βCCt, 
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or 36 with Xli-093, respectively, this had a similar abolishing antagonist effect of 36 on working 
memory deficits. The effects of 36 diminished back down to the chance level, which suggests that 
both receptor subtypes are required to exhibit an effect on cognitive functions.  
 
Figure 63. Flumazenil blocks the effects of 36 (GL-II-73) on percent alternation rate in the Y-maze spatial 
alternation task assessing working memory in mice. The chronic restraint stress (CRS) paradigm was used to 
induce a working memory deficit in young (2-3 months) animals. The animals were injected with vehicle, 36 
(10 mg/kg) or a combination of 36 (10 mg/kg) and flumazenil (10 mg/kg) i.p. 30 min before testing. ANOVA 
revealed statistical significance on the overall effect of the treatment. Differences between groups were detected 
using post-hoc Scheffe analysis (**p<0.01 and ***p<0.001 compared to the “control-vehicle” group / $p<0.05 
and $$p<0.01 compared to the “CRS-vehicle” group). n=4-6. Unpublished data. 
 
 
Figure 64. βCCt blocks the effects of 36 (GL-II-73) on percent alternation rate in the Y-maze spatial alternation 
task assessing working memory in mice. The chronic restraint stress (CRS) paradigm was used to induce a 
working memory deficit in young (2-3 months) animals. The animals were injected with vehicle, 36 (10 mg/kg) 
152 
 
or a combination of 36 (10 mg/kg) and βCCt (10 mg/kg) i.p. 30 min before testing. ANOVA revealed statistical 
significance on the overall effect of the treatment. The differences between groups were detected using post-
hoc Scheffe analysis (**p<0.01 and ***p<0.001 compared to the “Control-Vehicle” group / $p<0.05 and 
$$p<0.01 compared to the “CRS-vehicle” group). n=5-6. Unpublished data. 
 
 
Figure 65. Xli-093 blocks the effects of 36 (GL-II-73) on the percent alternation rate in the Y-maze spatial 
alternation task assessing working memory in mice. The chronic restraint stress (CRS) paradigm was used to 
induce a working memory deficit in young (2-3 months) animals. The animals were injected with vehicle, 36 
(10 mg/kg) or a combination of 36 (10 mg/kg) and XLi-093 (10 mg/kg) i.p. 30 min before testing. ANOVA 
revealed statistical significance on the overall effect of the treatment. Differences between groups were detected 
using post-hoc Scheffe analysis (**p<0.01 and ***p<0.001 compared to the “control-vehicle” group / $p<0.05 
and $$ p<0.01 compared to the “CRS-vehicle” group). n=5-6. Unpublished data. 
 
2.2.3.6.4. The Lead Compound GL-II-73 on the Study of the Effects of Morphology of 
Mice Brain (CONFIDENTIAL UNPUBLISHED DATA) 
To visualize the changes in brain morphology after treatment with amide 36 (GL-II-73) in 
the normal age-related cognitive deficit of memory loss in Y-maze alternation task, a Golgi-cox 
study was conducted by the morphological analysis of pyramidal cells in Layers II/III of the mouse 
prefrontal cortex (PFC) between young, old and old-treatment groups.  
In short, mice, which were the 22 months old, were treated with freshly-prepared solutions 
of 30 mg/kg 36 (GL-II-73) in the drinking water daily for 8 weeks. After which the mice were 
153 
 
tested behaviorally in the Y maze alternation task, as described in the previous section. The mice 
were then euthanized using the cervical dislocation method, and the brains were harvested and 
stained for 2 weeks in Golgi staining solution. After a rinse and section, the sample included the 
basal and apical dendrites of pyramidal cells in Layers II/III of PFC and they were imaged and 
analyzed by a microscope. The details are in Methods Section 2.2.6.20.   
The quantitative data of the study of morphology included dendrograms, spine density x 
branch orders and Sholl analysis. The summary of the quantitative morphology of Layers II/III of 
pyramidal cells of PFC is presented in Table 19.  
 Table 19. Summary of morphological analysis of young, old, old-treated mice in the prefrontal cortex (PFC) 
between groups. (CONFIDENTIAL unpublished data) 
 
 
A. Behavioral Efficacy 
As described in the previous section,117 mice were tested in the Y-maze spontaneous 
alternation task. ANOVA analysis revealed a significant difference between groups 
(F(2;25)=11.34; p<0.001) in the alternation rates. Post hoc analysis presented a significant 
reduction in alternation rate in the normal aging groups (p<0.001) and the 36 treated old mice 
group significantly reversed the age-related working memory deficits by increasing the alternation 




Figure 66. Alternation rate in the age-related model of cognitive dysfunction in the Y-maze task in young, old 
and old+treatment groups. (CONFIDENTIAL unpublished data) 
 
B. Morphological characterization  
 The representative images, as shown in Figure 67, are a dendritic segment of pyramidal 
cells of young, old, and old+treatment groups, respectively. In the following qualitative 
observations: young mice exhibited more arborizations of the dendritic morphology than old and 
old+treatment mice (Upper panel of Figure 67. A-C). Moreover, the spine counts were much 
higher in young mice than old and old+treatment (36) mice (lower panel of Figure 67. A-C).  
Notably, old+treatment mice exhibited a higher spine count than old mice (the box). The 
quantitative comparisons of dendritic lengths, total spine counts and overall spine density between 































Figure 67. Representative images of PFC pyramidal cells between groups (young, old, and old+treatment).  
Compared to young mice (A), all aged mice showed reductions in spine counts of pyramidal cells (the box in 
lower panels of A-C).  It was noted that old+treatment mice showed a higher spine count than old mice [Scale 
bars: 5 um].  Note: The quantitation of spine subtypes was not included in the current study. (CONFIDENTIAL 
unpublished data) 
 
C. Analysis of Morphological 
 Examination of the data in Figure 68A for the total dendritic lengths, a significant decrease 
was observed in old mice, as compared to young mice (p<0.05), whereas there was no difference 
found in old+treatment mice (p>0.05). As illustrated in Figure 68B in the break-down analysis of 
total apical and basal dendrites, it did not show any difference in the basal dendrite between young, 
old, and old+treatment groups (Figure 68B, p>0.05).  However, in the apical dendrites, higher total 
dendritic lengths of apical dendrites were observed in both young and old+treatment mice groups, 
as compared to that in old mice, respectively (p<0.05). Not any difference between young and 




Figure 68. Comparison of total dendritic lengths of pyramidal cells as well as the break-down analysis between 
young, old, and old+treatment groups. (CONFIDENTIAL unpublished data) 
 
 As shown in Figure 69A in the analysis of total spine counts, a significant decrease of total 
spine counts was found in old mice, as compared to young mice, respectively (p<0.05). In addition, 
the spine counts were higher in the old+treatment mice than old mice (p<0.05).  In the break-down 
analysis of total spine counts of apical and basal dendrites, a significant reduction was observed 
only in old mice in comparison with young mice, as presented in Figure 69B (p<0.05).  In the 
apical dendrites, the spine counts in old mice were significantly lower than both young and 
old+treatment mice, respectively (p<0.05).  There were not any differences found in both basal 




Figure 69. Comparison of total spine counts of pyramidal cells as well as the break-down analysis between 
young, old, and old+treatment groups. (CONFIDENTIAL unpublished data) 
 
 As demonstrated in Figure 70A for the analysis of overall spine density, a significant 
decrease in spine density of old and old+treatment mice was found in comparison with young mice, 
respectively (p<0.05). In addition, a higher density in old+treatment mice was observed than old 
mice (p<0.05)*.  In the break-down analysis of the overall spine density of apical and basal 
dendrites, a significant reduction was observed only in Old mice in comparison with young mice, 
as presented in Figure 70B (p<0.05).  In the apical dendrites, a higher density in young mice was 
found than both old and old+treatment mice, respectively (p<0.05).  There were not any differences 
found in the spine density of both basal and apical dendrites between old and old+treatment mice. 
(p>0.05), which was likely due to the sample size being compromised by the break-down analysis. 
*It was noted that the p-value was on the margin of statistical significance, given the sample size 




Figure 70. Comparison of overall spine density of pyramidal cells as well as the break-down analysis between 
young, old, and old+treatment groups. (CONFIDENTIAL unpublished data) 
 
2.2.4. Discussion 
It is clear that ligand design to target specific GABAAR subtypes without adverse effects 
is very difficult, in part, due to the absence of crystal structures for the α2β3γ2, α3β3γ2 and α5β3γ2 
ion channels, as well as the diversity of the receptor subunit expression in different regions of the 
brain. Although an electron microscopy structure has been reported for a pentameric GABA ion 
channel for α1β3γ2 GABAARs, the lack of a similar structure of the α5β3γ2 subunit with diazepam 
or an α5 subtype-selective ligand in the binding site renders ligand design difficult except for the 
use of the Milwaukee-based unified pharmacophore/receptor model and the α5 homology 
model.154 In the present research, a number of ligands have been successfully designed and 
synthesized with the C(4) S-CH3 stereochemistry. This series of esters, amides, and bioisosters of 
the lead compound 2 are devoid of the liable ester functionality at C(3) to enhance metabolic 
stability. The synthesis of these analogs, importantly, were inexpensive and straightforward with 
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improved yields over the previous routes.43 More importantly, these reactions can be easily scaled 
up to gram quantities. The novel ligands 8c and 9a are metabolically stable in the presence of 
human and mouse liver microsomes and exhibit excellent safe cytotoxicity (LD50) values. 
Furthermore, the ligands do not induce sedative effects, which is a major problem of classical 
benzodiazepine drugs. Taken together, this research on the S-CH3 enantiomers have provided 
several novel ligands that possess good safety and metabolic profiles for further in vivo behavioral 
testing in animal models in both schizophrenia and depression.23-25, 31-32 The in vivo activity of 8c 
and 9a in models of schizophrenia and depression is ongoing and preliminary studies look very 
promising.50 
Behavioral Study in Animal Models of Schizophrenia 
According to the efficacy data of the four ligands 64, 65, 66 and 67, as illustrated in Figures 
38 and 39 , it is clear that both of the S-isomer analogs at 100 nM concentration elicited a stronger 
receptor potentiation than the R-isomer, and the C(8)-bromine atom slightly increased the 
potentiation at all subtypes irregardless of chirality at the C(4) position. Moreover, ligand 65 
exhibited the highest potentiation at both concentrations for all subtypes especially at the α2 
subtypes at 1 μM, as compared to the other 5 GABA/Bz subtypes. Due to the more potent efficacy 
of 65, the behavioral effects of this compound were more profound than those from the other three 
less potent oxazole analogs. Ligand 65 reduced the hyperlocomotion induced by MK-801 to almost 
a control level with a 10 mg/kg dose of 65. Although the efficacy of four ligands was very similar 
to that of DZP, it was much less potent than DZP and would be less prone possible to induce severe 
sedative effect. However, data from the rotarod study, as shown in Figure 25, revealed that ligand 
65 did produce a slight sedative effect at 40 mg/kg via oral gavage. However, a similar effect was 
not observed in studies in a model of schizophrenia. The discrepancy should not be overestimated 
160 
 
due to the dose, which was much higher in the rotarod study. Moreover, the dose of 10 mg/kg was 
potent enough to achieve a significant reduction of the hyperlocomotion induced by MK-801 in a 
schizophrenia-relevant model. Therefore, the high dose, which produced slight sedation at 40 
mg/kg, would not be reached to provide a desired pharmacological engagement effect for 
schizophrenia. Since 65 was a very potent ligand, with the aid of later PK study, the dose could be 
further optimized to reduce any possible side effects. Importantly, it should not be overlooked that 
the high potentiation of 65 at α1 could confound the anti-anxiety and anti-schizophrenia effects in 
animal models. Therefore, a binding assay is needed on 65 to determine the affinity at all subtypes 
for further evaluation of 65 in a go no go sense. 
EPM for anxiolytic effects 
All three target amides 36-38 were tested for their potential anxiolytic properties in vivo. 
The amides 36, 37 as well as the control DZP illustrated a similar and significant anxiolytic effect 
in the animal model, as shown in Figure 50, irregardless of their different efficacy profiles. Ligand 
38 exhibited a non-significant anxiolytic effect but with a strong trend (p = 0.07) toward anxiolysis. 
It is noticed that ligand 38 from efficacy studies in HEK cells elicited a much stronger potentiation 
at α1 subtypes even at 100 nM, as compared to the other subtypes as well as to 36 and 37. The lack 
of a significant anxiolytic effect observed in EMP of ligand 38 may be the result of reduced 
locomotor activity 30 minutes after the treatment dose, due to the possible sedative effects from 
potentiation of α1 subtypes, which might confound or even override the anxiolytic effects of 38. 
Antidepressant effects evaluated by the forced swim test (FST) 
All three amides 36-38 from the first batch exhibited antidepressant properties without any 
observation of locomotor impairment at doses up to 10 mg/kg after i.p. administration after 1 hour. 
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However, the cyclopropyl amide 38 displayed a hypolocomotor activity up to 40 minutes after i.p. 
administration, which was, presumably, due to its potent efficacy at α1 GABAARs and led to a 
slightly sedative effect at 10 mg/kg. This hypolocomotor effect washed out over time, indicating 
the brain concentration of this ligand was decreased presumably by metabolism or expulsion from 
the brain by some p-glycoprotein or diffusion. The other two amides 36 and 37 were less potent in 
regard to α1 subtypes at a dose of 10 mg/kg as compared to 38; the tendency for a hypolocomotor 
impairment was relatively lower than in ligand 38. Unlike the three amides, the non-selective DZP, 
on the contrary, increased the immobility, suggesting it is not antidepressant or it induced a 
depressant behavioral activity because of efficacy at the α1 sedating/ ataxic subtypes. In fact, there 
is proof of this effect. Witkin, Li, Babu, et al. gave a mixture of the α1 preferring antagonist bCCt 
admixed with diazepam and this formulation was antidepressant in the FST. 
In addition to ligands 36-38, another two compounds 53 and 30 in the S-series also elicited 
an antidepressant effect in the FST. The ligand 53 shared a similar pattern as compound 36 and 37 
at 10 mg/kg, on the other hand, the ligand 30 exhibited the most significant antidepressant effect 
in the FST among all the compounds tested at a lower dose (5 mg/kg). The efficacy profile of 53 
was similar to that of 36, but it was much less potent and less selective, which may be the reason 
on the antidepressant effect, was less significant than amide 36. As expected, the compounds from 
the 2'N series usually are less potent in efficacy at all subtypes than the 2'F analogs. However, the 
ability of a compound to induce an antidepressant effect may require activity at α5 subtypes, but 
not a very potent effect. A lot of PK work is left to be done to understand this. From the PK study, 
the ligand 53 reached a much larger value of AUC in the brain than most of the test compounds at 
only 3 mg/kg 53, which might also confound the physiological effects at the other subtypes. The 
case of enantiomer 30, might be slightly different than the compounds discussed above. This ligand 
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is from the S-series, whereas all other compounds that have an antidepressant effect are from the 
R-series. It has been shown that the efficacy and binding affinity is much better in the S-series of 
compounds, as compared to the R-series. Therefore, although the efficacy of 30 was not evaluated 
yet, it can be predicted that this ligand will be much potent than its amide enantiomer 36. As 
a consequence, the S-isomer 30 would be expected to induce a much more significant 
antidepressant effect at a lower dose as confirmed with the FST. Another factor that complicates 
the biology is that all of the FST active-compounds, S-enantiomer 30 has the shortest half-life. It 
was less than 1 hour and a short Tmax (5 minutes) than most of the compounds in the brain, 
indicating a rapid metabolic rate and brain penetration, which might help to explain its fast-acting 
ability and profound effect as compared to the other relatively stable antidepressant compounds. 
It is important to make a longer-acting form of S-30. 
Based on the results from the FST, the active compounds above displayed antidepressant 
properties, which were different from DZP. Further studies on antidepressant effect are still 
necessary by applying other genetic models.  
Analysis of spatial working memory (cognitive effect) via the use of the Y-maze  
Among the 22 ligands that were tested, 10 of them have shown moderate to excellent pro-
cognitive properties in the stress-induced working memory deficits assay using the Y-Maze. The 
parent compound ethyl ester 1 (SH-053-2'F-R-CH3) was not active at 30 mg/kg in male mice, and 
the positive result on female mice was not able to repeat, thus overall it was counted as an inactive 
compound in Y-maze task. The α5 subtype-selective ligand, 35 (MP-III-022), which did not show 
any potency at α1 BzR, was only active in the FST but not the Y-maze cognition task. The 
enantiomers of both compounds, 2 (SH-053-2'F-S-CH3) and 25 (MP-III-023), were inactive in 
both assays, due to rapid metabolism and sedative effects, respectively. The isopropyl amide 39 
163 
 
(GL-III-66) did not show any effect in the Y-maze task. The ligand exhibited sedative and 
anxiogenic effects at the 15 mg/kg, suggesting possible sedative effects at 10 mg/kg, which, 
presumably could have suppressed the alternation rates in the Y-maze task. The ligand 40 (GL-II-
76) exhibited very slight α5 subtype selective efficacy, which was similar but less potent as 
compared to 36. However, 40 was not tested in any animal models because of the fast-metabolic 
rate in MLM, which then led to a low brain fraction from the PK study by Savic et al., which 
suggests an amide with larger N-alkyl side chain might reduce the metabolic stability. This ligand 
40 is more lipophilic and has more sites to undergo CYP450 radical oxidation. Any achiral ligands, 
such as the methyl amide 49 (RV-II-04) and the methyl oxadiazole 52 (GL-III-23), did not display 
any pro-cognitive activity in the Y-maze task, regardless of the C(3) functional group. This again 
implicates α5 subtypes or a chiral R-CH3 function for this approach to depression or schizophrenia. 
The methyl amide in the 2'N series 50 (GL-II-31) was not active in both the FST nor the Y-maze 
task, which may be due to the very low solubility of 50 and low brain fraction in mice.  
Interestingly, the introduction of the C(8)-cyclopropyl group nearly abolished the efficacy 
at all subtypes at both 100 nM and 1 µM concentrations in Figure 36 and 37, as compared to the 
corresponding dimethyl amide 36 (GL-II-73) and ethyl amide 37 (GL-II-74). The expected 
reduction of the desired pro-cognitive effect, on the other hand, was NOT observed. On the 
contrary, the dimethyl C(8)-cyclopropyl analog 47 (GL-III-70), began to show the increased 
alternation rates at 1 mg/kg, at which dose 36 was not active. By replacing the acetylene by a C(8) 
cyclopropyl group, the C(8) cyclopropyl ethyl amide 48 (GL-III-68) exhibited pro-cognitive 
effects, whereas the acetylene ethyl amide 37 did not show any effect in the Y-maze task. The 
ligand 46 (GL-III-67), the bromo analog of 37, shared a similar but much stronger efficacy profile 
as 37, but 46 was also not active in the stress-induced working memory deficits assay just like 37.  
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In the oxadiazole series, the ligands, which were not active in the Y-maze task, are the 
achiral methyl oxadiazole 52 (GL-III-23), the oxadiazole 53 (GL-II-54) with an antidepressant 
property, and one cyclopropyl oxadiazole in the 2'F series  61 (GL-III-63). The other oxadiazoles 
exhibited moderate to good pro-cognitive effects in the Y-maze task. In the 2'N series, the 
introduction of a C(8) cyclopropyl group in ligand 54 (GL-III-64) reduced slightly the pro-
cognitive effect, as compared to the acetylene analog 51 (GL-II-33), which may result from the 
decrease of the potency at all subtypes with a C(8) cyclopropyl group in place of an acetylene. As 
described above, the cyclopropyl group increased the pro-cognitive effects in the amides but 
decreased the effect in oxadiazoles. The lack of results from the ethinyl analog 55 (MP-IV-004) in 
the 2'F series, as compared to the cyclopropyl analog 61 (GL-III-63), which was precognitive, is 
difficult to resolve. If all cyclopropyl oxadiazoles are less potent than the acetylene substituted 
oxadiazoles regardless of the 2'X substituent, the desired activity in 55 might have been expected. 
Although the cyclopropyl analog 61 was inactive, its enantiomer 31 (GL-I-65) and the bromo 
analog 58 (GL-III-60) exhibited the increase of the alternation rates in the Y-maze test. It is not 
possible to resolve the SAR above without more data including binding affinity.  
In summary, in the stress-induced working memory impairment (Y-maze) task, several 
compounds have shown the desired effect by increasing the alternation rates of the stressed animal 
in the Y-maze assay. Only three compounds were active in both the Y-maze and the FST test: 30 
(GL-I-54), 36 (GL-II-73), and 38 (GL-II-75). The compound 30 was not further investigated in 
the aging-related Y-maze task due to the rapid rate of metabolism, but this potent ligand 30 can be 
applied as a short-acting agent in the requested condition. However, it is reasonable to replace 
the C(3) moiety with a more metabolically stable group with a similar bioisosteric function 
to the C(3) amide. Only 2 out of the 22 compounds were carried on for the Y-maze experiment 
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in young and old mice to determine their pro-cognitive effect. The dimethyl amide 36 successfully 
reversed the memory deficits in normal aging old mice to a level similar to that of young mice in 
a 10-days sub-chronic administration in the Y-maze test. Moreover, in the group of young mice, 
the pro-cognitive effect of 36 was maintained in the Y-maze when cognition deficits had been 
induced by CRS, whereas, the ligand 38 did not show a significant effect in these experiments.  
The implications of α5-GABAARs on cognitive processes have been investigated 
substantially during the past decades that the cognitive learning processes and anxiety might be 
mediated by α5 GABAARs.
155-156 The present results from the FST and Y-maze task on the novel 
IMDZs suggested that the pro-cognitive effects might not only be mediated by α5 subtypes, but 
also accompanied by slight activation at α1 receptors as well. The compounds, according to the 
HEK efficacy studies of Janet Fisher did, potentiate both α5 and some α1 subtypes, such as 36 
(GL-II-73) and 38 (GL-II-75). They demonstrated the desired antidepressant effect and pro-
cognitive effect without sedation. It is the ligand 36, which exhibited moderate activation at 
GABAARs subtypes, restored working memory deficits in the sub-chronic administrative Y-maze 
task, not the non-selective but more potent ligand 38. On the other hand, the classical non-selective 
high-affinity DZP did not reverse the working memory deficits and even induced cognitive 
impairment, as compared to the chance level. This is because of the sedating effects from efficacy 
at α1 receptors always present with diazepam. This impairment can be reversed by blocking the 
potentiation at α1-subtypes or became worse by blocking the activation of α5 subtypes.118 Thus, 
in order to further unmask this low-affinity, and moderate-efficacy mechanism, blockade 
experiments not only at the α1-subtypes but also at the α5-subtypes must be carried out. In addition, 
antagonism of all BzR subtypes could also be done. Antagonist studies were conducted by using 
the antagonist Xli-093 (α5 blockade), the antagonist βCCt (α1 blockade), and the antagonist 
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flumazenil (BZD receptor sites blockade). In short, all three of them abolished the pro-cognitive 
effects of 36 in the stress-induced working memory assay using the Y-Maze, when combined one 
at a time with 36. This was quite interesting and unexpected. It may be true that efficacy is required 
for a small amount of PAM efficacy at α1 subtypes in combination with α5-PAM for pro-cognitive 
effects. 
Does this hypothesis help to rationalize why the α5 subtype selective ligands exhibit no or 
much less activation at α1 subtypes, such as 1 (SH-053-2'F-R-CH3), 35 (MP-III-022), as well as 
the novel ligand 37 (GL-II-74), which only exhibited the antidepressant effects in the FST, but not 
the cognitive effect the in Y-maze? This hypothesis in regard to the α5/α1 binding and efficacy for 
cognition is a very interesting point, but also one that is very difficult to untangle. Certainly, a 
“titration” experiment is reasonable to conduct by a combination of a selective an α5-PAM with a 
selective α1-PAM to determine if the activity of 36 can be mimicked. However, the combination 
of any two ligands introduces additional unknowns, therefore, the behavioral tests in double α2/α3 
knock-in mice would be one realistic way to test the idea in regard to the concordant beneficial 
effect via α1 and α5 GABAAR subtypes. On the other hand, the alternative approach 'genuinely 
mine' is to combine MP-III-022 and WYS8, the latter of which is one of the most selective α1 
compounds that is known and might be used as an α1 partial agonist.157-158  It would definitely be 
a challenge to titrate the doses of MP-III-022 and WYS8, but since these two compounds have 
been studied, therefore, they are 'manageable'. To date, WYS8 was only been tested in rats. A PK 
study in mice is necessary, especially for the free fraction of the mixture at 100 nM. One needs to 
design the experiment to determine how to combine the two ligands with an aim to obtain minimal 
activity at α1 and potent α5 activity and selectivity. If the result of this combination confirmed that 
the dual moderate α1/5 combination is indeed beneficial (anxiolytic, antidepressant, and pro-
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cognitive), it would be both, novel and non-obvious, and may even be an excellent candidate for 
clinical trials. Certainly it would help to define the actual mechanism of action of important ligand 
GL-II-73 (36). 
The study of the effects of 36 (GL-II-73) on brain morphology 
The results presented here, provided evidence of a significant difference in morphological 
properties of Layers II/III pyramidal cells of PFC between young, old, and old+treatment mice. In 
general, a significant decrease in spine morphology of pyramidal cells, including total dendritic 
lengths, total spine counts and overall spine density, was found in old mice in comparison with 
young mice. Notably, old+treatment mice exhibited a relatively higher spine density (p=0.0457) 
than old mice, although further confirmation of this finding is recommended and might require a 
larger sample size of mice brains. More importantly, it will be informative for future studies to 
examine the drug efficacy/effects upon the morphology of spine subtypes (thin, stubby, mushroom, 
etc.) between groups. 
Accordingly, these recent findings confirmed the difference in spine morphology between 
young, old and 36 (GL-II-73) treated old mice in the prefrontal cortex. Importantly, the aging-
induced dendritic shrinkage in the old mice was reversed to 80-90 % of the level of the young mice 
after 8 weeks of 36 administrated in the mice’s daily drinking water. This suggests (with GL-II-
73) a feasible drug treatment program to administer the α5 selective PAM of GABAARs to reverse 
the loss of spine and dendrites morphology in aging-related diseases including Alzheimer’s disease, 






Based on the structure and activity of the parent chiral compounds 1 (SH-053-2'F-R-CH3) 
and its enantiomer 2 (SH-053-2'F-R-CH3), a series of analogs, including those substitution with 
very different functional groups such as esters, amides, thioamides, oxadiazoles and oxazoles, 
were designed, synthesized and evaluated in in vitro studies to determine their metabolism, 
cytotoxicity, receptor binding affinity, and efficacy at different GABAARs subtypes. The 
compounds that possessed the desired in vitro profile were selected from the above assays and 
carried out for the further investigation in in vivo animal models. This was done to determine the 
PK profiles, to identify possible CNS side effects, and potential useful pharmacological effects, 
such as anti-inflammatory, anti-schizophrenic, anxiolytic, antidepressant and pro-cognitive effects.  
The data, up to date, indicated several possible compounds for different diseases among all 
the analogs evaluated and some may have clinical potential at this time point (May 2019). The 
isopropyl oxadiazole 57 (MP-IV-010) exhibited the most significant reduction of nitric oxide in 
the Griess assay to the control level without any CNS side effects nor profound cytotoxicity, 
consequently, it was selected as the lead anti-neuroinflammatory compound. In addition, the C(8)-
bromo oxazole 65 (GL-III-76) in the 2'F series was the ligand that presented the strongest anti-
schizophrenic-like activity in the murine model of MK-801 induced hyperlocomotion, while being 
devoid of sedative properties, which suggests a candidate for further studies and perhaps for the 
treatment of schizophrenia. Moreover, three compounds, S-dimethyl amide 30 (GL-I-54), R-
dimethyl amide 36 (GL-II-73) and R-cyclopropyl amide 38 (GL-II-75), exhibited both 
antidepressant and pro-cognitive effects and the latter two compounds elicited anxiolytic effects 
as well. The ligand 30 can be applied as a short-acting agent for acute use due to its fast distribution 
in the brain and rapid metabolic rate in depression, but perhaps a longer-lived C(3) bioisostere can 
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be found to replace the amide. The other two ligands 36 and 38 are chosen to be the lead 
compounds for depression due to their significant potency. The most recent finding demonstrated 
that the dimethyl amide 36, not only was active in reversing the stress-induced working memory 
deficits in young mice, but also restored the normal aging-induced dendritic shrinkage in the old 
mice to nearly a level (80-90 %) that is normally only seen in young mice. This effect was in the 
prefrontal cortex, which suggests a novel therapy for depression and aging-related diseases by 
using α5-GABAAR PAM with an interesting low-efficacy and low-affinity profile, unlike the 
classical high-potent drugs. This is a very important result in terms of depression, schizophrenia, 
Alzheimer's disease, and age-associated memory loss. These results have gained a lot of attention 
throughout the world. It was presented at the AAAS meeting and engendered a lot of press, 
including The New Daily, The Guardian as well as an interview with the BBC-TV World News. 
Now the GL-II-73 antidepressant project has been moved forward to other studies on larger 
animals such as dogs, and more work is underway at this time to develop better α5-subtype 
preferred anxiolytic, antidepressant and pro-cognitive ligands. In turn studies on the exact 
mechanism of GL-II-73 on the regrowth of dendrites and spines is underway. The mechanism of 
action on this novel and potential pharmacological approach for the treatment of schizophrenia, 
depression and other neurodegenerative, aging-related brain disorders such as Alzheimer's disease 








2.2.6.1. Catalepsy Assay (Nicholas J. Raddatz and Dr. David A. Baker, Marquette 
University) 
Animals 
Male Sprague Dawley rats (350-450 g) were singly housed and kept on a reverse 12 hr dark/light 
cycle (lights on 7:00 pm) with food and water provided ad libitum. The behavioral testing occurred 
between the hours of 9:00 am, and 4:00 pm with all animals individually handled a minimum of 
five minutes each for two days prior to the testing days. 
Drugs 
SH-053-2ꞌF-R-CH3 (1), SH-053-2ꞌF-S-CH3 (2), and haloperidol (Sigma-Aldrich, St. Louis, MO) 
were dissolved in dimethyl sulfoxide to a final concentration of 30 and 0.1 mg/mL, respectively. 
Dimethyl sulfoxide, while not an ideal vehicle for animal behavioral work, is an acceptable 
formulation for rats (Gad et al., 2006). The phencyclidine hydrochloride (NIDA Drug Supply 
Program, Research Triangle, NC) was dissolved in saline at a concentration of 1.5 mg/mL. 
Catalepsy assay104 
Catalepsy was tested as per the methods reviewed by Sanberg et al. (1988). In short, the subjects 
were placed in a test box that has an open top and a stainless steel floor and grey plastic walls 
(34.50 cm x 19.60 cm x 23.00 cm). The box contains a stainless steel bar 1.25 cm in diameter 
laterally mounted 12.50 cm above the floor and 8.50 cm from one end of the box. Haloperidol (0.1 
mg/kg), SH-053-2ꞌF-S-CH3, SH-053-2ꞌF-R-CH3 (30 mg/kg), or vehicle was administered 
intraperitoneally, and subjects were tested at 30, 60, and 120 min post-injection with a maximum 
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of five trials per session. The time (seconds) was measured from the placement of the subject’s 
front paws on the bar until one paw moves or slips from the bar. A maximum of five consecutive 
trials was attempted. Criteria time for a completed trial is between ten seconds and five minutes. 
After five trials, if the subject had not remained on the bar for a minimum of five seconds, the 
longest time of the five trials was recorded. 
 
2.2.6.2. Prepulse Inhibition (Nicholas J. Raddatz and Dr. David A. Baker, Marquette 
University) 
The prepulse inhibition of acoustic105 was run according to the method of Bakshi and Geyer (1995). 
The subjects were placed on a platform in a sound-attenuating chamber (10.875”x14”x19.5”; 
Hamilton-Kinder, CA) that rested on a motion sensing plate. A matching session was conducted 
to determine the magnitude of the startle response for each subject. This session consisted of a five 
minute habituation period followed by 20 trials; 17 trials involving the presentation of a single 
auditory stimulus (pulse stimulus; 50 dB above a 60 dB background noise) and three trials in which 
a prepulse stimulus (10 dB above background) was presented 100 milliseconds before the auditory 
pulse stimulus. Subjects were then assigned to the various treatment groups based on the 
magnitude of their startle response. At least one day later, an experimental session was conducted 
to assess sensorimotor gating. Subjects were given an intraperitoneal injection of SH-053-2ꞌF-S-
CH3, SH-053-2ꞌF-R-CH3 (30 mg/kg), or vehicle 60 min before testing, followed by subcutaneous 
injection of either phencyclidine hydrochloride (1.5 mg/kg) or saline ten minutes prior to testing. 
In the experimental session, after a five or ten minute habituation period, subjects received 58 
discrete trials; 26 trials during which the pulse stimulus (50 dB above background) was presented 
alone, 8 trials each in which the pulse stimulus was preceded by a pre-pulse stimulus (5, 10, or 15 
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dB above background) and 8 background trials with no pulse and only background noise. The first 
6 pulse alone trials were not included in the average startle stimulus to achieve a relatively stable 
level of startle reactivity. The percent of prepulse inhibition was determined as 100-(average 
prepulse startle response/average startle stimulus alone)*100. 
Statistical comparisons in each experiment were analyzed using a repeated measures analysis of 
variance (ANOVA) with drug treatment as between-subject variables and time of prepulse 
intensity as within-subjects variables for catalepsy and prepulse inhibition, respectively. 
Significant interactions and main effects were further analyzed using a Fisher LSD post hoc test 
(p<0.05). 
 
2.2.6.3. Seizure Protection in the 6 Hz Electroshock Assay (ETSP) 
Adult male CF1 mice (18-25 g) were pretreated intraperitoneally (i.p.) with the test compound at 
either 100 or 150 mg/kg. Each treatment group (n = 4 mice/group) was examined for 
anticonvulsive effects at one of five time points (1/4, 1/2, 1, 2, and 4 hr) after treatment with the 
test compound. Following pretreatment, each mouse received a drop of 0.5% tetracaine 
hydrochloride applied to each eye. The mouse was then challenged with the low-frequency (6 Hz) 
stimulation for 3 sec delivered through corneal electrodes. The low-frequency (6 Hz), long-
duration (3 sec) stimuli are initially delivered at 32 mA intensity. Animals are manually restrained 
and released immediately following the stimulation and observed for the presence or absence of 
seizure activity. If the test compound is effective in the 6 Hz screen, mice were assessed in a dose-




2.2.6.4. Ataxic Assessment in the Rotorod Assay (ETSP) 
Adult mice were dosed (i.p.) 30 minutes prior to being placed on a rotating rod at a speed of 6 
rpm.159 The ligand was considered toxic (sedating/ataxia) if the animal fell off this rotating rod 
three times during a 1-min period. In addition to minimal motor impairment, animals may exhibit 
a circular or zigzag gait, abnormal body posture and spread of the legs, tremors, hyperactivity, lack 
of exploratory behavior, somnolence, stupor, catalepsy, loss of righting response and changes in 
muscle tone and are noted accordingly by the observer. Toxicity equates to sedation and/or ataxia.  
 
2.2.6.5. Microsomal Stability Assay (Revathi Kodali, UWM) 
The 4 µL of 1 mM test compound at a final concentration of 10 µM was dissolved in DMSO/ACN/ 
methanol/ ethanol and was preincubated at 37 °C for 5 minutes on a digital heating shaker dry bath 
(Fischer Scientific, Pittsburgh, PA) in a mixture containing 282 µL of water, 80 µL of phosphate 
buffer (0.5 M, pH 7.4), 20 µL of NADPH Regenerating System Solution A (BD Bioscience, San 
Jose, CA) and 4 µL of NADPH Regenerating System Solution B (BD Bioscience, San Jose, CA) 
in a total volume of 391.2 µL. Following the preincubation, the reaction progress was initiated by 
addition of 8.8 µL of either human liver microsomes (BD Gentest, San Jose, CA), or mouse liver 
microsomes (Life technologies, Rockford, IL), at a protein concentration of 0.5 mg/mL. Aliquots 
of 50 µL were taken at time intervals of 0 (without microsomes), 10, 20, 40, 60, 90 and 120 minutes. 
Each aliquot was added to 100 µL of cold acetonitrile solution containing 1 µM/2 µM internal 
standard (Verapamil or 4,5-diphenyl imidazole). This was followed by sonication for 10 seconds 
and centrifugation at 10,000 rpm for 5 minutes. The 100 µL of the supernatant was transferred into 
Spin-X HPLC filter tubes (Corning Incorporated, NY) and centrifuged at 13,000 rpm for 5 minutes. 
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The filtrate was diluted 100-fold and subsequently analyzed by LC-MS/MS with a Shimadzu 
LCMS 8040, (Shimadzu Scientific Instruments, Columbia, MD). The ratio of the peak areas of the 
internal standard and test compound was calculated for every time point, and the natural log of the 
ratio was plotted against time to determine the linear slope (k). The metabolic rate (k*C0/C), half-
life (0.693/k), and internal clearance (V*k) were calculated, where k was the slope, C0 was the 
initial concentration of test compound, C was the concentration of microsomes, and V was the 
volume of incubation in µL per microsomal protein in mg. All experiments were repeated three 
times in duplicates. 
 
2.2.6.6. Cytotoxicity Assay (Dr. Michael R. Stephen, UWM) 
The human liver hepatocellular carcinoma (HEPG2) and human embryonic kidney 293T 
(HEK293T) cell lines were purchased (ATCC) and cultured in 75 cm2 flasks (CellStar). Cells were 
grown in DMEM/High Glucose (Hyclone, #SH3024301) media to which non-essential amino 
acids (Hyclone, #SH30238.01), 10 mM HEPES (Hyclone, #SH302237.01), 5 x 106 units of 
penicillin and streptomycin (Hyclone, #SV30010), and 10% of heat-inactivated fetal bovine serum 
(Gibco, #10082147) were added. The cells were harvested using 0.05% Trypsin (Hyclone, 
#SH3023601), washed with PBS, and dispensed into sterile white, optical bottom 384-well plates 
(NUNC, #142762). After two hours, the small molecule solutions were transferred with a Tecan 
Freedom EVO liquid handling system equipped with a 100 nL pin tool (V&P Scientific). The 
controls were 3-dibutylamino-1-(4-hexyl-phenyl)-propan-1-one (25 mM in DMSO, positive 
control) and DMSO (negative control). The cells were incubated for 48 hours, and this was 
followed by the addition of CellTiter-Glo™, a luminescence-based cell viability assay (Promega, 
Madison, WI). All luminescence readings were performed on a Tecan Infinite M1000 plate reader. 
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The assay was carried out in quadruplet with three independent runs. The data was normalized to 
the controls and analyzed by nonlinear regression (GraphPad Prism). 
 
2.2.6.7. Rotorod Assay via Oral Gavage (Nick Zahn, and Alec Huber, UWM) 
Swiss Webster mice were trained to maintain balance at a constant speed of 15 rpm on the rotarod 
apparatus (Omnitech Electronics Inc., Nova Scotia, Canada) until mice could perform for 3 
minutes for three consecutive trials. Separate groups of nine mice received oral gavage of vehicle 
(2% hydroxypropyl methylcellulose and 2.5% polyethylene glycol) or compounds (40 mg/kg) in 
a volume of 200 μL. The control compound diazepam was given as an i.p. injection at 5 mg/kg in 
10% DMSO, 40% propylene glycol, and 50% PBS. The mice were placed on the rotarod at three 
separate time points of 10, 30, and 60 minutes after each oral gavage drug administration. A fail 
was classified for each mouse falling twice prior to 3 minutes, as it is common for a mouse injected 
with a vehicle to occasionally fall once. Hence after a second fall, it would be considered a failure, 
and that time point would be recorded. 
 
2.2.6.8. Rotorod Assay via I.P. Administration (Dr. Aleksandra Vidojevic and Dr. 
Miroslav Savic, University of Belgrade) 
The rotarod test (Ugo Basile, Comerio, Italy) measured the capacity of the animal to maintain itself 
on the rod revolving 15 rpm, as a qualitative phenomenon. The test was performed in animals that 
received 15 mg/kg of treatment in SLA i.p. with eight days of washout period. Two days before 
testing, rats or mice were trained in three sessions in a row with each session lasting 180 s (with a 
pause of 30 minutes between them). On the test day, the selection was made and rats fulfilling the 
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criteria of maintaining themselves on the rod for 180 s without falling off (N = 40) were included 
in the test. Rats or mice were tested 20 minutes after the application of corresponding treatment 
dosed at 3, 5, 10, 15, 20, 30, 45, 60 and 90 mg/kg (N = 1-3 per treatment), depending on the test 
compounds. The latency to fall from the rod was recorded manually by an experimenter blind to 
the treatment assignment. The animals were given two trials and the higher value of the two (in 
sec) was used for further observation. Graphical analysis was performed in SigmaPlot 12 software 
(Systat, USA). 
 
2.2.6.9. Spontaneous Locomotor Activity (Dr. Aleksandra Vidojevic and Dr. Miroslav 
Savic, University of Belgrade)  
All compounds were tested on spontaneous locomotor activity (SLA) to determine the influence 
of the ligands in young mice (n=27). A white and opaque Plexiglas chamber (40×25×35 cm) was 
used as the apparatus under dim red light (20 lux). The mouse was injected i.p. with either vehicle 
or test compounds and placed immediately in the center of the chamber. Animal activity was 
recorded by a digital camera above the apparatus. ANY-maze Video Tracking System software 
(Stoelting Co, Wood Dale, IL, USA) was used to track and analyze the animal activity for a total 
of 60 min. The 70% ethanol was used to clean the chambers after each trial. 
 
2.2.6.10. Grip Strength (Dr. Aleksandra Vidojevic and Dr. Miroslav Savic, University of 
Belgrade)  
Rats were tested in the grip strength test after the rotarod assay. A grip strength meter (Ugo Basile, 
Milan, Italy, model 47105) was used to assess muscle strength. The rat grasped the trapeze that 
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was connected to a force transducer when the tail was pulled. This apparatus measured the peak 
force of pull (in grams) that was necessary to overcome the strength of the animal's forelimbs grip. 
Each rat was given 3 consecutive trials, and the median value was normalized against the body 
weight, which was used for further observation. Graphical analysis was performed in SigmaPlot 
12 software (Systat, USA). 
 
2.2.6.11. Binding Studies (PDSP) 
The HEK-293 cells were used to conduct the binding studies following the methods as previously 
described. Human embryonic kidney (HEK) 293 cells (AmericanType Culture Collection ATCCs 
CRL-1574™) were maintained in Dulbecco's modified Eagle medium (DMEM, high glucose, 
GlutaMAX™  supplement, Gibco61965-059, ThermoFisher, Waltham, Massachusetts, USA) 
supplemented with MEM (Non-Essential Amino Acids Gibco 11140-035, ThermoFisher, 
Waltham, Massachusetts, USA), 100U/ml Penicillin-Streptomycin (Gibco 15140-122, 
ThermoFisher, Waltham, Massachusetts, USA), and 10% fetal calf serum (Sigma-AldrichF7524, 
St. Louis, Missouri, USA) in 10 cm Cell culture dishes (Cell+, Sarstedt, Nürnbrecht, Germany) at 
37 °C and 5% CO2. HEK293 cells were transfected with cDNAs encoding rat GABAAR subunits 
that were subcloned into pCI expression vectors. The 3 mg of α(1,2,3 or 5): 3 mg of β3 and 15 mg 
of γ2 per 10 cm dish were used as the ratio of plasmids, which was employed for the transfection 
with the calcium phosphate precipitation method (Chen and Okayama,1987). After transfection 
for 4–6 h, the medium was changed. The cells were harvested 72 days after transfection by scraping 
into phosphate buffered saline. After centrifugation (10 min,12000 g, 4°C) cells were resuspended 
in TC50 (50 mM Tris-citrate pH¼7.1), homogenized with an Ultra-Turraxs (IKA, Staufen, 
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Germany) and centrifuged (20 min,50000 g). The membranes were washed 3 times in TC50 as 
described above and frozen at -20 °C until use. The frozen membranes were then thawed, re-
suspended in TC50 and incubated for 90 min at 4°C in a total of 500 mL of a solution containing 
150 mM NaCl, 50 mM Tris/citrate buffer, pH=7.1, and 2 nM [3H]-Flunitrazepam (Perkin Elmer 
New England Nuclear, Waltham, Massachusetts, USA) in the absence or presence of either 5 mM 
diazepam (Nycomed, Opfikon, Switzerland) (to determine unspecific binding) or various 
concentrations of test compounds (dissolved in DMSO, final DMSO concentration 0.5 %). 
Membranes were filtered through Whatman GF/B filters, and the filters were rinsed twice with 4 
mL of ice-cold 50 mM Tris/citrate buffer. The filters were transferred to scintillation vials and 
subjected to scintillation counting after the addition of 3 mL Rotiszint Eco plus liquid scintillation 
cocktail. The non-specific binding, which was determined in the presence of 5 mM DZP, was 
subtracted from the total [3H]-flunitrazepam binding to determine specific binding. In order to 
determine the equilibrium binding constant KD of 3H-Flunitrazepam for the various receptor-
subtypes, membranes were incubated with various concentrations of 3H-flunitrazepam in the 
absence or presence of 5 mM DZP. The saturation binding experiments were analyzed by using 
the equation Y=Bmax*X/(KD+X). The non-linear regression analysis of the displacement curves 
used the equation: log(inhibitor) vs. response-variable slope with Top = 100 % and Bottom = 0 % 
Y = 100/(1+10^((logIC50-x)*Hill-slope)). Both analyses were performed using GraphPad Prism 
(LaJolla California USA). The drug concentrations which resulted in half-maximal inhibition of 
specific 3H-flunitrazepam binding (IC50) were converted to Ki values by using the Cheng-Prusoff 
relationship (Cheng and Prusoff, 1973) Ki = IC50/(1+(S/KD)) with S being the concentration of the 




2.2.6.12. KOR Stimulation Response Test (Dr. Petra Scholze, University of Vienna) 
The HitHunter Chinese hamster ovary cells (CHO-K1) stably expressing the human κ-opioid 
receptor (OPRK1, catalog no. 95-0088C2) were purchased from DiscoverX Corp. (Fremont, CA). 
The cells were maintained in F-12 media with 800 μg/mL geneticin (Mirus Bio, Madison, WI), 
10% fetal bovine serum (Life Technologies, Grand Island, NY), and 1% penicillin/streptomycin/L-
glutamine (Life Technologies). All cells were grown at 37 °C and in 5% CO2 in a humidified 
incubator. The data of forskolin-induced cAMP accumulation were analyzed using nonlinear 
regression analysis in GraphPad Prism 5.0 software (GraphPad, La Jolla, CA) to generate 
sigmoidal dose-response curves for the cAMP accumulation assay. The cAMP accumulation data 
were normalized to vehicle and forskolin only control values. All ligands were tested in parallel 
assays in triplicate in ≥ 2 individual experiments. The EC50 and Emax values were reported as the 
means ± SEM and were represented by the average of each experiment following nonlinear 
regression analysis. This method was reported in Riley, A. P.; Groer, C. E.; Young, D.; Ewald, A. 
W.; Kivell, B. M.; Prisinzano, T. E. Synthesis and kappa-opioid receptor activity of furan 
substituted salvinorin A analogs. J. Med. Chem. 2014, 57, 10464−10475; and Crowley, R.S., et. 
al. Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent 
and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability J. Med. Chem., 2016, 59 
(24), pp 11027–11038. 
 




The electrophysiological recordings were performed following the methods described in Alexeev 
et al. The full-length cDNAs for GABAAR subtypes (generously provided by Dr. David Weiss, 
the University of Texas Health Science Center, San Antonio, TX and Dr. Robert Macdonald, 
Vanderbilt University) in mammalian expression vectors were transiently transfected into HEK-
293T cell lines (GenHunter, Nashville, TN). All subtypes were rat clones except for α2, which was 
a human clone. The cells were transiently transfected using calcium phosphate precipitation. The 
plasmids encoding GABAAR subtype cDNAs were added to the cells in 1:1:1 ratio (α:β:γ) of 2 μg 
each. The cells were patch-clamped at −50 mV in the whole-cell recording configuration. GABA 
was diluted into the bath solution from freshly made or frozen stocks in water. The test compounds 
were dissolved in DMSO and diluted into a bath solution with the highest DMSO level applied to 
cells of 0.01%. The solutions containing GABA or GABA + compounds were employed to cells 
for 5 s using a 3-barrelled solution delivery device controlled by a computer-driven stepper motor 
(SF-77B, Harvard Apparatus, Holliston, MA, open tip exchange time of  < 50 ms). There was a 
continuous flow of external solution through the chamber. An Axon 200B (Foster City, CA) patch 
clamp amplifier was used to record the currents. The whole-cell currents were analyzed using the 
programs Clampfit (pClamp9 suite, Axon Instruments, Foster City, CA) and Prism (GraphPad, 
San Diego, CA). The concentration-response data was fit with a four-parameter logistic equation 
current =
minimum current+(maximum current−minimum current)
1+(10(logEC50−log(modulator))n)
 where n represents the Hill number. All 
fits were made to normalized data with current expressed as a percentage of the response to GABA 
alone for each cell. 
 
2.2.6.14. Pharmacokinetic Studies (Dr. Aleksandra Vidojevic and Dr. Miroslav Savic, 
University of Belgrade) 
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Young mice (n = 15) were divided into 5 groups; each group contained 3 animals and corresponded 
to predetermined time intervals (5, 20, 60, 180, and 720 min). The mice were administrated (i.p.) 
with test compounds at the 10 mg/kg dose (a volume of 10 mL/kg). The brain concentrations were 
measured 20 min after i.p. injection at the dose of 1 mg/kg, as well as after 3 i.p. injections, 
administered 24 h, 20 h and 1 h prior to the measurement of concentration. 
The mice were anesthetized with ketamine solution (10% Ketamidor, Richter Pharma Ag, Wels 
Austria, dosed at 100 mg/kg i.p.) at the appropriate time intervals. The blood samples were then 
collected via cardiac puncture of mice in heparinized syringes, and the plasma samples were 
obtained after centrifuging at 800 rcf for 10 min. Mice were decapitated, and brains were weighed, 
which were homogenized in 1.25 mL of methanol and centrifuged at 3400 rcf for 20 min. The 
compounds were extracted from plasma and supernatants of brain tissue homogenates by solid 
phase extraction, using Oasis HLB cartridges (Waters Corporation, Milford, Massachusetts). The 
procedure of sample preparation and determination of concentration by ultraperformance liquid 
chromatography-tandem mass spectrometry (UPLC–MS/MS) with Thermo Scientific Accela 600 
UPLC system connected to a Thermo Scientific TSQ Quantum Access MAX triple quadrupole 
mass spectrometer (Thermo Fisher Scientific, San Jose, California), equipped with the electrospray 
ionization (ESI) source, has been already described in detail. The non-compartmental 
pharmacokinetic analysis was performed using PK functions for Microsoft Excel software (by Joel 
Usansky, Atul Desai, and Diane Tang-Liu were), while graphs were constructed in commercial 
statistical software Sigma Plot 12 (Systat Software Inc., USA).  
In vitro hydrolytic stability study in plasma 
The hydrolytic stability of the test compounds was conducted in vitro at 37 °C, and the blank 
mouse plasma was used to spike with the respective compound as well as the internal standard 
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(SH-I-048A; synthesized at the Department of Chemistry and Biochemistry, University of 
Wisconsin–Milwaukee, USA). 
Plasma protein and brain tissue binding studies  
The rapid equilibrium dialysis assay determined the free fraction of GL-II-73, GL-II-74, and GL-
II-75 in mouse plasma and brain tissue was the same as in the previously described method. The 
free concentrations in the brain for GL-II-73, GL-II-74, and GL-II-75 were calculated by 
multiplying the total brain concentrations obtained with the appropriate free fractions determined 
by rapid equilibrium dialysis (12.14%, 4.49% and 1.34%, respectively). 
 
2.2.6.15. Griess Assay and Toxicity Assay (Amanda Nieman, UWM) 
The 80 μL of non-activated mouse microglia (1x106 cells/mL) were plated in sterile 384 well 
plates.  The culture, which remained, was activated with 50 ng/mL LPS and 150 U/mL IFNγ and 
distributed into the 384 well plates. The 0.1 μL of 800 μM GABA diluted in MilliQ water (final 
concentration of 1 μM), and appropriate concentrations of compounds of interest diluted in DMSO 
were added via a TECAN automated liquid handling robot. The assay plate was incubated for 24 
h at 37 °C, spun down, and 40 μL of supernatant was removed to a new plate for analysis by the 
Griess Assay (Promega, Madison, WI).  Absorbance at 530 nM was read using a TECAN Infinite 
M1000 plate reader.  The remaining 40 μL containing cells was analyzed for toxicity by the Cell 
Titer-Glo Assay (Promega, Madison, WI). Luminescence was read using a TECAN Infinite 




2.2.6.16. Anti-Schizophrenic-like Behavioral Study Induced by MK-801 (Dr. Aleksandra 
Vidojevic and Dr. Miroslav Savic, University of Belgrade) 
The SLA was performed in 10 ± 2 week-old male naïve C57BL/6 mice (N = 64) in the apparatus 
which consisted of four white and opaque Plexiglas chambers (40×25×35 cm) under dim red light 
(20 lux). A digital camera mounted above the apparatus recorded the animal's activity, which was 
analyzed using ANY-maze Video Tracking System software (Stoelting Co, Wood Dale, IL, USA). 
A test was conducted in two stages. The first stage (“Habituation”) started when a single mouse 
was placed in the center of the chamber in order to habituate for 60 min; immediately after the 
appropriate treatment was administered and the animal's activity was recorded for an additional 
120 minutes (second stage; “MK-801 challenge”). The testing of animals was balanced for the 
time of the day (am or pm), treatment and chamber. The chambers and the upper surface of the 
stand were cleaned with 70 % ethanol after every test. 
The dose of MK-801, which robustly induces hyperlocomotion, was determined after reviewing 
the literature (Kalinichev et al. 2008., the text of the article is in the attachment), while the dose of 
compounds was chosen based on the laboratory experience. The MK-801 was applied as a maleate 
(Tocris Bioscience, Bristol, UK) in a dose of 0.32 mg/kg and compounds (synthesized at the 
University of Wisconsin-Milwaukee, Milwaukee, USA) were dosed at 10 mg/kg. The dosage form 
of MK-801 maleate was prepared by dissolving it in the saline (SAL), while the compounds were 
readily suspended in the solvent (SOL) containing 85% distilled water, 14% propylene glycol and 
1% Tween 80 with the aid of sonication. The treatments administered were: SAL in the 
combination with SOL as a different injection administered immediately after the first one at the 
animal’s counter site (SOL + SOL), then SAL + GL-III-36, SAL + GL-III-73, SAL + GL-III-76, 
SAL + GL-III-78, MK-801 + SOL, MK-801 + GL-III-36, MK-801 + GL-III-73, MK-801 + GL-
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III-76 and MK-801 + GL-III-78. The treatments were applied intraperitoneally in a total volume 
of 20 ml/kg (10 mL/kg each injection). 
 
2.2.6.17. Anxiety-Like Behaviors in the Elevated Plus Maze (Dr. Thomas D. Prevot and Dr. 
Etienne Sibille, CAMH) 
The anxiety-like behaviors from the test compounds were assessed by the use of the elevated plus 
maze (EPM) in rodents. The maze is made of four white Plexiglas arms, which included two open 
arms (29x7 cm), and two enclosed arms (29x7x17 cm). These four arms formed a cross shape with 
the two open arms opposite each other. The maze is 90 cm above the floor and illuminated at 100 
lux. Prior to test 30 minutes, the young male and female (50 %) mice (Jackson Laboratories) were 
administrated i.p. with either vehicle, 5 or 10 mg/kg dose of test compound or 1.5mg/kg of DZP. 
The mice were placed in the center of the platform individually, and they were facing an open arm, 
then allowed to explore the maze for 10 min. The animal activity was recorded with a digital 
camera and analyzed using ANY-maze Video Tracking System software (Stoelting Co, Wood 
Dale, IL, USA). The time in the open arm was used to calculate the percentage of time in the open 
arm by the following formula: the % time in open arm = (time in the open arm)/(total time)  x 100. 
 
2.2.6.18. Antidepressant Predictability via Forced Swim Test (Dr. Thomas D. Prevot and 
Dr. Etienne Sibille, CAMH) 
Under normal housing conditions (12 h light ON cycle starting at 7am / water and food ad libitum), 
the 8 weeks-old C57Bl/6 male mice (Jackson Laboratories) were group housed (4-5 mice/cage) 
for one week. All drugs were dissolved in a vehicle solution containing 14% propylene glycol 
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(Sigma Aldrich), 1% Tween 80 (Sigma Aldrich) and 85% H2O. The working solutions (20 mg/mL) 
was injected i.p. with vehicle or αPAM in mice at doses of 1, 5 or 10 mg/kg. After the injection 
for 1 h, mice were placed in an inescapable transparent tank filled with water (25 cm, 25-26 oC) to 
a level, where they are unable to touch the bottom and unable to escape. Animal activity was 
recorded for a period of 6 min for the immobile time in the tank. Compounds that reduced the time 
spent immobile in the FST are considered to have potential antidepressant effects. 
 
2.2.6.19. Cognitive Flexibility via Y-Maze Test (Dr. Thomas D. Prevot and Dr. Etienne 
Sibille, CAMH) 
Young animals and chronic stress procedure: the C57/Bl6 mice, males, and females were ordered 
from Jackson Laboratories at 8 weeks old and were kept in normal housing conditions (12 h light 
ON cycle starting at 7am / water and food ad libitum) for one week. During this week, animals 
were singly housed and handled to reduce the anxiety-like response toward the experimenter. To 
induce a working memory deficit, mice were subjected to a chronic restraint stress protocol (CRS). 
They were placed in a 50ml falcon® tube, twice a day, for 1 h during their diurnal cycle. The time 
of occurrence of the stress was randomized every day to avoid predictability. The CRS was not 
applied on testing days. The Y-maze test occurred 15 h minimum after the last stressor.  
Testing in young versus old Animals testing: C57/Bl6 male mice males were ordered from Jackson 
Laboratories at 10 months-old and were kept in normal housing conditions (12 h light ON cycle 
starting at 7am / water and food ad libitum) until they reached the age of 22 months. A younger 
cohort of 8 week old animals was used as controls for the experiment. Before testing, animals were 
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handled to reduce the anxiety-like response toward the experimenter. Normal aging induced-
working memory deficits were assessed using the Y-maze test, as described below.  
Y-maze Protocol: The mice were first habituated to the Y-maze apparatus and distal cues during 
2 consecutive days over a 10 min free exploration session (one session per day). The next day, 
animals performed a training session consisting of seven successive trials separated by a 30 s inter-
trial interval (ITI); during this training session, mice were familiarized with the experimental 
procedure (opening and closing of the doors and confinement into the goal arms). For each trial, 
the mice remained in the start-box for a 30 s ITI. Then, the door was opened, and the mouse was 
allowed to enter freely one of the two goal arms; the chosen arm was closed, and the choice was 
recorded. After a 30 s confinement period into the chosen arm, the mouse was removed and 
brought back to the start-box for a second trial identical to the first one and this procedure was 
repeated over the series of trials.  
The same general procedure used in the training session was implemented 24 h later, except that 
the ITI was lengthened to 90 s. For this experiment, animals were acutely injected i.p. with vehicle 
or an α PAM, 30 min before the beginning of the test. To dissociate memory deficits from an 
eventual progressive loss of motivation to alternate over the series, an 8th trial was added to the 
series which was separated from the 7th trial by a shorter ITI (5 s). All animals failing to alternate 
at the 8th trial were excluded. The mean alternation rate was calculated and was expressed in 
percentage (number of alternation done by the animal / total number of alternation possible × 100) 
± SEM. The percentage of alternation during the entire task was considered as an index of working 
memory performance (50% of it being a random alternation rate). A factorial ANOVA was applied 
to the data to reveal differences between groups. If the ANOVA was significant for group effect 
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(p<0.05), Scheffe post-hoc analysis was conducted to identify which groups are different from 
each other.  
Drug preparation and administration: All drugs were diluted in a vehicle solution containing 85% 
H2O, 14% propylene glycol (Sigma Aldrich) and 1% Tween 80 (Sigma Aldrich). The working 
solutions (10 mg/mL) and injected i.p. to the mice. For all Y-maze experiments, animals were 
acutely injected i.p. with vehicle or α PAM at the dose of 1, 5, 10 or 20 mg/kg, 30 min before the 
beginning of the test. 
 
2.2.6.20. A Golgi-Cox Study (Dr. Thomas D. Prevot and Dr. Etienne Sibille, CAMH) 
The old (22 months old) and young (2 months) C57BL/6 male mice (Charles River) were used in 
this study. A subset of old mice received the compound GL-II-73 for 8 weeks in the drinking water 
at the concentration of 30 mg/kg. Prior to administration of the compound to the animals, the 
average volume consumed was measured to obtain the daily consumption of 8 mL per day. Based 
on this assessment, the compound was prepared in drinking water and provided fresh to the animals 
every other day. The group details are as follow: Young (N=9); Old (N=13) and Old+Treatment 
(N=6). 
The mice were then behaviorally tested in the Y maze alternation task, as described in Prevot et al. 
(2019), prior to euthanasia using the cervical dislocation method. The brains were harvested and 
soaked in Golgi staining solution (provided by the CRO) for 2 weeks. The brains were then rinsed 
and kept in 30% sucrose solution for shipment to the CRO. Brains were sectioned using a cryostat, 
and coronal sections were mounted on a slice. The slides included serial coronal sections that 
covered the anterior-to-posterior axis of the brain.  The sampling of ROIs included the basal and 
apical dendrites of pyramidal cells in Layers II/III of PFC. The ROIs were then chosen and 
analyzed using a stereology-based software, termed NeuroLucida, v10 (Microbrightfield, VT), 
installed on a Dell PC workstation that controlled Zeiss Axioplan 2 image microscope with 
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Optronics MicroFire CCD camera (1600 x 1200) digital camera, motorized X, Y, and Z-focus for 
high-resolution image acquisition and digital quantitation.   
I. Sample selection criteria: 
The sampling process was conducted as follows: The investigators first 1) previewed the entire 
rostrocaudal axis of ROIs, under low-mag Zeiss objectives (10x and 20x), 2), then compared and 
located those with the least truncations of distal dendrites as possible under high-mag Zeiss 
objectives (40x and 63x), 3), and then 4) used a Zeiss 100x objective with immersion oil to perform 
3D dendritic reconstruction, followed by counting of the spines throughout the entire dendritic 
trees.  The criteria for selecting candidate neurons for analysis were based on i) visualization of a 
completely filled soma with no overlap of neighboring soma and completely filled dendrites, ii) 
the tapering of most distal dendrites; iii) the visualization of the complete 3-D profile of dendritic 
trees using the 3-D display of imaging software.  Neurons with incomplete impregnation and/or 
neurons with truncations due to the plane of sectioning were not collected.  Moreover, cells with 
dendrites labeled retrogradely by impregnation in the surrounding neuropil were excluded (derived 
from Wu et al. [2004], PNAS).   
With the systematic registration and digital monitoring, the software was able to accurately record 
every step of the tracing/contouring and generate a 3D reconstructed dendritic morphology for 
subsequent spine counting.  Automatic navigation of the digital probes with registered x-y-z 
coordinates of each 2D image stack was able to create a complete 3D digital profile for the 
dendrograms, spine density, and Sholl analysis (see below). 
II. Spine sampling criteria & quantitative analysis: 
i) Spine sampling: Only spines orthogonal to the dendritic shaft were readily resolved and included 
in this analysis, whereas spines protruding above or beneath the dendritic shaft were not sampled 
(see below).  This principle remained consistent throughout the course of the analysis.  Also, due 
to the inevitable truncations of most distal ends of the sections and shrinkage after the impregnation 
process and optical limit to resolving most distal dendrites in the deep z-axis. This process under-
estimates the actual dendritic lengths and spine numbers would be expected.  The above limitations, 





ii) Quantitative analysis: After tracing and spine counting, the raw data were extrapolated and 
quantitated using the NeuroExplorer program (Microbrightfield, VT).  In addition, to further 
investigate the change in spine morphology, Sholl analysis was performed to characterize the spine 
properties in reference to a series of concentric circles (spheres in 3D) around the soma of the 
sampled neurons.  Within each sphere, various measures were obtained, including 1) Frequency 
of intersections (or dendritic ramification) and 2) Spine density based on every 30um interval or 
concentric circle from the soma (see “Schematic diagram” below).   Note: Frequency of 
intersections represents the intersections or ramifications of dendritic processes interacting with 




Schematic diagram of Sholl analysis.  
After completion, the digital profile of neuron morphology was extrapolated and transported 
to a multi-panel computer workstation for quantitative analysis, including the dendrograms, spine 












All reactions were carried out in oven-dried round-bottom flasks and cooled under an argon 
atmosphere. All organic solvents and chemicals were purchased from commercial suppliers, then 
further dried and purified with the PURESOLV Solvent Purification System (Innovative 
Technology, Inc.) and KNF LABOPORT diaphragm laboratory vacuum pumps. Reactions were 
analyzed and monitored on TLC plates from Dynamic Adsorbents Inc. under a fluorescence 
indicator (UV254). The purification of some compounds were completed by column 
chromatography on silica gel (230-400 mesh, Dynamic Adsorbents) using a glass column. The 
melting points were determined on a Stuart melting point SMP3 apparatus manufactured by 
Barloworld Scientific US Ltd. The 1H and 13C NMR spectra were obtained on a Bruker Spectrospin 
300 MHz or 500 MHz instruments in CDCl3 or DMSO-d6. Chemical shifts were reported in δ 
(ppm) relative to TMS as an internal standard. The NMR multiplicities are presented as follows: 
singlet (s), broad singlet (br s), doublet (d), triplet (t), quartet (q), and multiplet (m). The 
determination of compound purity (> 95%) was performed by HPLC-MS on a Shimadzu LCMS-
2020, and HRMS was performed on a Shimadzu LCMS-IT-TOF at the Milwaukee Institute for 







The (2-amino-5-bromophenyl)(2-fluorophenyl)methanone 3 (150 g, 510.0 mmol) and Boc-D-
alanine (160 g, 845.6 mmol) were dissolved in dry DCM (500 mL) and stirred at 0 oC. Then 
dicyclohexylcarbodiimide (DCC; 186.9 g, 905.8 mmol) was dissolved in dry DCM (250 mL) to 
form a homogenous solution, which was added to the former mixture dropwise over a 30 min 
period at 0 oC. The solution was allowed to stir for 22 h at rt. The dicyclohexyl urea byproduct 
which was formed was filtered off and washed with DCM until the solid was colorless. The organic 
layers were combined and concentrated under reduced pressure. The crude solid was dissolved in 
hexane at 45 oC, and the Boc analog 4 was recrystallized when cooled down to rt after adding seed 
crystals. The crystals were further washed with hexane to afford the majority of Boc analog 4. The 
filtrate was combined, concentrated and purified on a flash column chromatography (silica gel, 
DCM/hexane 1:1) to yield additional amide 4 (230 g, 97 %): 1H NMR (300 MHz, CDCl3) δ 11.68 
(s, 1H), 8.71 (d, J = 9.0 Hz, 1H), 7.69 (dd, J = 9.0, 2.3 Hz, 1H), 7.64 – 7.53 (m, 2H), 7.51 – 7.42 
(m, 1H), 7.35 – 7.27 (m, 1H), 7.21 (t, J = 9.1 Hz, 1H), 5.13 (s, 1H), 4.37 (s, 1H), 1.52 (d, J = 7.2 
Hz, 3H), 1.45 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 195.47 (s), 172.42 (s), 159.56 (d, J = 253.2 
Hz), 155.28 (s), 139.68 (s), 137.97 (s), 135.97 (d, J = 1.9 Hz), 133.62 (d, J = 8.4 Hz), 130.31 (d, 
J = 2.4 Hz), 126.77 (d, J = 14.5 Hz), 124.51 (s), 124.46 (s), 122.63 (s), 116.55 (d, J = 21.4 Hz), 
114.95 (s), 80.26 (s), 51.86 (s), 28.26 (s), 18.58 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd 
for C21H23BrFN2O4 465.0820; found 465.0845. This was used in the next step without further 







Amide 4 (221.6 g, 467.2 mmol) was dissolved in dry DCM (1 L) and cooled to 0 oC. Anhydrous 
HCl (g) was slowly added until the solution was saturated, about 2 h, and the solution was allowed 
to stir overnight at rt. The reaction mixture was then washed with a sat aq solution of NaHCO3 (2 
x 500 mL) and water (2 x 300 mL). A mild exotherm was observed during the addition of a 
saturated aq NaHCO3 workup. The organic layer was concentrated under reduced pressure and 
the oil which resulted was dissolved in methanol-water (3:2, 1.7 L) while the pH was adjusted to 
8.5 using a solution of 1 M aq NaOH. The reaction mixture was allowed to stir at rt overnight. The 
solution was concentrated under reduced pressure and water (100 mL) was added. The solution 
was extracted with DCM and the organic layer was washed with brine, dried (Na2SO4), and 
concentrated under reduced pressure. The recrystallization of the benzodiazepine 5 was conducted 
in the mixture of EtOAc and hexanes in a ratio of 1:9 after adding seed crystals. The crystals were 
washed with a solution of EtOAc and hexanes (1:9), and the filtrate was combined, concentrated 
and purified on a flash column chromatography (silica gel, EtOAc/hexane 1:2) to yield the 
additional benzodiazepine 5 (129 g, 78.5 %): [α] 26D = -169.1 (c 0.71, EtOAc); 1H NMR (300 MHz, 
CDCl3) δ 9.66 (s, 1H), 7.64 – 7.53 (m, 2H), 7.45 (dq, J = 6.3, 1.6 Hz, 1H), 7.36 (d, J = 1.9 Hz, 
1H), 7.24 (t, J = 7.5 Hz, 1H), 7.12 (d, J = 8.7 Hz, 1H), 7.05 (t, J = 9.0 Hz, 1H), 3.80 (q, J = 6.5 
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Hz, 1H), 1.79 (d, J = 6.5 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 172.30 (s), 164.48 (s), 160.43 (d, 
J = 251.9 Hz), 136.47 (s), 134.70 (s), 132.14 (d, J = 8.6 Hz), 132.06 (d, J = 2.0 Hz), 131.54 (d, J 
= 2.4 Hz), 130.11 (s), 127.12 (d, J = 12.4 Hz), 124.41 (d, J = 3.6 Hz), 122.89 (s), 116.48 (s), 
116.28 (d, J = 21.6 Hz), 58.84 (s), 16.94 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for 




2.2.7.3. Ethyl (R)-8-bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4] 
diazepine-3-carboxylate (SH-I-047, 6) 
 
The 1,4-benzodiazepine 5 (100 g, 288 mmol) was dissolved in dry THF (1.4 L) and cooled to -35 
oC. The K-t-BuO (38.8 g, 345.6 mmol) was then added in one portion and the solution was allowed 
to warm to rt where the temperature was held for 30 min. The reaction was then cooled to -50 oC 
and diethyl chlorophosphate (70.8 g, 403.3 mmol) was added. The solution was allowed to warm 
to rt and the temperature was held there for 1 hour. The reaction was then cooled to -78 oC and 
ethyl isocyanoacetate (45.6 g, 403.3 mmol) was added, followed by a second portion of K-t-BuO 
(38.8 g, 345.6 mmol). The reaction was allowed to warm to rt and stirred overnight. The reaction 
was quenched by addition of a cold sat aq solution of NaHCO3 (1 L) and extracted with EtOAc. 
195 
 
The organic layers were combined and washed with brine (2 x 250 mL), dried (Na2SO4) and the 
solvent was removed under reduced pressure to afford a brown solid. The majority of the bromide 
6 can be crystallized in methyl t-butyl ether or EtOAc after cooling from 60 ˚C, and the additional 
portion was purified with flash column chromatography (silica gel, EtOAc:hexane, 3:2) to afford 
pure IMDZ 6 as an off-white solid (95.6 g, 75%): [α] 26D = -10.9 (c 0.53, EtOAc); 1H NMR (300 
MHz, CDCl3) δ 7.90 (s, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.55 (t, J = 7.3 Hz, 1H), 7.46 (d, J = 8.6 
Hz, 1H), 7.44 – 7.33 (m, 2H), 7.20 (t, J = 7.5 Hz, 1H), 6.98 (t, J = 9.3 Hz, 1H), 6.66 (q, J = 7.1 
Hz, 1H), 4.71 – 3.81 (m, 2H), 1.36 (t, J = 7.1 Hz, 3H), 1.24 (d, J = 7.3 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 162.89 (s), 162.63 (s), 160.04 (d, J = 250.7 Hz), 141.51 (s), 134.87 (s), 134.82 (s), 
133.62 (s), 132.94 (s), 132.07 (d, J = 8.2 Hz), 131.17 (s), 131.05 (s), 129.50 (s), 128.38 (d, J = 
12.4 Hz), 124.52 (d, J = 3.5 Hz), 123.73 (s), 120.89 (s), 116.17 (d, J = 21.5 Hz), 60.73 (s), 50.07 
(s), 14.84 (s), 14.40 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C21H18BrFN3O2 442.0561; 
found 442.0563. The spectral data for 6 were identical to the literature.160 
 
2.2.7.4. Ethyl (R)-6-(2-fluorophenyl)-4-methyl-8-((trimethylsilyl)ethynyl)-4H-benzo[f]imi 
dazo[1,5-a][1,4]diazepine-3-carboxylate (7) 
 
The IMDZ 6 (55 g, 124.4 mmol) was dissolved in triethylamine (400 mL) and acetonitrile (550 
mL). Trimethylsilylacetylene (18.3 g, 186.5 mmol) and bis(triphenylphosphine)-palladium (II) 
acetate (5.12 g, 6.8 mmol) were added. A reflux condenser was attached and the mixture was 
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degassed under vacuum with argon; this process was repeated four times. The reaction mixture 
was heated to reflux under argon and stirred for 8 hours. The solution was cooled to rt, filtered 
through celite, and washed with EtOAc. The filtrate was concentrated under reduced pressure. The 
black residue which resulted was purified by a wash column (silica gel, EtOAc/hexanes 1:1) to 
afford the TMS-analog 7 as an off-white solid (44.6 g, 77.7 %): [α] 26D = +28.2 (c 0.48, EtOAc); 
1H NMR (300 MHz, CDCl3) δ 7.93 (s, 1H), 7.66 (d, J = 7.9 Hz, 1H), 7.59 (t, J = 7.3 Hz, 1H), 
7.53 (d, J = 8.3 Hz, 1H), 7.44 (td, J = 7.3, 1.6 Hz, 1H), 7.36 (s, 1H), 7.24 (dd, J = 10.9, 4.1 Hz, 
1H), 7.04 (t, J = 9.2 Hz, 1H), 6.68 (q, J = 7.2 Hz, 1H), 4.53 – 4.23 (m, 2H), 1.41 (t, J = 7.1 Hz, 
3H), 1.25 (d, J = 7.3 Hz, 3H), 0.23 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 163.34 (s), 162.94 (s), 
160.14 (d, J = 250.6 Hz), 141.69 (s), 135.16 (s), 134.80 (s), 134.12 – 133.69 (m), 133.40 (s), 
131.85 (d, J = 8.3 Hz), 131.20 (s), 129.60 (s), 129.48 (s), 128.76 (d, J = 13.2 Hz), 124.43 (d, J = 
3.4 Hz), 122.67 (s), 122.10 (s), 116.22 (d, J = 21.5 Hz), 102.50 (s), 97.31 (s), 60.74 (s), 50.08 (s), 
14.76 (s), 14.42 (s), -0.26 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C26H27FN3O2Si 
460.1851; found 460.1833. The spectral data for 7 were identical to the literature.160 
 
2.2.7.5. Ethyl (R)-6-(2-fluorophenyl)-4-methyl-8-((triisopropylsilyl)ethynyl)-4H-benzo[f] 
imidazo[1,5-a][1,4]diazepine-3-carboxylate (8) 
 
Tri(O-tolyl)phosphine (1.94 g, 6.38 mmol) was suspended in ACN (200 mL), and then Pd(OAc)2 
(0.72 g, 3.2 mmol) was added under Ar at rt to form an orange cloudy solution. The mixture was 
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allowed to stir at rt for 40 min untill the color of the solution turned yellow, which was an indication 
for the formation of the Pd complex generated in situ. TIPS-acetylene and the bromide 6 were 
suspended in ACN (250 mL), which was added to the former mixture, and this was followed by 
addition of TEA. The mixture was stirred until the starting material 6 was consumed, as indicated 
by TLC (silica gel), in about 4 h. The reaction mixture was cooled down to rt, and the solvent was 
removed to 1/4th of the original volume. The solid, which resulted, was filtered off and washed 
with EtOAc. The filtrate was combined and concentrated under reduced pressure. The residue 
which resulted was purified by a wash column (silica gel, EtOAc/hexanes 2:3) to afford pure 
triisopropylsilyl analog 8 (29.9 g, 86.0 %): 1H NMR (300 MHz, CDCl3) δ 7.90 (s, 1H), 7.58 (dd, 
J = 19.5, 7.9 Hz, 2H), 7.51 (d, J = 8.3 Hz, 1H), 7.36 (dt, J = 7.4, 6.1 Hz, 1H), 7.28 (s, 1H), 7.17 
(t, J = 7.5 Hz, 1H), 6.96 (t, J = 9.3 Hz, 1H), 6.63 (q, J = 7.0 Hz, 1H), 4.47 – 4.20 (m, 2H), 1.33 (t, 
J = 7.1 Hz, 3H), 1.21 (d, J = 8.3 Hz, 3H), 1.03 (s, 21H); 13C NMR (75 MHz, CDCl3) δ 163.29 (s), 
162.88 (s), 160.09 (d, J = 250.6 Hz), 141.60 (s), 135.26 (s), 134.87 (s), 134.01 (s), 133.28 (s), 
131.79 (d, J = 8.8 Hz), 131.17 (s), 130.84 (ddd, J = 261.9, 259.9, 12.8 Hz), 129.52 (s), 129.40 (s), 
124.36 (s), 122.91 (s), 122.14 (s), 116.03 (d, J = 21.5 Hz), 104.58 (s), 94.01 (s), 60.62 (s), 50.05 
(s), 18.52 (s), 14.77 (s), 14.36 (s), 11.14 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for 
C32H39FN3O2Si 544.2790; found 544.2785. 
 
2.2.7.6. Ethyl (R)-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4] 




The intermediate 7 (44.4 g, 96.6 mmol) was dissolved in THF (400 mL) and cooled to -78 oC. This 
was treated with tetrabutylammonium fluoride hydrate (1 M solution in THF, 145 mmol), and this 
was followed by water (45 mL). The reaction mixture was stirred until the starting material was 
consumed as indicated by TLC (silica gel), about 1 h. The reaction mixture was allowed to warm 
to rt, and water (200 mL) was slowly added. The solution was extracted with EtOAc and the 
organic extracts were combined, washed with brine, dried (Na2SO4), and the solvent was removed 
under reduced pressure. The residue which resulted was purified by a wash column (silica gel, 
EtOAc/hexanes 1:1) to afford pure ethyl ester 1 as a white powder (36 g, 96.3 %). The deprotection 
of the triisopropylsilyl analog 8 (27.2 g, 50.0 mmol) followed the same procedure as the 
deprotection of the trimethylsilyl analog 7 to produce the same product ethyl ester 1 (17.4 g, 
89.8 %): [α] 26D = +20.9 (c 0.89, EtOAc); 1H NMR (300 MHz, CDCl3) δ 7.93 (s, 1H), 7.69 (d, J 
= 8.1 Hz, 1H), 7.57 (t, J = 9.6 Hz, 2H), 7.48 – 7.36 (m, 2H), 7.24 (t, J = 7.5 Hz, 1H), 7.02 (t, J = 
9.3 Hz, 1H), 6.69 (q, J = 7.1 Hz, 1H), 4.54 – 4.27 (m, 2H), 3.15 (s, 1H), 1.40 (t, J = 7.1 Hz, 3H), 
1.27 (d, J = 7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 163.20 (s), 162.91 (s), 160.08 (d, J = 252.0 
Hz), 141.64 (s), 135.17 (s), 134.86 (s), 134.49 (s), 133.88 (s), 131.93 (d, J = 8.2 Hz), 131.17 (s), 
129.59 (s), 129.50 (s), 128.64 (d, J = 12.6 Hz), 124.47 (d, J = 3.3 Hz), 122.23 (s), 121.62 (s), 
116.16 (d, J = 21.5 Hz), 81.40 (s), 79.78 (s), 60.75 (s), 50.07 (s), 14.85 (s), 14.41 (s); HRMS 
(ESI/IT-TOF) m/z: [M + H]+ Calcd for C23H19FN3O2 388.1456; found 388.1439. The spectral data 




2.2.7.7. Tert-Butyl (S)-(1-((4-bromo-2-(2-fluorobenzoyl)phenyl)amino)-1-oxopropan-2-yl) 
carbamate (9) 
 
The carbamide 9 was synthesized as described in 2.2.7.1, with 3 (100 g, 340.0 mmol), the Boc-L-
alanine (90 g, 467.0 mmol) and DCC (100 g, 484.7 mmol) were employed to afford 9 (144 g, 
91 %): 1H NMR (300 MHz, CDCl3) δ 11.67 (s, 1H), 8.70 (d, J = 9.0 Hz, 1H), 7.67 (dd, J = 9.0, 
2.3 Hz, 1H), 7.68 – 7.56 (m, 2H), 7.53 – 7.44 (m, 1H), 7.34 – 7.28 (m, 1H), 7.22 (t, J = 9.1 Hz, 
1H), 5.13 (s, 1H), 4.33 (s, 1H), 1.51 (d, J = 7.2 Hz, 3H), 1.42 (s, 9H); 13C NMR (75 MHz, CDCl3) 
δ 195.46 (s), 172.43 (s), 159.59 (d, J = 253.2 Hz), 155.27 (s), 139.64 (s), 137.98 (s), 135.96 (d, J 
= 1.9 Hz), 133.61 (d, J = 8.4 Hz), 130.33 (d, J = 2.4 Hz), 126.78 (d, J = 14.5 Hz), 124.50 (s), 
124.45 (s), 122.61 (s), 116.52 (d, J = 21.4 Hz), 114.93 (s), 80.27 (s), 51.85 (s), 28.25 (s), 18.57 (s); 
HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C21H23BrFN2O4 465.0820; found 465.0841. This 
material was used in the next step without further characterization. The spectral data for 9 were 
identical to the literature.160 
 
2.2.7.8. (S)-7-Bromo-5-(2-fluorophenyl)-3-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-




The 1,4-benzodiazepine 10 was synthesized, as described in 2.2.7.2, by using carbamide 9 (135 g, 
290.1 mmol) as the starting material to afford 10 (83 g, 83 %): [α] 26D = +168.8 (c 0.73, EtOAc); ); 
1H NMR (300 MHz, CDCl3) δ 9.65 (s, 1H), 7.63 – 7.52 (m, 2H), 7.46 (dq, J = 6.3, 1.6 Hz, 1H), 
7.35 (d, J = 1.9 Hz, 1H), 7.24 (t, J = 7.5 Hz, 1H), 7.14 (d, J = 8.7 Hz, 1H), 7.03 (t, J = 9.0 Hz, 
1H), 3.82 (q, J = 6.5 Hz, 1H), 1.77 (d, J = 6.5 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 172.31 (s), 
164.49 (s), 160.47 (d, J = 251.9 Hz), 136.46 (s), 134.71 (s), 132.15 (d, J = 8.6 Hz), 132.07 (d, J = 
2.0 Hz), 131.56 (d, J = 2.4 Hz), 130.12 (s), 127.11 (d, J = 12.4 Hz), 124.43 (d, J = 3.6 Hz), 122.87 
(s), 116.49 (s), 116.27 (d, J = 21.6 Hz), 58.85 (s), 16.93 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ 
Calcd for C16H13BrFN2O 347.0190; found 347.0187. The spectral data for 10 were identical to that 
found in the literature.160 
 
2.2.7.9. Ethyl (S)-8-bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4] 




The IMDZ 11 was synthesized as described in section 2.2.7.3, by using 1,4-benzodiazepine 10 (70 
g, 201.6 mmol) as the starting material to afford 11 (65 g, 73 %): [α] 26D = +10.6 (c 0.53, EtOAc); 
1H NMR (300 MHz, CDCl3) δ 7.92 (s, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.56 (t, J = 7.3 Hz, 1H), 
7.44 (d, J = 8.6 Hz, 1H), 7.45 – 7.34 (m, 2H), 7.25 (t, J = 7.5 Hz, 1H), 6.99 (t, J = 9.3 Hz, 1H), 
6.65 (q, J = 7.1 Hz, 1H), 4.74 – 3.83 (m, 2H), 1.32 (t, J = 7.1 Hz, 3H), 1.23 (d, J = 7.3 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 162.88 (s), 162.65 (s), 160.06 (d, J = 250.7 Hz), 141.55 (s), 134.89 
(s), 134.83 (s), 133.61 (s), 132.95 (s), 132.04 (d, J = 8.2 Hz), 131.16 (s), 131.04 (s), 129.52(s), 
128.33 (d, J = 12.4 Hz), 124.55 (d, J = 3.5 Hz), 123.71 (s), 120.88 (s), 116.16 (d, J = 21.5 Hz), 
60.75 (s), 50.05 (s), 14.85 (s), 14.41 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for 
C21H18BrFN3O2 442.0561; found 442.0568. The spectral data for 11 were identical to the literature. 
160 
 
2.2.7.10. Ethyl (S)-6-(2-fluorophenyl)-4-methyl-8-((trimethylsilyl)ethynyl)-4H-benzo[f]imi 




The TMS-protected acetylene 12 was synthesized as described in 2.2.7.4., by using IMDZ 11 (30 
g, 67.8 mmol) as the starting material to afford 12 (26.5 g, 85.0 %): [α] 26D = -27.8 (c 0.46, EtOAc);  
1H NMR (300 MHz, CDCl3) δ 7.94 (s, 1H), 7.68 (d, J = 7.9 Hz, 1H), 7.56 (t, J = 7.3 Hz, 1H), 
7.51 (d, J = 8.3 Hz, 1H), 7.48 (td, J = 7.3, 1.6 Hz, 1H), 7.37 (s, 1H), 7.26 (dd, J = 10.9, 4.1 Hz, 
1H), 7.06 (t, J = 9.2 Hz, 1H), 6.68 (q, J = 7.2 Hz, 1H), 4.52 – 4.21 (m, 2H), 1.42 (t, J = 7.1 Hz, 
3H), 1.24 (d, J = 7.3 Hz, 3H), 0.22 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 163.37 (s), 162.96 (s), 
160.16 (d, J = 250.6 Hz), 141.68 (s), 135.14 (s), 134.81 (s), 134.13 – 133.67 (m), 133.43 (s), 
131.86 (d, J = 8.3 Hz), 131.21(s), 129.61 (s), 129.49 (s), 128.77 (d, J = 13.2 Hz), 124.42 (d, J = 
3.4 Hz), 122.68 (s), 122.11 (s), 116.23 (d, J = 21.5 Hz), 102.55 (s), 97.31 (s), 60.75 (s), 50.09 (s), 
14.71 (s), 14.41 (s), -0.26 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C26H27FN3O2Si 
460.1851; found 460.1830. The spectral data for 12 were identical to the literature.160 
 
2.2.7.11. Ethyl (S)-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4] 




The ethyl ester SH-053-2'F-R-CH3 2 was synthesized as described in section 2.2.7.6., by using the 
benzodiazepine 12 (18.4 g, 40.0 mmol) as the starting material to afford 2 (14.9 g, 96 %): mp 218-
220 °C; [α] 26D = -21.5 (c 0.89, EtOAc); 1H NMR (300 MHz, CDCl3) δ 7.97 (s, 1H), 7.71 (d, J = 
8.2 Hz, 1H), 7.61 (dd, J = 15.0, 7.8 Hz, 2H), 7.46 (dd, J = 14.2, 7.1 Hz, 2H), 7.25 (t, J = 7.5 Hz, 
1H), 7.05 (t, J = 9.3 Hz, 1H), 6.71 (q, J = 7.0 Hz, 1H), 4.67 – 4.05 (m, 2H), 3.16 (s, 1H), 1.42 (t, 
J = 7.1 Hz, 3H), 1.29 (d, J = 7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 163.95 (s), 162.69 (s), 
160.12 (d, J = 252.3 Hz), 141.32 (s), 135.61 (s), 134.97 (s), 134.52 (s), 134.21 (s), 132.44 (d, J = 
8.2 Hz), 131.35 (d, J = 2.1 Hz), 129.49 (s), 129.16 (s), 127.98 (s), 124.58 (d, J = 3.5 Hz), 122.39 
(s), 121.85 (s), 116.27 (d, J = 21.4 Hz), 81.28 (s), 79.92 (s), 60.92 (s), 49.85 (s), 14.92 (s), 14.41 
(s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C23H19FN3O2 388.1456; found 338.1448. The 
spectral data for 2 were in excellent agreement with the literature.160 
 
2.2.7.12. (S)-Ethyl-8-cyclopropyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (GL-I-78, 13)  
 
To a solution of the bromo ethyl ester 11 (5.0 g, 11.3 mmol) in toluene (100 mL) and water (14.5 
204 
 
mL), cyclopropyl boronic acid (4.9 g, 57.0 mmol), potassium phosphate (10.3 g, 48.6 mmol) and 
bis(triphenylphosphine)palladium(II) diacetate (0.85 g, 1.13 mmol) were added under argon. A 
reflux condenser was attached and the mixture was degassed under vacuum with argon; this 
process was repeated four times. The mixture was stirred and heated to 100°C. After 12 h the 
reaction was completed on analysis by TLC (silica gel) and it was then cooled to rt. Water (10 mL) 
was added and the mixture was extracted with EtOAc (3 × 15 mL), after which the filtrate was 
washed with brine (10 mL), dried (Na2SO4) and concentrated under reduced pressure. The black 
residue which resulted was purified by a wash column (silica gel, EtOAc/hexane 7:3) to afford the 
desired 8-cyclopropyl-imidazodiazepine 13 as a white solid (3.74 g, 82%): mp 106-108 °C; []D25 
= +65.34 (c 0.81, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.88 (s, 1H), 7.54 (t, J = 7.0 Hz, 1H), 
7.48 – 7.32 (m, 2H), 7.19 (t, J = 7.6 Hz, 2H), 7.08 – 6.85 (m, 2H), 6.63 (q, J = 6.9 Hz, 1H), 4.34 
(dd, J = 14.4, 7.1 Hz, 2H), 2.11 (d, J = 7.0 Hz, 1H), 1.91 – 1.72 (m, J = 4.0 Hz, 1H), 1.37 (t, J = 
7.1 Hz, 3H), 1.23 (d, J = 7.0 Hz, 2H), 0.95 (d, J = 8.1 Hz, 2H), 0.59 (dd, J = 10.1, 4.6 Hz, 2H); 
13C NMR (75 MHz, CDCl3): δ 164.15 (s), 163.09 (s), 160.10 (d, JC-F = 250.1 Hz), 143.86 (s), 
141.56 (s), 134.84 (s), 132.06 (s), 131.65 (s), 131.54 (s), 131.20 (d, JC-F = 1.3 Hz), 129.16 (d, JC-
F = 12.8 Hz), 129.08 (d, JC-F = 9.4 Hz), 128.44 (s), 127.85 (s), 124.30 (d, JC-F = 3.3 Hz), 121.93 
(s), 115.97 (d, JC-F = 21.6 Hz), 60.58 (s), 50.03 (s), 15.02 (s), 14.62 (s), 14.42 (s), 9.88 (s); HRMS 
(ESI/IT-TOF) m/z: [M + H]+ Calcd for C24H23FN3O2 404.1769; found 404.1766. 
 
2.2.7.13. (S)-Methyl-8-bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-




The ethyl ester SH-053-2'F-S-CH3 2 (2.0 g, 4.52 mmol) was dissolved in methanol (120 mL). 
Sodium methoxide (0.98 g, 18.1 mmol) was added in one portion and the solution was heated to 
reflux. The reaction mixture was monitored on analysis by TLC (silica gel, EtOAc/hexane 4:1) 
until the starting material had been consumed. This took about 30 min. The reaction mixture was 
cooled to rt and then quenched with a saturated aq solution of NaHCO3 (20 mL). Water (50 mL) 
was then added to the solution and the methanol was removed under reduced pressure. The product 
was extracted with EtOAc (3 x 100 mL) and the organic layers were combined, washed with brine 
(50 mL) and dried (Na2SO4). The solution was concentrated under reduced pressure. The solid, 
which resulted, was purified by flash column chromatography (silica gel, EtOAc/hexane 4:1) 
which provided pure methyl ester 14 as an off-white solid (1.68 g, 87% yield): mp 194-195 °C; 
[]D25 = −4.55 (c 0.22, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.92 (s, 1H), 7.70 (d, J = 8.5 Hz, 
1H), 7.57 (t, J = 7.0 Hz, 1H), 7.51 – 7.36 (m, 3H), 7.23 (t, J = 7.5 Hz, 1H), 7.02 (t, J = 9.3 Hz, 
1H), 6.67 (q, J = 7.2 Hz, 1H), 3.89 (s, 3H), 2.13 (d, J = 7.3 Hz, 1H), 1.26 (d, J = 7.3 Hz, 2H); 13C 
NMR (75 MHz, CDCl3): δ 163.29 (s), 162.70 (s), 160.06 (d, JC-F = 251.3 Hz), 141.56 (s), 134.89 
(s), 133.57 (s), 133.01 (s), 132.18 (s), 132.07 (s) 131.18 (d, JC-F = 2.0 Hz), 131.10 (s), 129.22 (s), 
128.35 (d, JC-F = 12.5 Hz), 124.56 (d, JC-F = 3.4 Hz), 123.69 (s), 120.98 (s), 116.21 (d, JC-F = 21.4 
Hz), 51.86 (s), 50.04 (s), 14.86 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C20H16BrFN3O2 





a][1,4]diazepine-3-carboxylate (MP-III-021, 16)  
 
The ethyl ester SH-053-2'F-S-CH3 2 (150 mg, 0.387 mmol) was dissolved in MeOH (20 mL). 
Sodium methoxide (84 mg, 1.55 mmol) was added in one portion and the solution was heated to 
reflux. The reaction mixture was monitored by analysis by TLC (silica gel, EtOAc/hexane 4:1) 
until the starting material had been consumed. This took about 30 min. The reaction mixture was 
cooled to rt and then quenched with a saturated aq solution of NaHCO3 (4 mL). Water (10 mL) 
was then added to the solution and the methanol was removed under reduced pressure. The methyl 
ester 16 was then extracted with EtOAc (3 x 40 mL). The organic layers were combined, washed 
with brine (10 mL) and dried (Na2SO4). The solution was concentrated under reduced pressure. 
The solid, which resulted, was purified by flash column chromatography (silica gel, EtOAc/hexane 
4:1) which provided pure methyl ester 16 as an off-white solid (117 mg, 81% yield): mp 119-
120 °C; []D25 = +6.00 (c 2.0, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.96 (s, 1H), 7.71 (d, J = 
8.3 Hz, 1H), 7.59 (t, J = 9.5 Hz, 2H), 7.49-7.40 (m, 2H), 7.29-7.21 (m, 1H), 7.04 (t, J = 9.3 Hz, 
1H), 6.69 (q, J = 7.2 Hz, 1H), 3.92 (s, 3H), 3.16 (s, 1H), 2.16 (d, J = 7.3 Hz, 1H), 1.29 (d, J = 7.1 
Hz, 2H); 13C NMR (75 MHz, CDCl3): δ 163.71 (s), 161.17 (s), 161.16 (d, JC-F = 251.1 Hz), 141.47 
(s), 135.49 (s), 135.01 (s), 134.46 (s), 134.13 (s), 132.30 (d, JC-F = 7.1 Hz), 131.30 (s), 129.30(s), 
129.21 (s), 128.58 (d, JC-F = 9.4 Hz), 124.58 (d, JC-F = 3.2 Hz), 122.33 (s), 121.83 (s), 116.40 (d, 
JC-F = 21.2 Hz), 81.31 (s), 79.90 (s), 51.93 (s), 49.88 (s), 14.92 (s); HRMS (ESI/IT-TOF) m/z: [M 
207 
 
+ H]+ Calcd for C22H17FN3O2 374.1299; found 374.1307. 
 
General procedure for the synthesis of esters (17-20) 
The ethyl ester SH-053-2'F-S-CH3 2 (200 mg, 0.52 mmol) was stirred in dry THF (20 mL) in an 
oven-dried flask under an argon atmosphere at 40 °C. Simultaneously, the corresponding 
anhydrous alcohol R2-OH (5 mL) was stirred in a separate oven-dried flask under argon at 40 °C. 
Small pieces of freshly cut Li rod (excess) were quickly added to the dry alcohol solution, and the 
suspension was stirred for 30 min under argon. The ethyl ester solution was then added to the 
alcohol/lithium mixture, and the reaction was monitored on analysis by TLC (silica gel) until the 
starting material had been consumed. This took 30-45 min. The reaction mixture was then 
quenched with a saturated aq solution of NaHCO3 aq (15 mL), and the product was extracted with 
EtOAc (3 x 20 mL). The organic layers were combined, washed with brine (20 mL), dried (Na2SO4) 
and the solvent was removed under reduced pressure. The solid, which resulted, was purified by 
flash column chromatography to afford the corresponding pure esters 17-20.  
 
2.2.7.15. (S)-Propyl-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-




The ester 17 was prepared from 2 following the general procedure for esters with dry 1-propanol. 
The crude residue was purified by flash column chromatography (silica gel, EtOAc/hexane 7:3) to 
yield the pure propyl ester 17 as a white powder (0.17 g, 82%): mp 204-205 °C; []D25 = +5.26 (c 
0.19, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.95 (s, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.59 (dd, J = 
15.9, 7.7 Hz, 2H), 7.46 (dd, J = 14.0, 6.5 Hz, 2H), 7.31 – 7.22 (m, 1H), 7.05 (t, J = 9.2, 1H), 6.71 
(q, J = 6.6 Hz, 1H), 4.42 – 4.22 (m, 2H), 3.16 (s, 1H), 1.94 – 1.76 (m, 2H), 1.29 (d, J = 6.8 Hz, 
3H), 1.03 (t, J = 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 163.23 (s), 163.02 (s), 160.11 (d, JC-
F = 250.9 Hz), 141.64 (s), 135.18 (s), 134.88 (s), 134.54 (s), 133.93 (s), 131.95 (d, JC-F = 8.3 Hz), 
131.19 (s), 129.63 (s), 129.59 (s), 128.66 (d, JC-F = 11.6 Hz), 124.49 (d, JC-F = 3.4 Hz), 122.21 (s), 
121.62 (s), 116.21 (d, JC-F = 21.4 Hz), 81.43 (s), 79.70 (s), 66.38 (s), 50.14 (s), 22.09 (s), 14.88 








The isopropyl ester 18 was prepared from 2 following the general procedure for esters with dry 
isopropanol. The crude residue was purified by flash column chromatography (silica gel, 
EtOAc/hexane 3:7) to yield the pure isopropyl ester 18 as a white powder (0.20 g, 97%): mp 231-
232 °C; []D25 = +14.89 (c 0.94, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.93 (s, 1H), 7.69 (d, J 
= 8.2 Hz, 1H), 7.58 (dd, J = 16.6, 7.7 Hz, 2H), 7.44 (dd, J = 14.2, 6.6 Hz, 2H), 7.25 (t, J = 7.5 
Hz, 1H), 7.04 (t, J = 9.2 Hz 1H), 6.70 (q, J = 7.0 Hz, 1H), 5.36 – 5.20 (m, 1H), 3.15 (s, 1H), 1.40 
(dd, J = 9.4, 6.4 Hz, 6H), 1.28 (d, J = 7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 163.19 (s), 
162.52 (s), 160.12 (d, JC-F = 251.9 Hz), 141.63 (s), 135.16 (s), 134.76 (s), 134.57 (s), 133.92 (s), 
131.92 (d, JC-F = 8.7 Hz), 131.18 (s), 129.87 (s), 129.62 (s), 128.73 (d, JC-F = 6.0 Hz), 124.48 (d, 
JC-F = 3.4 Hz), 122.20 (s), 121.60 (s), 116.19 (d, JC-F = 21.5 Hz), 81.44 (s), 79.67 (s), 68.26 (s), 
50.14 (s), 21.95 (s), 14.85 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C24H21FN3O2 
402.1612; found 402.1610.  
 
2.2.7.17. (S)-tert-Butyl-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-




The t-butyl ester 19 was prepared from 2 following the general procedure for esters with dry t-
butanol. The crude residue was purified by flash column chromatography (silica gel, 
EtOAc/hexane 3:7) to yield the pure t-butyl ester 19 as a white powder (0.21 g, 96%): mp 214-
215 °C; []D25 = + 15.29 (c 0.85, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.92 (s, 1H), 7.69 (d, J 
= 7.3 Hz, 1H), 7.65 – 7.51 (m, 2H), 7.45 (dd, J = 15.0, 6.9 Hz, 2H), 7.28 – 7.21 (m, 1H), 7.05 (t, 
J = 9.3 Hz, 1H), 6.67 (q, J = 6.9 Hz, 1H), 3.15 (s, 1H), 1.63 (s, 9H), 1.28 (d, J = 7.3 Hz, 3H); 13C 
NMR (75 MHz, CDCl3): δ 163.17 (s), 162.24 (s), 160.12 (d, JC-F = 250.7 Hz), 141.19 (s), 135.14 
(s), 134.69 (s), 134.58 (s), 133.91 (s), 131.91 (d, JC-F = 8.2 Hz), 131.16 (s), 130.85 (s), 129.59 (s), 
128.73 (d, JC-F = 13.1 Hz), 124.49 (d, JC-F = 3.5 Hz), 122.22 (s), 121.50 (s), 116.21 (d, JC-F = 21.4 
Hz), 81.51 (s), 79.60 (s), 50.23 (s), 28.33 (s), 21.97 (s), 14.85 (s); HRMS (ESI/IT-TOF) m/z: [M 
+ H]+ Calcd for C25H23FN3O2 416.1769; found 416.1768. 
 
2.2.7.18. (S)-tert-Pentyl-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-




The 2-methylbutyl ester 20 was prepared from 2 following the general procedure for esters with 
dry 2-methylbutan-2-ol. The crude residue was purified by flash column chromatography (silica 
gel, EtOAc/hexane 1:1) to yield the pure 2-methylbutyl ester 20 as a white powder (0.17 g, 77%): 
mp 94-96 °C; []D25 = +34.15 (c 0.41, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.92 (s, 1H), 7.69 
(d, J = 8.1 Hz, 1H), 7.66 – 7.50 (m, 2H), 7.45 (dd, J = 16.3, 8.6 Hz, 2H), 7.29 – 7.19 (m, 1H), 7.05 
(t, J = 9.2 Hz, 1H), 6.66 (q, J = 7.2 Hz, 1H), 3.15 (s, 1H), 1.98 (q, J = 7.4 Hz, 2H), 1.59 (s, 6H), 
1.28 (d, J = 3.6 Hz, 3H), 0.99 (t, J = 7.5 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 163.17 (s), 
162.15 (s), 160.11 (d, JC-F = 250.2 Hz), 141.12 (s), 135.15 (s), 134.68 (s), 133.89 (s), 131.96 (s), 
131.85 (s), 131.16 (d, JC-F = 1.6 Hz), 130.80 (s), 129.58 (s), 128.71 (d, JC-F = 13.2 Hz), 124.49 (d, 
JC-F = 3.4 Hz), 122.24 (s), 121.49 (s), 116.20 (d, JC-F = 21.5 Hz), 84.17 (s), 81.48 (s), 79.61 (s), 
50.24 (s), 33.47 (s), 25.91 (s), 25.73 (s), 14.91 (s), 8.47 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ 
Calcd for C26H25FN3O2 430.1925; found 430.1928. 
 
2.2.7.19. (S)-8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-




The ethyl ester SH-053-2'F-S-CH3 2 (5.0 g, 12.91 mmol) was dissolved in EtOH (200 mL), after 
which sodium hydroxide pellets (4.1 g, 103.25 mmol) were added to the solution. This reaction 
mixture was heated to 55 ˚C for 0.5 h and the EtOH was removed under reduced pressure. Water 
(50 mL) was added to the residue to form an aq solution, which was then stirred at 0 ˚C for 10 min 
and then aq HCl (1 M) was added dropwise to the solution until the pH was 5 (pH paper). A pale 
white precipitate which formed, was left in the solution for 10 min and was then collected by 
filtration, washed with cold water and the aq layer also allowed to stand at rt for 10 h to yield 
additional acid 23. The combined solids were dried under vacuum for 7 h to provide pure acid 23 
as a white powder (4.6 g, 99%): mp 217-218 °C; []D25 = -14.58 (c 0.48, CHCl3); 1H NMR (300 
MHz, DMSO-d6): δ 8.36 (s, 1H), 7.92 (d, J = 7.9 Hz, 1H), 7.79 (d, J = 7.2 Hz, 1H), 7.55 (dt, J = 
7.8, 6.5 Hz, 2H), 7.32 (t, J = 7.4 Hz, 1H), 7.21 (t, J = 9.3 Hz, 2H), 6.61 (d, J = 7.6 Hz, 1H), 4.36 
(s, 1H), 1.13 (d, J = 6.6 Hz, 3H); 13C NMR (75 MHz, DMSO-d6): δ 164.63 (s), 162.92 (s), 159.85 
(d, JC-F = 242.7 Hz), 141.08 (s), 136.73 (s), 135.57 (s), 134.68 (d, JC-F = 2.7 Hz), 133.19 (s), 133.14 
(s), 132.64 (d, JC-F = 6.1 Hz), 131.89 (s), 129.36 (d, JC-F = 2.3 Hz), 128.85 (d, JC-F = 8.2 Hz), 
125.14 (d, J = 3.0 Hz), 123.98 (s), 121.15 (s), 116.39 (d, JC-F = 20.3 Hz), 83.42 (s), 81.97 (s), 49.82 
(s), 15.02 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C21H15FN3O2 360.1143; found 
360.1142. 
 
General procedure for the synthesis of esters/thioester/amides (21, 22, 7, 26-30) 
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A mixture of the acid SH-053-2'F-S-CH3-acid 23 (200 mg, 0.56 mmol), thionyl chloride (0.407 
mL, 5.6 mmol) and dry DCM (20 mL) was placed in an oven dried round bottom flask under argon. 
This suspension, which formed, was allowed to reflux at 60 ˚C for 1 h under argon. The absence 
of the starting material was confirmed on analysis by TLC (silica gel). The organic solvent and 
excess thionyl chloride were removed under reduced pressure on a rotovapor. This procedure was 
repeated five times with dry DCM (15 mL). The yellow residue, which remained was dissolved in 
dry DCM (20 mL) and cooled to 0 ˚C for 10 min under argon. Then the appropriate nucleophilic 
alcohol/thiol/amine (5.6 mmol), followed by triethylamine (0.78 mL, 5.6 mmol) was added to the 
reaction mixture at 0˚C and the mixture (individually) was then allowed to warm to rt and stirred 
for 1-2 h. After the completion of the reaction by TLC (silica gel), the solvent was removed under 
reduced pressure. The residue was treated with ice cold water (15 mL) and extracted with DCM 
(3 x 20 mL). The combined organic layer was washed with brine (20 mL) and dried (Na2SO4). The 
solvent was removed under reduced pressure and the residue was purified by column 
chromatography to yield the corresponding pure esters, thioesters or amides described below: 
 
2.2.7.20. (S)-2,2,2-Trifluoroethyl-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-
benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (GL-I-36, 21) 
 
The trifluoroethyl ester 21 was prepared from carboxylic acid 23 following the general procedure 
for esters/thioester/amides with dry 2,2,2-trifluoroethanol as the nucleophile. The crude residue 
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was purified by flash column chromatography (silica gel, EtOAc/hexane 2:3) to yield the pure 
trifluoroethyl ester 21 as a white powder (0.20 g, 82%): mp 226-227 °C; []D25 = +9.43 (c 0.53, 
CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.98 (s, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.57 (d, J = 7.9 
Hz, 2H), 7.50 – 7.36 (m, 2H), 7.23 (t, J = 7.3 Hz, 1H), 7.01 (t, J = 8.9 Hz, 1H), 6.60 (q, J = 7.0 
Hz, 1H), 4.88 – 4.54 (m, 2H), 3.16 (s, 1H), 1.26 (d, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3): 
δ 163.41 (s), 161.09 (s), 160.07 (d, JC-F = 250.9 Hz), 143.06 (s), 135.54 (s), 135.29 (s), 134.19 (s), 
133.89 (s), 132.08 (d, JC-F = 8.1 Hz), 131.16 (s), 129.61 (s), 128.45 (d, JC-F = 12.7 Hz), 127.72 (s), 
124.53 (d, JC-F = 3.2 Hz), 123.04 (q, JC-F = 276.5 Hz), 122.31 (s), 121.95 (s), 116.20 (d, JC-F = 
21.4 Hz), 81.27 (s), 79.99 (s), 60.15 (q, JC-F = 36.9 Hz), 50.10 (s), 14.70 (s); HRMS (ESI/IT-TOF) 
m/z: [M + H]+ Calcd for C23H16F4N3O2 442.1173; found 442.1176. 
 
2.2.7.21. (S)-Cyclopropyl-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (GL-I-38, 22)  
 
The cyclopropyl ester 22 was prepared from the carboxylic acid 23 following the general procedure 
for esters/thioester/amides with dry cyclopropanol as the nucleophile. The crude residue was 
purified by flash column chromatography (silica gel, EtOAc/hexane 3:2) to yield the pure 
cyclopropyl ester 22 as a white powder (0.16 g, 71%): mp 230-231 °C; []D25 = +11.38 (c 1.23, 
CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.92 (s, 1H), 7.67 (d, J = 7.4 Hz, 1H), 7.55 (d, J = 7.9 
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Hz, 2H), 7.49 – 7.32 (m, 2H), 7.22 (t, J = 7.0 Hz, 1H), 7.00 (t, J = 8.6 Hz, 1H), 6.64 (q, J = 6.6 
Hz, 1H), 4.38 – 4.21 (m, 1H), 3.15 (s, 1H), 1.24 (d, J = 5.6 Hz, 3H), 0.87 (d, J = 7.1 Hz, 2H), 0.77 
(d, J = 5.5 Hz, 2H); 13C NMR (75 MHz, CDCl3): δ 163.77 (s), 163.25 (s), 160.06 (d, JC-F = 250.6 
Hz), 141.87 (s), 135.20 (s), 134.93 (s), 134.39 (s), 133.88 (s), 131.97 (d, JC-F = 9.0 Hz), 131.15 (s), 
129.58 (s), 129.04 (s), 128.60 (d, JC-F = 11.4 Hz), 124.49 (d, JC-F = 3.1 Hz), 122.25 (s), 121.69 (s), 
116.17 (d, JC-F = 21.5 Hz), 81.37 (s), 79.85 (s), 50.02 (s), 49.32 (s), 14.82 (s), 5.22 (s); HRMS 
(ESI/IT-TOF) m/z: [M + H]+ Calcd for C24H19FN3O2 400.1456; found 400.1453. 
 
2.2.7.22. (S)-S-Ethyl-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carbothioate (GL-I-77, 24)  
 
The thioester 24 was prepared from the carboxylic acid 23 following the general procedure for 
esters/thioester/amides with dry ethanethiol as the nucleophile. The crude residue was purified by 
flash column chromatography (silica gel, EtOAc/hexane 2:3) to yield the pure thioethyl ester 24 
as a white powder (0.18 g, 79%): mp 210-211 °C; []D25 = +21.43 (c 0.98, CHCl3); 1H NMR (300 
MHz, CDCl3): δ 7.91 (s, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.64 – 7.50 (m, 2H), 7.48 – 7.38 (m, 2H), 
7.24 (t, J = 7.3 Hz, 1H), 7.02 (t, J = 9.1 Hz, 1H), 6.65 (q, J = 14.0, 6.8 Hz, 1H), 3.16 (s, 1H), 3.09 
– 2.89 (m, 2H), 1.33 (t, J = 7.4 Hz, 3H), 1.26 (d, J = 6.8 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 
187.81 (s), 163.16 (s), 160.11 (d, JC-F = 250.3 Hz), 138.17 (s), 135.44 (s), 135.17 (s), 134.48 (s), 
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134.34 (s), 133.95 (s), 131.97 (d, JC-F = 8.9 Hz), 131.23 (s), 129.66 (s), 128.61 (d, JC-F = 11.7 Hz), 
124.49 (d, JC-F = 3.4 Hz), 122.19 (s), 121.76 (s), 116.17 (d, JC-F = 21.5 Hz), 81.41 (s), 79.78 (s), 
49.85 (s), 22.56 (s), 14.79 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C23H19FN3OS 
404.1227; found 404.1229. 
 
2.2.7.23. (S)-8-Ethynyl-6-(2-fluorophenyl)-N,4-dimethyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxamide (MP-III-023, 25)  
 
The ethyl ester SH-053-2'F-S-CH3 2 (2 g, 5.2 mmol) was dissolved in DCM (10 mL) and was 
added to a sealed vessel fitted with a septum at -30 °C and treated with methyl amine (20 mL, 33% 
wt solution in EtOH). The vessel was sealed with a screw-cap and stirred at 55 °C for 18 h. The 
solution was then cooled to rt and the methyl amine and ethanol were removed under reduced 
pressure. The residue, which resulted, was purified by flash column chromatography (silica gel, 
EtOAc) to afford the pure methyl amide 25 as a pale white powder (1.7 g, 88.6 %): mp 136-137 °C; 
[]D25 = -11.54 (c 2.34, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.84 (s, 1H), 7.69 (d, J = 8.1 Hz, 
2H), 7.64 (t, J = 7.0 Hz, 1H), 7.54 (d, J = 8.3 Hz, 1H), 7.44 (dd, J = 14.1, 7.1 Hz, 1H), 7.25 (t, J 
= 7.5 Hz, 1H), 7.17 (s, 1H), 7.03 (t, J = 9.3 Hz, 1H), 6.91 (q, J = 6.5 Hz, 1H), 3.15 (s, 1H), 2.97 
(d, J = 5.0 Hz, 3H), 1.27 (d, J = 7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 163.41 (s), 162.86 
(s), 161.81(d, JC-F = 250.8 Hz), 138.68 (s), 135.31 (s), 134.58 (s), 134.14 (s), 133.46 (s), 132.28 
(s), 132.26 (d, JC-F = 6.4 Hz), 131.47 (s), 129.47 (s), 128.36 (d, JC-F = 10.0 Hz), 124.54 (d, JC-F = 
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3.5 Hz), 122.24 (s), 121.69 (s), 116.28 (d, JC-F = 21.5 Hz), 81.42 (s), 79.76 (s), 49.66 (s), 25.67 (s), 
15.06 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C22H18FN4O 373.1459, found: 373.1462. 
 
2.2.7.24. (S)-N-Ethyl-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxamide (GL-I-43, 26)  
 
The ethyl amide 26 was prepared from the carboxylic acid 23 following the general procedure for 
esters/thioester/amides with dry ethylamine as the nucleophile. The crude residue was purified by 
flash column chromatography (silica gel, EtOAc/hexane 1:1) to yield the pure ethyl amide 26 as a 
white powder (0.18 g, 88%): mp 208-209 °C; []D25 = -13.33 (c 0.6, CHCl3); 1H NMR (300 MHz, 
CDCl3): δ 7.97 (s, 1H), 7.69 (dd, J = 16.7, 7.9 Hz, 2H), 7.58 (d, J = 8.2 Hz, 1H), 7.46 (dd, J = 
13.4, 7.2 Hz, 2H), 7.27 (t, J = 7.4 Hz, 2H), 7.04 (t, J = 9.3 Hz, 1H), 6.93 (q, J = 7.2 Hz, 1H), 3.55 
– 3.37 (m, 2H), 3.16 (s, 1H), 1.29 (d, J = 7.2 Hz, 3H), 1.23 (t, J = 7.3 Hz, 3H); 13C NMR (75 
MHz, CDCl3): δ 162.82 (s), 162.51 (s), 160.10 (d, JC-F = 250.5 Hz), 138.79 (s), 134.97 (s), 134.70 
(s), 133.88 (s), 133.39 (s), 131.82 (d, JC-F = 4.8 Hz), 131.75 (s), 131.35 (d, JC-F = 1.5 Hz), 129.76 
(s), 128.84 (d, JC-F = 11.9 Hz), 124.45 (d, JC-F = 3.4 Hz), 122.06 (s), 121.37 (s), 116.06 (d, JC-F = 
21.5 Hz), 81.54 (s), 79.55 (s), 49.88 (s), 33.71 (s), 15.02 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ 





benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxamide (GL-I-55, 27) 
 
The cyclopropyl amide 27 as prepared from the carboxylic acid 23 following the general procedure 
for esters/thioester/amides with dry cyclopropylamine as the nucleophile. The crude residue was 
purified by flash column chromatography (silica gel, EtOAc/hexane 1:1) to yield the pure 
cyclopropyl amide 27 as a white powder (0.19 g, 86%): mp 225-226 °C; []D25 = -11.77 (c 0.17, 
CHCl3); 1H NMR (300 MHz, CDCl3): δ 8.00 (s, 1H), 7.69 (dd, J = 16.5, 8.1 Hz, 2H), 7.58 (d, J = 
8.3 Hz, 1H), 7.46 (dd, J = 14.0, 6.8 Hz, 3H), 7.27 (t, J = 7.3 Hz, 1H), 7.04 (t, J = 9.3 Hz, 1H), 
6.93 (q, J = 7.2 Hz, 1H), 3.17 (s, 1H), 2.85 (dq, J = 10.6, 3.6 Hz, 1H), 1.30 (d, J = 7.3 Hz, 3H), 
0.89 – 0.73 (m, 2H), 0.69 – 0.50 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 164.02 (s), 162.83 (s), 
160.12 (d, JC-F = 249.8 Hz), 138.93 (s), 134.96 (s), 134.66 (s), 133.91 (s), 133.36 (s), 131.82 (d, 
JC-F = 8.3 Hz), 131.59 (s), 131.37 (s), 129.79 (s), 128.84 (d, JC-F = 11.4 Hz), 124.46 (d, JC-F = 3.3 
Hz), 122.04 (s), 121.42 (s), 116.07 (d, JC-F = 21.5 Hz), 81.53 (s), 79.53 (s), 49.89 (s), 22.09 (s), 








The isopropyl amide 28 was prepared from the carboxylic acid 23 following the general procedure 
for esters/thioester/amides with dry isopropylamine as the nucleophile. The crude residue was 
purified by flash column chromatography (silica gel, EtOAc/hexane 2:3) to yield the pure 
isopropyl amide 28 as a white powder (0.16 g, 74%): mp 238-239 °C; []D25 = -6.19 (c 2.1, CHCl3); 
1H NMR (300 MHz, CDCl3): δ 7.81 (s, 1H), 7.62 (dd, J = 17.0, 7.9 Hz, 2H), 7.51 (d, J = 8.3 Hz, 
1H), 7.46 – 7.33 (m, 2H), 7.21 (t, J = 7.5 Hz, 1H), 7.02 – 6.94 (m, 2H), 6.88 (q, J = 6.9 Hz, 1H), 
4.21 (dq, J = 13.4, 6.6 Hz, 1H), 3.14 (s, 1H), 1.22 (dd, J = 13.5, 7.2 Hz, 9H); 13C NMR (75 MHz, 
CDCl3): δ 162.83 (s), 161.78 (s), 158.43 (s), 138.78 (s), 134.98 (s), 134.69 (s), 133.85 (s), 133.35 
(s), 131.85 (s), 131.74 (s), 131.35 (s), 129.73 (s), 128.83 (d, JC-F = 12.7 Hz), 124.43 (d, JC-F = 3.3 
Hz), 122.08 (s), 121.36 (s), 116.04 (d, JC-F = 21.6 Hz), 81.53 (s), 79.62 (s), 49.87 (s), 40.69 (s), 
22.93 (s), 22.85 (s), 15.00 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C24H22FN4O 
401.1772; found 401.1776. 
 
2.2.7.27. (S)-N-(tert-Butyl)-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-




The t-butyl amide 29 was prepared from the carboxylic acid 23 following the general procedure 
for esters/thioester/amides with dry t-butylamine as the nucleophile. The crude residue was 
purified by flash column chromatography (silica gel, EtOAc/hexane 1:1) to yield the pure t-butyl 
amide 29 as a white powder (0.19 g, 83%): mp 136-137 °C; []D25 = +8.7 (c 0.23, CHCl3); 1H 
NMR (300 MHz, CDCl3): δ 7.80 (s, 1H), 7.65 (dd, J = 15.1, 7.7 Hz, 2H), 7.51 (d, J = 8.3 Hz, 1H), 
7.44 (dd, J = 10.1, 7.6 Hz, 2H), 7.24 (t, J = 7.5 Hz, 1H), 7.02 (dd, J = 15.8, 5.8 Hz, 2H), 6.87 (q, 
J = 7.1 Hz, 1H), 3.15 (s, 1H), 1.46 (s, 9H), 1.27 (d, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3): 
δ 162.84 (s), 162.11 (s), 160.15 (d, JC-F = 250.3 Hz), 138.60 (s), 134.97 (s), 134.76 (s), 133.85 (s), 
133.02 (s), 132.59 (s), 131.84 (d, JC-F = 7.8 Hz), 131.39 (d, JC-F = 2.4 Hz), 129.81 (s), 128.79 (d, 
JC-F = 11.8 Hz), 124.45 (d, JC-F = 3.4 Hz), 122.07 (s), 121.37 (s), 116.07 (d, JC-F = 21.5 Hz), 81.56 
(s), 79.49 (s), 50.91 (s), 49.90 (s), 28.98 (s), 14.96 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd 
for C25H24FN4O 415.1926; found 415.1926. 
 
2.2.7.28. (S)-8-Ethynyl-6-(2-fluorophenyl)-N,N,4-trimethyl-4H-benzo[f]imidazo[1,5-




The dimethyl amide 30 was prepared from 23 following the general procedure with dry 
dimethylamine as the nucleophile. The crude residue was purified by column chromatography 
(silica gel, EtOAc and 1% MeOH) to yield pure dimethyl amide 30 as a light yellow powder (0.15 
g, 71%): mp 142-144 °C; []D25 = -16.0 (c 0.75, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.94 (s, 
1H), 7.73 (d, J = 8.1 Hz, 1H), 7.63 (t, J = 7.4 Hz, 1H), 7.52 (d, J = 8.2 Hz, 1H), 7.48 – 7.41 (m, 
2H), 7.26 (t, J = 7.5 Hz, 1H), 7.04 (t, J = 9.3 Hz, 1H), 4.33 (q, J = 6.0 Hz, 1H), 3.16 (s, 1H), 3.14 
(s, 3H), 3.01 (s, 3H), 1.94 (d, J = 6.5 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 166.14 (s), 162.60 
(s), 160.25 (d, JC-F = 252.3 Hz), 135.31 (s), 134.73 (d, JC-F = 7.2 Hz), 133.83 (s), 133.73 (s), 132.79 
(d, JC-F = 12.7 Hz), 132.05 (d, JC-F = 9.4 Hz), 131.78 (s), 131.28 (s), 129.25 (s), 127.69 (d, JC-F = 
10.8 Hz), 124.51 (d, JC-F = 3.4 Hz), 122.83 (s), 121.50 (s), 116.17 (d, JC-F = 21.7 Hz), 81.57 (s), 
79.46 (s), 52.21 (s), 39.09 (s), 35.03 (s), 18.50 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for 
C23H20FN4O 387.1616; found 387.1624. 
 
General Procedure for the Preparation of Oxadiazoles (31-33) 
The ethyl ester 2 (200 mg, 0.52 mmol) was dissolved in dry THF (20 mL) at rt under argon. In a 
separate flask which contained 3Å molecular sieves, the corresponding oxime (2.08 mmol) was 
dissolved in dry THF (30 mL) under argon and treated with sodium hydride (60% dispersion in 
mineral oil, 0.57 mmol). The mixture, which resulted, was stirred for 15 min at which point the 
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solution containing the ethyl ester was added. The reaction mixture, which resulted, was stirred at 
rt for 2 h until the starting material was consumed as indicated on analysis by TLC (silica gel). 
The reaction mixture was quenched with a saturated aq NaHCO3 solution (50 mL). Water (50 mL) 
was then added and the product was extracted with EtOAc (3 x 100 mL). The organic layers were 
combined, washed with brine (30 mL) and dried (Na2SO4). The solvent was removed under 
reduced pressure. The solid, which resulted, was purified by flash column chromatography (silica 
gel) to afford the pure corresponding oxadiazole, individually. 
 
2.2.7.29. (S)-5-(8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepin-3-yl)-3-methyl-1,2,4-oxadiazole (GL-I-65, 31) 
 
The methyl oxadiazole 31 was prepared from 2 following the general procedure for oxadiazoles 
with the methyl oxime (0.154 g, 2.08 mmol). The crude residue was purified by flash column 
chromatography (silica gel, EtOAc/hexane 3:2) to yield pure methyl oxadiazole 31 as a white 
powder (0.174 g, 85%): mp 225-226 °C; []D25 = +32.52 (c 2.86, CHCl3); 1H NMR (300 MHz, 
CDCl3): δ 8.08 (s, 1H), 7.74 (d, J = 8.2 Hz, 1H), 7.63 (d, J = 8.4 Hz, 2H), 7.48 (dd, J = 18.1, 11.6 
Hz, 2H), 7.27 (t, J = 7.5 Hz, 1H), 7.06 (t, J = 9.2 Hz, 1H), 6.75 (q, J = 7.1 Hz, 1H), 3.18 (s, 1H), 
2.47 (s, 3H), 1.35 (d, J = 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ 170.75 (s), 167.42 (s), 163.40 
(s), 160.09 (d, JC-F = 250.5 Hz), 139.26 (s), 136.32 (s), 135.34 (s), 134.17 (s), 134.05 (s), 132.06 
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(d, JC-F = 8.5 Hz), 131.20 (s), 129.63 (s), 128.55 (d, JC-F = 12.3 Hz), 124.83 (s), 124.50 (d, JC-F = 
3.2 Hz), 122.21 (s), 121.88 (s), 116.21 (d, JC-F = 21.4 Hz), 81.34 (s), 79.95 (s), 50.16 (s), 14.94 (s), 
11.66 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C23H17FN5O 398.1412; found 398.1419. 
 
2.2.7.30. (S)-3-Ethyl-5-(8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepin-3-yl)-1,2,4-oxadiazole (GL-I-66, 32) 
 
The ethyl oxadiazole 32 was prepared from 2 following the general procedure for oxadiazoles with 
the ethyl oxime (0.183 g, 2.08 mmol). The crude residue was purified by flash column 
chromatography (silica gel, EtOAc/Hexane 3:2) to yield pure ethyl oxadiazole 32 as a white 
powder (0.168 g, 79%): mp 199-200 °C; []D25 = +50.00 (c 0.22, CHCl3); 1H NMR (300 MHz, 
CDCl3): δ 8.08 (s, 1H), 7.75 (d, J = 8.2 Hz, 1H), 7.63 (d, J = 8.3 Hz, 2H), 7.54 – 7.40 (m, 2H), 
7.27 (t, J = 7.4 Hz, 1H), 7.06 (t, J = 9.2 Hz, 1H), 6.75 (q, J = 14.4, 7.2 Hz, 1H), 3.18 (s, 1H), 2.84 
(q, J = 7.6 Hz, 2H), 1.40 (d, J = 7.6 Hz, 3H), 1.36 (t, J = 3.6 Hz, 3H); 13C NMR (75 MHz, CDCl3): 
δ 171.88 (s), 170.70 (s), 163.41 (s), 160.10 (d, JC-F = 251.4 Hz), 139.22 (s), 136.26 (s), 135.33 (s), 
134.22 (s), 134.07 (s), 132.04 (d, JC-F = 8.7 Hz), 131.15 (s), 129.58 (d, JC-F = 6.0 Hz), 128.58 (d, 
JC-F = 11.9 Hz), 124.99 (s), 124.51 (d, JC-F = 3.2 Hz), 122.18 (s), 121.88 (s), 116.22 (d, JC-F = 21.5 
Hz), 81.34 (s), 79.90 (s), 50.23 (s), 19.74 (s), 14.97 (s), 11.51 (s); HRMS (ESI/IT-TOF) m/z: [M 





a][1,4]diazepin-3-yl)-3-isopropyl-1,2,4-oxadiazole (GL-I-81, 33)  
 
The isopropyl oxadiazole 33 was prepared from 2 following the general procedure for oxadiazoles 
with the isopropyl oxime (0.212 g, 2.08 mmol). The crude residue was purified by flash column 
chromatography (silica gel, EtOAc/hexane 3:2) to yield pure isopropyl oxadiazole 33 as a white 
powder (0.180 g, 82%): mp 205-206 °C; []D25 = +22.37 (c 0.76, CHCl3); 1H NMR (300 MHz, 
CDCl3): δ 8.06 (s, 1H), 7.66 (d, J = 8.3 Hz, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.53 (t, J = 7.3 Hz, 1H), 
7.44 – 7.30 (m, 2H), 7.17 (t, J = 7.5 Hz, 1H), 6.96 (t, J = 9.2 Hz, 1H), 6.67 (q, J = 7.0 Hz, 1H), 
3.14 (s, 1H), 3.09 (q, J = 7.0 Hz, 1H), 1.32 (d, J = 7.0 Hz, 6H), 1.28 (d, J = 7.5 Hz, 3H); 13C NMR 
(75 MHz, CDCl3): δ 175.24 (s), 170.61 (s), 163.38 (s), 160.03 (d, JC-F = 251.5 Hz), 139.17 (s), 
136.34 (s), 135.36 (s), 134.17 (s), 133.98 (s), 132.01 (d, JC-F = 8.3 Hz), 131.10 (s), 129.48 (s), 
128.58 (d, JC-F = 12.3 Hz), 124.96 (s), 124.48 (d, JC-F = 3.1 Hz), 122.28 (s), 121.82 (s), 116.16 (d, 
JC-F = 21.4 Hz), 81.30 (s), 80.03 (s), 50.22 (s), 26.70 (s), 20.57 (s), 20.51 (s), 14.94 (s); HRMS 
(ESI/IT-TOF) m/z: [M + H]+ Calcd for C25H21FN5O 426.1725; found 426.1728. 
 
2.2.7.32. (S)-8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4] 




The ethyl ester SH-053-2'F-S-CH3 2 (0.5 g, 1.40 mmol) was stirred in dry xylene (35 mL) at rt. 
Using a glass syringe and a metal needle, dimethylaluminum amine (0.67 M, 12.5 mL, 8.42 mmol) 
was carefully added to the solution of starting material 2. The reaction was then heated to 80 ˚C in 
an oil bath and was monitored on analysis by TLC (silica gel) until the starting material had been 
consumed in 2 h. Once the reaction was complete, the mixture was cooled to rt and then quenched 
with cold water (15 mL). The product was extracted with EtOAc (5 x 50 mL) and the organic 
layers were combined, washed with brine and dried (Na2SO4). The solvent was removed under 
reduced pressure. The solid, which resulted, was purified by flash column chromatography (silica 
gel, EtOAc/hexane 1:1) which afforded the nitrile 34 as a white solid (0.331 g, 75.4%): mp 131-
132 °C; []D25 = -165.16 (c 1.55, CHCl3); 1H NMR (300 MHz, CDCl3): δ 7.98 (s, 1H), 7.78 (d, J 
= 7.1 Hz, 1H), 7.67 (s, 1H), 7.62 – 7.53 (m, 1H), 7.49 (s, 2H), 7.28 (s, 1H), 7.04 (t, J = 8.7 Hz, 
1H), 4.36 (d, J = 4.8 Hz, 1H), 3.20 (s, 1H), 2.18 (d, J = 4.6 Hz, 3H); 13C NMR (75 MHz, CDCl3): 
δ 163.64 (s), 161.94 (d, JC-F = 253.4 Hz), 143.66 (s), 135.75 (s), 135.69 (s), 133.97 (s), 133.35 (s), 
132.89 (d, JC-F = 9.7 Hz),131.37 (s), 129.22 (s), 126.85 (d, JC-F = 13.0 Hz), 124.73 (d, JC-F = 6.5 
Hz), 122.88 (s), 122.64 (s), 116.50(d, JC-F = 19.7 Hz), 114.54 (s), 110.74 (s), 81.13 (s), 80.33 (s), 
51.68 (s), 18.09 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C21H14FN4 341.1137; found 
341.1142. 
Preparation of the 0.67 M dimethylaluminum amine solution 
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The ammonia gas was bubbled into dry DCM (20 mL) at 0 °C until the solution was saturated. 
This took about 10-15 min. The trimethylaluminum (10 mL, 2.0 M in toluene) was then added to 
the solution. The solution was stirred at rt for 5 min and transferred directly for use in the reaction 
above using a glass syringe and metal needle.120  
 
2.2.7.33. (R)-8-Ethynyl-6-(2-fluorophenyl)-N,4-dimethyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxamide (MP-III-022, 35)  
 
The ethyl ester SH-053-2'F-R-CH3 1 (2 g, 5.2 mmol) was dissolved in DCM (10 mL) and was 
added to a sealed vessel fitted with a septum at -30 °C and treated with methyl amine (75 mL, 33% 
wt solution in EtOH). The vessel was sealed with a screw-cap and stirred at 55 °C for 18 h. The 
solution was then cooled to rt and the methyl amine and ethanol were removed under reduced 
pressure. The residue, which resulted, was purified by flash column chromatography (silica gel, 
EtOAc) to afford the pure methyl amide 35 as a pale white powder (1.7 g, 88.5 %): 1H NMR (300 
MHz, CDCl3) δ 7.81 (s, 1H), 7.60 (dd, J = 17.1, 7.6 Hz, 2H), 7.50 (d, J = 8.3 Hz, 1H), 7.43 – 7.32 
(m, 2H), 7.26 – 7.12 (m, 2H), 6.96 (t, J = 9.3 Hz, 1H), 6.87 (q, J = 7.1 Hz, 1H), 3.14 (s, 1H), 2.91 
(d, J = 5.0 Hz, 3H), 1.23 (d, J = 6.7 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 163.27 (s), 162.79 (s), 
160.07 (d, J = 250.3 Hz), 138.63 (s), 134.98 (s), 134.66 (s), 133.85 (s), 133.51 (s), 131.75 (s), 
131.71 (s), 131.33 (s), 129.65 (s), 128.83 (d, J = 12.7 Hz), 124.40 (s), 122.10 (s), 121.32 (s), 116.02 
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(d, J = 21.5 Hz), 81.52 (s), 79.65 (s), 49.84 (s), 25.56 (s), 15.05 (s); HRMS (ESI/IT-TOF) m/z: 
[M + H]+ Calcd for C22H18FN4O 373.1459, found: 373.1469.  
 
2.2.7.34. (R)-8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4] 
diazepine-3-carboxylic acid. (SH-053-2'F-R-CH3-acid, 68)  
 
The ethyl ester SH-053-2'F-R-CH3 1 (20.0 g, 51.6 mmol) was dissolved in EtOH (500 mL), after 
which solid NaOH (16.6 g, 412.8 mmol) was added to the solution. This reaction mixture was 
heated to 55 ˚C for 0.5 h and the EtOH was removed under reduced pressure. The remaining aq 
solution was stirred at 0 ˚C for 10 min and then aq HCl (1 M) was added dropwise to the solution 
until the pH was 5 (pH paper). A pale white precipitate which formed, was left in the solution for 
10 min and was then collected by filtration, washed with cold water and the aq layer also allowed 
to stand at rt for 10 h to yield additional acid 68. The combined solids were dried under vacuum 
for 7 h to provide the pure acid 68 as a white powder (18.4 g, 99.2 % yield): mp 196-198 °C; []D25 
= +4 (c 0.46, CHCl3); 1H NMR (300 MHz, DMSO-d
6) δ 8.42 (s, 1H), 7.94 (d, 1H, J = 8.4 Hz), 
7.82 (d, 1H, J = 8.2 Hz), 7.56 (dt, 2H, J = 7.8, 6.5 Hz), 7.33 (t, 1H, J = 7.4 Hz), 7.22 (t, 2H, J = 
9.3 Hz), 6.53 (d, 1H, J = 7.1 Hz), 2.51 (s, 1H), 1.16 (d, 3H, J = 6.8 Hz); 13C NMR (75 MHz, 
DMSO) δ 165.07 (s), 162.78 (s), 159.82 (d, J = 248.4 Hz), 140.49 (s), 136.40 (s), 135.52 (s), 
134.78 (s), 133.18 (s), 132.62 (s), 131.87 (s), 129.35 (s), 128.95 (d, J = 12.6 Hz), 125.16 (s), 124.41 
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(s), 123.97 (s), 121.05 (s), 116.37 (d, J = 20.9 Hz), 83.37 (s), 82.01 (s), 49.77 (s), 15.00 (d, J = 
15.1 Hz); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C21H15FN3O2 360.1143; found 360.1140. 
 
2.2.7.35. (R)-8-Ethynyl-6-(2-fluorophenyl)-N,N,4-trimethyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxam (GL-II-73, 36) 
 
The amide 36 was prepared from 68 following the general procedure for esters/thioester/amides, 
via the acid chloride, with dry dimethylamine as the nucleophile. The crude residue was purified 
by column chromatography (silica gel, EtOAc and 1% MeOH) to yield pure dimethyl amide 36 as 
a light yellow powder (1.5 g, 3.9 mmol, 70%): mp 189-190 °C; []D25 = +40.98 (c 0.61, CHCl3); 
1H NMR (300 MHz, CDCl3): δ 7.92 (s, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.59 (t, J = 7.3 Hz, 1H), 
7.49 (d, J = 8.2 Hz, 1H), 7.45 – 7.35 (m, 2H), 7.21 (t, J = 7.5 Hz, 1H), 6.99 (t, J = 9.3 Hz, 1H), 
4.28 (q, J = 6.0 Hz, 1H), 3.14 (s, 1H), 3.09 (s, 3H), 2.96 (s, 3H), 1.89 (d, J = 6.6 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 166.10 (s), 162.69 (s), 160.19 (d, J = 250.4 Hz), 135.34 (s), 134.62 (d, 
J = 9.0 Hz), 133.90 (s), 133.71 (s), 132.94 (d, J = 8.4 Hz), 132.47 (s), 132.12 (d, J = 9.1 Hz), 
131.29 (s), 129.18 (s), 127.57 (d, J = 11.6 Hz), 124.51 (d, J = 2.2 Hz), 122.87 (s), 121.52 (s), 
116.17 (d, J = 21.3 Hz), 81.52 (s), 79.63 (s), 52.13 (s), 39.09 (s), 35.04 (s), 18.37 (s); HRMS 





a][1,4]diazepine-3-carboxamide (GL-II-74, 37) 
 
The amide 37 was prepared from 68 following the general procedure for esters/thioester/amides, 
via the acid chloride, with dry ethylamine as the nucleophile. The crude residue was purified by 
column chromatography (silica gel, 3:2 EtOAc and hexane) to yield pure ethyl amide 37 as a white 
powder (1.6 g, 4.3 mmol, 78%): mp 215-216 °C; []D25 = +44.07 (c 0.59, CHCl3); 1H NMR (300 
MHz, CDCl3): δ 7.83 (s, 1H), 7.65 (dd, J = 16.8, 7.8 Hz, 2H), 7.53 (d, J = 8.3 Hz, 1H), 7.47 – 7.39 
(m, 2H), 7.24 (t, J = 7.5 Hz, 1H), 7.17 (s, 1H), 7.01 (t, J = 9.3 Hz, 1H), 6.90 (q, J = 6.3 Hz, 1H), 
3.61 – 3.34 (m, 2H), 3.15 (s, 1H), 1.26 (d, J = 9.0 Hz, 3H), 1.22 (t, J = 7.3 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 162.81 (s), 162.51 (s), 160.13 (d, J = 250.7 Hz), 138.81 (s), 134.96 (s), 134.71 (s), 
133.90 (s), 133.37 (s), 131.84 (s), 131.76 (s), 131.37 (s), 129.78 (s), 128.86 (d, J = 10.6 Hz), 124.44 
(d, J = 3.4 Hz), 122.04 (s), 121.38 (s), 116.06 (d, J = 21.5 Hz), 81.55 (s), 79.52 (s), 49.89 (s), 








The amide 38 was prepared from 68 following the general procedure for esters/thioester/amides, 
via the acid chloride, with dry cyclopropylamine as the nucleophile. The crude residue was purified 
by column chromatography (silica gel, 1:1 EtOAc and hexane) to yield pure cyclopropyl amide 38 
as a white powder (1.8 g, 4.5 mmol, 82%): mp 231-232 °C; []D25 = +3.81 (c 0.46, CHCl3); 1H 
NMR (300 MHz, CDCl3): δ 7.80 (s, 1H), 7.64 (dd, J = 15.9, 7.6 Hz, 2H), 7.52 (d, J = 8.3 Hz, 1H), 
7.47 – 7.37 (m, 2H), 7.30 – 7.19 (m, 2H), 7.01 (t, J = 9.3 Hz, 1H), 6.89 (q, J = 7.0 Hz, 1H), 3.15 
(s, 1H), 2.93 – 2.67 (m, 1H), 1.26 (d, J = 6.8 Hz, 3H), 0.87 – 0.76 (m, 2H), 0.65 – 0.51 (m, 2H); 
13C NMR (75 MHz, CDCl3) δ 164.02 (s), 162.82 (s), 160.13 (d, J = 249.9 Hz), 138.91 (s), 134.97 
(s), 134.65 (s), 133.89 (s), 133.37 (s), 131.80 (d, J = 9.0 Hz), 131.58 (s), 131.36 (s), 129.78 (s), 
128.81 (d, J = 14.6 Hz), 124.45 (d, J = 3.4 Hz), 122.04 (s), 121.42 (s), 116.06 (d, J = 21.5 Hz), 
81.53 (s), 79.55 (s), 49.88 (s), 22.10 (s), 14.99 (s), 6.54 (s), 6.50 (s); HRMS (ESI/IT-TOF) m/z: 
[M + H] Calcd for C24H20FN4O 399.1616; found 399.1621. 
 
2.2.7.38. (R)-8-Ethynyl-6-(2-fluorophenyl)-N-isopropyl-4-methyl-4H-benzo[f]imidazo[1,5-




The amide 39 was prepared from 68 following the general procedure for esters/thioester/amides, 
via the acid chloride, with dry isopropylamine as the nucleophile. The crude residue was purified 
by column chromatography (silica gel, 1:1 EtOAc and hexane) to yield a mixture of rotamers 39 
as a white powder (2.9 g, 74.4 %): 1H NMR (300 MHz, CDCl3) δ 7.83 (s, 1H), 7.64 (dd, J = 17.1, 
8.0 Hz, 2H), 7.52 (d, J = 8.3 Hz, 1H), 7.43 (dd, J = 11.4, 5.8 Hz, 2H), 7.31 – 7.19 (m, 1H), 7.07 – 
6.96 (m, 2H), 6.89 (q, J = 7.2 Hz, 1H), 4.54 – 3.92 (m, 1H), 3.15 (s, 1H), 1.33 – 1.16 (m, 9H); 13C 
NMR (75 MHz, CDCl3) δ 162.92 (s), 161.76 (s), 159.42 (d, J = 144.0 Hz), 138.80 (s), 135.02 (s), 
134.70 (s), 133.91 (s), 133.33 (s), 131.91 (s), 131.83 (d, J = 3.2 Hz), 131.38 (s), 129.74 (s), 128.78 
(d, J = 11.6 Hz), 124.46 (d, J = 3.3 Hz), 122.08 (s), 121.41 (s), 116.07 (d, J = 21.5 Hz), 81.53 (s), 
79.58 (s), 49.86 (s), 40.73 (s), 22.95 (s), 22.86 (s), 15.01 (s); HRMS (ESI/IT-TOF) m/z: [M + H] 
Calcd for C24H22FN4O 401.1772; found 401.1773. 
 
2.2.7.39. (R)-(8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4] 




The amide 40 was prepared from 68 following the general procedure for esters/thioester/amides, 
via the acid chloride, with dry pyrrolidine as the nucleophile. The crude residue was purified by 
column chromatography (silica gel, 6:4 EtOAc and hexane) to yield a mixture of rotamers 40 as a 
white powder (3:2 ratio by 1H NMR, 1.8 g, 4.4 mmol, 80%): mp 173-174 °C; []D25 = -23.91 (c 
0.70, CHCl3); 1H NMR Major rotamer (300 MHz, CDCl3): δ 7.90 (s, 1H), 7.73 – 7.58 (m, 2H), 
7.51 (t, J = 9.0 Hz, 1H), 7.47 – 7.35 (m, 2H), 7.23 (t, J = 7.5 Hz, 1H), 7.01 (t, J = 9.3 Hz, 1H), 
4.31 (q, J = 6.1 Hz, 1H), 3.66 – 3.56 (m, 4H), 3.14 (s, 1H), 1.95 (d, J = 6.4 Hz, 3H), 1.93 – 1.69 
(m, 4H); 1H NMR Minor rotamer (300 MHz, CDCl3): δ 7.85 (s, 1H), 7.74 – 7.57 (m, 2H), 7.51 
(t, J = 9.0 Hz, 1H), 7.47 – 7.35 (m, 2H), 7.23 (t, J = 7.5 Hz, 1H), 7.01 (t, J = 9.3 Hz, 1H), 6.49 (q, 
J = 6.6 Hz, 1H), 3.82 (dd, J = 58.0, 32.3 Hz, 4H), 3.46 (d, J = 26.4 Hz, 4H), 3.14 (s, 1H), 1.28 (d, 
J = 6.4 Hz, 3H); HRMS (ESI/IT-TOF) m/z: [M + H] Calcd for C25H22FN4O 413.1772; found 
413.1772. 
 
General procedure with Lawesson’s reagent (LR)125-126 for the synthesis of thioamides (41-
44) 
The corresponding amide, and Lawesson’s reagent (6 eq) was suspended in dry THF in a sealed 
tube. Note, 5 mL THF is required for 1 mmol amide. The reaction mixture was heated to 80 
degrees for 36 h; a dark red clear solution was obtained. Caution, LR has a very unpleasant sulfur 
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smell, it should be handled carefully in a fume hood. The reaction mixture was cooled down to 
rt, and the solvent was removed under reduced pressure. The residue, which resulted, was 
dissolved in DCM and passed through a column of silica gel to remove the LR byproducts as the 
first milky fraction. The later fractions contain the desired thioamide product. After removal of the 
eluent, the thioamide was purified as yellow solid. The other thioamides were prepared by applying 
this general thionation procedure with the corresponding starting amide.  
 
2.2.7.40. (R)-8-Ethynyl-6-(2-fluorophenyl)-N,4-dimethyl-4H-benzo[f]imidazo[1,5-a][1,4] 
diazepine-3-carbothioamide (GL-III-84, 41) 
 
The methyl thioamide 41 was prepared from 35 (214 mg, 0.57 mmol) in THF (2.87 mL) following 
the general thionation procedure for thioamides with the LR (1.38 g, 3.4 mmol). The crude residue 
was purified by flash column chromatography (silica gel, EtOAc/hexane 2:3) to yield pure methyl 
thioamide 41 as a yellow powder (133.9 mg, 60 %): 1H NMR (300 MHz, CDCl3) δ 9.22 (s, 1H), 
7.76 (s, 1H), 7.71 – 7.58 (m, 3H), 7.50 (d, J = 8.3 Hz, 1H), 7.47 – 7.35 (m, 2H), 7.22 (t, J = 7.5 
Hz, 1H), 7.12 – 6.88 (m, 1H), 3.27 (d, J = 5.0 Hz, 3H), 3.15 (s, 1H), 1.27 (d, J = 7.3 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 187.73 (s), 163.28 (s), 160.13 (d, J = 250.3 Hz), 140.04 (s), 136.33 (s), 
135.04 (s), 134.75 (s), 133.71 (s), 132.50 (s), 131.88 (d, J = 8.3 Hz), 131.42 (d, J = 2.4 Hz), 129.85 
(s), 128.64 (d, J = 12.5 Hz), 124.45 (d, J = 3.5 Hz), 122.30 (s), 121.54 (s), 116.02 (d, J = 21.6 
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Hz), 81.50 (s), 79.65 (s), 50.23 (s), 31.42 (s), 14.27 (s); HRMS (ESI/IT-TOF) m/z: [M + H] Calcd 
for C22H18FN4S 389.1231; found 389.1228. 
 
2.2.7.41. (R)-8-Ethynyl-6-(2-fluorophenyl)-N,N,4-trimethyl-4H-benzo[f]imidazo[1,5-a][1,4] 
diazepine-3-carbothioamide (GL-III-85, 42)  
 
The dimethyl thioamide 42 was prepared from 36 (234 mg, 0.6 mmol) in THF (3 mL) following 
the general thionation procedure for thioamides with the LR (1.46 g, 3.6 mmol). The crude residue 
was purified by flash column chromatography (silica gel, EtOAc/hexane 4:1) to yield pure 
dimethyl thioamide 42 as a yellow powder (170.6 mg, 70 %): the ratio of major and minor rotamers 
is 1.8:1. 1H NMR Major rotamer (300 MHz, CDCl3) δ 7.93 (s, 1H), 7.66 (s, 1H), 7.57 (td, J = 
7.5, 1.6 Hz, 1H), 7.51 (d, J = 8.3 Hz, 1H), 7.44 – 7.33 (m, 2H), 7.20 (t, J = 7.4 Hz, 1H), 6.99 (t, J 
= 9.2 Hz, 1H), 4.26 (d, J = 5.7 Hz, 1H), 3.64 – 3.13 (m, 6H), 3.13 (s, 1H), 1.87 (d, J = 4.4 Hz, 
3H); 1H NMR Minor rotamer (300 MHz, CDCl3) δ 7.83 (s, 1H), 7.68 (s, 1H), 7.57 (td, J = 7.5, 
1.6 Hz, 1H), 7.51 (d, J = 8.3 Hz, 1H), 7.44 – 7.33 (m, 2H), 7.20 (t, J = 7.4 Hz, 1H), 6.99 (t, J = 
9.2 Hz, 1H), 6.37 – 6.11 (m, 1H), 3.64 – 3.13 (m, 6H), 3.13 (s, 1H), 1.26 (d, J = 4.4 Hz, 3H); 





[1,4]diazepine-3-carbothioamide (GL-III-86, 43)  
 
The ethyl thioamide 43 was prepared from 37 (250 mg, 0.65 mmol) in THF (3.2 mL) following 
the general thionation procedure for thioamides with the LR (1.57 g, 3.9 mmol). The crude residue 
was purified by flash column chromatography (silica gel, EtOAc/hexane 2:3) to yield pure ethyl 
thioamide 43 as a yellow powder (161.4 mg, 62 %): 1H NMR (300 MHz, CDCl3) δ 9.07 (s, 1H), 
7.78 (s, 1H), 7.72 – 7.58 (m, 3H), 7.51 (d, J = 8.3 Hz, 1H), 7.47 – 7.37 (m, 2H), 7.23 (t, J = 7.4 
Hz, 1H), 7.06 – 6.96 (m, 1H), 4.07 – 3.57 (m, 2H), 3.15 (s, 1H), 1.33 (t, J = 7.3 Hz,3H), 1.28 (d, 
J = 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 186.59 (s), 163.27 (s), 160.13 (d, J = 250.3 Hz), 
140.20 (s), 136.40 (s), 135.03 (s), 134.78 (s), 133.70 (s), 132.44 (s), 131.88 (d, J = 8.4 Hz), 131.43 
(d, J = 2.4 Hz), 129.89 (s), 128.63 (d, J = 12.3 Hz), 124.45 (d, J = 3.4 Hz), 122.29 (s), 121.56 (s), 
116.03 (d, J = 21.5 Hz), 81.50 (s), 79.64 (s), 50.25 (s), 39.26 (s), 14.26 (s), 13.39 (s); HRMS 
(ESI/IT-TOF) m/z: [M + H] Calcd for C23H20FN4S 403.1387; found 403.1381. 
 
2.2.7.43. (R)-N-Cyclopropyl-8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo 




The cyclopropyl thioamide 44 was prepared from 38 (223.6 mg, 0.56 mmol) in THF (2.8 mL) 
following the general thionation procedure for thioamides with the LR (1.36 g, 3.4 mmol). The 
crude residue was purified by flash column chromatography (silica gel, EtOAc/hexane 2:3) to yield 
the pure cyclopropyl thioamide 44 as a yellow powder (152.3 mg, 64 %): 1H NMR (300 MHz, 
CDCl3) δ 9.05 (d, J = 3.7 Hz, 1H), 7.72 (s, 1H), 7.67 – 7.55 (m, 3H), 7.48 (d, J = 8.3 Hz, 1H), 
7.45 – 7.33 (m, 2H), 7.21 (t, J = 7.5 Hz, 1H), 7.07 – 6.92 (m, 1H), 3.34 (td, J = 7.1, 4.2 Hz, 1H), 
3.14 (s, 1H), 1.25 (d, J = 7.7 Hz, 3H), 0.94 (q, J = 7.2 Hz, 2H), 0.72 (td, J = 6.8, 4.4 Hz, 2H); 13C 
NMR (75 MHz, CDCl3) δ 188.48 (s), 163.25 (s), 160.10 (d, J = 250.3 Hz), 140.08 (s), 136.15 (s), 
135.03 (s), 134.71 (s), 133.67 (s), 132.40 (s), 131.86 (d, J = 8.4 Hz), 131.40 (d, J = 2.4 Hz), 129.83 
(s), 128.64 (d, J = 12.5 Hz), 124.44 (d, J = 3.3 Hz), 122.32 (s), 121.55 (s), 116.01 (d, J = 21.6 
Hz), 81.49 (s), 79.72 (s), 50.22 (s), 27.62 (s), 14.23 (s), 7.28 (s), 7.06 (s); HRMS (ESI/IT-TOF) 
m/z: [M + H] Calcd for C24H20FN4S 415.49861387; found 415.1392. 
 
2.2.7.44. (R)-8-Bromo-6-(2-fluorophenyl)-N,N,4-trimethyl-4H-benzo[f]imidazo[1,5-




The bromo dimethyl amide 45 was prepared from bromo ethyl ester 6 (8 g, 19.3 mmol) following 
the general procedure with dry dimethylamine as the nucleophile. The crude residue was purified 
by column chromatography (silica gel, EtOAc and 1% MeOH) to yield pure bromo dimethyl amide 
45 as a light yellow powder (6 g, 70.6%): 1H NMR (300 MHz, CDCl3) δ 7.91 (s, 1H), 7.72 (d, J = 
8.2 Hz, 1H), 7.61 (t, J = 7.5 Hz, 1H), 7.49 – 7.36 (m, 3H), 7.24 (t, J = 7.5 Hz, 1H), 7.06 – 6.96 
(m, 1H), 4.30 (s, 1H), 3.26 (s, 1H), 3.17 – 2.85 (m, 6H), 1.91 (s, 3H); HRMS (ESI/IT-TOF) m/z: 
[M + H] Calcd for C21H19BrFN4O 441.0721; found 441.0719. 
 
2.2.7.45. (R)-8-Bromo-N-ethyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxamide (GL-III-67, 46)  
 
The bromo ethyl amide 46 was prepared from the bromo ethyl ester 6 (7 g, 16.9 mmol) by 
following the general procedure for esters/thioester/amides with dry ethylamine as the nucleophile. 
The crude residue was purified by flash column chromatography (silica gel, EtOAc/hexane 1:1) to 
yield the pure bromo ethyl amide 46 as a white powder (5 g, 70 %): mp 255-256 °C; 1H NMR 
(300 MHz, CDCl3) δ 7.82 (s, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.63 (t, J = 7.3 Hz, 1H), 7.50 – 7.37 
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(m, 3H), 7.23 (dd, J = 16.4, 8.9 Hz, 2H), 7.01 (t, J = 9.3 Hz, 1H), 6.90 (dd, J = 14.2, 7.0 Hz, 1H), 
3.44 (dd, J = 8.7, 4.3 Hz, 2H), 1.27 (d, J = 7.2 Hz, 3H), 1.22 (t, J = 7.3 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 162.45 (s), 162.32 (s), 160.10 (d, J = 248.8 Hz), 138.67 (s), 134.66 (s), 133.81 (s), 
133.31 (s), 132.97 (s), 131.99 (d, J = 7.6 Hz), 131.78 (s), 131.37 (s), 131.25 (s), 128.58 (s), 124.51 
(s), 123.54 (s), 120.72 (s), 116.10 (d, J = 21.5 Hz), 49.87 (s), 33.82 (d, J = 15.8 Hz), 15.02 (s), 
15.01 (s); HRMS (ESI/IT-TOF) m/z: [M + H] Calcd for C21H19BrFN4O 441.0721; found 441.0719. 
 
2.2.7.46. (R)-8-Cyclopropyl-6-(2-fluorophenyl)-N,N,4-trimethyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxamide (GL-III-70, 47)  
 
To a solution of the bromo dimethyl amide 45 (3.0 g, 6.8 mmol) in toluene (50 mL) and water 
(1.58 mL), cyclopropyl boronic acid (3 g, 34.0 mmol), potassium phosphate (6.2 g, 29.2 mmol) 
and bis(triphenylphosphine)palladium(II) diacetate (1.53 g, 2.04 mmol) were added under argon. 
A reflux condenser was attached and the mixture was degassed under vacuum with argon. This 
process was repeated four times. The mixture, which was resulted, was stirred and heated to 100 °C. 
After 3 h the reaction was completed on analysis by TLC (silica gel) and it was then cooled to rt. 
Water (20 mL) was added and the mixture was extracted with EtOAc (3 × 20 mL), after which the 
filtrate was washed with brine (20 mL), dried (Na2SO4) and concentrated under reduced pressure. 
The black residue which resulted was purified by a wash column (silica gel, EtOAc/hexane 4:1 
and 2 % MeOH) to afford the desired C(8)-cyclopropyl dimethyl amide 47 as a white solid (2.2 g, 
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81.5 %): mp 118-119 °C; 1H NMR (300 MHz, CDCl3) δ 7.86 (s, 1H), 7.57 (t, J = 6.7 Hz, 1H), 
7.38 (d, J = 7.6 Hz, 2H), 7.19 (t, J = 7.4 Hz, 2H), 7.04 – 6.86 (m, 2H), 4.26 (d, J = 6.6 Hz, 1H), 
3.07 (s, 3H), 2.96 (s, 3H), 1.88 (d, J = 6.5 Hz, 3H), 1.22 (t, J = 7.0 Hz, 1H), 0.95 (d, J = 7.7 Hz, 
2H), 0.77 – 0.45 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 166.41 (s), 163.60 (d, J = 18.7 Hz), 
160.21 (d, J = 251.3 Hz), 143.59 (s), 134.67 (s), 133.72 (s), 132.87 (s), 132.23 (s), 132.05 (s), 
131.73 (d, J = 7.9 Hz), 131.32 (s), 128.84 (s), 128.54 – 127.90 (m), 127.38 (s), 124.33 (s), 122.51 
(s), 115.97 (d, J = 21.6 Hz), 52.11 (s), 39.10 (s), 34.98 (s), 18.50 (s), 15.01 (s), 9.74 (s); HRMS 
(ESI/IT-TOF) m/z: [M + H] Calcd for C24H24FN4O 403.1929; found 403.1928. 
 
2.2.7.47. (R)-8-Cyclopropyl-N-ethyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxamide (GL-III-68, 48)  
 
To a solution of the bromo ethyl amide 46 (3.0 g, 6.8 mmol) in toluene (50 mL) and water (1.46 
mL), cyclopropyl boronic acid (3 g, 34.0 mmol), potassium phosphate (6.3 g, 29.7 mmol) and 
bis(triphenylphosphine)palladium(II) diacetate (1.52 g, 2.0 mmol) were added under argon. A 
reflux condenser was attached and the mixture was degassed under vacuum with argon. This 
process was repeated four times. The mixture was stirred and heated to 100°C. After 12 h the 
reaction was completed on analysis by TLC (silica gel) and it was then cooled to rt. Water (20 mL) 
was added and the mixture was extracted with EtOAc (3 × 25 mL), after which the filtrate was 
washed with brine (20 mL), dried (Na2SO4) and concentrated under reduced pressure. The black 
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residue which resulted was purified by a wash column (silica gel, EtOAc/hexane 4:1) to afford the 
desired C(8)-cyclopropyl ethyl amide 48 as a white solid (2.3 g, 85 %): mp 189-190 °C;  1H NMR 
(300 MHz, CDCl3) δ 7.79 (s, 1H), 7.61 (t, J = 6.6 Hz, 1H), 7.41 (t, J = 10.0 Hz, 2H), 7.31 – 7.14 
(m, 3H), 7.09 – 6.91 (m, 2H), 6.86 (d, J = 7.0 Hz, 1H), 3.62 – 3.24 (m, 2H), 1.94 – 1.71 (m, 1H), 
1.22 (dd, J = 15.1, 7.6 Hz, 6H), 0.98 (d, J = 7.9 Hz, 2H), 0.70 – 0.46 (m, 2H); 13C NMR (75 MHz, 
CDCl3) δ 163.84 (s), 162.71 (s), 160.15 (d, J = 249.0 Hz), 143.60 (s), 138.69 (s), 133.31 (s), 132.27 
(s), 131.57 (s), 131.40 (s), 129.35 (s), 129.29 (s), 128.49 (s), 128.29 (s), 127.85 (s), 124.28 (s), 
121.79 (s), 115.89 (d, J = 21.8 Hz), 49.82 (s), 33.65 (s), 15.03 (s), 14.82 (s), 9.82 (s); HRMS 
(ESI/IT-TOF) m/z: [M + H] Calcd for C24H24FN4O 403.1929; found 403.1927. 
 
2.2.7.48. 8-Bromo-6-(2-fluorophenyl)-N-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-
3-carboxamide (RV-II-04, 49) 
 
The bromo ethyl ester (2.0 g, 4.67 mmol) was dissolved in dry DCM (10 mL), which was added 
to a sealed vessel fitted with a septum at 0 ˚C and methylamine (20 mL; 33% by wt. solution in 
EtOH) was added. The vessel was sealed with a screw-cap and stirred at 60 ˚C for 15 h. The 
solution was then cooled to rt and the methylamine, DCM and ethanol were removed under 
reduced pressure. The residue which resulted was purified by a wash column (silica gel, 
EtOAc/hexane 7:3) to afford pure amide 49 as a yellow powder (1.35 g, 3.26 mmol, 70%); 1H 
NMR (500 MHz, CDCl3) δ 7.85 (s, 1H), 7.78 (dd, J = 8.5 Hz, 1.9 Hz, 1H), 7.73 (td, J = 7.7 Hz, 
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1.5 Hz, 1H), 7.50 -7.43 (m, 3H), 7.28 (t, J = 7.6 Hz, 1H), 7.12 (br s, 1H), 7.04 (t, J = 9.4 Hz, 1H), 
6.33 (br s, 1H), 4.13 (br s, 1H), 2.99 (d, J = 4.9 Hz, 3H); HPLC-MS (ESI): m/z 413.15 (M+H)+. 
 
2.2.7.49. (R)-Tert-Butyl(1-((4-bromo-2-picolinoylphenyl)amino)-1-oxopropan-2-yl)carb 
amate (GL-II-04, 71) 
 
The (2-amino-5-bromophenyl)(pyridin-2-yl)methanone 70 (100 g, 360.85 mmol) and Boc-D-
alanine (95.6 g, 505.196 mmol) were dissolved in dry DCM (400 mL) and stirred at 0 oC. 
Dicyclohexylcarbodiimide (DCC; 96.8 g, 469.1 mmol) was dissolved in dry DCM (500 mL) to 
form a homogenous solution, which was added to the former mixture dropwise over a 30 min 
period at 0 oC. The solution, which resulted, was allowed to stir for 22 h at rt. The dicyclohexyl 
urea byproduct, which was formed, was filtered off and washed with DCM until the solid was 
colorless. The organic layers were combined and concentrated under reduced pressure. The 
resulted crude was dissolved in EtOAc, and hexane was added for recrystallization at 45 oC, and 
the Boc analog 71 was recrystallized when cooled down to rt after adding seed crystals. This solid 
was further washed with EtOAc/hexane (1:19) to afford the majority of the Boc analog 71. The 
filtrate was combined, concentrated and purified by flash column chromatography (silica gel, 
EtOAc/hexane 2:3) to yield the additional amide 71 (159.5 g, 98.6 %): 1H NMR (300 MHz, CDCl3) 
δ 11.37 (s, 1H), 8.72 (d, J = 4.7 Hz, 1H), 8.60 (d, J = 9.0 Hz, 1H), 7.96 (d, J = 2.3 Hz, 1H), 7.94 
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– 7.89 (m, 2H), 7.65 (dd, J = 9.0, 2.2 Hz, 1H), 7.51 (dd, J = 8.8, 4.8 Hz, 1H), 5.21 (d, J = 6.5 Hz, 
1H), 4.35 (s, 1H), 1.63 – 1.15 (m, 12H); HRMS (ESI/IT-TOF) m/z: [M + H] Calcd for 





Amide 71 (157.5 g, 351.32 mmol) was dissolved in dry DCM (800 mL) and cooled to 0 oC. 
Anhydrous HCl (g) was slowly added until the solution was saturated, about 2 h, and the solution 
was allowed to stir overnight at rt. The reaction mixture was then washed with a sat aq solution of 
NaHCO3 (2 x 500 mL) and water (2 x 300 mL). A mild exotherm was observed during the 
addition of a saturated aq NaHCO3 during workup. The organic layer was concentrated under 
reduced pressure and the oil which resulted was dissolved in methanol-water (2:1, 1.5 L) and the 
pH was adjusted to 8.5 using a solution of 1 M aq NaOH (pH paper). The reaction mixture was 
allowed stir at rt for 48 h. The solution was concentrated under reduced pressure and water (100 
mL) was added. The solution was extracted with DCM and the organic layer was washed with 
brine, dried (Na2SO4), and concentrated under reduced pressure. The majority of 1,4-
benzodiazepine 72 precipitated out of solution as white solid, which was filtered off and washed 
with cold MeOH and water. The filtrated was combined and concentrated under reduced pressure, 
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and this was followed by the same washing procedure until no precipitate was left. The filtrate was 
then purified by flash column chromatography (silica gel, EtOAc/hexane 2:3) to yield additional 
1,4-benzodiazepine 72 (109 g, 94 %): 1H NMR (300 MHz, CDCl3) δ 9.67 (s, 1H), 8.61 (d, J = 4.2 
Hz, 1H), 7.99 (d, J = 7.9 Hz, 1H), 7.79 (td, J = 7.8, 1.6 Hz, 1H), 7.55 (dd, J = 8.6, 2.2 Hz, 1H), 
7.50 (d, J = 2.1 Hz, 1H), 7.39 – 7.31 (m, 1H), 7.04 (d, J = 8.6 Hz, 1H), 3.82 (q, J = 6.4 Hz, 1H), 
1.76 (d, J = 6.5 Hz, 3H);  13C NMR (75 MHz, CDCl3) δ 172.35, 166.34, 156.05, 148.86, 137.59, 
136.86, 134.52, 133.72, 128.26, 124.62, 124.16, 122.92, 115.92, 59.06, 16.93; HRMS (ESI/IT-
TOF) m/z: [M + H] Calcd for C15H13BrN3O 330.0236; found 330.0214. 
 
2.2.7.51. (R)-Ethyl 8-bromo-4-methyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diaz 
epine-3-carboxylate (GL-II-06, 73) 
 
The 1,4-benzodiazepine 72 (111.3 g, 337.1 mmol) was dissolved in dry THF (1.3 L) and cooled to 
-35 oC. The K-t-BuO (45.5 g, 404.5 mmol) was then added in one portion and the solution was 
allowed to warm to rt where the temperature was held for 1.5 h. The reaction was then cooled to -
50 oC and diethyl chlorophosphate (82.85 g, 471.9 mmol) was added. The solution was allowed to 
warm to rt and the temperature was held there for 3 h. The reaction was then cooled to -78 oC and 
ethyl isocyanoacetate (53.38 g, 471.9 mmol) was added, followed by a second portion of K-t-BuO 
(45.5 g, 404.5 mmol). The reaction was allowed to warm to rt and stirred overnight, a dark red 
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solution was obtained. The reaction was quenched by addition of a cold sat aq solution of NaHCO3 
(1 L) and extracted with EtOAc. The organic layers were combined and washed with brine (2 x 
250 mL), dried (Na2SO4) and the solvent was removed under reduced pressure to afford a brown 
solid. The majority of the bromide 73 can be recrystallized from methyl t-butyl ether or EtOAc 
after cooling from 60 ˚C. The solid 73 was then filtered and washed with large amount of water, 
and followed by ether until the solid was not pinkish in color. The filtrate was extracted with 
EtOAc, and concentrated under reduced pressure. This solid was further purified by flash column 
chromatography (silica gel, EtOAc:hexane, 3:2) to afford the pure bromo ethyl ester 73 as an off-
white solid (97.5 g, 68 %): 1H NMR (300 MHz, CDCl3) δ 8.56 (d, J = 4.6 Hz, 1H), 8.01 (d, J = 
7.9 Hz, 1H), 7.82 (dd, J = 15.6, 6.3 Hz, 2H), 7.72 (dd, J = 8.5, 1.9 Hz, 1H), 7.46 (t, J = 6.0 Hz, 
2H), 7.36 (dd, J = 6.7, 5.3 Hz, 1H), 6.69 (q, J = 7.3 Hz, 1H), 4.52 – 4.23 (m, 2H), 1.40 (t, J = 7.1 
Hz, 3H), 1.27 (d, J = 7.3 Hz, 3H); 13C NMR (75 MHz, DMSO) δ 164.85, 157.38, 150.14, 148.57, 
140.94, 137.60, 136.69, 135.06, 134.99, 134.60, 130.44, 129.58, 125.46, 125.40, 124.04, 123.79, 
119.87, 119.49, 49.55, 14.75; HRMS (ESI/IT-TOF) m/z: [M + H] Calcd for C20H18BrN4O2 
425.0608; found 425.0610. 
 
2.2.7.52. (R)-Ethyl 4-methyl-6-(pyridin-2-yl)-8-((trimethylsilyl)ethynyl)-4H-benzo[f]imida 




The bromo ethyl ester 73 (24.77 g, 58.25 mmol) was dissolved in triethylamine (200 mL) and 
acetonitrile (300 mL). Trimethylsilylacetylene (8.58 g, 87.4 mmol) and bis(triphenylphosphine)-
palladium (II) acetate (2.4 g, 3.2 mmol) were added. A reflux condenser was attached and the 
mixture was degassed under vacuum with argon; this process was repeated four times. The reaction 
mixture was heated to reflux under argon and stirred for 8 h. The solution was cooled to rt, filtered 
through celite, and washed with EtOAc. The filtrate was concentrated under reduced pressure. The 
black residue which resulted was purified by a wash column (silica gel, EtOAc/hexanes 1:2) to 
afford the TMS-analog 74 as an off-white solid (23.2 g, 90.3 %): 1H NMR (300 MHz, CDCl3) δ 
8.54 (d, J = 4.3 Hz, 1H), 7.94 (d, J = 7.8 Hz, 1H), 7.86 (s, 1H), 7.77 (t, J = 7.7 Hz, 1H), 7.64 (d, 
J = 8.1 Hz, 1H), 7.50 (t, J = 7.2 Hz, 1H), 7.37 (s, 1H), 7.32 (dd, J = 6.6, 5.6 Hz, 1H), 6.65 (q, J = 
7.2 Hz, 1H), 4.49 – 4.25 (m, 2H), 1.37 (t, J = 7.1 Hz, 3H), 1.21 (t, J = 6.0 Hz, 3H), 0.19 (s, 9H); 
13C NMR (75 MHz, CDCl3) δ 165.28, 163.00, 157.60, 148.61, 141.71, 136.80, 135.45, 135.31, 
134.95, 129.28, 127.88, 124.52, 123.97, 122.31, 121.98, 102.79, 96.91, 60.65, 49.79, 14.46, 14.39, 
-0.25; HRMS (ESI/IT-TOF) m/z: [M + H] Calcd for C25H27N4O2Si 443.1898; found 443.1901. 
 
2.2.7.53. (R)-Ethyl 8-ethynyl-4-methyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]dia 




The intermediate 74 (18 g, 40.6 mmol) was dissolved in THF (300 mL) and cooled to -78 oC. This 
was treated with tetrabutylammonium fluoride hydrate (1 M solution in THF, 61 mmol), and this 
was followed by water (18 mL). The reaction mixture was stirred until the starting material was 
consumed as indicated by TLC (silica gel), about 1 h. The reaction mixture was allowed to warm 
to rt, and water (200 mL) was slowly added. The solution was extracted with EtOAc and the 
organic extracts were combined, washed with brine, dried (Na2SO4), and the solvent was removed 
under reduced pressure. The residue which resulted was recrystallized from DCM and MeOH after 
cooling down from 60 oC. The crystals were filtered and washed with cold MeOH. The filtrated 
was combined, concentrated and further purified by a wash column (silica gel, EtOAc/hexanes 3:2) 
to afford additional ethyl ester 75 as a white powder (14.9 g, 95 %): 1H NMR (300 MHz, CDCl3) 
δ 8.58 (d, J = 4.4 Hz, 1H), 8.01 (d, J = 7.8 Hz, 1H), 7.89 (s, 1H), 7.83 (t, J = 7.6 Hz, 1H), 7.72 (d, 
J = 8.3 Hz, 1H), 7.55 (d, J = 8.3 Hz, 1H), 7.47 (s, 1H), 7.42 – 7.32 (m, 1H), 6.71 (q, J = 7.3 Hz, 
1H), 4.56 – 4.28 (m, 2H), 3.15 (s, 1H), 1.43 (t, J = 7.1 Hz, 3H), 1.28 (d, J = 7.3 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 165.14, 163.00, 157.52, 148.57, 141.71, 136.85, 135.82, 135.03, 134.99, 
129.36, 127.92, 124.57, 124.00, 122.40, 120.95, 81.66, 79.47, 60.71, 49.82, 14.55, 14.40; HRMS 
(ESI/IT-TOF) m/z: [M + H] Calcd for C22H19N4O2 371.1503; found 371.1502. 
 
2.2.7.54. (R)-8-Ethynyl-N,4-dimethyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4] 




The ethyl ester GL-II-19-2'N-R-CH3 (75, 1.7 g, 4.59 mmol) was dissolved in dry DCM (15 mL), 
which was added to a sealed vessel fitted with a septum at 0 ˚C and methyl amine (25 mL; 33% 
by wt. solution in EtOH) was added. The vessel was sealed with a screw-cap and stirred at 60 ˚C 
for 18 hours. The solution was then cooled to r.t. and the methyl amine, DCM and ethanol were 
removed under reduced pressure. Then DCM (5 mL) was added to the crude mixture, and it was 
stirred at 35 ˚C for 5 min, after which then pure product was filtered off. The filtrate was further 
purified by flash column chromatography (silica gel, EtOAc/hexane 7:3) to afford an additional 
portion of pure amide 50 as a white powder (1.2 g, 72 %); 1H NMR (500 MHz, CDCl3) δ 8.57 (d, 
J = 4.5 Hz, 1H), 8.07 (d, J = 7.9 Hz, 1H), 7.83 (t, J = 7.6 Hz, 1H), 7.77 (d, J = 3.3 Hz, 1H), 7.70 
(d, J = 8.2 Hz, 1H), 7.53 (d, J = 8.3 Hz, 1H), 7.48 (s, 1H), 7.40 – 7.32 (m, 1H), 7.18 (s, 1H), 6.91 
(q, J = 7.2 Hz, 1H), 3.15 (s, 1H), 2.97 (d, J = 5.0 Hz, 3H), 1.28 (d, J = 7.2 Hz, 3H); 13C NMR (75 
MHz, MeOD) δ 165.47, 163.87, 157.41, 148.30, 138.74, 137.34, 135.81, 135.57, 135.25, 135.17, 
134.26, 131.06, 127.84, 124.84, 124.22, 122.43, 121.10, 81.43, 79.66, 25.56, 14.45; HRMS 
(ESI/IT-TOF) m/z: [M + H] Calcd for C21H18N5O 356.1506; found 356.1504. 
 
2.2.7.55.  (R)-5-(8-Ethynyl-4-methyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diaze 




The methyl oxadiazole 51 was prepared from the ethyl ester 75 (2 g, 5.4 mmol) following the 
general procedure with the required oxime (800 mg, 10.8 mmol) and sodium hydride (60% 
dispersion in mineral oil, 324 mg, 8.1 mmol) in dry THF (100 mL). The crude residue was purified 
by column chromatography (silica gel, EtOAc) to yield pure oxadiazole 51 as a white powder (1.58 
g, 4.15 mmol, 77%); 1H NMR (300 MHz, CDCl3) δ 8.57 (d, J = 4.4 Hz, 1H), 8.00 (d, J = 5.6 Hz, 
2H), 7.81 (t, J = 7.8 Hz, 1H), 7.73 (d, J = 8.5 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.47 (s, 1H), 7.40 
– 7.32 (m, 1H), 6.71 (d, J = 7.3 Hz, 1H), 3.16 (s, 1H), 2.46 (s, 3H), 1.34 (d, J = 7.3 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 170.81, 167.42, 165.35, 157.45, 148.60, 139.28, 136.90, 136.45, 136.01, 
135.77, 135.54, 135.19, 127.95, 124.68, 124.03, 122.37, 121.21, 81.61, 79.61, 49.97, 14.67, 11.66; 
HRMS (ESI/IT-TOF) m/z: [M + H] Calcd for C22H17N6O 381.1458; found 381.1461. 
 
2.2.7.56. 5-(8-Ethynyl-6-(2-fluorophenyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)-3-




The methyl oxadiazole 52 was prepared from the ethyl ester (3.0 g, 8.03 mmol), which contained 
the 2'F group, following the general procedure with the methyl oxime (1.2 g, 16.06 mmol) and 
sodium hydride (60% dispersion in mineral oil, 482 mg, 12.04 mmol) in dry THF (100 mL). The 
crude residue was purified by column chromatography (silica gel, 7:3 EtOAc and hexane) to yield 
pure product 52 as a white powder (1.6 g, 4.17 mmol, 52%): 1H NMR (500 MHz, CDCl3): δ 8.11 
(s, 1H), 7.80 (d, J = 8.6 Hz, 1H), 7.69 (t, J = 7.5 Hz, 1H), 7.64 (d, J = 8.6 Hz, 1H), 7.51 (br s, 1H), 
7.49 (q, J = 6.4 Hz, 1H), 7.28 (t, J = 7.5 Hz, 1H), 7.06 (t, J = 9.1 Hz, 1H), 6.19 (br s, 1H), 4.52 
(br s, 1H), 3.19 (s, 1H), 2.48 (s, 3H); HRMS (ESI/IT-TOF) m/z: [M + H] Calcd for C22H15N5O 
384.1255; found 384.1273. 
 
2.2.7.57. (R)-5-(8-Bromo-4-methyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4] 
diazepin-3-yl)-3-methyl-1,2,4-oxadiazole (GL-II-54, 53)  
 
The methyl oxadiazole 53 was prepared from the bromo ethyl ester 73 (2.0 g, 4.7 mmol) following 
the general procedure with the methyl oxime (1.3 g, 17.5 mmol) and sodium hydride (60% 
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dispersion in mineral oil, 282 mg, 7.1 mmol) in dry THF (100 mL). The crude residue was purified 
by column chromatography (silica gel, EtOAc and 1% MeOH) to yield pure methyl oxadiazole 53 
as a white powder (1.7 g, 3.9 mmol, 85%); 1H NMR (500 MHz, CDCl3) δ 8.60 (d, J = 4.3 Hz, 
1H), 8.05 (d, J = 7.9 Hz, 1H), 8.00 (s, 1H), 7.84 (t, J = 7.0 Hz, 1H), 7.78 (d, J = 8.4 Hz, 1H), 7.52 
(d, J = 8.2 Hz, 2H), 7.40 (dd, J = 6.7, 5.0 Hz, 1H), 6.73 (t, J = 7.3 Hz, 1H), 2.49 (s, 3H), 1.37 (d, 
J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 170.81, 167.44, 164.77, 157.19, 148.60, 139.21, 
137.00, 136.40, 135.17, 134.99, 134.90, 134.70, 129.42, 124.82, 124.07, 123.81, 120.59, 49.99, 
14.70, 11.69; HRMS (ESI/IT-TOF) m/z: [M + H] Calcd for C20H16BrN6O 435.0564; found 
435.0557. 
 
2.2.7.58.  (R)-5-(8-Cyclopropyl-4-methyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4] 
diazepin-3-yl)-3-methyl-1,2,4-oxadiazole (GL-III-64, 54)  
 
To a solution of the bromo methyl oxadiazole 53 (4.0 g, 9.2 mmol) in toluene (100 mL) and water 
(7 mL), cyclopropyl boronic acid (1.98 g, 23.0 mmol), potassium phosphate (8.2 g, 38.6 mmol) 
and bis(triphenylphosphine)palladium(II) diacetate (1.38 g, 1.84 mmol) were added under argon. 
A reflux condenser was attached and the mixture was degassed under vacuum with argon; this 
process was repeated four times. The mixture was stirred and heated to 100 °C. After 3 h the 
reaction was completed on analysis by TLC (silica gel) and it was then cooled to rt. Then water 
251 
 
(20 mL) was added and the mixture was extracted with EtOAc (3 × 25 mL), after which the filtrate 
was washed with brine (20 mL), dried (Na2SO4) and concentrated under reduced pressure. The 
black residue which resulted was purified by a wash column (silica gel, EtOAc) to afford the 
desired C(8)-cyclopropyl methyl oxadiazole 54 as a white solid (2.18 g, 60 %): 1H NMR (300 
MHz, CDCl3) δ 8.56 (d, J = 4.5 Hz, 1H), 7.96 (d, J = 7.6 Hz, 2H), 7.80 (t, J = 7.6 Hz, 1H), 7.49 
(d, J = 8.3 Hz, 1H), 7.34 (t, J = 5.9 Hz, 1H), 7.26 (d, J = 9.3 Hz, 1H), 6.99 (s, 1H), 6.68 (q, J = 
7.1 Hz, 1H), 2.44 (s, 3H), 1.89 (ddd, J = 13.0, 8.3, 4.9 Hz, 1H), 1.31 (d, J = 7.2 Hz, 3H), 1.00 (d, 
J = 7.4 Hz, 2H), 0.66 (d, J = 4.0 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 171.04, 167.36, 166.39, 
157.95, 148.54, 143.40, 139.26, 136.83, 136.45, 133.06, 129.64, 129.19, 128.88, 127.51, 124.51, 
124.17, 122.11, 49.96, 15.16, 14.47, 11.68, 9.95, 9.89; HRMS (ESI/IT-TOF) m/z: [M + H] Calcd 
for C23H21N6O 397.1771; found 397.1770. 
 
2.2.7.59. (R)-5-(8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4] 
diazepin-3-yl)-3-isopropyl-1,2,4-oxadiazole (MP-IV-010, 57)  
 
The isopropyl oxadiazole 57 was prepared from the ethyl ester 1 (390 mg, 1mmol) following the 
general procedure for oxadiazoles with the isopropyl oxime (411.3 mg, 4.03 mmol) and NaH (44.3 
mg, 1.1 mmol). The crude residue was purified by flash column chromatography (silica gel, 
EtOAc/hexane 1:1) to yield pure isopropyl oxadiazole 57 as a white powder (373.6 mg, 87.2 %): 
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1H NMR (300 MHz, CDCl3) δ 8.06 (s, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.58 (dd, J = 15.4, 7.8 Hz, 
2H), 7.41 (ddd, J = 13.2, 6.2, 1.8 Hz, 2H), 7.21 (td, J = 7.5, 0.9 Hz, 1H), 7.00 (t, J = 9.2 Hz, 1H), 
6.70 (q, J = 7.1 Hz, 1H), 3.24 – 2.89 (m, 2H), 1.36 (d, J = 6.9 Hz, 6H), 1.32 (d, J = 7.3 Hz, 3H).  
13C NMR (75 MHz, CDCl3) δ 175.28 (s), 170.61 (s), 163.43 (s), 160.06 (d, J = 250.5 Hz), 139.17 
(s), 136.27 (s), 135.36 (s), 134.22 (s), 134.04 (s), 132.30 (s), 132.04 (d, J = 8.2 Hz), 131.12 (s), 
129.51 (s), 128.56 (d, J = 12.8 Hz), 124.51 (d, J = 3.2 Hz), 122.24 (s), 121.85 (s), 116.20 (d, J = 
21.4 Hz), 81.32 (s), 79.96 (s), 50.25 (s), 26.73 (s), 20.59 (s), 20.53 (s), 14.97 (s). HRMS (ESI/IT-
TOF) m/z: [M + H] Calcd for C25H21FN5O 426.1725, found 426.1720. 
 
2.2.7.60. (R)-5-(8-Bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4] 
diazepin-3-yl)-3-methyl-1,2,4-oxadiazole (GL-III-60, 58)  
 
The bromo methyl oxadiazole 58 was prepared from the bromo ethyl ester 6 (6 g, 13.5 mmol) 
following the general procedure for oxadiazoles with the methyl oxime (3 g, 40.5 mmol) and NaH 
(60% dispersion in mineral oil, 0.8 g, 14.9 mmol). The crude residue was purified by flash column 
chromatography (silica gel, EtOAc/Hexane 3:2) to yield the pure bromo methyl oxadiazole 58 as 
a white powder (5.6 g, 91.8 %): 1H NMR (500 MHz, CDCl3) δ 8.08 (s, 1H), 7.76 (dd, J = 8.5, 1.9 
Hz, 1H), 7.61 (t, J = 7.0 Hz, 1H), 7.55 (d, J = 8.6 Hz, 1H), 7.52 – 7.42 (m, 2H), 7.26 (td, J = 7.6, 
0.9 Hz, 1H), 7.11 – 6.99 (m, 1H), 6.74 (q, J = 7.3 Hz, 1H), 2.45 (s, 3H), 1.35 (d, J = 7.3 Hz, 3H); 
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13C NMR (126 MHz, CDCl3) δ 170.69 (s), 167.46 (s), 161.09 (s), 161.06 (d, J = 495.1 Hz), 139.12 
(s), 136.31 (s), 135.16 (s), 133.37 (s), 133.25 (s), 132.36 (d, J = 7.7 Hz), 131.26 (s), 131.02 (s), 
128.15 (d, J = 11.0 Hz), 124.87 (s), 124.61 (d, J = 3.3 Hz), 123.71 (s), 121.26 (s), 116.29 (d, J = 
21.4 Hz), 50.15 (s), 14.98 (s), 11.69 (s); HRMS (ESI/IT-TOF) m/z: [M + H] Calcd for 
C21H16BrFN5O 452.0517, found 452.0542. 
 
2.2.7.61. (R)-5-(8-Bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4] 
diazepin-3-yl)-3-ethyl-1,2,4-oxadiazole (GL-III-98, 59)  
 
The bromo ethyl oxadiazole 59 was prepared from the bromo ethyl ester 6 (2.5 g, 5.65 mmol) 
following the general procedure for oxadiazoles with the ethyl oxime (2.0 g, 22.6 mmol) and NaH 
(0.25 g, 6.2 mmol). The crude residue was purified by flash column chromatography (silica gel, 
EtOAc/Hexane 2:3) to yield pure bromo ethyl oxadiazole 59 as a white powder (2.2 g, 83.7 %): 
1H NMR (300 MHz, CDCl3) δ 8.05 (s, 1H), 7.71 (d, J = 8.6 Hz, 1H), 7.53 (d, J = 8.6 Hz, 2H), 
7.44 – 7.31 (m, 2H), 7.19 (t, J = 7.5 Hz, 1H), 6.98 (t, J = 9.2 Hz, 1H), 6.69 (q, J = 7.1 Hz, 1H), 
2.77 (q, J = 7.6 Hz, 2H), 1.32 (t, J = 7.6 Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 171.82 (s), 170.67 
(s), 162.84 (s), 160.03 (d, J = 250.7 Hz), 139.10 (s), 136.28 (s), 135.07 (s), 133.35 (s), 133.11 (s), 
132.18 (d, J = 8.0 Hz), 131.16 (s), 131.00 (s), 128.30 (d, J = 12.4 Hz), 124.54 (d, J = 3.0 Hz), 
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123.75 (s), 121.13 (s), 116.20 (d, J = 21.4 Hz), 50.20 (s), 19.72 (s), 14.95 (s), 11.50 (s); HRMS 
(ESI/IT-TOF) m/z: [M + H] Calcd for C22H18BrFN5O 468.0655, found 468.0659. 
 
2.2.7.62. (R)-5-(8-Bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4] 
diazepin-3-yl)-3-isopropyl-1,2,4-oxadiazole (GL-IV-01, 60)  
 
The bromo isopropyl oxadiazole 60 was prepared from the bromo ethyl ester 6 (3.5 g, 7.91 mmol) 
following the general procedure for oxadiazoles with the isopropyl oxime (3.2 g, 31.6 mmol) and 
NaH (60% dispersion in mineral oil, 0.35 g, 8.7 mmol). The crude residue was purified by flash 
column chromatography (silica gel, EtOAc/Hexane 1:1) to yield pure bromo isopropyl oxadiazole 
60 as a white powder (3.0 g, 78.2 %): 1H NMR (300 MHz, CDCl3) δ 8.04 (s, 1H), 7.70 (d, J = 8.8 
Hz, 1H), 7.53 (d, J = 8.6 Hz, 2H), 7.43 – 7.31 (m, 2H), 7.19 (t, J = 7.5 Hz, 1H), 6.98 (t, J = 9.1 
Hz, 1H), 6.69 (q, J = 7.0 Hz, 1H), 3.11 (dt, J = 13.8, 6.9 Hz, 1H), 1.33 (d, J = 7.0 Hz, 6H), 1.31 
(d, J = 9.3 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 175.26 (s), 170.58 (s), 162.85 (s), 160.02 (d, J 
= 250.7 Hz), 139.06 (s), 136.26 (s), 135.08 (s), 133.37 (s), 133.11 (s), 132.60 (s), 132.18 (d, J = 
8.0 Hz), 131.11 (s), 130.96 (s), 128.31 (d, J = 12.3 Hz), 124.57 (s), 123.75 (s), 121.11 (s), 116.20 
(d, J = 21.4 Hz), 50.25 (s), 26.72 (s), 20.59 (s), 20.53 (s), 14.96 (s); HRMS (ESI/IT-TOF) m/z: 





a][1,4]diazepin-3-yl)-3-methyl-1,2,4-oxadiazole (GL-III-63, 61)  
 
To a solution of the bromo methyl oxadiazole 58 (1.6 g, 3.6 mmol) in toluene (100 mL) and water 
(1.3 mL), cyclopropyl boronic acid (0.55 g, 6.4 mmol), potassium phosphate (3.18 g, 15.0 mmol) 
and bis(triphenylphosphine)palladium(II) diacetate (0.56 g, 0.75 mmol) were added under argon. 
A reflux condenser was attached and the mixture was degassed under vacuum with argon; this 
process was repeated four times. The mixture was stirred and heated to 100 °C. After 4 h the 
reaction progress was complete on analysis by TLC (silica gel) and it was then cooled to rt. Then 
water (20 mL) was added and the mixture was extracted with EtOAc (3 × 25 mL), after which the 
filtrate was washed with brine (20 mL), dried (Na2SO4) and concentrated under reduced pressure. 
The black residue which resulted was purified by a wash column (silica gel, EtOAc) to afford the 
desired C(8)-cyclopropyl methyl oxadiazole 61 as a white solid (1.05 g, 72 %): 1H NMR (300 
MHz, CDCl3) δ 8.03 (s, 1H), 7.59 (t, J = 7.5 Hz, 1H), 7.51 (d, J = 8.3 Hz, 1H), 7.47 – 7.36 (m, 
1H), 7.24 (dd, J = 14.9, 7.4 Hz, 2H), 7.08 – 6.95 (m, 2H), 6.69 (q, J = 7.3 Hz, 1H), 2.44 (s, 3H), 
1.87 (dt, J = 12.6, 6.8 Hz, 1H), 1.32 (d, J = 7.2 Hz, 3H), 1.00 (d, J = 8.2 Hz, 2H), 0.64 (dd, J = 
10.7, 4.7 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 170.97 (s), 167.38 (s), 161.81 (s), 161.50 (d, J = 
454.5 Hz), 144.23 (s), 139.19 (s), 136.30 (s), 131.91 (s), 131.80 (s), 131.30 (s), 129.12 (s), 128.99 
(s), 128.69 (s), 128.11 (s), 127.32 (s), 124.38 (s), 121.93 (s), 116.06 (d, J = 21.8 Hz), 50.09 (s), 
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15.09 (s), 14.75 (s), 11.67 (s), 9.99 (s); HRMS (ESI/IT-TOF) m/z: [M + H] Calcd for C24H21FN5O 
414.1725, found 414.1728. 
 
2.2.7.64. (R)-5-(8-Cyclopropyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepin-3-yl)-3-ethyl-1,2,4-oxadiazole (GL-IV-03, 62)  
 
To a solution of the bromo ethyl oxadiazole 59 (1.1 g, 2.38 mmol), tri(O-tolyl)phosphine (85.5 mg, 
0.28 mmol),  cyclopropyl boronic acid (0.724 g, 8.43 mmol) and potassium phosphate (2.56 g, 
12.1 mmol) in toluene (30 mL) and water (0.65 mL), Pd(OAc)2 (31.5 mg, 0.14 mmol) was added 
under Ar at rt to form an orange cloudy solution. A reflux condenser was attached. The mixture 
was allowed to stir at rt for 5 min untill the color of the solution turned yellow, as an indication of 
the formation of the Pd complex generated in situ. The mixture was then placed into a pre-heated 
oil bath at 100 °C. After 2 h the reaction progress was complete on analysis by TLC (silica gel) 
and it was then cooled to rt. Then water (20 mL) was added and the mixture was extracted with 
EtOAc (3 × 25 mL), after which the filtrate was washed with brine (20 mL), dried (Na2SO4) and 
concentrated under reduced pressure. The black residue which resulted was purified by a wash 
column (silica gel, DCM and 5 % MeOH) to afford the desired C(8)-cyclopropyl ethyl oxadiazole 
62 as a white solid (815.5 mg, 81.6 %): 1H NMR (300 MHz, CDCl3) δ 7.98 (s, 1H), 7.46 (d, J = 
8.3 Hz, 2H), 7.38 – 7.25 (m, 1H), 7.13 (t, J = 7.5 Hz, 2H), 6.93 (t, J = 9.1 Hz, 2H), 6.63 (q, J = 
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7.0 Hz, 1H), 2.73 (q, J = 7.6 Hz, 2H), 1.84 – 1.65 (m, 1H), 1.27 (dd, J = 14.1, 6.6 Hz, 6H), 0.90 
(d, J = 8.3 Hz, 2H), 0.54 (dd, J = 10.1, 4.8 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 171.70 (s), 
170.95 (s), 164.32 (s), 160.06 (d, J = 250.5 Hz), 144.12 (s), 139.17 (s), 136.28 (s), 131.72 (s), 
131.62 (s), 131.17 (s), 129.05 (t, J = 6.2 Hz), 128.61 (s), 127.96 (s), 127.20 (s), 124.36 (d, J = 8.0 
Hz), 122.68 (s), 121.94 (s), 115.94 (d, J = 21.6 Hz), 50.13 (s), 19.69 (s), 15.02 (s), 14.68 (s), 11.49 
(s), 9.89 (s); HRMS (ESI/IT-TOF) m/z: [M + H] Calcd for C25H23FN5O 428.1881, found 428.1889.  
 
2.2.7.65. (R)-5-(8-Cyclopropyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepin-3-yl)-3-isoproyl-1,2,4-oxadiazole (GL-IV-04, 63)  
 
To a solution of the bromo isopropyl oxadiazole 60 (2.0 g, 4.16 mmol), tri(O-tolyl)phosphine 
(126.6 mg, 0.416 mmol),  cyclopropyl boronic acid (1.07 g, 12.5 mmol) and potassium phosphate 
(3.8 g, 17.9 mmol) in toluene (40 mL) were added as well as water (0.96 mL). Then Pd(OAc)2 
(46.7 mg, 0.21 mmol) was added under Ar at rt to form an orange cloudy solution. A reflux 
condenser was attached. The mixture was allowed to stir at rt for 5 min untill the color of the 
solution turned yellow, as an indication for the formation of the Pd complex generated in situ. The 
mixture was then placed into a pre-heated oil bath at 100 °C. After 2.5 h the reaction progress was 
complete on analysis by TLC (silica gel) and it was then cooled to rt. Then water (20 mL) was 
added and the mixture was extracted with EtOAc (3 × 25 mL), after which the filtrate was washed 
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with brine (20 mL), dried (Na2SO4) and concentrated under reduced pressure. The black residue, 
which resulted, was purified by a wash column (silica gel, DCM and 5 % MeOH) to afford the 
desired C(8)-cyclopropyl isopropyl oxadiazole 63 as a white solid (1.45 g, 78.8 %): 1H NMR (300 
MHz, CDCl3) δ 8.00 (s, 1H), 7.70 – 7.43 (m, 1H), 7.42 – 7.30 (m, 1H), 7.26 – 7.11 (m, 1H), 6.98 
(d, J = 13.2 Hz, 1H), 6.65 (q, J = 7.1 Hz, 1H), 3.11 (dt, J = 13.8, 6.9 Hz, 1H), 1.81 (ddd, J = 13.1, 
8.4, 5.0 Hz, 1H), 1.31 (dd, J = 15.3, 7.1 Hz, 4H), 0.95 (d, J = 8.2 Hz, 1H), 0.58 (dd, J = 10.3, 4.8 
Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 175.19 (s), 170.88 (s), 164.35 (s), 160.09 (d, J = 250.5 
Hz), 144.11 (s), 139.14 (s), 136.21 (s), 131.80 (s), 131.64 (s), 131.15 (s), 129.32 – 128.95 (m), 
128.65 (s), 128.02 (s), 127.25 (s), 124.47 (d, J = 18.9 Hz), 122.68 (s), 121.92 (s), 116.00 (d, J = 
21.5 Hz), 50.21 (s), 26.71 (s), 20.60 (s), 20.54 (s), 15.04 (s), 14.74 (s), 9.89 (s); HRMS (ESI/IT-
TOF) m/z: [M + H] Calcd for C26H25FN5O 442.2038, found 442.2046.  
 
2.2.7.66. (R)-8-Bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diaze 
pine-3-carbaldehyde (GL-III-35, 78) 
 
The preparation of PDBBA: The potassium tert-butoxide (29.3 g, 261 mmol) was suspended in 
dry THF (261 mL). DIBALH (261 mL, 1.0 M in hexane, 261 mmol) was added dropwise to the 
solution of potassium tert-butoxide at 0 °C using an ice-water bath. The mixture was allowed to 
stir at rt for 2 h to achieve a colorless homogeneous solution. The concentration of PDBBA 
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solution in THF-hexanes was measured by GC analysis by hydrolysis of the solution with a 
mixture of t-butyl alcohol-THF (1:1) at 0 °C.130, 161 
The reduction of bromo ethyl ester 6 to aldehyde 78: The bromo ethyl ester 6 (5.6 g, 12.7 mmol) 
was dissolved in dry DCM (30 mL) at 0 °C. The ice-water bath was removed, and the PDBBA 
solution (0.42 M in THF-hexanes, 69 mL) was added in one portion with vigorous stirring. The 
reaction was monitored by TLC (silica gel) after each 3 min and was completed in 20 min, and 
this was followed by hydrolysis of the mixture in 1N aq HCl at 0 °C. Then water (50 mL) was 
added to the mixture, and it was stirred for 0.5 h. The aluminum salt was formed and filtered off 
on a celite pad. The filtrate was extracted with DCM (3 x 10 mL). The organic layers were 
combined and concentrated with reduced pressure, and this was followed by washing with brine 
and dried (Na2SO4). The solid residue was purified by flash chromatography (silica gel packed 
with DCM, eluent: DCM/EtOAc 3:2) to afford the bromo aldehyde 78 as a white solid (4.0 g, 79.4 % 
yield): 1H NMR Major rotamer (500 MHz, CDCl3) δ 10.26 (s, 1H), 8.01 (s, 1H), 7.83 (d, J = 8.3 
Hz, 1H), 7.69 (t, J = 7.2 Hz, 1H), 7.50 (dd, J = 23.6, 11.0 Hz, 2H), 7.32 – 7.26 (m, 2H), 7.07 (t, J 
= 9.3 Hz, 1H), 4.42 (d, J = 6.6 Hz, 1H), 2.22 (d, J = 6.7 Hz, 3H); 1H NMR Minor rotamer (500 
MHz, CDCl3) δ 10.07 (s, 1H), 8.01 (s, 1H), 7.83 (d, J = 8.3 Hz, 1H), 7.69 (t, J = 7.2 Hz, 1H), 7.50 
(dd, J = 23.6, 11.0 Hz, 5H), 7.32 – 7.26 (m, 4H), 7.07 (t, J = 9.3 Hz, 2H), 6.60 (d, J = 7.2 Hz, 1H), 
1.32 (d, J = 6.7 Hz, 3H).Ratio of rotamers is 2:1. 13C NMR (126 MHz, CDCl3) δ 184.37 (d, J = 
4.8 Hz), 162.64 (s), 160.21 (d, J = 251.8 Hz), 142.58 (s), 137.61 (s), 135.97 (s), 135.35 (s), 133.10 
(s), 132.77 (s), 132.70 (s), 131.30 (s), 130.78 (s), 126.65 (d, J = 11.8 Hz), 124.69 (s), 124.65 (s), 
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121.73 (s), 116.32 (d, J = 21.3 Hz), 53.08 (s), 19.97 (s); HRMS (ESI/IT-TOF) m/z: [M + H] Calcd 
for C19H14BrFN3O 398.0299, found 398.0310. 
 
2.2.7.67. (R)-5-(8-Bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diaze pin-3-yl)oxazole (GL-III-36, 78) 
 
The toluenesulfonylmethyl isocyanide (TosMIC, 1.6 g, 8.2 mmol), K2CO3 (3.12 g, 22.6 mmol) 
and the aldehyde 78 (3.0 g, 7.5 mmol) were placed in a dry two neck round bottom flask. Dry 
MeOH (200 mL) was added to the mixture under an argon atmosphere at rt. The reaction mixture 
was allowed to heat slowly to reflux for 3 h. After completion of the reaction on analysis by TLC 
(silica gel, DCM/EtOAc 3:2), the reaction mixture was quenched with cold water (200 mL) and 
additional saturated NaHCO3 solution (400 mL) was added, after which the mixture was then 
stirred for 30 min. Dilution and additional base is needed to further neutralize the tosic acid 
formed in the reaction and reduce the possibility of the conversion to the [C(4)-N(5)] imine-
migrated byproduct. The mixture was extracted with EtOAc (3 x 10 mL). The organic layers were 
combined and this was followed by washing with brine. The solution was then dried (Na2SO4) and 
concentrated under reduced pressure to dryness. The solid residue, which formed, was purified by 
flash chromatography (silica gel packed with DCM, eluent: DCM/EtOAc 3:2) to afford the bromo 
oxazole 64 as a white solid (2.7 g, 82 % yield): 1H NMR Major rotomer (500 MHz, CDCl3) δ 
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8.00 (d, J = 8.0 Hz, 1H), 7.94 (d, J = 19.8 Hz, 1H), 7.78 (d, J = 7.9 Hz, 1H), 7.65 (t, J = 6.8 Hz, 
1H), 7.54 – 7.43 (m, 3H), 7.39 (d, J = 23.7 Hz, 1H), 7.26 (t, J = 7.5 Hz, 1H), 7.06 (t, J = 7.9 Hz, 
1H), 4.39 (d, J = 6.7 Hz, 1H), 1.89 (d, J = 6.6 Hz, 3H); Minor rotomer: δ 8.00 (d, J = 8.0 Hz, 
1H), 7.94 (d, J = 19.8 Hz, 1H), 7.73 (d, J = 6.1 Hz, 1H), 7.59 (t, J = 6.5 Hz, 1H), 7.54 – 7.43 (m, 
3H), 7.39 (d, J = 23.7 Hz, 1H), 7.26 (t, J = 7.5 Hz, 1H), 7.06 (t, J = 7.9 Hz, 1H), 6.24 (d, J = 7.1 
Hz, 1H), 1.35 (d, J = 7.0 Hz, 3H). Ratio of major and minor rotomer 0.53:0.46. HRMS (ESI/IT-
TOF) m/z: [M + H] Calcd for C21H15BrFN4O 437.0408, found 437.0420. 
 
2.2.7.68. 5-(8-Bromo-6-(2-fluorophenyl)-4-methyl-6H-benzo[f]imidazo[1,5-a][1,4]diazepin 
-3-yl)oxazole (GL-III-36A/76A, 79) 
 
This achiral imine-migrated oxazole byproduct [C(4)-N(5)] was formed during the workup of the 
desired chiral oxazole 64 and was purified by the same flash column (silica gel, DCM/EtOAc 3:2). 
The yield of 79 was minimized by dilution of the reaction mixture with water and addition of more 
aq NaHCO3 solution. However, high temperature and strong acidic conditions resulted in the 
formation of this undesired byproduct 79, as a white solid (0.4 g, 12 % yield from the optimized 
reaction for 64).  The byproduct GL-III-76A from the reaction of the enantiomer 65 was found to 
be the same compound as 79, as expected. 1H NMR (500 MHz, CDCl3) δ 8.29 (td, J = 7.3, 2.0 
Hz, 1H), 8.15 (s, 1H), 8.00 (s, 1H), 7.57 (dt, J = 6.5, 3.2 Hz, 1H), 7.53 (s, 1H), 7.47 – 7.40 (m, 
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2H), 7.38 (d, J = 8.5 Hz, 1H), 7.17 – 7.07 (m, 1H), 6.97 (d, J = 1.7 Hz, 1H), 5.66 (s, 1H), 2.41 (s, 
3H). 13C NMR (75 MHz, CDCl3) δ 160.18 (d, J = 246.8 Hz), 158.92 (s), 150.81 (s), 145.65 (s), 
138.30 (s), 137.11 (s), 133.25 (s), 132.02 (s), 131.01 (s), 130.67 (d, J = 3.6 Hz), 129.95 (s), 129.71 
(d, J = 8.1 Hz), 126.00 (s), 125.77 (d, J = 8.8 Hz), 125.38 (s), 124.68 (d, J = 3.4 Hz), 123.54 (s), 
122.60 (s), 115.56 (d, J = 21.0 Hz), 58.07 (d, J = 3.2 Hz), 25.51 (s). HRMS (ESI/IT-TOF) m/z: 
[M + H] Calcd for C21H15BrFN4O 437.0408, found 437.0405. 
 
2.2.7.69. (R)-5-(6-(2-Fluorophenyl)-4-methyl-8-((trimethylsilyl)ethynyl)-4H-benzo[f]imida 
zo[1,5-a][1,4]diazepin-3-yl)oxazole (GL-III-72, 80) 
 
The oxazole 64 (1.4 g, 3.2 mmol) was dissolved in triethylamine (30 mL) and acetonitrile (50 mL). 
Trimethylsilylacetylene (0.63 g, 6.4 mmol) and bis(triphenylphosphine)-palladium (II) acetate 
(0.132 g, 0.18 mmol) were added to the solution. A reflux condenser was attached and the mixture 
was degassed under vacuum with argon; this process was repeated four times. The reaction mixture 
was heated to reflux under argon and stirred for 8 hours. The solution was cooled to rt, filtered 
through celite, and washed with EtOAc. The filtrate was concentrated under reduced pressure. The 
black residue, which resulted, was purified by a wash column (silica gel, DCM/EtOAc 3:2) to 
afford the TMS-oxazole 80 as an off-white solid (1.08 g, 74.4 %): the ratio of rotamers was 1:1. 
Rotamer 1: 1H NMR (300 MHz, CDCl3) δ 7.98 (s, 1H), 7.89 (d, J = 10.1 Hz, 1H), 7.71 – 7.47 
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(m, 3H), 7.34 (d, J = 12.7 Hz, 3H), 7.19 (t, J = 7.3 Hz, 1H), 6.98 (t, J = 8.2 Hz, 1H), 6.17 (d, J = 
6.7 Hz, 1H), 1.26 (d, J = 6.4 Hz, 3H), 0.18 (s, 9H). Rotamer 2: 1H NMR (300 MHz, CDCl3) δ 
7.98 (s, 1H), 7.89 (d, J = 10.1 Hz, 1H), 7.71 – 7.47 (m, 3H), 7.34 (d, J = 12.7 Hz, 3H), 7.19 (t, J 
= 7.3 Hz, 1H), 6.98 (t, J = 8.2 Hz, 1H), 4.31 (d, J = 6.2 Hz, 1H), 1.82 (d, J = 5.7 Hz, 3H), 0.18 (s, 
9H). 13C NMR (75 MHz, CDCl3) δ 163.30, 162.79, 161.92, 161.76, 158.58, 158.45, 150.50, 
149.85, 146.46, 145.62, 135.68, 135.43, 135.27, 134.72, 134.35, 134.14, 133.51, 133.17, 132.89, 
132.19, 132.09, 131.89, 131.77, 131.29, 131.11, 129.36, 129.16, 128.92, 128.77, 127.47, 127.37, 
125.90, 125.29, 124.45, 122.79, 122.72, 122.29, 121.95, 116.37, 116.09, 102.59, 97.22, 52.49, 




zepin-3-yl)oxazole (GL-III-73, 66) 
 
The intermediate 80 (722 mg, 1.59 mmol) was dissolved in THF (15 mL) and cooled to 0 oC. This 
mixture was then treated with tetrabutylammonium fluoride hydrate (1 M solution in THF, 2.38 
mmol), and this was followed by water (0.7 mL). The reaction mixture was stirred until the starting 
material was consumed as indicated by TLC (silica gel), about 20 min. The reaction mixture was 
allowed to warm to rt, and water (20 mL) was slowly added. The solution was extracted with 
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EtOAc and the organic extracts were combined, washed with brine, dried (Na2SO4), and the 
solvent was removed under reduced pressure. The residue which resulted was purified by a wash 
column (silica gel, EtOAc) to afford the pure 1,3-oxazole 66 as a white powder (591.5 mg, 97.4 %). 
1H NMR (300 MHz, CDCl3) δ 8.01 (s, 1H), 7.92 (d, J = 10.9 Hz, 1H), 7.69 (d, J = 11.3 Hz, 1H), 
7.58 (t, J = 9.9 Hz, 2H), 7.39 (t, J = 12.8 Hz, 3H), 7.24 (dd, J = 14.6, 7.5 Hz, 1H), 7.03 (t, J = 8.3 
Hz, 1H), 6.22 (d, J = 6.2 Hz, 0.5H), 4.37 (d, J = 5.3 Hz, 0.5H), 1.86 (d, J = 5.2 Hz, 1.5H), 1.32 
(d, J = 5.8 Hz, 1.5H). 13C NMR (75 MHz, CDCl3) δ 163.14, 162.68, 161.84, 158.49, 150.52, 
149.87, 146.43, 145.58, 135.72, 135.28, 134.74, 134.47, 134.00, 133.65, 132.86, 132.14, 131.96, 
131.27, 131.10, 129.33, 129.18, 128.82, 128.66, 127.44, 127.23, 125.90, 125.30, 124.47, 122.82, 
122.03, 121.64, 121.24, 116.31, 116.03, 81.45, 79.83, 52.48, 50.60, 18.67, 15.63. HRMS (ESI/IT-
TOF) m/z: [M + H] Calcd for C23H16FN4O 383.1303, found 383.1308. 
 
2.2.7.71. (S)-8-Bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diaze 
pine-3-carbaldehyde (GL-III-75, 81) 
 
The enantiomer 81 of 78 was synthesized as described in section 2.2.7.66., with the bromo ethyl 
ester 11 (7 g, 15.83 mmol) as the starting material and a solution of PDBBA (0.42 M in THF-
hexanes, 48 mL) in DCM (200 mL) to afford 81 (5.3 g, 84.1 %) 1H NMR Major rotamer (300 
MHz, CDCl3) δ 10.22 (s, 1H), 7.99 (s, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.64 (d, J = 7.0 Hz, 1H), 7.58 
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– 7.38 (m, 3H), 7.31 – 7.18 (m, 1H), 7.03 (t, J = 9.3 Hz, 1H), 4.39 (d, J = 6.5 Hz, 1H), 2.18 (d, J 
= 6.4 Hz, 3H). 1H NMR Minor rotamer (300 MHz, CDCl3) δ 10.03 (s, 1H), 7.99 (s, 1H), 7.80 
(d, J = 8.1 Hz, 1H), 7.64 (d, J = 7.0 Hz, 1H), 7.58 – 7.38 (m, 3H), 7.31 – 7.18 (m, 1H), 7.03 (t, J 
= 9.3 Hz, 1H), 6.56 (d, J = 6.2 Hz, 1H), 1.29 (d, J = 5.3 Hz, 3H). Ratio of major and minor 
rotamer: 2:1. Major rotamer 13C NMR (75 MHz, CDCl3) δ 184.46 (s), 162.81 (s), 162.60 (s), 
160.24 (d, J = 252.3 Hz), 142.41 (s), 137.70 (s), 135.91 (d, J = 16.8 Hz), 135.26 (s), 132.95 (d, J 
= 30.2 Hz), 132.75 (s), 131.26 (s), 126.68 (d, J = 16.2 Hz), 124.70 (s), 124.51 (s), 123.68 (s), 
121.72 (s), 116.32 (d, J = 21.3 Hz), 53.11 (s), 19.96 (s); HRMS (ESI/IT-TOF) m/z: [M + H] Calcd 
for C19H14BrFN3O 398.0299, found 398.0298. 
 
2.2.7.72. (S)-5-(8-Bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4]diaze 
pin-3-yl)oxazole (GL-III-76, 65) 
 
The enantiomer of 64 was synthesized as described in section 2.2.7.67., with the bromo aldehyde 
as the starting aldehyde 81 (4.5 g, 11.3 mmol), TosMIC (2.43 g, 12.43 mmol), and K2CO3 (6.25 g, 
45.2 mmol) in MeOH (250 mL) at reflux for 1.5 h to afford 81 (3.5 g, 71 %) and the byproduct 79 
(1.3 g, 26.3 %). 1H NMR Major rotamer (300 MHz, CDCl3) δ 7.98 (s, 1H), 7.92 (d, J = 8.6 Hz, 
1H), 7.71 (t, J = 10.9 Hz, 1H), 7.64 – 7.56 (m, 1H), 7.52 – 7.34 (m, 4H), 7.24 (t, J = 7.4 Hz, 1H), 
7.03 (t, J = 9.3 Hz, 1H), 4.37 (d, J = 6.1 Hz, 1H), 1.87 (d, J = 6.0 Hz, 3H). 1H NMR Minor 
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rotamer (300 MHz, CDCl3) δ 7.98 (s, 1H), 7.92 (d, J = 8.6 Hz, 1H), 7.71 (t, J = 10.9 Hz, 1H), 
7.64 – 7.56 (m, 1H), 7.52 – 7.34 (m, 4H), 7.24 (t, J = 7.4 Hz, 1H), 7.03 (t, J = 9.3 Hz, 1H), 6.22 
(d, J = 6.6 Hz, 1H), 1.33 (d, J = 6.3 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 162.62, 162.16, 161.80, 
158.58, 150.54, 149.90, 146.42, 145.55, 135.57, 135.42, 135.02, 134.63, 133.87, 133.68, 133.13, 
132.77, 132.33, 132.12, 131.26, 131.12, 130.79, 127.59, 127.21, 125.98, 125.45, 124.57, 124.30, 
123.47, 122.91, 121.03, 120.61, 116.41, 116.13, 52.56, 50.69, 18.89, 18.68, 15.68. HRMS 
(ESI/IT-TOF) m/z: [M + H] Calcd for C21H15BrFN4O 437.0408, found 437.0407. 
 
2.2.7.73. (S)-5-(6-(2-Fluorophenyl)-4-methyl-8-((trimethylsilyl)ethynyl)-4H-benzo[f]imida 
zo[1,5-a][1,4]diazepin-3-yl)oxazole (GL-III-77, 82) 
 
The enantiomer 82 of 80 was synthesized as described in section 2.2.7.69., with the bromo oxazole 
65 (2.9 g, 6.63 mmol) as the starting material, trimethylsilylacetylene (2.6 g, 26.5 mmol) and 
bis(triphenylphosphine)-palladium (II) acetate (0.54 g, 0.365 mmol) in triethylamine (60 mL) and 
acetonitrile (100 mL) at reflux for 1.5 h to afford the TMS-oxazole 82 as an off-white solid  (2.7 
g, 90 %): 1H NMR (300 MHz, CDCl3) δ 7.99 (s, 1H), 7.90 (d, J = 9.0 Hz, 1H), 7.72 – 7.47 (m, 
3H), 7.43 – 7.28 (m, 3H), 7.21 (t, J = 7.4 Hz, 1H), 7.01 (t, J = 9.1 Hz, 1H), 6.19 (d, J = 6.7 Hz, 
0.5H), 4.33 (d, J = 6.0 Hz, 0.5H), 1.84 (d, J = 5.5 Hz, 1.5H), 1.28 (d, J = 6.3 Hz, 1.5H), 0.20 (s, 
9H). 13C NMR (75 MHz, CDCl3) δ 163.29, 162.79, 161.86, 158.61, 150.50, 149.85, 146.45, 145.62, 
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135.65, 135.48, 135.27, 134.70, 134.38, 134.16, 133.54, 133.19, 132.91, 132.07, 131.87, 131.29, 
131.14, 129.39, 129.21, 128.94, 128.80, 127.48, 125.93, 125.36, 124.46, 122.73, 122.32, 121.94, 
116.39, 116.10, 102.59, 97.20, 52.52, 50.64, 18.70, 15.56, -0.26. HRMS (ESI/IT-TOF) m/z: [M + 
H] Calcd for C26H24FN4OSi 455.1698, found 455.1697. 
 
2.2.7.74. (S)-5-(8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-a][1,4]dia 
zepin-3-yl)oxazole (GL-III-78, 67) 
 
The S-enantiomer 67 of 66 was synthesized as described in section 2.2.7.70., with the TMS-
acetylene oxazole 82 (2.6 g, 5.72 mmol), tetrabutylammonium fluoride hydrate (1 M solution in 
THF, 8.58 mmol) in THF (100 mL) and water (2.5 mL) at 0 oC for 0.5 h to afford the ethinyl 1,3-
oxazole 67 as an off-white solid  (1.98 g, 91 %): 1H NMR (300 MHz, CDCl3) δ 7.99 (s, 1H), 7.90 
(d, J = 6.8 Hz, 1H), 7.68 (s, 1H), 7.55 (d, J = 8.3 Hz, 2H), 7.38 (dd, J = 12.0, 10.5 Hz, 3H), 7.21 
(t, J = 7.5 Hz, 1H), 7.00 (t, J = 9.2 Hz, 1H), 6.20 (d, J = 6.0 Hz, 0.5H), 4.35 (d, J = 5.8 Hz, 0.5H), 
1.84 (d, J = 5.0 Hz, 1.5H), 1.30 (d, J = 5.6 Hz, 1.5H);13C NMR (75 MHz, CDCl3) δ 163.15, 
162.72, 161.85, 158.49, 150.54, 149.89, 146.41, 145.60, 135.68, 135.53, 135.30, 134.72, 134.08, 
133.71, 132.91, 132.17, 131.98, 131.27, 129.27, 127.49, 125.97, 125.43, 124.50, 122.87, 122.03, 
121.67, 121.33, 116.58, 116.36, 116.07, 81.53, 81.48, 79.93, 79.71, 52.52, 50.65, 18.70, 15.66; 





2.3.1.  Introduction 
Asthma is well known as one of the most common long-term inflammatory, non-
communicable diseases, which affects about 334 million people globally.162 It is prominent in both 
adults and children of all ages, and is expected to reach a number of 400 million163 effected in a 
decade. It is diagnosed by variable and recurring respiratory symptoms, reversible airflow 
limitation, increased mucus production, as well as bronchoconstriction.164 The most common 
symptoms include wheezing, coughing, tightness or pain in the chest, and shortness of breath or 
trouble breathing.162, 164-165 Asthma can be triggered by the interactions of a series of genetic and 
environmental factors, such as allergens, irritants, exercise, occupational hazards, air pollution, 
smoke, airway infections, cold air, and medical uses. 162, 164-165 Less care or non-efficient control 
at an early stage can lead to the development of severe asthma, which can cause airway remodeling, 
increase in the intensity of airway inflammation. It might eventually develop into chronic 
obstructive pulmonary disease (COPD),162 which often can lead to death. In fact, because of the 
serious health concern and societal impact, the cost of asthma increases the economic burden daily, 
which grows steadily and is now up to about $56 billion annually in the US in 2011, and exceeds 
the total cost of AIDS and tuberculosis combined.166  
The choice of the most effective approaches for different asthma patients is a significant 
challenge. Numerous potential targets for new asthma treatments are emerging readily and still 
suffer from side effects since asthma is such a highly complex disease. The initiation of asthmatic 
inflammation can include multiple factors and pathological processes. For instance, allergens 
interact with macrophages, dendritic cells and mast cells, which can activate the CD4T 
lymphocytes at lymph nodes and lead to eosinophilia as a character of asthmatic inflammation. A 
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series of pathological effects result from this inflammation such as swelling of the bronchial wall, 
decreased lumen diameter, airway remodeling, infiltration of immune cells, mucus overproduction, 
goblet cell hyperplasia, ASM thickening, and contracting (see Figure 71 for the structural 
comparison of normal and asthmatic bronchial walls).163, 167-170 This complex development of 
asthma contains several pathways, mediators, inflammatory cells and proteins, which provide 
different targets for different therapies based on the patient’s condition.  
 
Figure 71. Anatomic structure of the normal and asthmatic bronchial wall. The asthmatic bronchial wall 
exhibits a series of pathological effects such as swelling, decreased lumen diameter, airway remodeling, 
infiltration of immune cells, mucus overproduction, goblet cell hyperplasia, ASM thickening, and 




Unfortunately, current treatments for asthma do not cure the disease completely, but 
alleviate the symptoms and achieve only some control, and in other patients very poor control. 
This can lead eventually to COPD and death, as mentioned above. Bronchodilators, particularly 
β2-adrenergic agonists, are the mainstay for relieving bronchoconstriction. Later, the anti-
inflammatory medications, such as corticosteroids, have been used for the treatment of asthma 
after the identification of airway inflammation as one of the critical causes of asthma. Depending 
on the severity of asthma, the pharmacological treatment is stepwise162 according to the Global 
Initiative for Asthma (GINA): step1, using short-acting β2 agonists (SABA) as bronchodilators, 
such as salbutamol (Figure 72), for quick symptom relief. Step 2, a regular low dosage of inhaled 
corticosteroid (cortisol, see Figure 72) with the combination of SABA for better control of 
symptoms. Step 3, a low dosage of an inhaled corticosteroid as an anti-inflammatory agent together 
with a long-acting β2 agonist (LABA), such as salmeterol (Figure 72). This is for patients with 
uncontrolled symptoms due to poor adherence, improper use of inhalers, and comorbidities.  Step 
4, the medium dosage of an inhaled corticosteroid together with LABA for the uncontrolled 
asthmatic with the other variables listed above addressed. Step 5 (or severe asthma), in addition to 
a high dosage of corticosteroid and LABA, specific injectable biologic therapies162, 171 and other 
add-on therapies such as muscarinic antagonists,172 leukotriene receptor antagonists,173 
theophylline,174 immunosuppressants,175 and bronchial thermoplasty176 can be considered for 
treatment. Although a series of emerging therapies have been approved over the years, 
patients with severe asthma respond poorly to the current therapies, moreover, long-term 
use and overuse of the medications cause numerous detrimental effects such as diabetes, 
cataracts, cardiovascular dysfunction, suppression of growth of children, CNS effects, etc.162, 
164-165, 171-176 Therefore, there is an urgent unmet need for novel treatments for asthma that can 
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reduce inflammation, and mitigate the breathing problems with limited or no CNS side effects, 
cardiovascular issues or other side effects. 
 




A large amount of pharmacological, and biochemical evidence has been identified, which 
indicates GABAARs are not restricted to the brain and spinal neurons but are also found in the 
peripheral tissues and cells, such as the liver, heart, and lung.1 An early study indicated that 
GABAARs expressed in the lung were associated with the inhibition of cholinergic outflow,
177-178 
which supports the muscle relaxant effects for asthma.  However, there was not enough evidence 
to fully illustrate the specific location and function of GABAARs in the lung tissue. Over the past 
few years, the expression of GABAARs in the lung has attracted broad interest in the search for 
alternative treatments for asthma. It was first reported by the research group of Dr. Charles Emala 
that functional α4-, α5-, β3- and γ2- GABAARs subtypes were expressed in the airway smooth 
muscle (ASM) in native human lungs and guinea pigs. The activation of GABAAR enhanced the 
β-agonist-regulated relaxation through calcium-activated potassium channels of both 
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precontracted ASM of human and guinea pig tracheal rings determined from organ bath studies.56, 
179-181  
In particular, evidence from Dr. Emala and others has shown that GABAARs expressed in 
the airway epithelium mediated the mucus overproduction,182 which may be a detrimental effect 
for using GABAAR agonists to reduce ASM contraction. However, this mucus production was not 
mediated by α4β3γ2 or α5β3γ2 subtypes. Consequently, a balance of reduction of ASM contraction 
and inflammation, in the absence of over-excreting mucus, and the immune response should all be 
considered and emphasized in regard to the use of GABAergic signaling for the treatment of 
airway dysfunction and diseases, such as asthma. It must be emphasized that the subtypes that 
were found in the airway epithelium were β2-, β3- and π-containing GABAAR,
182 whereas the 
subtypes in ASM are α4, α5, β3, and γ2.180 Even if the β3 subtypes are expressed in both epithelium 
and ASM, the amount of its total receptor composition is much less than other subtypes. This 
balancing issue can be addressed by the design of subtype selective ligands for GABAARs that 
only interact with the subtypes in ASM to achieve ASM relaxation and decrease inflammation, but 
not induce an additional immune response or mucus overproduction. In this vein, PAMs for 
Bz/GABAAR, especially an α4- or α5-subtype selective PAMs appear to be promising drug targets 
for asthma. This is not only because of their ability to increase ASM relaxation, but also because 
IMDZ ligands only bind at the interface of α and γ subunits, which eliminates the possible 
activation of the β2/3- and π-containing GABAAR pathway in the airway epithelium. This provides 
a potential therapy by using these α4- or α5 PAMs as improved bronchodilators or pills for asthma 
patients by targeting only ASM in the lungs, but not interacting with the subtypes in the brain to 
avoid CNS side effects nor the other subtypes in the epithelium to decrease the chance of an 
immune response and mucus production. 
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Over the last few years, the research on α4- or α5-subtype selective ligands for their SAR 
on ASM has been ongoing and produced a series of important results in regard to the development 
of novel treatments for asthma. Two α4 PAMs, XHe-III-74 and CMD-45 (Figure 73), were shown 
to exhibit the ability to relax the precontracted tracheal rings from guinea pig,179 wild-type mouse, 
and human ASM at low doses.183 These results were further confirmed when XHe-III-74 reduced 
the acute bronchospasm by inhalation in an in vivo murine asthma model of house dust mite (HDM) 
sensitization. This provided a direct approach to target only the lungs and limit the CNS effects 
due to systematic drug absorption.183 A series of analogs of XHe-III-74 were later developed184-185 
to improve the PK profile and avoid side effects from the binding and efficacy of ligands at the 
GABAAR in the CNS. Two of the other two analogs, XHe-III-74EE and XHe-III-74A (Figure 73), 
alleviated the asthmatic symptoms such as inflammation, ASM contraction, airway eosinophilia, 
airway hyperresponsiveness (AHR) and mucus overproduction, partially.185  
 
Figure 73. The structures of the α4 selective ligands, CMD-45, XHe-III-74, XHe-III-74EE (ethyl ester) and 
XHe-III-74A (acid). 
 
In addition to the α4-subtype selective ligands for bronchorelaxation, targeting the α5β3γ2-
containing receptors in the ASM in the lungs was investigated as well simultaneously. The 
question to answer was whether the α5 PAMs have a similar capacity to affect ASM relaxation as 
the α4 PAMs did since both α4 and α5 subtypes are expressed in human ASM. The first α5 PAM 
that was evaluated for effects on ASM relaxation was 1 (SH-053-2'F-R-CH3), an α5 subtype 
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selective ligand83 with a chiral (R)-methyl group at the C(4) position. This ligand alleviated the 
bronchoconstriction of precontracted ASM in both human ASM strips and guinea pig tracheal 
rings.58 However, the ethyl ester 1 exhibited mild sedation at 200 mg/kg, which was due to 
activation of other BZD subtypes at the higher dose.121 This was predictable since the ligand was 
originally designed to cross the BBB for CNS effects18, 67 in the studies of treatment of other 
diseases such as schozophrenia95-96 and MDD.97 Despite the insignificant CNS effect of 1, the 
effect on ASM relaxation provided a direction for further ligand design. This strategy was to 
maintain the backbone the “privileged structure” of 1 and the R-chirality, but modify other moieties 
on the molecule in order to avoid penetration through the BBB and minimize the possible 
unwanted CNS effects.  
For this purpose, a series of structurally related ligands,  Hz-166 (76), SH-I-048A (10) and 
α5 subtype selective ligands (Figure 74) SH-053-2'F-R-CH3 (1), SH-053-2'F-R-CH3-acid (68), 
MP-III-004 (83), MP-III-058 (84), were synthesized and evaluated for their electrophysiological 
GABAAR response in Xenopus laevis oocytes (unpublished results, Figure 75) and the effect on 




Figure 74. The structures of Hz-166 (76), SH-I-048A (10) and α5 subtype selective ligands SH-053-2'F-R-CH3 
(1), SH-053-2'F-R-CH3-acid (68), MP-III-004 (83), MP-III-058 (84), that were evaluated in an organ bath assay 
for the effect of bronchorelaxation on guinea pig tracheal rings, and the study of electrophysiology.  
 
As previously described, Hz-166 (76) is an α2/3 subtype selective ligand, which was used 
as a control for it was felt it would not induce ASM relaxation effects due to its very low efficacy 
at α5 subtypes. This was confirmed by the organ bath study; that there was no significant relaxation 
observed with 76, as compared to the vehicle EtOH. The BZD so-called “super-agonist” SH-I-
048A (10) contained the opposite chirality at the C(4) position did potentiate GABAAR response 
at all α1-3,5 subtypes. Because of the high efficacy at α5 subtypes of 10, it exerted the best effect 
on ASM relaxation. No further PK studies were done for this compound. This was because Dr. 
Savic showed 10 was sedating and ataxic, and did penetrate the BBB.186 The structure of 10 was 
very close to diazepam, and some of the CNS effects induced by 10, were not unexpected. The 
carboxylic acid of the ethyl ester, SH-053-2'F-R-CH3-acid (68), was the best α5 subtype preferring 
compound up to this point; however, it only exhibited moderate ASM relaxation and was similar 
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to the parent ethyl ester 1. The methyl ester analog MP-III-004 (83) of the ethyl ester 1, and the 
C(8)-bromo methyl ester MP-III-058 (84) shared a similar efficacy profile; they were α5 subtype-
selective, but both were less potent than the parent compound 1 at 100 nM. The C(8)-ethinyl 
methyl ester 83 improved the effect on ASM relaxation only a small amount, as compared to 1. 
However, the C(8)-bromo methyl ester 84  was shown to exhibit a significant muscle force 
reduction (ASM) almost as potent as the non-selective super-agonist 10.  
 
Figure 75. The oocyte efficacy of the Hz-166 (76), SH-I-048A (10), and the α5 subtype selective ligands. 
Concentration curves on GABAAR using an EC3 GABA concentration (n = 3 – 5). (Unpublished results from 





Figure 76. The results of Hz-166 (76), SH-I-048A (10) and α5 subtype selective ligands on the airway muscle 
relaxation effects from the precontracted guinea pig tracheal rings induced by substance P (1 µM). This was 
followed by vehicle (0.1% EtOH) or a test ligand (50 µM) in an organ bath, and the muscle force was measured. 
** and *** represent p< 0.01 and 0.001 as compared to vehicle control, respectively; $$$ p< 0.001 compared to 
SH-053, n = 6-17. SH-053 = SH-053-2'F-R-CH3; SH-053 Acid = SH-053-2'F-R-CH3-acid. (Unpublished results 
from the Ph. D. thesis of  M. Poe, in collaboration with Dr. Ernst’s group)120 
 
A PK study was carried out by Dr. Arnold, and the study demonstrated that three esters 1, 
83 and 84 all penetrated the BBB, whereas the acid 68 was almost non-detectable in samples from 
rodent brain. It should be noted that the ester function will be hydrolyzed in the liver or blood by 
esterases to rapidly produce the acid as a metabolite, which indicated these esters could be used 
for the treatment of asthma since they will be, presumably, metabolized to the active acid. On the 
other hand, acid 68 will not exhibit CNS effects due to its high hydrophilicity. It has been shown 
not capable of passing through the BBB. In addition to low penetration into the brain, the acid 68, 
which possessed good stability from PK studies and could potentially be administrated by oral 
administration.99 This will be discussed in a later section. This acid could provide a better α5-
preferring target for the treatment of asthma than the esters in regard to the reduction of CNS 
effects and both preferred routes of administration (aerosol and oral) to lower the possibility of 




2.3.3. Chemistry and Results 
Based on the results of SH-053-2'F-R-CH3 (1) and previously made analogs, SH-053-2'F-
R-CH3-acid (68) and MP-III-058 (84) were resynthesized for follow-up experiments, such as PK 
studies, and studies of the mechanism of action of IMDZs in models of asthma.99 Subsequentially, 
the novel analogs of 68: GL-II-93 (85), GL-III-43 (86), GL-III-54 (87), GL-IV-14 (88), and 
tetrazoles were designed, synthesized and evaluated. From this study acid GL-II-93 (85) exhibited 
the highest efficacy on ASM relaxation ex vivo and significantly reduced AHR in vivo to nearly 
the control level.187-188 Most importantly, CNS effects, which are always a significant concern for 
current asthma treatments, were not observed for GL-II-93 (85) in a long term study at high 
dosages on the rotarod and PK studies. Importantly, with acid 85, (administrated orally), no mucus 
overproduction187 or any adverse immunotoxicological effects in mice on oral administration were 
observed. These effects will be discussed in detail in the following sections.189 This evidence, 
taken together, suggested acid 85 was a very promising orally active drug candidate for the 
treatment of asthma. Due to its high efficacy of the desired pharmacological effects, this ligand 85 
is being investigated further as regards to phase I and II metabolites. Here the sodium salt form of 
acid 85 [GL-IV-18 (89)] and the open-ring form of acid 85 [GL-IV-19 (90)] from hydrolysis of 
the [C(6)-N(5)] imine bond are being studied as well.  
 
2.3.3.1. SH-053-2'F-R-CH3-acid (Follow-up Experiments) 
Both SH-053-2'F-R-CH3-acid (68) and MP-III-058 (84) exhibited the capacity to reduce 
precontracted ASM, as previously described. The acid 68 was chosen to study further due to the 
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concern for CNS effects of 84. Although, the methyl ester 84, at that time, exhibited the most 
significant effect on ASM relaxation.  
The synthesis of SH-053-2'F-R-CH3-acid 68 
99 was presented in the first part of this 
dissertation. As compared to the parent compound 1, the acid analog 68, significantly improved 
the metabolic stability of this series and also reduced AHR and inflammation with no side CNS 
effects. These studies were not carried out with the ethyl ester 1 because this ligand exhibited CNS 
effects at higher dose, which were not tested in 1 before, at which dose level it did not elicit any 
CNS effects, as compared to data in Table 20.  
Table 20. Comparison of the essential pharmacological features of SH-053-2'F-R-CH3 (1) and SH-053-
2'F-R-CH3-acid (68).99 
Code number SH-053-2'F-R-CH3 (1) SH-053-2'F-R-CH3-acid (68) 
Structure 
  
Microsomal stability Poor Good 
PK Poor Good 
CNS effects at high doses Yes NO 
Smooth muscle relaxation Yes Yes 
AHR Not determined Reduced 
Inflammation Not determined Reduced 
 
 
In order to further study the ability of SH-053-2'F-R-CH3-acid 68 to relax the precontracted 
ASM, two asthma models were employed: the acetylcholine (ACh)-induced human ASM model 
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and the substance P-induced tracheal ring contraction in a guinea pig model. These experiments 
were carried out by Dr. Emala’s research group, at Columbia University. In the first model, human 
tracheal ASM strips were precontracted by ACh at an EC50 concentration and then treated with 50 
uM of acid 68. The muscle force was then measured and recorded at four-time points: 15, 30, 45 
and 60 minutes. Examination of the results indicated that the acid exhibited a time-dependent ASM 
relaxation response and it significantly reduced the muscle contractions after 15 min, as depicted 
in Figure 77A. In the second model, the tracheal rings of the guinea pig were pre-treated with a 
contractile agent, substance P, to induce muscle contraction. The acid 68 was applied at different 
concentrations after the contraction, and the muscle force was then measured and recorded. From 
a study of the data, the acid exerted a dose-dependent response and significant muscle relaxation 
on ASM was observed at 50 μM in the presence of the acid 68, as shown in Figure 77B. 
 
Figure 77. The contractile force of ASM measurement in the presence of 68. (A) The human tracheal airway 
smooth muscle strips were contracted with an EC50 concentration of acetylcholine (Ach) and then treated with 
100 μM of the acid 68 or the vehicle 0.2% ethanol. The muscle force was measured at 15, 30, 45, and 60 minute 
time points after addition of 68. The percent of the initial Ach-induced contractile force was presented as shown. 
Individual muscle strips were used from at least seven humans. (B) Guinea pig tracheal rings were contracted 
with 1 μM substance P and then treated with different concentrations of 68. The percent of remaining 
contractile force was measured at 30 min and expressed as compared to the initial substance P-induced 
contractile force as a percent of control (N = 3). *, ** and *** represents p < 0.05, p < 0.01 and p < 0.001, 
respectively, as compared to the vehicle control. (Modified from the figure in Forkuo et al.)99  
 
Since airway hyperresponsiveness (AHR) represents an important feature of asthma, the 
experiment to test the ability of the acid to reduce AHR was conducted by measuring the specific 
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airway resistance (sRaw), which was carried out by Dr. Arnold’s research group (Gloria Forkuo), 
at UWM. Ova s/c mice were treated with the acid 68 at 100 mg/kg orally twice daily for 5 days 
during the challenge period. Mice were exposed to increasing concentrations of aerosolized 
methacholine, which led to bronchoconstriction and was used for the challenge test to assess the 
sensitivity of lung function. Then the AHR to methacholine at 1 minute was measured and recorded. 
As shown in Figure 78, the acid exhibited a decrease of sRaw, and successfully protected the 
animal against the AHR challenged by methacholine. The effect was significant at a high dosage 
(6.25 and 12.5 mg/mL) of the acid 68, which almost brought the sRaw value down to the control 
level. 
 
Figure 78. Effect of 68 on AHR. The sRaw was measured at an increasing dose of MCh by a DSI’s Buxco 
FinePointe noninvasive airway mechanics instrument. Ligand 68 was orally administered in ova s/c BALB/c 
mice at 100 mg/kg twice daily for 5 days. Data represent mean ± SEM (n=10). *, **, and *** represents 
significance p < 0.05, p < 0.01, and p < 0.001, respectively, as compared to the vehicle control. a5-acid = 68 
(Modified from the Figure in Forkuo et al.)99 
 
A good pharmacokinetic (PK) profile is a crucial factor for any drug candidate. It illustrates 
how the drugs affect organs and vice versa and give information on distribution, absorption, 
metabolism, and excretion, as well as optimization of the dosage of the medication. The PK 
analysis data of the acid at 25 mg/kg via oral gavage is illustrated in Figure 79, which was carried 
out by Dr. Arnold’s research group (Revathi, Kodali), at UWM. The acid was well absorbed and 
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distributed with a Tmax of 60 min both in blood and lung AUC = 2648.9 and 1687.7 ug*min/g, 
respectively. The Cmax in blood and lung are high and similar. Moreover, the half-life of the acid 
is significantly longer in blood, about 15 h, and can still be detected after 8 h in both lung and 
blood. Most importantly, there is almost no detection of the acid in the brain, which indicated a 
perfect PK profile for an asthma drug candidate, which limits CNS effects with little or no 
distribution in the brain. To further confirm there were no CNS effects, the acid 68 was 
administrated orally at 100 mg/kg to mice on a rotarod. Their performance on the rotarod was 
recorded at 10, 30 and 60 min after the drug treatment, and diazepam was used as a negative control. 
This was carried out by Dr. Arnold’s research group (Nick Zahn), at UWM. The results indicated 
there was no sedation nor ataxia observed, as shown in Figure 80, which correlated with the PK 
data and confirmed the lack of CNS effects of orally administrated SH-053-2'F-R-CH3-acid (68).  
 
Figure 79. The pharmacokinetic data of 68 in blood, lungs, and brain in mice. The time-dependent systemic 





Figure 80. The effect of 68 on sensorimotor coordination in vivo. The Swiss Webster mice received a single 
intragastric gavage of the ligand at 100 mg/kg or diazepam (5 mg/kg i.p.) and were placed on a rotarod at 15 
rpm for 3 minutes, and the performance was recorded after 10, 30 and 60 minute time points of drug 
administration. A fail was assigned to a mouse if they had fallen twice within 3 minutes. The latency to fall is 
presented as mean ± SEM (n = 9). The vehicle was used as the negative control, and diazepam as the positive 
control. a5-acid = 68. (Modified from the Figure in Forkuo et al.)99 
 
In addition to the assays above for the acid, this key α5-agonist did not increase mucus 
production,99 which is also a detrimental pharmacological feature of asthma. However, importantly 
this α5 PAM did not significantly affect the CD4+ T cell response in broncho-alveolar lavage fluid 
(BALF) or the ex vivo response of current change.99 The reason for no response may be due to the 
lack of α5 subtype expression in those immune cells,190-191 or it might be because of other possible 
inflammatory signals. Consequently, the exact mechanism remains unclear.  
To summarize the effect99 of the acid SH-053-2'F-R-CH3-acid (68): it reduced AHR, 
relaxed ASM ex vivo,  exerted no observed CNS effects in vivo, exhibited a good PK profile, was 
an α5 subtype selective ligand, and was active against the effects of asthma in vivo. This key α5-
GABAAR agonist acid is the first orally active asthma drug candidate from MIDD and was further 




2.3.3.2. GL-II-93 (MIDD0301) 
2.3.3.2.1. Development and Synthesis  
As previously demonstrated, it was discovered that a PAM of the α5-GABAAR, SH-053-
2'F-R-CH3-acid (68), which exhibited the best α5 efficacy
99 among a library of over 650 IMDZ 
ligands,18, 67 exhibited no CNS side effects. This was possible for this ligand did not penetrate the 
BBB and had a very good PK profile for a drug candidate for asthma.99 However, the relaxation 
of contracted ASM only reached a moderate level. Meanwhile, another PAM of the α5-GABAAR, 
MP-III-058 (84), exerted a better effect on ASM relaxation, as compared to 68, but the α5 efficacy 
was not as potent as 68. Moreover, the methyl ester 84 induced mild CNS effects, which 
disqualified it for an orally active asthma drug, but the presence of the C(8)-bromo group and the 
increased relaxation on ASM was significant, even though the C(8)-bromo analogs are normally 
sedating similar to diazepam. 
In order to design a better ligand that retains the desired properties but reduces or avoids 
the drawbacks from the previously made ligands, it was critical to take an in-depth look at the SAR 
of the active ligands. From a structural point of view, when one functional group was altered at a 
time, it was clear that the ester and carboxylic acid function at the C(3) position did not improve 
the ASM relaxation effect significantly (see Figure 81 for a combined ASM Figure). However, the 
acid function remarkably increased the α5 subtype selectivity and efficacy as compared to both the 
ethyl and methyl esters (Figure 75 for efficacy). Furthermore, this acid 68 was hydrophilic and did 
not cross the BBB for CNS interactions. This is a fundamental PK feature required for these asthma 
drugs. Consequently, the carboxylic acid function should be taken into consideration during ligand 
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design to prevent CNS activity. Notwithstanding the acid function, comparison of the substituents 
at the C(8) position of the SH-series for example 83 and 84, there was no perceptible difference 
efficacy-wise between these ligands. However, the C(8)-bromo ligand 84 significantly improved 
the relaxation effect on precontracted ASM, whereas the C(8)-ethinyl ligand 83 exhibited only a 
moderate effect. According to this difference, the bromine atom at the C(8) position appeared to 
exhibit a critical role for the purpose of better relaxation of pre-contracted ASM.  
From an examination of the SAR, efficacy, and biology of the compounds above, it was 
deemed essential to keep the C(3)-carboxylic acid function and the C(8)-bromo substituent in the 
backbone of the IMDZ structure for future ligand design. Based on this hypothesis, MIDD0301 
(85), originally termed GL-II-93, and a series of its analogs were designed, synthesized, and 
evaluated. Accumulative evidence187-189 confirmed this hypothesis was rational for the design of 
ligands for asthma. Gratifyingly, it turns out that 85 is the best orally active asthma compound 
developed, to date (Figure 81). The performance of this compound in various in vitro studies and 
in vivo animal assays is presented in detail in the following sections.  
 





The synthesis of GL-II-93 (85) was straight forward in high yield (Scheme 15) by 
hydrolyzing the C(8)-bromo ethyl ester SH-I-47 (6),82, 120 which was the intermediate in the 
synthesis of the parent compound 1. The reaction was conducted in ethanol with sodium hydroxide 
under refluxing conditions. The reaction progress was monitored by TLC (silica gel). After 
removal of the solvent, the acid precipitated out of solution after acidifying with an aqueous 
solution of hydrochloric acid. The precipitates, which formed, were filtered and were then washed 
with water. The remaining organic impurities can be washed away with ethyl acetate.  
 
Scheme 15. Synthesis of GL-II-93 (85).  
 
2.3.3.2.2. Efficacy on α1-5 GABAAR Subtypes and Receptor Binding 
It was imperative to determine if GL-II-93 (85) exhibited good efficiency and selectivity 
for GABAARs. In order to answer this question, electrophysiological recordings were performed. 
Mammalian clones of GABAARs with β3 and γ2 in addition to the indicated α subunits were 
transiently transfected into the HEK-293T cells, and voltage-clamp recordings were used to 
measure the currents in response to two concentrations of 85 (0.1 and 1 μM) and GABA (EC3-5). 
The whole-cell configuration was carried out by Dr. Janet Fisher’s research group, University of 
South Carolina School of Medicine. As illustrated in Figure 82, acid 85 as highly effective at 
potentiating GABAAR subtypes, however, it is only slightly selective at α4 subtypes at a lower 
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concentration and did not show subtype selective efficacy at 1 μM. Thus, by changing the C(8) 
acetylene function to a bromine atom overall, this resulted in the loss of selectivity in this molecule, 
but improved the efficacy at the other subtypes, as compared to acid 68. On the other hand, 
comparison of the efficacy of 85 regardless of the substituents at C(8) resulted in an increase of 
the efficacy at α1-4 subtypes. Overall, despite the enhancement at the α1-4 subtypes, the α5 
selectivity was decreased only in comparison with acid 68. The efficacy of 85 at the α5 subtypes 
is actually improved, as compared to other ligands in the same 2'F-R-CH3 series. Based on the 
results of the electrophysiology, the bromo acid 85 did potentiate α1-containing GABAARs. This 
could become a significant concern for asthma drugs for the binding at the α1 subtype would result 
in CNS side effects. Fortunately, the α1 subtypes are not expressed in lung.57-58, 180-181 Furthermore, 
by design, 99   this carboxylic acid 85 did not pass through the BBB negating any possible GABA-
mediated  CNS pharmacological effects. This data will follow in the section on PK. At this point, 
the bromo acid 85 exhibited high efficacy at both α4 and α5 subtypes both of which are found in 
the lungs and might be the reason for the more potent ASM relaxation for GL-II-93 (85).  
 
Figure 82. The potentiation of GL-II-93 (85) at α-containing GABAARs. The transiently transfected HEK-293T 
cells with α subunits with β3 and γ2L subunits of GABAAR were used to measure the average enhancement of 
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current evoked to GABA by 0.1 μM or 1 μM 85 by patch clamp. Data represented mean ± SEM (n = 5). 
(Adopted from the figure in Forkuo et al.)187 
 
At present, it appears that GL-II-93 (85) acts through GABAARs. In order to determine if 
any other receptor interactions with acid 85 would occur throughout the body, the ligand was sent 
to the National Institute of Mental Health (NIMH) Psychoactive Drug Screening Program (PDSP) 
for screening on a series of CNS receptors, ion channels, and transporters to determine any other 
possible receptor interactions.137 The primary binding assay was conducted first to determine if 
there was any significant inhibition (over 50%), which PDSP would consider as a hit and be further 
tested in the secondary binding assay to obtain a Ki (nM) value. As shown in Table 21, 85 only 
bound at the BzR rat brain sites, as expected, with 72.5% inhibition in the primary binding assay 
and a Ki = 86 nM from the secondary binding assay. The binding affinity to the rat brain 
homogenized BzR sites was expected for it contains a mixture of all Bz/GABA(A) receptors. As 
requested, the secondary binding assay was also employed for the binding to both hERG and 
peripheral benzodiazepine receptors (PBR) for an accurate Ki value to eliminate possible heart 
issues and cholesterol disruptions. The ligands exhibited a deficient inhibition for hERG and PBR 
from the primary binding assay, 2.8% and -19.9% (negative value only represents stimulation of 
binding), respectively. From the secondary binding assay, the Ki value for hERG and PBR 
was 8223.3 nM and over 10000 nM, respectively, which indicated very low or no binding 
interaction at hERG or PBR. This was extremely important in drug design for asthma. 
Table 21. Primary and secondary binding assay for GL-II-93 in a panel of CNS receptors, channels, and 











5-HT1A 10.1   GABAA a6     
5-HT1B 28.4   GABAB     
5-HT1D 32.7   GPCRome     
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5-ht1e 3.2   H1 -5.4   
5-HT2A -4.7    H2 10.7  
5-HT2B 6.2   H3 -13.3   
5-HT2C 8.1   H4 26.2  
5-HT3 0.3   HCA2     
5-HT4      HERG     
5-ht5a 





5-HT6 2.4   Imidazoline 1     
5-HT7 6.5   KA     
A1      KOR -9.1   
A2      M1 -7.3   
A2A      M2 -4.1   
A2A mouse      M3 -1.9   
A2B      M3D     
A2B2      M4 -5.6   
A2B4      M4D     
A3B2      M5 -4.6   
A3B4      mGlur2     
A4B2      mGluR3     
A4B2**      mGlur4     
A4B4      mGlur5     
A7 
     
mGluR5_Guinea 
pig     
A7** 
     
mGluR5_RatBrai
n     
Alpha1A -4.9    mGlur6     
Alpha1B 14.3   mGluR7     
Alpha1D -9    mGluR8     
Alpha2A -18.2    MOR -0.3   
Alpha2B -14.1    NET 2   
Alpha2C -16.2    NK-1     
AMPA      NMDA 20.2  
AT2      NOP     
B2      NR2B     
Beta1 -16    NTS1     
Beta2 -9.1    NTS2     
Beta3 -3.8    Oxytocin -1   
BZP Rat Brain 
Site 72.5 86  
P2RY12 
    
Calcium 
Channel 13.4   
PBR 
-19.9  >10,000 
CB1      PKCalpha     
CB1 H      PKCbeta     
CB2      PKCdelta     
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D1 4.4   PKCepsilon     
D2 14.8   PKCgamma     
D3 -3.5    SERT 26.1  
D4 -8.2    Sigma 1 11.2  
D5 2.4   Sigma 1 GP     
DAT -15.9    Sigma 2 1.6  
DOR -13.4    Sigma 2 PC12     
EP2      Sodium Channel     
EP3      V1A 19.6  
EP4      V1B -1.5   
GABA a1      V2     
GABAA 12.7   VMAT1     
GABAa a2      VMAT2     
GABAa a3      Y2     
GABAa a5            
The data represent mean % inhibition (N = 4) for the tested compound at receptor panels. Significant inhibition 
is considered > 50 %. Negative inhibition (-) represents stimulation of binding. Occasionally, compounds at 
high concentrations will increase binding affinity non-specifically. The default concentration is 10 uM for the 
primary binding assay. Data represented as Ki (nM) values, which were obtained from non-linear regression 
of radioligand competition binding isotherms. The Ki values were calculated from best fit IC50 values by using 
the Cheng-Prusoff equation. A * next to a value number represents IC50. Green indicates 1° Assay <50%.137  
 
2.3.3.2.3. Pharmacokinetic Study, CNS Exposure as well as Cytotoxicity 
Since the acid GL-II-93  (85) is structurally similar to SH-053-2'F-R-CH3-acid (68), it was 
possible to predict a similar PK profile for both ligands. Indeed, this was confirmed by a 24 hour-
period PK study in mice at a dose of 25 mg/kg of acid 85 on oral administration, see Figure 83. 
The experiment was carried out by Dr. Arnold’s research group (Revathi, Kodali), at UWM. The 
compound was well absorbed within 40 min (Tmax) in both blood and lung. The Cmax of 85 was 
higher in blood than lung, with 8.24 vs 4.39 μg/g, respectively. The area under the curve (AUC) 
indicated that the distribution of the 85 was good in blood with 2807.1 μg*min/g and with 1390.5 
μg*min/g in the lung. The elimination rate of the compound was very slow in the blood, slightly 
faster in the lung, at 0.001 and 0.003 min-1, respectively. This led to a relatively long half-life of 
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836 min or 34.8 hours in blood than lung of 234 minutes or 9.8 hours, respectively. This was still 
a very good profile for GL-II-93 (85).  
 
Figure 83. The pharmacokinetic data of GL-II-93 (85) in blood, lungs, and brain in mice. The time-dependent 
systemic distribution of GL-II-93 was determined at 25 mg/kg via oral gavage. (Adopted from the figure in 
Forkuo et al.)187 
 
Examination of the in vitro microsomal stability study indicated (see Table 22) that acid 
85 was much more stable in human liver microsomes (HLM) than in mouse liver microsomes 
(MLM), with a half-life of 64 and 23 hours, respectively (Table 22). The percentage of 85 
remaining in HLM was 91% after 2 hours incubation, whereas it was only 83% in MLM. The 
metabolism rate was much slower in HLM than MLM, with 0.9261 and 2.624 nmol/min/mg, 
respectively. This is to be expected since mice liver enzymes are up-regulated (“they eat garbage”), 
and their metabolic rate is also faster than humans. In addition, from the examination of the data 
in Table 23, the plasma protein binding of 85 was 88.25% in the mouse, which was carried out by 
Dr. Arnold’s research group (M. S. Rashid Roni), at UWM. 
Table 22. Summary of microsomal stability studies for GL-II-93.  
GL-II-93 (85) HLM MLM 
Half-life (min) 1546 ± 501 549 ± 81 
Vd (μL/mg) 2000 2000 
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Internal Clearance (μL/min/mg) 0.0463 0.1312 
Metabolic Rate (nmol/min/mg) 0.9261 2.624 
% remaining at end of 2 hrs. (%) 91 ± 0.25 83 ± 0.20 
The acid GL-II-93 was incubated with human liver microsomes (HLM) or mouse liver microsomes (MLM) for 
30 min at 37 oC at a final concentration of 10 µM. The percentage of compound remaining after incubation was 
measured by LC-MS/MS. (Modified from the figure in Forkuo et al.)187 
 
Table 23. Summary of plasma protein binding in mice.  
Result % 
GL-II-93 Unbound drug Bound drug 
Average (n = 3) 11.75 ± 1.42 88.25 ± 1.42  
The 5 μL of 1 mM GL-II-93 was added to the mouse plasma and this was shaking for 4 h; then the sample was 
transferred to tubes on ice to precipitate protein, which was vortexed and incubated for 30 min and then 
analyzed by LCMS/MS. (Modified from the figure in Forkuo et al.)187 
 
The clearance of the acid 85 was further evaluated after a 28-day chronic immunotoxicity 
study. This data will be discussed in detail in a later section. In this PK study, the average 
concentration of acid 85 was quantified in urine and feces by LCMS/MS at day 28.189 After the 
collection of urine and feces, intact 85 was recovered with a concentration of 113.0 ± 27.9 μM in 
urine, and 841.0 ± 188.6 μmol/kg in feces, which indicated that most of the compound was cleared 
through feces, accompanied by a relatively slow renal secretion rate.  
Due to the carboxylic acid function of GL-II-93 (85), the penetration of the BBB did not 
occur to any significant level, which results in an extremely low Cmax and AUC in the brain and 
indicated minimal or no CNS side effects. To further confirm this, the acid was tested in a rotarod 
study to see if any possible side effects, such as motor impairment or sedative effects, occurred in 
Dr. Arnold’g research group (Nick Zahn and Alec Huber), at UWM. In the initial rotarod study, 
mice were treated with vehicle, or a positive control diazepam at 5 mg/kg, or an increased dosage 
of 85 from 50 to 800 mg/kg orally. The performance of the mice on the rotarod was recorded. No 
fall from the rotarod was counted as a successful performance during the 3 minute test period for 
293 
 
15, 30, 60 minute time points. Examination of the data indicated the mice were able to stay on the 
rotarod during the test period and no motor impairment was observed, which demonstrated the 
absence of CNS effects after the treatment with 85. This held true from doses, which ranged from 
50 mg/kg to an extremely high dosage 800 of mg/kg, as presented in Figure 84. Moreover, there 
was no loss of righting response. The rotarod data eliminated the possible CNS side effects from 
the treatment with acid GL-II-93 (85).  
 
Figure 84. The incremental rotarod study of GL-II-93 (85) in mice. The Swiss Webster mice received a single 
intragastric gavage of GL-II-93 at an increased dosage 50-800 mg/kg rate or diazepam (5 mg/kg ip) and were 
placed on a rotarod at 15rpm for 3 minutes, and the performance was recorded after 10, 30 and 60 minutes. A 
fail was assigned to a mouse if they had fallen twice within 3 minutes. The latency to fall is presented as mean 
± SEM (n = 9). The vehicle was used as the negative control and diazepam as positive control. 
 
Examination of the rotarod study not only indicated the absence of possible CNS adverse 
effects but also provided some indication if the compound had any toxic metabolites that affect 
the performance of mice on the rotarod. Since the mice all successfully performed well on the 
294 
 
rotarod, it reflected the fact that GL-II-93 (85) did not produce toxic metabolites in mice and 
permitted its use for animal models. In addition to the rotarod study, the cytotoxicity study was 
conducted in both a human embryonic kidney cells (HEK293T) and human liver cancer cell line 
(HEPG2) to further investigate the toxicity of 85 at the cellular level. These experiments were run 
by Dr. Michael Stephen from Dr. Cook’s group. The LD50 values of 85 in HEK293T and HEPG2 
are both higher than 400 µM, as displayed in Figure 85, which demonstrated a very good safety 
profile for the acid 85.   
 
Figure 85. In vitro cytotoxicity data of GL-II-93 (85). GL-II-93 was incubated with HEK293T cells and HEPG2 
cells, respectively, for 48 hours followed by detection of cell viability using a Cell-Titer Glo (Promega). The 
results were normalized using DMSO as a negative control and 3-dibutylamino-1-(4-hexyl-phenyl)-propan-1-
one (150 mM in DMSO final concentration, as a positive control. Data was determined by three independent 
experiments carried out in quadruplet. 
 
2.3.3.2.4. The Relaxation of Contracted Smooth Muscle Ex Vivo and In Vivo 
As described above, acid 85 exhibited high potentiation at GABAARs and possessed a very 
good PK profile for an asthma drug candidate; the next question was if the compound exhibited 
the desired pharmacological effects including the ability to relax precontracted ASM. The ex vivo 
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relaxation of ASM experiment was performed by Dr. Emala’s research group at Columbia 
University. The tracheal rings from guinea pigs were removed and isolated. And then they were 
suspended in an organ bath. The EC50 of ACh was determined; the strips which had a similar EC50 
were used for the experiments. The muscle contraction was achieved by applying 1 µM substance 
P from the resting tension, and this was, followed by the treatment of a series of increasing 
concentrations of 85 or vehicle. The percentage of remaining muscle force was recorded at four-
time points: 15, 30, 45, 60 min. As shown in Figure 86, acid 85 successfully relaxed the 
precontracted ASM induced by substance P in a dosage-dependent and time-dependent manner. It 
exhibited the desired pronounced effect on ASM relaxation at 25 µM and higher dose. The 
significance of effect occurred at 15 min, and the effect was enhanced over the next 60-minute 





Figure 86. The GL-II-93 (85) relaxed the contracted muscle induced by substance P ex vivo. Muscle force in 
guinea pig ASM contracted with 1 μM substance P. GL-II-93 (25−100 μM) significantly produced a relaxation 
of substance P induced contraction of guinea pig tracheal rings, as compared to vehicle (0.1% DMSO). Muscle 
force is presented as a percent of the first muscle force remaining at different time points. The significance was 
determined by a two-way ANOVA repeated measures analysis. *, **, and *** represents p < 0.05, 0.01, or 0.001, 
respectively, as compared to vehicle (n = 33). (Adopted from the Figures in Forkuo et al.)187 
 
In addition to the organ bath studies where substance P was employed to contract smooth 
muscle, histamine, which is usually involved in immune and inflammatory reponses192 as a 
neurotransmitter, was also used as an alternative clinically relevant agent to induce muscle 
contraction in the organ bath. The guinea pig tracheal rings were suspended in organ baths, as 
previously described, and contraction was achieved by 10 µM histamine. After a steady 
contraction was achieved, the tracheal rings were then treated with acid 85 from an increasing 
concentration of 10 – 100 µM. The contractile force was measured and recorded. The bromo acid 
85 again exhibited a significant dose-dependent relaxation at 25 µM and higher concentrations and 
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was consistent with the ASM relaxation data obtained from organ bath experiments, which 
employed substance P for muscle contraction, as illustrated in Figure 87. Furthermore, the effect 
was pronounced at 15 minutes and magnified over the 60 minute test period, as compared to the 
vehicle (DMSO).  
 
Figure 87. The GL-II-93 (85) relaxed the contracted muscle induced by histamine ex vivo. A: The contractile 
force of the guinea pig tracheal ring was presented as a percentage remaining versus time in an organ bath.  
The tracheal rings were exposed to 10 µM histamine, which was used to induce a rapid contractile force. Once 
a stable peak was achieved, GL-II-93, or DMSO as vehicle control, was added. B: GL-II-93 presented a dose-
dependent decrease in the contractile force, and the significant effect was observed at 25, 50, and 100 µM at 15 
minutes, as compared to the control DMSO. The significance was determined by a two-way ANOVA repeated 
measures analysis (n=6-9), p<0.05. (Adopted from the figure in Yocum et al.)188 
 
The organ bath experiment was not only conducted on guinea pig tracheal rings but was 
also tested on human tracheal ASM strips obtained from 5 human donors, whom had lung surgery 
for another issue at Columbia University Hospital with Dr. Emala, an anesthesiologist. The assay 
employed the same procedure, as described above, only the resting tension was set to 1.5 g as 
compared to 1 g for the previous experiment. Histamine was again used to contract the human 
ASM strips at 10 µM. Once the contraction stabilized, then the strips were treated with vehicle 
DMSO or 100 µM of 85. After exposure to 85, the relaxation effect was measured at three time 
points and recorded. As expected, 85 was also able to reduce the contracted human ASM 
significantly with an average relaxation effect that was significant at 30 minutes in comparison 




Figure 88. The human tracheal ASM strips were relaxed by GL-II-93 ex vivo. A: The contractile force of guinea 
pig tracheal ring was presented as a percentage remaining versus time in the organ bath. The tracheal rings 
were exposed to 10 µM of histamine. Once a stable peak was achieved, 100 µM GL-II-93 or DMSO as vehicle 
control, was added. B: The GL-II-93 at 100 uM relaxed ASM contractile force significantly by 30 minutes, as 
compared to the control DMSO. The significance was determined by a two-way ANOVA repeated measures 
analysis(n=6-10), *, and ** indicated p<0.05 and p<0.01, respectively. (Adopted from the Figure in Yocum et 
al.)188 
 
The experiments, which employed ex vivo precision-cut lung slice (PCLS) from mouse 
peripheral airways were performed as well, in addition to the organ bath experiments. The PCLS 
experiment permits the observation of the ligand’s effectiveness directly from the tissue section 
analysis. This airway diameter study was performed on the PCLS obtained from 3 mice. The 
airway lumenal area was calculated from a visualized microscopy image over time after 100 nM 
methacholine (MCh) exposure. This was followed by acid 85 treatment at 100 µM in the presence 
of MCh. As depicted in Figure 89, MCh reduced 34% of the airway lumen area as compared to 
the control, whereas acid 85 was able to relax the MCh induced-contraction to a 20% decrease of 





Figure 89. The mouse peripheral airways in PCLS was relaxed by GL-II-93 ex vivo. The 100 nM MCh was used 
to induce the contraction of the peripheral airways of an A/J mouse lung slices, which was exposed to 100 µM 
GL-II-93 subsequently, while the microscopy image of airway luminal was recorded continuously. A: The still 
photos tracing of airway luminal was presented over time during the experiments. B: The percentage of the 
overtime tracing of airway luminal area during the experiment. C: A significant reduction of MCh-induced 
ASM contraction was observed with GL-II-93 treatment. *** indicates p<0.001, (n=3). (Adopted from the 
Figure in Yocum et al.)188           
 
2.3.3.2.5. Effects on Asthmatic Properties of Acid 85 
Beside bronchoconstriction, there are a variety of other critical properties in asthma, such 
as airway inflammation, airway hyperresponsiveness (AHR), inflammatory cell recruitment, 
mucus hypersecretion, airway edema, epithelial desquamation, etc. To obtain a more 
comprehensive spectrum of GL-II-93 (85) in asthma, a series of assays for investigation of these 
effects of 85 on these features of asthma were performed. The results will now be discussed in 
detail. The experiments were conducted by Dr. Arnold’s research group (Gloria Forkuo), at UWM, 
and Dr. Emala’s group, Columbia University. 
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First of all, since the airway hyperresponsiveness (AHR) to allergens is one of the critical 
features of asthma, different doses of 85 were given to the ova s/c mice for 5 days and this was 
followed by a nebulized methacholine (MCh) challenge in an increasing concentration from 1.56 
to 12.5 mg/mL. The specific airway resistance (sRaw) value was determined as quantification of 
AHR and compared with the control group. As illustrated in Figure 90, the treatment with 85 at 
100 mg/kg significantly reduced the AHR at all concentrations of MCh. A similar effect was 
observed with 50 mg/kg of 85 treatment at only 12.5 mg/mL MCh, whereas sRaw values at other 
lower MCh concentrations were moderate in this study here. At a 20 mg/kg dosage of 85, the effect 
of overcoming AHR was decreased at 12.5 mg/mL MCh challenge. Furthermore, 1 mg/kg of the 
approved LABA salmeterol was tested in the same model, however, it did not show the anti-AHR 
effect to protect the animal from MCh challenge at all concentrations.     
 
Figure 90. The examination of orally administered GL-II-93 and salmeterol on AHR. The sRaw was measured 
at an increasing dosage of MCh on a DSI’s Buxco FinePointe noninvasive airway mechanics instrument. A, B, 
C: GL-II-93 was orally administered in ova s/c BALB/c mice twice daily for 5 days at a dosage of 100, 50, and 
20 mg/kg, respectively. D: Salmeterol was administrated at 1 mg/kg twice daily for 5 days. Data represent mean 
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± SEM (n=10). The significance was determined by a two-way ANOVA repeated measures analysis. *, **, and 
*** represents significance p < 0.05, p < 0.01, and p < 0.001, respectively. (Adapted from the figure in Forkuo 
et al.)187  
 
The assessment of the effect from orally administrated 85 on AHR demonstrated the 
capacity of the ligand to protect the animal from AHR in the MCh challenge assay. It would be 
interesting to investigate the effect of the compound as an aerosol, which is the common method 
of administration for the treatment of asthma. Therefore, the in vivo airway resistance experiment 
was performed in mice. Briefly, after receiving nebulized 5 mM 85, the mice were given a 
nebulized MCh challenge in the apparatus with an increasing concentration (0-25 mg/mL), and the 
central lung resistance (Rn) values were measured and recorded. As displayed in Figure 91, acid 
85 was able to reduce the Rn and protect the mice from the MCh challenge, which mimicked the 
effect of an inhaler on an asthma patient. Examination of the results indicated 85 is active not only 
when administrated orally but also effective as an aerosol. This expands the spectrum of use of 85 
by employing effectively different methods of administration. 
 
Figure 91. The bronchoconstriction in mice was reduced by GL-II-93 (85) treatment in vivo.  The A/J mice 
were given an inhaled, MCh challenge, anesthetized and mechanically ventilated, then the mice received 
nebulized GL-II-93 at 5 mM, for 10 s nebulization (50 % duty cycle) or 25% ethanol in PBS as vehicle control. 
The resistance of mice receiving GL-II-93 was significantly reduced in regard to airway resistance during the 
MCh challenge with an increasing concentration. Data represent mean ± SEM (n=6). The significance was 
determined by a two-way ANOVA repeated measures analysis, * indicated p<0.05. (Adopted from the Figure 
in Yocum et al.)188          
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After the assessment of the airway resistance, and after the treatment with 85 for 10 seconds 
via nebulized administration, the concentration of 85 in brain, lung, and serum was determined at 
two time points: 10 minutes and 30 minutes from the mice. The average concentration of 85 after 
10 and 30 minutes was 86 and 47 ng/g in serum, respectively; 1334 and 412 ng/g in the lung, 
respectively; 58 and 9.6 ng/g in the brain, respectively. As shown in Figure 92, the concentration 
of the acid 85 was significantly lower in both serum and brain tissue, whereas, the inhaled 85 
concentration in the lung was extremely high in the first 10 minutes, and was eliminated at a very 
rapid rate after 30 minutes with about 70% clearance. These results indicate that the inhaled 85 
can be used to alleviate ASM contractions in asthma and achieve a profound relaxation effect 
within 10 minutes acting much like a SABA inhaler. 
 
Figure 92. The concentrations of GL-II-93 (85) in serum, lung, and brain in mice after inhalation, was followed 
by the airway resistance assay. The concentration of GL-II-93 was determined in the serum, lung, and brain 
tissues from the A/J mice with GL-II-93 treatment after inhalation at 30 min. The mean concentrations (n=6 
mice) were 412.8±44.8 ng/g in the lung, whereas 9.6±3.0 ng/g in the brain. (Adopted from the figure in Yocum 
et al.)188          
 
Secondly, in addition to AHR, airway inflammation is another cardinal feature of asthma, 
which involves an over-expression of different types of immune cells, such as monocytes, 
eosinophils, neutrophils, basophils, lymphocytes, etc.193 These immune cells infiltrate or migrate 
to the location where inflammation occurs to protect the body from external bacterias, allergens, 
303 
 
viruses, etc.194 Therefore, 85 was tested to assess the ability to reduce inflammation by 
quantification of different types of mice immune cells in the bronchoalveolar lavage fluid (BALF). 
After treatment with 20, 50, 100 mg/kg 85, or 1 mg/kg salmeterol for a continuous 5 day period 
via oral gavage, flow cytometry195 was employed to quantify the amount of total inflammatory 
cells, CD4+T cells, F4/80 cells, and Siglec F cells by applying different antibodies. This included 
anti-mouse CD45 as a common leukocyte marker,196 anti-mouse CD4 as a marker for a T cell 
subset,197-198 anti-mouse F4/80 referenced mouse macrophage marker199 and anti-mouse Siglec F 
as an eosinophils marker,195 respectively. Ligand 85 was able to suppress the number of total 
inflammatory cells, and the effect was significant at 100 mg/kg, whereas the marketed drug 
salmeterol did not show a significant effect at 1 mg/kg, as illustrated in Figure 93A. Both 85 at all 
doses and salmeterol significantly decreased the CD4+ T cell numbers on oral administration, 
which indicated both were effective for reducing the lymphocyte population,197-198 as shown in 
Examination of Figure 93 B. From Figure 93 C and D, 85 was shown to be effective to reduce the 
number of BALF F4/80 cells, and Siglec F cells and the significance was achieved at 100 mg/kg, 
which demonstrated the ability of 85 to suppress the macrophage199 and eosinophils195 types, 






Figure 93. The influence of GL-II-93 and salmeterol on airway inflammatory cells. The vehicle, GL-II-93 (20, 
50, or 100 mg/kg), or salmeterol (1 mg/kg) were orally administrated in the ova s/c mice twice daily for 5 days. 
BALF was obtained from each animal and analyzed for by flow cytometry (A) Quantification of total 
inflammatory cells using anti-CD45 APC antibody, (B) CD4+ T cell, (C) F4/80+ cell, and (D) Siglec F+ cell. 
Data represent mean ± SEM (n = 10). The significance was determined by a two-way ANOVA repeated 
measures analysis. *, **, and *** indicated the significance p < 0.05, p < 0.01, and p < 0.001, respectively, as 
compared to vehicle control. (Adopted from the figure in Forkuo et al.)187 
 
Based on the results on the bromo acid 85, which was able to reduce the numbers of airway 
inflammatory cells, the experiment for the visualization of this effect was performed by an EdU 
staining assay.200 The EdU (5-ethynyl-2′-deoxyuridine) is an analog of thymidine, which can 
incorporate with the DNA in the cells that are undergoing the dividing stage, therefore EdU is used 
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to detect DNA synthesis. The visualization was achieved by click chemistry wherein the EdU 
labeled DNA reacts with the Alexa Fluor 488 azide in the presence of copper sulfate.201 The 
formation of the covalent bond from azide and alkyne, produced a detectable fluorescence, which 
visualized the cells that were undergoing the DNA replication, as illustrated in Scheme 16. The 
lung of ova s/c mice treated with vehicle and 85 were both stained with EdU, as shown in Figure 
94, column 1. All nuclei were stained by 5 μg/mL Hoechst 33342, see Figure 94, column 2. 
Examination of the data in column 3 depicts the superimposed images of columns 1 and 2. It is 
clear that the non-asthmatic mice in the negative control group did not show any cell staining 
(Figure 94 column 1 and row 1). The lung tissue of the asthmatic mice exhibited intense cell 
staining (Figure 94 column 1, and row 2), whereas the lung cells from the 85 treated mice stained 
to a much lower level (Figure 94 column 1, and row 3). The bronchiole alveolar cells and blood 
vessels were not stained, which indicated the mucosa, pneumocytes, and ASM cells did not 
proliferate fast enough in the asthmatic lung tissue. On the other hand, the leukocytes that infiltrate 
might be visualized, such as macrophages, eosinophils, and maybe lymphocytes. Consequently, 
reduction of the stained cells from the acid 85 treated group was visualized, the results of which 
were in agreement with the results from the inflammation cell count assay.   
 
Scheme 16. A. The structure of EdU. B. The “click” chemistry between EdU labeled DNA and Alexa Fluor 488 
azide. The alkyne of EdU reacted with the azide in the presence of a copper catalyst to form a detectable triazole 





Figure 94. The effect of GL-II-93 treatment on the cellular difference of the asthmatic mouse lung. The EdU 
was injected i.p. into the mice lungs and they were harvested after 4 h. A fluorescent azide was applied to the 
lung section with “Click” chemistry to produce the conjugation of EdU to visualize cells that underwent the 
dividing stage in a 4 hour-period (column 1). The Hoechst 33342 (column 2) was used to counterstain the 
sections, and the images were superimposed images as shown in column 3. The lung images of control mice 
were shown in Row 1. The images of vehicle-treated ova s/c mice are presented in Row 2. The images of GL-II-
93 (100 mg/kg) treated ova s/c mice were shown in Row 3. (Adopted from the figure in Forkuo et al.)187 
 
Thirdly, mucus overproduction is another key feature of the asthma lung, in addition to 
AHR, and infiltration with inflammatory cells. Therefore, it was necessary to assess the effect of 
85 on mucus accumulation, which was achieved by visualization of the epithelium of the lung 
tissue with periodic acid fluorescent Schiff’s stain. The lung of asthmatic ova s/c mice exhibited a 
significant increase in mucosa than the control mice. Both salmeterol at 1 mg/kg and 85 at a dosage 
from 20 to 100 mg/kg did not induce a significant mucus volume change, as compared to the 




Figure 95. The effect on mucin production with GL-II-93 or salmeterol treatment. A: Images of lungs in control 
mice, ova s/c mice, salmeterol treated mice at 1 mg/kg, and GL-II-93 treated mice at 100 mg/kg twice daily for 
5 days. Scale bar indicates 100 μm. Periodic acid fluorescent Schiff’s stain agent was used to color the slides, 
and green represented the airway epithelium green, and mucin is in red. B: The mucin volume density of each 
group was measured. Data represent the mean ± SEM (n = 6). The significance was determined by a two-way 
ANOVA repeated measures analysis. (Adopted from the figure in Forkuo et al.)187 
 
Finally, importantly, cytokines exhibit an essential role in chronic bronchial asthma due to 
their contribution to initiation, coordination, and persistence during the inflammatory process. It 
has been well documented that cytokines are extracellular signaling proteins involved in a series 
of interactions between cells through the surface receptors for both acute and chronic inflammatory 
responses.202 Because of the pleiotropic and overlapping properties of cytokines, it is difficult to 
classify them easily. However, based on the knowledge of different abnormalities in features of 
asthma, cytokines might be divided into several groups, which result from the pathogenesis, such 
as lymphokines, pro-inflammatory cytokines, anti-inflammatory cytokines, chemotactic cytokines, 
and growth factors.203 Since T-lymphocytes are the key enforcers of the immune response to 
external viruses, allergens, and bacterias, the cytokines that are related to lymphocytes draw much 
attention. The T-lymphocytes are classified into T helper 1 cells (Th1), T helper 2 cells (Th2), T 
helper 17 cells (Th17) and regulatory T cells (Treg).204 To evaluate the cytokine expression with 
the treatment with acid 85, the concentration of several T-lymphokines (TH1: IL-2, IFN-γ, and 
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TNFα; TH2: IL-4, IL-6, and IL-10; and TH17: IL-17A cytokines) were determined by flow 
cytometry. The results, as depicted in Figure 96, indicate that a remarkable increase was observed 
in the levels of IL-10, IL-17A, IL-4, and TNFα cytokine concentration in the ova s/c mice, as 
compared to the control group. Whereas there was no substantial change in IFN-γ, IL-6, IL-2. 
Despite IL-10 cytokines, acid 85 was able to reduce the expression of the lymphokines, which 
underwent a considerable increase in concentration than the control group. There was no 
significant effect of 85 on the other three cytokines that did not show a significant effect between 
the ova s/c mice and the control mice. 
 
Figure 96. The evaluation of cytokine expression with GL-II-93 treatment in the lung. The quantification of 
mouse Th1/Th2/Th17 cytokines in mouse tissue homogenates was determined by applying the BD mouse 
Th1/Th2/Th17 cytometric bead array kit. Ova s/c mice were treated orally with 100 mg/kg GL-II-93 or vehicle 
twice a day for 5 days. The significance was determined by a two-way ANOVA repeated measures analysis. *, 
**, and *** represented the significance p < 0.05, p < 0.01, and p < 0.001, respectively. Data represent mean ± 




2.3.3.2.6. Immunotoxicity (Evaluation over a 28-Day Period) with Acid 85 
The assessment of potential immunotoxicity of any new drug is required for the drug 
development process to eliminate the possible adverse effects from any off-target immune 
responsiveness reduction or suppression. The previous results of the 5-day treatment of 85 in mice 
at 100 mg/kg (orally administrated) indicated that 85 did not show any side effects during the 
treatment; therefore, a long-term immunotoxicity study could be performed. This was carried out 
to evaluate the pharmacological effects of 85 at 100 mg/kg with a twice-daily dosage over a 28-
day test period. Both male and female mice, which was carried out by Dr. Arnold’s research group 
(Nick Zahn, M. S. Rashid Roni, and Alec Huber), at UWM were employed. Before the test, the 
training of consuming peanut butter (the vehicle) was conducted at 100 mg/kg twice a day for a 
week to ensure the animal was used to the testing diet. These mice were then divided into two 
groups; the acid 85 treatment group and the peanut butter control group. The third group of mice 
did not receive either 85 nor peanut butter.  
As presented in Figure 97, the average weight of the female mice in all three groups was 
lower than the male mice throughout the testing period, with about 26 and 32 grams, respectively. 
On the last day of the test, the average weight of female and male mice were about 28 and 36 
grams, respectively, as expected in this strain of mice. During the 28-day course, there was no 
significant average weight change among the three groups in both male and female mice. At 21 
days both weights were lower than the non treated control group, however, a similar weight was 
achieved at the end of the test for all groups. Furthermore, there was no gastrointestinal distress, 
nor abnormal behaviors observed, such as respiratory depression, impaired movement and 
aggressive behaviors, etc. Therefore, the data indicated that treatment with acid 85 did not affect 




Figure 97. The effect of GL-II-93 on the average mouse body weights during the 28‐day study. Peanut butter 
without or with 100 mg/kg MIDD0301 was administrated orally twice daily in both male and female Swiss 
Webster mice at the age of 8 weeks in a separate container. Mice without GL-II-93 treatment stayed in the 
same containers. Body weights were measured every week. Data represent mean ± SEM (n = 5). The 
significance was determined by a two-way ANOVA repeated measures analysis. *, and **,  represented the 
significance p < 0.05, and p < 0.01, respectively. (Adopted from the figure in Zahn et al.)189 
 
The effect of acid 85 on the immune response was determined by immunization of the 
Swiss Webster mice in vivo with 50 μg dinitrophenyl hapten-keyhole limpet hemocyanin (DNP‐
KLH), employed as a T cell-dependent antigen to induce an antigen-specific immune response,205-
207 on days 1 and 21. The average weight was measured on days 14 and 28. A high dose of the 
novel ligand 85 (100 mg/kg twice daily), and the asthma drug prednisone (5 mg/kg/day), which 
was used as corticosteroid, were administrated orally to the mice. The results of the average weight 
change are presented in Figure 98. All groups exhibited a percentage of positive weight increase 
during the four weeks. In both female and male mice, the change in weight with the peanut butter 
with and without DNP-KLH groups were not significant. The acid 85 treatment group did not 
induce considerable weight changes over the test period. However, the prednisone treatment group 
reduced the average weight slightly in female mice, and the effect was significant in male mice, as 




Figure 98. Evaluation of average body‐weight with DNP‐KLH immunization. Peanut butter without or with 
100 mg/kg MIDD0301, or peanut butter + prednisone (5 mg/kg daily) was administrated orally twice daily to 
both male and female Swiss Webster mice at the age of 6 weeks in a separate container. DNP‐KLH 
immunization was applied on days 1 and 21 for these 3 groups. Body weights were measured on day 14 and 28. 
Data represent mean ± SEM (n = 5). The significance was determined by a two-way ANOVA repeated measures 
analysis.  *** indicates P < 0.001. (Adopted from the figure in Zahn et al.)189 
 
At day 28, the small intestine, thymus, and spleen were dissected from the mice for each 
group. The weight of the organs was measured. The numbers of Peyer’s patches from the intestine 
were counted, as illustrated in Figure 99. The weight of the thymus and spleen from the mice that 
were treated with or without DNP-KLH in both female and male mice were similar to each other. 
The acid 85 treated groups administrated 100 mg/kg twice daily in both sexes did not exhibit a 
remarkable change in weight of either the thymus or the spleen. However, the weight of the spleen 
and thymus from the prednisone-treated group in the female mice were both reduced, and the 
weight decrease was significant in male groups, as compared to the control group. The total 
numbers of Peyer’s patches in the acid 85 or prednisone groups in both sexes were all similar to 






Figure 99. Effect of 28 days of treatment of GL-II-93 on lymphoid organs and Peyer's patches from Swiss 
Webster mice immunized with DNP-KLH. Peanut butter without or with 100 mg/kg MIDD0301, or peanut 
butter + prednisone (5 mg/kg daily) was administrated orally twice daily in both female (A-C) and male (D-F) 
Swiss Webster mice at the age of 6 weeks. The DNP‐KLH immunization was applied on days 1 and 21 for these 
3 groups. After the 28 day test period, organs were obtained and weighed, and small intestines were dissected 
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for the counting of Peyer's patches. Data represent mean ± SEM (n = 5). The significance was determined by a 
two-way ANOVA repeated measures analysis. *, **, and *** represented the significance p < 0.05, p < 0.01, 
and p < 0.001, respectively. (Adopted from the figure in Zahn et al.)189 
 
Since it has been reported that the overuse or long-time use of a corticosteroid can cause 
changes in the spleen,208, therefore, it was necessary to determine any possible histological change 
of the lymphoid organs after long term treatment with acid 85, which led to the H&E-staining 
experiment for comparison. The experiment was performed after the spleen and thymus were 
removed and measured for the data shown in the Experiment above. As shown in Figure 100, the 
white and red pulp from the spleen did not exhibit a significant change with  treatment with 85 in 
both sexes, except the mice, which received the treatment with prednisone, exhibited a smaller size 
of the white pulp (lymphoid follicles), which is in agreement with the reduction of spleen weight, 
as described above. There was no remarkable change in the thymus histology of all groups 
regardless of gender or treatment. Consequently, a high dosage of 85 treatment for 28 consecutive 





Figure 100. The mouse spleens (A-H, 40x) and thymus (I-P, 100x) H&E staining. A and I) male mice, peanut 
butter; B and J) female mice, peanut butter; C and K) DNP-KLH-immunized male mice, peanut butter; D and 
L) DNP-KLH-immunized female mice, peanut butter; E and M) DNP-KLH-immunized male mice, peanut 
butter with 100 mg/kg GL-II-93 twice daily for 28 days; F and N) DNP-KLH-immunized female mice, peanut 
butter with 100 mg/kg GL-II-93 twice daily for 28 days. G and O) DNP-KLH-immunized male mice, peanut 
butter with 5 mg/kg prednisone daily for 28 days; H and P) female DNP-KLH-immunized mice, peanut butter 
with 5 mg/kg prednisone daily for 28 days. (Adopted from the figure in Zahn et al.)189 
 
In order to evaluate the pharmacological effect of acid 85 on the T-dependent humoral 
immune response, the serum DNP-immunoglobulin G (IgG)209 quantification was investigated at 
day 28 by ELISA for all groups. As presented in Figure 101, the DNP-specific antibody IgG level 
was remarkably increased in both sexes in the DNP-KLH immunized group, as compared to the 
peanut butter the only group. The IgG level indicated there was no significant difference in both 
85 nor the prednisone groups, which indicated that 28-day treatment with 100 mg/kg twice a day 
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with acid 85 did not suppress or interfere with the off-target systemic immune response by a 
common T-dependent antibody.  
 
Figure 101. The mouse serum DNP IgG. The peanut butter without or with 100 mg/kg MIDD0301, or peanut 
butter + prednisone 5 mg/kg daily was administrated orally twice daily in both female (A) and male (B) Swiss 
Webster mice. The DNP-KLH immunization applied on days 1 and 21, and quantification of DNP-specific IgG 
was measured on day 28. Data represent mean ± SEM (n = 5). The significance was determined by a two-way 
ANOVA repeated measures analysis. ** represented the significance p < 0.01. (Adopted from the figure in Zahn 
et al.)189 
 
2.3.3.2.7. Stability Studies 
The bioavailability of a drug candidate is one of the critical pharmacokinetic properties for 
preclinical research, which provides information in regard to how much of the drug reaches the 
systemic circulation in its original form. The bioavailability is considered to be 100 % only by i.v. 
administration. The reason the route of administration is always a concern is because other routes 
of administration are usually not as efficient as an i.v. injection. Factors, such as an insufficient 
absorption time, low water solubility, and first-pass metabolism, can affect the bioavailability to a 
variable extent especially when given i.p. or p.o. Since the oral route was employed for the 
administration of 85, the absorption of the drug must pass the digestive system before the first-
pass metabolism takes place in the liver. The stability of 85 was critical for its absorption, therefore 
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the chemical stability of the ligand was determined under both acidic and basic conditions to mimic 
the drug stability in the stomach and intestine, respectively. In order to perform the experiment, 
the acid 85 was first converted into the open ring form and also the sodium salt form in the presence 
of 1 N aq HCl or 1 eq of sodium hydroxide, respectively, as shown in Scheme 17. 
 
Scheme 17. Synthesis of the keto (ring-opened) form GL-IV-19 (90) and the sodium salt form GL-IV-18 (89) 
from GL-II-93 (85). 
 
To perform the stability study, it was necessary to use a suitable solvent for the experiment. 
The solubility of the three ligands in different solvents at 37 °C is presented in Table 24. 






Based on examination of the solubility data in the table above, all three compounds were 
found soluble in MeOH and DMSO. Usually MeOH would be a convenient solvent for use due to 
the efficient compound recovery process. However, in this case MeOH was found unsuitable for 
Solvent GL-IV-19 (90) GL-II-93 (85) GL-IV-18 (89) 
H2O No No Yes 
MeOH Yes Yes Yes 
EtOH partial partial Yes 
ACN No No No 
DMSO Yes Yes Yes 
EtOAc No partial No 
Acetone No No No 
MTBE No No No 
DCM No partial No 
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conduction of the experiment because the open ring keto form of 85 was converted back to its 
original cyclized 7-membered ring in MeOH. This was found by accident while measuring the 
mass spectrum by LCMS. The mass of both compound 85 (414, 416) and 90(432, 434) were 
detected in the mass spectrum, however, the completion of the recyclization was monitored and 
confirmed by NMR. To evaluate this chemical stability with both compounds GL-II-93 (85) and 
GL-IV-19 (90) in MeOH, the experiment was conducted at 1, 20, 40, 60-minute time points. As 
presented in Figure 102, 90 started to convert back into 85 once the compound had been dissolved 
in MeOH at the first minute, and the conversion reached an equilibrium in about 1 hour. The 




Figure 102. A, B, C, D: The mass spectra of GL-IV-19 (90) in 4-time points, respectively and examination of 
them indicated the conversion of GL-IV-19 to GL-II-93 took place in a time-dependent manner. The 
equilibrium was reached at 1 h, as compared to longer reaction times, which was very similar, data not shown 
here.  
 
In addition to MeOH, the same experiment was repeated in DMSO. As compared to the 
instability of 90 in MeOH, the keto form 90 was much more stable in DMSO. The conversion into 
GL-II-93 (85) was very similar to each other at the 0.5 and 1 hour time points and the equilibrium 
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was achieved slowly only after 6 hours, as shown in Figure 103. Therefore, the data from the 
stability experiments indicated DMSO should be employed as the solvent for the experiment under 
acidic and basic conditions.  
 
Figure 103. A, B, C: The mass spectra of GL-IV-19 (90) in DMSO at 0.5 min, 1 min, and 6 h time points, 
respectively. It indicated the conversion of GL-IV-19 to GL-II-93 in a time-dependent manner. The equilibrium 
was reached at 6 h, as compared to longer time points, data not shown here.  
 
As presented in Figure104, the 1H NMR spectra, comparison of 85 (upper spectra) and 90 
(lower spectra) in a 1:1 mixture of DMSO and D2O is depicted. The doublet of the C(4)-methyl 
group was shifted from 1.2 ppm to 1.4 ppm (two doublets because of the effect of the two rotamers 
on the C(4) methyl group in 90), and the quartet of the C(4)-hydrogen atom shifted from 6.4 ppm 
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to 4.2 ppm. Since these sets of the peak had the highest intensity and clear splitting pattern, 
therefore, they were chosen to be monitored and quantified during the addition of acid and base in 
the NMR spectroscopy experiments.  
 
Figure 104. The 1H NMR spectra comparison of GL-II-93 85 (upper spectra in red) and GL-IV-19 90 (lower 
spectra in blue). The doublet of the C(4)-methyl group was shifted from 1.2 ppm to 1.4 ppm (two double are 
the rotamers of the methyl group in 90), and quartet of the C(4)-hydrogen atom from 6.4 ppm to 4.2 ppm. The 
peaks disappeared in the spectra of 90 as indicated by yellow arrows, whereas the peak that appeared was 
colored in green. The DMSO peak was at 2.5 ppm; the D2O peak was at 4.8 ppm. 
 
The stability of acid 85 was conducted in a 1:1 mixture of DMSO and D2O at a low 
concentration (1 mg/mL). The DCl/D2O solution (5.125 M) was added by a micropipette in a small 
portion with the final volume of DCl as 0, 0.1, 1, 2, 3, 4, 5, 8, 11, 21 μL for a equilibrium study 
and also for the determination of the volume to conduct the kinetic study at pH = 2 (pH paper). In 
the equilibrium study, there was no change that occurred in the NMR spectra; the final spectra 
were saved for each addition of DCl. The bottom spectra is the 1H NMR spectrum of GL-II-93 (85) 
in the DMSO/ D2O mixture, and the spectra are presented with an increase of DCL (0.1, 1, 2, 3, 4, 
5, 8, 11, 21 μL) in an order from bottom to the top of Figure 105.  It appeared that the reaction 
reached equilibrium very rapidly, but the full conversion from 85 to 90 required harsh conditions 
and a large volume of DCl (21 μL). The desired pH at 2 can be achieved by the addition of 2 μL 
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of DCl (5.125 M), which was used for the next kinetic experiment with 85 under acidic conditions 
at pH = 2 to mimic the physiological pH in the stomach. The graphs were integrated by an area of 
an appearing or disappearing peak against the amount of acid added, as illustrated in Figure 106. 
The left panel of Figure 106 depicts the area-concentration curve of the C(4) methyl group at 1.4 
ppm (the second rotamer for higher intensity), and 1.2 ppm for the right panel under acidic 
conditions. The concentration that resulted in a significant shift of peaks was consistent for both 
appearing and disappearing peaks in the proton NMR spectra, which was found at about 0.01 M 
of DCl in 1 mg/mL of 85 solution. 
 
Figure 105. The 1H NMR spectra for the equilibrium study of the conversion from GL-II-93 (85) into the open 
ring form GL-IV-19 (90) with a increased volume of DCl (5.125 M) from bottom to the top the spectra follow 





Figure 106. The area-concentration curve of the C(4) methyl group at (A) 1.4 ppm (the peak for the second 
rotamer was due to higher intensity), and (B) 1.2 ppm for the right panel under acidic conditions. 
 
The kinetic study under acidic conditions was carried out by the addition of 2 μL of DCl 
solution in one portion. Once the desired concentration or pH was achieved, the NMR tube was 
shaken rapidly and vigorously to ensure a homogenous mixture. In the kinetic study, as shown in 
Figure 107, the 1H NMR spectra were then obtained and saved for each time interval with one data 
point per minute for 1 hour under acidic conditions. Only 13 spectra were selected to show the 
obvious peak changes at 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 15, 20, 30, 40, 50, 62-minute time points. As 
described above, the peaks of the C(4) methyl group and the hydrogen atom were shifted from the 
position indicated with red arrows (peak decreased) to the position with green arrows (peak 
appeared). The graphs were integrated by an area of appearing or disappearing peak against time 
at certain concentrations for the desired pH to 2, as presented in Figure 108. This reaction reached 
equilibrium at about the 50 minute time point, and the half-life was about 20 minutes for both the 
appearing or disappearing peak. The results indicated that if given GL-II-93 (85) orally, it will not 
be stable in the original form in the stomach at pH to 2 and will start the conversion from the C(6)-
N(5) imine form to the open keto form immediately. This will take about 20 minutes to hydrolyze 
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50 % of 85 to the open keto form 90. The intensity-time curve and the half-lives were similar to 
the area-time curve (see details in Appendix VII).  
 
Figure 107. The 1H NMR spectrum of 13 spectra in the kinetic study at pH = 2. The spectra were selected to 
show the obvious peak changes at specific time points. The bottom spectrum is the 1H NMR spectrum of GL-
II-93 (85) in the DMSO/ D2O mixture, and the spectra with an increase of time points at 1, 2, 3, 4, 5, 6, 7, 8, 9, 
11, 15, 20, 30, 40, 50, 62 minute time points in order from bottom to the top. As described above, the peaks for 
the C(4) methyl group and hydrogen atom were shifted from the position indicated with red arrows (peak 





Figure 108. The area (lg)-time curve for the C(4) methyl group of GL-II-93 (85) at pH = 2. The panel on the left 
is the rotamer appearing at 1.4 ppm, and the right-hand panel is for the disappearing methyl group peak 
originally at 1.2 ppm. The half-life for these two peaks is 1201 seconds and 1189 seconds, respectively. 
 
A second experiment based on the addition of NaOD was carried out in order to determine 
the time and concentration of the C(6)-N(5) imine reformation of keto GL-II-19 (90) back into its 
original C(6)-N(5) imine form GL-II-93 (85) and further to determine if the sodium salt form of 
the acid GL-IV-18 (89) would take place in more basic conditions. To the solution of GL-IV-19 
(90) at 1 mg/mL in the mixture of 1:1 DMSO/D2O, the NaOD/D2O solution (7.32 M) was added 
in small portions (0.001, 0.005, 0.01, 0.02, 0.05, 0.075, 0.1, 0.2, 0.5, 1, 2 μL) for the equilibrium 
study. This mixture will be utilized for further determination of the volume of NaOD to create a 
pH = 8-9 solution to mimic the physiological pH in the intestine. In the equilibrium study, there 
was no change, which occurred in the NMR spectrum and the final spectrum was saved for each 
addition of NaOD. It was noticed that during the first three additions, the peak of the C(4) methyl 
group of keto GL-II-93 (85) had already appeared in high intensity without any addition of base 
and no significant change was observed when a small amount of base was added to first three-
volume 0.001, 0.005, 0.01 μL, which was unexpected, as shown in Figure 109 for the last four 
spectra on the bottom. It was later found that GL-IV-19 (90) was actually a hydrochloric acid salt 
of the free amine. When it was dissolved in DMSO, it stayed in the salt form, therefore the C(4)-
methyl group of 90 was the only the peak at the upper field in the NMR spectrum. However, it 
was ionized when D2O was added as part of the solvent system, and the pH was found out to be 
around 4, as presented in Figure 110. The neutralization reaction had already begun the very 
second D2O was added, therefore it explained the formation of the peak from the original imine 
GL-II-93 (85). The pH after each addition was measured on the further addition of NaOD. As 
shown in Figure 109, when the pH was 5 or slightly higher than 5, a significant amount of the 
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closed imine 85 was formed, which is consistent with the synthesis of 85 where the acidification 
of the salt GL-IV-18 (89) to pH = 5 would occur to form 85. When the pH was even higher, the 
imine was hydrolyzed to the ring-opened form 90 and was completely eliminated and turned into 
its sodium salt.  
 
Figure 109. The 1H NMR spectra of equilibrium study of the conversion from 1 mg/mL of GL-IV-19 (90) to the 
original form GL-II-93 (85) or its sodium salt GL-IV-18 (89) with an increased volume of NaOD (7.23 M) from 
bottom to the top spectra as following order: 0, 0.001, 0.005, 0.01, 0.02, 0.05, 0.075, 0.1, 0.2, 0.5, 1, 2 μL.The pH 





Figure 110. The 1H NMR spectra of GL-IV-19 (90) in the DMSO/D2O mixture and DMSO only. The pH in the 
mixture was about 4, and the peak of the product GL-II-93 (85) at 1.2 ppm had started to appear in the mixture, 
whereas this was not observed in the solution of DMSO only.  
 
The graphs of the equilibrium study from NMR spectroscopy under basic conditions were 
integrated by the area of an appearing or disappearing peak against the amount of added base, as 
illustrated in Figure 111. The left panel shows the area-concentration curve of the C(4) methyl 
group at 1.4 ppm (the second rotamer for higher intensity), and 1.2 ppm for the right panel under 
acidic conditions. The red dot on the Y-axis represented the trials without any addition of base but 
just in the mixture of DMSO and D2O. It is obvious that the reaction reacted rapidly when D2O 
was added, and one was not able to monitor the mixture within one minute due to the time for 
sample preparation. The concentration that resulted in significant shifts of the peak was consistent 
for both the appearing and disappearing peaks, which was about 0-0.001 M of NaOD in 1 mg/mL 




Figure 111. In panel A is represented the area-concentration curve of the C(4) methyl group at 1.4 ppm (the 
peak for the second rotamer due to higher intensity), and panel B represents 1.2 ppm under basic conditions. 
The red dot on the Y-axis represented the trials without any addition of base but just in the mixture of DMSO 
and D2O. 
 
The kinetic study under basic conditions was carried out by the addition of 0.025 μL of 
NaOD solution in one portion (initial pH = 8-9). Once the desired concentration or pH was 
achieved, the NMR tube was shaken rapidly and vigorously to ensure a homogenous mixture. In 
the kinetic study, as shown in Figure 112, the 1H NMR spectra were then obtained and saved for 
each time interval with one data point per minute for 3 hours under basic conditions. Only 13 
spectra were selected to show the obvious peak changes at 1, 9, 20, 30, 40, 50, 60, 80, 100, 120, 
140, 160, 180-minute time points. As described above, the peaks of the C(4) methyl group and 
hydrogen atom were shifted back to its original C(6)-N(5) imine positions. The graphs of the 
kinetic study were integrated by the area of appearing or disappearing peak in the NMR spectra 
against a time point at certain concentrations for the desired initial pH to 8, as presented in Figure 
113. The intensity-time curve and the half-lives were similar to the area-time curve (see details in 
Appendix VII). This reaction exhibited a half-life about 135 minutes for both the appearing (at 1.2 
ppm) or disappearing (at 1.4 ppm) peak. This was tested when the final pH of the reaction was 
about 5-6 pH units. It should be noted that this is not exactly the pH conditions in the intestine that 
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has a stable balance of pH = 8-9 with a complex buffer conditions. Furthermore, the reaction began 
relatively fast after it was dissolved in D2O. Therefore, the actual initial point was missing and 
undetectable due to the time for physical sample preparation, which time was very limited. All 
these factors influenced the determination of kinetic profile of the hydrolyzed form GL-IV-19 (90), 
especially the attempt to mimic the real conditions in the human body from the open ring keto 
form in the stomach and the recyclized form back to the seven-membered ring imine form in the 
intestine. However, these data revealed some insight into the kinetics and stability of the three 
forms of GL-II-93 (85) at different pH conditions (pH = 2, 5, and 8). The acid 85 was not stable 
under low pH conditions, and would be readily converted into the open ring keto form 90 and 
reaches to an equilibrium between the open ring keto form and the closed ring form 85. This 
equilibrium would remain unless harsh conditions were applied such as heating and the presence 
of more acid. The open ring form 90 was also not stable; it would start to react in the presence of 
water only rapidly. At this point, any added base would only neutralize the hydrochloric acid salt 
to form the free amine first. When the solution reached a pH close to 5, the significant amount of 
the free amine would be cyclized back to the original form 85. At higher pH, the sodium salt of 85 




Figure 112. The 1H NMR of 13 spectra in the kinetic study at pH = 8. The spectra were selected to show the 
obvious peak changes at time points. The spectra were presented with an increase in time point at 1, 9, 20, 30, 
40, 50, 60, 80, 100, 120, 140, 160, 180 minutes in order from bottom to the top. As described above, the peaks of 
the C(4) methyl group and the C(4) hydrogen atom were shifted as indicated with green arrows (peak decreased 
at 1.2 ppm and 6.4 ppm) to the position with red arrows (peak appeared at 1.4 ppm and 4.2 ppm).  
 
  
Figure 113. The area (lg)-time curve for the C(4) methyl group of GL-IV-19 (90) at pH = 8, the left panel is for 
the disappearing rotamer at 1.4 ppm, and the right panel is for the appearing methyl group peak originally at 





2.3.3.3. Analog Research on GL-II-93  
2.3.3.3.1. Synthesis of Analogs   
To further explore the SAR based on the evidence accumulated on the lead compound Gl-
II-93 (85) for the treatment of asthma, a series of carboxylic acid and tetrazole bioisosteres of 85 
was designed and synthesized. Since the C(3)-acid function was critical for the high hydrophilicity 
to prevent penetration across the BBB to limit possible CNS effects, most of the analogs of 85 
retain this acid moiety. With the exception of the “privileged IMDZ” backbone, the chirality at the 
C(4) position, the substituents at the 2 prime position, bioisosteres of the carboxylic acid function 
at the C(3) position as well as the functional group at the C(8) position were all considered for 




Figure 114. Analogs of 85 by modification of the substituents at the C(3), C(4), C(8) and 2'X positions.  
 
It is reasonable to design the synthesis of the enantiomer of the most active compound GL-
II-93 (85) if the target has a chiral center in the molecule. Moreover, the parent enantiomer (S-CH3) 
2 exhibited higher potency and better binding affinity83 as compared to 1 not only at α5 subtypes 
but also at α2 and α3 subtypes. Therefore, the S-isomer GL-III-20 (91), the enantiomer of 85, was 
synthesized as a negative control compound to evaluate the S-isomer in the animal models of 
asthma. Besides 91, the S-isomer with the C(8)-ethinyl carboxylic acid was previously made as 
the enantiomer of the α5 agonist SH-053-2'F-R-CH3-acid (23). This could also be screened for 
SAR to determine if a molecule with a different chiral center exhibit activity in asthma, as 
compared with the key R-isomer. These S isomers might be expected to cause inflammation and 
mucus overproduction confirming that the α4 and α5 subtypes are the targets of choice and 
supporting the approach to an (R) drug target here. Consequently, the synthesis of both 91 and 23 
was carried out by hydrolyzing the ethyl ester of the S-isomers, which contained the C(8)-bromo 
or ethinyl substituent, respectively, into their corresponding carboxylic acids in excellent yield, as 
shown in Scheme 18. 
           
Scheme 18. Synthesis of GL-III-20 (91) and SH-053-2'F-S-CH3-acid (23) from the corresponding ethyl esters in 




It is necessary always to use older valuable information from previous work. The data 
published a decade ago,83 which demonstrated that the in vitro binding affinity at all subtypes from 
JY-XHe-053 were much higher than effects at 1, 2 and 85, see Table 25. Furthermore, from the in 
vitro efficacy data, JY-XHe-053 exhibited the best efficacy compared to the other related 
compounds under study here including 1, 2 and even 85 at all subtypes at 100 nM, see Table 26. 
However, it did exhibit, the most potent efficacy (0.7 nM) at α5 subtypes observed to date. This 
concentration at 100 nM is the physiologically relevant concentration in clinical trials. The 
difference between JY-XHe-053 and 1 or 2 is the chirality at the C(4) position, wherein JY-XHe-
053 does not contain a chiral methyl group. This makes it an ideal negative control compound. 
Initially, the chiral methyl group was introduced to reduce the binding at α1-subtypes for CNS 
disorders such as anxiety, epilepsy, and schizophrenia and patent protection. However, α1-
containing GABAAR subtypes are not expressed in lung tissue. Moreover, since the carboxylic 
acid function greatly retards the penetration through the BBB, this further limits the effect of α1 
subtypes on CNS-mediated side effects. Therefore, JY-XHe-053 was brought back into focus 
again. In this vein, the carboxylic acid analog of JY-XHe-053 could be an interesting ligand to 
investigate, due to its high efficacy and potent binding affinity pattern at α5 if it contained a C(3) 
acid function. Therefore, the C(8)-bromo acid analog, GL-III-19 (92), was synthesized via this 
hypothesis. The C(8)-ethinyl carboxylic acid, GL-II-79 (93), was made for this SAR study. The 
synthesis of these two acids was straight forward and performed with the same procedure for the 
synthesis of the acids, GL-III-19 (92) and GL-II-79 (93), as shown in Scheme 19.  
Table 25. The binding affinity at α1-6β3γ2 GABAAR BzR. Measurements were generated in duplicate. Ki 





 ND, not determined. 
b
 The binding affinity at α4-GABAARs and α6-GABAARs have not been determined, 
but since the 6-phenyl group is present, there will be no ligand binding to these receptors. 
 
Table 26. Efficacy at α1-3,5β3γ2 GABAARs as % of the control current at the concentration of 0.1 and 1 μM. 
Data are presented as 0.1μM/1 μM. (Modified from the Figure in Fischer et al.)83 Data determined in the 




Scheme 19. Synthesis of GL-III-19 (92) and GL-II-79 (93) negative controls from the corresponding ethyl esters 
in the achiral 2'F series. 
 
Since the 2'-F analogs from the R-isomer series were active in asthma and ligands in the 
2'-N series were active in other assays, as described in the previous section for the treatment of 
schizophrenia and depression, it was logical to synthesize analogs from this 2'-N-R-CH3 series for 
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a comprehensive SAR study for asthma as well. Therefore, at the 2 prime positions, instead of the 
C-F bond, a pyridine ring N was introduced for both C(8)-bromo and C(8)-ethinyl intermediates. 
The corresponding carboxylic acid analogs, GL-II-51 (94) and GL-II-30 (95), were synthesized 
applying the same procedure of saponification, as previously described. The synthesis is illustrated 
in Scheme 20.   
 
Scheme 20. Synthesis of GL-II-51 (94) and GL-II-30 (95) from the corresponding ethyl esters in the 2'N-R-CH3 
series. 
 
In addition to the modifications at the C(3) and C(4) positions, the C(8)-substituents also 
play an essential role in terms of pharmacological effects, such as the Br vs. acetylene comparison 
as discussed in the previous sections. With a perspective from medicinal chemistry, Br, as one of 
the heavy halogens, usually is not the first choice of halogen-containing drugs due to several 
reasons: 1. A higher MW. 2. A possible undesired increase in lipophilicity. 3. The impact on the 
size of the molecule. 4. A possible lower solubility. 5. A weaker carbon aromatic bond as compared 
to chlorine or fluorine, which might lead to a shorter shelf-life than smaller size halogens.210 6. 
Also safety concerns such as photoreactivity, phototoxicity, and the formation of reactive 
metabolites,211 which results from photoreactions with light. However, even with these possible 
issues listed above, there are still 70 drugs, which contain Br, approved for the drug market, and 
only 7 of them have been withdrawn due to the exhibition of toxicity. (Source https://www.drug 
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bank.ca/. by searching keyword “bromide”). Even though GL-II-93 (85) does not exhibit any side 
effects at the current stage, the concerns over the shelf stability of a Br atom should always be kept 
in mind. It is prudent to further explore the SAR with several other functional groups at the C(8) 
position.  
As compared to Br, Cl is a safer halogen to use and might still possess the desired properties 
as bromine. If the C(8)-Cl ligand displays a similar effect as 85, this analog might well be a good 
backup compound to 85 with less phototoxicity and provide a better shelf-life. This is because an 
aromatic C-Cl bond is stronger than a C-Br bond. The synthesis of the C(8)-Cl analog, GL-III-54 
(87), was carried out in a procedure similar to that employed for 85 except that C(8)-Cl 
benzophenone 87 substrated for the C(8)-bromo benzophenone as the required building block, as 
shown in Scheme 21.  
 




Because the cyclopropyl group, occupied a similar van der Waals radii as an ethinyl 
function, the former group was introduced at the C(8) position.  Since the cyclopropyl group can 
rotate at will at the C(8) position, the electron density map of a cyclopropyl group, ethinyl moiety 
and Br are very similar. Consequently, a C(8)-cyclopropyl group might exhibit the desired 
biological activity due to similar interactions in the binding pocket as acetylene. Moreover, the 
formation of a possible reactive metabolite from acetylene or bromine can be avoided by different 
metabolic pathways. Therefore, the C(8)-cyclopropyl analog, GL-III-43 (86) was synthesized 
based on this hypothesis. The aryl-bromide ethyl ester intermediate 6 was treated with cyclopropyl 
boronic acid in the presence of a Pd catalyst via a Suzuki cross-coupling reaction110 to yield the 
C(8)-cyclopropyl ethyl ester. The ester at C(3) was then saponified to furnish the corresponding 
carboxylic acid, as shown in Scheme 22.  
 
Scheme 22. Synthesis of GL-III-43 (86); the C(8)-cyclopropyl analog of 85. 
 
A phenolic group is one of the most common constituents for pharmaceuticals and has been 
widely used in industrial synthesis. In addition to the replacement of the Cl and cyclopropyl groups 
at the C(8) position, the hydroxyl group was also used to substitute for a Br atom at the C(8) 
position. If active, the phenolic hydroxyl group would increase the hydrophilicity and further 
reduce the possible CNS effects due to its lower permeability across the BBB. Moreover, the C(8) 
OH analog might be a metabolite. The C(8)-OH analog, GL-IV-14 (88), was synthesized by a 
highly efficient copper-catalyzed one-pot SnAr reaction212 of the bromo ethyl ester intermediate 
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with potassium hydroxide in PEG-4000 (polyethylene glycol) as the solvent at 120-Celsius degrees 
for 12 hours at low cost and in good yield, as illustrated in Scheme 23. The other advantage of this 
process rests on its compatibility because the ethyl ester can be hydrolyzed into the corresponding 
acid in the same process while replacing the bromine with a phenolic hydroxyl group. This 
provides the C(8)-phenolic analog of GL-II-93 (85) for metabolic studies if need be, as well as the 
guinea pig tracheal ring assay.   
 
Scheme 23. Synthesis of GL-IV-14 (88); the C(8)-OH analog of 85. 
 
The carboxylic acid function has proven to be extremely valuable for the design of IMDZs, 
which target GABAARs for the novel treatment of asthma with limited CNS side effects due to its 
low permeability across the BBB. However, it has been reported that metabolism of a carboxylic 
acid might cause toxicity issues and adverse reactions which may result from the formation of 
reactive metabolic conjugates, such as acyl-coenzyme A thioesters derivatives (acyl-CoAs),213 
which might induce dysfunction of mitochondria as well as acyl glucuronides, which might trigger 
an immune response.214 It can not be concluded that the key carboxylic acid moiety should be 
avoided due to potential side effects or toxicity, since there are more than 450 approved 
drugs215 on the market, which contains this moiety. Moreover, people are actually exposed to 
food and products which contain the acid functional group, such as fatty acids or vinegar. However, 
attention should be paid to this structural alert and the possibility of reactive metabolites. Although 
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85 did not exhibit any side effects in recent in vivo rodent models and in vitro assays, it is 
reasonable to explore the surrogate structures of the carboxylic acid moiety while evaluating other 
properties of 85.  
One class of common surrogates for an atom or a functional group is bioisostere, which 
generally can be used as a primary strategy in medicinal chemistry. That is because bioisosteres 
have similar electron density, volume, and physiochemical properties as the functional group in 
question, which can result in similar pharmacological effects and perhaps a longer duration of 
action as well. Indeed, there are numerous bioisosteres of carboxylic acids due to its essential role 
in drug design. A recent structural-property relationship study reported the physiochemical 
parameters of 24 classes of carboxylic acid bioisosteres, such as acidity, lipophilicity, permeability, 
solubility, etc.215 Based on this report, most of the bioisosteres are much more soluble than the 
carboxylic acid, itself, which provides another strategy to improve the solubility of 85 other than 
simple salt formation. Moreover, since a tetrazole is one of the carboxylic acid bioisosteres that 
has been studied in detail in the past few decades,216 several parameters of the tetrazole and 
carboxylic acid were compared in this study. A tetrazole exhibits similar acidity and lipophilicity 
as compared to the carboxylic acid.216 However, on the contrary to the previous studies that 
tetrazole showed remarkably less permeability across the BBB and much stronger hydrogen 
bonding interactions than the carboxylic acid. This finding indicated that a tetrazole might be a 
suitable replacement for the carboxylic acid moiety in 85 not only to further reduce the penetration 
across the BBB but also avoid possible reactive metabolites that the acid might produce. Therefore, 
the C(3)-tetrazole analog of 85, GL-IV-21 (96) was synthesized.  
The synthesis of a tetrazole moiety has been widely studied, most of which is by [3+2] 
cycloadditions between an azide and a nitrile. However, most of the nitriles are toxic, and sodium 
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azide is expensive and somewhat dangerous because of explosions. Therefore, the synthesis of the 
tetrazole analog GL-IV-21 (96), was conducted with a one-pot “click” synthesis217 by the reaction 
of an aldehyde, hydroxylamine, and 1-butyl-3-methylimidazolium azide ([bmim]N3) as a “green” 
azide source, in the presence of 20 mol% Cu(OAc)2 as the catalyst, as shown in Scheme 24. This 
chemistry was pioneered by Nobel Laureate Barry Sharpless. 
 
Scheme 24. Synthesis of GL-IV-21 (96); tetrazole analog of 85. 
 
2.3.3.3.2. Evaluation of GL-II-93 Analogs, to Date  
The analogs of 85 were sent to Dr. Michael R. Stephen at UWM for the assessment of 
cytotoxicity on both HEK293T and HEPG2 cell lines for a 48 h incubation time. As expected, the 
LD50 values of GL-II-93 analogs in HEK293T and HEPG2 are all higher than 400 µM, as 
illustrated in Table 27, which further indicates that the carboxylic acid function and its analogs 
have a very good safety profile in these two cell lines. This is regardless of any modifications in 
85. The further biological data on other analogs awaits the assays. 
Table 27. Cytotoxicity of GL-II-93 (85) analogs.  
No. Compound HEK293 LD50 (μM) HEPG2 LD50 (μM) 
1 GL-II-93 >400 >400 
2 SH-053-2'F-R-CH3-acid >400 >400 
3 SH-053-2'F-S-CH3-acid >400 >400 
4 GL-II-30 >400 >400 
5 GL-II-51 >400 >400 
340 
 
6 GL-II-79 >400 >400 
7 GL-III-19 >400 >400 
8 GL-III-20 >400 >400 
9 GL-III-43 >400 >400 
10 GL-III-54 >400 >400 
11 GL-IV-14   
12 GL-IV-21   
 
The C(8)-cyclopropyl analog GL-III-43 (86) was evaluated in the airway 
hyperresponsiveness (AHR) assay at 100 mg/kg twice daily for 5 days in Dr. Arnold’s group 
(Gloria Forkuo) to determine if the compound can induce any reduction on AHR reduction effect. 
Unfortunately, 86 presented a similar sRaw value, as compared to the ova s/c control, which 
indicated that 86 did not protect the MCh challenged mice at all concentrations and is an inactive 
compound in this asthma model, as depicted in Figure 115.  
 
Figure 115. The effect of GL-III-43 (86) on AHR, orally administered. The sRaw was measured at an increasing 
dosage of MCh by a DSI’s Buxco FinePointe noninvasive airway mechanics instrument. GL-III-43 was orally 
administered in ova s/c BALB/c mice at 100 mg/kg twice daily for 5 days. Data represent mean ± SEM (n=10). 
*** represents significance p < 0.001. 
 
After the synthesis of GL-III-54 (87), the C(8)-Cl analog was sent to Dr. Janet Fisher’s 
research lab at the University of South Carolina for the evaluation of efficacy by 
electrophysiological recordings. Illustrated below in Figure 116 is the efficacy data of 87 as 
compared to 85 at 0.1 and 1 μM. Overall, (data not received on α6 subtypes yet), the C(8)-Cl 
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analog 87 was able to potentiate all subtypes with the exception of α4 subtypes, which remained 
at the baseline GABA 100 %, but was slightly less potent than the C(8)-bromo 85.  It was 
interesting that the bromo acid 85 was more subtype selective at α4 subtype,s as compared to the 
other subtypes at 0.1 μM. However, the chloro and 87 did not show any α4 subtype selectivity at 
both 0.1 and 1 μM. At the higher concentration of 1 μM, the efficacy of 87 appeared similar to the 
normal efficacy pattern of diazepam, but with no potentiation at α4 subtypes. The diazepam related 
compounds with a pendant phenyl ring normally do not bind at DI (α4, α6) subtypes. 
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Figure 116. Potentiation of GL-III-54 and GL-II-93 in comparison at α1-5-containing GABAARs. The transiently 
transfected HEK-293T cells with α subunits of GABAAR were used to measure the average enhancement of 
current evoked to GABA EC3 by 0.1 μM or 1 μM GL-III-54 and GL-II-93 by patch clamp. Data represented 
mean ± SEM (n = 5). 
 
Because 87 was able to potentiate most of the GABAAR subtypes and exhibited a structural 
similarity to 85, this C(8)-Cl analog was expected to be active in the organ bath assay for relaxation 
of pre-contracted ASM. This was carried out by Dr. Emala’s group, at Columbia University. In 
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order to confirm this hypothesis, 87 was examined in this asthma ex vivo model. Indeed chlrolide 
87, demonstrated in Figure 117 below, did relax the effect on ASM on a pre-existing substance P-
induced contraction on guinea pig tracheal rings. The comparator 85 was run side-by-side in the 
same assay with tissue from the same animals and vehicle controls. There are a couple of 
observations regarding the data below. In this series of experiments, bromide 85 was much more 
potent than in our previous published data187 (Furkuo GS, 2018, see Figure 86 for comparison). 
There are a number of explanations that could explain this increase in activity, such as handling 
the mice differently, the experience of the person who ran the assay, etc. Notably, 85 did exhibit a 
relatively larger relaxation effect on ASM in the most recent experiments, as compared to the 
earlier published findings.187 Furthermore, the C(8)-chloro analog 87 was also able to reduce the 
ASM contraction at 25 μM similar to 85, and it induced a significant relaxation at 50 and 100 μM, 
which was also observed from the previously published Figures on the bromo acid 85. However, 
at the highest concentration (100 μM), 85 relaxed ASM much more, as compared to 87 at all 4 
time points measured. This dose demonstrates the C(8)-bromo analog 85 is more potent in the 



































































































































































































Figure 117. The ASM contractile force in guinea pig tracheal rings contracted with 1uM substance P and then 
treated with 25, 50 or 100 μM GL-II-93 (85) or GL-III-54 (87) in comparison.  Data are expressed as the amount 
of muscle force remaining at 15, 30, 45 and 60 minutes, as compared to the initial substance P-induced 
contractile force.  *, **, *** represented the significance p < 0.05, 0.01, 0.001 as compared to vehicle control 
(0.1% DMSO), respectively.  $, $$, $$$ represents p< 0.05, 0.01, 0.001 compared to 100 μM GL-III-54, 
respectively. The significance was determined by a two-way ANOVA repeated measures analysis with 
Bonferroni selected post-test comparisons  n = 7 for GL compounds or 14 for vehicle controls. 
 
2.3.4. Discussion 
Current treatments of asthma usually include the β2-adrenergic agonists and corticosteroids. 
However, those therapies are either not very effective in some patients due to improper use of 
inhalers by children and the elderly, or the compounds induce severe adverse effects, which may 
be exacerbated with overuse or long-term use of the prescribed medications. Based on the 
discovery of the expression of α4/5-containing GABAAR subtypes in the lung by Emala et al., the 
investigation of a novel treatment for asthma with “privileged structure of IMDZ” has been 
underway for the last few years. This is ample preclinical data which indicate this is a novel and 
important approach.57-58, 99, 180-181, 183, 185, 187-189  
The continued study of SH-053-2'F-R-CH3-acid (68), the α5-agonist, has shown it 
exhibited mild ASM relaxation effects on guinea pig tracheal rings ex vivo but did not induce any 
CNS effects due to limited or no penetration of the BBB. Whereas its parent compound, the ethyl 
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ester 1, caused mild sedation at higher doses.185 Moreover, acid 68 demonstrated a good PK profile, 
as mentioned with nearly no brain distribution and very good metabolic stability. It also protected 
the mice in vivo from MCh induced airway inflammation after a 5-day treatment. The compound 
did not cause overproduction of mucus.185  
From the unpublished results, the C(8)-bromo methyl ester MP-III-058 (84) demonstrated 
the most significant ASM relaxation, as compared to all compounds screened, yet the ester 
function was considered a problem for the molecule could pass through the BBB and trigger CNS 
effects. In order to keep the desired properties of both 84 and 68, a new ligand 85 was designed, 
synthesized and evaluated in several asthma models. The carboxylic acid function was reinstated 
to prevent penetration through the BBB, while the C(8)-bromo atom was retained to improve the 
effect on ASM relaxation.   
Consequently, the bromo acid 85 exhibited good in vitro properties on several parameters, 
which resulted in evaluation of the ligand in animal models. First of all, the electrophysiological 
recordings have demonstrated that 85 exhibited good potentiation at α1-5-containing GABAAR at 
both 0.1 and 1 µM, and it was slightly more potent at the α4 subtype at 0.1 µM, as compared to 
the other subtypes.187 In addition to GABAARs, it did not bind to other receptors, channels or 
transport proteins. Importantly, there was no hERG or PBS affinity from the PDSP study (Dr. Roth, 
North Carolina). Secondly, due to the acid function, 85 was nearly non-detectable in the brain on 
PK studies, and had good tissue distribution, as well as a relatively long half-life in blood and lung. 
The low brain fraction indicates that the carboxylic acid function is too hydrophilic to pass across 
the lipophilic BBB. Examination of the data wherein no motor impairment nor sedation was 
observed from the rotarod study further confirmed the acid function was critical to avoid CNS side 
effects. Thirdly, the in vitro metabolism data indicated that 85 was metabolically very stable with 
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more than 90 % remaining after 2 hour-incubation in HLM.187 Fourth, only 10 % of the original 
85 was detected in mouse urine and feces after oral administration daily.189 Finally, the compound 
demonstrated a safe cytotoxicity profile with an LD50 value higher than 400 µM in both HEK293T 
and HEPG2 cell lines. 
Since bronchoconstriction is one of the essential hallmarks of asthma, GL-II-93 
(MIDD0301) 85 was investigated in an ASM contraction model in different species. In an ASM 
relaxation organ bath assay, 85 exhibited the capacity to alleviate the pre-contracted ASM by 
substance P (1 µM) in guinea pig tracheal rings in a time-dependent (0 - 60 min) and dose-
dependent (0 - 100 µM) manner. With the use of a different clinically relevant agent, histamine, 
employed for the induction of muscle contraction at 10 µM, and 85 again demonstrated a 
significant reduction of the muscle force in the same manner as in the substance P induced 
contraction assay. Additionally, the organ bath assay on human tracheal ASM strips was also 
conducted with histamine-induced contraction at 10 µM. The bromo acid 85 (100 mg/kg) exhibited 
a significant reduction of the ASM contraction within 30 min, as compared to the vehicle DMSO. 
Moreover, acid 85 dilated the lumenal area of the MCh-contracted (100 nM) airway significantly 
in the ex vivo precision-cut lung slice (PCLS) experiments from mouse peripheral airways. In all 
ASM relaxation assays, 85 was able to mitigate the muscle contraction significantly, regardless of 
animal species.  
Besides the ability to relax bronchoconstriction, the 85 was also evaluated in other asthma 
models to determine its effects on several clinical features of asthma. First, an oral administration 
of 85 was able to protect mice from nebulized MCh challenge at an increasing concentration in a 
dosage-dependent manner, whereas the marketed drug salmeterol failed to do so in the AHR 
assay.187 In addition, a similar test was performed, but with nebulized 5 nM 85 and the results 
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illustrated that 85 reduced the central lung resistance values significantly. After the resistance 
assay, the concentration of 85 was measured in serum, lung and brain. Examination of the results 
of 85 indicated high levels of 85 were found only in lung other than serum and brain, and it was 
rapidly eliminated within 30 minutes with only 30 % remaining.188 These data expanded the use 
of 85 for not only can it be administrated as an orally active pill similar to the long-acting β2 
agonists for chronic asthma, but also as an aerosol similar to short-acting β2 agonists for acute 
asthmatic attacks. Secondly, besides AHR, airway inflammation is also an important factor in 
asthma, which usually induces more immune cell over-expression. The acid 85 reduced the 
population of total immune cell numbers, CD4+ T cells, Siglec F+ cell (eosinophils) as well as 
F4/80+ cells (macrophages). The reduction of leukocytes was further visualized by EdU with 
“click chemistry.” Thirdly, mucus over-expression is another essential feature of asthma; the 5-
day treatment of 85 from 20 mg/kg to 100 mg/kg did not induce a significant change of mucus 
levels at all dosages. Fourth, 85 was able to decrease the expression of IL-17A, IL-4, and TNF-α, 
which are important lung cytokines in mice without affecting the expression of IL-10, an anti-
inflammatory cytokine.187 
In addition to the ability to relax contracted ASM and several other anti-asthmatic 
properties, immunotoxicity studies of 85 for possible off-target immune response reduction or side 
effects were conducted at 100 mg/kg with a twice-daily dose over a 28-day long-term period in 
both male and female mice.189 The acid 85 treatment did not induce a change in animal weights; 
in organ weights such as the spleen, thymus, or Peyer’s patches from the intestine, which have 
been reported to be reduced by other anti-inflammation drugs.218 The consumption of 85  twice 
daily for 28 days did not decrease the systemic immune suppression induced by DNP-specific 
antibody after quantifying the IgG level. Analysis of the results from immunotoxicity studies 
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indicated there was no off-target immunotoxicity effects observed when orally administrated twice 
daily for a 28-day treatment with 85. 
Stability studies indicated that 85 was not stable under acidic conditions such as in the 
stomach due to the hydrolysis of the [C(6)-N(5)] imine and reached equilibrium rapidly. 
Subsequently, the open ring hydrochloric salt 90, which was resulted, would be neutralized under 
basic conditions to the free imine, and further cylized back to the original form 85 at pH = 5. The 
higher pH such as the conditions in the intestines would produce the salt form of the 85. Further 
investigation of the bioavailability of 85 is ongoing in Dr. Arnold’s research group.  
Based on the accumulated evidence on 85, its analog research on analogs is underway as 
well. By modification of the chirality at the C(4) position, the S-isomer of 85 and the non-chiral 
analogs were synthesized to explore the role of the chirality in the structure to the anti-asthmatic 
activity. By changing substituents at the C(8) position, several analogs were made with a different 
functional group, such as a chlorine atom, a cyclopropyl group, and a hydroxyl group. A carboxylic 
acid bioisostere was also synthesized by introducing a tetrazole ring at the C(3) position. From the 
cytotoxicity data, the carboxylic acid bioisosteres are c non-toxic. To date, only two of the new 
analogs have been evaluated biologically. The C(8)-cyclopropyl analog 86 did not protect the 
animals from the MCh challenge in the AHR assay. The C(8)-Cl analog 87 was found to have a 
similar potentiation at α1/2/3/5 GABAARs but did not show any efficacy at α4, whereas 85 was 
slightly more potent at the α4 subtypes at 0.1 µM. However, 87 was predicted to have a similar 
effect to 85 because a chlorine atom is very similar to a bromine atom. Therefore 87 was tested in 
the organ bath assay. This ligand exhibited significant ASM relaxation effects, as expected, but 85 
exhibited a statistically significant more potent effect than 87 at the highest dose of 100 mg/kg in 




Taken together, GL-II-93 (85) is a novel ligand that acts through GABAARs, possesses 
good PK, safety and metabolic stability profiles. It also exhibited significant effects on ASM 
relaxation irregardless of animal species. It reduced airway hyperresponsiveness and airway 
inflammation significantly without any binding at the other 48 receptors at PDSP nor demonstrated 
any off-target detrimental immunotoxicity effects. It did not interact with PBR nor hERG receptors, 
which is very important. The QT issues in the heart should be minimized and cholesterol transport 
unaffected. All this evidence supports the identification of GL-II-93 (85) as a potential treatment 
for asthma for administration both as an orally active (pill) or as a constituent in an aerosol. Most 
importantly, there was little or none acid 85 in the brain due to the lack of BBB penetration. 
Therefore, it provides an asthma drug candidate without any CNS side effects observed, to date. 
The synthesis of 85 has been modified and presented to GMP companies, such as Alcami 
Corporation. Further evaluation of 85, such as a Phase I/II metabolism studies, is ongoing, as well 
as analog optimization studies with the aid of molecular modeling programs. This ligand GL-II-
93 (85) provides a potential novel treatment of asthma, which can be applied by both the oral route 









2.3.6.1. ASM Relaxation of SH-053-2'F-R-CH3-acid (Dr. Emala, Columbia University)99 
These experiments were carried out by Dr. Emala’s research group, Columbia University. All 
studies were run after approval of the Columbia University IACUC. Adult male Hartley guinea 
pigs were euthanized by i.p. injection of 100 mg/kg of pentobarbital. The tracheas with 2 cartilage 
rings were removed and transected, which was followed by rinsing for 1 h with 5 buffer exchanges 
to remove any remaining pentobarbital. A cotton swab was used to remove the epithelium, after 
which a 4 mL jacketed organ bath (Radnoti Glass Technology) was used to suspend the strips. One 
of the strips was attached to a stationary hook, and the other one was linked to an FT-03 force 
transducer (Grass-Telefactor, West Warwick, RI), and Acqknowledge 7.3.3 software (Biopac 
Systems, Goleta, CA) was used to couple it to the computer. The tracheal rings were bathed in 4 
mL of KH buffer solution with the following compositions (in mM): 5.6 KCl, 1.3 NaH2PO4, 118 
NaCl, 0.2 MgSO4, 0.5 CaCl2, 25 NaHCO3, 5.6 D-glucose) with 10 μM indomethacin (DMSO 
vehicle final concentration of 0.01 %), which had 5% CO2 and 95% O2 at pH 7.4, and at 37 °C 
bubbled in continuously. The tracheal rings were equilibrated at 1 g of isotonic tension for 1 h with 
the addition of new KH buffer every 15 min. All tracheal rings were precontracted with 10 μM N-
vanillylnonanamide and then two cycles of cumulatively increasing concentrations of ACh 
(0.1−100 μM) with a buffer wash extensively between and after the two cycles with 1.0 g of the 
resting tension. Pyrilamine (10 μM) and tetrodotoxin (1 μM) were then added to the buffer in the 
baths in order to eliminate the effects of airway nerves and histamine receptors. Once a stable peak 
line at 1.0 g resting tension was achieved, 1 μM of substance P was used to induce the contraction 
of the tracheal ring. After a stable contraction was established, the compound or vehicle (0.1% 
DMSO) was added to the organ bath mixture. After the exposure of compound, the percentage of 
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initial contractile force remaining at specific time points was obtained as compared to a percentage 
of the remaining force in tissues with the vehicle. 
In other human ASM, strips were also dissected from the human trachea, which was obtained from 
lung transplantations incidentally from healthy donor lungs. The Columbia University IRB has 
reviewed the study protocol and confirmed it is not human subject research. ASM strips were 
suspended in organ baths, as described above in KH buffer, which was oxygenated at 37 °C, and 
reached 1.5 g of resting tension. The buffer exchanges were conducted for 1 h to reach equilibration 
at every 15 min, after which then the ASM strips were contracted by an increasing concentration 
of ACh (100 nM - 1 mM) for 3 cycles, which was followed by buffer exchanges extensively 
between and after these pre-contractions. The buffer was added with pyrilamine (10 μM), 
tetrodotoxin (1 μM) and MK571 (10 μM) before the contraction of each strip to calculate the EC50 
concentration of ACh. Once a stable contractile force was established at 15 min, the buffer was 
added with 100 μM of a compound or the vehicle (0.2% ethanol), and the stable contractile force 
was measured over 1h continuously. The remaining contractile force at different time points 15, 
30, 45 and 60 min was reported as a percentage of the initial ACh-mediated contractile force. 
 
2.3.6.2. Evaluation of AHR of SH-053-2'F-R-CH3-acid (Dr. Gloria Forkuo, UWM)99 
These experiments were carried out by Gloria Forkuo from Dr. Arnold’s research group, at UWM. 
The DSI’s Buxco FinePointe Non-Invasive Airway Mechanics instrument was used to measure 
the AHR to MCh in conscious, spontaneously breathing mice. Before measurements, mice were 
trained to climb the chambers daily for 15 min for 5 days. Before data collection, the calibration 
of the chamber was conducted at each time. Briefly, a combination of the thoracic chamber and 
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the nasal chamber provides the computation of sRaw. The sRaw value was calculated by the 
FinePointe software with additional ventilatory parameters by the NAM analyzer. Mice were 
exposed to nebulized PBS (baseline), or MCh (1.5625 − 12.5 mg/mL) for 1 min. The readings 
were recorded and the average was calculated for 3 min for nebulization. Data were expressed as 
sRaw versus the MCh concentration (mg/mL), which was used to produce the aerosol. 
 
2.3.6.3. Pharmacokinetic Study of SH-053-2'F-R-CH3-acid (Revathi Kodali, UWM)99 
These experiments were carried out by Revathi Kodali from Dr. Arnold’s research group, at UWM. 
The Swiss Webster female mice received the test compound or vehicle in 2.5 % polyethylene 
glycol and 2% hydroxypropyl methylcellulose solution at 25 mg/kg by intragastric gavage. At each 
time point 10, 20, 40, 60, 120, 240 and 480 minutes, four mice were sacrificed by CO2 anesthesia 
and this was followed by cervical dislocation. Blood was collected into heparinized tubes, whereas 
lungs and brain were obtained as well by disection. Liquid nitrogen was used to store the samples 
until analysis. 
The sample preparation and LC/MS: Blood samples were thawed on ice, then vortexed for 10 s. A 
100 μL sample was added to ACN (400 μL) and mixed with Hz-166 (100 nM) as an internal 
standard. The samples were vortexed for 30 s and then centrifuged for 10 min at 12,000 x g. The 
clean tubes were used for transferring the supernatant. The mixture, which resulted, was then 
concentrated by using a Speedvac concentrator. The residue was added to 400 μL of mobile phase 
solution and 0.22 μm nylon centrifugal filter units (Costar) were used for the required spin-
filtration. After reconstitution, the samples were diluted properly, followed by addition of the 
verapamil control, then the injection of 5 μL the sample was performed into the LC-MS/MS. After 
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the brain and lung tissue samples were thawed, weighed, and homogenized by a Cole Palmer 
LabGen 7B Homogenizer, and they were added separately to a 400 μL ACN solution containing 
then internal standard. All samples were centrifuged at 12,000 x g for 10 min. The supernatant was 
recovered, and the sample preparation for LC-MS/MS analysis was the same protocol employed 
for the blood samples. 
The high-performance liquid chromatography (HPLC) was conducted with a Shimadzu Nexera 
X2 LC30AD series pump (Shimadzu, Kyoto, Japan). Analytes were separated by a C18 column 
(2.1 mm × 100 mm, 5 um particle size, Restek, California, US) under a gradient elution at a flow 
rate of  0.4 mL/min for the compound. The ACN and water (both containing 0.1% formic acid) 
were used as the mobile phase. The time program followed in this order: 20 % B → 70 % B (3 
min) → 99 % B (5 min), held at 99 % B (8 min), return to 10 % B (9 min), held (9.5 min) and 70 % 
B → 70 % B (6 min), and the column temperature was at 40 °C. 
A Shimadzu 8040 triple quadrupole mass analyzer (Shimadzu, Kyoto, Japan) was used to monitor 
the analytes with electrospray; moreover, atmospheric pressure ionization runs were done in dual 
(DUIS) mode under the positive mode. A multiple reaction monitoring (MRM) mode was applied 
for monitoring the following transitions. The transition ion pairs for SH-053-2’F-R-CH3-acid are 
at m/z 360.0 > m/z 342.10, m/z 360.0 > m/z 316.00, m/z 360.0 > m/z 301.10, m/z 360.0 > m/z 
249.05, and m/z 360.0 > m/z 219.90. Hz-166 transition pairs are as follows: m/z 356.90 > m/z 
311.15, m/z 356.90 > m/z 283.15, and m/z 356.90 > m/z 282.15. The transition pairs for verapamil 
were m/z 454.70 > m/z 165.05, m/z 454.70 > m/z 150, as well as m/z 454.70 > m/z 303.0. The 
optimal sensitivity was obtained by the optimization of the collision energy for each transition. 
The operation conditions of the mass spectrometer were at the heat block temperature of 400°C, 
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with a 15 L/min drying gas flow, with 250 °C as the desolvation line temperature, a 1.5 L/min 
nebulizing gas flow, and 4.5 kV for both needle and interface voltages. LabSolutions software was 
used to perform the response acquisition. A linear regression analysis was used to fit the standard 
curve, and the calibration curve was used to calculate the validation samples of that day. The 
calculation of the mean and the coefficient of variance was conducted accordingly. A comparison 
of calculated concentrations to the corresponding nominal was performed for the accuracy. PK 
solutions software 2.0 was used for the calculation of pharmacokinetic parameters and the 
calculation was fitted to the equation as following: c = A•e-at + B•e-bt + C•e-ct. 
 
2.3.6.4. The Rotarod Study of SH-053-2'F-R-CH3-acid (Revathi Kodali, Nick Zahn, and 
Alec Huber, UWM)99 
These experiments were carried out by Revathi Kodali, Nick Zahn, and Alec Huber from Dr. 
Arnold’s research group, at UWM. The Swiss Webster mice were trained to stay on the rotarod 
apparatus (Omnitech Electronics Inc., Nova Scotia, Canada) at a steady speed of 15 rpm in order 
to maintain balance until the mice performance was achieved for 3 min at 3 different time points. 
The 100 mg/kg test compounds or the vehicle (2.5% polyethylene glycol and 2% hydroxypropyl 
methylcellulose in about 200 μL)  were administrated orally to groups of 9 mice. An i.p. injection 
of 5 mg/kg diazepam as a positive control was given in a solution of 40% propylene glycol, 50% 
PBS, and 10% DMSO. After the drugs were administrated, the mice were put on a rotarod 
apparatus at 3 time points of 10, 30, and 60 min separately. Briefly, if the mouse fell off the rotarod 
twice within 3 min, this was considered as a failure and was recorded for that time point. If the 
mice fell off the rotarod for one fall, this was considered not significant. One fall was common 
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after injection of vehicle. After 2 or 3 days of resting time, mice were then used to perform another 
rotarod test for a different test compound.   
 
2.3.6.5. Patch Clamp Studies of GL-II-93 (Dr. Fisher, University of South Carolina School 
of Medicine)187 
These experiments were carried out by Dr. Janet Fisher’s research group, University of South 
Carolina School of Medicine. The human embryonic kidney HEK-293T cell line (GenHunter, 
Nashville, TN) was used for the transfection of full-length cDNAs for GABAAR subunits 
(generously provided by Dr. Robert Macdonald, Vanderbilt University and D  David Weiss, 
University of Texas Health Science Center, San Antonio, TX) in mammalian expression vectors. 
All of the GABAAR subtypes were cloned in rat except for a human clone at α2 subtypes. The 
solution for cell maintenance conditions was 100 μg/mL streptomycin, 100 IU/mL penicillin, 10% 
fetal bovine serum and Dulbecco’s modified Eagle’s medium (DMEM). The calcium phosphate 
precipitation was used to perform the transient transfection of HEK-293T cells. A 1:1:1 ratio (α:β:γ) 
of 2 μg each of cDNAs was used for the cells, which received plasmids encoding GABAAR 
subtype cDNAs. A 1 μg of the plasmid pHook-1 (Invitrogen Life Technologies, Grand Island NY), 
which contained cDNA encoding the surface antibody sFv, was also used for the cell transfection 
in order to identify positively transfected cells. A 15% glycerol solution in PBS buffer [(50 mM 
BES(N,N-bis[2- hydroxyethyl]-2-aminoethanesulfonic acid), 280 mM NaCl, 1.5 mM Na2HPO4)] 
was added to the cells for 30 s after an incubation for 4 to 6 h at 3% CO2. The pHook expression 
was conducted with the selection procedure after 18−52 h with 3−5 μL of magnetic beads, which 
were coated with antigen. These were used for the cell pass and mixture for 0.5 to 1 h for the 
pHook antibody with approximately 6 × 105 beads. A magnetic stand was used to isolate the bead-
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coated cells. The supplemented DMEM was used to resuspend the selected cells, which were 
plated onto glass coverslips. The collagen was applied for recordings on the next day as well as 
poly L-lysine. The whole-cell recording configuration was used for the cell patch clamp at −50 
mV. The bath solution contained the reagents as following (in mM): 6 MgCl2, 1 CaCl2, 8.1 KCl, 
and 142 NaCl, 10 HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid] at pH = 7.4 and 
295−305 mOsm for osmolarity. A solution that contains (in mM) 10 HEPES, 1 MgCl2, 153 KCl, 
and 5 K-EGTA (ethylene glycol-bis(β- aminoethyl ether N, N, N′, N′-tetraacetate), was used to 
fill the recording electrodes at pH = 7.4 and 295−305 mOsm for osmolarity. The frozen stocks in 
water or the freshly made bath solution was used for the dilution of GABA. The DMSO or diluted 
bath solution with the highest DMSO level of 0.01 % of cells, was used to dissolve the test 
compound. A two-stage puller (Narishige, Japan) was applied to pull the patch pipettes from 
borosilicate glass (World Precision Instruments, Sarasota, FL) with 5−10 MΩ of resistance. A 
computer-driven stepper motor (SF-77B, Harvard Apparatus, Holliston, MA, open tip exchange 
time of <50 ms) was applied to control the 3-barrelled solution delivery device for 5 s with the 
solutions containing GABA or GABA plus test compounds. A continuous flow of external solution 
was applied through the chamber. An Axon 200B (Foster City, CA) patch clamp amplifier was 
used to record the currents. The Prism (GraphPad, San Diego, CA) and programs Clampfit 
(pClamp9 suite, Axon Instruments, Foster City, CA) were applied for analyzing the whole cell 
currents. 
 
2.3.6.6. Pharmacokinetic Study of GL-II-93 (Dr. Arnold, UWM)187 




2.3.6.7. Liver Microsomal Stability Study of GL-II-93 (Revathi Kodali, UWM)187  
These experiments were carried out by Revathi Kodali from Dr. Arnold’s research group, at UWM. 
A digital dry bath, which was able to shake and heat (Fischer Scientific, Pittsburgh, PA) was used 
for the pre-incubation of  4 µL of 1 mM test compound at 10 µM as the final concentration in 
DMSO at 37 °C for 5 min. This process was carried out in a total volume of 391.2 µL mixture, 
which contained 80 µL of phosphate buffer (0.5 M, pH 7.4), 20 µl of NADPH Regenerating 
System Solution A and 4 µL of NADPH Regenerating System Solution B (BD Bioscience, an Jose, 
CA), as well as water (282 µL). 8.8 µL of MLMs (Life technologies, Rockford, IL) or 8.8 µL of 
HLMs (BD Gentest, San Jose, CA) was added to the preincubation mixture, at a protein 
concentration of 0.5 mg/mL, to initiate the reaction. The time intervals at 0 (without microsomes), 
10, 20, 40, 60, 90 and 120 min was the time point for taking 50 µL aliquots. A cold ACN solution 
(100 µL) containing 3 µM of 4,5-diphenylimidazole as an internal standard was used for the 
addition of each aliquot. After the addition, the mixture was sonicated for 10 seconds and then 
centrifuged for 5 min at 10,000 rpm. The Spin-X HPLC filter tubes (Corning Incorporated, NY) 
were employed for transferring the 100 µL of the supernatant layer, after which the tubes were 
centrifuged for 5 min at 13,000 rpm. A 100 fold dilution was carried out for the filtrate, and the 
mixture was analyzed by LC-MS/MS (Shimadzu LCMS 8040 instrument) subsequently. The 
calculation of the ratio of the peak areas of test compound and the internal standard was carried 
out at every time point, and the linear slope (k) was determined by plotting the natural log of the 
ratio against time. The calculation of the half-life (0.693/k), metabolic rate (k*C0/C), as well as 
the internal clearance (V*k) were carried out, where V is the volume of incubation in µL per 
microsomal protein in mg, C is the concentration of microsomes, k is the slope, and C0 is the initial 
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concentration of test compound. All experiments were carried out on two independent days and 
were repeated for three times to reach statistical significance.   
 
2.3.6.8. Evaluation of Mouse Plasma Binding of GL-II-93 (M. S. Rashid Roni, UWM)187 
These experiments were carried out by M. S. Rashid Roni from Dr. Arnold’s research group, 
UWM. The 500 nM of 4,5-diphenylimidazole and 1 mM MIDD0301(GL-II-93) were added in the 
tube in methanol. An Eppendorf tube was used to dispense the 495 μL of thawed mouse plasma 
with 5 μL of 1 mM GL-II-93. A rapid equilibrium dialysis device (Thermo Scientific) which 
contained a marked red retainer well was used for transferring 400 μL of the previous solution, 
and this was followed by the addition of 600 μL of PBS buffer in the adjacent buffer chamber, 
which was repeated for 3 times at different wells in the plate. The sealed plate was placed onto a 
shaker for 4 h at 250 rpm. An Eppendorf tube was used to transfer the 50 μL of the sample from 
the red well combined with 50 μL PBS. The proteins were precipitated after the addition of  300 
μL of cold methanol, which was then vortexed and incubated 30 minutes on ice, then centrifuged 
at 10000 rpm for 10 min. To a new tube, 50 μL of supernatant combined with 25 μL of a 500 nM 
4,5-diphenyl imidazole solution, as internal standard, and 425 μL of methanol was added. A 
Shimadzu 8040 instrument was used for the LCMS/MS analysis of samples. A calibration curve 
was applied for quantification. Three experiments were repeated for statistical analysis.  
 
2.3.6.9. Quantification of GL-II-93 by LCMS/MS (M. S. Rashid Roni, UWM)189 
These experiments were carried out by M. S. Rashid Roni from Dr. Arnold’s research group, at 
UWM. Urine collection: After feeding, the mouse was hung vertically by gently grasp on the back 
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of the neck of GL-II-93 treated mouse. Beneath the penis or female urethral orifice, a collection 
tube was placed to collect 50-100 μL urine without compulsion, which was used as a standard 
method for collecting urine after compound dosing. A solution containing 100 μL of urine, 400 μL 
methanol and SH-053-2’F-R-CH3-acid as an internal standard was used for the quantification of 
GL-II-93. The solution was then centrifuged for 10 min at 10,000 x g. The solvent of the 
supernatant sample was removed and evaporated(speedvac). The solid, which was obtained, was 
added to a solution of 400 μL of methanol and 4,5-diphenyl imidazole as a second internal standard; 
and a 0.22 μm nylon centrifugal filter unit (Costar) was used to filter off the solid. LCMS/MS was 
applied on the liquid for the quantification of GL-II-93. Faeces collection: From the bedding, the 
expressed faecal pellets were collected on the last dosing day, and any adherent wood bedding 
shavings were removed after collection. After combining the faecal samples from each cage 
housing a mouse with GL-II-93 treatment, the sample was dried overnight under vacuum (15 torrs). 
The 100 mg of dried faeces was pulverized and combined with 400 μL methanol with SH-053-
2’F-R-CH3-acid as an internal standard, and the same protocol for urine samples was employed 
for quantification of GL-II-93 in the faeces sample. 
 
2.3.6.10. Rotarod Assay of GL-II-93 (Dr. Arnold, UWM)187 
Refer to Section 2.3.6.4 for details. 
 
2.3.6.11. Cytotoxicity Study of GL-II-93 (Dr. Michael R. Stephen, UWM) 
These experiments were carried out by Dr. Michael R. Stephen from Dr. Cook’s research group, 
at UWM. The human embryonic kidney 293T (HEK293T) and human liver hepatocellular 
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carcinoma (HEPG2) cell lines were purchased (ATCC) and cultured in 75 cm2 flasks (CellStar). 
A DMEM/High Glucose (Hyclone, #SH3024301) media was used for cell growth. In addition, 5 
x 106 units of penicillin and streptomycin (Hyclone, #SV30010), 10 mM HEPES (Hyclone, 
#SH302237.01), 10% of heat-inactivated fetal bovine serum (Gibco, #10082147) and non-
essential amino acids (Hyclone, #SH30238.01) were added to the media. Then 0.05% Trypsin 
(Hyclone, #SH3023601) was used to harvest the cells, and this was followed by PBS washing. A 
sterile white, optical bottom 384-well plate (NUNC, #142762) was used for dispensing the washed 
cells. After 2 h, a Tecan Freedom EVO liquid handling system, which was equipped with a 100 
nL pin tool (V&P Scientific), was used for transferring the solution, which contained the 
compound. Then DMSO was used as a negative control, whereas the positive control was 3-
dibutylamino-1-(4-hexyl-phenyl)-propan-1-one (25 mM in DMSO, positive control). After 48 h-
incubation, the cells were tested on CellTiter-Glo™ (Promega, Madison, WI). A Tecan Infinite 
M1000 plate reader was applied for luminescence readings. The assay was performed in 
quadruplet with three repeats. The results were normalized to the control value, and GraphPad 
Prism was used for the nonlinear regression analysis. 
 
2.3.6.12. Ex Vivo Guinea Pig Tracheal Ring Organ Bath Induced by Substance P (Dr. 
Emala, Columbia University)188 
Refer to Section 2.3.6.1 for details. 
 




These experiments were carried out by Dr. Emala’s research group, at Columbia University. The 
guinea pigs were anesthetized by i.p. injection of 100 mg/kg pentobarbital. After removing the 
trachea, eight similar segments, which consisted of 2 cartilaginous rings were transected from each 
trachea under a dissecting microscope. The epithelium was denuded with a cotton swab from these 
segments, water jacketed (37°C) organ baths (Radnoti Glass Technology, Monrovia, CA) were 
used to suspend the two strings. One of them was attached to a stationary hook, and the other one 
was linked to an FT-03 force transducer (Grass-Telefactor, West Warwick, RI), and an 
Acqknowledge 7.3.3 software (Biopac Systems, Goleta, CA) was used to couple the computer to 
the transducer. The tracheal rings were bathed in 4 mL of KH buffer solution with the following 
composition (in mM): 5.6 KCl, 1.3 NaH2PO4, 118 NaCl, 0.2 MgSO4, 0.5 CaCl2, 25 NaHCO3, 5.6 
D-glucose) with 10 μM indomethacin (DMSO vehicle final concentration of 0.01 %). Then 5% 
CO2 and 95% O2 at pH 7.4, and at 37 °C was bubbled into the solution continuously. The tracheal 
rings were equilibrated at 1 g of isotonic tension for 1 h with the addition of new KH buffer at 
every 15 min before the assay.  
Capsaicin (10 μM) was added to the buffer in the baths in order to eliminate the airway neural 
contribution to the effect of the contraction of ASM. All tracheal rings were contracted with two 
cycles of cumulatively increasing concentrations of ACh (0.1 μM - 0.1 mM) for the determination 
of the EC50 of each tracheal ring with the 6 KH buffer wash extensively to achieve 1.0 g of resting 
tension. In addition, 10 μM pyrilamine as an anti-histamine, 10 μM indomethacin as the inhibitor 
of prostaglandin synthesis, as well as 1 μM tetrodotoxin to inhibit neural transmission were added 
to the buffer to limit the interference factors. 
Then 10 μM histamine was used to induce the contraction of the tracheal rings. After a stable 
contraction was established, 100 μM compound or vehicle (0.1% DMSO) was added to the organ 
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bath mixture, and the contractile force was monitored and recorded. The relaxation effect of 
tracheas treated with GL-II-93 and those treated with a vehicle on the rings at 15, 30, and 45 min 
were compared.  
 
2.3.6.14. Ex Vivo Human Tracheal Airway Smooth Muscle Strip Organ Bath (Dr. Emala, 
Columbia University)188 
These experiments were carried out by Dr. Emala’s research group, at Columbia University. The 
ASM from human trachea was dissected into strips, and the epithelium was removed, and this was 
followed by suspending the strips in the organ bath as described above. However, 1.5 g was set as 
the resting tension. The determination of the ACh EC50 was carried out for each ASM strip. Also, 
10 μM indomethacin, 10 μM MK571 as a leukotriene D4 receptor inverse agonist and 1 μM 
tetrodotoxin were added to the buffer to limit the interference factors. The10 μM histamine was 
used to induce the contraction of the tracheal rings. After the stable contraction was established, 
100 μM compound or vehicle (0.1% DMSO) was added to the organ bath mixture, and the 
contractile force was monitored and recorded. The relaxation effect of GL-II-93 treated strips and 
vehicle-treated strips on the rings at 15, 30, and 45 min was compared.  
 
2.3.6.15. Ex Vivo Mouse Precision-Cut Lung Slice Experiments (Dr. Emala, Columbia 
University)188 
These experiments were carried out by Dr. Emala’s research group, at Columbia University. The 
male A/J mice were euthanized, their thoracic cavities opened, and warm 2% agarose was used to 
inflate the lungs. The agarose was allowed to cool for 20 min at 4°C, and then the lungs were 
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harvested and immersed in ice-cold Hanks’ balanced salt solution (HBSS) for 15 min. A 6% gelatin 
was employed to form a block, which was used to fully cover up the separated lung lobes. A 
vibratome (VF-300; Precision Instruments, Greenville, NC, USA) was used for dissecting the 
block into serial 130 μm sections. The overnight incubation of the lung slices, which contained a 
small peripheral airway was conducted in a solution that consisted of penicillin, low-glucose 
Dulbecco's modified Eagle's medium, L-glutamine, 1×antibiotic solution, and streptomycin 
(Thermo Fisher Scientific, Waltham, MA) with 10% CO2 at 37 °C. The airway with a lumen 
diameter of 100–300 μm airways, which contained active (beating) ciliated epithelial cells were 
used as lung slices for the experiment. A custom-made perfusion chamber was applied for 
mounting the lung slices, and a 10X objective was used for visualization of the peripheral airways. 
During imaging at rt, the HBSS containing Hepes (20 mM) was used for slice superfusion at pH = 
7.4. A charge-coupled device camera (KP-M1A; Hitachi), with a frame grabber (Piccolo; Euresys), 
and image-acquisition software (Video Savant; IO Industries) was employed for the digital image 
recording. The 100 nM MCh superfused in HBSS was used to induce airway contractions. Once a 
stable contraction was achieved, 100 μM GL-II-93 was added to the buffer in the continuous 
presence of MCh where PCLS were exposed. Each recorded image was used for the calculation of 
the lumenal area by using custom-written macros and normalization of the area before stimulation 
with MCh. 
 
2.3.6.16. Evaluation of GL-II-93 on AHR (Dr. Gloria Forkuo, UWM)187 




2.3.6.17. Evaluation of In Vivo Mouse Airway Resistance (Dr. Emala, Columbia 
University)188 
These experiments were carried out by Dr. Emala’s research group, at Columbia University. The 
mice were anesthetized with pentobarbital, and this was followed by paralysis by i.p. injection of 
10 mg/kg succinylcholine. A tracheostomy (tidal volume 10 mg/kg, 150 breaths/min, positive end-
expiratory pressure 3 mmHg) was utilized to ventilate mice mechanically. Then nebulized vehicle 
(25% ethanol in PBS) or 5 mM GL-II-93 (10-sec nebulization, 50% duty cycle; ~25 μL delivered) 
was administrated to the mice 10 min before the central lung resistance measurement. This process 
was conducted by the forced oscillatory technique during the challenge from the increasing 
nebulized concentration of MCh (0-25 mg/ml). The temperature was monitored, as well as EKG, 
during the experiment. An average of 3 measurements were required to determine the resistance 
values for each mouse at each MCh dose.  
After following the in vivo airway resistance experiment, the GL-II-93-treated mice were utilized 
for PK studies by a collection of the lung, brain and serum samples after 30 min of administration. 
The samples of serum were frozen at -20 ºC in a freezer and liquid nitrogen was used to snap freeze 
the samples from lung and brain. Then LCMS/MS was applied to determine the tissue 
concentration of GL-II-93. 
 
2.3.6.18. Quantification of Airway Inflammatory Cells (Dr. Gloria Forkuo, UWM)187 
These experiments were carried out by Gloria Forkuo from Dr. Arnold’s research group, at UWM. 
The 1 mL of Ca2+ and Mg2+ free PBS was used as a solution to perform the bronchoalveolar lavage 
(BAL) on BALB/c mice. BD red blood cell lysis buffer (BD Pharmingen, San Jose, CA) was used 
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for the red blood cells lysis. Then 4 different tubes were utilized for BALF split, and 6 μg/mL of 
2.4G2 mouse BD Fc Block (BD Pharmingen, San Jose, CA) was used to block the nonspecific 
binding to Fc receptors for 5 min. At this point, 100 μL of BSA stain buffer (BD Pharmingen, San 
Jose, CA) was applied for BALF cell staining at 4 °C for 30 min. The final concentrations of the 
following antibodies were contained in the buffer: FITC rat antimouse CD4 (1:500, RM4−5, BD 
Pharmingen, San Jose, CA), PE rat anti-mouse Siglec-F (1:500, E50-2440, BD Pharmingen, San 
Jose, CA), anti-mouse CD45 APC (1:1000, 30-F11, Affymetrix eBiosciences, San Diego, CA), 
and FITC anti-mouse F4/80 (1:200, M1/70 Affymetrix eBiosciences, San Diego, CA). The BD 
FACS Calibur (BD Pharmingen, San Jose, CA) was utilized for the flow cytometric studies. The 
live/dead propidium iodide viability stain (BD Pharmingen, San Jose, CA) was applied to exclude 
the dead cells. Now quest pro software (BD Pharmingen, San Jose, CA) was applied to analyze 
the data. All samples were run on high (60 μL/min) for 180 s to obtain the total inflammatory cell 
count. The calculation of the total inflammatory cell count as cells/mL was conducted by the gated 
anti-mouse CD45 positive events in the fourth channel (FL4). The differential cell populations 
were calculated from the multiplication of the total inflammatory cell count (cells/mL) with the 
frequencies of Siglec-F+ F4/80+, and CD4+cell populations. 
 
2.3.6.19. EdU Staining (Dr. Gloria Forkuo, UWM)187 
These experiments were carried out by Gloria Forkuo from Dr. Arnold’s research group, at UWM. 
Before ketamine/xylazine overdose, a single i.p. injection of 100 mg/kg EdU (Invitrogen, Carlsbad, 
CA) was administrated to mice in separate treatment groups: 100 mg/kg GL-II-93 and vehicle-
treated ova s/c mice. After the injection for 4 h, mice were euthanized, and lungs were removed, 
fixed in formalin, and embedded with paraffin. The Fisher Superfrost Plus Slides were employed 
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for mounting of the 6 μm lung sections. A Click-iT EdU imaging kit (Invitrogen, Carlsbad, CA) 
was applied for the EdU staining and followed the manufacturer’s instructions. The 
deparaffinization of lungs was conducted in Histoclear, and graded ethanol was used for 
rehydration. Then 3% BSA (bovine serum albumin) in PBS was used to wash the tissue sections 
twice, and 0.5% Triton X-100 in PBS was further used to rinse the tissue for 20 min. The 3 % BSA 
in PBS was used for rinsing the permeabilized tissue slices twice, which was then incubated in the 
dark for 30 min with a Click-iT reaction cocktail that consisted of Alexa Fluor 488 azide, copper 
sulfate, and Click-iT reaction buffer. Then 3% BSA in PBS was used for the tissue slides after the 
previous step. The PBS wash was carried out once for the tissue slices, and 5 μg/mL Hoechst 
33342 was used for incubation for 30 min which to stain the DNA. The sections were rinsed with 
PBS twice, and Permount mounting media was used for coverslipping. All these steps were 
performed at ambient temperature. 
 
2.3.6.20. Histopathological Analysis of Lung Sections (Dr. Gloria Forkuo, UWM)187 
These experiments were carried out by Gloria Forkuo from Dr. Arnold’s research group, at UWM. 
After the collection of BALF using a tracheal cannula, 10% neutral buffered cold formalin was 
used for the lung perfusion. A suture was used to close the trachea which was removed from the 
mice and was further fixed at 4 °C for 2 days. The left lobe of the lung was dissected in cross-
section, then the dehydration, paraffin embedding, and sectioning were carried out for the prepared 
samples. The 6 μm slices were placed onto a positively charged glass, and this was followed by 
Histoclear dewaxing. An ethanol/water mixture was used to rehydrate the slides. Then periodic 
acid (1%) was used to conduct oxidation, which was incubated for 20 min with fluorescent Schiff’s 
reagent. The coverslip was washed by water then acidic alcohol by methyl salicylate and Canada 
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Balsam. A fluorescence microscope (EVOS, Invitrogen) was applied to stain slides. ImageJ 
software was used to analyze the quantification of the mucin volume density, which was 
determined by measuring the relationship between the stained area of glycoprotein and the length 
of the membrane basement. The same magnification scale was applied to all images. 
 
2.3.6.21. Expression of Cytokines (Dr. Gloria Forkuo, UWM)187 
These experiments were carried out by Gloria Forkuo from Dr. Arnold’s research group, at UWM. 
The lungs of the BALB/c mouse were removed and frozen in liquid nitrogen and stored at −80 °C 
in the freezer until cytokine analysis. A 200 μL T-PER tissue protein extraction reagent (Thermo 
Fisher Scientific Inc., Rockford, IL) with 1× protease inhibitor cocktail was used for the whole 
lung homogenization by a hand-held tissue homogenizer. They were centrifuged for 5 min at 
10,000 rpm and then transferred to pellet cell/tissue debris. A BD cytometric bead array mouse 
Th1/Th2/Th17 cytokine kit (BD Biosciences, San Jose, CA) was applied for the collection of tissue 
supernatant for further cytokine analysis using the manufacturer’s instructions. A CELLQuest and 
FCAP Array Software (BD Bioscience, San Jose, CA), as well as FACSCalibur (BD Bioscience, 
San Jose, CA) flow cytometry, was applied for sample analysis. The fluorescence intensities were 
presented for individual cytokine concentrations. 
 
2.3.6.22. The 28-Day Immunotoxicity Study of GL-II-93 (Nick Zahn, UWM)189 
These experiments were carried out by Nick Zahn from Dr. Arnold’s research group, at UWM. 
Specific pathogen-free conditions and standard conditions of humidity and temperature were 
applied for housing both the  8- and 6-week old male and female Swiss Webster mice (Charles 
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River Laboratory). The mice had free access to water and food under controlled 12-hr light and 
dark cycle. The University of Wisconsin−Milwaukee Institutional Animal Care and Use 
Committee (IACUC) had approved all animal experiments. 
Oral gavage: the mice received an oral gavage administration of 0.2 ml of GL-II-93 in a 2.5% 
polyethylene glycol (Sigma-Aldrich, St. Louis, MO, USA) and 2% hydroxypropylmethylcellulose 
solution (Sigma-Aldrich, St. Louis, MO, USA) with 20G gavage needles (Kent Scientific 
Corporation, Torrington CT, USA) twice daily for 7 days. The formulation of a dose of 100 mg/kg 
GL-II-93 was prepared with 100 mg of peanut butter. Morever, 100 mg of peanut butter with or 
without 100 mg of the compound was put in separate boxes for mice to consume this in the boxes 
which were outside of their homecages every other day. The mice stayed in the boxes while 
consuming the peanut butter and test compound; once they finished the treatment after 30 min, 
they returned to their home cages.  
 
2.3.6.23. Effect of GL-II-93 on DNP-KLH Immunization (Nick Zahn, UWM)189 
These experiments were carried out by Nick Zahn from Dr. Arnold’s research group, UWM. The 
100 mg of solid DNP-KLH (Sigma, 324121-100 mg) was used to prepare the 1 mg/mL DNP-KLH 
aqueous solution. To a mixture with 7.5 ml of a 40 mg/mL Al(OH)3 suspension (Thermo, Imject 
Alum 77161), 7.5 mL of the previously made solution was added. The immunization was carried 
out on days 1 and 21 by i.p. injection with 100 μL of this solution (50 μg DNP-KLH and 2 mg 




2.3.6.24. Study of GL-II-93 on Lymphoid Organs and Peyer’s Patches (Nick Zahn, 
UWM)189 
These experiments were carried out by Nick Zahn from Dr. Arnold’s research group, at UWM. 
Here CO2 asphyxiation was used for euthanizing the mice, which was followed by cervical 
dislocation and the blood withdrawn by cardiac puncture. The EDTA was used for the analysis of 
blood cells and platelets with half of the collected blood. For DNP-specific IgG ELISA, the other 
half of the blood was coagulated at rt and centrifuged at 2,000 rpm for 10 min. A 10 % neutral 
buffered formalin was used for fixing the spleen and thymus, which had been removed from 
animals overnight at 4°C. After gross pathology, the organs were washed with water for three 
times and then stored in 70% ethanol. The small intestine section was removed, and this was 
followed by washing with water by a syringe, after which the clean intestine was further washed 
with a solution containing 7% (vol/vol) acetic acid/PBS, and the lumen was rinsed by a syringe. 
The Peyer’s patches turned white after 5 min, and the visual examination was conducted. 
 
2.3.6.25. The experiment of H&E-Staining (Wisconsin Children’s Research Institute)189 
The Wisconsin Children’s Research Institute conducted the histology processing experiment, 
which included embedding, slicing, drying, as well as H&E staining. At the indicated 
magnification, light microscopy was applied for the visualization of the representative sections. 
 
2.3.6.26. DNP IgG Quantification (Nick Zahn, UWM)189 
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These experiments were carried out by Nick Zahn from Dr. Arnold’s research group, UWM. 
ELISA was applied for the quantification of DNP IgG, which used DNP coated wells (Kamiya 
Biomedical Company #KT-672). The dilution of Serum from non-immunized mice was set to 
1:10,000, where 1:100,000 for the blood of the DNP-KLH-immunized mouse. The manufacturer’s 
instructions were applied for conducting the assay. 
 
2.3.6.27. Cytotoxicity Study of GL-II-93 Analogs (Dr. Michael R. Stephen, UWM) 
Refer to Section 2.3.6.11 for details. 
 
2.3.6.28. Evaluation of AHR of GL-III-43 (Dr. Gloria Forkuo, UWM) 
Refer to Section 2.3.6.2 for details. 
 
2.3.6.29. Patch Clamp Study of GL-III-54 (Dr. Fisher, University of South Carolina School 
of Medicine) 
Refer to Section 2.3.6.5 for details. 
 
2.3.6.30. Relaxation of ASM by GL-III-54 in Guinea Pig Tracheal Rings with Substance P 
(Dr. Emala, Columbia University) 





General procedure for individual hydrolysis of esters 1, 6, 11, 73, 75, 100, 101, 108, and 109 
into their corresponding carboxylic acids 68, 85-87, and 91-95, respectively.  
The corresponding ethyl ester was dissolved in EtOH, after which sodium hydroxide pellets (8 eq, 
later changed to 4 eq) were added to the solution. This reaction mixture was heated to 70 ˚C for 
0.5 - 1 h, and the EtOH was removed under reduced pressure. The remaining aq solution was 
stirred at 0 ˚C for 10 min and then aq HCl (1 N) was added dropwise to the solution until the pH 
was 5 (pH paper). A pale white precipitate, which formed, was left in the solution for 10 min and 
was then collected by filtration, washed with cold water and the aq layer also allowed to stand at 
rt for 10 h to yield additional acid. The combined solids were dried under vacuum for 8 h to provide 
the pure acid. 
2.3.7.1. (R)-8-Ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylic acid. (SH-053-2'F-R-CH3-acid, 68)  
 
The ethyl ester 1 (20.0 g, 51.6 mmol) was dissolved in EtOH (500 mL), after which solid NaOH 
(16.6 g, 412.8 mmol) pellets were added to the solution. This reaction process then followed the 
general procedure for converting the ester into its corresponding acid. This hydrolysis provided 
the pure acid 68 as a white powder (18.4 g, 99.2 % yield):  mp 196-198 °C; []D25 = +4 (c 0.46, 
CHCl3); 1H NMR (300 MHz, DMSO-d
6) δ 8.42 (s, 1H), 7.94 (d, 1H, J = 8.4 Hz), 7.82 (d, 1H, J 
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= 8.2 Hz), 7.56 (dt, 2H, J = 7.8, 6.5 Hz), 7.33 (t, 1H, J = 7.4 Hz), 7.22 (t, 2H, J = 9.3 Hz), 6.53 
(d, 1H, J = 7.1 Hz), 2.51 (s, 1H), 1.16 (d, 3H, J = 6.8 Hz); 13C NMR (75 MHz, DMSO-d6) δ 
164.76, 162.81, 158.19, 140.57, 136.57, 135.54, 134.74, 133.18, 132.65, 131.88, 129.88, 129.35, 
125.17, 123.98, 121.09, 116.53, 116.25, 83.42, 82.01, 49.79, 15.08; HRMS (ESI/IT-TOF) m/z: 
[M + H]+ Calcd for C21H15FN3O2 360.1143; found 360.1140. 
 
2.3.7.2. (R)-8-Bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylic acid (GL-II-93, 85) 
 
The ethyl ester SH-I-47 82, 120 6 (20.0 g, 45.2 mmol) was dissolved in EtOH (400 mL) and DCM 
(50 mL), after which solid NaOH (7.2 g, 180.9 mmol) pellets were added to the solution. This 
reaction process then followed the general procedure for the conversion of the ester to its 
corresponding acid, and provided the pure acid 85 as a white powder (17.4 g, 92.9 % yield):  mp 
239-240 °C; []D25 = +12.9 (c 0.31, CHCl3); 1H NMR (500 MHz, CDCl3): δ 8.12 (s, 1H), 7.73 (d, 
J = 7.6 Hz, 1H), 7.63 (t, J = 6.9 Hz, 1H), 7.55 (d, J = 8.3 Hz, 1H), 7.45 (dd, J = 13.1, 6.7 Hz, 1H), 
7.41 (s, 1H), 7.25 (t, J = 7.3 Hz, 1H), 7.06 (t, J = 9.3 Hz, 1H), 6.78 (q, J = 6.8 Hz, 1H), 1.27 (d, J 
= 6.3 Hz, 3H); 13C NMR (500 MHz, CDCl3): δ 165.00 (s), 162.89 (s), 160.09 (d, J = 251.0 Hz), 
141.25 (s), 135.04 (s), 134.89 (s), 133.59 (s), 133.08 (s), 132.54 (d, J = 6.7 Hz), 132.16 (d, J = 7.8 
Hz), 131.34 (s), 131.11 (s), 128.25 (d, J = 11.2 Hz), 124.57 (s), 123.91 (s), 121.09 (s), 116.22 (d, 
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J = 21.3 Hz), 49.83 (s), 14.91 (s); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C19H14BrFN3O2 
414.0248 and 416.0230; found 414.0247 and 416.0246. 
 
2.3.7.3. Sodium (R)-8-bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (GL-IV-18, 89) 
 
The acid GL-II-93 85 (1.4 g, 3.5 mmol) and NaOH (0.14 g, 3.5 mmol) were added to EtOH (250 
mL) and the mixture was heated to 70 °C for 1.5 h. The reaction mixture was cooled to 40 °C and 
then concentrated to dryness under reduced pressure. The solid, which resulted, was washed with 
EtOAc (3 × 25 mL) to furnish the sodium salt 89 (1.43 g, 95.3 % yield): 1H NMR (300 MHz, 
DMSO) δ 8.05 (s, 1H), 7.81 (d, J = 8.1 Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.55 – 7.39 (m, 2H), 
7.28 (d, J = 7.9 Hz, 2H), 7.10 (d, J = 9.3 Hz, 1H), 6.47 (q, J = 7.4 Hz, 1H), 1.11 (d, J = 7.2 Hz, 
3H); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C19H13BrFN3NaO2 436.0067; found 436.0079. 
 
2.3.7.4. (R)-5-(1-Aminoethyl)-1-(4-bromo-2-(2-fluorobenzoyl)phenyl)-1H-imidazole-4-




The acid GL-II-93 85 (225.0 mg, 0.54 mmol) was suspended in water (2 mL), and this was 
followed by addition of 1 N aq HCl (2.16 mL). The reaction mixture was heated to 50 °C for 3 h, 
and the reaction progress was monitored by 1H NMR spectroscopy. After the reaction mixture 
cooled to rt, a white precipitate formed, which was washed with water (3 × 50 mL) and EtOAc (3 
× 70 mL). This solid was dried under high vacuum for 5 h to obtain the ring-opended analog 90 
(213.8 mg, 91.0 % yield):  1H NMR (300 MHz, MeOD) δ 8.06 (td, J = 9.0, 2.1 Hz, 1H), 7.96 (d, 
J = 32.1 Hz, 1H), 7.89 (d, J = 6.9 Hz, 1H), 7.83 – 7.68 (m, 2H), 7.64 (dd, J = 8.3, 5.8 Hz, 1H), 
7.39 (td, J = 7.7, 2.5 Hz, 1H), 7.30 (dd, J = 10.4, 8.8 Hz, 1H), 4.35 (dd, J = 16.8, 7.0 Hz, 1H), 
1.65 (dd, J = 6.4 Hz, 3H); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C19H16BrFN3O3 
434.0335; found 434.0339. 
 
2.3.7.5. (S)-8-Bromo-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylic acid (GL-III-20, 91) 
 
The ethyl ester SH-I-48B 11 (1.0 g, 2.26 mmol) was dissolved in EtOH (40 mL), after which 
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sodium hydroxide pellets (0.72 g, 18.1 mmol) were added to the solution. This reaction mixture 
was then treated under the same conditions as the general procedure for conversion of an ester into 
its corresponding acid. This process provided the pure acid 91 as a white powder (0.9 g, 96.2 % 
yield):  1H NMR (500 MHz, CDCl3): δ 8.11 (s, 1H), 7.74 (d, J = 7.6 Hz, 1H), 7.67 (t, J = 6.9 Hz, 
1H), 7.51 (d, J = 8.3 Hz, 1H), 7.42 (dd, J = 13.1, 6.7 Hz, 1H), 7.40 (s, 1H), 7.23 (t, J = 7.3 Hz, 
1H), 7.02 (t, J = 9.3 Hz, 1H), 6.76 (q, J = 6.8 Hz, 1H), 1.24 (d, J = 6.3 Hz, 3H); 13C NMR (500 
MHz, CDCl3): δ 165.03 (s), 162.88 (s), 160.03 (d, J = 251.0 Hz), 141.22 (s), 135.01 (s), 134.86 
(s), 133.58 (s), 133.04 (s), 132.52 (d, J = 6.7 Hz), 132.11 (d, J = 7.8 Hz), 131.32 (s), 131.10 (s), 
128.25 (d, J = 11.2 Hz), 124.54 (s), 123.90 (s), 121.04 (s), 116.22 (d, J = 21.3 Hz), 49.81 (s), 
14.90 (s);  HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C19H14BrFN3O2 414.0248 and 416.0230; 
found 414.0247 and 416.0242. 
 
2.3.7.6. 8-Ethynyl-6-(2-fluorophenyl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-
carboxylic acid (GL-II-79, 93) 
 
The ethyl ester JY-XHe-053 (3.7 g, 9.9 mmol) was dissolved in EtOH (100 mL), after which 
sodium hydroxide pellets (1.6 g, 39.4 mmol) were added to the solution. This reaction mixture was 
heated and then followed the general procedure for conversion of the ester into its corresponding 
acid (the pH was adjusted to 6, not 5 for this compound). This process provided the pure acid 93 
as a white powder (3.26 g, 95.9 % yield): mp °C; 1H NMR (300 MHz, DMSO) δ 8.43 (s, 1H), 
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7.91 (d, J = 7.9 Hz, 1H), 7.84 (d, J = 7.7 Hz, 1H), 7.70 – 7.47 (m, 2H), 7.32 (d, J = 7.6 Hz, 2H), 
7.19 (t, J = 9.5 Hz, 1H), 5.83 (s, 1H), 4.36 (s, 1H), 4.12 (s, 1H); HRMS (ESI/IT-TOF) m/z: [M + 
H]+ Calcd for C21H15FN3O2 360.1143; found 360.1149. 
 
2.3.7.7. (R)-8-Bromo-4-methyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-
3-carboxylic acid (GL-II-51, 94) 
 
The ethyl ester GL-II-06 73 (1.5 g, 3.5 mmol) was dissolved in EtOH (100 mL) and DCM (15 
mL), after which sodium hydroxide pellets (0.56 g, 14.1 mmol) were added to the solution. This 
reaction mixture was heated and then followed the general procedure for conversion of the ester 
into its corresponding acid. This process provided the pure acid 94 as a white powder (1.13 g, 
80.7 % yield):  1H NMR (500 MHz, DMSO) δ 8.51 (s, 1H), 8.38 (s, 1H), 8.01 (d, J = 7.5 Hz, 1H), 
7.98 – 7.88 (m, 2H), 7.84 (d, J = 7.6 Hz, 1H), 7.64 – 7.39 (m, 2H), 6.62 – 6.46 (m, 1H), 1.17 (d, J 
= 6.4 Hz, 3H); 13C NMR (75 MHz, DMSO) δ 164.85, 157.38, 150.14, 148.57, 140.94, 137.60, 
136.69, 135.06, 134.60, 130.44, 129.58, 125.40, 124.04, 123.79, 119.87, 119.49, 49.55, 14.75; 
HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C18H14BrN4O2 397.0295 and 399.0276; found 





a][1,4]diazepine-3-carboxylic acid (GL-II-30, 95) 
 
The ethyl ester GL-II-19-2'F-R-CH3 75 (1.0 g, 2.7 mmol) was dissolved in EtOH (100 mL) and 
DCM (15 mL), after which sodium hydroxide pellets (0.43 g, 10.8 mmol) were added to the 
solution. This reaction mixture was heated and then the method followed the general procedure 
for conversion of the ester into its corresponding acid (the pH was adjusted to 6, not 5 for this 
compound). This process provided the pure acid 95 as a white powder (0.8 g, 86.6 % yield):  1H 
NMR (500 MHz, CDCl3) δ 8.57 (d, J = 3.8 Hz, 1H), 8.08 – 7.98 (m, 2H), 7.84 (t, J = 6.6 Hz, 1H), 
7.69 (d, J = 8.0 Hz, 1H), 7.57 (d, J = 8.2 Hz, 1H), 7.42 (s, 1H), 7.37 (t, J = 5.6 Hz, 1H), 6.72 (q, 
J = 7.0 Hz, 1H), 6.13 (s, 1H), 3.15 (s, 1H), 1.25 (d, J = 7.0 Hz, 3H). 13C NMR (75 MHz, DMSO) 
δ 165.18, 164.04, 163.98, 148.11, 140.78, 138.71, 137.00, 135.68, 135.57, 135.52, 128.45, 127.54, 
125.96, 124.87, 124.12, 120.70, 83.37, 82.19, 49.42, 14.69; HRMS (ESI/IT-TOF) m/z: [M + H]+ 
Calcd for C20H15N4O2 343.1190; found 343.1190. 
 
2.3.7.9. (R)-Tert-Butyl(1-((4-chloro-2-(2-fluorobenzoyl)phenyl)amino)-1-oxopropan-2-




The (2-amino-5-chlorophenyl)(2-fluorophenyl)methanone 97 (40.0 g, 160.2 mmol) and Boc-D-
alanine (44.3 g, 233.9 mmol) were dissolved in dry CH2Cl2 (300 mL) and stirred at 0 °C. The 
dicyclohexylcarbodiimide (DCC; 46.3 g, 224.3 mmol) was dissolved in dry CH2Cl2 and was added 
dropwise over a 30 min period at 0 °C. The solution, which resulted, was allowed to stir for 15 h 
at rt, and the reaction was monitored by TLC (silica gel, EtOAc/hexanes, 1:5). The 
dicyclohexylurea byproduct, which formed, was filtered off and washed with CH2Cl2. The organic 
layers were combined and concentrated under reduced pressure. The solid, which formed, was 
recrystallized from the oily residue in hexanes at 0 °C. The crystals were filtered off and washed 
with hexanes until the yellow color (from starting benzophenone) was washed away. The filtrate 
was combined and concentrated under reduced pressure. Some additional product was isolated by 
repeating the washing steps. The Boc analog 98 was dried and used for the next step without further 
purification as white crystals (60.7 g, 90.0 % yield):  1H NMR (500 MHz, CDCl3) δ 11.68 (s, 1H), 
8.75 (d, J = 9.0 Hz, 1H), 7.56 (dd, J = 13.0, 6.9 Hz, 1H), 7.51 (dd, J = 9.0, 2.4 Hz, 1H), 7.43 (d, 
J = 2.0 Hz, 2H), 7.27 (d, J = 7.4 Hz, 1H), 7.18 (t, J = 8.7 Hz, 1H), 5.35 (s, 1H), 4.37 (s, 1H), 1.50 
(d, J = 6.7 Hz, 3H), 1.44 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 195.45, 172.50, 160.53, 158.50, 
155.37, 139.22, 135.02, 133.64, 133.57, 132.99, 130.28, 130.27, 127.61, 126.83, 126.72, 124.51, 
124.48, 124.12, 122.34, 116.60, 116.43, 80.32, 51.85, 28.27, 18.44; HRMS (ESI/IT-TOF) m/z: 







The benzophenone GL-III-51 98 (59.0 g, 140.2 mmol) was dissolved in dry DCM (400 mL) and 
cooled to -10 °C. Anhydrous HCl (g) was slowly purged through the mixture until the solution 
was saturated. The solution was allowed to stir until no starting material was left; it was monitored 
by TLC (silica gel, EtOAc/hexanes, 3:7), about every 1 h. A saturated aq solution of NaHCO3 (2 
x 100 mL) and water (2 x 100 mL) was added to the mixture, and the mixture was allowed to stir 
for 30 min until no more formation of CO2 was observed. The reaction mixture was extracted with 
DCM. The organic layers were combined and concentrated under reduced pressure. The oily 
residue, which resulted, was dissolved in MeOH (200 mL), and this was followed by addition of 
water (150 mL). The pH was adjusted to 8 using a solution of 1 M aq NaOH. The reaction mixture 
was allowed to stir at rt overnight. The solution was concentrated under reduced pressure and water 
(400 mL) was added. The solution was extracted with DCM and the organic layer was washed 
with brine, dried (Na2SO4), and concentrated under reduced pressure. Hexanes (200 mL) were 
added to the solid, which resulted, and the mixture was heated to 60 °C. This was followed by 
concentration under reduced pressure down to ½ of the original volume to yield most of the amide 
crystals. The crystals were filtered off and washed with hexanes, and the filtrates were combined 
and then concentrated under reduced pressure. The residue was purified by repeating the 
recrystallization steps to yield additional amide 99 as a white solid (30.7 g, 72.3 % yield):  1H 
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NMR (500 MHz, CDCl3) δ 10.05 (s, 1H), 7.60 (td, J = 7.5, 1.5 Hz, 1H), 7.45 (dd, J = 8.7, 2.3 Hz, 
2H), 7.27 – 7.20 (m, 3H), 7.06 (t, J = 9.0 Hz, 1H), 3.81 (q, J = 6.4 Hz, 1H), 1.80 (d, J = 6.5 Hz, 
3H); 13C NMR (126 MHz, CDCl3) δ 172.35, 164.74, 161.44, 159.44, 136.21, 132.26, 132.19, 
131.97, 131.62, 129.59, 129.12, 129.01, 127.07, 126.98, 124.44, 124.41, 122.81, 116.37, 116.20, 




a][1,4]diazepine-3-carboxylate (GL-III-53, 100) 
 
The amide GL-III-52 99 (25.0 g, 82.5 mmol) was dissolved in dry THF (300 mL), and cooled to -
50 °C using a dry ice bath, after which potassium t-butoxide (12.0 g, 107.3 mmol) was added in 
one portion. The reaction mixture was stirred until it reached 0 °C and then stirred for 0.5 h at 0 
°C. The mixture was then cooled to -50 °C, after which diethyl chlorophosphate (21.9 g, 125.0 
mmol) was added dropwise with an addition funnel. The dry ice bath was removed to allow the 
temperature to rise to 0 °C, after which it was allowed to stir for 2 h with an ice-water bath. The 
solution was then cooled to -78 °C with a dry-ice bath and ethyl isocyanoacetate (14.1 g, 125.0 
mmol) was added, and this was immediately followed by a second portion of potassium t-butoxide 
(12.0 g, 107.3 mmol). This solution was allowed to stir overnight during which period it was 
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allowed to warm to rt. The reaction progress was completed after 14 h on analysis by TLC (silica 
gel, EtOAc/hexanes, 1:1). The reaction mixture was quenched by the addition of a cold saturated 
aq solution of NaHCO3 (500 mL) and extracted with EtOAc. The organic layers were combined;  
washed with brine (2 x 200 mL), and dried (Na2SO4). The solvent was removed under reduced 
pressure to obtain a dark brown solid residue. The solid was washed with Et2O/EtOAc (9:1) to 
remove most of the impurities and the solid was further recrystallized from EtOAc and hexane 
(1:3), and this was followed by washing the solid with cold Et2O to afford the majority of the pure 
ethyl ester. Alternative recrystallization method: the residue was dissolved in MTBE and the 
mixture was heated to 50 °C, after which the solvent was removed under reduced pressure to 1/3 
of its original volume to obtain the precipitates. The solid was filtered off and washed with cold 
Et2O. The remaining filtrate was combined and purified by flash chromatography to obtain 
additional ethyl ester (silica gel, EtOAc/ hexanes  3/2) as an off-white solid 100 (22.8 g, 69.5 % 
yield):  1H NMR (500 MHz, CDCl3) δ 7.95 (s, 1H), 7.62 – 7.53 (m, 3H), 7.44 (td, J = 7.4, 1.4 Hz, 
1H), 7.28 – 7.20 (m, 2H), 7.03 (t, J = 9.2 Hz, 1H), 6.69 (q, J = 7.2 Hz, 1H), 4.48 – 4.20 (m, 2H), 
1.40 (t, J = 7.1 Hz, 3H), 1.27 (d, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 162.87, 161.07, 
159.08, 141.49, 134.91, 133.29, 133.17, 132.19, 132.13, 132.00, 131.20, 130.82, 130.14, 129.46, 
128.38, 128.28, 124.59, 124.56, 123.57, 116.31, 116.14, 60.81, 50.08, 14.86, 14.43; HRMS 
(ESI/IT-TOF) m/z: [M + H]+ Calcd for C21H18ClFN3O2 398.1066; found 398.1064. 
 
2.3.7.12. (R)-8-Chloro-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-




The ethyl ester GL-III-53 100 (3.0 g, 7.5 mmol) was dissolved in EtOH (200 mL) and DCM (3 
mL), after which sodium hydroxide pellets (1.2 g, 30.2 mmol) were added to the solution. This 
reaction mixture was heated and then followed the general procedure for conversion of the ester 
into its corresponding acid. This process provided the pure acid 87 as a white powder (2.7 g, 97.1 % 
yield):  1H NMR (500 MHz, DMSO) δ 8.42 (s, 1H), 7.97 (d, J = 8.6 Hz, 1H), 7.83 (d, J = 8.2 Hz, 
1H), 7.57 (dt, J = 19.4, 6.9 Hz, 2H), 7.34 (t, J = 7.4 Hz, 1H), 7.26 – 7.12 (m, 2H), 6.54 (d, J = 6.9 
Hz, 1H), 1.17 (d, J = 7.1 Hz, 3H); HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C19H14ClFN3O2 
370.0753; found 370.0752. 
 
2.3.7.13. (R)-Ethyl-cyclopropyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylate (GL-III-42, 101) 
 
To a solution of the bromo ethyl ester SH-I-4782, 120  6 (2.1 g, 4.8 mmol) in toluene (20 mL) and 
water (1.4 mL), cyclopropyl boronic acid (1.0 g, 12.0 mmol), potassium phosphate (4.1 g, 19.2 
mmol) and bis(triphenylphosphine)palladium(II) diacetate (0.72 g, 0.96 mmol) were added under 
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argon. A reflux condenser was attached and the mixture was degassed under vacuum with argon; 
this process was repeated four times. The mixture was stirred and heated to 100 °C. After 12 h the 
reaction was completed on analysis by TLC (silica gel, DCM and 1% MeOH) and it was then 
cooled to rt. Water (10 mL) was added, and the mixture was extracted with EtOAc (3 × 15 mL), 
after which the filtrate was washed with brine (10 mL), dried (Na2SO4) and concentrated under 
reduced pressure. The black residue which resulted was purified by a wash column (silica gel, 
DCM and 1% MeOH. Note: no separation with the EtOAc/hexane solvent system) to afford the 
desired 8-cyclopropyl-imidazodiazepine 101 as a light yellow solid (1.26 g, 64.9 % yield):  1H 
NMR (500 MHz, CDCl3) δ 7.88 (s, 1H), 7.55 (t, J = 7.1 Hz, 1H), 7.44 (d, J = 8.3 Hz, 1H), 7.42 – 
7.32 (m, 1H), 7.19 (dd, J = 12.9, 6.1 Hz, 2H), 6.98 (dd, J = 18.9, 9.9 Hz, 2H), 6.64 (q, J = 7.2 Hz, 
1H), 4.55 – 4.14 (m, 2H), 1.92 – 1.73 (m, 1H), 1.38 (t, J = 7.1 Hz, 3H), 1.24 (d, J = 7.3 Hz, 3H), 
1.03 – 0.87 (m, 2H), 0.68 – 0.48 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 164.17, 163.12, 161.12, 
159.12, 143.88, 141.58, 134.85, 132.09, 131.65, 131.58, 131.21, 129.22, 129.16, 129.04, 128.47, 
127.87, 124.33, 121.95, 116.08, 115.91, 60.59, 50.05, 15.04, 14.64, 14.44, 9.91, 9.89; HRMS 
(ESI/IT-TOF) m/z: [M + H]+ Calcd for C24H23FN3O2 404.1769; found 404.1763. 
 
2.3.7.14. (R)-8-Cyclopropyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo[1,5-




The ethyl ester GL-III-42 101 (0.9 g, 2.2 mmol) was dissolved in EtOH (12 mL), after which 
sodium hydroxide pellets (0.36 g, 8.9 mmol) were added to the solution. This reaction mixture was 
heated and then followed the general procedure for conversion of the ester into its corresponding 
acid (the pH was adjusted to 6, not 5 for this compound). This process provided the pure acid 86 
as a white powder (0.7 g, 83.6 % yield):  1H NMR (500 MHz, CDCl3) δ 8.04 – 7.99 (m, 1H), 7.63 
(s, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.47 – 7.40 (m, 1H), 7.25 (dd, J = 13.6, 6.7 Hz, 2H), 7.03 (dd, J 
= 19.1, 10.1 Hz, 2H), 6.73 (q, J = 7.2 Hz, 1H), 3.96 (s, 1H), 1.95 – 1.76 (m, J = 25.4 Hz, 1H), 
1.27 (d, J = 3.1 Hz, 3H), 1.02 (d, J = 7.8 Hz, 2H), 0.65 (d, J = 27.6 Hz, 2H); HRMS (ESI/IT-
TOF) m/z: [M + H]+ Calcd for C22H19FN3O2 376.1456; found 376.1453.  
 
2.3.7.15. (R)-6-(2-Fluorophenyl)-8-hydroxy-4-methyl-4H-benzo[f]imidazo[1,5-
a][1,4]diazepine-3-carboxylic acid (GL-IV-14, 88) 
 
The ethyl ester SH-I-4782, 120  6 (2.0 g, 4.5 mmol), CuI (86 mg, 0.9 mmol), KOH pellets (1.78 g, 
31.6 mmol), PEG 6000 (14.4 g), and water (3 mL) were added to a 100 mL sealed tube under Ar. 
The tube was degassed three times and backfilled with Ar and then the tube was quickly sealed 
and placed into a preheated oil bath at 100 °C under a positive pressure of Ar. The reaction was 
completed after 36 h, as confirmed by examination of the 1H NMR spectrum. The solution, which 
was resulted, was cooled to rt,  and this was followed by addition of water (10 mL). The 
acidification followed the general procedure by the addition of 10 % aq HCl dropwise, and the pH 
was adjusted to 5. A pale white precipitate, which formed, was left in the solution for 10 min and 
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was then collected by filtration, washed with cold water and the aq layer was allowed to stand at 
rt for 10 h to yield additional acid. The combined solids were dried under vacuum for 8 h to provide 
pure acid 88(1.23 g, 78.0 % yield): HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C19H15FN3O3 
352.1092; found 352.1107. 
 
2.3.7.16. (R)-8-Bromo-6-(2-fluorophenyl)-4-methyl-3-(1H-tetrazol-5-yl)-4H-
benzo[f]imidazo[1,5-a][1,4]diazepine (GL-IV-21, 96) 
 
The hydroxylamine hydrocholoide salt (208.5 mg, 3.0 mmol), K2CO3 (483.7 mg, 3.5 mmol) and 
3Å molecular sieves were added in DMF (50 mL) and the mixture was heated to 60 °C for 0.5 h. 
The aldehyde 78 (1 g, 2.5 mmol), [bmim]N3 (1.66 g, 9.5 mmol), and Cu(OAc)2 (90.8 mg, 0.5 
mmol) were then added to the mixture, and it was heated to 120 °C for 12 h. After completion of 
the reaction, as indicated by analysis by TLC (silica gel), the reaction mixture was quenched with 
H2O (50 mL) and extracted with EtOAc (2 × 50 mL). The aq layer was treated with 3 M HCl, until 
the pH was brought to 5. The mixture was extracted with EtOAc (2 × 50 mL). The organic layers 
were combined, washed with brine, dried (Na2SO4) and concentrated under reduced pressure. The 
residue, which resulted, was passed through a short pad of silica with 3% MeOH in DCM to yield 
the tetrazole 96 (0.94 g, 85.2 %): HRMS (ESI/IT-TOF) m/z: [M + H]+ Calcd for C19H14BrFN7 




Chapter 3. Design and Synthesis of Achiral α2/α3 Subtype-Selective 
Ligands and Their Use for the Treatment of Anxiety, Epilepsy, and 
Neuropathic Pain 
Section 3.1. to Section 3.2. of this dissertation have been adopted from the following article: 
• Li, G.; Golani, L. K.; Jahan, R.; Rashid, F.; Cook, J. M., Improved Synthesis of Anxiolytic, 
Anticonvulsant, and Antinociceptive alpha 2/alpha 3-GABA(A)-ergic Receptor Subtype 
Selective Ligands as Promising Agents to Treat Anxiety, Epilepsy, and Neuropathic. 
Synthesis-Stuttgart 2018, 50 (20), 4124-4132. 
 
3.1. Introduction 
In the central nervous system (CNS) gamma-aminobutyric acid type A receptors 
(GABAARs) are transmembrane pentameric ligand-gated ionotropic channels.219 They are the 
major inhibitory neurotransmitter receptors in the CNS and affect a wide variety of brain functions 
depending on the modulation of the GABAergic ligands at different subunits of the protein 
complex.220 Benzodiazepines (BZDs), which bind at the α+γ2− extracellular interface of 
GABAARs,18 are the classical psychoactive drugs prescribed for various CNS disorders including 
anxiety, convulsions, as well as insomnia.46-47, 221-222 They have been employed to treat patients for 
over 50 years. However, these drugs, for example, diazepam, are not effective in all patients, 
moreover, they produce serious adverse effects including sedation, ataxia, amnesia, and 
addiction.46 Consequently, there is an urgent need for improved treatments which are devoid of 
the above side effects.  
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Accumulating evidence suggests that α2β2/3γ2 and/or α3β2/3γ2 GABAAR subtype 
selective ligands exhibit agonist efficacy and are responsible for the anxiolytic, antinociceptive, 
and much of the anticonvulsant actions of the BZD when there is little or no efficacy at α1-
subtypes.47,81-83, 107, 109, 223-226 These previous results indicated that GABA(A) α2 or α3 agonists can 
be used for the treatment of anxiety, epilepsy, as well as neuropathic pain with reduced side effects.  
Previously, based on our BZD/GABA(A) pharmacophore model,18, 227 a series of 
imidazodiazepine (IMDZ) agonists that are selective at GABA(A) α2/3-subunits were synthesized 
and investigated. Ligand Hz-166 (76), as listed in Figure 118, was one of the first and the initial 
lead for IBZs, which contained an acetylene group at the C(8) position in order to reduce α1-
subtype efficacy and/or the binding affinity.18, 227 In both mice and rats, the lead compound 76 
exhibited antiseizure activity in a subcutaneous metrazole seizure (scMET) test in an animal model 
at ASP (NINDS) with both oral and i.p. administration.228 Later in the Vogel conflict assay, 76 
showed a non-sedating anxiolytic effect at 1 mg/kg in rhesus monkeys.83 Moreover, 76 was also 
active in models of inflammatory and neuropathic pain exerting a dose-dependent antihyperalgesic 
effect without sedation, motor impairment or development of tolerance, as compared to the 
commonly used drug gabapentin for the management of neuropathic pain.229 Although 76 was 
quite stable in human liver microsomes (HLMs), it was degraded very rapidly in mouse liver 
microsomes (MLMs) due to hydrolysis of the ester function to its carboxylic acid by enzymes in 
the liver.230 The C(3) acid metabolite was not able to penetrate the blood-brain barrier and achieve 
the desired effects a long period of time. This limited the ability to do ADME toxicity studies in 
rodents. The pharmacokinetic profile of a ligand is one of the major concerns that can result in 




Figure 118. Structure of Hz-166 (76), MP-III-080 (102), and KRM-II-81 (77). 
 
Currently, ester bioisosteres have been commonly used in drug development to increase 
metabolic stability and achieve better pharmacological effects.113, 231-233 In order to prevent 
hydrolysis of the liable ester moiety and maintain the anxiolytic-like properties of lead ligand 76, 
a number of bioisosteres to replace the C(3) ester functionality were designed, synthesized and 
evaluated.80, 82, 234 The most potent analogs among these ligands were the 1,2,4-oxadiazole MP-
III-080 (102) and the 1,3-oxazole KRM-II-81 (77), both of which markedly improved the 
pharmacokinetic properties in human, mouse, rat and god liver microsomes, as compared to the 
parent compound 76. More recent results were reported indicating oxazole 77 exhibited anxiolytic 
effects in a rat Vogel conflict assay at 10 mg/kg when given i.p. Furthermore, in a mouse marble-
burying assay,107, 109, 226, 235 as a model of anxiety, ligand 102 significantly reduced the marble-
burying activity at 10 mg/kg as an indication of anxiolytic-like effects, and both of the bioisosteres 
102 and 77 exerted anxiolytic activity at 30 mg/kg.107 All three ligands were shown to be α2/3 
subtype selective ligands, as positive allosteric modulators (PAMs), with little or no agonist 
efficacy at α1-containing GABAARs.
83, 109, 236 In addition, ligand 77 exhibited potent 
antinociceptive activity in a model of acetic acid- and lactic acid-induced pain in mice.236 Later in 
the motor function and anticonvulsant efficacy assays, 102 was an effective anticonvulsant versus 
388 
 
the GABAA negative modulator pentylenetetrazole (PTZ)-induced seizures with no observation 
of motor impairment at 30 mg/kg on i.p. administration.109  
Taken together all these results suggested that instead of the rapidly metabolized parent 
compound 76 in rodents, ligands 102 and 77, which are novel α2/3-subtype selective GABAARs 
PAMs, are stable in HLM, MLM, rat liver microsomes (RLM), and dog liver microsomes 
(DLM).107 This permits further investigation of ligands 102 and 77 in models of anxiety, epilepsy, 
neuropathic pain, and respiration in rodents as well as primates.83 Consequently, multigram 
quantities of both ligands were required for more critical evaluation in rodent models, as well as 
further important tests for ADME toxicity before human trials. As previously reported, the direct 
conversion from the ethyl ester 76 to the ethyl oxadiazole 102 earlier was only achieved in 
moderate yield from 40% to 71% 81-82, 107 on milligram scale. However, it was not possible to 
obtain a similar yield on gram scale. But the real major roadblock was the synthesis of the 1,3-
oxazole 77, the overall yield of which via the previous three-step procedure107, 234 was only 28% 
on a maximum scale of 3 grams.107 The most critical problem in the total synthesis of these two 
ligands was the low overall yield (17%) for the five-step route to the parent compound 76, which 
was used directly as the starting material for both 77 and 102. Therefore, the modification of the 
published routes or other efficient and inexpensive procedures were required. Herein, the 
optimization of the previous methods for the synthesis of 76 and 102, and an improved route for 
the synthesis of 77 are reported. They are applicable for the scale-up process with improved yields, 





3.2. Synthesis α2/α3 Subtype Selective Ligands  
As demonstrated above, the improvement of the synthesis of Hz-166 (76) would play a 
critical role in the development of GABAA α2/3-subtype selective ligands since it was the parent 
compound for all analogs in this series. After many changes and modifications in each step in the 
synthetic route for Hz-166 (76), this provided a better 5-step overall yield of 56% (Scheme 25), as 
compared to the previous yield of 17%.81  
The improved route began with the commercially available amine, 2-amino-5-bromo-
benzyl-2'-pyridyl ketone 70, which was acylated with bromoacetyl bromide in the presence of 
sodium bicarbonate. The intermediate 103, which formed, without further purification, was 
directly treated with a saturated solution of ammonia (gas) in methanol and gradually increasing 
the temperature from 0 °C to reflux to provide the 1,4-benzodiazepine 104 in 78% overall yield 
(two-steps) on the 120-gram scale. The amide 104 can be purified by recrystallization in methanol 
and dichloromethane while avoiding any column chromatography on a large scale. The imidazole 
ring was introduced by applying the modified procedure237 by treating the amide 104 with 
potassium t-butoxide and diethyl chlorophosphate at -50 °C for 2 h, after which the solution was 
allowed to warm up to 0 °C. Ethyl isocyanoacetate was then added to the reaction mixture, which 
was executed at -78 °C, and this was followed by addition of another equivalent of potassium t-
butoxide to provide IMDZ 105 in 81% yield. The yield of the imidazole ring formation by a 
previous method using sodium hydride as the base by Ian Fryer at -10 °C was only 37%. This 





Scheme 25. Optimized total synthesis of Hz-166 (76). 
 
The purification of 105 was easily executed by washing away the impurities with 10 % 
ethyl acetate in diethyl ether. The scale of this reaction was increased to 80 grams as compared to 
the previous one of 15 grams in the literature. A Heck-Cassar-Sonogashira type reaction was 
conducted with IMDZ 105 and trimethylsilylacetylene to provide the trimethylsilyl analog 106 in 
92% yield. The lead ligand Hz-166 (76) was obtained by the deprotection of the analog 106 using 
tetrabutylammonium fluoride in 96% yield. After workup (see Experimental Section) the pure 
material 76 was recrystallized from methanol, which had been heated to 50 °C and allowed to cool. 
With the optimized synthesis of the parent compound 76, the overall yield was improved 
from 17% to 56%. The purification process in the case of ligands such as 76 was more difficult 
than the other ligands in the IMDZ series in the 2ꞌ-F, 2ꞌ-H, etc. due to the 2ꞌ-pyridine nitrogen, 
which can be a problem when using column chromatography on a large scale. In this new 
procedure, all the products can be isolated by either washing with specific solvents or by 
crystallization to avoid column chromatography. This is a more practical, efficient and scalable 
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synthesis of 2ꞌ-pyridine-containing substituted IMDZ (76) as the starting material for other 
important analogs.  
The 1,2,4-oxadiazoles are well-known ester bioisosteres that ameliorate some of the 
problems of metabolism in the drug discovery process.113, 230-232, 238 The oxadiazole MP-III-080 
(102) was a very promising ligand in this series, which exhibited anxiolytic, anticonvulsant and 
antinociceptive effects in many animal models, as described above. The problems of inconsistent 
yields of 102 from 76 required a solution of scaleup. The development of efficient methods for the 
synthesis of 1,2,4-oxadiazoles has been ongoing for decades; however, most of the existing 
procedures either required harsh conditions or multiple steps from ester to the corresponding 
starting materials.239 This was deemed not suitable for the present case with ligands containing 
multiple functionalities. Therefore, many attempts were made to improve the yield of the 
oxadiazole formation for the synthesis of grams quantities of ligand 102. 
For this purpose several experiments were conducted under different conditions. It was 
found that the equivalents of sodium hydride, the reaction time for the formation of amidoxime 
anion, dry reaction conditions, as well as the reaction temperature all played a critical role for good 
yields. Initially, the ratio of sodium hydride to the ethyl ester (76) was 2.5:1 on milligram scale 
and the yield of the byproduct, in which the imine [N(5)-C(6)] double bond had been reduced, was 
comparable to the desired oxadiazole 102, as confirmed by analysis of the 1H NMR spectrum. The 
formation of the major byproduct resulted from the extra equivalent of sodium hydride which 
reduced the [N(5)-C(6)] imine bond of the parent compound 76. Hence, the amount of sodium 
hydride was lowered to 1.190 equivalents to avoid the unwanted imine reduction. Since esters are 
less reactive than the corresponding acyl chloride, the formation of the amidoxime anion was key 
and the only driving force for acylation; the first step toward oxadiazole formation. Therefore, the 
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reaction time of the amidoxime with sodium hydride should be adequate and 1H NMR 
spectroscopy was required to monitor the reaction to completion due to the inability to analyze this 
step by TLC. Commonly, the thermal cyclization of O-acylamidoximes is the second step required 
to prepare the 1,2,4-oxadiazoles;240 however, the higher temperature in the IMDZ series usually 
led to low yields (40-47%),8 along with the formation of byproducts. Consequently, instead of 
using the usual conditions of reflux, the reactions were performed at room temperature. In addition, 
3Å molecular sieves were added, the amount of which depended on the reaction scale. Efficient 
removal of water as an alternative method helped push the reaction at room temperature to 
completion. To date, with these optimizations, the yield of the one-step conversion from ester to 
oxadiazole was improved to 88%, as depicted in Scheme 26. It is consistent for gram scale 
processes.  
 
Scheme 26. Synthesis of MP-III-080 (102) from Hz-166 (76). 
 
Beside 1,2,4-oxadiazoles as bioisosteres, 1,3-oxazoles are unique bioisosteres with a 
similar electron density map to that of an ester function. Oxazole-containing compounds have been 
reported with the desired pharmacological effects and promising therapeutic profiles in the past.127-
129 Accordingly, the 1,3-oxazole analogs of the parent compound 76, which can be used as an 
alternative ester bioisostere, appeared to be a useful complement to 102. The development of the 
synthesis of oxazoles has been employed for years, and numerous methods have been reported.241 
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In the case under study here a one or two-step synthetic route would be appropriate in order to 
avoid low overall yields from multi-step synthesis. As compared to other approaches, the Van 
Leusen oxazole synthesis,242 which can be used to prepare 1,3-oxazoles by the direct conversion 
from the corresponding aldehyde, seemed advantageous because of the one-pot process and mild 
conditions. Indeed, this transformation provided good yields for oxazole formation in other series. 
However, the synthesis of the most potent oxazole bioisostere, KRM-II-81 (77), as described 
above (2ꞌ-N analog), was the most difficult bioisostere in the series of IMDZ analogs (i.e, 
compared to the 2ꞌ-F, 2ꞌ-H, 2ꞌ-Cl, isomers etc) to prepare. The problem was not from the formation 
of the oxazole, but the reduction reaction from the particular ester 76 to its corresponding aldehyde 
(107). 
After many attempts with many reducing agents, which either reduced the [N(5)-C(6)] 
imine bond or reduced the aldehyde, so formed, at C(3) to the alcohol, diisobutylaluminium 
hydride (DIBAL), a commonly used reducing agent, was employed efficiently in good yield (75-
80%) for the 2ꞌ-F and 2ꞌ-H series.107, 234 The reduction with DIBAL for the ethyl ester 76, however, 
failed to achieve the desired aldehyde in a temperature range of -78 °C to 25 °C due to the reduction 
to the corresponding alcohol and/or imine bond reduction as observed in the case of the oxadiazole 
synthesis. Moreover, the purification of this crude reaction mixture was tedious. After many 
attempts, it was found out it was difficult to stop the reduction in the 2ꞌN case at the aldehyde stage. 
The next strategy was to employ lithium aluminum hydride (LAH) to reduce the ester to the alcohol 
and then reoxidize it to the aldehyde with activated manganese dioxide, or pyridinium dichromate. 
This mixture of alcohols (desired and imine-reduced), which formed, was then directly oxidized 
to a mixture of aldehydes with activated manganese dioxide in an overall two-step yield of 39%, 
as reported previously.107 Even though the next step (the oxazole formation) was executed in 
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reasonable yield (73%), the three-step overall yield of 77 had fallen to 29%, which was not 
acceptable. 
In order to overcome this problem, a number of weaker reducing agents were employed, 
such as lithium borohydride, sodium borohydride, potassium borohydride, or the bulkier lithium 
tri tert-butoxy aluminum hydride, however, none of these agents provided the desired aldehyde in 
good yield, as shown in Scheme 27. The solution to this issue was to find a bulkier reducing agent, 
but also a selective reducing agent to prevent imine reduction and permit the aldehyde to remain 
at this stage in the absence of alcohol formation.  
 
Scheme 27. Attempts to prepare aldehyde (4) from Hz-166 (1). 
 
Because of work in another series, potassium diisobutyl-t-butoxy aluminum hydride 
(PDBBA)161 seemed to be a suitable reducing agent for this series. The PDBBA can be easily 
prepared by addition of DIBAL in hexane dropwise into a solution of the same number of 
equivalents of potassium t-butoxide in THF at 0 °C for 2 h.161 In theory, the PDBBA should not 
attack the imine double bond due to the three bulky groups; secondly, it can only offer one hydride 
atom in the reduction and might be easier to stop the reaction at the aldehyde stage, as compared 




hydride from PDBBA attacks the carbonyl carbon forming a tetrahedral intermediate, and the 
elimination of the ethoxy group yields the desired aldehyde.  
However, the first attempts were not successful under the reported conditions161 or at lower 
temperatures (entries 1-4 in Table 28). The reactions were stopped at 3 hours due to more alcohol 
formation. The reactions were then conducted by using different equivalents of PDBBA from 1.5 
to 2.5 at 0 °C at three time points 5, 30, 180 min, respectively (entries 5-14 in Table 28). The use 
of higher equivalents of PDBBA at 0 °C not only increased the yield of aldehyde but also the rate 
of reduction to the alcohol at the first 5 minute time point. Along with longer reaction times, the 
yields of aldehyde were not significantly improved and began to drop off at the 30 minute time 
point for 2 and 2.5 equivalents in trials of PDBBA (entries 9,10,12,13 in Table 28). The aldehyde, 
which formed, was immediately converted into the alcohol in this series of IMDZ, as observed at 
0 °C. If the reactivity of the ester could be increased, then it could compete with the aldehyde and 
as a result, additional aldehyde and less alcohol could be predicted. With this in mind, a 
modification was made to increase the reaction temperature. As expected, more aldehyde and less 
alcohol formation were observed within the first 5 minute at room temperature for all equivalents 
of PDBBA; the yields of the aldehyde quickly dropped to provide more alcohol after reaching the 
maximum yield of aldehyde in 5 minutes (entries 14-23 in Table 28), as compared to the condition 
at 0 °C. The best yield of aldehyde (107) from all the trials was 79% (entry 18 in Table 28) with 
1.5 equivalents of PDBBA at 25 °C; only 12% of the alcohol had formed. At 40 °C, the yield of 
aldehyde was worse, and the process rapidly formed the alcohol instead (entries 24, 25 in Table 
28).  











Yield (%) Yield (%) 
-CHO -CH2OH 
1 1.3 -78 720 0 0 
2 1.3 0 5 22 12 
3 1.3 0 30 31 14 
4 1.3 0 180 38 17 
5 1.5 0 5 45 20 
6 1.5 0 30 57 21 
7 1.5 0 180 60 29 
8 2.0 0 5 56 23 
9 2.0 0 30 62 31 
10 2.0 0 180 51 40 
11 2.5 0 5 58 22 
12 2.5 0 30 65 29 
13 2.5 0 180 40 51 
14 1.3 25 5 30 5 
15 1.3 25 30 56 28 
16 1.3 25 180 11 67 
17 1.5 25 1 62 8 
18 1.5 25 5 79 12 
19 1.5 25 30 18 68 
20 2.0 25 1 69 20 
21 2.0 25 5 61 28 
22 2.5 25 1 70 25 
23 2.5 25 5 56 38 
24 1.3 40 1 36 10 
25 1.3 40 5 40 33 
 
All reactions were conducted with 0.07 mmol of starting material (the ethyl ester 1) in dry DCM as the solvent 
of the reaction under different conditions listed above. The yields of aldehyde and alcohol were calculated after 
the isolation of the products. 
 
From the results above, the best condition to obtain a good yield (79%) of aldehyde was 
with 1.5 equivalents of PDBBA, which was a bit higher than reported,161 at room temperature. The 
reaction process had to be controlled carefully and monitored by TLC analysis for the first 5-10 
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min to avoid alcohol formation due to the very short reaction time. Most importantly, the imine 
bond was not reduced by PDBBA at all; the spectroscopy and properties of the aldehyde 107 match 
with the reported values as confirmed by NMR and LCMS. At lower temperatures such as at 0 °C, 
the ester was much less reactive than at 25 °C, the aldehyde, which formed at 0 °C, would favorably 
be reduced and resulted in a mixture of unreacted ester, desired aldehyde, and the alcohol 
byproduct. Moreover, longer reaction times should be avoided due to the reaction of aldehyde, as 
expected. 
Even though the reaction time was very short, this procedure can be applied on a large 
scale if monitored every 5-10 minutes by TLC. To date, the largest scale for this reduction reaction 
under the optimized reaction conditions was 20 grams and in 80% yield, as illustrated in Scheme 
28. The van Leusen reaction for the synthesis of the 1,3-oxazoles occurred smoothly. The oxazole 
77 can be purified via crystallization in ethyl acetate to replace the earlier employed column 
chromatography, that was reported previously.107  
 
Scheme 28. The optimized synthesis of oxazole 77 with a significantly improved overall yield. 
 
3.3. Results and Discussion of Biological Studies on KRM-II-81 (77) 
With the aid of an improved and practical synthesis, the 1,3-oxazole KRM-II-81 (77) has 
been synthesized on a large scale for efficient supplies and evaluated further in many animal 
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models of anxiety, epilepsy, pain, and depression in rodents, as well as other in vitro and in vivo 
models.  
The previous in vitro data of KRM-II-81 (77) including binding affinity, microsomal 
stability, cytotoxicity, and efficacy is briefly summarized here. The data obtained from PDSP has 
shown that 77 exhibited little to no binding affinity for a wide range of receptors, ion channels or 
transporters, including dopamine, calcium, histamine, opioid, adrenergic, serotonin, NMDA 
receptors, etc. Most importantly, 77 showed no hERG binding affinity, which reduced the possible 
influence on the heart QT problems. The oxazole 77 possesses a metabolically stable profile in 
vitro, as confirmed by the microsomal stability study on HLM and MLM after 30 minutes 
incubation at 37 degrees, more than 90 % of 77 remained in all human, mouse and rat liver 
microsomes in vitro. There was no cytotoxicity of oxazole 77 at 100 µM, which indicated the 
ligand was safe to use up to this concentration that is far above the dose level reached in a clinical 
therapeutic range.107 The electrophysiological recording of 77 illustrated that it was a very potent 
α2/3 GABAAR subtype-selective ligand at 100 nM, and the potentiation at α1 or α5 was nearly at 
the baseline similar to the GABA current alone (EC3 GABA),236 as depicted in Figure 119. This 
reduced the possibility of the development of tolerance to the antihyperalgesic and anticonvulsant 




Figure 119. The dose-responsive efficacy data of KRM-II-81 (77) at α1,2,3,5-containing GABAARs. EC3–5 
GABA value is presented in percentage of response to GABA alone. 
 
In addition to the efficacy profile in GABAARs, GABA current of KRM-II-81 (77) was 
also evaluated in dorsal root ganglia isolated from the spinal cord of rats. The negative current 
displayed a rapid activation by saturating GABA (1 mM) potentiation, after which slow 
desensitization occurred, as shown in Figure 120A. The GABA at current from EC10 was only 
activated partially without significant desensitization from the low GABA concentration. With 10 
μM of 77, the GABA current (EC10) was partially activated at a level of 355 % in a concentration-




Figure 120. The effect of KRM-II-81 (77) on the potentiation of native GABA currents in cultured DRG neurons. 
A: Manual patch clamp recording of currents activated by saturating GABA concentration (1mM), and by 
EC10 concentration of GABA (5µM) and 10 µM of 77. GABA current activated with a low concentration of 
5µM GABA was enhanced by 10µM of 77. B: Dose-response curve of 77 on currents activated with 5 µM GABA 
(EC10).  The potentiation is represented as % of increase produced by saturating GABA-activated current.  All 
values shown are mean ± SEM (n=4). (Adopted from Figure in Witkin et al., 2019) 245 
 
3.3.1. Anxiety 
Anxiety is one of the most common mental disorders and affects over 18% of the US 
population.246 It includes generalized anxiety disorder (GAD), obsessive-compulsive disorder 
(OCD), panic disorder, post-traumatic stress disorder (PTSD) and social phobia (or social anxiety 
disorder) among others, which can significantly dampen the quality of life for the patients and their 
families. The symptoms are usually characterized with the inability of letting go of worry or fear, 
stress that is more pronounced than the actual impact of the event, and restlessness. The standard 
treatment consists of a combination of psychotherapy, behavioral therapy, and medication. The 
common medications are classical BZDs, tricyclics, beta-blockers, and SSRI’s. Classical BDZ has 
major side effects such as tolerance, addiction, sedation, ataxia, respiratory depression, adverse 
psychological and physical effects. Beta-blockers can cause blurred vision, insomnia, 
disorientation, CNS system effects, and serious heart problems. SSRI’s takes 3-5 weeks to have 
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effect and also can cause sexual dysfunction.247-248 Patient compliance is a problem with all these 
treatments. Therefore, there is an unmet need for improved treatments that possess desired 
anxiolytic-like properties but are devoid of sedation, ataxia, amnesia, addiction, and tolerance. 
The marble burying assay has been widely used for its application to measure the possible 
anxiolytic properties of ligands on the text animal. It is based on the nature of the rodents that tend 
to bury any harmful or harmless objects underground due to fear or losing them or being anxious. 
A ligand which exerts anxiolytic-like properties will decrease this urge and will result in a reduced 
number of marbles, which are buried during the test period. This assay has been an effective 
method to evaluate the anxiolytic effects of the traditional BZDs, such as chlordiazepoxide 
(CDAP), and the novel IMDZ 1,3-oxazole KRM-II-81 (77), as illustrated in Figure 121. The male 
NIH Swiss mice (n=10/condition) were administrated either vehicle (1% carboxymethyl cellulose, 
CMC, a surfactant) or 30 mg/kg of CDAP or the 1,3-oxazole 77 i.p.  They were then placed or a 
rotarod (spinning at 4 rpm) for assessment of motor impairment. After rotarod testing, mice were 
placed in a chamber with 20 marbles on the surface of sawdust bedding. The number of marbles 
buried (2/3 by sawdust) was counted after 30 minutes. Both oxazole 77 and CDAP at 30 mg/kg 
exhibited a significant effect on the reduction of the number of marbles buried, as compared to 
vehicle, which was considered an effect observed after acute dosing with anxiolytic and 
antidepressant drugs. In the rotarod test, CDAP induced 6 failures due to its sedative properties, 
as expected. In contrast to CDAP, 77 at 30 mg/kg did not impair motor performance during the 2-
minute rotarod assay.  
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Figure 121. The evaluation of the anxiolytic-like activity of chlordiazepoxide and KRM-II-81 (77) in the marble 
burying assay. Male NIH Swiss Webster mice (n = 10) were administrated i.p. with either vehicle or 
chlordiazepoxide (CDAP) and KRM-II-81 (77) at 30 mg/kg 30 min prior to testing. The rotarod assay was 
performed (spinning at 4 rpm) for the assessment of motor impairment. Mice that fall off twice are scored as 
failures. Data were analyzed using ANOVA. Dunnett’s test: (∗) P < 0.05 vs vehicle. 
 
The Vogel conflict assay is another commonly used experimental method for the 
assessment of anxiolytic-like properties of test compounds. It is considered the gold standard as 
an assay. In general, the animal will be punished with a minimal electrical shock when they are 
trying to get water or food during the test by lever pressing, which will result in a reduction of the 
total number of times the press for water or food. If an anxiolytic is administrated, this number of 
times will be increased irregardless of the punishment. The parent ethyl ester Hz-166 (76), the 1,3-
oxazole KRM-II-81 (77) and chlordiazepoxide (CDAP) as a positive control, were tested in the 
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Vogel conflict assay in rats for their ability to reduce anxiety of animals induced by the electrical 
shock punishment, as illustrated in Figure 122.107 The ethyl ester 76 at 30 mg/kg did not exert any 
difference from the vehicle. On the other hand, as expected, the marketed anxiolytic CDAP at 20 
mg/kg significantly increased the number of times the animal lever press for water during the 
punishment phase but did not show any effect during the non-punishment period. The 1,3-oxazole 
77 did not induce any effect at the dose of 3 mg/kg, as compared to the vehicle. However, a 
significant increase in drinking behavior during the punishment phase was observed at 10 mg/kg 
ip dose with oxazole 77, and the rate of response was increased by 240 %. The ligand 77 exhibited 
a similar anxiolytic effect at 30 and 60 mg/kg with an increasing rate of response about 220 % and 
200 % in comparison to the control group, respectively. Again, CDAP exerted a significant 
increase of water licking behavior at 20 mg/kg and induced a 330 % responsive rate over the 
vehicle group. Moreover, 77 increased punished responding of rats without affecting un-punished 
responding, which suggested an anxiolytic property of 77 with no section nor ataxia. In contrast, 
CDAP produced a  trend toward decreasing un-punished responding, which suggests sedation, as 





















































Figure 122. The Vogel Conflict assessment of anxiolytic-like properties with male Sprague-Dawley rats (n = 6-
8). A. The evaluation of Hz-166 (76) and anxiolytic chlordiazepoxide (CDAP) administrated i.p. at 30 mg/kg 
and 20 mg/kg, respectively; B The dose response of KRM-II-81 (77) as compared to CDAP at 20 mg/kg. All 
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compounds were administered 30 minutes prior to testing. Results were analyzed using ANOVA. Each point 
represents the mean + SEM of 6-8 rats.  * p<0.05, significantly different than vehicle control.  (Dunnett’s test: 
* P < 0.05; Student t-test: ** P < 0.05). (Modified from the Figure in Poe et al.) 107 
 
3.3.2. Epilepsy 
Epilepsy is a chronic, life-threatening neurological disease that can occur at any age, which 
affects 2.3 million U.S. adults and 50 million people worldwide.249 It is characterized by symptoms 
such as disturbances of movement, strange sensations, convulsions, muscle spasms, and loss of 
consciousness from a mild to a severe level over an extended period. The most common type of 
epilepsy is termed idiopathic epilepsy. It has unknown causes and is not preventable, while 
secondary epilepsy or symptomatic epilepsy has known causes, such as prenatal brain damage, a 
stroke, a brain tumor, a head injury or infection, etc. Diverse medications including 
benzodiazepines (BZDs), carbamazepine, phenytoin, valproate, felbamate, gabapentin, 
lamotrigine, levetiracetam, are used generally in combination in status epilepticus in emergency 
rooms since seizures are not well controlled. The surgical approaches are also utilized for the 
treatment of epilepsy to reset the section of the brain wherein the seizures emanate. This is the last 
resort. Even though some epileptic symptoms can be controlled at certain level, there is an urgent 
unmet need for improved antiepileptic drugs that are able to fully control the symptoms and are 
devoid of the side effects of current drugs.250 This is especially important in medications given to 
children which can influence brain development, which lead to lifetime learning disabilities. This 
is a huge burden to the patients, the parents and the society as a whole. It has been widely reported 
that BZDs exhibit anticonvulsant activity through acting on both α1 and α2 GABAAR/Bz 
subtypes.251 The ligands that target α1 subtypes, as expected, are associated with the side effects, 
such as sedation, ataxia, addiction, tolerance, etc., which results in the greatest drawback of the 
application of BZDs to treat epilepsy. Only the ligands that target α2 or α2/3 subtypes are the ideal 
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candidates for the treatment of epilepsy due to their anticonvulsant activity with the elimination of 
the side effects from α1 efficacy, and the lack of possible tolerance from the coupling of α1 and 
α5 subtypes.252 Therefore, in addition to the parent compound Hz-166 (76), which has been shown 
to exhibit anticonvulsant activity, without the development of tolerance to this anticonvulsant 
effect. However, it is rapidly metabolized in rodents,120 consequently KRM-II-81 (77), was 
prepared as the metabolically much more stable bioisostere of 76. It has also been evaluated in 
both acute and chronic seizure models (https://panache.ninds.nih.gov/CurrentModels.aspx) for its 
anticonvulsant-like properties by the NIH Epilepsy Therapy Screening Program (ETSP) under the 
guidance of Dr. Shalini Sharma. The original reports of test compounds from ETSP are included 
in Appendix V, and 77 was anticonvulsant in every model it was tested in. Lastly, the evaluation 
of the seizure protection in the resistant epileptic human brain tissue was conducted with 77.  
 
3.3.2.1. Acute Seizure Models 
Three acute seizure models were utilized for the evaluation of the anticonvulsant activity 
of KRM-II-81 (77), which included the 6 Hz 44 mA seizure model in mice (i.p.), maximal 
electroshock seizure (MES) model, in rats (i.p.), and subcutaneous metrazol (pentylenetetrazole) 
seizure model (s.c. MET) in rats (p.o.). These “first-pass” animal models are critical and efficient 
for the fast identification of ligands that might exhibit anticonvulsant-like properties against 
therapy-resistant seizures. 
The 6 Hz kindled seizure model is commonly used for the initial screening for possible 
anticonvulsant drugs that can dampen the induced seizures by a long-duration, low frequency (6 
Hz) stimulation, which might not be detected by different screening methods. In brief, mice were 
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administrated p.o. with KRM-II-81 (77), and the 6 Hz stimulation was delivered for 3 seconds 
after 2 hours through corneal electrodes at 44 mA and the seizure activity in the animal was 
observed and recorded. A parallel group of mice was administrated with higher doses of 77 and 
observed for potential motor impairment and possible toxicity at 4 hours after dosing. At 10 mg/kg, 
KRM-II-81 (77) was unable to protect the mice (n = 8) that are subjected to 6 Hz stimulation. 
However, at the dose of 25 mg/kg, 3 out of 8 animals were protected by orally-administered 77, 
and full protection was observed at 50 mg/kg at 2 hours after oral dosing, as presented in Table 29. 
At the most effective dose of 50 mg/kg, there was no motor impairment observed, which indicated 
no overt toxicity induced from 77. Only mild tremors were observed at the dose of 100 mg/kg p.o. 
The loss of righting was observed at 150 mg/kg in 3/8 mice. More severe tremors were observed 
at a higher dose 200 mg/kg. Importantly, when 120 mg/kg of KRM-II-81 (77) was administrated 
to rats (p.o.) no side effects were observed. This may be because the metabolite level in rats is 
much lower than that in mice (Eli Lilly, Jeff Witkin et al.). 
Table 29. The effects of KRM-II-81 (77) p.o. in the 6 Hz seizure model and the motor effects. (Adopted from 
Figure in Witkin, et al) 253 
_____________________________________________________________________________________________ 
Dose  Number protected/number tested 
10  0/8 
25  3/8 
50  7/8 
Dose  Number with observed motor effects Observation 
50  0/8 
100  3/8      tremor  
150  5/8      tremor, unable to grasp  
200  8/8      more severe tremor,  




The maximal electroshock (MES) assay is one of the most common choice ofs initial in 
vivo animal models in search of new antiepileptic drugs.254 The 1,3-oxazole KRM-II-81 (77) was 
evaluated in the MES test, as compared with diazepam and Hz-166 (76).253 The male CD-1 mice 
(n = 10) were administrated i.p. with vehicle (1% CMC), diazepam (1, 3 or 6 mg/kg), ester 76 (3, 
10 or 30 mg/kg) or oxazole 77 (3, 10 or 30 mg/kg) 30 minutes prior to testing. During the testing, 
the tonic-clonic seizures  were induced by a 10 uA electroshock for 0.2 seconds. The indication of 
the protection of an animal by the test compound is the observation of the abolition of tonic and/or 
clonic seizures at the hindlimb, which is considered an anticonvulsant effect. As illustrated in 
Figure 123, diazepam (DZP) was able to reduce MES-induced convulsions at 3 mg/kg and fully 
protected the animals at 6 mg/kg.  The 1,3-oxazole KRM-II-81 (77) exhibited only a little effect 
at 3 mg/kg, however, a significant anticonvulsant effect was observed at 10 mg/kg and it also fully 
prevented the animals from seizures induced by MES at 30 mg/kg. However, the parent ethyl ester 
Hz-166 (76) was not active up to 30 mg/kg.  
 
Figure 123. The evaluation of the anticonvulsant activity of Diazepam, HZ-166 (76) and KRM-II-81 (77) in the 
MES assay. Male CD-1 mice (n = 10) were administrated i.p. 30 minutes prior to being tested with either vehicle 
(1% CMC), diazepam (1, 3 or 6 mg/kg), KRM-II-81 (3, 10 or 30 mg/kg) or HZ-166 (3, 10 or 30 mg/kg). Analyzed 




Pentylenetetrazole (PTZ), an antagonist of GABAARs, is commonly used for generalizing 
convulsions in animal models of seizures and epilepsy255 in order to search for new anticonvulsant 
drugs. The 1,3-oxazole KRM-II-81 (77) was evaluated in the PTZ-induced seizure test, as 
compared with diazepam (DZP) and Hz-166 (76).253 Thirty minutes after dosing DZP (3 or 10 
mg/kg), 76 (30 mg/kg) or 77 (10, 30 or 60 mg/kg), PTZ was administered at a dose of 35 mg/kg 
to induce the seizures, and the effects on the animal were observed and recorded. As illustrated in 
Figure 124 A, DZP was able to produce some reduction of PTZ-induced seizures at 3 mg/kg and 
produced full protection at 10 mg/kg. The parent ethyl ester 76 only exhibited some anticonvulsant 
tendency toward efficacy up to 30 mg/kg. The 1,3-oxazole 77 exerted some reduction at 10 mg/kg 
and offered full protection at 30 and 60 mg/kg from PTZ-induced convulsions in rats. The efficacy 
of the full protection by DZP was 10x more potent than 77. These results are consistent with the 
results obtained from the MES-induced seizure assay. The possible motor impairments of 76 and 
77 were evaluated on the inverted screen. This assay was performed before the PTZ-induced 
seizure assay. The rats were evaluated on the inverted screen test after 25 min of dosing and were 
scored after 1 minute. As indicated in Figure 124 B, DZP had a minimal toxic dose (MTD) of 10 
mg/kg, where sedation/ataxia was observed, whereas at 150 mg/kg for 77 (see more details in the 
ETSP report in Appendix V). There was no ataxia/sedation, even p.o. at a dose of 250 mg/kg. Thus, 
when calculating the protective index (PI) = (MTDinverted screen/MEDPTZ convulsions), the PI value for 




Figure 124. The anticonvulsant effects of Hz-166 (76), KRM-II-81 (77), and diazepam against (A) 
pentylenetetrazole (PTZ)-induced seizures (35 mg/kg, s.c.) and (B) their motor performances on an inverted 
screen in rats. Data represent mean ± SEM (n=5-8). Significant probability was analyzed by Fisher’s Exact 
Probability test (*: p<0.05). For the motor score, n = 5 (diazepam, 3 mg/kg) or 8 (all other data) rats, 0=climbed 
over to the top of the screen, 1= hanging on to screen, 2= fell off. Data were analyzed by ANOVA followed by 
Dunnett’s test with * p<0.05. PTZ alone produced convulsions in 96 ± 4%. The baseline motor scores were 0.12 
± 0.8. (Adopted from Figure in Witkin et al.) 253 
  
The pentylenetetrazole (PTZ)-induced seizure threshold test is used to determine the 
threshold limit of test compounds on the decrease of seizure threshold, as a follow-up experiment. 
During i.v. PTZ infusion, the threshold dose of PTZ to induce convulsions was assessed in rats 
with and without drug pretreatment. The dose of PTZ required to produce seizures was  35 mg/kg  
(PTZ threshold = 37.1 ± 1.9 mg/kg) given as a bolus, as described above. Examination of the 
results was illustrated in Figure 125 indicated that the pretreatment with diazepam (DZP), Hz-166 
(76) and KRM-II-81 (77) all increased the dose of PTZ required to induce seizures. DZP at 1 
mg/kg was able to increase the dose of PTZ to 49 mg/kg as the required dose. The ethyl ester 76 
did not increase the required dose of PTZ up to 60 mg/kg, whereas the oxazole 77 at 10 mg/kg 
offered a significant increase of the amount of PTZ and required a 71 mg/kg dose to induce 
convulsions. This effect was significant and dose-dependent, and the 60 mg/kg of 77 administered 
increased the PTZ dose to 108 mg/kg and is much greater than the anticonvulsant drug, valproic 
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acid, that required 300 mg/kg of which to increase the PTZ dose to 81 mg/kg. Thus, it is obvious 
that DZP was much more potent than the 76 and 77 but was less efficacious, however, 77 exhibited 
a much wider range of efficacy to increase the dose of PTZ required to produce seizures (both 
ligands were equally efficacious against MES and acute PTZ-induced convulsions).  
 
Figure 125. The threshold measurement of Hz-166 (76), KRM-II-81 (77), and diazepam (DZP) against PTZ-
induced seizures. The threshold procedure (B) dosed diazepam, KRM-II-81, HZ-166 or valproic acid 30 
minutes prior to an i.v. infusion of pentylenetetrazole until convulsions were observed in rats, n = 8. Analyzed 
using ANOVA (Dunnett’s test: * P < 0.05). (Modified from Figure in Witkin, et al) 253 
 
As described above, the protective index (PI), can be calculated from the minimal dose that 
has a toxic effect (inverted screen) over its anticonvulsant potency in the PTZ-induced seizure 
model.  The PI > 1 illustrated a margin between efficacy and side-effect doses; PI = 1 represents 
no separation between the side effects and as an anticonvulsant potency; whereas PI < 1 indicates 
that the potency to produce the desired effect is less than the potency to induce a toxic effect. A 
summary of the PI for DZP and 77 is listed in Table 30, which demonstrated that the oxazole 77  
exhibited a much wider safety margin between the dose producing an anticonvulsant effect and 
the dose inducing motor impairment, as compared to DZP. In all of the acute seizure models, 
oxazole 77 demonstrated a robust anticonvulsant profile that was able to protect the animals from 
both chemical (PTZ) and electrical (6 Hz and MES) stimulus-induced seizures in rodent models. 
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Table 30. Protective indices (PI) for DZP and 77. (Modified from Figure in Witkin et al.) 
 
 
3.3.2.2. Chronic Seizure Models 
Up to date, four chronic seizure models, were used for further evaluation of the 
anticonvulsant effect of KRM-II-81 (77) in rodents. The four models, as discussed in this section, 
are the corneal kindled seizure model in mice (p.o.), lamotrigine (LTG) resistant amygdala-kindled 
seizure model in rats (i.p.), model of mesial temporal lobe epilepsy (mTLE) induced by focal 
chemoconvulsant injection in mice (p.o.), and chronic post-SE (KA) spontaneously seizing in rats: 
Stage 1 (i.p.). The results, obtained from the acute seizure models as described above, suggested a 
potential anticonvulsant ligand, KRM-II-81 (77), and this ligand was then carried on for further 
investigation in the chronic seizure models. It was important that the large scale synthesis of KRM-
II-81 (77) and MP-III-080 (102) had been developed at this point. 
The corneal kindled mouse model is a seizure model developed by repeated stimulation of 
an electrical shock or an epileptogenic drug. It is a rapid and low-cost initial screen for the 
development of potential anticonvulsant ligands at the ETSP. In addition, the anticonvulsant 
results obtained with a corneal kindled mouse is consistent with the pharmacological profile of the 
Witkin et al – KRM-II-81                                                           1 
 
 




Assay    KRM-II-81  Diazepam 
 
Electroshock
    
15  3.3 
PTZ Clonus    5  1 
PTZ Threshold
  
 15  10 





Seizure Severity   15  1 
 
__________________________________________________________________________________________________________ 
aPI values were calculated as the minimal effective dose producing motor impairment 
/minimal effective doses producing efficacy.  Values for HZ-166 could not be calculated 




test drugs from human partial epilepsy, which suggests this model is a reliable and effective 
method for the early stage screening for antiepileptic substances. In brief, the male CF-1 mice 
received a twice-daily kindled electrical 3-second stimulation, 3 mA, 60 Hz by corneal electrodes 
for 10-14 consecutive days to reach the criterion of Stage 5 seizures. The test started at 5-7 days 
post the last stimulation, after which stimulation was given to the mice to ensure the animals were 
with Stage 5 seizures. Mice (n = 8) were then administrated p.o. with the doses at 1, 3, 8, 15, 25, 
30 mg/kg of KRM-II-81 (77), and the time of peak effect (TPE) was determined at the 2-hour 
time-point. As presented in Table 31, 77 exhibited moderate anticonvulsant effects at 3 mg/kg, and 
significant effects were observed at 8 mg/kg. The mice were fully protected by 77 at 15 mg/kg. 
The lower the seizure score, the better the anticonvulsant effect. Based on the previous results, the 
toxicity data was not determined at this point since 77 did not produce toxicity up to 50 mg/kg in 
mice nor 120 mg/kg in rats. 
Table 31. The effect of KRM-II-81 in a corneal kindled mouse model. (Unpublished data) 
 
 
The lamotrigine (LTG)-resistant amygdala-kindled rat model is a useful method not only 
for the identification of substances that are active against symptomatic seizures but also for the 
differentiation of drugs that may be active against resistant epilepsy. It has been reported that, 
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during the seizure developmental stage, daily administration of lamotrigine (5 mg/kg) results in an 
LTG-resistant state rather than protecting the animal from the development of seizures. These 
research findings indicated that a subsequent resistance to Na+ channel blockers resulted from the 
presence of LTG during the kindling acquisition state, which suggests a useful model of resistant 
epilepsy. The 1,3-oxazole KRM-II-81 (77) was evaluated in this resistant epilepsy model. In brief, 
an electrode was implanted into the left amygdala in anesthetized male rats. After one week of 
recovery, animals started to receive a daily 200 µAmp stimulus until they all reached to stage 4 or 
5 seizures. The LTG at 30 mg/kg was injected i.p. to the fully kindled animals to induce resistant 
seizures. After the washout of LTG for 3 days, animals were administrated with KRM-II-81 (77) 
at doses of 1, 5, 10, 20, and 40 mg/kg, then challenged with the stimulus at the predetermined time 
of peak effect at 1 hour. As depicted in Figure 126 A, 77 was able to protect the animals at a 
moderate level at 5 and 10 mg/kg, and it reached to 50 % protection at 20 mg/kg. The protection 
was significant at 40 mg/kg as compared to the vehicle; 6 out of 8 rats were protected by the 
administration of oxazole 77  after 1 hour. Furthermore, at the dose of 40 mg/kg, the seizure score 
of 77 was significantly reduced from 5 to 2.13, and the seizure duration was also decreased 
significantly from 123 seconds to 66 seconds, as compared to the vehicle, as demonstrated in 
Figure 126 B and C, which suggested that 77 was effective against LTG-induced resistant epilepsy 






Figure 126. The effect of KRM-II-81 (77) in lamotrigine (LTG)-resistant amygdala-kindled rat model. (A)The 
percentage of seizure protection by 77 at the doses of 1, 5, 10, 20, and 40 mg/kg, (B) the seizure severity score 
of vehicle and 77 at 40 mg/kg, (C) the seizure duration of vehicle and 77 at 40 mg/kg, The average seizure scores 
± S.E.M.and afterdischarge duration is noted, as are the number of animals protected from seizure (defined as 
a Racine score < 3) over the number of animals tested. (Unpublished data) 
 
Mesial temporal lobe epilepsy (MTLE) makes up the largest rate of causes of human 
refractory epilepsy, which originates from the hippocampus of the brain in patients with 
epilepsy. The MTLE mouse model includes many features observed in human patients with 
temporal lobe epilepsy (TLE). In brief, the injection i.v. of kainic acid (KA) at 1 mmol in 100 mL 
of vehicles, as a neurotoxic and epileptogenic agent, into the dorsal hippocampus of a mouse, 
induces non-convulsive severe epilepsy (SE), which can last for hours. An electrode was implanted 
into the left part of the hippocampus in male rats. After the KA injection for 4 weeks, 
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spontaneous recurrent KA-induced seizures, which occur 30-60 times per hour and last 
about 15-20 seconds, can only be recorded in the hippocampus region, no paroxysmal 
hippocampal discharges (HPD) is detected in other regions in the brain of animals. A group 
of 4 or 5 MTLE mice was injected i.v. with 15 or 30 mg/kg of KRM-II-81 (77), respectively, and 
the behaviors of the animal were recorded by digital EEG recordings for 20 minutes before-
injection and 90 minutes after-injection. The number of HPDs were recorded and analyzed during 
a 20 minute period for 10 minutes before and 10 minutes after the peak time of effect. As shown 
in the Table 32, at the dose of 15 mg/kg, 77 was able to reduce the KA-induced epilepsy in rats to 
31.27 % as compared to the baseline HPD values, whereas a more significant suppression was 
observed to 8.69 % percent peak effect at dose of 30 mg/kg of 77, which indicated the 
anticonvulsant effect of 77 in MTLE mice model was robust and provided a possible candidate for 
the treatment of the most common refractory epilepsy of human.  
Table 32. The effect of KRM-II-81 (77) at 15 mg/kg on in MTLE mice model. (Unpublished data) 
 
Table 33. The effect of KRM-II-81 (77) at 30 mg/kg on in MTLE mice model. (Unpublished data) 
 
 
Status epilepticus (SE) is a severe emergency characterized as a continuous seizure 
lasting more than 30 minutes, or at least two of them are too close without full recovery. 
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Seizure control mechanisms can be overwhelmed. In status-epilepticus, uncontrollable, recurrent 
generalized seizures occur. In order to evaluate the effect of KRM-II-81 (77) in SE, a SE-induced 
spontaneous recurrent seizure model in rats was utilized. In brief, chronic epilepsy in rats with 
status epilepticus was induced by a repeated low-dose of kainic acid (KA) at 7.5 mg/kg i.p. at 
every hour up to 4 hours until animals achieved Stage 5 seizures. After 10 weeks of chronic 
treatment, the rats were implanted with a wireless telemeter into the peritoneal space from the 
stomach to the head underneath the skin for the EEG monitor. Only the rats with the highest seizure 
burden scores were selected (n = 24). During the test period, a baseline seizure rate is determined 
in week 1. During week 2, the rats were administrated with 20 mg/kg of KRM-II-81 (77) over 5 
days, Monday-Friday. Rats are split into groups of 12 for the vehicle group and another 12 for the 
drug-treated groups. Once the treatment was completed in week 2, rats were monitored during 
week 3 with only vehicle treatment (washout period). In order to avoid any possible design 
variations, the cross-over paradigm was utilized. Similar to the first group (n = 6), the second group 
(n = 6) received vehicle first, followed by the treatment of 77. A list of potential detected events 
generated and listed. As illustrated in Figure 127, KRM-II-81 (77) significantly dampens KA-
induced status epilepticus in regardless of treatment time either administrated in the second week 
or the third week. The daily seizure burden was significantly decreased to 1.6, as compared to the 
baseline 6.5, whereas the vehicle group exhibited a similar value as 6.7. Half of the drug-treated 
rats (6 out of 12) were protected from KA-induced status epilepticus, the baseline and the 
vehicle did not show any difference in seizure freedom rate. Overall, without the treatment of 
77, the generalized seizures were reoccurrence during the vehicle treatment period. These results 
indicated that KRM-II-81 was able to reduce the KA-induced status epilepticus, which 




Figure 127. The effect of KRM-II-81 (77) in the SE-induced spontaneous recurrent seizures model in rats. 
During the test period, a baseline seizure rate is determined in week 1. An initial group of 12 rats enrolled in 
Stage 1 chronic monitoring were split into two (N=6/group) treatment groups. During week 2, the first group 
of rats was administrated with 20 mg/kg of KRM-II-81 (77) over 5 days, Monday-Friday. Once the treatment 
is completed in week 2, rats will be monitored during week 3 with only vehicle treatment. Similar to the first 
group (n = 6), the second group (n = 6) receives vehicle first, followed by the treatment of 77. Each data 
represents a seizure event. * p<0.05 as compared to the vehicle group. (Unpublished data) 
 
3.3.2.3. Evaluation of Seizure Protection in Resistant Epileptic Human Cortical Tissue 
Due to the improved anticonvulsant profile of KRM-II-81 (77), the effect of 1,3-oxazole 
77 was evaluated to determine if there was any suppression of the firing rate in human cortical 
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tissue from two juveniles with intractable or resistance epilepsy after surgical treatment. The slices 
were prepared, and the electrophysiological recording was performed by using a 60-
microelectrode array. The two neuronal stimulants, picrotoxin as a GABAAR antagonist, or 4-
aminopyridine (AP-4) as the K+ ligand, were utilized to induce the increase of firing rate frequency 
(Hz), as illustrated in Figure 121. Since the human epileptic tissue is usually not active without 
excitation, the slices was bathed in 10 µM picrotoxin. At least 30 channels of the array were able 
to be evoked for the test, which was monitored for 1 hour as the baseline with an average firing 
rate of 0.05 Hz ± 0.01. The 1,3-oxazole was added at 30 µM and the neuronal activity was recorded 
in the presence of picrotoxin for another hour. The average firing rate after 77  treatment was 
significantly reduced to 0.01 Hz ± 0.005, as illustrated in Figure 128 (left panel). On a separate 
slice, 50 µM of AP-4 (K+ channel-driven) was used as the neuroexcitant instead of picrotoxin, and 
all 60 channels were activated of the microelectrode array with an average firing rate of 0.08 Hz ± 
0.01. With the oxazole 77  treatment at 30 µM, the neuronal activity was significantly attenuated 
to an average of 0.01 Hz ± 0.005, which indicated its anticonvulsant activity was not from the 
competition with picrotoxin at BzR bindint sites. These results illustrated that KRM-II-81 (77) 
was able to significantly suppress the firing rate of epileptic seizures induced under both 
picrotoxin and AP-4 stimulation, which strengthens the confidence of the use of this ligand 




Figure 128. Functional blockade of the epileptic phenomenon in cortical slices of KRM-II-81 (77) from juvenile 
epileptic patients. Data of network firing rate frequency (Hz) was collected for 1 hour under each condition 
(unfilled circle EACSF, no 77 treatment; filled circle EACSF + 30 µM of 77) with either 10 µM of picrotoxin 
(left panel) or 50 µM AP-4 (right panel) as a neuronal stimulant.  A 60-microelectrode array was used for 
recording. (paired t-test: P < 0.05). (Adopted from the Figure in Witkin et al.) 
 
Taken all together with the preclinical findings on KRM-II-81 (77) in models of epilepsy, 
as summarized in Table 34, indicated significant suppression of firing rate induced by picrotoxin 
and AP-4 in human cortical tissue and enhanced the potentiation of GABA currents in dissociated 
dorsal root ganglion neurons. Although 77 was not active in the 6 Hz rat model, oxazole 77 
produced robust anticonvulsant-like properties in all other rodents models. Together with the 
human tissue data, this effect significantly enhanced the confidence for pushing 77 forward to 
clinical trials for the treatment of refractory/resistant epilepsy in children as well as adults. 
Table 34. Pre-clinical results of KRM-II-81 (77) in different animal models of epilepsy as well as in human 





3.3.3. Activity of 1,3-oxazole (77) in Different Types of Pain Models 
Pain disorder is a physical pain experience in one or several areas in the body. There are 
100 million (U.S. adults) and 1.5 billion people worldwide who suffer from different extents of 
pain. The health cost is, up to date, is $560-635 billion a year in the U.S. 
(https://www.thegoodbody.com/ chronic-pain-statistics/) It deters the patient from proper function 
in life events for days or years. Pain disorders usually originate in several subtypes, such as chronic 
pain, complex regional pain syndrome, back pain, cancer pain, neuropathic pain, inflammatory 
pain, bladder pain, etc. The standard treatment consists of stress management, psychotherapy, 
behavioral therapy, acupuncture, and medication. The common medications used for the treatment 
of pain are addictive opioids, NSAIDs, acetaminophen, COX-2 inhibitors, tricyclic antidepressants, 
anti-epileptics SSRI’s, and etc. Opioids antagonists are effective for severe pain; however, for 
every opioid on the market addiction, tolerance and constipation are serious problems (opioid 
epidemic).256 The NSAIDS cause severe stomach pains, bleeding and can lead to death. 
Acetaminophen increases the risk of kidney damage and liver failure over time. COX-2 inhibitors, 
such as celecoxib, can cause kidney problems, fluid retention, increase the risk of heart attacks and 
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strokes, as well as high blood pressure.257-258 Patient compliance is a problem with all these 
treatments. Indeed, an unmet urgent need is urgent for the development of novel non-opoid 
treatments of pain disorders. Over the past decade, there has been a large amount of growing 
evidence that an subtype selective ligand targeting α2-containing GABAAR can be applied in the 
treatment of pain disorders. The 1,3-oxazole KRM-II-81 (77), as an α2/3 GABAAR PAM, is active 
in animal models of pain due to its potency at these two subtypes, which are involved in the 
association of antihyperalgesic and antinociceptive effects. Therefore, oxazole 77 was evaluated 
to determine the efficacy of antinociceptive properties in a series of pain models, including visceral 
pain, inflammatory pain, and neuropathic pain. 
 
3.3.3.1. Visceral Pain Model 
Over the past few decades, a series of animal models of diseases have been established and 
developed in the area of antinociceptive activity. Visceral pain has been studied, which is induced 
by evoking the organs of the abdomen or pelvis with chemical, mechanical, or electrical noxious 
stimuli. One of the most common methods to study the nociceptors is the acetic acid writhing 
model,259 which measures the spontaneous pain. KRM-II-81 (77) was evaluated in this acid-
induced writhing test to determine if there was any antinociceptive-like effect. Acetic acid (0.6 %) 
was injected in mice, and the number of writhes (stretching, retracting, or pressing the belly against 
the floor) was recorded and counted with a mean of 46.29 ± 3.859. The opioid receptor agonist 
morphine, as the positive control, was able to reduce the acetic acid-induced writhing in a dose-
dependent manner and the effect was significant at 0.32 mg/kg. Both KRM-II-18B and KRM-II-
81 were able to attenuate the acetic acid-induced writhes. The significance was reached at 3.2 and 
10 mg/kg of KRM-II-18B, whereas it was reached at 5.6 and 10 mg/kg of KRM-II-81, as compared 
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to the vehicle. No larger doses of both ligands were applied due to the sedative potentials at higher 
doses. A weaker chemical stimulus, 0.32 % of lactic acid, was used to induce writhes because both 
of the two PAMs only reduced 0.6% acetic acid-induced writhes partially, which might be too 
strong for the ligands. Under this condition, the vehicle group exhibited 27.33 ± 3.138 writhes. 
Morphine also able to attenuate the lactic-acid-induced writhing, which was more potent than in 
that of using 0.6% acetic acid and the significance was reached at 0.32 and 1.0 mg/kg. Both 
GABAAR PAMs reduced the 0.32 % lactic acid-induced writhes significantly at 10 mg/kg, as 
compared to the vehicle and 3.2 mg/kg treatment, as shown in Figure 129. The mechanism of this 
effect of mediating the antinociceptive effect through GABAAR was confirmed by the blockade 
of the antinociceptive effect of the two PAMs with the GABAAR antagonist flumazenil at a dose 
of 3.2 mg/kg, as depicted in Figure 130. These results suggested that the antinociceptive effects of 




Figure 129. The assessment of antinociceptive effects of morphine, KRM-II-18B, and KRM-II-81 on (A) 0.6% 
acetic acid and (B) 0.32% lactic acid-induced writhing (n = 6−8 per group) observed in the 25 min observation 






Figure 130. The assessment of flumazenil on the antinociceptive effects of KRM-II-18B- and KRM-II-81 in the 
acid-induced writhing model (n = 6−8 per group). Bars represent the mean and error bars show SEM. *P < 
0.05, ***p < 0.001. (Adopted from Figure in Lewter et al.) 236 
 
3.3.3.2. Inflammatory Pain Models 
The von Frey test is the gold standard for the evaluation of the mechanical allodynia in 
rodents and has been widely used in multiple animal models of diseases such as inflammatory pain, 
neuropathic pain, cancer pain, muscle pain, spinal injury and back pain, etc. In brief, rats (n = 6) 
are individually placed in cages with a wire grid floor or mesh. The induction of inflammation was 
achieved by the injection of 0.1 mL of complete Freund’s adjuvant (CFA), a solution of antigen 
emulsified in mineral oil and used as an immunopotentiator, in the right hind paw of the rats. The 
left contralateral paw as unaffected and was the control paw. A filament was used to penetrate the 
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surface of the floor and poke the plantar surface of the hind paw until the fiber bends, which 
generates a constant force on the rat paw and is recorded.260 Any exhibited response such as licking, 
withdraw or shaking of paw, is considered a positive response during the administration of the 
stimulus or immediately post the removal of the filament. The paw withdrawal threshold (PWT) 
was measured every 15 minutes. In the mechanical hyperalgesia study, rats received intermittent 
injections (every 20 min.) of increasing doses of flumazenil (or saline)  immediately following 
pre-treatment with KRM-II-81 (77). The results of the CFA-induced inflammatory pain model in 
rats are illustrated in Figure 131. KRM-II-81 (i.p.) significantly increased pain thresholds in the 
Von-Frey test in rats after injection of the CFA in a dose-dependent and time-dependent manner. 
The withdrawal threshold reached a maximum effective dose at 5.6 mg/kg and at 60 minutes in all 
doses. The antinociceptive effects of treatment with 77 with a dose of 5.6 mg/kg can be completely 
attenuated by the GABAAR antagonist flumazenil at 10 mg/kg in the CFA-induced pain model via 
















































































Figure 131. The withdrawal threshold by KRM-II-81 (77) treatment in the CFA-induced inflammatory pain in 
von Frey test in rats (n = 6) at 1.78, 3.2, 5.6 mg/kg up to 270 minutes test period. Each point represents the 
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mean + SEM of 6 rats. (Lewter, L., Cook, J.M. Li, J. The Behavioral effects of novel GABA(A) receptor positive 
allosteric modulators in rats. Biology, Behavior, and Chemistry Meeting, San Antonio, TX.,Mar. 2016) 
 
 
Figure 132. The assessment of flumazenil on the antinociceptive effects of KRM-II-81 (77) in CFA-induced 
inflammatory pain in rats (n = 6). The filled circle represented the PAM (5.6 mg/kg) + flumazenil group. The 
unfilled circles represent the PAM + saline group. The effect of KRM-II-81 (77) was completely blocked by 
flumazenil at 10 mg/kg. (Lewter, L., Cook, J.M. Li, J. The Behavioral effects of novel GABA(A) receptor 
positive allosteric modulators in rats. Biology, Behavior, and Chemistry Meeting, San Antonio, TX.,Mar. 2016) 
 
The evaluation of possible tolerance to the antinociceptive effects of KRM-II-81 (77) was 
conducted in rats (n=6) that received 5.6 mg/kg (i.p.) of KRM-II-81 twice a day for 11 consecutive 
days in a CFA-induced inflammatory pain in the von Frey test versus the acute dose. Inflammatory 
pain was induced by Complete Freund’s adjuvant (CFA) inoculations. The assay began 2 days 
after CFA treatment; mechanical hyperalgesia was measured on days 0, 4, 8, and 12. On days 1-3,  
5-7, and 9-11 rats were treated with KRM-II-81 or saline twice a day (A.M. injections at 9:00-
10:30 and P.M. injections at 5:00-6:30) in their home cages.  On days 0, 4, and 8 rats will only 
receive P.M. injections due to the mechanical hyperalgesia test done in the A.M. The following 
doses of PAM were given at 5.6 mg/kg of KRM-II-81. In the acute study, they only received 5.6 
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mg/kg of KRM-II-81 (77) on day 12. On days that mechanical hyperalgesia was tested, cumulative 
dose-response curves included the following doses: KRM-II-81 (1.0-5.6 mg/kg). Tolerance to the 
antinociceptive effects of KRM-II-81 (77) did not develop in a 11 consecutive day study in CFA-
induced inflammatory pain in von Frey test in rats, as illustrated in Figure 133 versus the control 
tests. The maximum percentage effect (MPE) of 77 treated group and vehicle group were nearly 
identical at all time, which indicated no tolerance of the antinociceptive effect of 77 had developed.  
 
Figure 133. The evaluation of possible tolerance to the antinociceptive effects of KRM-II-81 (77) was conducted 
in rats (n=6) that received 5.6 mg/kg (i.p.) of KRM-II-81 twice a day for 11 consecutive days in CFA-induced 
inflammatory pain in von Frey test.Starting two days after CFA treatment, rats (n=6) were given 5.6 mg/kg of 
KRM-II-81, twice a day, for 11 consecutive days. On days 0, 4, and 8 rats will only receive P.M. injections due 
to the mechanical hyperalgesia test done in the A.M. (Unpublished data) 
 
In addition to the CFA-induced inflammatory pain by the von Frey assay, KRM-II-81 (77) 
was also assessed in the formalin assay, which is a popular and reliable assay used as a chemical-
induced inflammatory nociception model, to determine its ability to reduce the formalin-induced 
tactile hypersensitivity. The advantage of this assay over other inflammatory pain models is that it 
can produce both acute and chronic pain by a single dose of dilute formalin in a short period of 
time approximately 1 h. Briefly, rats were allowed to acclimate to the test chamber. The 50 μL of 
5% formalin solution (in 0.9% saline) was given by i.p. injection to rats at the plantar surface of 
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the right hind paw. The response of the rat to the formalin-induced inflammatory pain was 
monitored and recorded for a period of 50 minutes. The behavioral response such as licking, resting 
or sniffing was observed and considered as the number of events. The response is the amount of 
time the animals spend licking the injected paw. Data were analyzed separately for two phases: 
the first 5 minutes and the later phase from 10-50 minutes. As illustrated in Figure 134, oxazole 
77 was able to reduce the nociceptive response in the late phase of the test in a dose-dependent 
manner. The effect reached significance at 30 mg/kg, which was as efficacious as 80 mg/kg of the 
chronic used tramadol as the positive control. In the early phase of the test, only the positive control 
and 77 at 100 mg/kg significantly suppress the tactile-induced allodynia, as compared to the 
vehicle.  
 
Figure 134. The assessment of antinociceptive effect of KRM-II-81 (77) in the formalin assay by reducing the 
paw-withdrawal thresholds. KRM-II-81 was given by i.p. injection to rats at a dose of 1-, 30, and 100 mg/kg, 
the positive control tramadol at 80 mg/kg. 77 (30 min prior) significantly reduced the nociceptive responses in 
the late phase at the dose of 30 mg/kg, whereas 100 mg/kg for the early stage. As a positive control, tramadol 
was active in both phases. Each point represents the mean±SEM of the same 8 rats *p<.05 compared to vehicle. 




3.3.3.3. Neuropathic Pain Model 
The spinal nerve ligation model is one of the direct peripheral nerve injury models for 
neuropathic pain.259 In the spinal nerve ligation model, the L5 and L6 spinal nerves are separated 
and ligated with surgical silk strand tightly, which induces axonal degeneration and will affect all 
different types of axons in the area of the ligation. This leads to pronounced mechanical allodynia 
along with an unrecoverable spontaneous pain, which can last for months. The 1,3-oxazole KRM-
II-81 (77) was evaluated in this spinal (L5/6) nerve-ligation (SNL)-induced neuropathic pain 
model for its potential analgesic effects. In brief, male rats went through SNL surgery 90 to 104 
days prior to testing. After obtaining a baseline, rats were administrated i.p. with either vehicle (1% 
CMC), gabapentin (50 mg/kg) or 77 (30 mg/kg). During the test, the mechanical sensitization the 
rats underwent was measured with von Frey filaments to determine the paw withdrawal threshold 
(PWT) at every hour for a total of 4 hours of the test period. Gabapentin was used as a positive 
control since it is a commonly used medication for nerve pain and as an anticonvulsant. As 
illustrated in Figure 135, both the oxazole 77 and gabapentin reversed the SNL induced 
hyperalgesia at the 1 hour and 2-hour point after i.p. administration by increasing the PWT values. 
The oxazole 77 exhibited a greater reversal of antihyperalgesic effect than gabapentin with a lower 
dose, which would lower the possible concerns of side effect in higher doses resulting from the 




Figure 135. The assessment of KRM-II-81 (77) and gabapentin in the spinal (L5/6) nerve-ligation-induced 
neuropathic pain via the von Frey filament assay. Male Sprague-Dawley rats (n = 5) were administrated i.p. 
either vehicle, 77 (30 mg/kg), or gabapentin (50 mg/kg) and 30 minutes before testing. Analyzed using ANOVA 
(Dunnett’s test: * P < 0.05). (Adopted from the Figure in Witkin et al, 2019) 
 
A second SNL-induced pain experiment was performed using p.o. dosing rather than i.p. 
as the first experiment described above. As illustrated in Figure 129, the baseline levels of PWT 
were reduced to 0.65 ± 0.21 g by the sensitization methods of training before testing, as compared 
to the first experiment with a PWT value of 5.1 ± 2.8 g (Figure 136). Both 30 and 100 mg/kg of 
77 administrated p.o., significantly increased PWT at 4 hour-point, whereas gabapentin tended to 
exhibit significance after 1 hour at 75 mg/kg, p.o. These results indicated a significant oral 




Figure 136. The assessment of KRM-II-81 (77) and gabapentin in the chronic spinal (L5/6) nerve-ligation-
induced neuropathic pain in the von Frey filament assay under conditions of sensitization training. Male 
Sprague-Dawley rats (n = 5) were administrated p.o. either vehicle, 77 (10, 30, or 100 mg/kg), or gabapentin 
(75 mg/kg) and 30 minutes before testing. Analyzed using ANOVA (Dunnett’s test: * P < 0.05).  
 
The pain, that cancer patients suffer from, is not only from cancer itself but also from the 
treatments used against cancer. Chemotherapy-induced neuropathic pain (CINP) may occur during 
the treatment in cancer patients. In order to test the ability of possible alleviation of the pain from 
the chemotherapy-induced peripheral pain, KRM-II-81 (77) was further evaluated in the acute and 
chronic CINP model. In brief, vehicle or 4 mg/kg i.p. administration of the chemotherapy agent, 
Paclitaxel (PTX) used as a medication for cancer pain, was injected into mice to increased 
sensitivity to many sensory modalities such as mechanical and thermal hyperalgesia at day 0, 2, 4. 
On day 7, 11, 13 and on Day 15 (prior to the dose-response), mechanical hyperalgesia in the von 
Frey test, as described previously, and thermal allodynia (the length of the reaction) induced by 
acetone injection into the hind paw were measured. The dose-response was carried out at day 15 
at the following cumulative doses: 0.1, 1, 5, 10, 15, 20 mg/kg with 6 injections, one every 30 min. 
After completing the dose-response study, treatments were decoded, and the ED 80 from 
mechanical data (Figure 137) was used to determine the dose for corresponding chronic treatment: 
20 mg/kg for KRM-II-81 or 16 mg/kg for MP-III-080. From day 18, every even day up to day 40, 
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mice received an injection of their chronic treatment (vehicle, 20 mg/kg KRM-II-81 or 16 mg/kg 
MP-III-080) and then 30 minutes later, the measurements of mechanical hyperalgesia (3x per each 
hind paw) and thermal allodynia (2x per each hind paw) were recorded, as shown in Figure 138. 
Both KRM-II-81 and MP-III-080 are very effective in the CINP model at attenuating both 
mechanical and thermal allodynia. On odd days (19-30), the same processes were repeated, 
however, all measurements were taken prior to the chronic treatment injections, as presented in 
Figure 139. The results indicated that there was no tolerance to the anti-pain effects observed 
following chronic administration. 
  
Figure 137. Acute dose-response effects of KRM-II-81 and MP-III-80 on (A) mechanical hyperalgesia and (B) 
thermal allodynia (n = 4). Veh represents mean of measurements from paclitaxel pre-treated animals in the 





Figure 138. Effects of daily KRM-II-81 and MP-III-80 administration on chronic neuropathic pain (Day 18-
40). Data for days 18-40 represent measurements of (A) mechanical hyperalgesia and (B) thermal allodynia (n 
= 4) 30 minutes after KRM-II-81, MP-III-80 or Vehicle administration. Ptx – Paclitaxel pre-treatment group, 
Veh – Vehicle pre-treatment or treatment groups. Error bars - ±SEM 
 
 
Figure 139. Effects of daily KRM-II-81 and MP-III-80 administration on chronic neuropathic pain (Day 19-
39). Data for days 19-39 represent measurements of (A) mechanical hyperalgesia and (B) thermal allodynia (n 
= 4) before KRM-II-81, MP-III-80 or vehicle administration. Ptx – Paclitaxel pre-treatment group, Veh – 
Vehicle pre-treatment or treatment groups. 
 
Take together all the data from different stimulus (chemical, thermal, mechanical) induced 
pain models; oxazole 77 was able to produce the desired antinociceptive or antihyperalgesic effects 
without the development of tolerance, which significantly widens the spectrum of oxazole 77 and 
its related analogs. No sedation, ataxia, amnesia loss of righting response no dependence was 





Since depression is usually comorbid along with patients with anxiety, epilepsy, and pain, 
it is important to determine if the active drug can also produce an antidepressant effect as a 
beneficial property. As described in the previous chapter, the forced-swim test (FST), which is 
commonly used for the assessment of antidepressant-like effects of conventional and novel 
antidepressant drugs in pharmacological studies, was utilized for the possible desired effect of the 
1,3-oxazole KRM-II-81 (77). It was administrated at its anxiolytic-producing doses, as an α2/3-
selective PAM. This ligand was also tested in a related model, the tail-suspension test. Prior to the 
FST about 30 minutes, NIH Swiss mice were administrated i.p. with vehicle (1% CMC), oxazole 
77 (3, 10 or 30 mg/kg) or the positive control imipramine at dose of 15 mg/kg, and placed in a 
chamber that was filled with water to a level that the mice can neither touch the bottom or escape. 
The reduction of immobility of mice indicates the animal was less depressed and would still 
continue to swim and search for a way to escape. The animal had not given up. 
In the forced swim test, KRM-II-81 (77) exhibited an antidepressant effect at doses of 10 
and 30 mg/kg by decreasing the immobility in a dose-dependent manner, as depicted in Figure 140. 
The marketed drug imipramine at 15 mg/kg ip, as expected, significantly reduced the immobility, 
as compared to vehicle (F4,32=8.19, p < 0.0001). These results suggest there may be an alternative 
pathway, in addition to the serotonergic and/or noradrenergic systems,261 for the treatment of 
depression by targeting at the α2-containing GABAAR. It has also been reported that the α2 subunit 
might be involved in the antidepressant activity in a knockout study.262 Furthermore, it was also 
suggested by Julian Mao (NIH). That antinociceptive agents that are both anxiolytic and 




Figure 140. The antidepressant effect of KRM-II-81 (77) in male NIH Swiss mice in the FST. Mice were injected 
i.p. with vehicle (1% HEC, 0.25% Tween 80, 0.05% antifoam), KRM-II-81 (3, 10 or 30 mg/kg) or imipramine 
(15 mg/kg), n=6. *p < 0.05; ***p < 0.0001 as compared to vehicle by Dunnett's test. 
 
3.3.5. Evaluation of the Lack of Side Effects in Other Animal Models 
3.3.5.1. Respiratory Depression Effects 
One of the critical side-effects of BZDR ligands, when combined with opioids, is 
respiratory depression, which significantly increases the emergency room visits as well as in 
overdose of BZDs combined with opioids or fentanyl. Therefore, KRM-II-81 (77) was evaluated 
for any possible respiratory depression effects. As presented in Figure 141, the non-selective 
GABAAR agonist, alprazolam, exhibited a significant decrease on the respiration rate at 0.32 
mg/kg (p < 0.01) and 3.2 mg/kg (p < 0.01), whereas only at the highest tested dose 10.0 mg/kg of 
77 actually have an effect on significantly reduced the respiration rate(p < 0.05). All doses of both 
77 and alprazolam did not exhibit a significant change in tidal volume. Alprazolam reduced the 
overall minute volume /kg value only at the highest dose at 3.2. mg/kg (p < .05), whereas no 
significant decrease was observed with the administration of 77 at any dose. Analysis of the oxygen 
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Figure 141. The effect comparison with administration i.p. of KRM-II-81 (30 min prior) and alprazolam (15 
min prior) on measures of respiration in rats. a) Respiration rate, b) Tidal Volume c) Minute Volume / Kg. 
Data are means±S.E.M. (n = 8). *p < 0.05. (Adopted from Figure in Witkin et al., 2019)245  
 
3.3.5.2. Drug Abuse Liability 
Drug discrimination is a widely used method for determining the in vivo pharmacology of 
drugs abuse liability for by determining whether the known drug of abuse can be substituted by a 
new test ligand that produces a similar desired pharmacological effect as the known drug. In brief, 
rats are subjected to a 15-minute daily training. During the training section, lever pressing was 
reinforced by given a sugar pellet. Before the test session, rats are administrated with either 3.2 
mg/kg midazolam, a known drug of abuse, or vehicle. Responses on pressing the "drug lever" are 
reinforced during drug training sessions; the same procedure was used for the training on pressing 
"vehicle lever" during vehicle training sections. Test ligand KRM-II-81 (77) at the antinociceptive 
dose of 5.6 mg/kg was injected into rats for the determination of its abuse ability by the responses 
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of rats that mimic or alter the response of midazolam. If the new ligand exhibited more than 80 % 
responding on the midazolam drug level, it would be considered as high risk of abuse potential, 
20-80 % are partially generalized, less than 20 % indicates low abuse liability than the midazolam 
training drug. As an illustration in Figure 142, KRM-II-81 at 5.6 mg/kg, which produced a 
maximal analgesic effect in von Frey assay in the inflammatory chronic pain model, does not 
substitute for 3.2 mg/kg of midazolam in the drug discrimination assay. However, it elicited a 
moderate abuse liability at 17.8 mg/kg. The response rate was nearly at baseline at 32 mg/kg of 
77, which indicated a high potential of abuse, since higher doses of known drug of abuse do not 
produce a response. Examination of the data in this assay shows that at a dose that is anywhere 




Figure 142. Drug discrimination assessment of increasing dose (3.2, 5.6, 10, 17.8, 32 mg/kg) of KRM-II-81 as 
compared to the known drug of abuse, midazolam at 3.2 mg/kg. Upper panel, midazolam lever responding 
percentage; lower panel, responses per second. KRM-II-81 at 5.6 mg/kg does not substitute for midazolam in 
the drug discrimination assay. 
 
In addition to the drug discrimination test on KRM-II-81 (77), an assay of pain-depressed 
intracranial self-stimulation (ICSS) was also utilized to explore the potential abuse liability as a 
second approach, since it has been reported that the preclinical potential of drug liability can be 
indicated by drug-induced facilitation of ICSS in the absence of a noxious stimulus. In brief, rats 
were trained to press a level in response to the pulses of electrical brain stimulation. The ketorolac, 
an analgesic NSAID, was used as a positive control and diazepam as a negative control since it 
was not active in pain models but produced drug abuse potential. After a baseline was obtained, 
rats were administrated i.p. with either vehicle, or 0.32-10 mg/kg KRM-II-81 (n=8) and 0.1-10 
mg/kg ketorolac (n=6) or 0.32-10 mg/kg diazepam (n=6) in the absence of the dilute lactic acid, 
as an acute visceral noxious stimulus, which produce an reduced response of ICSS and can be 
mitigated by clinically effective analgesics. A frequency-dependent increase in ICSS rates was 
achieved in the baseline condition by the electrical brain stimulation. As presented in Figure 143, 
neither ketorolac nor 77 at all tested doses significantly influenced ICSS rates, whereas a dose-
dependent increase in ICSS rates was observed with diazepam treatment, especially at the dose of 
1.0 and 3.2 mg/kg administration. These results suggest that both ketorolac and 77 did not affect 
the ICSS response in the absence of the noxious stimulus, which indicated a low potential of abuse 




Figure 143. The effects of ketorolac (n=6), KRM-II-81 (n=8) or diazepam (n=6) effects on ICSS in the absence 
of the acid noxious stimulus in rats. Top panels show frequency-rate curves. Significance (p<0.05) is indicated 
by filled symbols, as compared to vehicle. Bottom panels show the total stimulations earned across all 
frequencies expressed as a baseline % for each frequency-rate curve on the top. Upward arrows indicate a 
significant increase in ICSS. All points and bars represent mean (± S.E.M.). (Adopted from the Figure in 
Moerke et al., 2018) 
 
3.3.5.3. No Motor Impairment in the Rotarod Study 
Since CNS side effects are major concerns for using imidazodiazepines (IMDZs) that bind 
to BzR site, KRM-II-81 (77) was evaluated in the rotarod test with a longer test period and higher 
doses to determine the possible toxicity-production dose and duration. As reported, 77 did not 
produce any sedative or ataxic effects on the rotarod at 30 mg/kg as the effective dose for anxiolytic 
effects. However, tremors, the latency of righting reflex and sedation were observed with p.o. 




Figure 144. The observation of possible tremors of KRM-II-81 administrated p.o. at 120 mg/kg for 24 hours, 
n = 9.  
 
Figure 145. The observation of righting reflex of KRM-II-81 administrated p.o. at 120 mg/kg for 24 hours, n 
= 9. 
 



















































Administration of KRM-II-81 at 120 mg/kg and n = 9:
























































Figure 146. The observation of sedation of KRM-II-81 administrated p.o. at 120 mg/kg for 24 hours, n = 9, on 
rotarod test. 
 
The study of metabolites in MLM (mouse), RLM (rat), MLM (monkey) and HML (human) 
from Eli Lilly on KRM-II-81 (Appendix VI) illustrated that the concentration of the metabolites 
in mice were much less in rats and nearly undetectable in monkey and not detectable in human 
liver microsomes, which suggested that the possible toxic metabolites induced tremor and latency, 
might not be produced in other species or only a trace of them was produced but too small an 
amount to induce a toxic effect. Importantly, ETSP/NINDS demonstrated that when the 
administrated 120 mg/kg in rats p.o., there were no side effects observed. This is a key result in 
regard to toxicity. Therefore, further identification of metabolites and their activity in mice or rats 
would be helpful to determine the exact toxic metabolites in mice, furthermore, the ligand design 
can be optimized from that data to avoid the metabolite-induced side effects observed in mice.  
 
 









































In conclusion, modifications of previous procedures for the synthesis of Hz-166 (76), MP-
III-080 (102) and KRM-II-81 (77) are presented in this work under milder conditions and with 
much-improved yields. Moreover, an alternative method for the synthesis of the aldehyde (107) 
from ester (76) was optimized and overcame the long-standing problem of N(5)-C(6) imine bond 
reduction in good yield. These methods have been employed for larger scale reactions. In addition, 
there is no need for column chromatography for most of the compounds, which provided a much 
more practical route. With the improved synthesis, large quantities of these three α2/3-subtype 
selective GABAARs PAMs, which exhibited anxiolytic, anticonvulsant and antinociceptive effects 
in many tests, can now be supplied with high-efficiency for investigation in many behavior assays 
including those in primates or other animal models for anxiety and epilepsy, pain as well as for 
depression.   
Preclinical in vitro studies suggest that the 1,3-oxazole KRM-II-81 (77) represents a 
promising novel lead compound with the desired pharmacological profile, including α2/α3-
GABAAR subtype selectivity, no binding affinity for 46 other receptors (no hERG), an excellent 
PK profile, no cytotoxicity, metabolically stable on liver microsomes (human, rat, mice), and good 
lipophilicity (clogP = 2.3; ChemAxon program). In summary in the various animal models, 1,3-
oxazole 77 demonstrated a wide range of beneficial behavioral effects, including the anxiolytic 
effect in marble bury assay and Vogel conflict assay; the excellent anticonvulsant effects from a 
series of both acute and chronic seizure models, resistant epilepsy as well as the ability to reduce 
the firing rate from human cortical epileptic tissues; the antinociceptive effect in acid-induced 
visceral pain model, the antihyperalgesic effect in the CFA induced mechanical allodynia in the 
von Frey test with no development of tolerance in the models of inflammatory pain. In addition, 
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oxazole 77  showed no SNL-induced hyperalgesia as well as no thermo-induced allodynia in the 
models of neuropathic pain. Importantly, the oxazole 77  had an antidepressant effect in the FST, 
no respiratory depression; no drug abuse potential (ICSS) as well as no sedation at all at important 
pharmacological concentrations. Taken together, all these evidence on 1,3-oxazole 77 strengthens 
the fact that an α2/3 GABAAR PAM 77 should be very valuable and efficient for the treatment of 
anxiety, epilepsy, and pain. Further investigations on metabolite studies, ADME-Tox studies, 
GMP synthesis and analog synthesis based on this oxazole, should provide better drugs for anxiety, 
pain, and respiratory/resistance epilepsy as well as depression.  
 
3.5. Methods 
3.5.1. Dorsal Root Ganglion Electrophysiology (Dr. Kevin Freeman, University of 
Mississippi Medical Center) 
The culture of dorsal root ganglion neurons were prepared as described (Bleakman et al., 1996). 
Briefly, DRG were isolated from 2-month old rats (235–310 g) and enzymatically digested with 3 
mg/mL of type II collagenase at 37 °C for 50 min. After 50 min of digestion, the tissue was 
mechanically dissociated with a series of sterile fire-polished glass pipettes of decreasing diameter. 
The dissociated neurons were plated directly on Nunc 35×10 tissue culture dishes and incubated 
in Nb Active1 (Brainbits LLC, Springfield, IL) supplemented with 5% dialyzed fetal bovine serum, 
0.25% Glutamax (Gibco). Cell cultures were maintained in a tissue incubator (37 °C, 5% CO2) 
and used within seven days. DRG neurons were recorded at room temperature using conventional 
whole-cell voltage clamp methods as described (Cerne et al., 2016). Cells were voltage clamped 
at −80 mV for the duration of the experiment. GABA currents were activated by 4 s perfusion with 
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GABA at an EC10 concentration using a ValveBank II eight channel perfusion system (AutoMate 
Scientific, Berkley, CA). Stock solutions of test compounds were prepared in DMSO and diluted 
into the external solution or the GABA EC10 solution such that DMSO concentrations did not 
exceed 0.1% (v/v). The test compound was perfused for 2 min followed by 4 s co-administration 
with GABA. During the recording, the Nunc 35×10 tissue culture dishes were continuously 
perfused with an external solution using a gravity flow perfusion system, as described (Witkin et 
al., 2019). The data were normalized to the baseline GABA EC10–evoked current amplitude and 
reported as the mean ± standard error of the mean (SEM). The concentration-response data were 
fit using the four parameter Hill equation. 
 
3.5.2. Marble Burying Assay (CRO) 
The ligands were evaluated in the marble burying assay in mice using the previously published 
methods (Li, et al., Life Sci., 2006, 78, 1933 – 1939). Mice were administrated i.p. with either 
vehicle (1% carboxymethyl cellulose) or a test compound 30 min prior to testing. Mice were then 
placed in a 17 x 28 x 12 cm high plastic tub with 5 mm sawdust shavings (Harlan Sani-Chips, 
Harlan-Teklad, Indianapolis, IN) on the floor. The 20 blue marbles (1.5 cm diameter) were placed 
in the center of the tub. Mice were left in the tub for 30 min. The marbles that were buried (2/3 
covered with sawdust) by mice were counted and recorded. 
 
3.5.3. Vogel Conflict Assay (Dr. Jeffrey M. Witkin, Wikin Consulting) 
The ligands were evaluated in male Sprague-Dawley rats (Harlan Industries, Indianapolis, IN) 
weighing between 200-300 grams in the Vogel conflict assay using the previously published 
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methods (Alt, et al., Neuropharmacology, 2007, 52, 1482 – 1487). Operant behavior test chambers 
ENV-007 (Med Associates Inc., Georgia, Vermont, USA) 30.5 x 24.1 x 29.2 cm, were used for 
conducting the assay. The data were recorded by a Compaq computer running MED-PC Version 
IV (Med Associates Inc., Georgia, Vermont, USA)., Water was withheld for 24 h before the first 
training session. A 6 min drinking session after the first lick was considered of the training. The 
unpunished component was at the first 3 min, and the punished component was at the last three 
min of the assay. There was no shock given in the punished component during the first two training 
days. After training, rats were placed back into their homecages and water was accessible to the 
animal for 30 min before being deprived for the next 24 h prior to the next session. On the third 
day, 30 min prior to testing (n = 6 – 8), the rats were administrated i.p. with either vehicle (0.5% 
Tween 80, 1% hydroxyethyl cellulose, 0.05% Dow anti-foam administered at 3 mL/kg), 
chlordiazepoxide (20 mg/kg at 1 mL/kg), Hz-166 (30 mg/kg at 3 mL/kg) or KRM-II-81 (3, 10, 30, 
or 60 mg/kg; 3 and 10 mg/kg at 1 mL/kg, 30 mg/kg at 3 mL/kg, and 60 mg/kg at 6 mL/kg). During 
the punished section on the third day, rats received a minimal electrical shock (100 msec, 0.5 mA) 
after every 20th lick (FR20). The recorded value of the mean number of licks during both punished 
and unpunished were analyzed as compared to the control vehicle group. Dose-effect functions 
were analyzed by ANOVA followed by post-hoc Dunnett’s test with vehicle treatment as the 
control standard. Statistical probabilities ≤ 0.05 were considered significant. 
 
3.5.4. 6 Hz 44mA Seizure Model (ETSP) 
In briefly, mice were administrated p.o. with KRM-II-81 (77), and the 6 Hz stimulation was 
delivered for 3 seconds after 2 hours through corneal electrodes at 44 mA, and the seizure activity 
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in the animal was observed and recorded. A parallel group of mice was administrated with higher 
doses of 77 and observed for potential motor impairment and possible toxicity at 4 hours after 
dosing. 
 
3.5.5. Maximal Electroshock Seizure (MES) Model (ETSP) 
This assay detects the anticonvulsant effects of the test compounds that produced generalized 
seizures and those that alleviated seizure spread. Male, CD1 mice (Taconic Farms) were studied 
at weights of 21-32 g. The Wahlquist Model H stimulator with 0.2-sec stimulation with corneal 
electrodes was used in the assay. Diazepam was dissolved in 1% hydroxyethylcellulose/0.25% 
Tween- 80/0.05% Dow antifoam in water. KRM-II-81 and HZ-166 were suspended in 
carboxymethylcellulose. The dose volume for diazepam was 1 mL/kg for rats, and 10 ml/kg was 
used for mice. KRM-II-81 and HZ-166 were dosed in volumes of 10 mL/kg in mice. HZ-166 was 
dosed in a volume of 5 mL/kg in rats and KRM-II-81 was dosed at 1 mL/kg in rats below doses of 
30 mg/kg; 30 mg/kg (dosed at 3 mL/kg), 60 mg/kg (dosed at 6 mL/kg). Mice were administrated 
i.p. with diazepam (1, 3 or 6 mg/kg), 76 (3, 10 or 30 mg/kg) or 77 (3, 10 or 30 mg/kg) 30 minutes 
prior to testing, and were observed for approximately 10 sec after administration of the electrical 
stimulus (10 uA) and the types of convulsions were recorded (0 = no convulsion, 1 = clonus, 2 = 
tonic flexion, 3 = tonic extension). Mice were euthanized immediately for the following test. The 
tonic extension at hindlimb was recorded as the primary endpoint. The Fisher’s Exact probability 
test was used to analyze the percentage of animals exhibiting convulsions. 
 
3.5.6. Inverted Screen Test (ETSP) 
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Male, Sprague Dawley rats (Harlan Sprague Dawley, Indianapolis, IN) were used, which weighed 
90-110 g for this assay. The apparatus consisted of four 13 x 16 cm squares of a round hole, 
perforated stainless steel mesh (18 holes/square inch, 3/16 inch diameter, ¼ inch staggered centers, 
50% open area) mounted 15 cm apart on a metal rod, 35 cm above the table top. Rats were 
administrated with test compounds p.o. with diazepam (3 or 10 mg/kg), 76 (30 mg/kg) or 77 (10 
or 30 or 60 mg/kg), and returned to their home cage. The rats were evaluated on the inverted screen 
test after 25 min of dosing and were scored after 60 seconds as follows: 0=climbed over to the top 
of the screen, 1= hanging on to screen, 2= fell off). 
 
3.5.7. Pentylenetetrazole (PTZ)-Induced Seizures (ETSP) 
The rats were administrated i.p. with pentylenetetrazol (35 mg/kg, s.c.) in a volume of 1 ml/kg. A 
cage (40.6 x 20.3 x 15.2 cm) with a floor containing 0.25 inches of wood chip bedding material 
was used for placing the rats for observation. The dose of PTZ (35 mg/kg) was determined to be 
~ EC97 for inducing the clonic seizures. The rats were then observed for 30 min post-PTZ for 
clonus seizures which the rat demonstrated loss of righting of fore- and hindlimbs or for tonic 
seizures as indication by loss of righting accompanied with tonic hindlimb extension. Fisher’s 
Exact probability test was used to analyze the percentage of animals exhibiting convulsions. 
 
3.5.8. Pentylenetetrazole (PTZ)-Induced Seizure Threshold (ETSP) 
Male F-344 Harlan rats (Indianapolis, IN) were randomly assigned to treatment groups and 
administrated vehicle or test compounds. Rats were placed in a restrained container, and a winged 
infusion needle was inserted into the lateral tail vein. Intravenous infusion with 10 mg/ml PTZ at 
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a rate of 0.5 ml/min was initiated until a clonic seizure was observed, and the time to produce a 
seizure was recorded in sec or a maximum for four min was recorded and was calculated by the 
infusion rate concentration of PTZ, time to clonic convulsion, and animal weight. After the test of 
infusion, rats were euthanized. 
 
3.5.9. Corneal Kindled Mouse Model (ETSP) 
In brief, the male CF-1 mice are receiving a twice-daily kindled electrical 3-sec stimulation, 3 mA, 
60 Hz by corneal electrodes for 10-14 consecutive days to reach the criterion of Stage 5 seizures. 
Mice were continuously given this twice daily stimulations until they achieved the criterion to 
ensure they were fully kindled. Any mouse not reaching the criterion was not included for the 
experiment for assessment of novel test compounds. The test started at 5-7 days post the last 
stimulation, after which stimulation was given to the mice to ensure the animals were at Stage 5 
seizures. Mice (two groups, each group has 4 fully kindled mice) were then administrated p.o. with 
the doses at 1, 3, 8, 15, 25, 30 mg/kg of KRM-II-81 (77), and the time of peak effect (TPE) was 
determined at the 2 hour time-point. After the test, the corneal kindled mice were placed back into 
their home cage and were allowed to wash out the test compounds for 3-4 days.  
 
3.5.10. Lamotrigine (LTG)-Resistant Amygdala Kindled Rat Model (ETSP) 
In brief, an electrode was implanted into the left amygdala in anesthetized male Sprague-Dawley 
rats (250-300 g). After one week of recovery, animals started to receive a daily 200 µAmp stimulus 
until they all reached to the Stage 4 or 5 seizures. LTG at 30 mg/kg was injected i.p. to the fully 
kindled animals to induce resistant seizures, before being stimulated to confirm the LTG sensitivity 
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of the vehicle group, as well as the LTG-resistance group. After the washout of LTG for 3 days, 
animals were administrated with KRM-II-81 (77) at the doses of 1, 5, 10, 20, and 40 mg/kg, then 
challenged with the stimulus at the predetermined time of peak effect at 1 hour. After the test, the 
corneal kindled mice were placed back to their home cage and were allowed to wash out the test 
compounds for 3-4 days.  
 
3.5.11. Model of Mesial Temporal Lobe Epilepsy (ETSP) 
In brief, the injection i.v. of kainic acid  (KA) at 1 mmol in 100 mL into the dorsal hippocampus 
of adult male C57/Bl6 mice, induces non-convulsive severe epilepsy. An electrode was implanted 
into the left hippocampus in male mice. After the KA injection for 4 weeks, a group of 4 MTLE 
mice was injected i.v. of 15 mg/kg of KRM-II-81, and the behaviors of the animal were recorded 
by digital EEG recordings for 20 minutes before-injection and 90 minutes after-injection. The 
number of HPDs were recorded and analyzed during a 20 minutes period for 10 minutes before 
and 10 minutes after the peak time of effect.  
 
3.5.12. Chronic Post-SE (KA) Spontaneously Seizing Rats: Stage 1 with IP Administration 
(ETSP) 
Chronic epilepsy in rats with status epilepticus was induced by a repeated low-dose of kainic acid 
(KA) at 7.5 mg/kg i.p. at every hour up to 4 hours until animal achieved Stage 5 seizures. The dose 
can be reduced as long as the animal retains lower-stage convulsions. Rats were received 3 mL of 
Ringers solution to keep them from dehydrating. After 10 weeks of chronic treatment, the rats 
were implanted a wireless telemeter into the peritoneal space from the stomach to the head 
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underneath the skin. In the EEG suites, an initial seizure rate is recorded over a week in rats. Only 
the rats with the highest seizure burden scores will be selected (n = 24). During the test period, a 
baseline seizure rate is determined in week 1. During week 2, the rats were administrated with 20 
mg/kg of KRM-II-81 (77) over 5 days, Monday-Friday. Rats are split into groups of 12 for the 
vehicle group and another 12 for the drug-treated groups. Once the treatment is completed in week 
2, rats will be monitored during week 3 with only vehicle treatment (washout period). In order to 
avoid any possible design variations, the cross-over paradigm was utilized. Similar to the first 
group (n = 6), the second group (n = 6) receives vehicle first, followed by the treatment of 77. A 
list of potential detected events (focal seizures for the drug treatment, generalized seizures for the 
vehicle treatment) are automatically accumulated and generated by a seizure detection algorithm 
via a MATLAB GUI. The results were presented by seizure burden, frequency, and distribution of 
Racine scores. 
 
3.5.13. Evaluation of Seizure Protection in Resistant Epileptic Human Brain Tissue (Dr. 
Jeffrey M. Witkin, Wikin Consulting)  
The tissue was prepared as previously described (Zwart et al., 2014). Slices were perfused at 1.0 
mL/min with normal ACSF (NACSF) solution for 1 h at 37 ° C. If there was no spontaneous 
activity developed after 1 h, the tissue was then bathed in excitable ACSF (EACSF) solution 
containing 5 mM K+ to induce a robust local field potential (LFP) activity in cortical tissues, after 
which 10 µM of picrotoxin was added, and the activity was recorded for 1 h to establish a baseline. 
Then 30 µM of KRM-II-81 was added, and the tissue activity was recorded for another hour. A 
second experiment was carried out with 50 µM of AP-4 following the same procedure described 
above with all 60 channels activated. Time points were binned at 4 ms. Two-way ANOVA was 
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performed to ensure whether KRM-II-81 was effective and whether the drug effect was dependent 
upon different channels, as described in (Witkin et al., 2018). 
 
3.5.14. Acetic Acid and Lactic Acid-Induced Writhing Model (Dr. Lakeisha A. Lewter and 
Jun-Xu Li, University at Buffalo) 
Mice were administrated i.p. with either 0.32% lactic acid or 0.6% acetic acid. The number of 
acid-induced writhes was observed and counted in a 25 min period, starting 5 min after the 
injection of acetic acid or 10 min after the injection of lactic acid. Writhe was defined as a 
contraction of the abdomen following a stretch of the hind limbs. Mice in treatment groups 
received subcutaneous (s.c.) injections of either morphine (0.1−3.2 mg/kg, 10 min pretreatment), 
KRM-II-18B (1−10 mg/kg, 30 min pretreatment), or KRM-II-81 (3.2−10 mg/kg, 30 min 
pretreatment). In the flumazenil blockade experiment, mice received s.c.injections of flumazenil 
15 min before the injections of each PAM. 
 
3.5.15. CFA-Induced Inflammatory Pain Model by the Von Frey Test (Dr. Lakeisha A. 
Lewter and Jun-Xu Li, University at Buffalo) 
Subjects: Adult male Sprague-Dawley rats (Harlan, Indianapolis, IN, USA) were housed 
individually on a 12/12 h light/dark cycle. Behavioral studies were conducted during the light 
period. Animals had free access to water and food except during experimental sessions. Animals 
were maintained and experiments will be conducted in accordance with guidelines of the 
International Association for the Study of Pain (Zimmermann, 1983A) and were approved by the 
Institutional Animal Care and Use Committee, University at Buffalo, the State University of New 
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York (Buffalo, NY ), and with the 2011 Guide for the Care and Use of Laboratory Animals 
(Institute of Laboratory Animal Resources on Life Sciences, National Research Council, National 
Academy of Sciences, Washington, DC).  
Induction of inflammatory pain: Inflammatory pain was induced by Complete Freund’s adjuvant 
(CFA) inoculations, as previously described (Li et al., 2014). CFA contains approximately 0.05 
mg of Mycobacterium butyricum, inducing inflammation and increasing paw thickness. 0.1 mL of 
CFA (Difco, Detroit, MI, USA) was injected in the right hind paw of Sprague Dawley male rats 
under isoflurane anesthesia (2% isoflurane mixed with 100% oxygen at a flow rate of 5 L/min). 
Mechanical nociception tests were conducted 48 hours after CFA inoculation. 
Mechanical hyperalgesia:  Mechanical hyperalgesia was measured using von Frey filaments (1.4 
g - 26 g; North Coast Medical, Morgan Hill, CA), 2 days after CFA treatment. Rats (n=6 per group) 
were placed in elevated boxes with a mesh floor (IITC Life Science Inc., Woodland Hills, CA). 
The von Frey filaments were applied perpendicularly to the medial plantar surface of the hind paw, 
starting with the lowest filament (1.4 g), and then applied in ascending order until a behavioral 
response (withdrawal of the hind paw) was elicited. Filaments were applied until buckling of the 
filament occurred and was maintained for approximately 2 seconds.  After each measurement, rats 
received the next dose of the drug (every 20 min) until the maximum threshold (26 g) was observed. 
Tolerance development: Starting 2 days after CFA treatment, mechanical hyperalgesia was 
measured on days 0, 4, 8, and 12. On days 1-3,  5-7, and 9-11 rats were treated with PAMs (KRM-
II-18B, KRM-II-81, or midazolam) or saline twice a day (AM injections (9:00-10:30) and P.M. 
injections (5:00-6:30)) in their home cages.  On days 0, 4, and 8 rats will only receive PM injections 
due to the mechanical hyperalgesia test done in the A.M. The following doses of PAMs were given: 
Twice a day 3.2 mg/kg of KRM-II-18B, and 5.6 mg/kg KRM-II-81 and midazolam were given.  
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On days that mechanical hyperalgesia was tested, cumulative dose-response curves included the 
following doses: KRM-II-18B (1.0-5.6 mg/kg), KRM-II-81 (1.0-5.6 mg/kg) , and midazolam 
(1.78-10 mg/kg). 
Drugs: 
The following drugs were used: KRM-II-18B, KRM-II-81, and midazolam. KRM-II-18B and 
KRM-II-81 were dissolved in a mixture containing, 20% DMSO, 10% emulphor, and 70% saline. 
Midazolam (Akorn, Inc.) was dissolved in 0.9% saline. Doses were expressed as the weight of the 
drug in milligrams per kilogram of body weight, and drugs were administered intraperitoneally. In 
the antagonist, study rats received intermittent injections (every 20 min.) of increasing doses of 
flumazenil (or saline)  immediately following pre-treatment of PAMs. 
  
3.5.16. Formalin Assay (Dr. Jeffrey M. Witkin, Wikin Consulting) 
Briefly, rats were allowed to acclimate to the test chamber (SR-Lab Startle Response System, San 
Diego Instruments, San Diego, CA). The 50 μL of 5% formalin solution (in 0.9% saline) was given 
by i.p. injection to rats at the plantar surface of the right hind paw. The response of the rat to the 
formalin-induced inflammatory pain were monitored and recorded for a period of 50 minutes by a 
force-transducer. The behavioral response such as licking, resting or sniffing was observed and 
considered as the number of events. The response is the amount of time the animals spend licking 
the injected paw. Data were analyzed separately for two phases: the first 5 minutes and later phase 
from 10-50 minutes by ANOVA followed by post-hoc Dunnett's test with p < .05 being considered 




3.5.17. SNL-Induced Hyperalgesia Model of Neuropathic Pain (Dr. Jeffrey M. Witkin, 
Wikin Consulting) 
Male Sprague-Dawley rats (Harlan Industries, Indianapolis, IN), weighing between 225 and 300 
g went through SNL surgery (as described in Witkin et al., 2019) 90 to 104 days prior to testing. 
After obtaining a baseline, rats (n = 5 for all groups) were administrated i.p. with either vehicle 
(1% CMC), gabapentin (50 mg/kg) or 77 (30 mg/kg). During the test, mechanical sensitization 
was subjected to the rats with von Frey filaments to determine the paw withdrawal threshold (PWT) 
at every hour for a total of 4 hours test period. Any exhibited response such as licking, withdraw 
or shaking of paw, is considered a positive response during administration of the stimulus or 
immediately post the removing of the filament. Paw withdrawal threshold (PWT) was measured 
every 15 minutes. In the mechanical hyperalgesia study, rats received intermittent injections (every 
20 min.) of increasing doses of flumazenil (or saline)  immediately following pre-treatment of 
drugs. In the second study, rats (n = 5) were administrated p.o. either vehicle, 77 (10, 30, or 100 
mg/kg), or gabapentin (75 mg/kg) and 30 minutes before testing. 
 
3.5.18. Chemotherapy Induced Neuropathic Pain (CINP) Models (Dr. Bronwyn Kivell, 
Victoria University of Wellington) 
All experimental work involving animals was conducted on male C57BL/6J mice in the Victoria 
University of Wellington Australia Animal facility. 
Acute treatment 
On day 0 mice were allocated to either paclitaxel (n=12) or vehicle (n=4) pre-treatment groups. 
The paclitaxel group received 4 mg/kg intraperitoneally (i.p.) paclitaxel in a vehicle of one part 
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1:1:18 mix of kolliphor EL, ethanol and saline and the vehicle group received vehicle only. These 
injections were repeated on Day 2, 4 and 6 to give a cumulative paclitaxel dose of 16 mg/kg/i.p.  
Prior to any measurement, mice were acclimatized to the experimental room with the experimenter 
present for 1 hour and then to the experimental chambers for a minimum of 10 min. On Day 0, 2 
and 4 (before the paclitaxel injections), on Day 7, 11, 13 and on Day 15 (before the dose-response) 
mechanical hyperalgesia and thermal allodynia were measured. These measurements were 
conducted in transparent raised enclosures with a grated floor to allow access to the underside of 
the animal’s paws. Mechanical hyperalgesia was measured using an electronic von Frey 
anesthesiometer (IITC Inc., Life Science Instruments, Woodland Hills, CA, USA). A trained 
experimenter applied a slowly increasing force to the center of the underside of a rear hind paw 
through a filament until a sharp withdrawal response was observed. The force required to observe 
this reaction was recorded. Mechanical hyperalgesia measurements were recorded three times for 
both hind paws on each measurement day. Thermal allodynia was measured by applying acetone 
to the hind paw with a syringe, and the length of the reaction (raising, licking, shaking or biting of 
the paw) was recorded. Thermal allodynia measurements were recorded twice for both hind paws 
on each measurement day. 
Dose-response study 
On Day 15 the Paclitaxel pre-treated mice were allocated to each of the dose-response treatments: 
KRM-II-81, MP-III-80, and Vehicle (n=4). These treatments were blinded to the experimenter. 
During the dose-response all mice received six injections, one every 30 min. KRM-II-81 and MP-
III-80 injections were at the following cumulative doses: 0.1, 1, 5, 10, 15, 20 mg/kg. Two 
measurements of mechanical hyperalgesia and one measurement of thermal allodynia for each 
hind paw were performed ~ 30 min after each injection. 
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Chronic neuropathic pain 
Following the dose-response measurements on day 15, the treatment groups were decoded, and 
the ED80 dose from the mechanical hyperalgesia data was used to determine the chronic treatment 
doses for both KRM-II-81 and MP-III-80 in CINP. During the chronic experiment, KRM-II-81 
and MP-III-80 or vehicle controls received a 1:2:7 ratio of drug or vehicle in tween 80: dimethyl 
sulfoxide: saline. The Paclitaxel pre-treated animals then received chronic treatments of either 
KRM-II-81, MP-III-80 or vehicle (n=4/group), with these treatments blinded to the experimenter. 
On every even day from Day 18-40 mice received an injection of their chronic treatment and then 
30 min later three measurements of mechanical hyperalgesia and two measurements of thermal 
allodynia were recorded for each hind paw. On odd days (Day 19-39) the same processes were 
performed as on even days. However all measurements were taken immediately prior to the 
chronic treatment injections.  
 
3.5.19. Respiratory Depression (Dr. Kevin Freeman, University of Mississippi Medical 
Center) 
Using a method adapted from Bassi et al. (2015), rats (n = 8) were allowed 60 min to acclimate to 
the recording chamber before being tested. Next, the chamber was opened, the animal was 
administered vehicle or drugs KRM-II-8 (1.0, 3.2, and 10 mg/kg, i.p., 30 min prior) or alprazolam 
(0.32, 1.0, and 3.2 mg/kg, i.p., 15 min prior). Subsequently, the chamber was filled with air (21% 
of O2 and 0.04% CO2), then sealed, and pressure fluctuations were measured for 1 min. One 
milliliter of air was then pumped into the chamber for pressure calibration. Pulmonary ventilation 
was measured by one-way ANOVA, with Dunnett's multiple comparisons and calculated using a 
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plethysmography method adapted from Bassi et al. (2015). Respiratory frequency (f) and tidal 
volume (VT) were determined for each baseline and drug condition by selecting data within the 1-
min sampling period that contained rhythmic breathing using PowerLab data acquisition software. 
Minute Volume was determined by formulas adapted from Bassi et al. (2015). All statistical tests 
were performed with Prism 6 (GraphPad Software, San Diego, CA). 
 
3.5.20. Pain-Depressed Intracranial Self-Stimulation (ICSS model, Dr. Megan Moerke and 
Dr. Steve Nuggus, Virginia Commonwealth University 
Adult male Sprague-Dawley rats from Envigo (Indianapolis, IN), weighed 310-350 g were trained 
under a fixed-ratio 1 (FR 1) schedule of electrical brain stimulation using a reported procedure as 
described previously (Negus et al., 2012). After a baseline was obtained, rats were administrated 
i.p. with either vehicle, or 0.32-10 mg/kg KRM-II-81 (n=8) and 0.1-10 mg/kg ketorolac (n=6) or 
0.32-10 mg/kg diazepam (n=6) in the absence of the dilute lactic acid. the reinforcement rate in 
stimulations per frequency trial was normalized and converted into percent Maximum Control 
Rate (% MCR), as the mean of the maximal rates observed as compared to the baseline, as 









3.6.1. 7-Bromo-5-(pyridin-2-yl)-1H-benzo[e][1,4]diazepin-2(3H)-one (104) 
 
The 2'-pyridyl ketone 70 (120 g, 433.2 mmol) was dissolved in dry DCM (1.4 L) in a 3-neck round 
bottom flask and was stirred with an overhead mechanical stir for 15 min to obtain a homogenous 
solution. Then solid NaHCO3 (72.8 g, 866.4 mmol) was added to the solution with vigorous stirring 
to avoid clogging of the stirrer, and the mixture was cooled to 0 °C using an ice bath. The 
bromoacetyl bromide (144.9 g, 714.8 mmol) was dissolved in dry DCM (200 mL) and was then 
added dropwise at 0 °C with an addition funnel. The reaction mixture was allowed to warm to rt 
and was stirred overnight until the starting material was consumed as monitored on analysis by 
TLC (silica gel, EtOAc/hexanes, 1:1). The reaction mixture was quenched with ice-water (500 
mL) and stirred at rt for 30 min. The organic layer was then separated, and the aq layer was 
extracted with DCM (3 x 250 mL). The organic layers were combined, as well as washed (200 mL 
each) sequentially with a saturated aq solution of NaHCO3, water, 10% HCl, brine and then dried 
(Na2SO4). The combined organic layer was then concentrated to 1/4
th of the original volume under 
reduced pressure. The intermediate 103, which was prepared, was used for the next step without 
further purification. 
Methanol (1.4 L) was cooled to 0 °C using an ice-water cooling bath and saturated with anhydrous 
ammonia gas. The DCM solution of intermediate 103 was added to the solution of saturated 
MeOH/NH3 at 0 °C. The mixture was allowed to warm to rt and slowly heated to reflux with 
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caution (mild exotherm observed) until the starting material was consumed on analysis by TLC 
(silica gel) in 12 h. The reaction mixture was then cooled to rt and the solvent was removed under 
reduced pressure. The solid which remained was filtered and washed with water (3 x 150 mL), 
cold EtOAc (3 x 50 mL) and DCM (3 x 50 mL). The crude solid was dissolved in MeOH (600 
mL) and DCM (100 mL) at 60 °C, and the solution was concentrated to 1/4th of the original volume. 
The amide 104 was crystallized at rt and filtered off, after which it was washed with DCM to 
obtain the majority of the pure amide 104 as white crystals. The filtrate was combined and 
concentrated under reduced pressure to an oily residue, which was further purified by flash 
chromatography on silica gel (EtOAc/hexanes, 1:1 and 1% of TEA) to afford additional amide 104 
(108.6 g, 78% yield over the two steps): mp 228-229 °C; Rf = 0.4 (EtOAc-hexanes, 1:1 and 1% of 
TEA); 1H NMR (300 MHz, DMSO-d6): δ = 10.63 (s, 1H), 8.55 (d, J = 4.1 Hz, 1H), 8.04 (d, J = 
7.7 Hz, 1H), 7.93 (d, J = 7.4 Hz, 1H), 7.69 (d, J = 8.6 Hz, 1H), 7.54-7.44 (m, 1H), 7.42 (s, 1H), 
7.18 (d, J = 8.7 Hz, 1H), 4.23 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ = 170.3, 168.1, 156.3, 
148.9, 139.3, 137.5, 134.4, 134.1, 127.9, 125.4, 123.9, 123.6, 114.5, 57.6; HRMS (ESI/IT-TOF): 
m/z [M + H]+ calcd for C14H11BrN3O: 316.0080; found: 316.0076. 
 





The amide 104 (80 g, 253.2 mmol) was suspended in dry THF (1.5 L), and cooled to -50 °C using 
a dry ice bath, after which potassium t-butoxide (34.1 g, 303.8 mmol) was added in one portion. 
The reaction mixture was stirred until it reached 0 °C and then stirred for 0.5 h at 0 °C. The mixture 
was then cooled to -50 °C, after which diethyl chlorophosphate (61.2 g, 354.5 mmol) was added 
dropwise with an addition funnel. The dry ice bath was removed to allow the temperature to rise 
to 0 °C, after which it was allowed to stir for 2 h with an ice-water bath. The solution was then 
cooled to -78 °C with a dry-ice bath and ethyl isocyanoacetate (40.1 g, 354.5 mmol) was added, 
immediately followed by a second portion of potassium t-butoxide (34.1 g, 303.8 mmol). This 
solution was allowed to stir overnight during which period it was allowed to warm to rt. The 
reaction was completed after 14 h on analysis by TLC (silica gel, EtOAc/hexanes/DCM, 2:2:1, 
and 1% TEA). The reaction mixture was quenched by addition of a cold saturated aq solution of 
NaHCO3 (500 mL) and extracted with EtOAc. The organic layers were combined and washed with 
brine (2 x 200 mL), and dried (Na2SO4). The solvent was removed under reduced pressure to obtain 
a dark brown solid residue. The solid was washed with Et2O/EtOAc (9:1) to remove most of the 
impurities and the solid was further recrystallized from EtOAc and hexane (1:4), and this was 
followed by washing the solid with cold Et2O to afford the majority of the pure ethyl ester 105. 
The remaining filtrate was combined and purified by flash chromatography to obtain additional 
ethyl ester 105 (silica gel, EtOAc/ hexanes/DCM 2/2:1 and 1% TEA) as an off-white solid (84.2 
g, 81% yield): mp 212-213 °C; Rf = 0.3 (EtOAc-hexanes-DCM, 2:2:1 and 1% of TEA); 1H NMR 
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(300 MHz, CDCl3): δ = 8.60 (d, J = 4.4 Hz, 1H), 8.11 (d, J = 7.9 Hz, 1H), 8.00 (s, 1H), 7.86 (td, 
J = 8.0, 1.7 Hz, 1H), 7.80 (dd, J = 8.6, 2.2 Hz, 1H), 7.60 (d, J = 2.1 Hz, 1H), 7.51 (d, J = 8.6 Hz, 
1H), 7.41 (dd, J = 7.1, 5.2 Hz, 1H), 6.13 (d, J = 10.4 Hz, 1H), 4.51 – 4.33 (m, 2H), 4.17 (d, J = 
11.6 Hz, 1H), 1.44 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ = 167.0, 162.9, 156.2, 148.7, 
138.4, 136.9, 135.3, 135.0, 134.5, 134.4, 129.3, 128.5, 124.9, 124.3, 123.9, 120.5, 60.7, 45.0, 14.4; 
HRMS (ESI/IT-TOF): m/z [M + H]+ calcd for C19H16BrN4O2: 411.0451; found: 411.0454. 
 
3.6.3. Ethyl-6-(pyridin-2-yl)-8-((trimethylsilyl)ethynyl)-4H-benzo[f] imidazo[1,5a]-[1,4]dia 
zepine-3-carboxylate (106) 
 
The ethyl ester 105 (63.8 g, 155.1 mmol) was dissolved in TEA (400 mL) and dry CH3CN (600 
mL) and placed in a 3-neck round bottom flask with a reflux condenser attached. The solution was 
then degassed three times under vacuum and argon. The trimethylsilylacetylene (22.9 g, 232.7 
mmol) and bis(triphenyl phosphine)-palladium (II) acetate (6.4 g, 8.53 mmol) were added to the 
solution under argon, and the mixture was degassed  four times (as above). The reaction mixture 
was then heated to reflux under argon and allowed to stir overnight. The reaction process was 
completed in 15 h as monitored on analysis by TLC (silica gel, EtOAc/hexanes, 7:3, and 1% TEA). 
The reaction mixture was then cooled to 0 °C and filtered through celite. This was followed by 
washing with EtOAc and drying (Na2SO4). The filtrate was concentrated under reduced pressure. 
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The black residue, which resulted, was loaded onto a silica plug (4 g of silica gel/1 g of the product) 
and washed with a mixture of EtOAc and hexanes (1:1 with 1% TEA) to remove the baseline 
impurities and the material was recrystallized from EtOAc. The crystals were filtered and washed 
with Et2O to afford pure trimethylsilyl ethyl ester 106. The filtrate was purified by flash 
chromatography to afford additional ester 106 as an off-white solid (61.1 g, 92% yield): mp 203-
204 °C; Rf = 0.5 (EtOAc-hexanes, 1:1 and 1% of TEA); 1H NMR (300 MHz, CDCl3): δ = 8.56 (d, 
J = 4.1 Hz, 1H), 8.02 (d, J = 7.8 Hz, 1H), 7.90 (s, 1H), 7.78 (t, J = 7.7 Hz, 1H), 7.70 (d, J = 8.3 
Hz, 1H), 7.51 (d, J = 9.2 Hz, 2H), 7.34 (t, J = 5.9 Hz, 1H), 6.08 (d, J = 9.2 Hz, 1H), 4.47 – 4.31 
(m, 2H), 4.10 (d, J = 6.9 Hz, 1H), 1.41 (t, J = 7.0 Hz, 3H), 0.21(s, 9H); 13C NMR (75 MHz, 
CDCl3): δ = 167.8, 162.9, 156.6, 148.8, 138.5, 136.8, 135.7, 135.2, 135.1, 134.5, 129.3, 127.0, 
124.7, 124.0, 122.7, 122.2, 102.8, 97.0, 60.7, 45.0, 14.4, -0.2; HRMS (ESI/IT-TOF): m/z [M + 
H]+ calcd for C24H25N4O2Si: 429.1741; found: 429.1747. 
 
3.6.4. Ethyl-8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4] diazepine-3-carboxy 
late (HZ-166, 76) 
 
The trimethylsilyl ethyl ester 106 (50 g, 116.8 mmol) was dissolved in THF (1 L) and cooled to -
78 °C. Tetrabutylammonium fluoride hydrate (1 M solution in THF, 175.1 mmol) was added to 
the solution, and this was followed by water (50 mL). The reaction mixture was stirred at -78 °C 
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until the starting material was consumed in 0.5 h, as indicated by TLC (silica gel). The reaction 
mixture was allowed to warm to 0 °C and quenched by a slow addition of water (500 mL). The 
organic layer was separated and the aq layer was extracted with EtOAc (5 x 300 mL). The 
combined organic layers were washed with brine (2 x 400 mL) and dried (Na2SO4). The solvent 
was removed under reduced pressure and the residue, which resulted, was dissolved in a mixture 
of DCM (100 mL) and MeOH (400 mL) at 50 °C and the solution was concentrated to 1/3rd of its 
original volume. The majority of the ethyl ester 76 was recrystallized at rt with addition of a seed 
crystal, and the solid was further washed with cold MeOH. The filtrate was combined and purified 
by a wash column (silica gel, EtOAc/hexanes/DCM 8:1:2, and 1% TEA) to afford additional ethyl 
ester 76 as a white powder (37.8 g, 96% yield): mp 243-244 °C; Rf = 0.4 (EtOAc-hexanes-DCM, 
8:1:2 and 1% of TEA); 1H NMR (300 MHz, CDCl3): δ = 8.59 (d, J = 4.6 Hz, 1H), 8.08 (d, J = 
7.9 Hz, 1H), 7.96 (s, 1H), 7.83 (td, J = 7.8, 1.6 Hz, 1H), 7.77 (dd, J = 8.4, 1.7 Hz, 1H), 7.61 – 7.54 
(m, 2H), 7.38 (dd, J = 7.0, 5.3 Hz, 1H), 6.12 (d, J = 10.6 Hz, 1H), 4.56 – 4.27 (m, 2H), 4.16 (d, J 
= 10.2 Hz, 1H), 3.17 (s, 1H), 1.44 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3): δ = 167.6, 
162.8, 156.2, 148.6, 138.4, 137.1, 136.2, 135.4, 135.4, 134.6, 129.2, 127.0, 124.9, 124.1, 122.9, 
121.3, 81.6, 79.6, 60.9, 45.0, 14.4; HRMS (ESI/IT-TOF): m/z [M + H]+ calcd for C21H17N4O2: 
357.1346; found: 357.1344. 
 
3.6.5. 3-Ethyl-5-(8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a] [1,4]diazepin-3-yl)-




The ethyl ester 76 (4.4 g, 12.4 mmol) was dissolved in dry THF (200 mL) at rt under argon. In a 
separate flask that contained 3Å molecular sieves, N-hydroxypropionimidamide (4.35 g, 49.4 
mmol) was dissolved in dry THF (50 mL) under argon and then treated with sodium hydride (60% 
dispersion in mineral oil, 360 mg, 14.8 mmol). The mixture was allowed to stir for 1.5 h and was 
then added dropwise to the solution of ethyl ester 76. The reaction was completed in 3 h as 
analyzed by TLC (silica gel). The reaction mixture was quenched with a saturated aq NaHCO3 
solution (10 mL) and extracted with EtOAc (3 x 250 mL). The organic layers were combined, 
washed with brine, and dried (Na2SO4). The solvent was removed under reduced pressure. The 
solid, which resulted, was purified by flash chromatography (silica gel, EtOAc/hexanes 4:1 and 
1% TEA) to afford pure 1,2,4-oxadiazole 102 as a white powder (4.1 g, 88% yield); mp 204-205 
°C; Rf = 0.6 (EtOAc-hexanes, 4:1 and 1% of TEA);
13 1H NMR (500 MHz, CDCl3): δ = 8.58 (d, J 
= 4.3 Hz, 1H), 8.07 (d, J = 8.0 Hz, 1H), 8.05 (s, 1H), 7.83 (dd, J = 11.8, 4.4 Hz, 1H), 7.78 (dd, J 
= 8.4, 1.3 Hz, 1H), 7.61 (d, J = 8.3 Hz, 1H), 7.57 (d, J = 1.0 Hz, 1H), 7.38 (dd, J = 6.7, 5.3 Hz, 
1H), 6.16 (d, J = 11.4 Hz, 1H), 4.29 (d, J = 11.2 Hz, 1H), 3.19 (s, 1H), 2.85 (q, J = 7.6 Hz, 2H), 
1.44 (t, J = 7.6 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ = 171.9, 170.8, 167.9, 156.3, 148.7, 
137.1, 136.3, 136.2, 135.9, 135.5, 135.2, 127.1, 125.0, 124.8, 124.1, 122.9, 121.4, 81.6, 79.7, 44.9, 




3.6.6. 8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4] diazepine-3-carbaldehyde 
(GL-III-13, 107) 
 
The preparation of PDBBA. The potassium tert-butoxide (29.3 g, 261 mmol) was suspended in 
dry THF (261 mL). The DIBALH (261 mL, 1.0 M in hexane, 261 mmol) was added dropwise to 
the solution of potassium tert-butoxide at 0 °C using an ice-water bath. The mixture was allowed 
to stir at rt for 2 h to achieve a colorless homogeneous solution. The concentration of PDBBA 
solution in THF-hexanes was measured by GC analysis by hydrolysis of the solution with a 
mixture of t-butyl alcohol-THF (1:1) at 0 °C.161 
The reduction of ethyl ester 76 to aldehyde 107: The ethyl ester 76 (20 g, 56.1 mmol) was dissolved 
in dry DCM (500 mL) at 0 °C. The ice-water bath was removed, and the PDBBA solution (0.42 
M in THF-hexanes, 200 mL) was added in one portion with vigorous stirring. The reaction was 
monitored by TLC (silica gel) after each 3 minutes and was completed in 20 min, and this was 
followed by hydrolysis of the mixture with 1N aq HCl at 0 °C. Water (200 mL) was added to the 
mixture, and it was stirred for 0.5 h. The aluminum salt was formed and filtered off on a celite pad. 
The filtrate was extracted with DCM (3 x 150 mL). The organic layers were combined and 
concentrated with reduced pressure, and this was followed by washing with brine and dried 
(Na2SO4). The solid residue was dissolved in a mixture of DCM (100 mL) and EtOAc (100 mL) 
at 50 °C. A seed crystal was added to the mixture and the solvent was reduced to 1/4th of its original 
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volume. The aldehyde 107 was recrystallized from the mixture at rt and washed with cold Et2O. 
The filtrate was combined and further purified by flash chromatography (silica gel, EtOAc and 1% 
each of TEA and MeOH) to afford additional aldehyde 107 as a white solid (14 g, 80% yield): mp 
242-243 °C; Rf = 0.6 (EtOAc and 1% of TEA); 1H NMR (300 MHz, CDCl3): δ = 10.04 (s, 1H), 
8.54 (d, J = 4.1 Hz, 1H), 8.06 (d, J = 7.9 Hz, 1H), 7.96 (s, 1H), 7.78 (dd, J = 17.3, 8.8 Hz, 2H), 
7.56 (dd, J = 4.6, 3.3 Hz, 2H), 7.35 (dd, J = 6.6, 5.1 Hz, 1H), 5.99 (s, 1H), 4.18 (s, 1H), 3.18 (s, 
1H); 13C NMR (75 MHz, CDCl3): δ = 186.8, 167.8, 156.3, 148.7, 137.9, 136.9, 136.7, 136.3, 
135.5, 135.3, 135.0, 127.2, 124.9, 124.0, 122.8, 121.4, 81.6, 79.8, 44.4; HRMS (ESI/IT-TOF): 
m/z [M + H]+ calcd for C19H13N4O: 313.1084; found: 313.1087. 
 
3.6.7. 5-(8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4] diazepin-3-yl)oxazole ( 
KRM-II-81, 77).  
 
The toluenesulfonylmethyl isocyanide (TosMIC, 10.6 g, 54.6 mmol), K2CO3 (18.9 g, 136.5 mmol) 
and the aldehyde 107 (14.2 g, 45.5 mmol) were placed in a dry two neck round bottom flask. Dry 
MeOH (600 mL) was added to the mixture under an argon atmosphere at rt. The reaction mixture 
was allowed to heated slowly to reflux for 2 h. After completion of the reaction on analysis by 
TLC (silica gel, EtOAc and 1% each of TEA and MeOH), the reaction mixture was quenched with 
cold water (300 mL) and extracted with EtOAc (3 x 100 mL). The organic layers were combined 
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and this was followed by washing with brine. The solution was then dried (Na2SO4) and 
concentrated under reduced pressure to dryness. The solid residue, which formed, was dissolved 
in EtOAc (200 mL) at 60 °C, and the solvent was reduced to 1/4th of its original volume. A seed 
crystal was then added to the solution. The majority of oxazole 77 was crystallized at rt and filtered. 
This was followed by washing with cold Et2O. The filtrate was combined and further purified by 
flash chromatography (silica gel, EtOAc and 1% each of TEA and MeOH) to afford additional 
oxazole 77 as a white solid (14.2 g, 89% yield): mp 241-242 °C; Rf = 0.3 (EtOAc and 1% each of 
MeOH and TEA);13 1H NMR (500 MHz, CDCl3): δ = 8.55 (d, J = 4.5 Hz, 1H), 8.00 (d, J = 7.9 
Hz, 1H), 7.95 (s, 1H), 7.92 (s, 1H), 7.78 (t, J = 7.4 Hz, 1H), 7.72 (d, J = 8.2, 0.8 Hz, 1H), 7.58-
7.49 (m, 2H), 7.42 (s, 1H), 7.33 (dd, J = 6.9, 5.3 Hz, 1H), 5.72 (d, J = 11.9 Hz, 1H), 4.27 (d, J = 
12.0 Hz, 1H), 3.16 (s, 1H); 13C NMR (126 MHz, CDCl3): δ = 167.8, 156.6, 149.8, 148.8, 146.6, 
136.9, 136.3, 135.7, 135.4, 135.2, 129.8, 127.4, 126.9, 124.8, 123.9, 122.7, 122.5, 120.9, 81.8, 
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Appendix II: PDSP Data 
Table 35. PDSP compound list. 
Compound # Name 
Molecular 
Weight 
Formula Received Date 
30611 SH-053-2'F-R-CH3 387.41 C23H18FN3O2 30-Oct-13 
30612 SH-053-2'F-S-CH3 387.41 C23H18FN3O2 30-Oct-13 
30613 MP-III-004 373.38 C22H16FN3O2 30-Oct-13 
30614 MP-III-021 373.38 C22H16FN3O2 30-Oct-13 
30615 MP-III-019 340.35 C21H13FN4 30-Oct-13 
30616 MP-III-018.A 340.35 C21H13FN4 30-Oct-13 
30617 MP-III-022 372.39 C22H17FN4O 30-Oct-13 
30618 MP-III-023 372.39 C22H17FN4O 30-Oct-13 
30619 SH-I-85 423.24 C20H12BrFN4O 30-Oct-13 
37713 MP-III-068 358.39 (not set) 1-Jul-15 
37714 MP-III-080 380.4 (not set) 1-Jul-15 








359.35 (not set) 1-Jul-15 
37719 MP-III-018.B 358.37 (not set) 1-Jul-15 
37720 MP-III-019.B 358.37 (not set) 1-Jul-15 
37721 MP-IV-004 397.4 (not set) 1-Jul-15 
37722 GL-I-65 397.4 (not set) 23-Oct-17 
37723 MP-IV-005 411.43 (not set) 1-Jul-15 
37724 GL-I-66 411.43 (not set) 1-Jul-15 
37725 MP-IV-010 425.46 (not set) 1-Jul-15 
37726 GL-I-81 425.46 (not set) 23-Oct-17 
514 
 
37728 SH-I-085 423.23 (not set) 1-Jul-15 
37729 KRM-II-18B 368.36 (not set) 1-Jul-15 
37730 KRM-II-73 405.24 (not set) 1-Jul-15 
37731 KRM-II-82 350.37 (not set) 1-Jul-15 
37732 KRM-II-97 406.23 (not set) 1-Jul-15 
37733 KRM-II-81 351.36 (not set) 1-Jul-15 
37734 KRM-II-68 336.34 (not set) 1-Jul-15 
37735 KRM-II-08 292.3 (not set) 1-Jul-15 
37736 KRM-II-3B 307 (not set) 1-Jul-15 
42621 KRM-III-59 437.26 C21H14BrFN4O 23-Oct-17 
42622 KRM-III-65 382.38 C23H15FN4O 23-Oct-17 
42623 KRM-III-66 419.27 C21H15BrN4O 23-Oct-17 
42624 KRM-III-67 364.39 C23H16N4O 23-Oct-17 
42625 KRM-III-79 365.38 C22H15N5O 23-Oct-17 
42626 KRM-III-70 275.3 C17H13N3O 23-Oct-17 
42627 KRM-III-77 308.76 C18H13ClN2O 23-Oct-17 
42628 KRM-III-78 420.26 C20H14BrN5O 23-Oct-17 
42633 Ro5-4846 319.19 C16H12Cl2N2O 23-Oct-17 
42634 Ro7-9277 335.18 C16H12Cl2N2O2 23-Oct-17 
42635 GL-I-74 305.16 C15H10Cl2N2O 23-Oct-17 
42636 GL-II-39 377.22 C18H14Cl2N2O3 23-Oct-17 
42637 GL-II-05 330.18 C15H12BrN3O 23-Oct-17 
42638 GL-II-06 425.28 C20H17BrN4O2 23-Oct-17 
42639 GL-II-18 442.59 C25H26N4O2Si 23-Oct-17 
42640 GL-II-19 370.4 C22H18N4O2 23-Oct-17 
42641 GL-II-30 342.35 C20H14N4O2 23-Oct-17 
42642 GL-II-31 355.39 C21H17N5O 23-Oct-17 
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42643 GL-II-32 356.38 C21H16N4O2 23-Oct-17 
42644 GL-II-33 380.4 C22H16N6O 23-Oct-17 
42645 GL-II-51 397.23 C18H13BrN4O2 23-Oct-17 
42647 GL-II-53 410.27 C19H16BrN5O 23-Oct-17 
42648 GL-II-54 435.28 C20H15BrN6O 23-Oct-17 
42651 GL-II-57 394.43 C23H18N6O 23-Oct-17 
42653 GL-II-59 344.21 C16H14BrN3O 23-Oct-17 
42654 GL-II-60 361.51 C21H23N3OSi 23-Oct-17 
42655 GL-II-61 289.33 C18H15N3O 23-Oct-17 
42656 GL-I-30 415.46 C25H22FN3O2 23-Oct-17 
42657 GL-I-31 401.43 C24H20FN3O2 23-Oct-17 
42658 GL-I-32 401.43 C24H20FN3O2 23-Oct-17 
42659 GL-I-33 429.49 C26H24FN3O2 23-Oct-17 
42660 GL-I-38 399.42 C24H18FN3O2 23-Oct-17 
42661 GL-I-36 441.38 C23H15F4N3O2 23-Oct-17 
42662 GL-I-43 386.42 C23H19FN4O 23-Oct-17 
42663 GL-I-41 414.47 C25H23FN4O 23-Oct-17 
42664 GL-I-55 398.43 C24H19FN4O 23-Oct-17 
42665 GL-I-54 386.42 C23H19FN4O 23-Oct-17 
42666 GL-I-77 403.47 C23H18FN3OS 23-Oct-17 
42667 GL-I-78 403.45 C24H22FN3O2 23-Oct-17 
50093 SH-I-044 347.18 C16H12BrFN2O 2-Nov-17 
50094 SH-I-047 442.28 C21H17BrFN3O2 2-Nov-17 
50095 SH-I-060 459.59 C26H26FN3O2Si 2-Nov-17 
50096 MP-III-058 428.25 C20H15BrFN3O2 2-Nov-17 
50097 SH-I-048A 347.18 C16H12BrFN2O 2-Nov-17 
50098 SH-I-048B 442.28 C21H17BrFN3O2 2-Nov-17 
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50099 SH-I-055 459.59 C26H26FN3O2Si 2-Nov-17 
50101 YT-III-31 340.38 C21H16N4O 2-Nov-17 
50102 YT-III-271 730.72 C43H28F2N6O4 2-Nov-17 
50103 SR-II-54 328.32 C19H12N4O2 2-Nov-17 
50104 GL-II-73 386.42 C23H19FN4O 2-Nov-17 
50105 GL-II-74 386.42 C23H19FN4O 2-Nov-17 
50106 GL-II-75 398.43 C24H19FN4O 2-Nov-17 
50107 GL-II-76 412.46 C25H21FN4O 2-Nov-17 
50108 GL-I-50 382.21 C18H12BrN3O2 2-Nov-17 
50109 GL-II-93 414.23 C19H13BrFN3O2 2-Nov-17 
50110 GL-I-65 397.4 C23H16FN5O 2-Nov-17 
50111 GL-I-81 425.46 C25H20FN5O 2-Nov-17 
50112 GL-III-19 427.27 C20H16BrFN4O 2-Nov-17 
50114 GL-I-61 364.49 C21H21FN2OSi 2-Nov-17 
50117 GL-I-63 364.49 C21H21FN2OSi 2-Nov-17 
50120 GL-III-26 347.48 C20H21N3OSi 2-Nov-17 
50121 GL-III-27 275.3 C17H13N3O 2-Nov-17 
50122 GL-III-59 260.29 C17H12N2O 2-Nov-17 
50123 GL-III-57 333.459 C19H19N3OSi 2-Nov-17 
50124 GL-III-58 261.27 C16H11N3O 2-Nov-17 
50125 GL-III-35 398.23 C19H13BrFN3O 2-Nov-17 
50126 GL-III-36 437.26 C21H14BrFN4O 2-Nov-17 
50127 KRM-III-18A 437.26 C21H14BrFN4O 2-Nov-17 
50128 GL-III-38 343.35 C21H14FN3O 2-Nov-17 
50129 GL-III-72 454.57 C26H23FN4OSi 2-Nov-17 
50130 GL-III-73 382.39 C23H15FN4O 2-Nov-17 
50132 GL-III-42 403.45 C24H22FN3O2 2-Nov-17 
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50133 GL-III-43 375.4 C22H18FN3O2 2-Nov-17 
50134 GL-III-52 302.73 C16H12ClFN2O 2-Nov-17 
50135 GL-III-53 397.83 C21H17ClFN3O2 2-Nov-17 
50136 GL-III-54 369.78 C19H13ClFN3O2 2-Nov-17 
50137 GL-III-60 452.28 C21H15BrFN5O 2-Nov-17 
50138 GL-III-63 413.45 C24H20FN5O 2-Nov-17 
50139 GL-III-64 396.44 C23H20N6O 2-Nov-17 
50140 GL-III-66 400.45 C24H21FN4O 2-Nov-17 
50141 GL-III-67 441.3 C21H18BrFN4O 2-Nov-17 
50142 GL-III-68 402.46 C24H23FN4O 2-Nov-17 
50143 GL-III-69 441.3 C21H18BrFN4O 2-Nov-17 
50144 GL-III-70 402.46 C24H23FN4O 2-Nov-17 
50145 GL-III-75 398.23 C19H13BrFN3O 2-Nov-17 
50146 GL-III-76 437.26 C21H14BrFN4O 2-Nov-17 
50147 GL-III-76A 437.26 C21H14BrFN4O 2-Nov-17 
50148 GL-III-77 454.57 C26H23FN4OSi 2-Nov-17 
50149 GL-III-78 382.39 C23H15FN4O 2-Nov-17 
 




Name 5-HT1A 5-HT1B 5-HT1D 5-ht1e 5-HT2A 5-HT2B 
30611 SH-053-2'F-R-CH3 18 9.3 16.4 -8.8 -10.7 17.3 
30612 SH-053-2'F-S-CH3 8.5 4.8 12.8 -4.6 19.4 20.4 
30613 MP-III-004 37.5 0.6 32.5 -3.3 9.4 44.2 
30614 MP-III-021 18.8 3.3 34.4 -12.5 -0.9 36.6 
30615 MP-III-019 -1.4 2.1 37 -9.5 -9.6 50 
30616 MP-III-018.A 8.3 2.4 23.1 -5.8 38.5 47.3 
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30617 MP-III-022 1.7 0.9 9.6 -2 8.8 10.4 
30618 MP-III-023 6.9 2.3 20.1 -0.3 12.4 44.5 
30619 SH-I-85 22.9 9.4 14 -12 7 54.7 
37713 MP-III-068 2.4 5.6 -0.7 3.1 -20 -16.8 
37714 MP-III-080 18.8 11 -3.5 2.2 -11.7 1.3 








7.1 14.2 -2.9 -1 4.8 -8.9 
37719 MP-III-018.B 12 3.1 -2.5 1.6 -0.2 -8.4 
37720 MP-III-019.B 1.5 14.2 -9.2 2.7 17.3 0.8 
37721 MP-IV-004 8.7 8.2 -7 0.7 32.8 -8.2 
37722 GL-I-65 9.3 -2.8 -15.1 -10.4 -10.5 -7 
37723 MP-IV-005 19.6 17.3 2.2 -1.1 18.9 1.4 
37724 GL-I-66 24 16.5 -0.6 -2.3 4.6 12.6 
37725 MP-IV-010 19.4 28.7 6 -6.7 -0.6 0.2 
37726 GL-I-81 16.3 41.5 37.6 -14.9 29 50.2 
37728 SH-I-085 43.4 28.8 13.9 -9.6 -3.1 5.9 
37729 KRM-II-18B 51.2 27.6 16 -2.9 3.5 -8.5 
37730 KRM-II-73 43.4 29.3 15.7 -6.8 -3.7 -8.9 
37731 KRM-II-82 56.6 38.8 20.1 -2.7 7.7 -11.3 
37732 KRM-II-97 22.9 5.9 -0.4 -3.3 16.8 -5.5 
37733 KRM-II-81 29.5 -1.6 -0.3 4.9 16 -1.5 
37734 KRM-II-68 15.5 -5.2 3.6 10 20.1 -3.1 
37735 KRM-II-08 9.6 3.6 9.2 1.1 -2.3 8 
37736 KRM-II-3B 17.8 1.2 6.9 -2.7 11 88.9 
42621 KRM-III-59 29.6 -12.5 -5 -14 4 5.6 
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42622 KRM-III-65 39.1 13.4 -9.9 9.2 21.2 0.6 
42623 KRM-III-66 22.2 19.2 -3 -9.2 10.5 10.9 
42624 KRM-III-67 30.6 32.8 9.7 12.4 27.6 6.8 
42625 KRM-III-79 7.4 32.2 1.2 7.8 6.6 8.6 
42626 KRM-III-70 19.3 19.2 15.9 7.1 16.8 10.3 
42627 KRM-III-77 14.4 6.5 8 -4.9 12.7 9.5 
42628 KRM-III-78 20.7 20.9 6.1 -2.6 15.1 15.2 
42633 Ro5-4846 10.4 3.7 -13.5 -9.8 -4.5 -2.1 
42634 Ro7-9277 -4.9 -11.5 -13.1 -1.1 -5.4 2.1 
42635 GL-I-74 16.2 24.7 -5.2 -5.1 6.3 15.3 
42636 GL-II-39 -0.5 20.4 -6 0.3 5.1 17.8 
42637 GL-II-05 12.8 24.3 -5.1 4.1 4.1 13.3 
42638 GL-II-06 28.3 23.5 -2.3 3.9 4.8 10.6 
42639 GL-II-18 9.4 27.9 9.8 -9.2 16.3 28.7 
42640 GL-II-19 -1.5 29.7 3.4 1.8 6.6 13.5 
42641 GL-II-30 -8.1 21 3.9 14.1 9.5 10.3 
42642 GL-II-31 -3.4 -5 6.6 3.9 -3.9 17.2 
42643 GL-II-32 8.1 6.4 2.8 -4.2 -14.5 2.4 
42644 GL-II-33 5.4 24.8 -6.3 -2.4 4.3 11.2 
42645 GL-II-51 -1.6 22.5 -1.7 -7 -0.2 9.2 
42647 GL-II-53 -6.9 18.8 -9.9 -13.5 -1.2 11.2 
42648 GL-II-54 19.6 -4 -14.4 -4.4 13.3 10 
42651 GL-II-57 -0.4 10.4 -5.2 -10 -4.7 16.7 
42653 GL-II-59 2.4 11.9 -2.3 -5 -6.4 14.1 
42654 GL-II-60 0.3 2.4 -0.9 -7.5 4.5 18 
42655 GL-II-61 2.9 -19.8 -4.3 -2.1 2.3 18.7 
42656 GL-I-30 12.9 1.1 0.3 -14.3 -6.4 4.2 
520 
 
42657 GL-I-31 5.9 -2.8 -0.6 -3.5 0 -4.1 
42658 GL-I-32 1.5 21 5.7 9.2 -1.3 2.9 
42659 GL-I-33 2.6 30.3 20 5.2 19.4 13 
42660 GL-I-38 3.3 17.6 8.8 8.2 -0.2 7.3 
42661 GL-I-36 6.7 18.4 14.6 13.5 4.2 20.9 
42662 GL-I-43 2.7 17.1 19.9 9.3 -2.4 6.9 
42663 GL-I-41 5.1 14.4 12.4 2.3 8.8 9.9 
42664 GL-I-55 -1.2 26.1 3.7 2.3 7.6 9.6 
42665 GL-I-54 -7.3 0.6 6.4 12.6 9.9 19.5 
42666 GL-I-77 1 -10.6 19.2 -15.6 1 2.8 
42667 GL-I-78 6.8 3.4 -12.2 -17.2 25.1 7.8 
50093 SH-I-044 -2.5 16.5 16.8 -12.1 2.2 29.3 
50094 SH-I-047 2.2 16.4 4.4 6.6 22.6 31.2 
50095 SH-I-060 13.4 32.5 44.9 7.8 60.8 30.6 
50096 MP-III-058 16.5 27.9 12.8 -13.1 -17.3 -8.7 
50097 SH-I-048A 10.1 31.9 16.2 -13.8 -8.5 8.9 
50098 SH-I-048B 3.5 31.8 21.3 -10.1 -7.9 11.6 
50099 SH-I-055 23.6 8.5 66.6 14.3 57.2 44.6 
50101 YT-III-31 32.8 23.5 43 1.5 -1.2 8.6 
50102 YT-III-271 15.2 12.6 53.5 -0.6 11.3 11.1 
50103 SR-II-54 6.9 15 54.2 16.3 1.4 17.7 
50104 GL-II-73 7.5 16.1 34.1 26.9 10.1 31.5 
50105 GL-II-74 15 18.3 0.9 5.8 11.2 35.3 
50106 GL-II-75 11.3 25.3 10.4 6.4 -11.5 6.3 
50107 GL-II-76 6.5 23.7 6.7 -2 -13 14.2 
50108 GL-I-50 10 24 21.1 2.6 -3.2 16.5 
50109 GL-II-93 10.1 28.4 32.7 3.2 -4.7 6.2 
521 
 
50110 GL-I-65 16 -4.8 48.1 12.9 3.2 13.7 
50111 GL-I-81 -3.8 -11.9 53.2 9.2 22.2 48.8 
50112 GL-III-19 -8.7 -9.9 43 11.6 1.9 15.6 
50114 GL-I-61 15.9 2.4 40 -6.5 45.6 30.9 
50117 GL-I-63 -1.3 4.3 14.9 -5.5 59.5 39.2 
50120 GL-III-26 -10.3 2.2 -17.4 -13.5 20.9 31.2 
50121 GL-III-27 -10.4 13.1 -8.7 0.6 -5.9 5.5 
50122 GL-III-59 -3.9 31 -8.3 -18.7 0.8 9.7 
50123 GL-III-57 -6.4 14.6 1 2.8 5.6 14.1 
50124 GL-III-58 -7.9 11.8 -4.1 4.5 -3.4 0.8 
50125 GL-III-35 -5.5 -14.8 -10.3 -17.1 -0.3 0.1 
50126 GL-III-36 16.5 -1.7 -3.7 -9.5 -3.7 5.5 
50127 KRM-III-18A 39.3 6.5 9 -31.5 14.7 15.2 
50128 GL-III-38 11.9 13.2 1.3 -13.6 -1.5 15.3 
50129 GL-III-72 37.4 22.7 27.4 20.7 62.9 28.9 
50130 GL-III-73 17.3 23.1 -9 -13.1 -2.4 0.5 
50132 GL-III-42 11.7 21.2 -13 -8.8 -1.6 22 
50133 GL-III-43 -2.3 4.4 -2.7 -10.4 -19.3 0.8 
50134 GL-III-52 -2.5 24.5 -4.4 -6 -9.2 4.9 
50135 GL-III-53 20 -14 -3.1 6.1 -24.1 8.5 
50136 GL-III-54 1.2 22 3.4 -0.4 7.7 15.2 
50137 GL-III-60 -0.4 5.9 1.2 8.2 5.7 8 
50138 GL-III-63 15 -2.2 -0.3 4.3 4.3 12.3 
50139 GL-III-64 -7.6 3.2 6.2 10.9 -10.2 7.1 
50140 GL-III-66 -2.1 15.2 20.4 19.8 -0.8 2.2 
50141 GL-III-67 -3.6 14.1 -5.2 8.8 -3.6 -2.8 
50142 GL-III-68 -8.5 14.4 7.9 8.5 18.3 48.4 
522 
 
50143 GL-III-69 -16 5.7 8.1 0.9 -0.4 6.3 
50144 GL-III-70 -16.3 10.8 0.2 3.7 -5.3 23.8 
50145 GL-III-75 -7.2 7.7 0.7 -15.1 3.4 -2.1 
50146 GL-III-76 9.7 7.3 8.1 -11.8 0.6 1.4 
50147 GL-III-76A 30.5 5.8 8 -2.9 8.4 6.3 
50148 GL-III-77 38.2 -53.5 66.9 19.5 67.5 51.3 
50149 GL-III-78 28.3 2.1 0.3 -7.7 8.2 8.8 
 




Name 5-HT2C 5-HT3 5-ht5a 5-HT6 5-HT7 Alpha1A 
30611 SH-053-2'F-R-CH3 17.4 -3.8 11.5(AVE)  16.8 8.2 4.8 
30612 SH-053-2'F-S-CH3 23.4 -10.7 4.9(AVE)  8.6 7.9 3.9 
30613 MP-III-004 24.5 36.6 -3.9(AVE)  11.1 24.4 7.7 
30614 MP-III-021 14.6 1.1 1.4(AVE)  4.1 47.8 1.7 
30615 MP-III-019 19.6 -6.5 7.7(AVE)  18.5 32.9 1.3 
30616 MP-III-018.A 17.2 -2.9 11.6(AVE)  4.8 38.2 2 
30617 MP-III-022 15.8 -1.7 3.5(AVE)  14.1 -1.8 -5.3 
30618 MP-III-023 35 6.1 9.5(AVE)  20.3 3.2 -11.4 
30619 SH-I-85 14.8 -5.3 12.2(AVE)  18.8 18.6 -11 
37713 MP-III-068 -4.7 -15.3 -9.2 -15.2 2.6 15.3 
37714 MP-III-080 92.6 -11.4 11.9 -17.6 18.9 11 








-0.6 -1.2 -6.8 -5 -7.1 2.2 
523 
 
37719 MP-III-018.B 10.2 6.3 3.7 11.2 -1.9 9.3 
37720 MP-III-019.B 14 0.9 9.4 2.2 4.5 16.7 
37721 MP-IV-004 10.4 0.8 12.2 21.1 3.1 12.9 
37722 GL-I-65 -4.8 -1.5 -19.3 1.9 5.5 0.4 
37723 MP-IV-005 11.2 -0.3 11.8 21.6 7 13.2 
37724 GL-I-66 7 -1.8 19.3 15.1 7 23.8 
37725 MP-IV-010 -1.9 12.8 11.3 21.2 -5.4 2.1 
37726 GL-I-81 -2.2 1.2 -5.4 -0.6 17 8.6 
37728 SH-I-085 24.1 3.9 14.6 -0.3 10.2 4.2 
37729 KRM-II-18B 21.8 4.9 18.4 8.2 -4.5 4.3 
37730 KRM-II-73 24.2 17.3 18.9 -1.7 8.1 -0.2 
37731 KRM-II-82 16.4 11.5 14 -5.4 1.8 2.2 
37732 KRM-II-97 21.9 13.3 8.1 -1.5 5.4 5.2 
37733 KRM-II-81 17.3 6.7 9.4 -1.3 4.3 -9.6 
37734 KRM-II-68 10.7 12.5 3.9 7.3 1.7 7.4 
37735 KRM-II-08 15.3 18 17.6 11.6 10.9 10.2 
37736 KRM-II-3B 65.9 -6.7 26.3 20.8 13 2.5 
42621 KRM-III-59 6.9 10.8 -2.6 -0.8 -5.1 -6.1 
42622 KRM-III-65 6.2 9.1 7.1 8 0.2 6.4 
42623 KRM-III-66 5.7 14 5.9 3.4 7 5.3 
42624 KRM-III-67 0.7 10.4 12.4 4.1 -6.9 7.2 
42625 KRM-III-79 0.8 5.7 3.5 5.9 -3.7 3.4 
42626 KRM-III-70 0.5 -1.7 4.1 14.5 7.5 11 
42627 KRM-III-77 -5.1 1.9 13.6 8.9 7.9 -2.4 
42628 KRM-III-78 -5.9 11.9 2.8 -2.8 -15.4 0.7 
42633 Ro5-4846 -2.3 -0.7 -6.8 6.6 -12.2 1.9 
42634 Ro7-9277 -0.5 -0.5 -3.1 -2.8 -2.2 2 
524 
 
42635 GL-I-74 5.8 -0.8 -2.8 0.7 3.9 7.8 
42636 GL-II-39 15.8 5.8 -1 8.2 6.9 -3 
42637 GL-II-05 -3.1 6.4 -3.1 4.6 2.2 -5.4 
42638 GL-II-06 -0.8 6.8 6.5 0.3 -0.4 5.9 
42639 GL-II-18 5.1 19.2 18.2 -6.6 7.4 1.9 
42640 GL-II-19 -6.2 13.6 16.5 -8.8 2.2 3.9 
42641 GL-II-30 -4.4 16.7 6.5 -6.3 -1.3 -5.4 
42642 GL-II-31 -12.2 23 -0.8 -14 -10.5 4.7 
42643 GL-II-32 6.1 -8.8 -18.5 -3.1 -19 9.5 
42644 GL-II-33 -10 -5.6 6.3 -5.3 -6.9 -3.9 
42645 GL-II-51 2.8 -12 -0.4 -0.9 6.4 -10.8 
42647 GL-II-53 -2.8 -8.6 4.1 6.7 -1.8 -4 
42648 GL-II-54 -1.8 -3.4 11 -0.1 0.6 -7.5 
42651 GL-II-57 -3.6 3.3 14.5 11.1 3.4 -8.1 
42653 GL-II-59 -2.2 -3 8.3 -3.3 6.1 -7.7 
42654 GL-II-60 11.7 2.1 16.1 -5.2 6 -3.6 
42655 GL-II-61 -8.4 20.8 10.3 -2.2 -4.9 -7.2 
42656 GL-I-30 -10.4 11.1 -8.5 -7.4 -13.7 7.5 
42657 GL-I-31 -4.3 6.5 -6.3 -3.9 1.8 4 
42658 GL-I-32 -8.2 -4.1 -2.4 2.2 -14 -3.2 
42659 GL-I-33 -2.6 17 14.3 -2.4 14.5 -5.5 
42660 GL-I-38 2.4 7.4 0.9 7.5 9.5 -0.9 
42661 GL-I-36 14 2.3 7.5 2.3 16 1.2 
42662 GL-I-43 2.4 10.5 8 8.8 12.7 -8.8 
42663 GL-I-41 4.6 2.5 9.2 9.9 4 -6.5 
42664 GL-I-55 6.9 19.4 17.1 0.9 11.3 2.4 
42665 GL-I-54 7.6 60.1 15.7 -6.4 1 -12.3 
525 
 
42666 GL-I-77 2.4 -2.6 -16 0.9 3.8 -5.8 
42667 GL-I-78 -17.8 20.4 -16.9 9.2 -8.3 13.5 
50093 SH-I-044 0.7 28.5 -5.6 14.8 24.4 -16.7 
50094 SH-I-047 5.6 48.7 -10.7 7.4 16.6 2.3 
50095 SH-I-060 10.4 16.4 31.6 10.5 -11.3 3.7 
50096 MP-III-058 -5.2 14.7 -16.6 -11.8 -5.8 -2.6 
50097 SH-I-048A -2.3 -0.1 3.9 -15.9 -8.5 -6.9 
50098 SH-I-048B 3.9 -11.2 -12.2 -6.9 -2.8 2.7 
50099 SH-I-055 -6.3 8.5 19.8 -5.5 2.6 8.3 
50101 YT-III-31 -5.5 9.3 -19.6 -7.7 3.5 -10.7 
50102 YT-III-271 -6.3 29.8 -3.6 0.4 -0.9 -3.6 
50103 SR-II-54 -10.8 18.4 -11.8 -7.6 5 -18.4 
50104 GL-II-73 -10.5 44.1 -8.4 0.7 -1.4 -13.7 
50105 GL-II-74 -16.8 56.1 -8.1 -3.5 1.3 4.1 
50106 GL-II-75 -3.9 1 -14.9 2.4 -2.7 15.8 
50107 GL-II-76 6.4 -16.9 -17.9 0.3 -2.5 -5.4 
50108 GL-I-50 11.3 32.6 -15.1 -2.8 -5.6 1.1 
50109 GL-II-93 8.1 0.3 7.9 2.4 6.5 -4.9 
50110 GL-I-65 1 29.6 -0.9 6.4 2.3 -1.2 
50111 GL-I-81 8.4 10.5 25.4 2.8 8.4 0.5 
50112 GL-III-19 7 5 1.5 7.3 18.7 12.1 
50114 GL-I-61 15.9 37.3 12.3 0 -7.5 -1.3 
50117 GL-I-63 16.4 44.6 25.2 0.2 4.2 0.1 
50120 GL-III-26 -1.6 51.6 -8.9 -8.2 11.6 88.3 
50121 GL-III-27 4.5 -0.3 -11.9 -16.9 -69.8 30.1 
50122 GL-III-59 0.6 -3.9 3.9 -15.6 13.4 77.8 
50123 GL-III-57 0.1 -1.3 -6.3 8.4 -34.4 87.2 
526 
 
50124 GL-III-58 4.4 13.2 -8.3 -5.8 14.3 53.3 
50125 GL-III-35 5.4 1.2 -0.4 -10.3 23.4 74.1 
50126 GL-III-36 -1.8 23.6 9.9 47.5 5 62.3 
50127 KRM-III-18A -0.8 1.4 9.4 -2.2 7.2 61.9 
50128 GL-III-38 1.4 -8.9 4.9 8.7 8.9 53.3 
50129 GL-III-72 19.7 -13.4 13.5 21.1 -3.4 55.9 
50130 GL-III-73 -1.5 6.9 7.4 38.1 8.4 1.6 
50132 GL-III-42 -3 15.7 13.2 30.7 -18.6 46.8 
50133 GL-III-43 2.3 -6.9 37.2 -0.1 4.2 -2.4 
50134 GL-III-52 -8.1 -1.1 1.5 -1.3 5.9 4.1 
50135 GL-III-53 13.3 -1.6 -2.3 11.8 -3.8 -2.9 
50136 GL-III-54 -2.9 -8.2 3.3 6.9 -9 -11.4 
50137 GL-III-60 -0.9 11.1 0.1 -1.9 -2.7 -12.7 
50138 GL-III-63 -9.4 11 14.5 28.8 14.6 24.9 
50139 GL-III-64 -3.4 7.6 -3.1 2.8 -0.4 -5.6 
50140 GL-III-66 -10.6 12 -3.8 6.2 2.8 -7.5 
50141 GL-III-67 -18.6 -7.5 2 17.7 9.6 -4.4 
50142 GL-III-68 23.2 -1.3 25.6 66 12.4 49.3 
50143 GL-III-69 -13.6 -8.9 -1.5 10.1 -0.7 2.5 
50144 GL-III-70 -12 9.2 7.5 9.4 13.4 28.8 
50145 GL-III-75 -19.5 -15.6 0.3 2.5 15.1 3.9 
50146 GL-III-76 5.8 -11 3.3 18.4 -6.6 7.3 
50147 GL-III-76A 15.5 -14.7 2.8 7 10.9 3.1 
50148 GL-III-77 37.3 11.5 34.4 22.3 -1.2 60 
50149 GL-III-78 -2.7 6.7 7.8 22.9 18.3 13.5 
 














-7.1 10.7(AVE)  16.6 18.9(AVE)  18.9(AVE)  19.4(AVE)  
30613 MP-III-004 2.4 7.5(AVE)  14.4 13.6(AVE)  19.3(AVE)  14.5(AVE)  
30614 MP-III-021 -7 5.4(AVE)  8 10.5(AVE)  1.7(AVE)  21.4(AVE)  
30615 MP-III-019 -4.7 8.5(AVE)  -4.8 3.3(AVE)  -4.3(AVE)  21.4(AVE)  
30616 MP-III-018.A -3.6 12.8(AVE)  11.6 17.1(AVE)  2.9(AVE)  42.9(AVE)  
30617 MP-III-022 39.6 6.7(AVE)  1.9 0.7(AVE)  1.8(AVE)  32.2(AVE)  
30618 MP-III-023 23.4 -1.2(AVE)  -1.0 4.3(AVE)  27.5(AVE)  26.5(AVE)  
30619 SH-I-85 22 26.8(AVE)  8.5 28.3(AVE)  12.8(AVE)  19.2(AVE)  
37713 MP-III-068 15.8 2.5 5 23.8 -5.2 -19.4 
37714 MP-III-080 3.5 -10.5 23 35 1.2 -19.9 








-15.2 -9.1 21.2 16.2 0.9 -5.9 
37719 MP-III-018.B 12.3 -8.9 5 21.1 -5.3 -14.1 
37720 MP-III-019.B -3.9 -4.6 29.4 18.3 19.3 -2.1 
37721 MP-IV-004 1.5 4.5 22 9.7 3.8 -3.7 
37722 GL-I-65 4.7 -10.3 4.3 21 10.2 13 
37723 MP-IV-005 8.3 5.9 30.5 20.5 20.9 5.6 
37724 GL-I-66 23.9 11.4 12.9 30.2 27 8 
37725 MP-IV-010 14.6 9 14.1 28.8 30.9 6.4 
37726 GL-I-81 4.7 8.1 23.1 25 8.9 17.3 
37728 SH-I-085 27 3.6 14.9 37.8 11 -17.1 
528 
 
37729 KRM-II-18B 26.1 12 13.4 23.7 2.6 11.6 
37730 KRM-II-73 18.7 8.6 17 50 20 6.9 
37731 KRM-II-82 27.4 6.8 16.3 36.3 13.1 -6.6 
37732 KRM-II-97 17.8 13.5 15 79.5 17.6 -4.6 
37733 KRM-II-81 22.3 0.1 20.9 55 0.1 -12.2 
37734 KRM-II-68 9.7 -6.1 14.7 12.2 4.2 -9.6 
37735 KRM-II-08 27.9 -11.6 27.7 2.6 -6.7 -13.3 
37736 KRM-II-3B 8.1 -4.7 37.1 26.2 23.7 -6.1 
42621 KRM-III-59 24.5 -7.2 17.6 55.6 4.1 15.8 
42622 KRM-III-65 30.1 -5.9 15.7 40 9.6 -5.9 
42623 KRM-III-66 21.1 -10.3 28.1 65.1 21.7 9.3 
42624 KRM-III-67 21 -7.2 23.2 37.2 21.4 2.8 
42625 KRM-III-79 24.2 -10 25.2 49.8 6 4.7 
42626 KRM-III-70 11.8 -1.1 20.3 14.2 2.9 10.4 
42627 KRM-III-77 6.5 -18.8 20.5 13.3 6.8 4 
42628 KRM-III-78 24.6 -15.8 21.8 77.4 26.9 15.5 
42633 Ro5-4846 -4.3 -11.2 11.2 13.2 15.8 23 
42634 Ro7-9277 -4.1 0.5 5.9 17.8 -18.9 3.5 
42635 GL-I-74 3.3 2.4 11.9 19.1 2 -2.1 
42636 GL-II-39 -0.6 -9.2 12.5 24.8 -4 1.1 
42637 GL-II-05 14.8 -2.1 13.1 7 -3 3 
42638 GL-II-06 4.9 -10.3 18.1 64.7 5.2 5.7 
42639 GL-II-18 6.7 -9.7 57.4 40.1 35.3 -2 
42640 GL-II-19 4.4 -10.3 27.4 38.7 4.6 17.1 
42641 GL-II-30 8.8 -12.2 18.4 2.6 -5.5 19.3 
42642 GL-II-31 12.5 -5.6 16.2 16.6 10.3 19.2 
42643 GL-II-32 -18.4 -17.1 -8.7 35.7 12.6 17.5 
529 
 
42644 GL-II-33 -1.2 -7.9 -8.4 18.1 -4.3 18.8 
42645 GL-II-51 -8.1 -5 0.7 11 -5.3 14.5 
42647 GL-II-53 -9.7 -12.7 -4.1 26.9 -9.3 2.3 
42648 GL-II-54 -19.2 -12.2 6 45.7 5.5 16.3 
42651 GL-II-57 -9.9 -10.2 5.5 9.8 1.8 13.9 
42653 GL-II-59 -7.8 -1.8 4.6 12.4 18.4 25.9 
42654 GL-II-60 -1.3 -13.4 2 11.6 19.5 23.6 
42655 GL-II-61 -2.8 -11.7 5.9 20.6 7.4 6.8 
42656 GL-I-30 12.7 6.9 15.7 25.1 18.4 15.3 
42657 GL-I-31 -5.1 -6 -4 30.7 22.7 -4.8 
42658 GL-I-32 21.7 5.3 7.8 47.6 3.6 42.9 
42659 GL-I-33 11.4 -1.8 18.4 42.2 19.9 -2.6 
42660 GL-I-38 15 -1.5 0.9 36.4 9.5 -11 
42661 GL-I-36 14.9 5.4 5.5 9.6 23.6 -9.9 
42662 GL-I-43 20.8 4.4 9.5 5.4 5.5 -3.6 
42663 GL-I-41 1.3 9.9 16.6 18 5.6 2.3 
42664 GL-I-55 -4.2 -14.1 5.8 15.9 4.8 8 
42665 GL-I-54 3.3 -4.8 9.4 -2.1 6.2 -1.3 
42666 GL-I-77 20.9 -7.4 25.3 21.6 42.3 12 
42667 GL-I-78 16.8 4.6 22.9 52.3 23.2 18.1 
50093 SH-I-044 -5.8 -11 19 1.1 1 -12 
50094 SH-I-047 -19.5 -4 -16.7 4.6 6.9 -0.9 
50095 SH-I-060 -0.5 9.5 44.5 61.5 64.9 20.8 
50096 MP-III-058 12 -8.1 0 36.8 2.7 -9.2 
50097 SH-I-048A -0.3 -5 9.8 -2.1 -0.9 -15.1 
50098 SH-I-048B 14.5 -15.3 7.3 16 -14.6 -10.2 
50099 SH-I-055 12.7 15.7 45 48.6 38.3 13.1 
530 
 
50101 YT-III-31 14.4 -8.6 16.7 -1.6 -7.6 -7.7 
50102 YT-III-271 14.5 10 25.2 -7.9 -0.3 -1.5 
50103 SR-II-54 2.7 -1 1.9 -18.2 -2.2 -14.7 
50104 GL-II-73 -8 0.1 6.2 6.5 -17.6 7.2 
50105 GL-II-74 -15.3 -0.5 -13.9 -4.6 -19 10.1 
50106 GL-II-75 7.9 -4.3 -19.1 -4.6 -6.7 0.1 
50107 GL-II-76 21.8 2.5 -5.8 26.3 -11.7 -7.5 
50108 GL-I-50 20.3 -5.7 -7.6 -0.7 -4 -15.6 
50109 GL-II-93 14.3 -9 -18.2 -14.1 -16.2 -16 
50110 GL-I-65 14 2.8 -3.7 5 -11.6 15.8 
50111 GL-I-81 10.7 -0.6 8 29.9 6.4 -19 
50112 GL-III-19 23.1 -13.4 -2.5 3.6 -10.1 -12.4 
50114 GL-I-61 15.7 -10.1 18.4 44.8 45.4 6.5 
50117 GL-I-63 -11.4 -1.5 42.7 35.7 53.4 22.5 
50120 GL-III-26 -13.4 -16 -1.6 34.6 29.1 3.3 
50121 GL-III-27 -15.2 -15.1 -16.5 -2.8 4.5 -9.6 
50122 GL-III-59 -3.7 11.5 -19.7 -11.2 -10.1 1.9 
50123 GL-III-57 -4.3 -4.3 5.3 13.1 2.7 0.4 
50124 GL-III-58 18.5 -7.1 -14.4 1.9 -5.2 -9.4 
50125 GL-III-35 6.5 0.7 -4.5 25.6 -11.8 -5.6 
50126 GL-III-36 19.6 -11.3 -9.6 37.1 7 -2.1 
50127 KRM-III-18A 15.9 -6 27.1 94 65.6 5.9 
50128 GL-III-38 9.4 -12.9 -5.8 17.2 4 -17.1 
50129 GL-III-72 44 18.4 64.4 63.6 61.4 22.5 
50130 GL-III-73 17.1 -18.3 12.1 9.9 -4.1 4.6 
50132 GL-III-42 12.1 16.9 6 22.9 13.5 6.1 
50133 GL-III-43 -4.3 -11.3 17.5 7.7 -3 8.3 
531 
 
50134 GL-III-52 -15.7 -8.3 31.3 10.9 13 10.8 
50135 GL-III-53 4.3 -6.1 5.8 -1.8 -0.4 -8.5 
50136 GL-III-54 7.2 -5.7 15 -1.1 -15.2 -4.2 
50137 GL-III-60 3.9 -13.8 5.1 1.9 1.2 37.2 
50138 GL-III-63 29.2 22.2 31.6 24.2 4.1 4.9 
50139 GL-III-64 6.3 -16.7 5.9 59.9 -12.8 -7 
50140 GL-III-66 3.9 -15.4 -5.8 -4 32.1 6.7 
50141 GL-III-67 1.3 -13.4 64.8 73.3 -6.9 26.5 
50142 GL-III-68 16 47.1 8.8 35.5 -3.1 33.8 
50143 GL-III-69 9.6 -18.1 -2.9 55.2 -14.1 19.4 
50144 GL-III-70 4.2 15.7 1.4 15.1 -12.8 9.5 
50145 GL-III-75 4 -6.1 34.9 7.2 0.4 17 
50146 GL-III-76 19.6 29.8 14.9 22.3 -7.1 20 
50147 GL-III-76A 9.7 13.5 9.9 82.1 28.5 -20.3 
50148 GL-III-77 36.9 65.1 73.3 74.4 57.4 26.9 
50149 GL-III-78 22.2 15.3 14.7 18.2 4.8 -0.7 
 
Table 39. PDSP primary binding data for Beta2, Beta3, BZP Rat Brain Site, Calcium 
Channel, D1, and D2. 
Compound 
# 













-1.8 0.3(AVE)  91.5(AVE)    11.2 7.9(AVE)  
30613 MP-III-004 16.8 -12.4(AVE)  76.3(AVE)    16 22.7(AVE)  
30614 MP-III-021 22.9 -11.0(AVE)  87.3(AVE)    33.2 20.1(AVE)  
30615 MP-III-019 31.1 1.0(AVE)  49.0(AVE)    15.2 14.3(AVE)  
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30616 MP-III-018.A 19 7.9(AVE)  93.1(AVE)    14.2 3.7(AVE)  
30617 MP-III-022 18 0.2(AVE)  93.5(AVE)    9.7 12.6(AVE)  
30618 MP-III-023 5.6 18.5(AVE)  97.0(AVE)    2.4 14.8(AVE)  
30619 SH-I-85 5.2 15.7(AVE)  98.2(AVE)    26.7 13.6(AVE)  
37713 MP-III-068 29.4 -2.5 87.6 -7.7 -4.6 -10.3 
37714 MP-III-080 8.2 15.4 88.2 -10.6 11.1 -5.8 








19.7 -16.2 92.9 -8.1 -4.3 -8.4 
37719 MP-III-018.B 19.2 6.5 96.6 6.3 4.9 1.3 
37720 MP-III-019.B 3.1 16.6 94.1 10 10 -4.8 
37721 MP-IV-004 7.8 14.8 63.4 -2.3 9.3 -1.1 
37722 GL-I-65 -10.1 -9.9 78.6 1.8 -3.9 -8.5 
37723 MP-IV-005 22.2 29.6 67.7 -17.1 20.5 -0.8 
37724 GL-I-66 9.7 25.6 80.2 18.9 15.7 8.2 
37725 MP-IV-010 20.5 38.2 64.1 14.9 27.8 25.1 
37726 GL-I-81 -2 -1.4 83.1 43.1 23.4 -15.9 
37728 SH-I-085 26.7 -0.5 97 18.7 19.5 29.4 
37729 KRM-II-18B -8.2 -1.4 96.8 15.3 12.9 13.9 
37730 KRM-II-73 -18 -8.5 96.9 10.7 26.4 21.6 
37731 KRM-II-82 -10.5 -2.9 94.6 23.8 18 15.4 
37732 KRM-II-97 -18.7 -5.8 93.4 41.8 8.1 23.6 
37733 KRM-II-81 -28.4 -14 85.6 23.1 14.3 13.6 
37734 KRM-II-68 -12.2 -7.4 74.8 20.5 0.6 16.4 
37735 KRM-II-08 -7.2 -12.4 94.8 -4.1 5.5 19.1 
37736 KRM-II-3B -5.2 5.9 69.4 -19.8 25.3 -1.7 
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42621 KRM-III-59 -9.3 -18.9 96.3  -2.2 3.2 
42622 KRM-III-65 -4.1 -17.2 96  7.7 11.2 
42623 KRM-III-66 -1.2 -4.6 85.6  7 12.5 
42624 KRM-III-67 -13.9 -8.8 70.7  -4 14.7 
42625 KRM-III-79 -19.8 -13.4 80.7  5.1 11.2 
42626 KRM-III-70 -17.1 -13.1 79.7  -2.9 10.5 
42627 KRM-III-77 -18.8 -7.3 85.5  -7.7 16.1 
42628 KRM-III-78 -13.1 32.8 83.9  23.5 2.6 
42633 Ro5-4846 -17.2 18.5 52.7  -0.3 -0.1 
42634 Ro7-9277 -19.5 7.7 47  -2.6 -8.5 
42635 GL-I-74 -11.8 13 55.5  8.4 13.6 
42636 GL-II-39 -4.2 28.7 40.6  4.1 16.5 
42637 GL-II-05 8.7 30.6 50  2.5 16.1 
42638 GL-II-06 -1.8 30.9 81.3  8.9 15.2 
42639 GL-II-18 -2.2 33.7 55  16.6 17.2 
42640 GL-II-19 -1.3 8.5 70.9  4.2 22 
42641 GL-II-30 -5 -2.7 65.2  -0.3 12 
42642 GL-II-31 -5.6 -3.8 72.2  16.8 -10.6 
42643 GL-II-32 -6.1 -12.2 62.5  13.8 -12.9 
42644 GL-II-33 -0.1 0.1 98.2  10.5 -12.9 
42645 GL-II-51 -9 -14.5 84.4  3.1 -13.6 
42647 GL-II-53 -0.2 11.9 79  -1.7 -19.2 
42648 GL-II-54 19 7.5 66.3  2.8 -6.4 
42651 GL-II-57 -4.4 21.5 86.6  3.9 -8.4 
42653 GL-II-59 -7.5 20.3 88.3  -4.3 0.1 
42654 GL-II-60 0.2 -11.2 88.1  11.5 3.4 
42655 GL-II-61 -12.2 15.7 80.7  14.3 -10.6 
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42656 GL-I-30 -18.7 -4 96.2  16.9 -14.7 
42657 GL-I-31 0 40.3 97  -10.1 -14.7 
42658 GL-I-32 -18.6 1.5 98.3  -2.6 -5.4 
42659 GL-I-33 -1.8 32.1 96  6.9 -11.7 
42660 GL-I-38 1.9 -1.2 95.5  -5.1 -14.7 
42661 GL-I-36 35.6 -6.5 77.2  -1 -15.2 
42662 GL-I-43 -3.8 -18.4 93.8  -9.3 -9.2 
42663 GL-I-41 -14.8 -10 89.9  -3.9 -7.8 
42664 GL-I-55 -7.5 -4.8 95  -11.1 0.7 
42665 GL-I-54 -7.6 -6.6 93.7  -6.5 -4.3 
42666 GL-I-77 0.3 -2 92.3  5.6 -12.1 
42667 GL-I-78 -5.1 11.1 76  -5.3 -14.9 
50093 SH-I-044 1.4 32.1 72.8 5.8 -16.2 -17.9 
50094 SH-I-047 -6.8 41.1 83.9 -10.5 -8.6 2.9 
50095 SH-I-060 3.5 63.8 75.7 33.2 34.1 0.9 
50096 MP-III-058 6 31.3 86.4 22.5 -8.2 -17.4 
50097 SH-I-048A -4.4 54.1 68.6 32.4 -14.1 -9.6 
50098 SH-I-048B -5.1 49.2 61.4 24.1 0.3 1.8 
50099 SH-I-055 3.5 63.5 52.1 35.6 23.3 11.5 
50101 YT-III-31 13.2 33.9 81.9 11.9 -4 6.5 
50102 YT-III-271 8.7 38.1 72.6 -18.2 14.7 15.3 
50103 SR-II-54 1.9 35 79.9 24.3 7.7 18 
50104 GL-II-73 -13.7 18.5 74.6 -18.5 4.9 27.2 
50105 GL-II-74 -16.6 7.3 84.2 3 17.5 11.6 
50106 GL-II-75 -2.8 3.5 85 -5 8.4 0 
50107 GL-II-76 -5.2 -0.7 43.3 -13.8 -2.5 4 
50108 GL-I-50 -8.5 8.7 42.2 -14.9 -2.7 6.1 
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50109 GL-II-93 -9.1 -3.8 72.5 13.4 4.4 14.8 
50110 GL-I-65 8.6 10.9 33.2 17.3 3.3 16.7 
50111 GL-I-81 7.1 4.8 81.4 28.1 15.3 29.1 
50112 GL-III-19 11.7 -18.5 79.5 11.9 7 24.5 
50114 GL-I-61 12.8 28.1 76.6 0.9 31.3 14.8 
50117 GL-I-63 1.3 11.2 82 30 23.1 29.4 
50120 GL-III-26 -2.8 -6.7 71 16.4 17.3 30.4 
50121 GL-III-27 2.1 -11.3 80.2 9.5 -3.4 -17.5 
50122 GL-III-59 5.8 -8.9 85.7 38.8 -0.3 10.1 
50123 GL-III-57 -9.6 1 56.3 39.8 4.5 -17.2 
50124 GL-III-58 -9.5 14.7 58.9 22.2 3.3 -14 
50125 GL-III-35 1.5 25.1 78.6 7.6 -8.2 -5.8 
50126 GL-III-36 8.8 4.2 85.7 10.6 -3.2 -12 
50127 KRM-III-18A 18.2 16.7 54.5 41.9 10.6 -19.8 
50128 GL-III-38 11.5 -1.6 61.6 28 3.5 -11.3 
50129 GL-III-72 -0.1 61.4 82.8 -0.1 31.4 -3 
50130 GL-III-73 -6.1 -4.9 65.1 1.9 -7 -15 
50132 GL-III-42 -2.1 18.1 62.1 21.4 24.1 -7.8 
50133 GL-III-43 1.6 13.3 45.6 1.4 -3.2 -15.7 
50134 GL-III-52 -2.7 33.6 52.4 20.3 2.9 -16.5 
50135 GL-III-53 3.1 22.2 63.6 12.9 -4.8 -19 
50136 GL-III-54 21.1 4.7 139.1 37.9 -18.3 6.3 
50137 GL-III-60 7.6 12.7 109.4 45.6 -18.1 -15.8 
50138 GL-III-63 3.3 -2.5 28.1 49.6 68.8 27.3 
50139 GL-III-64 -10.5 -0.5 92.4 15.8 46.7 -12.5 
50140 GL-III-66 -10 0.2 87.5 4 -5.1 10.7 
50141 GL-III-67 -16.3 1.1 106.9 -9.3 -3.8 7.9 
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50142 GL-III-68 -1.1 -3.4 136.5 17.2 46.5 8 
50143 GL-III-69 12.5 -14.5 118.1 21.2 20.9 13.3 
50144 GL-III-70 19 2.9 113.7 28.5 31.9 13.3 
50145 GL-III-75 21.5 9.6 95.2 38.8 35.7 10 
50146 GL-III-76 18.5 30 121.8 41.2 39.5 11.2 
50147 GL-III-76A 15.1 42.4 83 46 -5.8 -3.6 
50148 GL-III-77 14.5 39.9 50 59.9 50 14.5 
50149 GL-III-78 -4 43.3 100.7 66.3 11.2 10 
 
Table 40. PDSP primary binding data for D3, D4, D5, DAT, DOR, and GABAA. 
Compound 
# 








6.8(AVE)  3.1 25.1(AVE)  38.1(AVE)  25.2(AVE)  -12.6(AVE)  
30613 MP-III-004 9.6(AVE)  -5.5 19.6(AVE)  32.3(AVE)  21.0(AVE)  -6.0(AVE)  
30614 MP-III-021 7.5(AVE)  4.9 21.7(AVE)  36.9(AVE)  20.2(AVE)  -13.4(AVE)  
30615 MP-III-019 -9.8(AVE)  42.5 20.6(AVE)  65.4(AVE)  13.6(AVE)  -11.1(AVE)  
30616 MP-III-018.A 12.9(AVE)  -7.4 8.1(AVE)  34.0(AVE)  27.1(AVE)  -10.4(AVE)  
30617 MP-III-022 11.1(AVE)  -7.1 1.0(AVE)  48.6(AVE)  16.9(AVE)  -19.5(AVE)  
30618 MP-III-023 6.2(AVE)  -15.7 14.1(AVE)  41.6(AVE)  15.0(AVE)  -24.4(AVE)  
30619 SH-I-85 4.2(AVE)  2 13.9(AVE)  33.6(AVE)  35.2(AVE)  -17.7(AVE)  
37713 MP-III-068 -5 -4.7 -17.2 7.8 18.7 9.4 
37714 MP-III-080 12.1 -0.3 11.7 -6.4 0 -0.6 










-2.8 -3.7 -13.3 3.6 17.6 -3.8 
37719 MP-III-018.B 2.3 -6.5 -9.1 11 9.7 -14.4 
37720 MP-III-019.B 20.4 -6.2 -0.4 21.8 -9.9 -19.4 
37721 MP-IV-004 6.9 -2.9 11.6 32.2 9.8 -8.5 
37722 GL-I-65 -11.8 -10.5 26.5  6.6 -4.6 
37723 MP-IV-005 10 4.7 30.7 26.6 23.4 -5.6 
37724 GL-I-66 13.2 0.6 26.1 10.7 1.5 -5.7 
37725 MP-IV-010 15 4.8 28.7 13.5 5.1 -7.6 
37726 GL-I-81 -16.3 6 19.8 4.2 24.7 14.7 
37728 SH-I-085 1.5 -4.5 13.3 17.8 11 -1.2 
37729 KRM-II-18B 4.6 -1.8 5.9 18.9 20.1 -11.2 
37730 KRM-II-73 3.3 5 9 19.3 31.7 -17.5 
37731 KRM-II-82 9.4 7.6 1 20.3 19.6 -15.3 
37732 KRM-II-97 9.9 3.2 14 21.3 8.3 -14.8 
37733 KRM-II-81 6.6 -2.8 -7 26.9 15.2 -7.9 
37734 KRM-II-68 11.2 -1 -8.7 39.5 -6 -0.6 
37735 KRM-II-08 17 4.3 5.1 -15.2 -7.2 -19.8 
37736 KRM-II-3B 35.8 -12 -2.9 -17.7 11.9 -16.1 
42621 KRM-III-59 -3.9 -20.2 23.7  10.5 39.2 
42622 KRM-III-65 1.4 19.8 22.2 -6.8 15.8 40.2 
42623 KRM-III-66 0.4 25 18.7 1.4 11.4 17.8 
42624 KRM-III-67 -2.5 26.6 21.1 -8 2.6 27.9 
42625 KRM-III-79 8.5 32.4 17.5  1.4 32.2 
42626 KRM-III-70 11.8 33.8 17.4  -9.7 9.9 
42627 KRM-III-77 23.4 24 12.5  -12.5 9.8 
42628 KRM-III-78 11 31.7 15 -8.2 -1.5 3.6 
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42633 Ro5-4846 -3 -15.1 4.3 11.3 7.5 10.7 
42634 Ro7-9277 -5.5 -8 7.5 -0.8 -8.2 14.8 
42635 GL-I-74 9.1 13.7 14.6 6.2 5.4 26.8 
42636 GL-II-39 11.7 11.3 8.9 8.9 2 15.4 
42637 GL-II-05 9.5 16.5 5.1 1.1 0.3 30.8 
42638 GL-II-06 16.3 28.1 6.9 -3.3 8.8 25.9 
42639 GL-II-18 36.2 35.9 17.5 28.2 74.5 31 
42640 GL-II-19 32.1 3.6 6.1 6.3 1.8 0.7 
42641 GL-II-30 18.7 13.8 9.6 7.6 3.8 -5.4 
42642 GL-II-31 -19.7 31.5 -9.4 5.5 2.6 14.8 
42643 GL-II-32 -11.3 -10 -15.6 -34.1 -7.1 21.2 
42644 GL-II-33 -9 -2 -5.1 -67.6 9.9 33 
42645 GL-II-51 -12 -3.8 -7.1 -28.3 -6.7 36.6 
42647 GL-II-53 -13.5 -2.3 -4.1 -8.6 1.1 45.8 
42648 GL-II-54 -10.3 -13 5.1 -16.2 -1.8 38.6 
42651 GL-II-57 -4.3 -6.1 -1.8 -4.1 4.6 27.8 
42653 GL-II-59 3.1 -2.4 1.2 9.4 -3.5 44.3 
42654 GL-II-60 5.2 12.3 5.7 -0.6 11.7 16 
42655 GL-II-61 -5.1 -0.8 8.6 5.9 9.3 1 
42656 GL-I-30 -0.5 -13.6 5 -2.5 7.4 -1.1 
42657 GL-I-31 -10.6 -12.9 15.5 -23.4 8.2 18.3 
42658 GL-I-32 -17.6 -9 18 -9.5 13.9 19.5 
42659 GL-I-33 1.2 -6.3 23.9 -0.3 25.3 18.3 
42660 GL-I-38 -4.4 -7.8 17.6 -5.4 15.8 29.7 
42661 GL-I-36 -5.2 0.6 23.6 -11.4 -0.6 33.3 
42662 GL-I-43 -4.5 -5.6 5.1 -2.8 2.8 48.5 
42663 GL-I-41 7.2 1.2 10.1 7.3 9.6 45.2 
539 
 
42664 GL-I-55 13.1 5.4 12 9.8 23.8 23.7 
42665 GL-I-54 2.5 5.5 16.5 5.6 11.3 6.5 
42666 GL-I-77 -13.4 4.7 -8.6 -2.6 4.1 20.4 
42667 GL-I-78 -7.6 4.5 -16.5  40.5 18.4 
50093 SH-I-044 5.4 18.5 -4 9.3 -6.6 -0.4 
50094 SH-I-047 6.5 21.8 -2.6 7.4 -9.5 -2.2 
50095 SH-I-060 25.5 16.1 61.7 32.2 47.7 -0.4 
50096 MP-III-058 -11.4 -15.3 2.4 7 3.5 25 
50097 SH-I-048A -5.1 -2 -1.3 -6.7 0.6 32.4 
50098 SH-I-048B -13.6 -1.5 -3.5 7.5 -0.7 27.8 
50099 SH-I-055 17.3 -1.9 54.1 30 16.7 18.5 
50101 YT-III-31 -12 -3 1.4 -22.2 -2.9 11.4 
50102 YT-III-271 3.5 -14.1 12.7 -8.9 16.8 21 
50103 SR-II-54 16.6 -1.7 9.4 -1.8 1.4 12.7 
50104 GL-II-73 7.8 -9.4 -5.7 -11.4 -12.4 -10.4 
50105 GL-II-74 8.4 1.2 1 -38.2 -7.1 -4.4 
50106 GL-II-75 -12.4 3.6 -2.6 -14 3.3 0.8 
50107 GL-II-76 -18.9 1.3 0 -7.1 -6 12.5 
50108 GL-I-50 -17.2 -9.6 -2.6 -11.2 -9.1 11.5 
50109 GL-II-93 -3.5 -8.2 2.4 -15.9 -13.4 12.7 
50110 GL-I-65 10 5.6 22 -0.4 35 16.7 
50111 GL-I-81 6.7 -2.9 4.6 11.7 4.7 5.9 
50112 GL-III-19 18.6 -11 -6.5 23.7 3.6 21.7 
50114 GL-I-61 26.7 -4.1 50 41.8 29.2 -4.1 
50117 GL-I-63 55.1 4 43.8 -11 10.9 -6.2 
50120 GL-III-26 50 16.9 4.4 -4.5 64.6 5.2 
50121 GL-III-27 -16.6 -0.4 12.3 -15 -1.9 -1.7 
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50122 GL-III-59 -9.1 -17.6 2.7 -4.5 -5.3 11.1 
50123 GL-III-57 2 -19.7 5.4 10.9 23 35.1 
50124 GL-III-58 2.7 -12.5 4.1 7.6 0.1 31.4 
50125 GL-III-35 1.9 1.1 11.1 12.6 -14.4 19.9 
50126 GL-III-36 1.9 -10.3 8.4 17.8 12.4 12.3 
50127 KRM-III-18A 7.2 -0.4 17.6 48.1 27.2 19.2 
50128 GL-III-38 -6.4 -10.5 11.8 38 14 0.1 
50129 GL-III-72 52.3 16 29.2 44.2 82.8 -45.8 
50130 GL-III-73 -7.7 7.4 4.4 -20.3 3.5 -18.7 
50132 GL-III-42 -13 15.6 2.2 18 13.3 -17.2 
50133 GL-III-43 -7.1 -1.8 7.8 8 21.5 1.1 
50134 GL-III-52 -8.5 -5.4 6.9 3.8 19.6 3.6 
50135 GL-III-53 -5.5 -6.8 10.8 -4.4 1 15 
50136 GL-III-54 -19.4 -12.5 -19 -39 -5.8 6.5 
50137 GL-III-60 1.3 -3.1 -8.9 -18.4 18.3 -6.3 
50138 GL-III-63 -18.8 -10.1 33 -9.8 31.3 17.9 
50139 GL-III-64 -2.7 14.4 44 -7.1 13.6 -12.8 
50140 GL-III-66 -6.5 -4 1.8 -9.8 -5.8 11.7 
50141 GL-III-67 -7.4 -2.9 23.8 0.4 -8 -1.8 
50142 GL-III-68 8.7 21.8 41.5 1.5 9.7 -4.5 
50143 GL-III-69 0.6 22.2 21.3 5.8 10 -3.8 
50144 GL-III-70 -2.8 25.5 24.2 6.3 49.5 -4.8 
50145 GL-III-75 0.8 19.7 25.3 10.9 -17.3 -10.9 
50146 GL-III-76 -7.4 6.1 -16.2 11.7 -2.6 -13 
50147 GL-III-76A -4 -16.5 -4.5 5.9 0.3 -16.3 
50148 GL-III-77 43.9 -2.5 70.7 59.4 77.9 -3.3 




Table 41. PDSP primary binding data for H1, H2, H3, H4, HERG binding, and KOR. 
Compound 
# 




30611 SH-053-2'F-R-CH3 35.6 1 -2.6 9.7(AVE)  10.6 90.9(AVE)  
30612 SH-053-2'F-S-CH3 50.0 -7 0.4 13.9(AVE)  15.3 95.7(AVE)  
30613 MP-III-004 44.5 -9 -6.6 12.9(AVE)  21.7 80.3(AVE)  
30614 MP-III-021 44.8 -5.8 -1.8 12.1(AVE)  16.1 97.5(AVE)  
30615 MP-III-019 59.5 8.6 -19.1 20.5(AVE)  15 45.5(AVE)  
30616 MP-III-018.A 53.7 -2.7 -1.2 16.5(AVE)  27.6 71.1(AVE)  
30617 MP-III-022 25.5 5.5 12.5 10.4(AVE)  25.3 87.0(AVE)  
30618 MP-III-023 17.3 -3.2 12 14.1(AVE)  9.4 96.1(AVE)  
30619 SH-I-85 3.2 -5.5 4.8 -6.3(AVE)  4.1 95.6(AVE)  
37713 MP-III-068 24.9 12.4 2.3 -3.2 -10.5 28.5 
37714 MP-III-080 89.3 2.6 7.9 7.1 5.3 46.6 








78 7.7 8 -7.6 -4.4 20.1 
37719 MP-III-018.B 71.3 1.2 3 -1.1 0.4 50.9 
37720 MP-III-019.B 58.3 -0.8 -0.2 -0.1 2 62.1 
37721 MP-IV-004 44.1 -6.9 -5.5 8.4 18.6 86 
37722 GL-I-65 -9.8 7.1 -12.5 -4.1 -8.8 88.4 
37723 MP-IV-005 20.8 0.7 -1.2 5.6 18.5 89.3 
37724 GL-I-66 19.6 6.1 -29.9 13.5 37.8 91.7 
37725 MP-IV-010 19 28.2 -17.9 5.7 28.8 93.6 
37726 GL-I-81 8 21.7 -11.9 3.4 8.8 92.9 
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37728 SH-I-085 19.3 11.6 16.2 15.5 17.8 91.3 
37729 KRM-II-18B 5.1 9.6 22.2 19 17.6 88.9 
37730 KRM-II-73 -8.1 0.7 16.6 14.8 17.9 83.1 
37731 KRM-II-82 -11.3 19.6 13.1 32.8 16.3 77.9 
37732 KRM-II-97 -32.6 -4.7 2.4 15.2 20 61.6 
37733 KRM-II-81 -13.5 -11.7 8.6 11.7 -16.4 45.9 
37734 KRM-II-68 4.2 79.1 -1 4.9 6.1 20.3 
37735 KRM-II-08 89 1.7 -11.4 20.5 3 80.2 
37736 KRM-II-3B 42.9 -0.7 -6.8 -4.9 -9.2 54.7 
42621 KRM-III-59 -5 20.1 5.5  9.3 73.4 
42622 KRM-III-65 0.8 8.9 -2.2 -1.1 7.7 64.1 
42623 KRM-III-66 -15.6 22.3 13.4  11.4 66.5 
42624 KRM-III-67 -11.6 15.9 9  4.3 48.1 
42625 KRM-III-79 -12.8 2.8 -13.2 4.3 -14.2 8.9 
42626 KRM-III-70 0.3 -3.6 1.3  -6.2 -4.6 
42627 KRM-III-77 -8.4 7.4 -1.3 6.8 -2.3 59.1 
42628 KRM-III-78 -5.4 14.6 13  2.9 42 
42633 Ro5-4846 -10 11.6 -10.8  4.6 57.5 
42634 Ro7-9277 0.5 7.5 -4.3  -1.5 19.4 
42635 GL-I-74 16.1 16.5 -2.2 15.8 14.2 62.4 
42636 GL-II-39 4.7 3.2 17.6 17.8 8.6 31.4 
42637 GL-II-05 28.4 1.8 11.2 33.6 -2.9 25.8 
42638 GL-II-06 27.6 0.9 10.6 18.3 3.3 78.8 
42639 GL-II-18 28.1 10.6 14 15.8 58.5 7.3 
42640 GL-II-19 2.5 0.1 31.4 16.4 4.6 43.5 
42641 GL-II-30 12.4 0.2 28.1 9.3 -0.2 -15.6 
42642 GL-II-31 17.6 6.9 9.4 13.7 -15.6 22.9 
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42643 GL-II-32 -5 22.7 31.2 4.2 -12.7 35.2 
42644 GL-II-33 -18.1 18.3 1.1 9.1 -2.8 88.8 
42645 GL-II-51 -14.4 11.1 2.3 14.8 1.4 11.2 
42647 GL-II-53 -6 11.5 5.6 7.4 -3.8 78.1 
42648 GL-II-54 -19.5 14.7 -12.1 17.2 3.1 80 
42651 GL-II-57 -11.7 30.3 -7 12.8 5.8 96 
42653 GL-II-59 -4.1 21.1 8.8 8.6 6.7 93.6 
42654 GL-II-60 -16.8 26.5 2.9 11.2 13.3 89.9 
42655 GL-II-61 -6.8 16.9 7.1 7.5 18.7 3.5 
42656 GL-I-30 7.2 29.7 4.7 -37.1 -6.9 94.9 
42657 GL-I-31 11.4 22.8 -19.3 -9.6 -15.8 94.2 
42658 GL-I-32 2 73.1 8.4 0.2 14.6 94.5 
42659 GL-I-33 10.5 21.7 -4.6 24.7 27.3 93.7 
42660 GL-I-38 14.9 12.8 0.1 -4.6 6.8 95.2 
42661 GL-I-36 7.6 12.1 1 36.6 15 84.9 
42662 GL-I-43 10 13.8 10.9 3.8 12.3 95.2 
42663 GL-I-41 2.1 19.3 36 -7.1 14.4 97 
42664 GL-I-55 2.6 21.5 4.3 0.4 23.8 93.1 
42665 GL-I-54 1 7.1 17.4 0.9 14.7 77.9 
42666 GL-I-77 23.7 29.3 1.6 4.6 -12.9 95 
42667 GL-I-78 15.8 57.7 11 -5 -7.6 95.7 
50093 SH-I-044 -15.6 20 1.2 8.9 -16.1 31.3 
50094 SH-I-047 -10.3 -6.9 -9.6 -16.7 -1.5 82.4 
50095 SH-I-060 15.3 40 17.6 3.7 69.1 2.5 
50096 MP-III-058 -1.5 12.5 -7.8 -9.9 -1.2 83.6 
50097 SH-I-048A 1.7 16.4 -9.4 5.6 -13.7 6.3 
50098 SH-I-048B 2.6 19.6 -2.9 14.1 -0.3 95.2 
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50099 SH-I-055 24.3 40.8 4.5 30 68.5 38.9 
50101 YT-III-31 -10.7 -2.6 34.8 68.1 13.4 89.2 
50102 YT-III-271 -3.4 13.9 21.6 6.7 13 58.3 
50103 SR-II-54 -12.8 2.7 0.7 28.3 -15.9 8.9 
50104 GL-II-73 0.1 2.2 -1 2.7 -9.3 58.1 
50105 GL-II-74 -8 32 -8.5 -11.1 2.8 86 
50106 GL-II-75 9.8 16.1 0.9 -16.6 4.8 80.9 
50107 GL-II-76 -5.1 13.2 -13.4 24.3 5.8 80.4 
50108 GL-I-50 -13.6 33 2.4 27.8 8.1 -11.1 
50109 GL-II-93 -5.4 10.7 -13.3 26.2 2.8 -9.1 
50110 GL-I-65 -8 19.9 -18.3 -1.5 13.7 79.3 
50111 GL-I-81 10 19.2 -0.2 41.9 37.1 86.9 
50112 GL-III-19 0.9 11.3 0.2 13.6 20.9 81.5 
50114 GL-I-61 19.2 56.2 21.7 -10.2 34.7 -18.1 
50117 GL-I-63 15.6 66.5 26.5 -18.2 63.8 -6.7 
50120 GL-III-26 14.7 56.1 15.8 -6.1 23.1 12.2 
50121 GL-III-27 26.4 42.5 24.6 -5 -4.8 -13.1 
50122 GL-III-59 4.8 11.4 19.6 -13.2 -5.7 15.8 
50123 GL-III-57 16.8 14.5 4.1 6.8 7.1 13 
50124 GL-III-58 2 11.3 13.2 0.7 -12.3 15.5 
50125 GL-III-35 -4 9.5 -11.5 -7.2 -4.3 77 
50126 GL-III-36 6.5 16.8 18.7 2.4 -6.5 87.8 
50127 KRM-III-18A -2.7 31.2 -14.7 -12.6 1.1 62 
50128 GL-III-38 2.1 1.5 -15.8 -6.2 -14.8 38.2 
50129 GL-III-72 -0.3 67.2 0.8 -14.4 44 3.3 
50130 GL-III-73 3.4 54.9 5.8 -0.2 -14.5 74.3 
50132 GL-III-42 29 47.5 8.5 -0.9 6.1 86.1 
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50133 GL-III-43 1 15.6 11 11.8 -0.5 50.2 
50134 GL-III-52 -12.1 18.2 13.3 13.7 -17.8 39.9 
50135 GL-III-53 -7.9 25.6 9.4 11.3 -19.7 91.7 
50136 GL-III-54 12.3 -14.9 -14.7 -8.6 -16.8 22 
50137 GL-III-60 50 -5.9 -18.6 10.7 -5.1 87.4 
50138 GL-III-63 40.8 16.9 25.7 -83.1 12.2 77.5 
50139 GL-III-64 53.7 -7.1 -7.5 19.4 6.4 60.2 
50140 GL-III-66 39.4 -4.7 -7.6 25.2 0.5 62.9 
50141 GL-III-67 11.4 0.2 -13.6 -6.4 -8.1 87.3 
50142 GL-III-68 64.2 71.9 -4.7 16.3 23.4 88.3 
50143 GL-III-69 -12.7 16 3 -7.2 1.8 75.1 
50144 GL-III-70 -12.5 19.1 -4.6 -10.3 -14.9 67.7 
50145 GL-III-75 -11.7 7.7 15.5 18.9 -2.9 61.2 
50146 GL-III-76 -13.4 -16.9 18.3 -9.2 0.8 83.2 
50147 GL-III-76A 0.8 1.7 -16.2 -10.1 2.6 39.4 
50148 GL-III-77 54.1 60.7 4.1 -10.3 57.4 10.4 
50149 GL-III-78 31.2 11.6 -6 -4.7 -1.3 74.1 
 
Table 42. PDSP primary binding data for M1, M2, M3, M4, M5, and mGlur5. 
Compound 
# 
Name M1 M2 M3 M4 M5 mGlur5 
30611 SH-053-2'F-R-CH3 -4.9 17.9 26.1(AVE)  7.7(AVE)  0 31.7 
30612 SH-053-2'F-S-CH3 -8.5 11.7 12.8(AVE)  12.6(AVE)  -1.9 24.8 
30613 MP-III-004 -7.8 -0.7 7.9(AVE)  1.0(AVE)  3.6 4.8 
30614 MP-III-021 -6.2 2.9 9.3(AVE)  5.8(AVE)  0.8 -5.1 
30615 MP-III-019 -4.5 2.1 1.7(AVE)  9.2(AVE)  6 -7.3 
30616 MP-III-018.A -7.2 -3.2 2.3(AVE)  43.3(AVE)  8.3 54.4 
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30617 MP-III-022 -11.4 4.7 -0.9(AVE)  -3.9(AVE)  5.7 29.1 
30618 MP-III-023 -2.2 10 9.1(AVE)  -2.3(AVE)  2.6 -0.6 
30619 SH-I-85 -10.2 0.6 10.8(AVE)  1.4(AVE)  2.4 28.6 
37713 MP-III-068 7.2 19.5 15.4 18.2 -2.7   
37714 MP-III-080 4 25.9 7.8 26.6 11.5   








5.8 20.7 12.3 20.7 -0.1   
37719 MP-III-018.B 10.6 50 16.7 29.7 6.6   
37720 MP-III-019.B 4.2 50 8.1 28.6 14.1   
37721 MP-IV-004 -9.8 26.5 -5.5 27.7 12.4   
37722 GL-I-65 -7.5 -8.6 36.5 38.8 -2.8   
37723 MP-IV-005 -11.3 22.3 7.3 22.2 12   
37724 GL-I-66 -16 50 -4.7 37.7 20.8   
37725 MP-IV-010 -11.2 10.5 -0.4 8.4 26.2   
37726 GL-I-81 -1.4 -17 47.7 22.5 4.9   
37728 SH-I-085 -3.4 17.1 -3.9 14.2 28.2   
37729 KRM-II-18B -1.4 4.9 7.7 9 30.5   
37730 KRM-II-73 -4.5 6.6 4.9 15.4 50   
37731 KRM-II-82 -4.3 0 3.8 13.5 33.5   
37732 KRM-II-97 10.1 3.5 6.7 12 38.3   
37733 KRM-II-81 3.2 2.4 -8.9 11.2 37.5   
37734 KRM-II-68 6.9 0.1 -8.3 12.8 26.2   
37735 KRM-II-08 11.8 3.5 -0.1 18 25.4   
37736 KRM-II-3B -5 -1.3 15.2 -7.5 10.3   
42621 KRM-III-59 -9 -18.3 -18.3 -4 2.3   
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42622 KRM-III-65 -17 -8.8 -0.1 -0.1 -2   
42623 KRM-III-66 -8.7 -12.5 24.9 0.1 3   
42624 KRM-III-67 -6.2 -9.9 23.8 3.3 -3.9   
42625 KRM-III-79 11.8 3.7 23 -6.1 7.7   
42626 KRM-III-70 3.9 -9.4 18.4 -4.8 2   
42627 KRM-III-77 3.5 -13.7 1.3 18.1 -3.3   
42628 KRM-III-78 3.5 0.8 3.6 9.2 6.1   
42633 Ro5-4846 -4 -7.5 8 7.8 16.7   
42634 Ro7-9277 5 4.4 32.8 11.4 9.3   
42635 GL-I-74 -2.2 6 39.6 -11.9 0   
42636 GL-II-39 2.8 11.9 29.6 -10.5 7.9   
42637 GL-II-05 19.2 7.1 21.8 16.7 -10.3   
42638 GL-II-06 11 2.8 16.4 30.6 -11.2   
42639 GL-II-18 -0.7 -1.2 -1.1 2.6 -1.7   
42640 GL-II-19 -13.9 -0.6 8.6 5.7 8.2   
42641 GL-II-30 2.3 -0.7 -7.7 -3 -3.8   
42642 GL-II-31 -6.6 0.4 -12.6 -2.3 -10.2   
42643 GL-II-32 -1.9 2.8 -7.1 -4 -9.4   
42644 GL-II-33 -4.1 1.3 16.9 0.6 -6.2   
42645 GL-II-51 3.3 -6.4 18.5 -8.9 -1.2   
42647 GL-II-53 -14.3 4.2 1.3 23 -6.5   
42648 GL-II-54 -8.1 2.1 8.3 -2.2 -10.8   
42651 GL-II-57 -4.4 3.9 -0.1 3.1 -13.8   
42653 GL-II-59 -15.5 -3.9 4.2 -13.5 -2   
42654 GL-II-60 0.2 5.9 -1 2.4 -4.4   
42655 GL-II-61 -6.4 2.4 -5.6 -9.7 -10.5   
42656 GL-I-30 -7.1 8.9 -8.6 -2.3 -4.7   
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42657 GL-I-31 -7.6 11.3 -0.2 1.3 -6.6   
42658 GL-I-32 -13.2 -13.4 0.9 17.2 -2.1   
42659 GL-I-33 -2.4 -9 -6.2 -12.2 -8.6   
42660 GL-I-38 -0.5 2.2 -13.1 -18.4 -11   
42661 GL-I-36 6.5 3.2 3.7 -8.1 -6.7   
42662 GL-I-43 5.3 -3.3 -16.6 -15.6 -6.5   
42663 GL-I-41 -9.3 -5.6 -11.4 43.6 2.6   
42664 GL-I-55 4.9 -7.9 -10 32.5 4.6   
42665 GL-I-54 5.1 -2.4 -10.6 22.5 -4.9   
42666 GL-I-77 11.4 -0.2 -19.9 38.2 2.6   
42667 GL-I-78 3.1 15.3 -16.6 14 -3.5   
50093 SH-I-044 -1.2 -14.1 -4 1.6 13.2   
50094 SH-I-047 -6.3 -11 9.5 -13.4 1.3   
50095 SH-I-060 2.5 -13.3 -4.7 1.5 -1.6   
50096 MP-III-058 3.1 4.3 -16 -8.1 2.7   
50097 SH-I-048A -13 1 -9.3 -0.3 2.6   
50098 SH-I-048B -16.3 4.3 4.8 3.7 6.6   
50099 SH-I-055 -5.6 25.2 22.6 12.2 3.4   
50101 YT-III-31 -2.7 -4.9 4.2 -1 4.6   
50102 YT-III-271 0 -7.3 -5.3 -8.4 10.9   
50103 SR-II-54 -17.9 3.5 5.6 -5.9 6.3   
50104 GL-II-73 -5.2 -2.9 1.4 4.8 11.7   
50105 GL-II-74 -1.8 4.2 -2 -13.7 -6.4   
50106 GL-II-75 0.9 -0.6 8.7 -13.6 -16.9   
50107 GL-II-76 -0.6 11.8 -4.8 -5.5 -10.1   
50108 GL-I-50 -8.2 1.7 -7.7 -8.8 -2.5   
50109 GL-II-93 -7.3 -4.1 -1.9 -5.6 -4.6   
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50110 GL-I-65 -1.2 1.4 7.8 -17.7 -0.2   
50111 GL-I-81 16.2 5.6 -3.5 -11.7 -1.9   
50112 GL-III-19 2.8 0.9 -0.7 -14.3 8.6   
50114 GL-I-61 -8.2 0.8 -5.8 -2.8 15.2   
50117 GL-I-63 9.7 -5.4 -3.3 -1.5 23.6   
50120 GL-III-26 -3.5 -6.3 -3.7 1.7 12.7   
50121 GL-III-27 4.8 5.8 -6.6 2.1 -6.5   
50122 GL-III-59 10.9 13.8 -13.1 8.1 6.6   
50123 GL-III-57 -4.3 9.8 1.9 11 3.1   
50124 GL-III-58 -7.7 8.9 -5.8 13.2 5.8   
50125 GL-III-35 -0.5 7.7 23.9 10.4 11.2   
50126 GL-III-36 0.6 10.4 -9.6 -2.9 3.8   
50127 KRM-III-18A -13.8 8.2 -10.4 6.3 10.1   
50128 GL-III-38 -15.3 0.8 -5.8 1.2 17   
50129 GL-III-72 -3.6 3.1 11.4 12.8 19.6   
50130 GL-III-73 -17.6 -0.6 0.7 -4.7 -7.4   
50132 GL-III-42 -18.2 5.1 3.9 -2.2 -14.4   
50133 GL-III-43 -14.1 -13.2 -6.1 8.3 -12.8   
50134 GL-III-52 -18.2 -4.5 -0.1 7.9 -10.8   
50135 GL-III-53 -17.1 15.3 -6.5 5.3 -11.8   
50136 GL-III-54 80.1 20.1 14.7 11.3 53.6   
50137 GL-III-60 73.5 -20 -18.5 13.2 48.5   
50138 GL-III-63 -3.7 19.4 -18.1 -17.3 -18   
50139 GL-III-64 56.2 -8.6 24.1 23.1 44.7   
50140 GL-III-66 40.5 -7.6 25.2 14.6 51.4   
50141 GL-III-67 4.7 1.1 40.5 27.7 59.6   
50142 GL-III-68 0.1 -5.5 62.4 15.4 50.1   
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50143 GL-III-69 -9.3 -6.3 50.1 3.7 35.9   
50144 GL-III-70 -17 7.4 38.2 -5.7 21.7   
50145 GL-III-75 0.7 11 50 15.9 -0.6   
50146 GL-III-76 16.1 22.8 76.9 -8.3 16.4   
50147 GL-III-76A 5.9 17.2 -7.4 -12.5 57.6   
50148 GL-III-77 0.3 -17.6 11.3 17.6 7.8   
50149 GL-III-78 -1.8 -13.3 50 22.8 10.3   
 
Table 43. PDSP primary binding data for MOR, NET, NMDA, Oxytocin, PBR, and SERT. 
Compound 
# 
Name MOR NET NMDA Oxytocin PBR SERT 
30611 SH-053-2'F-R-CH3 15.7(AVE)  -11.3   13.9 12.3(AVE)  -14.3 
30612 SH-053-2'F-S-CH3 15.6(AVE)  -5.5   18.1 18.2(AVE)  -9.5 
30613 MP-III-004 -2.2(AVE)  -14.2   42.1 30.1(AVE)  -12.5 
30614 MP-III-021 2.1(AVE)  -11.8   16.8 25.5(AVE)  -9 
30615 MP-III-019 2.7(AVE)  -22   15.9 22.5(AVE)  -4.2 
30616 MP-III-018.A 8.8(AVE)  -6.4   7.6 1.9(AVE)  5.4 
30617 MP-III-022 4.1(AVE)  -11.4   12.5 16.6(AVE)  -6.1 
30618 MP-III-023 -5.7(AVE)  7.9   21.8 15.1(AVE)  -10 
30619 SH-I-85 10.8(AVE)  -26.8   30.2 60.4(AVE)  1.1 
37713 MP-III-068 24.8 -11.3     61.8 -12.7 
37714 MP-III-080 -1.1 -3.4     84.8 -13.4 








-2.5 38.9     17.7 2.1 
37719 MP-III-018.B 2 38.5     22.3 -5.4 
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37720 MP-III-019.B 2 32.8     34.4 -2 
37721 MP-IV-004 7 19     47.6 10.9 
37722 GL-I-65 2.4 -8.1     30.2 -5.6 
37723 MP-IV-005 20.6 27.2     38.2 13.3 
37724 GL-I-66 28.1 19.7     49.7 23.7 
37725 MP-IV-010 32.7 -2.2     27.7 21.7 
37726 GL-I-81 63.7 5.8     -16.7 0 
37728 SH-I-085 10.9 -12.1     80.3 6.4 
37729 KRM-II-18B 10.9 -2.2     38.4 11.5 
37730 KRM-II-73 10.5 16.6     67.9 3.5 
37731 KRM-II-82 5.4 9.8     42.7 21.1 
37732 KRM-II-97 18.1 26.6     93.4 0.7 
37733 KRM-II-81 6.5 41.1     93.1 -9.1 
37734 KRM-II-68 6.1 37.3     37.8 -3.7 
37735 KRM-II-08 5 38.3     81.6 7.7 
37736 KRM-II-3B -12.3 39.4     66.5 33.4 
42621 KRM-III-59 -0.6 -9.9     71.4 -11.3 
42622 KRM-III-65 -5.9 -4     21.2 -14.5 
42623 KRM-III-66 11.7 -9.7     59 -9.9 
42624 KRM-III-67 30.4 1.2     26 -2.2 
42625 KRM-III-79 32.4 -2.7     85.6 0.6 
42626 KRM-III-70 5.1 -18.5     9.4 -15.2 
42627 KRM-III-77 29.8 3.1     56 -9.7 
42628 KRM-III-78 29 9.7     63.2 12.8 
42633 Ro5-4846 19.1 -9.1     83.7 7.2 
42634 Ro7-9277 -11.5 -11.5     73.2 9.2 
42635 GL-I-74 -17.3 4     62.6 19.2 
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42636 GL-II-39 1.1 -5.7     86.7 14.6 
42637 GL-II-05 5.5 -8.4     12 15.4 
42638 GL-II-06 10.6 -1.6     76.4 15.2 
42639 GL-II-18 25.4 20.4     39.3 24.3 
42640 GL-II-19 16.6 -6.7     73.5 22 
42641 GL-II-30 19.9 14.1     17.5 14.7 
42642 GL-II-31 17.1 14     70.2 -3.3 
42643 GL-II-32 31.7 13     50 3.6 
42644 GL-II-33 -15 17.6     18.5 9.4 
42645 GL-II-51 -11.6 23.4     20.8 0.1 
42647 GL-II-53 -1.3 13.6     19.8 0.5 
42648 GL-II-54 -10.7 9.5     97.2 6.1 
42651 GL-II-57 11.7 11.6     14.1 11.1 
42653 GL-II-59 8 4.1     5.7 17.1 
42654 GL-II-60 6.5 12.1     7.4 18.2 
42655 GL-II-61 2.1 23.5     -5.3 19.3 
42656 GL-I-30 53.7 16.4     28.9 0 
42657 GL-I-31 31.6 0.1     16.8 4.7 
42658 GL-I-32 9.2 2.6     16.4 7.4 
42659 GL-I-33 30.2 11.3     74.7 4.1 
42660 GL-I-38 18 -4.8     22.9 1.2 
42661 GL-I-36 8.1 4.3     12.1 4.3 
42662 GL-I-43 22 -2.6     13 4.2 
42663 GL-I-41 40.2 5     27.2 3.8 
42664 GL-I-55 16.6 -1.2     8.1 17.9 
42665 GL-I-54 17.9 12.3     -2.1 19.7 
42666 GL-I-77 41.3 22.3     33.7 18.9 
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42667 GL-I-78 31.9 -13.3     83.4 21.9 
50093 SH-I-044 7.5 33.2 69.2 -0.9 15 18.9 
50094 SH-I-047 16.4 -5.4 68.4 3.1 33.3 -7.4 
50095 SH-I-060 9.8 44.4 54 32.1 28.2 14.6 
50096 MP-III-058 -3.8 -1.9 -0.1 18.9 63.3 5.6 
50097 SH-I-048A -7.2 19.4 -0.2 -6.3 7 3.4 
50098 SH-I-048B 0.3 -4.7 5.1 3.6 21.5 12.9 
50099 SH-I-055 21.3 24.3 9.3 16.5 1.1 1.1 
50101 YT-III-31 17.5 9 -6.8 13.1 -6.5 -24.3 
50102 YT-III-271 24.1 -0.4 2.8 12.5 3.6 -17.4 
50103 SR-II-54 7.6 24.1 13.8 13.3 7.2 -19.7 
50104 GL-II-73 5.8 4.6 31.8 7.8 8.7 -20.7 
50105 GL-II-74 10.2 11.8 21 8.9 28.8 -13.6 
50106 GL-II-75 -9.3 -2.1 13 45.1 11.5 6.4 
50107 GL-II-76 -0.8 -2.4 -11.6 29.7 -13.9 21.8 
50108 GL-I-50 0.7 10.8 13.9 0 -11.4 35.7 
50109 GL-II-93 -0.3 2 20.2 -1 -19.9 26.1 
50110 GL-I-65 0.9 1.5 37.9 5.8 7.9 7.4 
50111 GL-I-81 29.9 17.9 15.8 9.3 1.3 -6.5 
50112 GL-III-19 -4.9 4.4 44.1 -1.7 -2.1 -9.8 
50114 GL-I-61 24.4 38.9 30.1 9.7 29 3.4 
50117 GL-I-63 21.6 31 22.3 8.8 10.7 25.9 
50120 GL-III-26 16.7 20.9 31.7 27.9 25 28 
50121 GL-III-27 -8.4 -4.7 31.8 15.7 5.1 27.1 
50122 GL-III-59 0 0.7 16.5 20.1 3.7 46.6 
50123 GL-III-57 -10.7 22.9 25.7 13 34 41 
50124 GL-III-58 8.7 -0.4 36.6 -0.7 -4.8 35.1 
554 
 
50125 GL-III-35 4.1 -0.5 5.2 2.3 3.3 19.9 
50126 GL-III-36 -4.1 17.6 30.8 7.3 40 27.2 
50127 KRM-III-18A -9.9 4.4 39.1 11.9 43.3 8.5 
50128 GL-III-38 10.1 3.8 7.2 10.3 7.7 4.6 
50129 GL-III-72 25.1 49.7 16.2 20.5 7.5 33.3 
50130 GL-III-73 12.1 -6.2 45 3.8 33.5 -5.4 
50132 GL-III-42 -7.9 -8.5 38.7 8.6 72.1 -1 
50133 GL-III-43 -16.6 2 -6 9.2 40.5 -4.6 
50134 GL-III-52 -5.5 9.7 22.9  6.8 -7.4 
50135 GL-III-53 -9.1 -6.4 5.7  -9.5 -3.5 
50136 GL-III-54 -2 -7.9 -11.8  44.7 -1.1 
50137 GL-III-60 25.7 29 -10.2  61 -2.4 
50138 GL-III-63 8.1 16.7 7.7  60 -3.6 
50139 GL-III-64 6.6 8 33.6  55.1 -15 
50140 GL-III-66 -17.4 9.1 43.2  24.5 -15.2 
50141 GL-III-67 -4.4 10.2 46.7  29.5 -16.4 
50142 GL-III-68 -4.5 22.6 48.3  61 -5.1 
50143 GL-III-69 -3.5 20.7 -13.8  25 -4.5 
50144 GL-III-70 -16.9 27 -18.6  33.1 -10.6 
50145 GL-III-75 -8.7 22.2 -2.3  32.7 -17.6 
50146 GL-III-76 3.2 29.7 -2.1  25 -12.7 
50147 GL-III-76A 8 -8.5 -10.1  10.2 1.8 
50148 GL-III-77 37.1 58.9 -14.4  12.6 44 
50149 GL-III-78 10.4 21 43  2.6 -4.7 
 
Table 44. PDSP primary binding data for Sigma 1, Sigma 1 GP, Sigma 2, Sigma 2 PC12, 





Name Sigma 1 Sigma 1 GP Sigma 2 Sigma 2 PC12 V1A V1B V2 
30611 SH-053-2'F-R-CH3   -5.3(AVE)    -2.8 9.2 31.3 2 
30612 SH-053-2'F-S-CH3   -3.0(AVE)    -5.0 10.7 32.3 7.5 
30613 MP-III-004   7.5(AVE)    -7.1 4.7 18.1 5.6 
30614 MP-III-021   8.9(AVE)    5.5 9.7 13.2 9.1 
30615 MP-III-019   3.2(AVE)    -22.5(AVE)  7.1 10 6.6 
30616 MP-III-018.A   -0.7(AVE)    -8.4 17.4 -2.5 8.6 
30617 MP-III-022   -8.1(AVE)    -7.6 5.4 17.9 15.7 
30618 MP-III-023   -15.3(AVE)    -9.9 10 23.1 14.1 
30619 SH-I-85   -12.7(AVE)    30.3 14.6 44.7 4.2 
37713 MP-III-068   25.5   -16.6       
37714 MP-III-080   36.3   24.1       








  12.6   -3.8       
37719 MP-III-018.B   18.5   11.6       
37720 MP-III-019.B   28   26.2       
37721 MP-IV-004   22.2   62.4       
37722 GL-I-65 28.1            
37723 MP-IV-005   25.3   63.2       
37724 GL-I-66   23.8   64.8       
37725 MP-IV-010   34.9   64.2       
37726 GL-I-81 5            
37728 SH-I-085   11.6   44.8       
37729 KRM-II-18B   -1.5   45.8       
556 
 
37730 KRM-II-73   6.3   58.1       
37731 KRM-II-82   -5.5   47.5       
37732 KRM-II-97   -13.1   30.7       
37733 KRM-II-81   -14.9   34.5       
37734 KRM-II-68   -8.2   14.9       
37735 KRM-II-08   -6.3   41.5       
37736 KRM-II-3B   17.5   54.6       
42621 KRM-III-59 29   39.5         
42622 KRM-III-65 87.6   24.7         
42623 KRM-III-66 92.4   70.1         
42624 KRM-III-67 33.8   67.5         
42625 KRM-III-79 -7.2   45.1         
42626 KRM-III-70 88.6   20.4         
42627 KRM-III-77 74.9   13.8         
42628 KRM-III-78 88.6   41.7         
42633 Ro5-4846 18.7   34.9         
42634 Ro7-9277 34.4   9.4         
42635 GL-I-74 6.4   30.7         
42636 GL-II-39 50   29.4         
42637 GL-II-05 4.1   13.7         
42638 GL-II-06 24.8   33.6         
42639 GL-II-18 50   63.9         
42640 GL-II-19 -14.3   30.9         
42641 GL-II-30 -5.7   -16         
42642 GL-II-31 94.1   -12         
42643 GL-II-32 -3   15.7         
42644 GL-II-33 -8.7   60         
557 
 
42645 GL-II-51 -17.5   -0.9         
42647 GL-II-53 -12.7   29.6         
42648 GL-II-54 1.1   58.9         
42651 GL-II-57 3.2   50.3         
42653 GL-II-59 -12.3   28.3         
42654 GL-II-60 -8.4   39.2         
42655 GL-II-61 -5.1   16         
42656 GL-I-30 -0.4   72.3         
42657 GL-I-31 10.4   55.6         
42658 GL-I-32 17.4   65         
42659 GL-I-33 6   67.3         
42660 GL-I-38 7.2   46.7         
42661 GL-I-36 -2.7   26.3         
42662 GL-I-43 12.4   35.2         
42663 GL-I-41 -1   44.9         
42664 GL-I-55 0.3   40.9         
42665 GL-I-54 -3   26.9         
42666 GL-I-77 -4.7   60.9         
42667 GL-I-78 9.6   67.1         
50093 SH-I-044 0.2   28.7       
50094 SH-I-047 11.8   53.7       
50095 SH-I-060 26.8   73.3       
50096 MP-III-058 -4.1   42.5       
50097 SH-I-048A 7   38.3       
50098 SH-I-048B 7   40.6       
50099 SH-I-055 21.7   75.5       
50101 YT-III-31 9   18.3       
558 
 
50102 YT-III-271 10.5   33.7       
50103 SR-II-54 1.4   10.5       
50104 GL-II-73 12.2   18.4   2.9 16.4   
50105 GL-II-74 19.6   45.6   27.7 -7.8   
50106 GL-II-75 16.1   53   10.4 2.6   
50107 GL-II-76 13   33.5   5.5 -1.3   
50108 GL-I-50 18   -9.4   6.3 -0.7   
50109 GL-II-93 11.2   1.6   19.6 -1.5   
50110 GL-I-65 25.8   52.4   11.9 -1.6   
50111 GL-I-81 30.7   69.2   11.5 2.2   
50112 GL-III-19 5   39.9   12 6.2   
50114 GL-I-61 33.5   75.8   22.3 10.2   
50117 GL-I-63 36   74.6   16.2 -2.9   
50120 GL-III-26 44.3   54.3   -2.7 -3.7   
50121 GL-III-27 40.4   3.7   0.2 2.4   
50122 GL-III-59 27.7   6.4   23.5 1   
50123 GL-III-57 47.2   50.5   13.1 6.7   
50124 GL-III-58 28   5.9   8.3 4.3   
50125 GL-III-35 25.1   33.6   2.5 9.8   
50126 GL-III-36 40.8   68.4   7.1 3   
50127 KRM-III-18A 43.2   72.8   6.8 11.2   
50128 GL-III-38 26   39.3   6.6 10.8   
50129 GL-III-72 44.8   85.5   8.9 -16.6   
50130 GL-III-73 41.9   68.7   4.5 -7.5   
50132 GL-III-42 34.5   82.3   15.8 2.7   
50133 GL-III-43 27.2   43.8   23.7 4.3   
50134 GL-III-52 39.8   49.5   23.1 8.8   
559 
 
50135 GL-III-53 37.1   29.9   17.2 7.2   
50136 GL-III-54 3.5   -44.2   8.9 3.6   
50137 GL-III-60 81.1   76.4   13.9 0.4   
50138 GL-III-63 64.3   36.6   13.5 4.9   
50139 GL-III-64 46.3   35.3   41.7 12.9   
50140 GL-III-66 9.2   -9   23.9 3.4   
50141 GL-III-67 -0.8   9.3   -0.3 6.8   
50142 GL-III-68 -13.6   48.5   5.4 10.8   
50143 GL-III-69 -13.7   24.3   17 12.9   
50144 GL-III-70 5   32.4   5.2 11.2   
50145 GL-III-75 17.6   25   17.3 9.7   
50146 GL-III-76 25.7   47.6   2.5 7.5   
50147 GL-III-76A 13   13.7   3.1 1.7   
50148 GL-III-77 26.4   49.1   14.6 7.2   
50149 GL-III-78 10.8   34.1   27.7 -13.5   
 







5-HT1D 5-ht1e 5-HT2A 5-HT2B 
30611 SH-053-2'F-R-CH3 
      
30612 SH-053-2'F-S-CH3 
      
30613 MP-III-004 
      
30614 MP-III-021 
      
30615 MP-III-019 
     
>10,000 
30616 MP-III-018.A 
      
30617 MP-III-022 
      
30618 MP-III-023 




     
>10,000 
37713 MP-III-068 
      
37714 MP-III-080 
      
37715 MP-III-085 








      
37719 MP-III-018.B 
      
37720 MP-III-019.B 
      
37721 MP-IV-004 
      
37722 GL-I-65 
      
37723 MP-IV-005 
      
37724 GL-I-66 
      
37725 MP-IV-010 
      
37726 GL-I-81 
     
5,927.00 
37728 SH-I-085 




     
37730 KRM-II-73 




     
37732 KRM-II-97 
      
37733 KRM-II-81 
      
37734 KRM-II-68 
      
37735 KRM-II-08 
      
37736 KRM-II-3B 








      
42623 KRM-III-66 
      
42624 KRM-III-67 
      
42625 KRM-III-79 
      
42626 KRM-III-70 
      
42627 KRM-III-77 
      
42628 KRM-III-78 
      
42633 Ro5-4846 
      
42634 Ro7-9277 
      
42635 GL-I-74 
      
42636 GL-II-39 
      
42637 GL-II-05 
      
42638 GL-II-06 
      
42639 GL-II-18 
      
42640 GL-II-19 
      
42641 GL-II-30 
      
42642 GL-II-31 
      
42643 GL-II-32 
      
42644 GL-II-33 
      
42645 GL-II-51 
      
42647 GL-II-53 
      
42648 GL-II-54 
      
42651 GL-II-57 
      
42653 GL-II-59 
      
42654 GL-II-60 
      
42655 GL-II-61 
      
42656 GL-I-30 




      
42658 GL-I-32 
      
42659 GL-I-33 
      
42660 GL-I-38 
      
42661 GL-I-36 
      
42662 GL-I-43 
      
42663 GL-I-41 
      
42664 GL-I-55 
      
42665 GL-I-54 
      
42666 GL-I-77 
      
42667 GL-I-78 
      
50093 SH-I-044 
      
50094 SH-I-047 
      
50095 SH-I-060 





      
50097 SH-I-048A 
      
50098 SH-I-048B 



















   
50104 GL-II-73 
      
50105 GL-II-74 
      
50106 GL-II-75 




      
50108 GL-I-50 
      
50109 GL-II-93 
      
50110 GL-I-65 





   
50112 GL-III-19 
      
50114 GL-I-61 
      
50117 GL-I-63 




      
50121 GL-III-27 
      
50122 GL-III-59 
      
50123 GL-III-57 
      
50124 GL-III-58 
      
50125 GL-III-35 
      
50126 GL-III-36 
      
50127 KRM-III-18A 





      
50129 GL-III-72 




      
50132 GL-III-42 
      
50133 GL-III-43 
      
50134 GL-III-52 
      
50135 GL-III-53 




      
50137 GL-III-60 
      
50138 GL-III-63 




      
50140 GL-III-66 
      
50141 GL-III-67 
      
50142 GL-III-68 
      
50143 GL-III-69 
      
50144 GL-III-70 
      
50145 GL-III-75 
      
50146 GL-III-76 
      
50147 GL-III-76A 









      
 












      
30613 MP-III-004 
      
30614 MP-III-021 
      
30615 MP-III-019 




      
30617 MP-III-022 
      
30618 MP-III-023 
      
30619 SH-I-85 




      
37714 MP-III-080 3,660.0(AVE)  
     
37715 MP-III-085 
















      
37721 MP-IV-004 
      
37722 GL-I-65 
      
37723 MP-IV-005 
      
37724 GL-I-66 
      
37725 MP-IV-010 
      
37726 GL-I-81 
      
37728 SH-I-085 
      
37729 KRM-II-18B 
      
37730 KRM-II-73 
      
37731 KRM-II-82 
      
37732 KRM-II-97 
      
37733 KRM-II-81 
      
37734 KRM-II-68 
      
37735 KRM-II-08 
      
37736 KRM-II-3B 1,643.7(AVE)  
     
42621 KRM-III-59 
      
42622 KRM-III-65 




      
42624 KRM-III-67 
      
42625 KRM-III-79 
      
42626 KRM-III-70 
      
42627 KRM-III-77 
      
42628 KRM-III-78 
      
42633 Ro5-4846 
      
42634 Ro7-9277 
      
42635 GL-I-74 
      
42636 GL-II-39 
      
42637 GL-II-05 
      
42638 GL-II-06 
      
42639 GL-II-18 
      
42640 GL-II-19 
      
42641 GL-II-30 
      
42642 GL-II-31 
      
42643 GL-II-32 
      
42644 GL-II-33 
      
42645 GL-II-51 
      
42647 GL-II-53 
      
42648 GL-II-54 
      
42651 GL-II-57 
      
42653 GL-II-59 
      
42654 GL-II-60 
      
42655 GL-II-61 
      
42656 GL-I-30 
      
42657 GL-I-31 




      
42659 GL-I-33 
      
42660 GL-I-38 
      
42661 GL-I-36 
      
42662 GL-I-43 
      
42663 GL-I-41 
      
42664 GL-I-55 




    
42666 GL-I-77 
      
42667 GL-I-78 
      
50093 SH-I-044 
      
50094 SH-I-047 
      
50095 SH-I-060 
      
50096 MP-III-058 
      
50097 SH-I-048A 
      
50098 SH-I-048B 
      
50099 SH-I-055 
      
50101 YT-III-31 
      
50102 YT-III-271 
      
50103 SR-II-54 
      
50104 GL-II-73 




    
50106 GL-II-75 
      
50107 GL-II-76 
      
50108 GL-I-50 
      
50109 GL-II-93 
      
50110 GL-I-65 




      
50112 GL-III-19 
      
50114 GL-I-61 
      
50117 GL-I-63 




   
8,239.00 
50121 GL-III-27 




     
>10,000 
50123 GL-III-57 
    
2652 >10,000 
50124 GL-III-58 
     
>10,000 
50125 GL-III-35 
     
5,616.00 
50126 GL-III-36 





     
4,745.00 
50128 GL-III-38 
     
7,686.00 
50129 GL-III-72 
     
946 
50130 GL-III-73 
      
50132 GL-III-42 
      
50133 GL-III-43 
      
50134 GL-III-52 
      
50135 GL-III-53 
      
50136 GL-III-54 
      
50137 GL-III-60 
      
50138 GL-III-63 
      
50139 GL-III-64 
      
50140 GL-III-66 
      
50141 GL-III-67 
      
50142 GL-III-68 






      
50144 GL-III-70 
      
50145 GL-III-75 
      
50146 GL-III-76 
      
50147 GL-III-76A 
      
50148 GL-III-77 
     
>10,000 
50149 GL-III-78 
      
 
















      
30614 MP-III-021 












      
30618 MP-III-023 




      
37713 MP-III-068 
      
37714 MP-III-080 
      
37715 MP-III-085 











      
37719 MP-III-018.B 
      
37720 MP-III-019.B 
      
37721 MP-IV-004 
      
37722 GL-I-65 
      
37723 MP-IV-005 
      
37724 GL-I-66 
      
37725 MP-IV-010 
      
37726 GL-I-81 
      
37728 SH-I-085 
      
37729 KRM-II-18B 




   
37731 KRM-II-82 








   
37734 KRM-II-68 
      
37735 KRM-II-08 
      
37736 KRM-II-3B 




   
42622 KRM-III-65 




   
42624 KRM-III-67 
      
42625 KRM-III-79 
      
42626 KRM-III-70 
      
42627 KRM-III-77 








      
42634 Ro7-9277 
      
42635 GL-I-74 
      
42636 GL-II-39 
      
42637 GL-II-05 








    
42640 GL-II-19 
      
42641 GL-II-30 
      
42642 GL-II-31 
      
42643 GL-II-32 
      
42644 GL-II-33 
      
42645 GL-II-51 
      
42647 GL-II-53 
      
42648 GL-II-54 
      
42651 GL-II-57 
      
42653 GL-II-59 
      
42654 GL-II-60 
      
42655 GL-II-61 
      
42656 GL-I-30 
      
42657 GL-I-31 
      
42658 GL-I-32 
      
42659 GL-I-33 
      
42660 GL-I-38 
      
42661 GL-I-36 
      
42662 GL-I-43 
      
42663 GL-I-41 




      
42665 GL-I-54 
      
42666 GL-I-77 




   
50093 SH-I-044 
      
50094 SH-I-047 
      
50095 SH-I-060 
  
774 10,000.0(AVE)  
  
50096 MP-III-058 
      
50097 SH-I-048A 
      
50098 SH-I-048B 
      
50099 SH-I-055 
      
50101 YT-III-31 
      
50102 YT-III-271 
      
50103 SR-II-54 
      
50104 GL-II-73 
      
50105 GL-II-74 
      
50106 GL-II-75 
      
50107 GL-II-76 
      
50108 GL-I-50 
      
50109 GL-II-93 
      
50110 GL-I-65 
      
50111 GL-I-81 
      
50112 GL-III-19 
      
50114 GL-I-61 
      
50117 GL-I-63 




      
50121 GL-III-27 




      
50123 GL-III-57 
      
50124 GL-III-58 
      
50125 GL-III-35 
      
50126 GL-III-36 
      
50127 KRM-III-18A 
  
149.5(AVE)  8,411.3(AVE)  
  
50128 GL-III-38 
      
50129 GL-III-72 
 
2,278.00 1,027.5(AVE)  10,000.0(AVE)  
  
50130 GL-III-73 
      
50132 GL-III-42 
      
50133 GL-III-43 
      
50134 GL-III-52 
      
50135 GL-III-53 
      
50136 GL-III-54 
      
50137 GL-III-60 
      
50138 GL-III-63 




   
50140 GL-III-66 
      
50141 GL-III-67 
 
7,941.00 10,000.0(AVE)  
   
50142 GL-III-68 




   
50144 GL-III-70 
      
50145 GL-III-75 
      
50146 GL-III-76 




   
50148 GL-III-77 1,686.00 1,566.00 1,670.0(AVE)  6,076.8(AVE)  
  
50149 GL-III-78 




Table 48. PDSP secondary binding data for Beta3, BZP Rat Brain Site, D1, D3, D5, and DAT. 
Compound 
# 































































































































































































    
42634 Ro7-9277 




    
42636 GL-II-39 





























































































































    







    
50097 SH-I-048A 6125 3.3 




    





























    
50107 GL-II-76 
      
50108 GL-I-50 




    
50110 GL-I-65 






























































    












    
50133 GL-III-43 


































































    
 
Table 49. PDSP secondary binding data for DOR, H1, H2, H3 , H4, and HERG binding. 
Compound 
# 










































      
30619 SH-I-85 
















































      
37722 GL-I-65 




      
37724 GL-I-66 




      
37726 GL-I-81 
      
37728 SH-I-085 




























































































      
42636 GL-II-39 
      
42637 GL-II-05 
      
42638 GL-II-06 
      
42639 GL-II-18 2,313.0(AVE)  
    
>10,000 
42640 GL-II-19 
      
42641 GL-II-30 
      
42642 GL-II-31 
      
42643 GL-II-32 
      
42644 GL-II-33 
      
42645 GL-II-51 
      
42647 GL-II-53 
      
42648 GL-II-54 
      
42651 GL-II-57 
      
42653 GL-II-59 




      
42655 GL-II-61 
      
42656 GL-I-30 








   
42659 GL-I-33 
      
42660 GL-I-38 
      
42661 GL-I-36 
      
42662 GL-I-43 
      
42663 GL-I-41 
      
42664 GL-I-55 
      
42665 GL-I-54 
      
42666 GL-I-77 




   
50093 SH-I-044 
      
50094 SH-I-047 
      
50095 SH-I-060 













      
50099 SH-I-055 
     
1,268.00 
50101 YT-III-31 






      
50103 SR-II-54 




     
>10,000 
50105 GL-II-74 
     
>10,000 
50106 GL-II-75 
     
>10,000 
50107 GL-II-76 
      
50108 GL-I-50 
      
50109 GL-II-93 
     
8,223.3(AVE)  
50110 GL-I-65 
      
50111 GL-I-81 
      
50112 GL-III-19 










50120 GL-III-26 1,168.8(AVE)  
 
4,183.00 
   
50121 GL-III-27 
      
50122 GL-III-59 
      
50123 GL-III-57 
      
50124 GL-III-58 
      
50125 GL-III-35 
      
50126 GL-III-36 




      
50128 GL-III-38 
      
50129 GL-III-72 3,152.0(AVE)  
 
2,301.00 




   
50132 GL-III-42 
      
50133 GL-III-43 
      
50134 GL-III-52 
      
50135 GL-III-53 








    
50138 GL-III-63 






    
50140 GL-III-66 
      
50141 GL-III-67 




   
50143 GL-III-69 
      
50144 GL-III-70 
      
50145 GL-III-75 
      
50146 GL-III-76 




      




      
 
Table 50. PDSP secondary binding data for KOR, M1, M2, M3, M4, M5 and mGlur5. 
Compou
nd # 








      
30613 MP-III-004 599 
      
30614 MP-III-021 122 
      
30615 MP-III-019 3,367.00 
      
30616 MP-III-018.A 
1,182.00 





30617 MP-III-022 381 
      
585 
 
30618 MP-III-023 119 
      
30619 SH-I-85 162 
      
37713 MP-III-068 
      
  
37714 MP-III-080 
      
  
37715 MP-III-085 


























   
  
37721 MP-IV-004 637.0(AVE)  
     
  
37722 GL-I-65 222 
     
  
37723 MP-IV-005 379.5(AVE)  







   
  
37725 MP-IV-010 149.0(AVE)  
     
  
37726 GL-I-81 127 
     
  
37728 SH-I-085 219.5(AVE)  
     
  
37729 KRM-II-18B 375.5(AVE)  




    
10,000
.0(AV









     
  
37733 KRM-II-81 





      
  
37735 KRM-II-08 713.0(AVE)  





     
  
42621 KRM-III-59 408 
     
  
42622 KRM-III-65 879 
     
  
42623 KRM-III-66 756 
     
  
42624 KRM-III-67 
      
  
42625 KRM-III-79 
      
  
42626 KRM-III-70 
      
  
42627 KRM-III-77 921 
     
  
42628 KRM-III-78 
      
  
42633 Ro5-4846 1,323.00 
     
  
42634 Ro7-9277 
      
  
42635 GL-I-74 1,404.00 
     
  
42636 GL-II-39 
      
  
42637 GL-II-05 
      
  
42638 GL-II-06 401 
     
  
42639 GL-II-18 
      
  
42640 GL-II-19 
      
  
42641 GL-II-30 
      
  
42642 GL-II-31 
      
  
42643 GL-II-32 
      
  
42644 GL-II-33 193 
     
  
42645 GL-II-51 
      
  
42647 GL-II-53 680 
     
  
42648 GL-II-54 504 




42651 GL-II-57 59 
     
  
42653 GL-II-59 90 
     
  
42654 GL-II-60 239 
     
  
42655 GL-II-61 
      
  
42656 GL-I-30 27 
     
  
42657 GL-I-31 65 
     
  
42658 GL-I-32 64 
     
  
42659 GL-I-33 34 
     
  
42660 GL-I-38 68 
     
  
42661 GL-I-36 411 
     
  
42662 GL-I-43 102 
     
  
42663 GL-I-41 39 
     
  
42664 GL-I-55 150 
     
  
42665 GL-I-54 788 
     
  
42666 GL-I-77 125 
     
  
42667 GL-I-78 48 
     
  
50093 SH-I-044 
      
  
50094 SH-I-047 110.0(AVE)  
     
  
50095 SH-I-060 
      
  
50096 MP-III-058 249.0(AVE)  
     
  
50097 SH-I-048A 
      
  
50098 SH-I-048B 63.5(AVE)  
     
  
50099 SH-I-055 





     
  
50102 YT-III-271 451.5(AVE)  
     
  
50103 SR-II-54 







     
  
50105 GL-II-74 228.5(AVE)  
     
  
50106 GL-II-75 353.5(AVE)  
     
  
50107 GL-II-76 418.0(AVE)  
     
  
50108 GL-I-50 
      
  
50109 GL-II-93 
      
  
50110 GL-I-65 362.5(AVE)  
     
  
50111 GL-I-81 752.0(AVE)  
     
  
50112 GL-III-19 264.5(AVE)  
     
  
50114 GL-I-61 
      
  
50117 GL-I-63 
      
  
50120 GL-III-26 
      
  
50121 GL-III-27 
      
  
50122 GL-III-59 
      
  
50123 GL-III-57 
      
  
50124 GL-III-58 
      
  
50125 GL-III-35 912.0(AVE)  
     
  
50126 GL-III-36 252.5(AVE)  





     
  
50128 GL-III-38 
      
  
50129 GL-III-72 
      
  
50130 GL-III-73 452.0(AVE)  
     
  
50132 GL-III-42 213.0(AVE)  





     
  
50134 GL-III-52 




50135 GL-III-53 226.5(AVE)  













    
  
50138 GL-III-63 795.7(AVE)  











    
>10,00
0   
50141 GL-III-67 
181.0(AVE)  
    
>10,00





































     
>10,00
0   
50148 GL-III-77 










Table 51. PDSP secondary binding data for MOR, NET, NMDA, PBR, Sigma 1, Sigma 2, 
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42667 GL-I-78 
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610   
50101 YT-III-31 
      
  
50102 YT-III-271 
      
  
50103 SR-II-54 
      
  
50104 GL-II-73 














00   
50107 GL-II-76 
      
  
50108 GL-I-50 
      
  
50109 GL-II-93 





     
1,323.




     
1,129.
00   
50112 GL-III-19 
      
  
50114 GL-I-61 
     
1,051.
00   
50117 GL-I-63 
     
1,047.
00   
50120 GL-III-26 
     
984   
50121 GL-III-27 
      
  
50122 GL-III-59 
      
  
50123 GL-III-57 
     
1,003.
00   
50124 GL-III-58 
      
  
50125 GL-III-35 
      
  
50126 GL-III-36 
     
998   
50127 KRM-III-18A 
     
565   
50128 GL-III-38 
      
  
50129 GL-III-72 
     
432   
50130 GL-III-73 
     
1,189.
00   
50132 GL-III-42 
   
966 
 
614   
50133 GL-III-43 
      
  
50134 GL-III-52 
      
  
50135 GL-III-53 
      
  
50136 GL-III-54 
      
  
50137 GL-III-60 
   
2,389.00 
9,586.7(
AVE)  468   
50138 GL-III-63 














      
  
50141 GL-III-67 
      
  
50142 GL-III-68 





      
  
50144 GL-III-70 
      
  
50145 GL-III-75 
      
  
50146 GL-III-76 
      
  
50147 GL-III-76A 






    
  
50149 GL-III-78 




















Appendix III: The master data file for anti-depression project 
Table 52. Pharmacokinetic parameters in mice and rats calculated for GL-II-73, GL-II-74, 



















































1910.44 0 2974.93 2981.44 1.13 0.66 
3 mg/kg  ± 190.95 ± 0.00  ± 429.88  ± 436.01 ± 0.24 ± 0.12 
  
PO 
528.54 1.78 3573.79 3714.7 2.76 0.26 
   ± 129.42 ± 1.13  ± 667.43  ± 642.36 ± 0.41 ± 0.04 
  
IP 
1412.33 0.25 4876.15 4883.35 1.13 0.67 




1816.24 0.25 3414.7 3416.05 1.1 0.63 
   ± 227.80 ± 0.08  ± 815.13  ± 815.27 ± 0.06 ± 0.03 
  
PO 
554.17 0.55 2897.87 2902.37 2.11 0.43 





0.33± 0.00  
5631.75 











981.66 0 450.49 456.25 1.61 0.42 
3 mg/kg  ± 184.23 ± 0.00  ± 46.77  ± 45.97 ± 0.15 ± 0.04 
  
PO 
13.27 2.33 75.76 94.28 5.67 0.2 
   ± 5.27 ± 0.67  ± 32.18  ± 21.19 ± 3.02 ± 0.08 
  IP 452.21 0.17 976.3 979.41 1.4 0.46 
597 
 




3343.61 0.08 1761.11 1788.35 1.78 0.39 
   ± 463.84 ± 0.00  ± 143.44  ± 139.97 ± 0.07 ± 0.01 
  
PO 
136.34 1.44 631.71 649.36 3.13 0.29 
   ± 61.97 ± 0.80  ± 298.55  ± 294.93 ± 1.26 ± 0.08 
  
IP 
959.19 0.25 4745.2 5368.98 3.79 0.43 
   ± 162.83 ± 0.08  
± 
1385.08  





340.07 0 630.86 631.16 1.12 0.62 
3 mg/kg  ± 73.23 ± 0.00  ± 297.47  ± 297.52 ± 0.01 ± 0.01 
  
PO 
195.4 1 894.63 902.16 1.42 0.54 
   ± 41.41 ± 0.00  ± 187.36  ± 190.71 ± 0.35 ± 0.11 
  
IP 
381.96 0.78 1143.66 1145.95 1.3 0.56 




418.68 0.25 389.02 389.33 1.26 0.56 
   ± 24.31 ± 0.08  ± 179.73  ± 179.66 ± 0.12 ± 0.06 
  
PO 
47.74 0.69 122.77 123.31 1.87 0.43 
   ± 10.09 ± 0.31  ± 64.36  ± 64.13 ± 0.54 ± 0.11 
  
IP 
168.6 0.33 382.88 383.2 1.2 0.58 




639.33 0 620.61 635.33 2.04 0.34 
3 mg/kg  ± 204.62 ± 0.00  ± 36.43  ± 37.88 ± 0.04 ± 0.01 
  
PO 
58.33 3 386.97 394.82 2.08 0.34 
   ± 13.71 ± 0.00  ± 81.52  ± 80.48 ± 0.20 ± 0.03 
  
IP 
180.44 0.33 819.66 849.45 2.38 0.31 
   ± 7.76 ± 0.00  ± 147.89  ± 149.74 ± 0.38 ± 0.04 
  Brain IV 708.92 0.08 732.82 795.57 2.67 0.28 
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   ± 167.01 ± 0.00  ± 145.63  ± 120.25 ± 0.45 ± 0.06 
  
PO 
25.2 6 184.38 234.32 4.55 0.17 
   ± 9.18 ± 3.00  ± 48.92  ± 29.38 ± 0.96 ± 0.04 
  
IP 
116.4 0.25 501.55 595.01 2.71 0.27 





1053.42 0 1324.67 1325.81 1.1 0.64 
3 mg/kg  ± 178.15 ± 0.00  ± 72.10  ± 72.41 ± 0.12 ± 0.06 
  
PO 
495.79 1 1419.4 1431.44 1.73 0.41 
   ± 92.02 ± 0.00  ± 288.19  ± 286.06 ± 0.16 ± 0.04 
  
IP 
914.38 0.08 1069.2 1073.74 1.5 0.47 




1041.87 0.08 936.37 936.41 0.85 0.81 
   ± 204.05 ± 0.00  ± 81.20  ± 81.20 ± 0.01 ± 0.01 
  
PO 
163.97 0.25 364.6 364.89 1.18 0.59 
   ± 21.32 ± 0.08  ± 108.18  ± 108.25 ± 0.08 ± 0.04 
  
IP 
708.5 0.25 1236.64 1236.78 0.85 0.84 




740.38 0 487.3 500.45 1.81 0.4 
3 mg/kg  ± 132.13 ± 0.00  ± 42.55  ± 47.09 ± 0.30 ± 0.06 
  
PO 
17.77 1.44 69.63 91.31 6.6 0.22 
   ± 7.92 ± 0.80  ± 18.64  ± 6.23 ± 4.06 ± 0.11 
  
IP 
256.08 0.17 240.18 250.65 2.37 0.31 




2720.98 0.08 1404.13 1430.22 1.82 0.38 
   ± 356.62 ± 0.00  ± 60.66  ± 58.02 ± 0.09 ± 0.02 
  
PO 
45.62 5.11 100.93 142.39 5.54 0.2 





502.48 0.25 553.6 568.4 1.74 0.63 





1390.42 0 2039.56 2039.68 0.88 0.79 
3 mg/kg  ± 222.26 ± 0.00  ± 50.53  ± 50.56 ± 0.02 ± 0.02 
  
PO 
339.7 0.55 1511.09 1511.18 0.9 0.78 
   ± 29.77 ± 0.22  ± 287.14  ± 187.17 ± 0.06 ± 0.05 
  
IP 
1283.79 0.08 2445.94 2445.96 0.74 0.94 




464.81 0.08 400.91 400.95 0.91 0.77 
   ± 117.94 ± 0.00  ± 21.65 ± 21.65 ± 0.04 ± 0.04 
  
PO 
83.43 0.33 199.71 199.77 1 0.7 
   ± 6.75 ± 0.00  ± 38.48 ± 38.47 ± 0.05 ± 0.04 
  
IP 
320.13 0.25 467.03 467.05 0.82 0.84 




1389.45 0 537.21 578.24 1.62 0.43 
3 mg/kg  ± 257.98 ± 0.00  ± 70.83 ± 70.22 ± 0.06 ± 0.02 
  
PO 
77.48 0.33 142.98 149.82 3.05 0.24 
   ± 35.02 ± 0.00  ± 43.91 ± 44.25 ± 0.42 ± 0.04 
  
IP 
979.87 0.17 487.07 490.08 1.72 0.4 




916.08 0.08 458.63 485.71 2.34 0.3 
   ± 196.67 ± 0.00  ± 64.25 ± 59.34 ± 0.17 ± 0.02 
  
PO 
114.97 0.33 322.24 347.25 0.37 1.9 
   ± 55.53 ± 0.00  ± 30.29 ± 29.89 ± 0.01 ± 0.05 
  
IP 
186.5 0.17 406.85 444.7 0.4 1.76 
  ± 65.09 ± 0.08  ± 69.29 ± 79.70 ± 0.02 ± 0.09 
GL-III-23 Mouse Plasma IV 164.27 0 392.05 457.81 3.37 0.29 
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3 mg/kg  ± 32.71 ± 0.00  ± 56.38 ± 86.29 ± 1.09 ± 0.14 
  
PO 
109.84 3 827.77 1317.38 5.91 0.34 
   ± 30.55 ± 1.00  ± 263.74 ± 626.00 ± 2.59 ± 0.25 
  
IP 
242.45 0.78 1199.56 1386.94 4.14 0.17 




524.04 0.08 931.76 974.14 2.5 0.31 
   ± 102.71 ± 0.00  ± 192.73 ± 191.48 ± 0.58 ± 0.07 
  
PO 
191.42 3 1170.4 1285.24 3.61 0.32 
   ± 60.45 ± 1.00  ± 340.95 ± 263.90 ± 1.97 ± 0.12 
  
IP 
479.03 2 3056.79 3284.04 2.67 0.47 




195.59 0 215.37 216.19 1.48 0.47 
3 mg/kg  ± 42.20 ± 0.00  ± 23.64 ± 23.64 ± 0.02 ± 0.01 
  
PO 
103.65 0.78 245.99 246.85 1.56 0.45 
   ± 34.15 ± 0.22 ± 119.30 ± 119.21 ± 0.17 ± 0.05 
  
IP 
63.62 0.39 281.37 334.37 4.42 0.17 




356.14 0.4 783.91 872.52 3.38 0.22 
   ± 72.29 ± 0.31 ± 117.03 ± 99.94 ± 0.64 ± 0.05 
  
PO 
128.73 5.33 822.11 1276.76 5 0.18 
   ± 24.94 ± 3.38  ± 147.77 ± 260.35 ± 1.73 ± 0.07 
  
IP 
175.58 0.08 952.11 1213.43 5.19 0.15 





111.24 0 175.3 212.91 4.4 0.16 
3 mg/kg  ± 34.45 ± 0.00  ± 34.25 ± 35.01 ± 0.41 ± 0.01 
  
PO 
59.54 3 442.5 803.7 10.73 0.3 





134.63 0.78 701.76 1019.78 7.61 0.1 




298.17 0.08 372.27 550.31 5.46 0.21 
   ± 67.12 ± 0.00  ± 189.23 ± 263.79 ± 2.13 ± 0.12 
  
PO 
85.81 3 508.42 631.34 3.11 0.36 
   ± 25.49 ± 1.00  ± 207.87 ± 307.79 ± 1.37 ± 0.18 
  
IP 
240.73 2 1386.97 1487.33 3.01 0.23 




104.15 0 50.61 51.77 2.12 0.33 





39.24 1.67 58.27 59.87 2.91 0.27 
   ± 21.86 ± 0.67 ± 27.70 ± 27.34 ± 0.73 ± 0.05 
  
IP 
4.75 0.17 9.5 12.7 5.83 0.12 




172.47 0.17 613.23 1944.91 17.95 0.05 
   ± 28.89 ± 0.08 ± 55.69 ± 688.72 ± 6.41 ± 0.02 
  
PO 
68.56 0.69 296.85 1361.21 25.35 0.2 
   ± 21.58 ± 0.31 ± 18.10 ± 985.70 ± 22.02 ± 0.14 
  
IP 
97.18 0.17 422.85 1003.05 15 0.2 





954.6 0 738.85 798.85 3.23 0.22 
3 mg/kg ± 134.45 ± 0.00 ± 85.08 ± 85.82 ± 0.27 ± 0.02 
  
PO 
137.05 3 872.15 993.08 3.61 0.23 
  ± 23.14 ± 1.00 ± 156.31 ± 148.20 ± 1.07 ± 0.08 
  
IP 
370.78 0.78 1672.11 1811.11 3.3 0.21 






877.97 0.08 1458.62 1459.02 1.07 0.65 
  ± 155.12 ± 0.00 ± 47.18 ± 47.12 ± 0.02 ± 0.01 
  
PO 
107.05 3 538.84 539.88 1.31 0.63 
  ± 30.65 ± 1.00 ± 225.47 ± 225.23 ± 0.40 ± 0.17 
  
IP 
352.86 2 2105.67 2119.37 1.53 0.49 




592.56 0 884.99 885.77 1.25 0.56 
3 mg/kg ± 79.89 ± 0.00 ± 131.29 ± 131.28 ± 0.02 ± 0.01 
  
PO 
230.93 1.67 939.87 947.33 1.58 0.51 
  ± 43.53 ± 0.67 ± 361.59 ± 357.39 ± 0.47 ± 0.13 
  
IP 
146.92 0.56 867 1021.54 4.46 0.18 




290.14 0.17 859.22 1284.87 6.51 0.11 
  ± 36.86 ± 0.08 ± 60.61 ± 17.83 ± 0.57 ± 0.01 
  
PO 
105.66 1.67 859.69 1600.41 9.13 0.17 
  ± 13.92 ± 0.67 ± 97.79 ± 348.96 ± 4.23 ± 0.11 
  
IP 
118.75 0.56 799.87 1988.85 14.49 0.06 





101.89 0 156.09 181.7 3.69 0.21 
3 mg/kg ± 34.49 ± 0.00 ± 29.81 ± 37.05 ± 0.87 ± 0.04 
  
PO 
51.35 3 363.06 575.32 7.2 0.32 
  ± 10.68 ± 1.00 ± 84.22 ± 140.25 ± 3.80 ± 0.24 
  
IP 
151.1 0.78 619.41 871.09 6.25 0.11 




230.63 0.08 286.56 288.39 1.65 0.42 
  ± 50.40 ± 0.00 ± 174.85 ± 175.90 ± 0.09 ± 0.02 
  PO 65.51 3 304.52 312.22 1.74 0.57 
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  ± 11.60 ± 1.00 ± 106.53 ± 99.28 ± 0.85 ± 0.19 
  
IP 
182.58 2 1029.72 1126.95 3.16 0.23 




116.77 0 150.23 151.23 1.74 0.4 
3 mg/kg ± 40.89 ± 0.00 ± 15.11 ± 15.11 ± 0.03 ± 0.01 
  
PO 
46.81 1.67 105.25 106.25 1.74 0.4 
  ± 20.78 ± 0.67 ± 20.10 ± 20.07 ± 0.06 ± 0.01 
  
IP 
24.71 0.33 76.83 78.03 2.09 0.33 




152.07 0.08 530.05 2031.38 20.31 0.06 
  ± 29.08 ± 0.00 ± 83.18 
± 
1099.74 
± 10.35 ± 0.03 
  
PO 
62.1 1.67 310.43 531.37 7.93 0.11 
  ± 18.05 ± 0.67 ± 16.93 ± 110.46 ± 2.74 ± 0.03 
  
IP 
92.43 0.17 447.07 730.43 8.46 0.09 




5384.54 0.08 4620.09 4626.35 1.2 0.58 
10 
mg/kg 
± 838.04 ± 0.00 ± 323.21 ± 322.80 ± 0.02 ± 0.01 
  
Brain IP 
1195.94 0.17 1311.86 1397.47 2.44 0.29 




777.76 0 434.48 435.03 1.21 0.58 
3 mg/kg ± 31.34 ± 0.00 ± 63.02 ± 62.92 ± 0.07 ± 0.03 
  
PO 
79.43 0.25 68.54 144.52 7.16 2.7 
  ± 50.72 ± 0.08 ± 19.28 ± 65.73 ± 1.82 ± 2.58 
  
Brain IV 
239.7 0.08 103.79 110.44 2.35 0.3 





20.5 1.22 54.09 68.79 7.2 0.16 




2840.74 0.08 2053.17 2102.62 1.84 0.38 
10 
mg/kg 
± 404.87 ± 0.00 ± 297.11 ± 298.38 ± 0.17 ± 0.03 
  
Brain IP 
3246.23 0.08 2218.83 2231.34 1.47 0.48 
  ± 184.90 ± 0.00 ± 177.52 ± 177.69 ± 0.07 ± 0.02 
Rat 
Plasma IV 
426.55 0 292.69 294.25 1.5 0.47 
3 mg/kg ± 77.06 ± 0.00 ± 4.72 ± 4.15 ± 0.13 ± 0.04 
  
Brain IV 
690.92 0.08 339.54 344.94 1.75 0.4 




2151.323 0.25 4845.31 4856.48 0.53 0.16 
10 
mg/kg 
± 81.07 ± 0.08 ± 118.92 ± 111.76 ± 0.06 ± 0.06 
  
Brain IP 
1410.23 0.33 3895.8 3907.26 1.43 0.49 


























BRIEF DESCRIPTION OF THE DRAWINGS 
 
 
Figure 1. The concentration–time profile of GL-II-73 after intraperitoneal (IP) 
administration of the 10 mg/kg dose in mouse plasma and brain (a) and after intravenous 
(IV) and peroral (PO) administration of the 3 mg/kg dose in rat  plasma and brain (b). n=3 





Figure 2. The concentration–time profile of GL-II-74 after intraperitoneal (IP) 
administration of the 10 mg/kg dose in mouse plasma and brain (a) and after intravenous 





Figure 3. The concentration–time profile of GL-II-75 after intraperitoneal (IP) 






Figure 4. The concentration–time profile of RV-II-04 after intravenous (IV), peroral (PO) or 
intraperitoneal (IP) administration of the 3 mg/kg dose (n=3 per time point) in mouse plasma 






Figure 5. The concentration–time profile of GL-II-31 after intravenous (IV), peroral (PO) or 
intraperitoneal (IP) administration of the 3 mg/kg dose (n=3 per time point) in mouse plasma 







Figure 6. The concentration–time profile of MP-III-023 after intravenous (IV), peroral (PO) 
or intraperitoneal (IP) administration of the 3 mg/kg dose (n=3 per time point) in mouse 






Figure 7. The concentration–time profile of GL-I-54 after intravenous (IV), peroral (PO) or 
intraperitoneal (IP) administration of the 3 mg/kg dose (n=3 per time point) in mouse plasma 






Figure 8. The concentration–time profile of GL-III-23 after intravenous (IV), peroral (PO) 
or intraperitoneal (IP) administration of the 3 mg/kg dose (n=3 per time point) in mouse 






Figure 9. The concentration–time profile of GL-II-33 after intravenous  (IV), peroral (PO) 
or intraperitoneal (IP) administration of the 3 mg/kg dose (n=3 per time point) in mouse 






Figure 10. The concentration–time profile of GL-II-54 after intravenous (IV), peroral (PO) 
or intraperitoneal (IP) administration of the 3 mg/kg dose (n=3 per time point) in mouse 






Figure 11. The concentration–time profile of GL-I-65 after intravenous (IV), peroral (PO) 
or intraperitoneal (IP) administration of the 3 mg/kg dose (n=3 per time point) in mouse 





Figure 12. Plasma and brain concentration–time profiles of GL-III-66 and calculated 
pharmacokinetic parameters in male C57BL/6 mice (n = 3 per time point) after 
intraperitoneally administration of the cassette solution containing 3 mg/kg of each GL-III-
66, GL-III-67, GL-III-68 and GL-III-63. Cmax = maximum concentration in plasma or brain; 
Tmax = time of maximum concentration in plasma or brain; AUC0-12 = area under the plasma 
or brain concentration–time curve from 0 to 12 h; AUC0-∞ = area under the plasma or brain 
concentration–time curve from 0 to extrapolated infinite time; t1/2 = elimination half-life 
from plasma or brain; β = elimination constant rate from plasma or brain. All values are 





Figure 13. Plasma and brain concentration–time profiles of GL-III-67 and calculated 
pharmacokinetic parameters in male C57BL/6 mice (n = 3 per time point) after 
intraperitoneally administration of the cassette solution containing 3 mg/kg of each GL-III-
66, GL-III-67, GL-III-68 and GL-III-63. Cmax = maximum concentration in plasma or brain; 
Tmax = time of maximum concentration in plasma or brain; AUC0-12 = area under the plasma 
or brain concentration–time curve from 0 to 12 h; AUC0-∞ = area under the plasma or brain 
concentration–time curve from 0 to extrapolated infinite time; t1/2 = elimination half-life 
from plasma or brain; β = elimination constant rate from plasma or brain. All values are 





Figure 14. Plasma and brain concentration–time profiles of GL-III-68 and calculated 
pharmacokinetic parameters in male C57BL/6 mice (n = 3 per time point) after 
intraperitoneally administration of the cassette solution containing 3 mg/kg of each GL-III-
66, GL-III-67, GL-III-68 and GL-III-63. Cmax = maximum concentration in plasma or brain; 
Tmax = time of maximum concentration in plasma or brain; AUC0-12 = area under the plasma 
or brain concentration–time curve from 0 to 12 h; AUC0-∞ = area under the plasma or brain 
concentration–time curve from 0 to extrapolated infinite time; t1/2 = elimination half-life 
from plasma or brain; β = elimination constant rate from plasma or brain. All values are 
represented as a mean ± standard error of the mean. GL-III-68 and GL-III-70 are 
stereoisomers and some issues in analytical separation were encountered, so 









Figure 15. Plasma and brain concentration–time profiles of GL-III-70 and calculated 
pharmacokinetic parameters in male C57BL/6 mice (n = 3 per time point) after 
intraperitoneally administration of the cassette solution containing 3 mg/kg of each GL-III-
70, GL-III-64 and GL-III-60. Cmax = maximum concentration in plasma or brain; Tmax = 
time of maximum concentration in plasma or brain; AUC0-12 = area under the plasma or 
brain concentration–time curve from 0 to 12 h; AUC0-∞ = area under the plasma or brain 
concentration–time curve from 0 to extrapolated infinite time; t1/2 = elimination half-life 
from plasma or brain; β = elimination constant rate from plasma or brain. All values are 
represented as a mean ± standard error of the mean. GL-III-68 and GL-III-70 are 
stereoisomers and some issues in analytical separation were encountered, so 





Figure 16. Plasma and brain concentration–time profiles of GL-III-63 and calculated 
pharmacokinetic parameters in male C57BL/6 mice (n = 3 per time point) after 
intraperitoneally administration of the cassette solution containing 3 mg/kg of each GL-III-
66, GL-III-67, GL-III-68 and GL-III-63. Cmax = maximum concentration in plasma or brain; 
Tmax = time of maximum concentration in plasma or brain; AUC0-12 = area under the plasma 
or brain concentration–time curve from 0 to 12 h; AUC0-∞ = area under the plasma or brain 
concentration–time curve from 0 to extrapolated infinite time; t1/2 = elimination half-life 
from plasma or brain; β = elimination constant rate from plasma or brain. All values are 





Figure 17. Plasma and brain concentration–time profiles of GL-III-64 and calculated 
pharmacokinetic parameters in male C57BL/6 mice (n = 3 per time point) after 
intraperitoneally administration of the cassette solution containing 3 mg/kg of each GL-III-
70, GL-III-64 and GL-III-60. Cmax = maximum concentration in plasma or brain; Tmax = 
time of maximum concentration in plasma or brain; AUC0-12 = area under the plasma or 
brain concentration–time curve from 0 to 12 h; AUC0-∞ = area under the plasma or brain 
concentration–time curve from 0 to extrapolated infinite time; t1/2 = elimination half-life 
from plasma or brain; β = elimination constant rate from plasma or brain. All values are 





Figure 18. Plasma and brain concentration–time profiles of GL-III-60 and calculated 
pharmacokinetic parameters in male C57BL/6 mice (n = 3 per time point) after 
intraperitoneally administration of the cassette solution containing 3 mg/kg of each GL-III-
70, GL-III-64 and GL-III-60. Cmax = maximum concentration in plasma or brain; Tmax = 
time of maximum concentration in plasma or brain; AUC0-12 = area under the plasma or 
brain concentration–time curve from 0 to 12 h; AUC0-∞ = area under the plasma or brain 
concentration–time curve from 0 to extrapolated infinite time; t1/2 = elimination half-life 
from plasma or brain; β = elimination constant rate from plasma or brain. All values are 










Table 54. Summary table (occupancy, efficacy, binding) 
Compound  Dose  
GABAA 
subtype 
Occ. Eff. Ki 
DZP 1.5 mg/kg 




α2 77.79 % /, (333 %) 13 nM 
α3 69.71 % /, (345 %) 20 nM 







α1 21.13 % 120% 759 nM 
α2 17.66 % 125% 948 nM 
α3 20.92 % 135% 768 nM 
α5 68.12 % 230% 95 nM 
MP-III-022 10 mg/kg 
α1 6.27 % 100% 850 µM 
α2 13.63 % 150% 55µM 
            
GL-II-73 10 mg/kg 
α1 0.57 % 131.68 % 55 µM 
α2 1.04 % 124.25 % 30  µM 
α3 0.50 % 129.08 % 63  µM 
α5 5.95 % 179.62 % 5 µM 
GL-II-74 10 mg/kg 
α1 19.45 % 146.18 % 1060 nM 
α2 24.03 % 150.02 % 809 nM 
α3 16.99 % 154.85 % 1250 nM 
α5 75.51 % 256.67 % 194 nM 
GL-II-75 10 mg/kg 
α1 8.34 % 162.90 % 542 nM 
α2 5.88 % 153.24 % 789 nM 
α3 9.31 % 139.49 % 480 nM 
α5 38.42 % 136.76 % 79 nM 
            
RV-II-04 10 mg/kg 
α1       
α2       
α3       
α5       
GL-II-31 10 mg/kg 
α1       
α2       
α3       
α5       
MP-III-023 10 mg/kg 
α1       
α2       
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α3       
α5       
GL-I-54 10 mg/kg 
α1       
α2       
α3       
α5       
            
GL-III-66 10 mg/kg 
α1       
α2       
α3       
α5       
GL-III-67 10 mg/kg 
α1       
α2       
α3       
α5       
GL-III-68 10 mg/kg 
α1       
α2       
α3       
α5       
GL-III-70 10 mg/kg 
α1       
α2       
α3       
α5       
            
GL-II-33 10 mg/kg 
α1       
α2       
α3       
α5       
GL-II-54 10 mg/kg 
α1       
α2       
α3       
α5       
GL-I-65 10 mg/kg 
α1       
α2       
α3       
α5       
GL-III-60 10 mg/kg 
α1       
α2       
α3       
α5       
GL-III-63 10 mg/kg α1       
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α2       
α3       
α5       
GL-III-64 10 mg/kg 
α1       
α2       
α3       
α5       




α1       
α2       
α3       
α5       
 













DZP         prodepr. no infl. 
SH-053-2’F-
RCH3 










0.6 hr 1.2 hr / / 




















1,3 hr 1,4 hr antidepr. procogn. 




























              
GL-III-66     8.8 hr 6.4 hr / No eff 
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GL-III-67     1.2 hr  1.9 hr / No eff 
GL-III-68     2.1 hr  2.7 hr / procogn. 
GL-III-70     2.1 hr  2.7 hr / procogn. 
              
GL-II-33         / procogn. 
GL-II-54         / / 
GL-I-65         / procogn. 
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GL-III-60     2.9 hr 5.5 hr / / 
GL-III-63     1.9 hr 3 hr / / 
GL-III-64     2. hr 6 hr / / 
              
MRK-016 
(NAM) 
        / / 
 








SLA  RR EPM 




hypo hypo anxl. 





MP-III-022 / / / 
no infl. 
no infl. no infl. 
(rats) 
              
GL-II-73 no infl. procogn. 
  





GL-II-74 anticogn. no infl. / hyper hypo anxl. 
GL-II-75 no infl. procogn. / hypo hypo anxl. 
              
RV-II-04 / / / hypo hypo / 
GL-II-31 / / / No eff No eff / 
MP-III-023 / / / hypo hypo / 
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GL-I-54 / / / No eff No eff / 
              

































No eff No eff 
              
GL-II-33 / / / No eff   / 
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GL-II-54 / / / No eff   / 
GL-I-65 / / / No eff   / 




No eff No eff  




No eff No eff  




No eff No eff  
              
MRK-016 
(NAM) 






Appendix IV: Additional Data for Anti-schizophrenic like Behavioral Study Induced by 
MK-801 
Total immobile episodes 
 
Figure 1. Total immobile episodes. The data analysed has been limited in the following way: 
Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + 
GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 0.32 mg/kg + SOL, MK-801 0.32 
mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-III-73 10 mg/kg, MK-801 0.32 mg/kg 
+ GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + GL-III-78 10 mg/kg and Trial = Habituation 


























































































































































































































T re a tm e n t
D ata plotted are m eans ± standard error
T ria l
H abituation trial
M K -801 challenge trial
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Maximum speed (m/s) 
 
Figure 2. Maximum speed. The data analysed has been limited in the following way: 
Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + 
GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 0.32 mg/kg + SOL, MK-801 0.32 
mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-III-73 10 mg/kg, MK-801 0.32 mg/kg 
+ GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + GL-III-78 10 mg/kg and Trial = Habituation 





























































































































































































































T re a tm e n t
D ata plotted are m eans ± standard error
T ria l
H abituation trial
M K -801 challenge trial
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Rotations of the animal's body 
 
Figure 3. Rotations of the animal's body. The data analysed has been limited in the following 
way: Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL 
+ GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 0.32 mg/kg + SOL, MK-801 0.32 
mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-III-73 10 mg/kg, MK-801 0.32 mg/kg 
+ GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + GL-III-78 10 mg/kg and Trial = Habituation 
































































































































































































































T re a tm e n t
D ata plotted are m eans ± standard error
T ria l
H abituation trial
M K -801 challenge trial
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Clockwise rotations of the animal's body 
 
Figure 4. Clockwise rotations of the animal's body. The data analysed has been limited in the 
following way: Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, SAL + GL-III-73 10 
mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 0.32 mg/kg + SOL, 
MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-III-73 10 mg/kg, MK-
801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + GL-III-78 10 mg/kg and Trial 








































































































































































































































T re a tm e n t
D ata plotted are m eans ± standard error
T ria l
H abituation trial
M K -801 challenge trial
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Anticlockwise rotations of the animal's body 
 
Figure 5. Anticlockwise rotations of the animal's body. The data analysed has been limited 
in the following way: Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, SAL + GL-III-
73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 0.32 mg/kg + 
SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-III-73 10 mg/kg, 
MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + GL-III-78 10 mg/kg and 










































































































































































































































T re a tm e n t
D ata plotted are m eans ± standard error
T ria l
H abituation trial
M K -801 challenge trial
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Total freezing episodes 
 
Figure 6. Total freezing episodes. The data analysed has been limited in the following way: 
Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + 
GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 0.32 mg/kg + SOL, MK-801 0.32 
mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-III-73 10 mg/kg, MK-801 0.32 mg/kg 
+ GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + GL-III-78 10 mg/kg and Trial = Habituation 



























































































































































































































T re a tm e n t
D ata plotted are m eans ± standard error
T ria l
H abituation trial
M K -801 challenge trial
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Total time freezing (s) 
 
Figure 7. Total time freezing. The data analysed has been limited in the following way: 
Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + 
GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 0.32 mg/kg + SOL, MK-801 0.32 
mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-III-73 10 mg/kg, MK-801 0.32 mg/kg 
+ GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + GL-III-78 10 mg/kg and Trial = Habituation 



























































































































































































































T re a tm e n t
D ata plotted are m eans ± standard error
T ria l
H abituation trial
M K -801 challenge trial
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Total distance travelled (m) 
 
Figure 8. Total distance travelled for tests where Trial is Habituation trial. The data analysed 
has been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, 
SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 
0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-
III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + GL-III-
78 10 mg/kg and Trial = Habituation trial or MK-801 challenge trial. 
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Figure 9. Total distance travelled for tests where Trial is MK-801 challenge trial. The data 
analysed has been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 
10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, 
MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg 
+ GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + 
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Average speed (m/s) 
 
Figure 10. Average speed for tests where Trial is Habituation trial. The data analysed has 
been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, SAL 
+ GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 0.32 
mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-III-73 
10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + GL-III-78 10 
mg/kg and Trial = Habituation trial or MK-801 challenge trial. 
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Figure 11. Average speed for tests where Trial is MK-801 challenge trial. The data analysed 
has been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, 
SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 
0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-
III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + GL-III-
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Total time mobile (s) 
 
Figure 12. Total time mobile for tests where Trial is Habituation trial. The data analysed has 
been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, SAL 
+ GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 0.32 
mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-III-73 
10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + GL-III-78 10 
mg/kg and Trial = Habituation trial or MK-801 challenge trial. 
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Figure 13. Total time mobile for tests where Trial is MK-801 challenge trial. The data 
analysed has been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 
10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, 
MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg 
+ GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + 
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Total time immobile (s) 
 
Figure 14. Total time immobile for tests where Trial is Habituation trial. The data analysed 
has been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, 
SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 
0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-
III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + GL-III-
78 10 mg/kg and Trial = Habituation trial or MK-801 challenge trial. 
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Figure 15. Total time immobile for tests where Trial is MK-801 challenge trial. The data 
analysed has been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 
10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, 
MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg 
+ GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + 
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Figure 16. Total mobile episodes for tests where Trial is Habituation trial. The data analysed 
has been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, 
SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 
0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-
III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + GL-III-
78 10 mg/kg and Trial = Habituation trial or MK-801 challenge trial. 
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Figure 17. Total mobile episodes for tests where Trial is MK-801 challenge trial. The data 
analysed has been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 
10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, 
MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg 
+ GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + 
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Figure 18. Total immobile episodes for tests where Trial is Habituation trial. The data 
analysed has been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 
10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, 
MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg 
+ GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + 
GL-III-78 10 mg/kg and Trial = Habituation trial or MK-801 challenge trial. 
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Figure 19. Total immobile episodes for tests where Trial is MK-801 challenge trial. The data 
analysed has been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 
10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, 
MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg 
+ GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + 
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Maximum speed (m/s) 
 
Figure 20. Maximum speed for tests where Trial is Habituation trial. The data analysed has 
been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, SAL 
+ GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 0.32 
mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-III-73 
10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + GL-III-78 10 
mg/kg and Trial = Habituation trial or MK-801 challenge trial. 
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Figure 21. Maximum speed for tests where Trial is MK-801 challenge trial. The data 
analysed has been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 
10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, 
MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg 
+ GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + 


















































































T im e  (s )
D ata plotted are m eans ± standard error
T re a tm e n t
S A L + S O L
S A L + G L-III-36 10 m g/kg
S A L + G L-III-73 10 m g/kg
S A L + G L-III-76 10 m g/kg
S A L + G L-III-78 10 m g/kg
M K -801 0.32 m g/kg + S O L
M K -801 0.32 m g/kg + G L-III-36 10 m g/kg
M K -801 0.32 m g/kg + G L-III-73 10 m g/kg
M K -801 0.32 m g/kg + G L-III-76 10 m g/kg
M K -801 0.32 m g/kg + G L-III-78 10 m g/kg
654 
 
Rotations of the animal's body 
 
Figure 22. Rotations of the animal's body for tests where Trial is Habituation trial. The data 
analysed has been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 
10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, 
MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg 
+ GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + 
GL-III-78 10 mg/kg and Trial = Habituation trial or MK-801 challenge trial. 
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Figure 23. Rotations of the animal's body for tests where Trial is MK-801 challenge trial. 
The data analysed has been limited in the following way: Treatment = SAL + SOL, SAL + 
GL-III-36 10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-
78 10 mg/kg, MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-
801 0.32 mg/kg + GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 
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Clockwise rotations of the animal's body 
 
Figure 24. Clockwise rotations of the animal's body for tests where Trial is Habituation trial. 
The data analysed has been limited in the following way: Treatment = SAL + SOL, SAL + 
GL-III-36 10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-
78 10 mg/kg, MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-
801 0.32 mg/kg + GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 
0.32 mg/kg + GL-III-78 10 mg/kg and Trial = Habituation trial or MK-801 challenge trial. 
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Figure 25. Clockwise rotations of the animal's body for tests where Trial is MK-801 challenge 
trial. The data analysed has been limited in the following way: Treatment = SAL + SOL, 
SAL + GL-III-36 10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + 
GL-III-78 10 mg/kg, MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, 
MK-801 0.32 mg/kg + GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or 
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Anticlockwise rotations of the animal's body 
 
Figure 26. Anticlockwise rotations of the animal's body for tests where Trial is Habituation 
trial. The data analysed has been limited in the following way: Treatment = SAL + SOL, 
SAL + GL-III-36 10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + 
GL-III-78 10 mg/kg, MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, 
MK-801 0.32 mg/kg + GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or 
MK-801 0.32 mg/kg + GL-III-78 10 mg/kg and Trial = Habituation trial or MK-801 challenge 
trial. 
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Figure 27. Anticlockwise rotations of the animal's body for tests where Trial is MK-801 
challenge trial. The data analysed has been limited in the following way: Treatment = SAL 
+ SOL, SAL + GL-III-36 10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, 
SAL + GL-III-78 10 mg/kg, MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 
mg/kg, MK-801 0.32 mg/kg + GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg 
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Total freezing episodes 
 
Figure 28. Total freezing episodes for tests where Trial is Habituation trial. The data 
analysed has been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 
10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, 
MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg 
+ GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + 
GL-III-78 10 mg/kg and Trial = Habituation trial or MK-801 challenge trial. 
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Figure 29. Total freezing episodes for tests where Trial is MK-801 challenge trial. The data 
analysed has been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 
10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, 
MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg 
+ GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + 
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Figure 30. Total time freezing for tests where Trial is Habituation trial. The data analysed 
has been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 10 mg/kg, 
SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, MK-801 
0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg + GL-
III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + GL-III-
78 10 mg/kg and Trial = Habituation trial or MK-801 challenge trial. 
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Figure 31. Total time freezing for tests where Trial is MK-801 challenge trial. The data 
analysed has been limited in the following way: Treatment = SAL + SOL, SAL + GL-III-36 
10 mg/kg, SAL + GL-III-73 10 mg/kg, SAL + GL-III-76 10 mg/kg, SAL + GL-III-78 10 mg/kg, 
MK-801 0.32 mg/kg + SOL, MK-801 0.32 mg/kg + GL-III-36 10 mg/kg, MK-801 0.32 mg/kg 
+ GL-III-73 10 mg/kg, MK-801 0.32 mg/kg + GL-III-76 10 mg/kg or MK-801 0.32 mg/kg + 
GL-III-78 10 mg/kg and Trial = Habituation trial or MK-801 challenge trial. 
 
 
Table 57. Raw data of anti-schizophrenia model. 
Ani




















1 SAL + SOL Habituation 118.410 0.033 2169.7 1430.3 206 205 
15 SAL + SOL Habituation 82.770 0.023 1718.9 1881.1 302 302 
26 SAL + SOL Habituation 93.715 0.026 2005.2 1594.8 261 260 
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40 SAL + SOL Habituation 57.969 0.016 1184.8 2415.2 280 280 
46 SAL + SOL Habituation 82.517 0.023 1790.0 1810.0 290 289 
51 SAL + SOL Habituation 84.018 0.023 1672.3 1927.7 317 317 
61 SAL + SOL Habituation 73.295 0.020 1380.4 2219.6 272 272 
64 SAL + SOL Habituation 65.808 0.018 1242.1 2357.9 276 275 
1 SAL + SOL MK-801 challenge 69.530 0.010 1355.7 5844.3 335 335 
15 SAL + SOL MK-801 challenge 65.374 0.009 1238.6 5961.4 314 314 
26 SAL + SOL MK-801 challenge 21.290 0.003 457.6 6742.4 144 144 
40 SAL + SOL MK-801 challenge 9.304 0.001 185.0 7015.0 72 72 
46 SAL + SOL MK-801 challenge 10.971 0.002 240.0 6960.0 83 82 
51 SAL + SOL MK-801 challenge 5.982 0.001 109.4 7090.6 55 55 
61 SAL + SOL MK-801 challenge 45.446 0.006 837.3 6362.7 330 330 
64 SAL + SOL MK-801 challenge 18.519 0.003 321.2 6878.8 126 126 
2 
SAL + GL-III-36 10 
mg/kg Habituation 121.637 0.034 2082.0 1518.0 285 285 
13 
SAL + GL-III-36 10 
mg/kg Habituation 91.649 0.025 1738.4 1861.6 289 289 
23 
SAL + GL-III-36 10 
mg/kg Habituation 96.470 0.027 2129.8 1470.2 229 228 
36 
SAL + GL-III-36 10 
mg/kg Habituation 111.018 0.031 2137.2 1462.8 262 261 
41 
SAL + GL-III-36 10 
mg/kg Habituation 124.912 0.035 2364.0 1236.0 324 323 
59 
SAL + GL-III-36 10 
mg/kg Habituation 98.491 0.027 2045.1 1554.9 310 310 
2 
SAL + GL-III-36 10 
mg/kg MK-801 challenge 31.496 0.004 607.0 6593.0 168 169 
13 
SAL + GL-III-36 10 




SAL + GL-III-36 10 
mg/kg MK-801 challenge 16.232 0.002 327.0 6873.0 77 77 
36 
SAL + GL-III-36 10 
mg/kg MK-801 challenge 14.427 0.002 309.2 6890.8 76 76 
41 
SAL + GL-III-36 10 
mg/kg MK-801 challenge 16.955 0.002 391.0 6809.0 107 107 
59 
SAL + GL-III-36 10 
mg/kg MK-801 challenge 28.677 0.004 553.5 6646.5 125 126 
3 
SAL + GL-III-73 10 
mg/kg Habituation 114.987 0.032 2192.3 1407.7 266 266 
16 
SAL + GL-III-73 10 
mg/kg Habituation 79.433 0.022 1590.5 2009.5 317 317 
22 
SAL + GL-III-73 10 
mg/kg Habituation 90.716 0.025 1891.0 1709.0 229 229 
33 
SAL + GL-III-73 10 
mg/kg Habituation 91.391 0.025 1730.2 1869.7 309 309 
45 
SAL + GL-III-73 10 
mg/kg Habituation 82.213 0.023 1643.0 1957.0 284 284 
58 
SAL + GL-III-73 10 
mg/kg Habituation 91.413 0.025 2253.2 1346.8 244 243 
3 
SAL + GL-III-73 10 
mg/kg MK-801 challenge 31.411 0.004 489.9 6710.1 101 101 
16 
SAL + GL-III-73 10 
mg/kg MK-801 challenge 21.265 0.003 461.8 6738.2 182 182 
22 
SAL + GL-III-73 10 
mg/kg MK-801 challenge 101.466 0.014 1481.7 5718.3 444 444 
33 
SAL + GL-III-73 10 
mg/kg MK-801 challenge 53.770 0.007 925.9 6274.1 261 261 
45 
SAL + GL-III-73 10 
mg/kg MK-801 challenge 11.197 0.002 180.2 7019.8 94 95 
58 
SAL + GL-III-73 10 




SAL + GL-III-76 10 
mg/kg Habituation 100.605 0.028 1964.0 1636.0 327 326 
14 
SAL + GL-III-76 10 
mg/kg Habituation 52.082 0.014 1209.7 2390.3 239 239 
29 
SAL + GL-III-76 10 
mg/kg Habituation 72.818 0.020 1429.7 2170.3 320 320 
35 
SAL + GL-III-76 10 
mg/kg Habituation 124.710 0.035 2154.1 1445.9 229 229 
47 
SAL + GL-III-76 10 
mg/kg Habituation 58.923 0.016 1218.5 2381.5 297 296 
60 
SAL + GL-III-76 10 
mg/kg Habituation 110.328 0.031 2193.9 1406.1 326 325 
4 
SAL + GL-III-76 10 
mg/kg MK-801 challenge 17.985 0.002 279.3 6920.7 64 64 
14 
SAL + GL-III-76 10 
mg/kg MK-801 challenge 29.250 0.004 454.1 6746.0 87 86 
29 
SAL + GL-III-76 10 
mg/kg MK-801 challenge 14.840 0.002 276.5 6923.5 56 56 
35 
SAL + GL-III-76 10 
mg/kg MK-801 challenge 16.061 0.002 285.5 6914.5 43 43 
47 
SAL + GL-III-76 10 
mg/kg MK-801 challenge 18.000 0.002 275.8 6924.2 67 67 
60 
SAL + GL-III-76 10 
mg/kg MK-801 challenge 27.547 0.004 407.1 6792.9 76 76 
5 
SAL + GL-III-78 10 
mg/kg Habituation 83.550 0.023 1539.2 2060.8 319 318 
12 
SAL + GL-III-78 10 
mg/kg Habituation 73.970 0.021 1590.6 2009.4 290 289 
30 
SAL + GL-III-78 10 
mg/kg Habituation 80.947 0.022 1589.4 2010.6 251 250 
34 
SAL + GL-III-78 10 




SAL + GL-III-78 10 
mg/kg Habituation 111.773 0.031 2298.3 1301.7 212 211 
52 
SAL + GL-III-78 10 
mg/kg Habituation 79.788 0.022 1389.0 2211.0 322 321 
5 
SAL + GL-III-78 10 
mg/kg MK-801 challenge 37.686 0.005 562.2 6637.8 124 124 
12 
SAL + GL-III-78 10 
mg/kg MK-801 challenge 23.076 0.003 405.1 6795.0 81 81 
30 
SAL + GL-III-78 10 
mg/kg MK-801 challenge 29.425 0.004 445.3 6754.7 61 61 
34 
SAL + GL-III-78 10 
mg/kg MK-801 challenge 36.985 0.005 745.9 6454.1 155 155 
43 
SAL + GL-III-78 10 
mg/kg MK-801 challenge 76.698 0.011 1302.8 5897.3 202 202 
52 
SAL + GL-III-78 10 
mg/kg MK-801 challenge 21.463 0.003 384.3 6815.7 83 83 
6 
MK-801 0.32 mg/kg + 
SOL Habituation 94.877 0.026 1776.3 1823.7 241 240 
11 
MK-801 0.32 mg/kg + 
SOL Habituation 88.069 0.024 1715.1 1884.9 338 337 
25 
MK-801 0.32 mg/kg + 
SOL Habituation 91.339 0.025 1609.8 1990.2 282 281 
39 
MK-801 0.32 mg/kg + 
SOL Habituation 96.167 0.027 1564.9 2035.1 257 257 
48 
MK-801 0.32 mg/kg + 
SOL Habituation 69.307 0.019 1261.9 2338.1 322 321 
57 
MK-801 0.32 mg/kg + 
SOL Habituation 87.071 0.024 1800.7 1799.3 315 314 
62 
MK-801 0.32 mg/kg + 
SOL Habituation 58.651 0.016 1251.6 2348.4 245 245 
6 
MK-801 0.32 mg/kg + 




MK-801 0.32 mg/kg + 
SOL MK-801 challenge 536.922 0.075 4891.2 2308.8 281 281 
25 
MK-801 0.32 mg/kg + 
SOL MK-801 challenge 331.255 0.046 4537.1 2663.0 284 284 
39 
MK-801 0.32 mg/kg + 
SOL MK-801 challenge 618.611 0.086 5650.1 1549.9 169 169 
48 
MK-801 0.32 mg/kg + 
SOL MK-801 challenge 271.965 0.038 4055.2 3144.8 385 384 
57 
MK-801 0.32 mg/kg + 
SOL MK-801 challenge 483.603 0.067 5112.3 2087.7 272 272 
62 
MK-801 0.32 mg/kg + 
SOL MK-801 challenge 480.560 0.067 5801.9 1398.1 227 227 
7 
MK-801 0.32 mg/kg + 
GL-III-36 10 mg/kg Habituation 104.045 0.029 1896.8 1703.2 263 263 
17 
MK-801 0.32 mg/kg + 
GL-III-36 10 mg/kg Habituation 81.126 0.023 1626.3 1973.7 308 308 
28 
MK-801 0.32 mg/kg + 
GL-III-36 10 mg/kg Habituation 86.459 0.024 1737.9 1862.1 358 358 
38 
MK-801 0.32 mg/kg + 
GL-III-36 10 mg/kg Habituation 85.601 0.024 1809.5 1790.5 269 269 
44 
MK-801 0.32 mg/kg + 
GL-III-36 10 mg/kg Habituation 97.086 0.027 1943.3 1656.7 214 213 
53 
MK-801 0.32 mg/kg + 
GL-III-36 10 mg/kg Habituation 87.084 0.024 1713.2 1886.8 309 309 
63 
MK-801 0.32 mg/kg + 
GL-III-36 10 mg/kg Habituation 78.832 0.022 1406.6 2193.4 324 323 
7 
MK-801 0.32 mg/kg + 
GL-III-36 10 mg/kg MK-801 challenge 376.727 0.052 4354.5 2845.5 320 321 
17 
MK-801 0.32 mg/kg + 
GL-III-36 10 mg/kg MK-801 challenge 263.060 0.037 3925.5 3274.5 333 332 
28 
MK-801 0.32 mg/kg + 




MK-801 0.32 mg/kg + 
GL-III-36 10 mg/kg MK-801 challenge 89.512 0.012 2694.1 4505.9 416 415 
44 
MK-801 0.32 mg/kg + 
GL-III-36 10 mg/kg MK-801 challenge 125.727 0.017 2648.3 4551.7 514 514 
53 
MK-801 0.32 mg/kg + 
GL-III-36 10 mg/kg MK-801 challenge 152.032 0.021 3113.1 4086.9 409 409 
63 
MK-801 0.32 mg/kg + 
GL-III-36 10 mg/kg MK-801 challenge 221.942 0.031 4420.3 2779.7 438 437 
8 
MK-801 0.32 mg/kg + 
GL-III-73 10 mg/kg Habituation 62.613 0.017 1211.3 2388.6 210 210 
18 
MK-801 0.32 mg/kg + 
GL-III-73 10 mg/kg Habituation 140.500 0.039 2561.6 1038.4 264 264 
27 
MK-801 0.32 mg/kg + 
GL-III-73 10 mg/kg Habituation 120.039 0.033 2043.9 1556.1 254 253 
37 
MK-801 0.32 mg/kg + 
GL-III-73 10 mg/kg Habituation 89.436 0.025 1631.8 1968.2 292 291 
50 
MK-801 0.32 mg/kg + 
GL-III-73 10 mg/kg Habituation 86.492 0.024 1829.9 1770.1 269 268 
55 
MK-801 0.32 mg/kg + 
GL-III-73 10 mg/kg Habituation 75.719 0.021 1500.9 2099.1 274 274 
8 
MK-801 0.32 mg/kg + 
GL-III-73 10 mg/kg MK-801 challenge 703.302 0.098 6235.5 964.5 176 175 
18 
MK-801 0.32 mg/kg + 
GL-III-73 10 mg/kg MK-801 challenge 299.045 0.042 3766.8 3433.2 393 393 
27 
MK-801 0.32 mg/kg + 
GL-III-73 10 mg/kg MK-801 challenge 629.346 0.087 5866.6 1333.4 245 244 
37 
MK-801 0.32 mg/kg + 
GL-III-73 10 mg/kg MK-801 challenge 376.363 0.052 5947.0 1253.0 257 257 
50 
MK-801 0.32 mg/kg + 
GL-III-73 10 mg/kg MK-801 challenge 255.332 0.035 4640.8 2559.2 478 477 
55 
MK-801 0.32 mg/kg + 




MK-801 0.32 mg/kg + 
GL-III-76 10 mg/kg Habituation 81.879 0.023 1302.8 2297.2 339 338 
19 
MK-801 0.32 mg/kg + 
GL-III-76 10 mg/kg Habituation 116.572 0.032 2090.9 1509.1 264 263 
21 
MK-801 0.32 mg/kg + 
GL-III-76 10 mg/kg Habituation 81.742 0.023 1635.3 1964.7 299 298 
32 
MK-801 0.32 mg/kg + 
GL-III-76 10 mg/kg Habituation 86.410 0.024 1636.9 1963.1 323 322 
42 
MK-801 0.32 mg/kg + 
GL-III-76 10 mg/kg Habituation 89.913 0.025 1946.9 1653.1 313 313 
56 
MK-801 0.32 mg/kg + 
GL-III-76 10 mg/kg Habituation 71.675 0.020 1632.8 1967.2 272 271 
9 
MK-801 0.32 mg/kg + 
GL-III-76 10 mg/kg MK-801 challenge 72.305 0.010 1945.9 5254.0 286 287 
19 
MK-801 0.32 mg/kg + 
GL-III-76 10 mg/kg MK-801 challenge 29.615 0.004 1445.9 5754.1 295 295 
21 
MK-801 0.32 mg/kg + 
GL-III-76 10 mg/kg MK-801 challenge 34.851 0.005 949.4 6250.6 277 278 
32 
MK-801 0.32 mg/kg + 
GL-III-76 10 mg/kg MK-801 challenge 53.357 0.007 1879.5 5320.5 289 289 
42 
MK-801 0.32 mg/kg + 
GL-III-76 10 mg/kg MK-801 challenge 39.306 0.005 1807.0 5393.0 308 309 
56 
MK-801 0.32 mg/kg + 
GL-III-76 10 mg/kg MK-801 challenge 117.862 0.016 2366.0 4834.0 393 393 
10 
MK-801 0.32 mg/kg + 
GL-III-78 10 mg/kg Habituation 134.519 0.037 2253.3 1346.7 194 194 
20 
MK-801 0.32 mg/kg + 
GL-III-78 10 mg/kg Habituation 77.400 0.022 1611.6 1988.4 344 343 
24 
MK-801 0.32 mg/kg + 
GL-III-78 10 mg/kg Habituation 79.378 0.022 1603.5 1996.5 338 337 
31 
MK-801 0.32 mg/kg + 




MK-801 0.32 mg/kg + 
GL-III-78 10 mg/kg Habituation 92.216 0.026 1811.9 1788.1 362 361 
54 
MK-801 0.32 mg/kg + 
GL-III-78 10 mg/kg Habituation 111.170 0.031 2139.6 1460.4 197 197 
10 
MK-801 0.32 mg/kg + 
GL-III-78 10 mg/kg MK-801 challenge 174.143 0.024 5198.8 2001.2 415 414 
20 
MK-801 0.32 mg/kg + 
GL-III-78 10 mg/kg MK-801 challenge 141.461 0.020 4651.2 2548.8 570 569 
24 
MK-801 0.32 mg/kg + 
GL-III-78 10 mg/kg MK-801 challenge 181.833 0.025 4641.7 2558.4 510 509 
31 
MK-801 0.32 mg/kg + 
GL-III-78 10 mg/kg MK-801 challenge 134.103 0.019 3245.6 3954.4 661 662 
49 
MK-801 0.32 mg/kg + 
GL-III-78 10 mg/kg MK-801 challenge 436.112 0.061 5151.6 2048.4 402 403 
54 
MK-801 0.32 mg/kg + 
GL-III-78 10 mg/kg MK-801 challenge 105.118 0.015 3028.5 4171.5 482 481 
 
 






















1 SAL + SOL Habituation 0.307 135 49 86 1493 2477.7 
15 SAL + SOL Habituation 0.351 140 73 67 1491 2401.6 
26 SAL + SOL Habituation 0.338 128 68 60 1479 2449.4 
40 SAL + SOL Habituation 0.265 87 40 47 1223 2712.6 
46 SAL + SOL Habituation 0.311 121 73 48 1281 2556.6 
51 SAL + SOL Habituation 0.293 115 37 78 1355 2346.7 
61 SAL + SOL Habituation 0.277 109 48 61 1220 2823.1 
64 SAL + SOL Habituation 0.377 99 70 29 1159 2698.8 
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1 SAL + SOL 
MK-801 
challenge 0.364 117 47 70 1044 6472.0 
15 SAL + SOL 
MK-801 
challenge 0.323 94 63 31 1160 6329.6 
26 SAL + SOL 
MK-801 
challenge 0.267 31 14 17 440 6946.7 
40 SAL + SOL 
MK-801 
challenge 0.185 16 4 12 233 7046.4 
46 SAL + SOL 
MK-801 
challenge 0.195 22 8 14 157 7069.7 
51 SAL + SOL 
MK-801 
challenge 0.188 6 5 1 133 7110.1 
61 SAL + SOL 
MK-801 
challenge 0.297 75 41 34 778 6664.3 
64 SAL + SOL 
MK-801 
challenge 0.244 25 16 9 331 6961.4 
2 
SAL + GL-III-36 
10 mg/kg Habituation 0.292 149 69 80 1436 2461.9 
13 
SAL + GL-III-36 
10 mg/kg Habituation 0.275 120 61 59 1423 2537.3 
23 
SAL + GL-III-36 
10 mg/kg Habituation 0.439 133 93 40 1444 2090.3 
36 
SAL + GL-III-36 
10 mg/kg Habituation 0.264 159 103 56 1633 2091.1 
41 
SAL + GL-III-36 
10 mg/kg Habituation 0.279 171 68 103 1831 2196.7 
59 
SAL + GL-III-36 
10 mg/kg Habituation 0.300 139 61 78 1662 2026.1 
2 
SAL + GL-III-36 
10 mg/kg 
MK-801 
challenge 0.238 58 30 28 427 6854.3 
13 
SAL + GL-III-36 
10 mg/kg 
MK-801 




SAL + GL-III-36 
10 mg/kg 
MK-801 
challenge 0.573 22 15 7 295 6953.7 
36 
SAL + GL-III-36 
10 mg/kg 
MK-801 
challenge 0.187 25 18 7 268 7002.6 
41 
SAL + GL-III-36 
10 mg/kg 
MK-801 
challenge 0.169 23 13 10 229 7026.5 
59 
SAL + GL-III-36 
10 mg/kg 
MK-801 
challenge 0.192 32 15 17 419 6754.3 
3 
SAL + GL-III-73 
10 mg/kg Habituation 0.319 145 69 76 1667 2107.6 
16 
SAL + GL-III-73 
10 mg/kg Habituation 0.313 117 57 60 1500 2525.6 
22 
SAL + GL-III-73 
10 mg/kg Habituation 0.289 145 64 81 1366 2593.8 
33 
SAL + GL-III-73 
10 mg/kg Habituation 0.317 144 95 49 1535 2491.5 
45 
SAL + GL-III-73 
10 mg/kg Habituation 0.274 104 60 44 1437 2621.1 
58 
SAL + GL-III-73 
10 mg/kg Habituation 0.241 135 72 63 1565 2344.7 
3 
SAL + GL-III-73 
10 mg/kg 
MK-801 
challenge 0.285 51 16 35 402 6813.4 
16 
SAL + GL-III-73 
10 mg/kg 
MK-801 
challenge 0.231 49 23 26 578 6883.4 
22 
SAL + GL-III-73 
10 mg/kg 
MK-801 
challenge 0.438 121 49 72 1215 6283.9 
33 
SAL + GL-III-73 
10 mg/kg 
MK-801 
challenge 0.280 83 52 31 759 6626.9 
45 
SAL + GL-III-73 
10 mg/kg 
MK-801 
challenge 0.217 19 9 10 171 7100.8 
58 
SAL + GL-III-73 
10 mg/kg 
MK-801 




SAL + GL-III-76 
10 mg/kg Habituation 0.305 137 66 71 1571 2304.5 
14 
SAL + GL-III-76 
10 mg/kg Habituation 0.242 99 63 36 1007 2854.1 
29 
SAL + GL-III-76 
10 mg/kg Habituation 0.397 108 34 74 1299 2646.6 
35 
SAL + GL-III-76 
10 mg/kg Habituation 0.301 156 90 66 1495 2023.4 
47 
SAL + GL-III-76 
10 mg/kg Habituation 0.249 87 36 51 1229 2623.9 
60 
SAL + GL-III-76 
10 mg/kg Habituation 0.298 148 108 40 1740 2174.6 
4 
SAL + GL-III-76 
10 mg/kg 
MK-801 
challenge 0.197 21 12 9 181 6978.0 
14 
SAL + GL-III-76 
10 mg/kg 
MK-801 
challenge 0.265 35 14 21 290 6922.6 
29 
SAL + GL-III-76 
10 mg/kg 
MK-801 
challenge 0.214 18 8 10 180 7018.7 
35 
SAL + GL-III-76 
10 mg/kg 
MK-801 
challenge 0.215 23 9 14 189 6972.8 
47 
SAL + GL-III-76 
10 mg/kg 
MK-801 
challenge 0.204 21 13 8 212 6964.4 
60 
SAL + GL-III-76 
10 mg/kg 
MK-801 
challenge 0.269 37 20 17 296 6865.2 
5 
SAL + GL-III-78 
10 mg/kg Habituation 0.316 117 51 66 1284 2693.6 
12 
SAL + GL-III-78 
10 mg/kg Habituation 0.271 110 34 76 1557 2537.6 
30 
SAL + GL-III-78 
10 mg/kg Habituation 0.327 148 59 89 1187 2559.2 
34 
SAL + GL-III-78 




SAL + GL-III-78 
10 mg/kg Habituation 0.265 147 63 84 1532 1802.2 
52 
SAL + GL-III-78 
10 mg/kg Habituation 0.281 94 43 51 1379 2522.5 
5 
SAL + GL-III-78 
10 mg/kg 
MK-801 
challenge 0.399 46 14 32 375 6854.2 
12 
SAL + GL-III-78 
10 mg/kg 
MK-801 
challenge 0.246 31 16 15 330 6920.6 
30 
SAL + GL-III-78 
10 mg/kg 
MK-801 
challenge 0.246 30 7 23 250 6907.2 
34 
SAL + GL-III-78 
10 mg/kg 
MK-801 
challenge 0.234 41 25 16 562 6761.8 
43 
SAL + GL-III-78 
10 mg/kg 
MK-801 
challenge 0.246 97 50 47 866 6109.3 
52 
SAL + GL-III-78 
10 mg/kg 
MK-801 
challenge 0.223 32 12 20 335 6917.2 
6 
MK-801 0.32 
mg/kg + SOL Habituation 0.278 146 80 66 1269 2577.1 
11 
MK-801 0.32 
mg/kg + SOL Habituation 0.285 129 65 64 1465 2380.2 
25 
MK-801 0.32 
mg/kg + SOL Habituation 0.300 131 68 63 1438 2513.9 
39 
MK-801 0.32 
mg/kg + SOL Habituation 0.324 129 72 57 1212 2428.9 
48 
MK-801 0.32 
mg/kg + SOL Habituation 0.283 85 27 58 1186 2708.2 
57 
MK-801 0.32 
mg/kg + SOL Habituation 0.276 116 49 67 1438 2522.1 
62 
MK-801 0.32 
mg/kg + SOL Habituation 0.248 86 61 25 864 3012.0 
6 
MK-801 0.32 
mg/kg + SOL 
MK-801 





mg/kg + SOL 
MK-801 
challenge 0.354 697 419 278 1320 2736.5 
25 
MK-801 0.32 
mg/kg + SOL 
MK-801 
challenge 0.334 780 671 109 1659 3441.8 
39 
MK-801 0.32 
mg/kg + SOL 
MK-801 
challenge 0.324 794 390 404 1129 1925.9 
48 
MK-801 0.32 
mg/kg + SOL 
MK-801 
challenge 0.285 634 233 401 1903 3660.1 
57 
MK-801 0.32 
mg/kg + SOL 
MK-801 
challenge 0.333 642 340 302 1858 3046.4 
62 
MK-801 0.32 
mg/kg + SOL 
MK-801 


































36 10 mg/kg 
MK-801 




36 10 mg/kg 
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36 10 mg/kg 
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36 10 mg/kg 
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36 10 mg/kg 
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36 10 mg/kg 
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73 10 mg/kg 
MK-801 




73 10 mg/kg 
MK-801 




73 10 mg/kg 
MK-801 




73 10 mg/kg 
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73 10 mg/kg 
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73 10 mg/kg 
MK-801 






























76 10 mg/kg 
MK-801 




76 10 mg/kg 
MK-801 




76 10 mg/kg 
MK-801 




76 10 mg/kg 
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76 10 mg/kg 
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76 10 mg/kg 
MK-801 






























78 10 mg/kg 
MK-801 




78 10 mg/kg 
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Appendix VI: Metabolites Study from Eli Lilly of KRM-II-81 and MP-III-080 


























































































































































































Appendix VII: Kinetic and Stability Studies of GL-II-93 in Acidic and Basic Condition.  
1. 2D NMR experiment (DCl addition) 
1.1.  DCl addition at pH = 2, at all range 
 




1.3. DCl addition at pH = 2, at 4.0-6.5 ppm 
 
 

























































5. DCl addition t1/2 list [intensity (lg)-time curve] 
 
 
6. 2D NMR experiment (NaOD addition) 





6.2. NaOD addition at pH = 8, at 0.4-2.0 ppm 
 






6.4. NaOD addition at all concentration, at all range 
 
 





6.6. NaOD addition at all concentration, at 7.0-8.0 ppm 
 










































































































Appendix VIII: BZD-related drugs reduced methamphetamine-related behaviors in rats via 
BZD-induced TSPO activation 
Our research has demonstrated that certain specific benzodiazepine-related drugs can powerfully 
reduce methamphetamine-related behaviors in rats, a finding which is likely related to 
benzodiazepine-induced TSPO activation. Other benzodiazepines may also activate TSPO and, 
therefore, may be useful in reducing methamphetamine–related behaviors. Structure-activity 
relationships suggest that benzodiazepines with a halogen moiety in the 4’ position possess higher 
affinity for TSPO 1,2. Several such possible drug candidates are described in the table below. We 
are currently testing Ro5-4864 for efficacy against methamphetamine self-administration in rats. 
While dosing parameters for these compounds are not currently available, we expect that doses of 
these compounds will be similar to other clinically-relevant benzodiazepines (rats: 1-50 mg/kg, 
intraperitoneally; humans: 1-20 mg, orally).  
 Structural Position 
 
 Structural Position 
Drug 1 7 
4' 
2' 3 6' 4 
Ro5-5115 CH3 H 
Cl 
H H H - 
Ro5-5119 CH3 H Cl H H H CH3 
Ro5-5120 CH3 NO2 Cl H H H - 
Ro5-5122 CH3 H F H H H - 
Ro5-5888 CH3 Cl Cl H H H H 
Ro5-4864 CH3 Cl Cl H H H - 
Ro5-6524 CH3 F Cl H H H CH3 
Ro5-6528 CH3 F Cl H H H H 
Ro5-6531 CH3 F Cl H H H - 
Ro5-6900 CH3 Cl Cl Cl H H - 
Ro5-6902 CH3 Cl Cl H H H H 
Ro5-6945 CH2CH=CH2 Cl Cl H H H - 
Ro5-6993 CH2CH3 Cl Cl H H H - 




We propose that these compounds will decrease methamphetamine-seeking and 
methamphetamine-taking behaviors by decreasing the activation of brain circuits involved in 
methamphetamine craving. We also propose that these compounds will reduce other cognitive and 
behavioral effects of methamphetamine. Methamphetamine users often exhibit neurocognitive 
impairments and are more likely to engage in risky sexual behaviors that promote sexual-
transmitted infections such as HIV 3–8. Chronic methamphetamine and HIV infection both induce 
a neuroinflammatory response characterized by a marked increase in TSPO binding and microglial 
activation9–17. TSPO activation is known to decrease sexual behavior and enhance memory 
functions, especially in animal models of neuroinflammation or neurodegeneration18–21. 
Therefore, targeting TSPO activation may decrease the neuroinflammatory response and alleviate 
the neurocognitive effects associated with prolonged methamphetamine use. 
  
To summarize: 
• We are proposing the development of compounds with the basic benzodiazepine structure, 
but with a halogen moiety (e.g., chlorine, fluorine) in the 4’ position instead of hydrogen.  These 
are referred to herein as TSPO compounds. Ro5-4864 is the prototype TSPO compound currently 
under investigation. 
• TSPO compounds will reduce craving (seeking) for methamphetamine. 
• TSPO compounds will halt and potentially reverse the cognitive deficits produced by 
methamphetamine. 
• TSPO compounds will reduce the increased risky sexual behaviors induced by 
methamphetamine.     
• By reducing the occurrence of methamphetamine-induced sexual behaviors, and by 
decreasing the neuroinflammatory response associated with HIV, TSPO compounds may reduce 
the consequences of HIV/AIDS in methamphetamine users.  
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Other classes of drugs which may potentiate the actions of TSPO compounds when used in 
combination: 
1. Agonists (activators) of potassium-chloride co-transporter 2 (KCC2) – These compounds 
activate the chloride extrusion pump in neurons (KCC2) to modify the driving force for chloride 
ions across the neuronal membrane. These agonists enhance the activity of other GABAergic drugs, 
including neurosteroids and benzodiazepines. The combination of KCC2 agonist and TSPO 
compound may enhance therapeutic effects by increasing the efficacy of downstream signaling 
events including GABA-gated chloride influx.1–4 
a. Specific KCC2 activators may include CLP257 [(5Z)-5-[(4-Fluoro-2-
hydroxyphenyl)methylene]-2-(tetrahydro-1-(2H)-pyridazinyl)-4(5H)-thiazolone] no other 
compounds identified. 
2. Inhibitors (antagonists) of 20alpha-hydroxysteroid dehydrogenase (20alpha-HSD) – This 
enzyme is responsible for the catabolism of GABA-active neurosteroids. A combination of 
20alpha-HSD inhibitor and TSPO compound may further enhance the levels of therapeutic 
neurosteroids by both enhancing the early steps of neurosteroid biosynthesis and preventing 
enzymatic breakdown by 20alpha-HSD.5–9 
a. Specific 20alpha-HSD inhibitors may include STZ26 (D-homo-16-oxa-4-androstene-





1. Kahle, K. T., Khanna, A., Clapham, D. E. & Woolf, C. J. Therapeutic Restoration of Spinal 
Inhibition via Druggable Enhancement of Potassium-Chloride Cotransporter KCC2-Mediated 
Chloride Extrusion in Peripheral Neuropathic Pain. JAMA Neurol. 71, 640–5 (2014). 
2. Gagnon, M. et al. Chloride extrusion enhancers as novel therapeutics for neurological 
diseases. Nat. Med. 19, 1524–8 (2013). 
3. Smith, S. S. The influence of stress at puberty on mood and learning: Role of the ??4???? 
GABAA receptor. Neuroscience 249, 192–213 (2013). 
4. Löscher, W., Puskarjov, M. & Kaila, K. Cation-chloride cotransporters NKCC1 and KCC2 
as potential targets for novel antiepileptic and antiepileptogenic treatments. Neuropharmacology 
69, 62–74 (2013). 
5. Higaki, Y. et al. Selective and potent inhibitors of human 20alpha-hydroxysteroid 
dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem. Biol. 
Interact. 143-144, 503–513 (2003). 
6. Dhagat, U., Endo, S., Sumii, R., Hara, A. & El-Kabbani, O. Selectivity determinants of 
inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the 
Compound Structure CAS # 
Ro5-5115 4'-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one N/A 
Ro5-5119 4’-chloro-1,3-dihydro-1,4-dimethyl-5-phenyl-2H-1,4-benzodiazepin-2-one N/A 
Ro5-5120 4’-chloro-1,3-dihydro-1-methyl-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one N/A 
Ro5-5122 4'-Fluoro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one N/A 
Ro5-5888 4',7-Dichloro-1,3,4-trihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one N/A 
Ro5-4864 4',7-Dichloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one N/A 
Ro5-6524 4'-Chloro-7-fluoro-1,3-dihydro-1,4-dimethyl-5-phenyl-2H-1,4-benzodiazepin-2-one N/A 
Ro5-6528 4'-Chloro-7-fluoro-1,3,4-trihydro-1,4-dimethyl-5-phenyl-2H-1,4-benzodiazepin-2-one N/A 
Ro5-6531 4'-Chloro-7-fluoro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one N/A 
Ro5-6900 2',4',7-trichloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one N/A 
Ro5-6902 4',6',7-Trichloro-1,3,4-trihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one N/A 
Ro5-6945 1-allyl-4',7-dichloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one N/A 
Ro5-6993 4',7-dichloro-1-ethyl-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one N/A 
Ro7-9277 4’,7-dichloro-1-hydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one N/A 
Diazepam 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one 439-14-5 
Oxazepam 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one 604-75-1 




enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid. J. 
Med. Chem. 51, 4844–8 (2008). 
7. Endo, S. et al. Substrate specificity and inhibitor sensitivity of rabbit 20α-hydroxysteroid 
dehydrogenase. Biol. Pharm. Bull. 36, 1514–8 (2013). 
8. Yoshida, S., Shiota, K., Nishihara, M. & Takahashi, M. A novel steroid inhibitor for a rat 
20alpha-hydroxysteroid dehydrogenase isozyme. Biol. Reprod. 57, 1433–7 (1997). 
9. Usami, N. et al. Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase 

























1. 2016 poster (Ro5-4846) 
Control/Tracking Number: 2016-S-13783-SfN 
Activity: Scientific Abstract 
Current Date/Time: 5/5/2016 1:46:06 PM 
Effects of Ro5-4864 on methamphetamine self-administration in male and female rats  
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Abstract: 
Methamphetamine abuse continues to be a serious and growing problem with no approved treatment. 
We have previously demonstrated differential effects of benzodiazepines on various 
methamphetamine-related behaviors based upon their relative affinities for either the “central” 
benzodiazepine (BZD) binding site associated with the GABAA receptor or the “peripheral” BZD 
binding site associated with the translocator protein of 18kDa (TSPO). Specifically, oxazepam, 
which binds to both receptors, decreases methamphetamine self-administration, conditioned place 
preference and drug discrimination. In contrast, alprazolam, which binds only to the central BZD 
binding site, augments the effects of methamphetamine at certain dose combinations. The current 
experiment was designed to investigate the effects of Ro5-4864 on methamphetamine self-
administration in rats. Ro5-4864 is a potent selective ligand for TSPO that does not bind to the 
GABAA receptor complex and lacks typical “central” benzodiazepine-like effects. Male and female 
Wistar rats were trained to self-administer methamphetamine (0.05 mg/kg/infusion) during daily 
two-hour sessions. After responding stabilized, several doses of Ro5-4864 were administered 
intraperitoneally 30 minutes before the start of the sessions. Self-administration was dose 
dependently decreased in both males and females; however, female rats were more sensitive to these 
effects. The TSPO receptor has an integral role in the ability of certain benzodiazepines to decrease 
methamphetamine self-administration and could be important in developing novel treatments for 
stimulant addiction.  
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Neuro Abstract 2018 
Research has shown that stress and the activation of the HPA axis play a major role in reward 
and drug reinforcement. Benzodiazepines, such as alprazolam and oxazepam, interact with α1 
subunits of GABAA receptors to increase dopaminergic activity in the VTA. However, oxazepam 
also has an affinity for a second binding site, the translocator protein 18 kDa (TSPO), also 
known as the peripheral benzodiazepine receptor. Binding at TSPO increases neurosteroid levels, 
which can reduce dopamine levels in regions associated with reward. Previous research has 
shown that oxazepam reduces cocaine self-administration as well as two measures of cocaine 
craving (i.e., cue reactivity and reinstatement) in rats. Another experiment showed that Ro5-
4864, a benzodiazepine derivative of diazepam with selective affinity for TSPO, dose 
dependently decreased methamphetamine self-administration in male and female rats without 
affecting food self-administration. The current study tested the effects of selective TSPO binding 
on cocaine and methamphetamine drug-primed reactivity and cue-reactivity. Male and female 
Wistar rats were trained to self-administer cocaine or methamphetamine. After stabilization of 
responding and a two-week abstinence period, rats were pretreated with Ro5-4864 or vehicle 
before testing in either a drug-primed reactivity or cue-reactivity session that measured drug-
seeking behavior. The rats were once again trained to self-administer cocaine or 
methamphetamine, placed into abstinence, and pretreated with vehicle or Ro5-4864 before 
reactivity testing. Drug-primed responding with cocaine and methamphetamine was reduced by 
Ro5-4864 in both male and female rats. However, cue-reactivity was reduced only in rats trained 
with methamphetamine. These data suggest that selective binding to TSPO may be a potential 
treatment for methamphetamine relapse. This research also demonstrates the potential for the 
















































Plasma samples nM time point
1 421.2504 animal sacrificed after 8 days
2 347.269 animal sacrificed after 8 days
3 1128.311 animal sacrificed after 72 h
Brain samples nmol/kg free fraction (nmol/kg) ng/g time point
1 2872.282 189.5706064 1069.609 animal sacrificed after 8 days
2 2005.054 132.3335313 746.6619 animal sacrificed after 8 days
3 12689.84 837.5293412 4725.569 animal sacrificed after 72 h
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5. Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 
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ABSTRACT BODY: 
Abstract: Benzodiazepines (BZD) are a common class of psychoactive medications for the 
treatment of CNS disorders such as anxiety, epilepsy, neuropathic pain, schizophrenia, 
depression and other diseases. However, not all patients have a positive response to BZDs, as 
well as the presence of serious side effects including amnesia, sedation, addiction, ataxia, 
withdraw and drug resistance. An alpha 2/alpha 3 GABA(A)R subtype-selective ligand Hz- 
166 (1) was the initial lead imidazobenzodiazepine (IBZ, Zeilhofer et al.) and was found to be 
anxiolytic in primates (Fischer et al.), an anticonvulsant in rats and mice (Rivas et al.), 
antihyperalgesia in a pain model (Paul et al.) with no tolerance and less sedative or ataxia 
effects were observed. However, the ester moiety in 1 was metabolized very rapidly in rodents 
to its corresponding carboxylic acid, which did not readily pass the blood-brain barrier, which 
would interfere with ADME TOX in rodents. Therefore, a series of novel ester bioisosteres at 
C-3 in place of the labile ester group were then designed and synthesized to improve the 
metabolic stability and achieve enhanced pharmacological effects. Among the series of novel 
bioisosteres, one of the most promising ligands, a 1,3-oxazole KRM-II-81 (2), was identified 
as an alpha 2/alpha 3 GABA(A)R subtype-selective ligand very little or no alpha 1 nor alpha 
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5 efficacy. KRMII- 81 had an excellent metabolic profile in vitro in human, mice, and rat liver 
microsomes, as compared to the parent ligand 1. The ligand 2 exhibited an anxiolytic effect in 
a rat Vogel conflict test and a mouse marble-burying assay without rotorod failures. Most 
recently, the ligand 2 (30 micro M) significantly attenuated the firing rates in human epileptic 
cortical tissue on a 60 microelectrode array and has a wider margin of effect compared to 
motor-impairment than diazepam. Moreover, 2 reduces tactile-induced allodynia after CFA-
induced pain in rats, and the behavior effects can be attenuated by the BZD receptor antagonist 
flumazenil. In addition, 2 did not develop tolerance to the antinociceptive effects in rats, nor 
decreased the respiration rate. The results here indicated that the oxazole 2 could be a potential 
anxiolytic, anticonvulsant and analgesic for the treatment of anxiety disorders, epilepsy and 
pain disorders. This work was supported by NIH grants, NS076517 and MH096463. Recent 
results will be presented. 
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